0001558370-24-01243010-K BIO-TECHNE Corp 20240822202408221630351630361630360 0 0001558370-24-012430 10-K 104 20240630 20240822 20240822 BIO-TECHNE Corp 0000842023 2836 411427402 MN 0630 10-K 34 000-17272 241232392 614 MCKINLEY PL N E MINNEAPOLIS MN 55413 6123798854 614 MCKINLEY PLACE NE MINNEAPOLIS MN 55413 TECHNE CORP /MN/ 19920703 10-K 1 tech-20240630x10k.htm 10-K http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense00008420232024FYfalsehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpenseBIO-TECHNE Corphttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense0000842023us-gaap:StateAndLocalJurisdictionMember2024-06-300000842023us-gaap:DomesticCountryMember2024-06-300000842023us-gaap:DomesticCountryMember2024-06-300000842023srt:ExecutiveOfficerMemberus-gaap:RestrictedStockMembertech:PerformanceIncentiveProgramsMember2023-07-012024-06-300000842023srt:ExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMembertech:PerformanceIncentiveProgramsMember2022-07-012023-06-300000842023srt:ExecutiveOfficerMemberus-gaap:RestrictedStockMembertech:PerformanceIncentiveProgramsMember2022-07-012023-06-300000842023srt:ExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMembertech:PerformanceIncentiveProgramsMember2021-07-012022-06-300000842023srt:ExecutiveOfficerMemberus-gaap:RestrictedStockMembertech:PerformanceIncentiveProgramsMember2021-07-012022-06-300000842023us-gaap:CommonStockMember2023-07-012024-06-300000842023us-gaap:CommonStockMember2022-07-012023-06-300000842023us-gaap:CommonStockMember2021-07-012022-06-300000842023us-gaap:RetainedEarningsMember2024-06-300000842023us-gaap:AdditionalPaidInCapitalMember2024-06-300000842023us-gaap:RetainedEarningsMember2023-06-300000842023us-gaap:AdditionalPaidInCapitalMember2023-06-300000842023us-gaap:RetainedEarningsMember2022-06-300000842023us-gaap:NoncontrollingInterestMember2022-06-300000842023us-gaap:AdditionalPaidInCapitalMember2022-06-300000842023us-gaap:RetainedEarningsMember2021-06-300000842023us-gaap:NoncontrollingInterestMember2021-06-300000842023us-gaap:AdditionalPaidInCapitalMember2021-06-300000842023us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-06-300000842023us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-06-300000842023us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-06-300000842023us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-06-300000842023tech:The2020EquityIncentivePlanMember2024-06-300000842023tech:The2020EquityIncentivePlanMember2020-10-310000842023tech:EmployeeStockPurchasePlan2014Member2014-10-300000842023tech:The2020EquityIncentivePlanMember2010-06-300000842023srt:MaximumMembertech:The2020EquityIncentivePlanMember2009-07-012010-06-300000842023us-gaap:RestrictedStockUnitsRSUMember2024-06-300000842023us-gaap:RestrictedStockMember2024-06-300000842023us-gaap:RestrictedStockUnitsRSUMember2023-06-300000842023us-gaap:RestrictedStockMember2023-06-300000842023us-gaap:RestrictedStockUnitsRSUMember2022-06-300000842023us-gaap:RestrictedStockMember2022-06-300000842023us-gaap:RestrictedStockUnitsRSUMember2021-06-300000842023us-gaap:RestrictedStockMember2021-06-300000842023us-gaap:RestrictedStockMember2023-07-012024-06-300000842023us-gaap:RestrictedStockMember2022-07-012023-06-300000842023us-gaap:RestrictedStockMember2021-07-012022-06-300000842023us-gaap:RestrictedStockUnitsRSUMember2022-07-012023-06-300000842023us-gaap:RestrictedStockUnitsRSUMember2021-07-012022-06-300000842023us-gaap:RestrictedStockUnitsRSUMember2023-07-012024-06-300000842023tech:The2020EquityIncentivePlanMember2023-07-012024-06-300000842023us-gaap:CorporateNonSegmentMember2023-07-012024-06-300000842023us-gaap:CorporateNonSegmentMember2022-07-012023-06-300000842023us-gaap:CorporateNonSegmentMember2021-07-012022-06-300000842023us-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember2023-07-012024-06-300000842023tech:QTHoldingsCorporationMembertech:ProteinSciencesMember2023-07-012024-06-300000842023tech:NamocellIncMember2023-07-012024-06-300000842023us-gaap:OperatingSegmentsMembertech:ConsumablesMembertech:ProteinSciencesMember2023-07-012024-06-300000842023us-gaap:OperatingSegmentsMembertech:ConsumablesMembertech:OtherRevenuesFromBusinessHeldForSaleMember2023-07-012024-06-300000842023us-gaap:OperatingSegmentsMembertech:ConsumablesMembertech:DiagnosticsAndGenomicsMember2023-07-012024-06-300000842023us-gaap:OperatingSegmentsMembertech:ConsumablesMember2023-07-012024-06-300000842023us-gaap:ServiceMember2023-07-012024-06-300000842023us-gaap:RoyaltyMember2023-07-012024-06-300000842023us-gaap:IntersegmentEliminationMember2023-07-012024-06-300000842023tech:RestOfWorldMember2023-07-012024-06-300000842023tech:ProductAndServicesMember2023-07-012024-06-300000842023tech:OtherRevenuesFromBusinessHeldForSaleMember2023-07-012024-06-300000842023tech:InstrumentsMember2023-07-012024-06-300000842023tech:EMEAExcludingUKMember2023-07-012024-06-300000842023tech:ConsumablesMember2023-07-012024-06-300000842023tech:APACExcludingGreaterChinaMember2023-07-012024-06-300000842023country:US2023-07-012024-06-300000842023country:GB2023-07-012024-06-300000842023country:CN2023-07-012024-06-300000842023us-gaap:OperatingSegmentsMembertech:ConsumablesMembertech:ProteinSciencesMember2022-07-012023-06-300000842023us-gaap:OperatingSegmentsMembertech:ConsumablesMembertech:DiagnosticsAndGenomicsMember2022-07-012023-06-300000842023us-gaap:OperatingSegmentsMembertech:ConsumablesMember2022-07-012023-06-300000842023us-gaap:ServiceMember2022-07-012023-06-300000842023us-gaap:RoyaltyMember2022-07-012023-06-300000842023us-gaap:IntersegmentEliminationMember2022-07-012023-06-300000842023tech:RestOfWorldMember2022-07-012023-06-300000842023tech:ProductAndServicesMember2022-07-012023-06-300000842023tech:InstrumentsMember2022-07-012023-06-300000842023tech:EMEAExcludingUKMember2022-07-012023-06-300000842023tech:ConsumablesMember2022-07-012023-06-300000842023tech:APACExcludingGreaterChinaMember2022-07-012023-06-300000842023country:US2022-07-012023-06-300000842023country:GB2022-07-012023-06-300000842023country:CN2022-07-012023-06-300000842023tech:ChangzhouEminenceBiotechnologyMembertech:ProteinSciencesMember2022-07-012022-09-300000842023us-gaap:OperatingSegmentsMembertech:ConsumablesMembertech:ProteinSciencesMember2021-07-012022-06-300000842023us-gaap:OperatingSegmentsMembertech:ConsumablesMembertech:DiagnosticsAndGenomicsMember2021-07-012022-06-300000842023us-gaap:OperatingSegmentsMembertech:ConsumablesMember2021-07-012022-06-300000842023tech:ChangzhouEminenceBiotechnologyMembertech:ProteinSciencesMember2021-07-012022-06-300000842023us-gaap:ServiceMember2021-07-012022-06-300000842023us-gaap:RoyaltyMember2021-07-012022-06-300000842023us-gaap:IntersegmentEliminationMember2021-07-012022-06-300000842023tech:RestOfWorldMember2021-07-012022-06-300000842023tech:ProductAndServicesMember2021-07-012022-06-300000842023tech:InstrumentsMember2021-07-012022-06-300000842023tech:EMEAExcludingUKMember2021-07-012022-06-300000842023tech:ConsumablesMember2021-07-012022-06-300000842023tech:APACExcludingGreaterChinaMember2021-07-012022-06-300000842023country:US2021-07-012022-06-300000842023country:GB2021-07-012022-06-300000842023country:CN2021-07-012022-06-300000842023us-gaap:EmployeeSeveranceMember2024-06-300000842023tech:AssetRelatedAndOtherMember2024-06-300000842023us-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember2023-06-300000842023us-gaap:EmployeeSeveranceMembertech:DiagnosticsAndGenomicsMember2021-07-012022-06-300000842023tech:AssetImpairmentMembertech:DiagnosticsAndGenomicsMember2021-07-012022-06-300000842023us-gaap:EmployeeSeveranceMember2024-04-012024-06-300000842023tech:ImpairmentOfAssetsHeldForSaleMember2024-04-012024-06-300000842023tech:AssetRelatedAndOtherMember2024-04-012024-06-300000842023us-gaap:EmployeeSeveranceMember2024-01-012024-03-310000842023tech:AssetRelatedAndOtherMember2024-01-012024-03-31000084202320232024-01-012024-03-310000842023us-gaap:EmployeeSeveranceMember2023-10-012023-12-310000842023tech:ImpairmentOfAssetsHeldForSaleMember2023-10-012023-12-310000842023tech:AssetRelatedAndOtherMember2023-10-012023-12-310000842023tech:QTHoldingsCorporationMemberus-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember2022-07-012023-06-300000842023tech:QTHoldingsCorporationMembertech:AssetImpairmentMembertech:ProteinSciencesMember2022-07-012023-06-300000842023tech:QTHoldingsCorporationMemberus-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember2022-07-012022-09-300000842023tech:QTHoldingsCorporationMembertech:AssetImpairmentMembertech:ProteinSciencesMember2022-07-012022-09-300000842023tech:QTHoldingsCorporationMembertech:ProteinSciencesMember2022-07-012022-09-300000842023tech:EmployeeSeveranceOnRelocationOfUSPlantMember2021-10-012021-12-310000842023us-gaap:EmployeeSeveranceMembertech:DiagnosticsAndGenomicsMember2021-07-012021-09-300000842023tech:AssetImpairmentMembertech:DiagnosticsAndGenomicsMember2021-07-012021-09-300000842023tech:DiagnosticsAndGenomicsMember2021-07-012021-09-30000084202320232023-10-012023-12-310000842023srt:MinimumMemberus-gaap:EquipmentMember2024-06-300000842023srt:MinimumMembertech:BuildingBuildingImprovementsAndLeaseholdImprovementsMember2024-06-300000842023srt:MaximumMemberus-gaap:EquipmentMember2024-06-300000842023srt:MaximumMembertech:BuildingBuildingImprovementsAndLeaseholdImprovementsMember2024-06-300000842023us-gaap:MachineryAndEquipmentMember2024-06-300000842023us-gaap:LandMember2024-06-300000842023us-gaap:ConstructionInProgressMember2024-06-300000842023us-gaap:BuildingAndBuildingImprovementsMember2024-06-300000842023us-gaap:MachineryAndEquipmentMember2023-06-300000842023us-gaap:LandMember2023-06-300000842023us-gaap:ConstructionInProgressMember2023-06-300000842023us-gaap:BuildingAndBuildingImprovementsMember2023-06-300000842023tech:ChangzhouEminenceBiotechnologyMember2022-09-012022-09-010000842023tech:SpearBioMemberus-gaap:SubsequentEventMember2024-07-232024-07-230000842023tech:WilsonWolfCorporationMember2023-03-312023-03-310000842023tech:WilsonWolfCorporationMember2021-12-012021-12-310000842023tech:NamocellIncMember2022-07-012022-07-010000842023tech:QTHoldingsCorporationMemberus-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember2022-10-012023-06-300000842023tech:QTHoldingsCorporationMembertech:AssetImpairmentMembertech:ProteinSciencesMember2022-10-012023-06-300000842023tech:QTHoldingsCorporationMembertech:ProteinSciencesMember2022-10-012023-06-300000842023us-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember2022-07-012023-06-300000842023us-gaap:EmployeeSeveranceMembertech:DiagnosticsAndGenomicsMember2021-10-012022-06-300000842023tech:AssetImpairmentMembertech:DiagnosticsAndGenomicsMember2021-10-012022-06-300000842023tech:DiagnosticsAndGenomicsMember2021-10-012022-06-300000842023us-gaap:NoncontrollingInterestMember2021-07-012022-06-300000842023tech:ChangzhouEminenceBiotechnologyMember2022-07-012023-06-300000842023us-gaap:StateAndLocalJurisdictionMembertech:OperatingLossCarryforwardsMember2024-06-300000842023us-gaap:ForeignCountryMembertech:OperatingLossCarryforwardsMember2024-06-300000842023us-gaap:DomesticCountryMembertech:OperatingLossCarryforwardsMember2024-06-300000842023us-gaap:OperatingSegmentsMembertech:ProteinSciencesMember2023-07-012024-06-300000842023us-gaap:OperatingSegmentsMembertech:DiagnosticsAndGenomicsMember2023-07-012024-06-300000842023us-gaap:OperatingSegmentsMember2023-07-012024-06-300000842023us-gaap:OperatingSegmentsMembertech:ProteinSciencesMember2022-07-012023-06-300000842023us-gaap:OperatingSegmentsMembertech:DiagnosticsAndGenomicsMember2022-07-012023-06-300000842023us-gaap:OperatingSegmentsMember2022-07-012023-06-300000842023us-gaap:OperatingSegmentsMembertech:ProteinSciencesMember2021-07-012022-06-300000842023us-gaap:OperatingSegmentsMembertech:DiagnosticsAndGenomicsMember2021-07-012022-06-300000842023us-gaap:OperatingSegmentsMember2021-07-012022-06-300000842023srt:ExecutiveOfficerMembertech:PerformanceIncentiveProgramsMember2023-07-012024-06-300000842023srt:ExecutiveOfficerMembertech:PerformanceIncentiveProgramsMember2022-07-012023-06-300000842023srt:ExecutiveOfficerMembertech:PerformanceIncentiveProgramsMember2021-07-012022-06-300000842023us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2023-07-012024-06-300000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMember2023-07-012024-06-300000842023us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012024-06-300000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012024-06-300000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-07-012024-06-300000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMember2022-07-012023-06-300000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-07-012023-06-300000842023us-gaap:AccumulatedTranslationAdjustmentMember2022-07-012023-06-300000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMember2021-07-012022-06-300000842023us-gaap:AccumulatedTranslationAdjustmentMember2021-07-012022-06-300000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012022-06-300000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-07-012022-06-300000842023tech:CreditAgreementMember2024-06-300000842023us-gaap:RevolvingCreditFacilityMembertech:CreditAgreementMember2022-08-012022-08-310000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023tech:ExchangedTradedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300000842023tech:ExchangedTradedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300000842023tech:ExchangeTradedInvestmentGradeBondFundsMember2023-06-300000842023tech:UnitedStatesAndCanadaMember2024-06-300000842023srt:EuropeMember2024-06-300000842023srt:AsiaMember2024-06-300000842023tech:UnitedStatesAndCanadaMember2023-06-300000842023srt:EuropeMember2023-06-300000842023srt:AsiaMember2023-06-300000842023tech:ChangzhouEminenceBiotechnologyMember2021-07-012022-06-300000842023tech:DiagnosticsAndGenomicsMember2022-07-012023-06-300000842023tech:ProteinSciencesMember2024-06-300000842023tech:DiagnosticsAndGenomicsMember2024-06-300000842023tech:ProteinSciencesMember2023-06-300000842023tech:DiagnosticsAndGenomicsMember2023-06-300000842023tech:ProteinSciencesMember2022-06-300000842023tech:DiagnosticsAndGenomicsMember2022-06-30000084202320232022-07-012022-09-300000842023srt:MinimumMembertech:LunaphoreTechnologiesSaMemberus-gaap:TradeNamesMember2024-06-300000842023srt:MinimumMemberus-

gaap:TradeNamesMember2024-06-300000842023srt:MinimumMemberus-gaap:OtherIntangibleAssetsMember2024-06-300000842023srt:MinimumMemberus-gaap:DevelopedTechnologyRightsMember2024-06-300000842023srt:MinimumMemberus-gaap:CustomerRelationshipsMember2024-06-300000842023srt:MaximumMemberus-gaap:TradeNamesMember2024-06-300000842023srt:MaximumMemberus-gaap:OtherIntangibleAssetsMember2024-06-300000842023srt:MaximumMemberus-gaap:DevelopedTechnologyRightsMember2024-06-300000842023srt:MaximumMemberus-gaap:CustomerRelationshipsMember2024-06-300000842023us-gaap:InProcessResearchAndDevelopmentMember2024-06-300000842023srt:MinimumMember2024-06-300000842023srt:MaximumMember2024-06-300000842023tech:AcquisitionOfAsuragenIncMemberus-gaap:DevelopedTechnologyRightsMember2023-06-300000842023tech:AcquisitionOfAsuragenIncMemberus-gaap:CustomerRelationshipsMember2023-06-300000842023tech:AcquisitionOfAsuragenIncMembertech:TradeNamesNonCompeteAgreementsMember2023-06-300000842023srt:MinimumMemberus-gaap:TradeNamesMember2023-06-300000842023srt:MinimumMemberus-gaap:OtherIntangibleAssetsMember2023-06-300000842023srt:MinimumMemberus-gaap:DevelopedTechnologyRightsMember2023-06-300000842023srt:MinimumMemberus-gaap:CustomerRelationshipsMember2023-06-300000842023srt:MaximumMemberus-gaap:TradeNamesMember2023-06-300000842023srt:MaximumMemberus-gaap:OtherIntangibleAssetsMember2023-06-300000842023srt:MaximumMemberus-gaap:DevelopedTechnologyRightsMember2023-06-300000842023srt:MaximumMemberus-gaap:CustomerRelationshipsMember2023-06-300000842023tech:WilsonWolfCorporationMember2023-06-300000842023us-gaap:TradeNamesMember2024-06-300000842023us-gaap:PatentsMember2024-06-300000842023us-gaap:OtherIntangibleAssetsMember2024-06-300000842023us-gaap:DevelopedTechnologyRightsMember2024-06-300000842023us-gaap:CustomerRelationshipsMember2024-06-300000842023us-gaap:TradeNamesMember2023-06-300000842023us-gaap:PatentsMember2023-06-300000842023us-gaap:OtherIntangibleAssetsMember2023-06-300000842023us-gaap:DevelopedTechnologyRightsMember2023-06-300000842023us-gaap:CustomerRelationshipsMember2023-06-300000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2023-06-300000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2022-06-300000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2023-07-012024-06-300000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2022-07-012023-06-300000842023tech:WilsonWolfCorporationMember2023-03-310000842023us-gaap:RetainedEarningsMember2023-07-012024-06-300000842023us-gaap:RetainedEarningsMember2022-07-012023-06-300000842023us-gaap:RetainedEarningsMember2021-07-012022-06-300000842023tech:CurrentAssetsHeldForSaleMembertech:ProteinSciencesMember2024-06-300000842023tech:ProteinSciencesMember2023-12-310000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-05-310000842023us-gaap:OtherNoncurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:OtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:OtherNoncurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:OtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:OtherNoncurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300000842023us-gaap:OtherNoncurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300000842023us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-06-300000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-06-300000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-06-300000842023us-gaap:NetInvestmentHedgingMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023tech:USProfitSharingAndSavingsPlanMember2023-07-012024-06-300000842023tech:GBProfitSharingAndSavingsPlanMember2023-07-012024-06-300000842023tech:USProfitSharingAndSavingsPlanMember2022-07-012023-06-300000842023tech:GBProfitSharingAndSavingsPlanMember2022-07-012023-06-300000842023tech:USProfitSharingAndSavingsPlanMember2021-07-012022-06-300000842023tech:GBProfitSharingAndSavingsPlanMember2021-07-012022-06-300000842023tech:TaxCreditCarryforwardsMember2024-06-300000842023tech:OperatingLossCarryforwardsMember2024-06-300000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000842023us-gaap:CommonStockMember2024-06-300000842023us-gaap:CommonStockMember2023-06-300000842023us-gaap:CommonStockMember2022-06-300000842023us-gaap:CommonStockMember2021-06-30000084202322022-10-28000084202322022-10-27000084202322022-06-30000084202322021-06-300000842023tech:LunaphoreTechnologiesSaMemberus-gaap:TradeNamesMember2024-06-300000842023tech:LunaphoreTechnologiesSaMemberus-gaap:DevelopedTechnologyRightsMember2024-06-300000842023tech:LunaphoreTechnologiesSaMemberus-gaap:CustomerRelationshipsMember2024-06-300000842023tech:LunaphoreTechnologiesSaMemberus-gaap:TradeNamesMember2023-07-070000842023tech:LunaphoreTechnologiesSaMemberus-gaap:DevelopedTechnologyRightsMember2023-07-070000842023tech:LunaphoreTechnologiesSaMemberus-gaap:CustomerRelationshipsMember2023-07-070000842023tech:NamocellIncMemberus-gaap:TradeNamesMember2023-06-300000842023tech:NamocellIncMemberus-gaap:NoncompeteAgreementsMember2023-06-300000842023tech:NamocellIncMemberus-gaap:DevelopedTechnologyRightsMember2023-06-300000842023tech:NamocellIncMemberus-gaap:CustomerRelationshipsMember2023-06-300000842023us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300000842023tech:AcquisitionOfAsuragenIncMember2023-06-300000842023tech:AcquisitionOfAsuragenIncMember2021-04-060000842023tech:NamocellIncMember2023-12-310000842023tech:AcquisitionOfAsuragenIncMember2023-12-310000842023tech:NamocellIncMember2022-07-010000842023tech:LunaphoreTechnologiesSaMember2023-07-072023-07-070000842023us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300000842023us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300000842023us-gaap:FairValueMeasurementsRecurringMember2023-06-300000842023us-gaap:SellingGeneralAndAdministrativeExpensesMembertech:ProteinSciencesMember2023-10-012023-12-310000842023tech:ChangzhouEminenceBiotechnologyMember2021-07-012022-06-300000842023us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember2023-07-012024-06-300000842023tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012024-06-300000842023us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember2022-07-012023-06-300000842023tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012023-06-300000842023us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember2021-07-012022-06-300000842023tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012022-06-300000842023tech:EmployeeStockPurchasePlan2014Member2023-07-012024-06-300000842023us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012023-06-300000842023us-gaap:CostOfSalesMember2022-07-012023-06-300000842023tech:EmployeeStockPurchasePlan2014Member2022-07-012023-06-300000842023us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012022-06-300000842023us-gaap:CostOfSalesMember2021-07-012022-06-300000842023tech:EmployeeStockPurchasePlan2014Member2021-07-012022-06-300000842023us-gaap:AdditionalPaidInCapitalMember2023-07-012024-06-300000842023us-gaap:AdditionalPaidInCapitalMember2022-07-012023-06-300000842023us-gaap:AdditionalPaidInCapitalMember2021-07-012022-06-300000842023us-gaap:EmployeeSeveranceMemberus-gaap:CorporateMember2023-07-012024-06-300000842023us-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember2023-07-012024-06-300000842023us-gaap:EmployeeSeveranceMembertech:DiagnosticsAndGenomicsMember2023-07-012024-06-300000842023tech:ImpairmentOfAssetsHeldForSaleMembertech:ProteinSciencesMember2023-07-012024-06-300000842023tech:AssetRelatedAndOtherMemberus-gaap:CorporateMember2023-07-012024-06-300000842023tech:AssetRelatedAndOtherMembertech:ProteinSciencesMember2023-07-012024-06-300000842023tech:AssetRelatedAndOtherMembertech:DiagnosticsAndGenomicsMember2023-07-012024-06-300000842023us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012024-06-300000842023us-gaap:EmployeeSeveranceMember2023-07-012024-06-300000842023us-gaap:CostOfSalesMember2023-07-012024-06-300000842023us-gaap:CorporateMember2023-07-012024-06-300000842023tech:ImpairmentOfAssetsHeldForSaleMember2023-07-012024-06-300000842023tech:DiagnosticsAndGenomicsMember2023-07-012024-06-300000842023tech:AssetRelatedAndOtherMember2023-07-012024-06-300000842023us-gaap:SellingGeneralAndAdministrativeExpensesMembertech:DiagnosticsAndGenomicsMember2022-07-012023-06-300000842023us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMembertech:DiagnosticsAndGenomicsMember2021-07-012022-06-300000842023us-gaap:SellingGeneralAndAdministrativeExpensesMembertech:AssetImpairmentMembertech:DiagnosticsAndGenomicsMember2021-07-012022-06-300000842023tech:QTHoldingsCorporationMembertech:ProteinSciencesMember2022-07-012023-06-300000842023tech:ProteinSciencesMember2022-07-012023-06-300000842023tech:DiagnosticsAndGenomicsMember2021-07-012022-06-300000842023us-gaap:NoncontrollingInterestMember2022-07-012023-06-300000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012023-06-300000842023us-gaap:RevolvingCreditFacilityMembertech:CreditAgreementMember2022-08-310000842023us-gaap:OtherNoncurrentAssetsMember2024-06-300000842023us-gaap:OtherNoncurrentAssetsMember2023-06-300000842023tech:ProteinSciencesMember2023-07-012024-06-300000842023tech:WilsonWolfCorporationMember2024-06-300000842023tech:WilsonWolfCorporationMembertech:FirstPartOfForwardContractMember2023-03-310000842023tech:WilsonWolfCorporationMembertech:SecondPartOfForwardContractMember2024-06-300000842023tech:WilsonWolfCorporationMember2022-07-012023-06-300000842023us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300000842023us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300000842023tech:LunaphoreTechnologiesSaMember2024-06-300000842023tech:LunaphoreTechnologiesSaMember2023-07-070000842023tech:NamocellIncMember2023-06-300000842023tech:LunaphoreTechnologiesSaMember2023-07-012024-06-300000842023tech:NamocellIncMember2022-07-012023-06-300000842023202302024-06-300000842023202302023-06-300000842023202302022-07-012023-06-300000842023202301-07-012022-06-300000842023202302024-04-012024-06-300000842023202312-31000084202322024-08-160000842023202307-012024-06-30xbrli:sharesiso4217:USDtech:itemxbrli:pureiso4217:USDxbrli:sharestech:segmentTable of Contentsâ€‹â€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, DC 20549FORMÂ 10-Kâ€‹â€‹â˜’ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934â€‹â€‹For the fiscal year ended June 30, 2024,
orâ€‹â€‹â˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the transition periodfrom Â toCommission file number 0-17272BIO-TECHNE CORPORATION(Exact name of registrant as specified in its charter)â€‹MinnesotaÂ 41-1427402(State or other jurisdiction ofincorporation or organization)Â (I.R.S. EmployerIdentification No.)Â Â 614 McKinley Place N.E.Minneapolis, MN 55413Â (612) 379-8854(Address of principal executive offices) (Zip Code)Â (Registrantâ€™s telephone number, including area code)â€‹Securities registered pursuant to SectionÂ 12(b)Â of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, $0.01 par valueTECHThe NASDAQ Stock Market LLCâ€‹Securities registered pursuant to SectionÂ 12(g)Â of the Act: NoneIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in RuleÂ 405 of the Securities Act. Â Â Yes â˜Â Â No â˜Indicate by check mark if the registrant is not required to file reports pursuant to SectionÂ 13 or SectionÂ 15(d)Â of the Act. Â YesÂ â˜Â Â NoÂ â˜Indicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. Â Â Yes â˜Â Â No â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files). Â Â Yes â˜Â Â No â˜Indicate by check mark if disclosure of delinquent filers pursuant to ItemÂ 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrantâ€™s knowledge, in definitive proxy or information statements incorporated by reference in PartÂ III of this FormÂ 10-K or any amendment to this FormÂ 10-K. Â Â â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ andâ€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act. (Check one):Â Large accelerated filerâ˜Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

â€œCompanyâ€ refer to Bio-Techne Corporation, Bio-Techne Corporation and its consolidated subsidiaries, or the consolidated subsidiaries of Bio-Techne Corporation, as the context requires.FORWARD-LOOKING INFORMATION AND CAUTIONARY STATEMENTSCertain statements included or incorporated by reference in this Annual Report, in other documents we file with or furnish to the Securities and Exchange Commission (â€œSECâ€), in our press releases, webcasts, conference calls, materials delivered to shareholders and other communications, are â€œforward-looking statementsâ€ within the meaning of the U.S. federal securities laws. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding: projections of revenue, expenses, profit, profit margins, pricing, tax rates, tax provisions, cash flows, our liquidity position or other projected financial measures; managementâ€™s plans and strategies for future operations, including statements relating to anticipated operating performance, cost reductions, new product and service developments, competitive strengths or market position, acquisitions and the integration thereof, strategic opportunities, dividends and executive compensation; growth, declines and other trends in markets we sell into; new or modified laws, regulations and accounting pronouncements; future regulatory approvals and the timing and conditionality thereof; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; future foreign currency exchange rates and fluctuations in those rates; general economic and capital markets conditions; the anticipated timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that Bio-Techne intends or believes will or may occur in the future. Terminology such as â€œbelieve,â€ â€œanticipate,â€ â€œshould,â€ â€œcould,â€ â€œintend,â€ â€œwill,â€ â€œplan,â€ â€œexpect,â€ â€œestimate,â€ â€œproject,â€ â€œtarget,â€ â€œmay,â€ â€œpossible,â€ â€œpotential,â€ â€œforecastâ€ and â€œpositionedâ€ and similar references to future periods are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. Forward-looking statements are based on assumptions and assessments made by our management in light of their experience and perceptions of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements are subject to a number of risks and uncertainties, including but not limited to the risks and uncertainties set forth below and under â€œItemÂ 1A. Risk Factorsâ€ in this Annual Report.Forward-looking statements are not guaranties of future performance and actual results may differ materially from the results, developments and business decisions contemplated by our forward-looking statements. Accordingly, you should not place undue reliance on any such forward-looking statements. Forward-looking statements speak only as of the date of the report, document, press release, webcast, call, materials or other communication in which they are made. Except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.Investment in our securities involves risk and uncertainty and you should carefully consider all information in this Annual Report on FormÂ 10-K prior to making an investment decision regarding our securities. Below is a summary of material risks and uncertainties we face, which are discussed more fully in â€œItemÂ 1A. Risk Factorsâ€:Economic and Industryâ—Conditions in the global economy, the particular markets we serve and the financial markets, whether brought about by material global crises or other factors, may adversely affect our business and financial results.â€‹â—International political, compliance and business factors, including the military conflict in Ukraine, Israelâ€™s conflict in Gaza, and trade tensions between the U.S. and China, can negatively impact our operations and financial results.â€‹â—The healthcare and life sciences industries that we serve face constant pressures and changes in an effort to reduce healthcare costs or increase their predictability, all of which may adversely affect our business and financial results.â€‹3 Table of ContentsAcquisition and Investment Risksâ—Our inability to complete acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, could negatively impact our growth rate and stock price.â€‹â—Our acquisition of businesses, investments, joint ventures and other strategic relationships, if not properly implemented or integrated, could negatively impact our business and financial results.â€‹â—We may be required to record a significant charge to earnings if our goodwill and other amortizable intangible assets or other investments become impaired, which could negatively impact our financial results or stock price.â€‹Strategic and Operational Risksâ—Our success will be dependent on recruiting and retaining highly qualified and diverse personnel and creating and maintaining a culture that successfully integrates the employees joining through acquisitions.â€‹â—Our growth depends in part on the timely development and commercialization of new and enhanced products and services that meet our customersâ€™ needs. Our growth can also be negatively impacted if our customers do not grow as anticipated.â€‹â—We face intense competition, and if we are unable to compete effectively, we may experience decreased demand and decreased market share or need to reduce prices to remain competitive.â€‹â—A significant disruption in, or breach of security of, our information technology systems or data, or violation of data privacy laws, could result in damage to our reputation, data integrity, and/or subject us to costs, fines, or lawsuits under data privacy or other laws or contractual requirements.â€‹â—If we suffer a loss to our supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed.â€‹â—The manufacture of many of our products is a complex process, and if we directly or indirectly encounter problems manufacturing products, our business and financial results could suffer.â€‹â—If we cannot adjust our manufacturing capacity or the purchases required for our manufacturing activities to reflect changes in market conditions or customer demand, our business and financial results may suffer. In addition, our reliance upon sole or limited sources of supply for certain materials, components and services can cause production interruptions, delays and inefficiencies.â€‹â—The Company relies heavily on internal manufacturing and related operations to produce, package and distribute its products which, if disrupted, could materially impair our business operations. Our business could be adversely affected by disruptions at our sites.â€‹â—Climate change and related environmental risks, or legal or regulatory measures to address climate change and/or related environmental risks, may negatively affect us.â—Defects, unanticipated use of or inadequate disclosure with respect to our products, or allegations thereof, can adversely affect our business and financial results.â€‹â—Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability.â€‹4 Table of ContentsIntellectual Property Risksâ—We are dependent on maintaining our intellectual property rights. If we are unable to adequately protect our intellectual property, or if third parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights.â€‹â—We may be involved in disputes to determine the scope, coverage and validity of othersâ€™ proprietary rights, or to defend against third-party claims of intellectual property infringement, any of which could be time-intensive and costly and may adversely impact our business.â€‹Financial and Tax Risksâ—We have entered into and drawn on a revolving credit facility, and we may incur additional debt in the future. The burden of this additional debt could adversely affect us, make us more vulnerable to adverse economic or industry conditions, and prevent us from funding our expansion strategy.â€‹â—Our business and financial results can be adversely affected by foreign currency exchange rates, changes in our tax rates, and tax liabilities and assessments (including as a result of changes in tax laws).â€‹â—Dividends on our common stock could be reduced or eliminated in the future.â€‹Legal, Regulatory, Compliance and Reputational Risksâ—Our business is subject to extensive regulation; failure to comply with these regulations could adversely affect our business and financial results.â€‹â—Significant developments or changes in U.S. laws or policies, including changes in U.S. trade policies and tariffs and the reaction of other countries thereto, can have an adverse effect on our business and financial results.â€‹â—Our business and financial results can be impaired by improper conduct of any of our employees, agents, or business partners.â€‹â—Certain of our businesses are subject to extensive regulation by the U.S. FDA and the USDA and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the healthcare industry and the privacy and security of health information. Failure to comply with those regulations could adversely affect our business and financial results.â€‹â—Failure to comply with privacy and security laws and regulations could result in fines, penalties and damage to the Companyâ€™s reputation and have a material adverse effect upon the Companyâ€™s business, a risk that has been elevated with recent acquisitions that use protected health information and utilize healthcare providers for laboratory testing services.â€‹5 Table of ContentsPARTÂ IITEMÂ 1. BUSINESSOVERVIEWBio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (Bio-Techne, we, our, us or the Company), develop, manufacture and sell life science reagents, instruments and services for the research,Â diagnostics and bioprocessingÂ markets worldwide. With our broad product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.We manage the business in two operating segmentsÂ â€“ our Protein Sciences segment and our Diagnostics and Genomics segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for protein analysis, automated western blot, and multiplexed ELISA workflows. Our Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-basedÂ molecular diagnosticÂ assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications.We are a Minnesota corporation with our global headquarters in Minneapolis, Minnesota. We were founded in 1976 as Research and Diagnostic Systems,Â Inc. We became a publicly traded company in 1985 through a merger with Techne Corporation, now Bio-Techne Corporation. Our common stock is listed on the NASDAQ under the symbol â€œTECH.â€ We operate globally, with offices in many locations throughout North America, Europe and Asia. Today, our product lines include hundreds of thousands of diverse products, most of which we manufacture ourselves in multiple locations in North America, as well as a location each in the U.K. and China.Our historical focus was on providing high quality proteins, antibodies and immunoassays to the life science research market and hematology controls to the diagnostics market. Since 2013, we have been implementing a disciplined strategy to accelerate growth in part by acquiring businesses and product portfolios that leveraged and diversified our existing product lines, filled portfolio gaps with differentiated high growth businesses, and expanded our geographic scope.Â From fiscalÂ years 2013 through 2024Â we have acquired, agreed to acquire, or made investments in twenty companies that have expanded the product offerings and geographic footprint of both operatingÂ segments, including the acquisition of Lunaphore SA (â€œLunaphoreâ€) at the beginning of fiscal year 2024. We also completed a 19.9% investment in Wilson Wolf Corporation (â€œWilson Wolfâ€) in fiscal year 2023, and will acquire the remaining ownership in Wilson Wolf by the end of calendar year 2027, if not earlier due to its achievement of revenue or earnings before interest, taxes, depreciation, and amortization (â€œEBITDAâ€) targets. Additionally, subsequent to fiscal 2024, we made an investment in Spear Bio, which is a leader in the development and manufacturing of ultra-sensitive immunoassays capable of measuring protein biomarkers at attomolar level from sub-microliter sample volume. Recognizing the importance of an integrated, global approach to meeting our mission and accomplishing our strategies, we have maintained many of the brands of the companies we have acquired, but unified under a single global brandÂ -- Bio-Techne.We are committed to providing the life sciences community with innovative, high-quality scientific tools that allow our customers to make extraordinary discoveries and treat and diagnose diseases. We intend to build on Bio-Techneâ€™s past accomplishments, high product quality reputation and sound financial position by executing strategies that position us to serve as the standard for biological content in the research market, and to leverage that leadership position to enter the diagnostics and other adjacent markets. Our strategic pillars include:Grow & Leverage the Core. Through collaborations with key opinion leaders, participation in scientific discussions and societies, and leveraging our internal talent we expect to be able to convert our continued significant investment in our research and development activities to be first-to-market with quality products that are at the leading edge of life science researchersâ€™ needs.6 Table of ContentsCapitalize on High Potential Markets. We will continue to leverage our strong balance sheet to gain access to new and differentiated technologies and products that improve our competitiveness in the current market, meet customersâ€™ expanding workflow needs and allow us to enter adjacent markets.Market Expansion Through Innovation & Acquisition. We will leverage our existing portfolio to expand our product offerings into novel research fields and further penetrate diagnostics and therapeutics markets. Acquisitions have, and will likely continue to play, an important role in our efforts to expand our portfolio of innovative tools and bioactive reagents, and support our initiatives to enter adjacent markets.Deliver Best-in-Class Customer Experience. We will continue to expand our sales staff and distribution channels globally in order to increase our global presence and make it easier for customers to transact with us. We strive for every interaction to be seamless, personalized, and exceeding expectations. We aim to deeply understand customers wants and needs while simultaneously offering high-quality service at every touchpoint. Develop People Through a Transofrmative Culture. As we continue to grow both organically and through acquisition, we are intentionally fostering an â€œEPICâ€ culture based on the ideals of Empowerment, Passion, Innovation and Collaboration. We strive to recruit, train and retain the most talented staff, who share these EPIC ideals to effectively implement our global strategies.PROTEIN SCIENCES SEGMENTProtein Sciences Segment Products and MarketsThe Protein Sciences segment is the larger of our two segments, representing approximately 72% of our net sales in fiscal 2024. It is comprised of two divisions with complementary product offerings serving many of the same customersÂ â€“ the Reagent Solutions division and the Analytical Solutions division.The Reagent Solutions division consists of specialized proteins, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera and cell selection technologies traditionally used by researchers to further their life science experimental activities and by companies developing next generation diagnostics and therapeutics, including companies developing cell- and gene-based therapeutics. We believe we are the world leader in providing high quality proteins, both for research use and under current Good Manufacturing Practices, or cGMP. Key product brands include R&D Systems, Tocris Biosciences and Novus Biologicals.Â Our combined chemical and biological reagents portfolio provides high quality tools that customers can use in solving complex biological pathways and glean knowledge that may lead to a more complete understanding of biological processes, and, ultimately, to the development of novel therapeutic strategies to address different pathologies. In recent years, we have made several acquisitions and investments that have expanded our product offerings for the cell and gene therapy market. Â These include a significant investment in state-of-the art facilities for production of both proteins and small molecules in large quantities manufactured in accordance with cGMP, as well as a 19.9% investment in â€“ and eventual acquisition of â€“ Wilson Wolf, which is a leading provider of cell culture devices for cell-based therapies. Â Through a collaborative marketing venture with Wilson Wolf and another company, we have leveraged the products we have or are developingÂ to provide a more complete offering for the cell and gene therapy market.The Analytical Solutions division includes manual and automated protein analysis instruments and immunoassays that are used in quantifying proteins in a variety of biological fluids. Products in this division include traditional manual plate-based immunoassays, fully automated multiplex immunoassays on various instrument platforms, and automated western blotting and isoelectric focusing analysis of complex protein samples. Key product brands include R&D Systems and ProteinSimple. A number of our products have been demonstrated to have the potential to serve as predictive biomarkers and therapeutic targets for a variety of human diseases and conditions including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. Immunoassays can also be useful in clinical diagnostics. In fact, we have received Food and Drug Administration (FDA) marketing clearance for a few of our immunoassays for use as in vitro diagnostic devices.Â 7 Table of ContentsProtein Sciences Segment Customers and Distribution MethodsOur customers for this segment include researchers in academia and industry (chiefly pharmaceutical and biotech companies as well as contract research organizations). This segment also sells to diagnostic/companion diagnostic and therapeutic customers, especially customers engaged in the development of cell- and gene-based therapies.Â Our biologics line of products in the Analytical Solutions division is used chiefly by production and quality control departments at biotech and pharmaceutical companies. We sell our products directly to customers who are primarily located in North America, Europe and China, as well as through a distribution agreement with Thermo Fisher Scientific. We also sell through third party distributors in China, Japan, certain eastern European countries and the rest of the world. Our sales are widely distributed, and no single end-user customer accounted for more than 10% of the Protein Sciences segmentâ€™s net sales during fiscal 2024, 2023, or 2022.DIAGNOSTICS AND GENOMICS SEGMENTThe Diagnostics and Genomics segment, representing approximately 28% of our net revenues in fiscal 2024, includes three divisions and is focused primarily on the diagnostic and research markets and includes spatial biology, liquid biopsy, molecular diagnostics kits and products, and diagnostics reagents.Diagnostics and Genomics Segment ProductsThe Spatial Biology division products sold under the Advanced Cell Diagnostics, or ACD, brand, are novel in-situ hybridization (ISH) assays for transcriptome, DNA copy, and structural variation analysis within intact cells, providing highly sensitive and specific spatial information at single cell resolution. Since these products preserve spatial context, they are particularly useful for complex tissue profiling. In the first quarter of fiscal year 2024, we closed on the acquisition of Lunaphore, a leading developer of fully automated spatial biology solutions using precision microfluidic technology capable of revealing hyperplex proteomic and transcriptomic biomarkers in tumors and other tissues at single-cell and subcellular resolution. Lunaphoreâ€™s COMET instrument automates ACDâ€™s RNAscope assays and utilizies antibodies to enable simultaneous hyperplex detection of protein and RNA biomarkers on the same slide at single-cell resolution.The Molecular Diagnostics division markets and sells products and services under the Exosome Diagnostics and Asuragen brands. Â The Exosome Diagnostics brand is based on exosome-based liquid biopsy techniques that analyze genes or their transcripts. Â It includes the ExoDx Prostate test, which is a urine-based assay for early detection of high-grade

prostate cancer used as an aid in deciding the need for biopsy in men with grey-zone prostate specific antigen (PSA) scores. ExoDX Prostate is offered by Exosome Diagnostics as a lab-developed test. We have also licensed exclusively the ExoTRU kidney transplant rejection test to Thermo Fisher Scientific. We also sell products for genetic carrier screening, oncology diagnostics, molecular controls,Â and research under the Asuragen brand. The Diagnostic Reagents division consists of regulated products traditionally used as calibrators and controls in the clinical setting. Also included are instrument and process control products for hematology, blood chemistry, blood gases, coagulation controls and reagents used in various diagnostic applications. We often manufacture these reagents on a custom basis, tailored to a customerâ€™s specific diagnostic assay technology. We supply these reagents in various formats including liquid, frozen, or inÂ lyophilized form. Most of these products are sold on an Original Equipment Manufacturer (OEM) basis to instrument manufacturers, with most products beingÂ FDA-cleared.Diagnostics and Genomics Segment Customers and Distribution MethodsThe customers for the Spatial Biology division include researchers in academia as well asÂ investigators inÂ pharmaceutical and biotech companies. We sell our products directly to those customers who are primarily located in North America, Europe, and China, and through distributors elsewhere. In addition to being useful research tools, our DNA and RNA in situ hybridization (ISH) assays have diagnostics applications as well, and several are cleared or currently under review by the FDA in partnership with diagnostics instrument manufacturers and pharmaceutical companies. In the United States, we offer the ExosomeDx Prostate test to physicians using our lab-developed non-invasive urine-based assay for prostate cancer detection. Our diagnostic laboratory is certified under and regulated by the State of Massachusetts pursuant to the Clinical Laboratory Improvement Amendments, or CLIA. We reach our customers through physicians prescribing such tests for their patients. This test is also available in Europe as a CE-marked product. The Asuragen-8 Table of Contentsbranded products are sold primarily to laboratories for use in lab-developed tests or in kit form as regulated diagnostic tests.The majority of Diagnostic Reagents Divisionâ€™s sales are throughÂ OEM agreements, but we sell some of our diagnostic reagent products directly to customers and, in Europe and Asia, also through distributors. No customer accounted forÂ 10% or more of the reporting segmentâ€™sÂ consolidated net sales during fiscalÂ years 2024, 2023 or 2022.MANUFACTURING AND MATERIALSOur manufacturing operations use a wide variety of raw materials and components, including electronic components, chemicals and biological materials. No single supplier is material, although for some components that require particular specifications or regulatory or other qualifications there may be a single supplier or a limited number of suppliers that can readily provide such components. We utilize a number of techniques to address potential disruption in and other risks relating to our supply chain, which in certain cases includes the use of safety stock, alternative materials, and qualification of multiple supply sources.The majority of our products are shipped within one day of receipt of the customersâ€™ orders, other than our instruments and related cartridges, which are typically shipped within one to two weeks of receipt of an order. There was no significant backlog of orders for our products as of the date of this Annual Report on FormÂ 10-K or as of a comparable date. For additional discussion of risks relating to supply chain and manufacturing, refer to â€œItemÂ 1A. Risk Factors.â€COMPETITIONAlthough our segments both generally operate in highly competitive markets, it is difficult to determine our competitive position, either in the aggregate or by segment, since none of our competitors offer all of the same product and service lines or serve all of the same markets as the Company, or any of its segments, does. Because of the range of the products and services we sell, we encounter a wide variety of competitors, including a number of large, global companies or divisions of such companies with substantial capabilities and resources, as well a number of smaller, niche competitors with specialized product offerings. We have seen increased competition in a number of our markets as a result of the entry of new companies into certain markets, the entry of competitors based in low-cost manufacturing locations, and increasing consolidation in particular markets. The number of competitors varies by product line. Key competitive factors vary among the Companyâ€™s businesses, but include the specific factors noted above with respect to each particular business and typically also include price, quality and safety, performance, delivery speed, application expertise, service and support, technology and innovation, distribution network, breadth of product, service and software offerings, and brand name recognition. We believe our competitive position is strong due to the unique aspects of many of our products and our product quality. Â For a discussion of risks related to competition, refer to â€œItemÂ 1A. Risk Factors.â€SEASONALITY OF BUSINESSBio-Techne believes there is some seasonality as a result of vacation and academic schedules of its worldwide customer base, particularly for the Protein Sciences segment. Â There is also some seasonality for the ExosomeDx Prostate test, as patients tend to avoid scheduling medical appointments during the summer and other holidays. Â A majority of Diagnostics Reagents division products are manufactured in large bulk lots and sold on a schedule set by the customer. Consequently, sales for that division can be unpredictable, and not necessarily based on seasonality. As a result, we can experience material and sometimes unpredictable fluctuations in our revenue from the Diagnostics and Genomics segment.GOVERNMENT CONTRACTSAlthough the Company transacts business with various government entities, no government contract is of such magnitude that renegotiation of profits or termination of the contract at the election of the government entity would have a material adverse effect on the Companyâ€™s financial results. As a party to these contracts, Bio-Techne does have to comply with 9 Table of Contentscertain regulations that apply to companies doing business with governments. For a discussion of risks related to government contracting requirements, see â€œItem 1A. Risk Factors.â€ NEW PRODUCTS AND RESEARCH AND DEVELOPMENTWe believe that our future success depends, to a large extent, on our ability to keep pace with changing technologies and market needs. Â Bio-Techne is engaged in continuousÂ research and development in all of our major product lines. Â We also carry out research to develop new products that build upon and expand the technologies we acquire through our acquisition strategy. Â In fiscal 2024, we introduced over 800 new products. Â While this is an area of focus for the Company, there is no assurance that any of the products in the research and development phases can be successfully completed or, if completed, can be successfully introduced into the marketplace. HUMAN CAPITAL Through its subsidiaries, Bio-Techne employed approximately 3,100 full-time and part-time employees as of June 30, 2024, of whom approximately 2,300 were employed in the United States and approximately 800 outside the United States. None of the United States employees are unionized. Outside the United States, the Company has government-mandated collective bargaining arrangements or work councils in certain countries.Bio-Techne is committed to attracting, developing, engaging, and retaining the best people possible from around the world to sustain and grow our leadership position in life sciences tools and diagnostics. We strive to create an employee experience that allows each to achieve their lifeâ€™s best work. This is demonstrated by leading with our EPIC values of Empowerment, Passion, Innovation and Collaboration. We continuously build on our people-first culture, led by uncompromising integrity, hosting a place of belonging, granting access to innovation and respecting human rights around the globe. Our talent management strategy spans multiple key dimensions, including the following:Culture and GovernanceOur four EPIC values of Empowerment, Passion, Innovation and Collaboration are the backbone for the way we approach the leadership and direction of our work force. Employees are empowered to realize their potential. Our culture supports and encourages a collaborative approach to working with each other and with our customers. We encourage innovation to continually improve our products, services and processes, and our passions for science and the missions of our customers are our guiding lights.Our EPIC values are embedded in our culture and practices. To further amplify our desired behaviors, we have an annual employee recognition program in which we ask for nominations and recognize winning individuals and teams across our business who have best demonstrated our EPIC values.Bio-Techneâ€™s Board of Directors reviews management succession planning at least annually, and its Compensation Committee reviews the Companyâ€™s talent management strategy periodically in connection with significant initiatives and acquisitions, as well as part of its oversight of our executive and equity compensation programs. At the management level, our Chief Human Resources Officer, who reports directly to our President and CEO, is responsible for the development and execution of the Companyâ€™s talent management strategy.Engagement and BelongingOur engagement strategy focuses on developing the best workplace and best people leaders to meet our employeesâ€™ needs. We believe that strong employee engagement helps enable higher retention and better business performance. We assess our engagement performance through regular consultation with our managers. Â We also engage more formally via an annual engagement survey that assesses our employeesâ€™ overall experience. In 2024, 74% of our global workforce participated, and 77% of those who responded provided favorable feedback. Â While these responses were quite positive, our management used the responses to inform and shape our future employee-focused initiatives. These initiatives in the past have resulted in changes in programs and policies, including expansion of our management and leadership development programs, addition of a parental leave program, expansion of our incentive programs to include annual cash 10 Table of Contentsbonuses to all employees, introduction of flexible working, addition of an internal communications function, leadership engagement focused on transparency and stronger feedback follow-up, Â and expansion of the breadth and resources of our Employee Resource Groups (ERGs). Â In fiscal year 2024, we empowered work/life integration through hybrid work models wherever feasible, continued to cultivate belonging and inclusion through deepened investment of resources to our ERGs, and paved the path for career growth through the personalized development and implementation of individual action plans. We believe a diverse workforce and culture of belonging is central to drive innovation, fuel growth and help ensure our technologies and products effectively serve a global customer base. The Companyâ€™s executive-sponsored Belonging initiative is focused on providing a welcoming working environment for all employees, continued education, broadening our candidate pools, and implementing and sustaining programs. One of the centerpieces of our talent development strategy is our ERGs, coordinated under the guidance of our executive-sponsored Employee Resource Group Council; they offer mentorship, support and engagement to help our employees, including those from underrepresented groups, succeed and thrive. As of June 30, 2024, we had 10 ERGs operating globally. As of June 30, 2024, 49% of our total employee population was female, and 43% of our managerial employees were female. 39% of our total employee population identified as nonwhite and 26% of our managerial employees identified as nonwhite. Â Recruitment and Retention Bio-Techne believes that sustaining its profitable growth will require a continued focus on recruiting and retaining top, diverse talent. We engage in a variety of recruiting strategies intended to locate and identify qualified candidates and create a talent pipeline. The Company offers competitive pay and benefits, from flexible work to financial planning resources to an employee stock purchase plan. In recent years, we bolstered our recruitment and retention efforts by expanding eligibility to receive stock options deeper into the organization and expanded our Long-Term Incentive program strategy to include a combination of stock options and restricted stock units, instead of exclusively stock options. Bio-Techne continues to offer a referral bonus with the understanding that this is one of our most successful sourcing methods. In addition to pay and benefits, Bio-Techne believes that the ability to retain employees requires an environment where they can work productively and where there are opportunities to grow and advance. The Company therefore seeks to cultivate a culture of empowerment and collaboration, where employees can observe the impact of their efforts, and where they see opportunities both laterally and vertically. The last fiscal year continued to see considerable employee mobility across all industries, including the biotechnology industry, but we nonetheless significantly reduced our attrition rate to maintain durable stability across our enterprise. We believe that Bio-Techneâ€™s sustained efforts on recruitment and retention will fortify our resilience in the face of increased employee mobility and economic challenges.Talent Development and Learning and DevelopmentBio-Techne invests in people development in the belief that growing and promoting employees from within the Company creates a more sustainable organization. High potential employees are identified through our annual talent review strategy, as well as through leadership development programs designed to cultivate future leaders. Â Employees identified as high potential are elevated to the attention of senior management for consideration for additional development, growth opportunities, and career advancement.Our global Learning and Development program delivers a wide range of initiatives including a validated suite of compliance training, and soft, technical, business, interpersonal and career skills. Bio-Techne also encourages and supports employees who wish to supplement their growth through external training and education. Â As a company that regularly acquires other businesses, we believe it is important for employees to be trained in the skills and mindsets that enable them to respond positively to change. This initiative allows individuals to deal with change easily and reduces the need to run large scale change management programs.11 Table of ContentsWell-Being and SafetyThe Company is committed to protecting the physical health, safety, and psychological well-being of our employees by providing a safe work environment and permitting hybrid work schedules wherever feasible. We actively monitor and adjust our crisis management plan and response protocol to protect our employees. Bio-Techne trains all employees on foundational safety principles and requires more rigorous safety and hazard awareness training where appropriate based on function, role, or team. At Bio-Techne, all employees are empowered and encouraged to maintain and create a safe workplace. In addition, we offer internal and external resources to provide for the psychological and emotional security of employees, including employee resource programs, mental health benefit coverage, and flexible work for many roles. Â CommunityThe Company believes in giving back and in supporting the local communities in which we live and work. The Company and its employees donate financially and by giving their time and energy. Most sites or departments engage in local charitable causes and activities. In some of our sites, employees are encouraged to give through regular payroll deductions and through the annual campaign week where employee contributions are matched by the Company. Some charitable causes are identified and promoted by our ERGs. Â In addition, United States employees receive a paid day off to participate in local opportunities to give back to the community as part of our volunteer time off benefit.INTELLECTUAL PROPERTYOur success depends in part upon our ability to protect our core technologies and intellectual property. To accomplish this, we rely on a combination of intellectual property rights, including patents, trade secrets and trademarks, as well as customary contractual protections in our terms and conditions and other sales-related documentation.As of JuneÂ 30, 2024, we had rights to approximately 710 granted patents and approximately 330 pending patent applications. Products in the Analytical Solutions and the Spatial Biology divisions are protected primarily through pending patent applications and issued patents. In addition, certain of our products are covered by licenses from third parties to supplement our own patent portfolio. Patent protection, if granted, generally has a life of 20Â years from the date of the patent application or patent grant. We cannot provide assurance that any of our pending patent applications will result in the grant of a patent, whether the examination process will require us to narrow our claims, and whether our claims will provide adequate coverage of our competitorsâ€™ products or services.In addition to pursuing patents on our products, we also preserve much of our innovation as trade secrets, particularly in the Reagent Solutions division of our Protein Sciences segment. Where appropriate, we use trademarks or registered trademarks in connection with our products. Â We have taken steps to protect our intellectual property and proprietary technology, in partÂ by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors. See the description of risks associated with the Companyâ€™s intellectual property in â€œItemÂ 1A. Risk Factors.â€We can give no assurance that Bio-Techneâ€™s products do not infringe upon patents or proprietary rights owned or claimed by others. Bio-Techne has not conducted a patent infringement study for each of its products. Where we have been contacted by patent holders with certain intellectual property rights, Bio-Techne typically has entered into licensing agreements with patent holders under which it has the exclusive and/or non-exclusive right to use patented technology as well as the right to manufacture and sell certain patented products to the research and/or diagnostics markets.All trademarks, trade names, product names, graphics, and logos of Bio-Techne contained herein are trademarks and registered trademarks of Bio-Techne or its subsidiaries, as applicable, in the United States and/or other countries. Â Solely for convenience, we may refer to trademarks in this Annual Report on Form 10-K without the â„¢ or Â® symbols. Â Such references are not intended to indicate that we will not assert our full rights to our trademarks. Â LAWS AND REGULATIONSOur operations, and some of the products we offer, are subject to a number of complex laws and regulations governing the production, marketing, handling, transportation, and distribution of our products and services. The following sections describe certain significant regulations pertinent to the Company. These are not the only laws and regulations applicable 12 Table of Contentsto the Companyâ€™s business. For a description of risks related to laws and regulations to which we are subject, refer to â€œItemÂ 1A. Risk Factors.â€Medical Device RegulationsA number of our products are classified as medical devices and are subject to restrictions under domestic and foreign laws, rules, regulations, self-regulatory codes and orders, including but not limited toÂ the U.S. Food, Drug and Cosmetic Act (the â€œFDCAâ€). The FDCA requires these products, when sold in the United States, to be safe and effective for their intended uses and to comply with the regulations administered by the U.S. Food and Drug Administration (â€œFDAâ€). The FDA regulates the design, development, testing, manufacture, advertising, labeling, packaging, marketing, distribution, import and export and record keeping for such products. Many medical device products are also regulated by comparable agencies in non-U.S. countries in which they are produced or sold.Any medical devices we manufacture and distribute are subject to pervasive and continuing regulation by the FDA and certain state and non-U.S. agencies. As a medical device manufacturer, our manufacturing facilities are subject to inspection on a routine basis by the FDA. We are required to adhere to the Current Good Manufacturing Practices (â€œcGMPâ€) requirements, as set forth in the Quality Systems Regulation (â€œQSRâ€), which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all phases of the design and manufacturing process.We must also comply with post-market surveillance regulations, including medical device reporting (â€œMDRâ€), requirements which require that we review and report to the FDA any incident in which our products may have caused or contributed to a death or serious injury. We must also report any incident in which our product has malfunctioned if that malfunction would likely cause or contribute to a death or serious injury it if were to recur.Labeling and promotional activities are subject to scrutiny by the FDA and, in

certain circumstances, by the Federal Trade Commission. Medical devices approved or cleared by the FDA may not be promoted for unapproved or uncleared uses, otherwise known as â€œoff-labelâ€ promotion. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.In the European Union (â€œEUâ€), our products are subject to the medical device laws of the various member states, which are currently based on a Directive of the European Commission. Additionally, the EU has adopted the In Vitro Diagnostic Regulation (the â€œEU IVDRâ€), which imposes stricter requirements for the marketing and sale of in vitro diagnostic medical devices, including in the area of clinical evaluation requirements, quality systems and post-market surveillance. ManufacturersÂ of in vitro diagnostics medical devices that have been marketed and sold under the prior regulatory regime now have to comply with some of the new EU IVDR requirements, while the effective date of other requirements have been delayed. Complying withÂ EU IVDR may require material modifications to our quality management systems, additional resources in certain functions, updates to technical files and additional clinical data in some cases, among other changes.One of our products under our Exosome Diagnostics brand is offered as a test by a certified laboratory under CLIA. Our Asuragen business also maintains a CLIA certification. Consequently, we must comply with state licensing regulations applicable to laboratories regulated under CLIA, governing laboratory practices and procedures.Other Healthcare LawsSeveral of the products sold in our Diagnostics and Genomics segment are subject to various health care related laws regulating fraud and abuse, research and development, pricing and sales and marketing practices, and the privacy and security of health information, including, among others:â—U.S. federal regulations regarding quality and cost by the U.S. Department of Health and Human Services (â€œHHSâ€), including the Centers for Medicare & Medicaid Services (â€œCMSâ€), as well as comparable state and non-U.S. agencies responsible for reimbursement and regulation of healthcare goods and services, including laws and regulations related to kickbacks, false claims, self-referrals and healthcare fraud.13 Table of Contentsâ€‹â—U.S. Federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration (including any kickback or bribe), directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made in whole or in part under a federal health care program, such as Medicare or Medicaid.â€‹â—Comparable laws and regulations similar to, and in some cases more stringent than, the U.S. federal regulations discussed above and below, including the UK Bribery Act and similar anti-bribery laws.â€‹â—The Health Insurance Portability and Accountability Act of 1996 (â€œHIPAAâ€), which prohibits knowingly and willfully (1) executing, or attempting to execute, a scheme to defraud any health care benefit program, including private payors, or (2) falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, also restricts the use and disclosure of patient identifiable health information, mandates the adoption of standards relating to the privacy and security of patient identifiable health information and requires the reporting of certain security breaches with respect to such information.â€‹â—The False Claims Act, which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program, knowingly makes, uses or causes to be made or used, a false record or statement material to a false or fraudulent claim, or knowingly makes a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government.â€‹â—The Open Payments Act requires manufacturers of medical devices covered under Medicare to, in certain circumstances, record payments and other transfers of value to a broad range of healthcare providers and teaching hospitals and to report this data as well as ownership and investment interests held by the physicians described above and their immediate family members to HHS for subsequent public disclosure, as well as similar reporting requirements in some states and in other countries.â€‹For a discussion of risks related to regulation by the FDA and comparable agencies of other countries, and the other regulatory regimes referenced above, please refer to section entitled â€œItemÂ 1A. Risk Factors.â€Data Privacy and Security LawsAs a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal and/or sensitive data in the course of our business. In addition to the U.S. HIPAA privacy and security rulesÂ mentioned above, which impact some parts of our business, individual states also regulate data breach and security requirements, and multiple governmental bodies assert authority over aspects of the protection of personalÂ privacy. In particular, a broad privacy law in California, the California Consumer Privacy Act (â€œCCPAâ€), came into effect in JanuaryÂ 2020. The CCPA has some of the same features as the GDPR (discussed below) and has already prompted several other states to follow with similar laws. The EU General Data Protection Regulation that became effective in MayÂ 2018 (â€œGDPRâ€) has imposed significantly stricter requirements in how we collect, transmit, process, and retain personal data, including, among other things, in certain circumstances a requirement for almost immediate notice of data breaches to supervisory authorities and prompt notice to data subjects with significant fines for non-compliance. Several other countries in which we do business have passed, and other countries are considering passing, laws that require personal data relating to their citizens to be maintained on local servers and impose additional data transfer restrictions. For a discussion of risks related to improper disclosure of private information particularly as a result of cyber security incidents, please refer to section entitled â€œItemÂ 1A. Risk Factors.â€Environmental Health and Safety LawsWe are also subject to various environmental health and safety laws and regulations both within and outside the U.S. Like other companies in our industry, our manufacturing and research activities involve the use and transportation of substances regulated under environmental health and safety laws including those relating to the transportation of hazardous materials.14 Table of ContentsOther Laws and Regulations Governing Our Sales, Marketing and Shipping ActivitiesWe are subject to the U.S. Foreign Corrupt Practices Act and various other similar anti-corruption and anti-bribery acts, which are particularly relevant to our operations in countries where the customers are government entities or are controlled by government officials. Both directly and indirectly through our distributors, we must comply with such laws when interacting with those entities.As Bio-Techneâ€™s businesses also include export and import activities, we are subject to pertinent laws enforced by the U.S.Â Departments of Commerce, State and Treasury. Other nationsâ€™ governments have implemented similar export/import control and economic sanction regulations, which may affect the Companyâ€™s operations or transactions subject to their jurisdictions.In addition, under U.S. laws and regulations, U.S. companies and their subsidiaries and affiliates outside the United States are prohibited from participating or agreeing to participate in unsanctioned foreign boycotts in connection with certain business activities, including the sale, purchase, transfer, shipping or financing of goods or services within the United States or between the United States and countries outside of the United States. If we, or certain third parties through which we sell or provide goods or services, violate anti-boycott laws and regulations, we may be subject to civil or criminal enforcement action and varying degrees of liability.We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by a reduction in revenue associated with these customers. We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.For a discussion of risks related to the above-referenced regulations, particularly with respect to our international operations, please refer to section entitled â€œItemÂ 1A. Risk Factors.â€INVESTOR INFORMATIONWe are subject to the information requirements of the Securities Exchange Act of 1934 (the Exchange Act). Therefore, we file periodic reports, proxy statements, and other information with the Securities and Exchange Commission (SEC). The SEC maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically.Financial and other information about us is available on our web site (https://investors.bio-techne.com/). We make available on our web site copies of our Annual Report on FormÂ 10-K, Quarterly Reports on FormÂ 10-Q, Current Reports on FormÂ 8-K, and amendments to those reports filed or furnished pursuant to SectionÂ 13 or 15(d)Â of the Exchange Act as soon as reasonably practicable after filing such material electronically or otherwise furnishing it to the SEC.EXECUTIVE OFFICERS OF THE REGISTRANTAs of the date of this Annual Report, the names, ages, positions and periods of service of each executive officer of the Company are as follows:â€‹â€‹â€‹

and to make appropriate investments that support our long-term strategy, could negatively impact our growth rate and stock price.One of our key strategies is growth through acquisition of other businesses and assets. Our ability to grow revenues, earnings and cash flow at or above our historic rates depends in part upon our ability to identify and successfully acquire and integrate businesses at appropriate prices and realize anticipated synergies, and to make appropriate investments that support our long-term strategy. We may not be able to consummate acquisitions at rates similar to the past, which could adversely impact our growth rate and our stock price. Promising acquisitions and investments are difficult to identify and complete for a number of reasons, including high valuations, competition among prospective buyers or investors, the availability of affordable funding in the capital markets and the need to satisfy applicable closing conditions and obtain applicable antitrust and other regulatory approvals on acceptable terms.Â Changes in accounting or regulatory requirements or instability in the credit markets could also adversely impact our ability to consummate acquisitions and investments.Our acquisition of businesses, investments, joint ventures and other strategic relationships, if not properly implemented or integrated, could negatively impact our business and financial results.As part of our business strategy, we acquire businesses, make investments and enter into joint ventures and other strategic relationships in the ordinary course of business, and we also from time to time complete more significant transactions. Â At the beginning of this fiscal year, we completed the acquisition of Lunaphore SA, a leading developer of fully automated spatial biology solutions. Bio-Techne also obtained a 19.9% ownership stake in Wilson Wolf and will acquire the remaining ownership no later than the end of calendar year 2027. We have also continued participating in our collaborative marketing venture, ScaleReady LLC, with Wilson Wolf and another partner, which addresses the needs of the rapidly expanding cell and gene therapy market. Â While we believe these business ventures will advance our business strategies and support our growth plans, we may not be successful in managing or integrating them into our company. Acquisitions, investments, joint ventures and strategic relationships involve a number of additional financial, accounting, managerial, operational, legal, compliance and other risks and challenges, including but not limited to the following, any of which could adversely affect our business and our financial results:â—businesses, technologies, services and products that we acquire or invest in sometimes under-perform relative to our expectations and the price that we paid, fail to perform in accordance with our anticipated timetable or fail to achieve and/or sustain profitability;â€‹â—we from time to time incur or assume debt in connection with our acquisitions and investments, which can result in increased borrowing costs and interest expense and diminish our future access to the capital markets;â€‹â—acquisitions, investments, joint ventures or strategic relationships can cause our financial results to differ from our own or the investment communityâ€™s expectations in any given period, or over the long-term;â€‹19 Table of Contentsâ—acquisitions, investments, joint ventures or strategic relationships can create demands on our management, operational resources and financial and internal control systems that we may be unable to effectively address;â€‹â—we can experience difficulty in integrating cultures, personnel, operations and financial and other controls and systems and retaining key employees and customers;â€‹â—we may be unable to achieve cost savings or other synergies anticipated in connection with an acquisition, investment, joint venture or strategic relationship;â€‹â—we have assumed and may assume unknown liabilities, known contingent liabilities that become realized, known liabilities that prove greater than anticipated, internal control deficiencies or exposure to regulatory sanctions resulting from the acquired companyâ€™s or investeeâ€™s activities and the realization of any of these liabilities or deficiencies can increase our expenses, adversely affect our financial position or cause us to fail to meet our public financial reporting obligations;â€‹â—in connection with acquisitions and joint ventures, we often enter into post-closing financial arrangements such as purchase price adjustments, earn-out obligations and indemnification obligations, which can have unpredictable financial results; andâ€‹â—investing in or making loans to early-stage companies often entails a high degree of risk, and we may not always achieve the strategic, technological, financial or commercial benefits we anticipate; we may lose our investment or fail to recoup our loan; or our investment may be illiquid for a greater-than-expected period of time.â€‹We may be required to record a significant charge to earnings if our goodwill and other amortizable intangible assets or other investments become impaired, which could negatively impact our financial results or stock price.We are required under generally accepted accounting principles to test goodwill for impairment at least annually and to review our goodwill, amortizable intangible assets, and other assets acquired through merger and acquisition activity for impairment when events or changes in circumstance indicate the carrying value may not be recoverable. Factors that could lead to impairment of goodwill, amortizable intangible assets, and other assets acquired via acquisitions include significant adverse changes in the business climate and actual or projected operating results (affecting our company as a whole or affecting any particular segment) and declines in the financial condition of our business. We may be required in the future to record additional charges to earnings if our goodwill, amortizable intangible assets or other investments become impaired. Any such charge would adversely impact our financial results.In addition, the Companyâ€™s expansion strategies include collaborations and investments in joint ventures and companies developing new products related to the Companyâ€™s business. These strategies carry risks that objectives will not be achieved and future earnings will be adversely affected. Strategic and Operational RisksOur success will be dependent on recruiting and retaining highly qualified and diverse personnel and creating and maintaining a culture that successfully integrates the employees joining through acquisitions.Recruiting and retaining qualified scientific, production, sales and marketing, and management personnel representing diverse backgrounds, experiences and skill sets are critical to our success. The market for highly skilled workers and leaders in our businesses, particularly in the areas of science and technology, is extremely competitive. Â While retention improved in fiscal 2024, a number of our businesses and departments continued to face recruitment and retention challenges, and faced labor availability constraints and inflationary costs. Our growth by acquisition also creates challenges in retaining employees. As we integrate past and future acquisitions and evolve our corporate culture to incorporate new workforces, some employees may not find such integration or cultural changes appealing. The failure to attract and retain such personnel could adversely affect our business.20 Table of ContentsOur growth depends in part on the timely development and commercialization of new and enhanced products and services that meet our customersâ€™ needs. Our growth can also be negatively impacted if our customers do not grow as anticipated.We generally sell our products and services in industries that are characterized by rapid technological change, frequent new product introductions and new market entrants and competitors. If we do not develop innovative new and enhanced products and services on a timely basis, our offerings will become obsolete over time and our business and financial results will suffer. Our success will depend on several factors, including our ability to:â—correctly identify and/or predict customer needs and preferences;â€‹â—allocate our research funding to products with higher growth prospects;â€‹â—anticipate and respond to our competitorsâ€™ development of new products and technological innovations;â€‹â—differentiate our offerings from our competitorsâ€™ offerings and avoid our products from becoming commodities;â€‹â—innovate and develop new technologies and applications, and acquire or obtain rights to third-party technologies that may have valuable applications in the markets we serve;â€‹â—obtain adequate intellectual property rights with respect to key technologies;â€‹â—successfully commercialize new technologies in a timely manner, price them competitively and cost-effectively manufacture and deliver sufficient volumes of new products of appropriate quality on time;â€‹â—obtain necessary regulatory approvals of appropriate scope (including with respect to certain diagnostic medical device products by demonstrating satisfactory clinical results where applicable, as well as achieving third-party reimbursement); andâ€‹â—stimulate customer demand for and convince customers to adopt new technologies.â€‹If we fail to accurately predict future customer needs and preferences or fail to produce viable technologies, we may invest heavily in research and development of products that do not lead to significant revenue, which would adversely affect our business and financial results. Even when we successfully innovate and develop new and enhanced products, we often incur substantial costs in doing so, and our profitability may suffer.We face intense competition, and if we are unable to compete effectively, we may experience decreased demand and decreased market share or need to reduce prices to remain competitive.We face intense competition across most of our product lines. Competitors include companies ranging from start-up companies, which may be able to more quickly respond to customersâ€™ needs, to large multinational companies, which may have greater financial, marketing, operational, and research and development resources than us. In addition, consolidation trends in the pharmaceutical, biotechnology and diagnostics industries have served to create fewer customer accounts and to concentrate purchasing decisions for some customers, resulting in increased pricing pressure on us. Moreover, customers may believe that consolidated businesses are better able to compete as sole source vendors, and therefore prefer to purchase from such businesses. The entry into the market by manufacturers in countries in Asia and other low-cost manufacturing locations is also creating increased pricing and competitive pressures, particularly in developing markets. In order to compete effectively, we must retain longstanding relationships with major customers and continue to grow our business by establishing relationships with new customers, continually developing new products and services to maintain and expand our brand recognition and leadership position in various product and service categories and penetrating new markets, including high-growth markets. Our ability to compete can also be impacted by changing customer preferences and requirements (for example increased demand for more environmentally-friendly products and supplier practices). Our failure to compete effectively and/or pricing pressures resulting from competition may adversely impact our business and financial results, and our expansion into new markets may result in greater-than-expected risks, liabilities and expenses.21 Table of ContentsA significant disruption in, or breach of security of, our information technology systems or data, or violation of data privacy laws, could result in damage to our reputation, data integrity and/or subject us to costs, fines, or lawsuits under data privacy or other laws or contractual requirements.The integrity and protection of our own data, and that of our customers and employees, is critical to our business. We rely on information technology systems, some of which are provided and/or managed by third parties, to process, transmit and store electronic information (including sensitive data such as confidential business information and personally identifiable data relating to employees, customers, other business partners and patients), and to manage or support a variety of critical business processes and activities (such as receiving and fulfilling orders, billing, collecting and making payments, shipping products, providing services and support to customers and fulfilling contractual obligations). These systems, products and services (including those we acquire through business acquisitions) can be damaged, disrupted or shut down due to attacks by computer hackers, computer viruses, ransomware, human error or malfeasance, power outages, hardware failures, telecommunication or utility failures, catastrophes or other unforeseen events, and in any such circumstances our system redundancy and other disaster recovery planning may be ineffective or inadequate. Attacks can also target hardware, software and information installed, stored or transmitted in our products after such products have been purchased and incorporated into third-party products, facilities or infrastructure. Security breaches of systems provided or enabled by us, regardless of whether the breach is attributable to a vulnerability in our products or services, or security breaches of third party systems we rely on to process, store or transmit electronic information, can result in the misappropriation, destruction or unauthorized disclosure of confidential information or personal data belonging to us or to our employees, partners, customers, patients or suppliers. These attacks, breaches, misappropriations and other disruptions and damage can interrupt our operations or the operations of our customers and partners, delay production and shipments, result in theft of our and our customersâ€™ intellectual property and trade secrets, result in disclosure of personally identifiable information, damage customer, patient, business partner and employee relationships and our reputation and result in defective products or services, legal claims and proceedings, liability and penalties under privacy laws and increased costs for security and remediation, in each case resulting in an adverse effect on our business and financial results.In addition, our information technology systems require an ongoing commitment of significant resources to maintain and enhance existing systems and develop or integrate new systems to keep pace with continuing changes in information processing technology, evolving legal and regulatory standards, evolving customer expectations, changes in the techniques used to obtain unauthorized access to data and information systems, and the information technology needs associated with our changing products and services. There can be no assurance that we will be able to successfully maintain, enhance and upgrade our systems as necessary to effectively address these requirements.If we are unable to maintain reliable information technology systems or appropriate controls with respect to global data privacy and security requirements and prevent data breaches, we may suffer regulatory consequences in addition to business consequences. As a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal and/or sensitive data in the course of our business. For example, in the United States, a small number of our businesses are subject to HIPAA. Entities that violate HIPAA due to a breach of unsecured patient health information, or that arise from a complaint about privacy practices or an audit by the HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Individual states regulate data breach and security requirements, and multiple governmental bodies assert authority over aspects of the protection of personal privacy. Most notably, in the last severalÂ years, some states, including California, Virginia, Utah, Colorado and Connecticut, have passed broad privacy legislation that could result in more material impacts as implementing regulations are issued. European laws require us to have an approved legal mechanism to transfer personal data out of Europe. Failure to comply with the requirements of GDPR and the applicable national data protection laws of the EU member states may result in fines of up to â‚¬20 million or up to 4% of the total worldwide annual turnover of the preceding financialÂ year, whichever is higher, and other administrative penalties. Several other countries such as China and Russia have passed, and other countries are considering passing, laws that require personal data relating to their citizens to be maintained on local servers and impose additional data transfer restrictions. Government enforcement actions can be costly and interrupt the regular operation of our business, and data breaches or violations of data privacy laws can result in fines, reputational damage and civil lawsuits, any of which may adversely affect our business, reputation and financial results.22 Table of ContentsIf we suffer loss to our supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed.Our supply chains, distribution systems and information technology systems may be subject to catastrophic loss due to fire, flood, earthquake, hurricane, power shortage or outage, public health crisis (including epidemics and pandemics) and the reaction thereto, war, terrorism, riot or other man-made or natural disasters. If any of these supply chains or systems were to experience a catastrophic loss, it could disrupt our operations, delay production and shipments, result in defective products or services, diminish demand, damage customer relationships and our reputation and result in legal exposure and significant repair or replacement expenses. The third-party insurance coverage that we maintain varies from time to time in both type and amount depending on cost, availability and our decisions regarding risk retention, and may be unavailable or insufficient to protect us against such losses.The manufacture of many of our products is a complex process, and if we directly or indirectly encounter problems manufacturing products, our business and financial results could suffer.The manufacture of many of our products is a complex process, due in part to strict regulatory requirements for some of our products. Problems can arise during manufacturing for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with reliable sourcing of raw materials or components, natural disasters and environmental factors, and, if not discovered before the product is released to market, can result in recalls and product liability exposure. Because of the quality requirements of some of our customers as well as stringent regulations of the FDA and similar agencies regarding the manufacture of certain of our products, alternative manufacturing or sourcing is not always available on a timely basis to replace such production capacity. Any of these manufacturing problems could result in significant adverse impacts to our business and financial results.If we cannot adjust our manufacturing capacity or the purchases required for our manufacturing activities to reflect changes in market conditions or customer demand, our business and financial results may suffer. In addition, our reliance upon sole or limited sources of supply for certain materials, components and services can cause production interruptions, delays and inefficiencies.We purchase materials, components and equipment from third parties for use in many of our manufacturing operations. Our profitability could be adversely impacted if we are unable to adjust our purchases to reflect changes in customer demand and market fluctuations, including those caused by seasonality or cyclicality. During a market upturn, suppliers from time to time extend lead times, limit supplies or increase prices. If we cannot purchase sufficient products at competitive prices and quality and on a timely enough basis to meet increasing demand, we may not be able to satisfy market demand, product shipments may be delayed, our costs may increase, or we may breach our contractual commitments and incur liabilities. Conversely, in order to secure supplies for the production of products, we sometimes enter into noncancelable purchase commitments with vendors, which can impact our ability to adjust our inventory to reflect declining market demands. If demand for our products is less than we expect, we may experience additional excess and obsolete inventories and be forced to incur additional charges and our business and financial results may suffer.In addition, some of our businesses purchase certain materials from sole or limited source suppliers for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design. If these or other suppliers encounter financial, operating or other difficulties or if our relationship with them changes, we might not be able to quickly establish or qualify replacement sources of supply. The supply chains for our businesses can also be disrupted by supplier capacity constraints, bankruptcy or exiting of the business for other reasons, decreased availability of key raw materials or commodities and external events such as natural disasters, pandemic health issues, war, terrorist actions, governmental actions (such as trade protectionism) and legislative or regulatory changes. Any of these factors can result in production interruptions, delays, extended lead times and inefficiencies. Because we cannot always immediately adapt our production capacity and related cost structures to changing market conditions, at times our manufacturing capacity

may exceed or fall short of our production requirements. Any or all of these problems can result in the loss of customers, provide an opportunity for competing products to gain market acceptance and otherwise adversely affect our business and financial results.23 Table of ContentsThe Company relies heavily on internal manufacturing and related operations to produce, package and distribute its products which, if disrupted, could materially impair our business operations. Our business could be adversely affected by disruptions at our sites.The Companyâ€™s internal quality control, packaging and distribution operations support the majority of the Companyâ€™s sales. Since certain Company products must comply with FDA regulations and because in all instances, the Company creates value for its customers through the development of high-quality products, any significant decline in quality or disruption of operations for any reasonÂ could adversely affect sales and customer relationships, and therefore adversely affect the business. While we have taken certain steps to manage these operational risks, the Companyâ€™s future sales growth and earnings may be adversely affected by perceived disruption risks or actual disruptions.We rely upon our manufacturing operations to produce many of the products we sell and our warehouse facilities to store products, pending sale. Any significant disruption of those operations for any reason, such as strikes or other labor unrest, power interruptions, fire, hurricanes or other events beyond our control could adversely affect our sales and customer relationships and therefore adversely affect our business. We have significant operations in California, near major earthquake faults, which make us susceptible to earthquake risk. Although most of our raw materials are available from a number of potential suppliers, our operations also depend upon our ability to obtain raw materials at reasonable prices. If we are unable to obtain the materials we need at a reasonable price, we may not be able to produce certain of our products or we may not be able to produce certain of these products at a marketable price, which could have an adverse effect on our results of operations.Climate change and/or related environmental risks, or legal or regulatory measures to address climate change and/or related environmental risks, may negatively affect us.Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere could present risks to our operations. Â For example, we have significant operations in California, where serious drought has made water less available and more costly and has increased the risk of wildfires. Changes in climate patterns leading to extreme heat waves or unusual cold weather at some of our locations can lead to increased energy usage and costs, or otherwise adversely impact our facilities and operations and disrupt our supply chains and distribution systems. Concern over climate change can also result in new or additional legal or regulatory requirements designed to reduce greenhouse gas emissions or mitigate the effects of climate change on the environment. Â Any such new or additional legal or regulatory requirements may increase the costs associated with, or disrupt, sourcing, manufacturing and distribution of our products, which may adversely affect our business and financial results. In addition, any failure to adequately address stakeholder expectations with respect to environmental, social and governance (â€œESGâ€) matters may result in the loss of business, adverse reputational impacts, diluted market valuations and challenges in attracting and retaining customers and talented employees. In addition, our adoption of certain standards or mandated compliance to certain requirements could necessitate additional investments that could impact our profitability. Â Defects, unanticipated use of, or inadequate disclosure with respect to our products, or allegations thereof, can adversely affect our business and financial results.Certain of our products and services are sold for use in diagnostics. For those products and services in particular, manufacturing or design defects in, unanticipated use of, safety or quality issues (or the perception of such issues) with respect to, â€œoff labelâ€ use of, or inadequate disclosure of risks relating to the use of products and services that we make or sell (including items that we source from third-parties) can lead to personal injury, death, and/or property damage and adversely affect our business and financial results. These events can lead to recalls or safety alerts, result in the removal of a product or service from the market and result in product liability or similar claims being brought against us. Recalls, removals and product liability and similar claims (regardless of their validity or ultimate outcome) result in significant costs, as well as negative publicity and damage to our reputation that could reduce demand for our products and services. Our business can also be affected by studies of the utilization, safety and efficacy of medical device products and components that are conducted by industry participants, government agencies and others. Any of the above can result in the discontinuation of marketing of such products in one or more countries and give rise to claims for damages from persons who believe they have been injured as a result of product issues, including claims by individuals or groups seeking to represent a class.24 Table of ContentsBecause we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability.Most of our reagent products need to be stored and shipped at certain cold temperatures. Consequently, we ship a significant portion of our products to our customers by express mail or air deliveryÂ through package delivery companies, such as FedEx in the U.S. and DHL in Europe. If one or more of these third-party package-delivery providers were to experience a major work stoppage, preventing our products from being delivered in a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our relationships with certain of our customers could be adversely affected. In addition, if one or more of these third-party package-delivery providers were to increase prices, and we were not able to find comparable alternatives or make adjustments in our delivery network, our profitability could be adversely affected.Intellectual Property RisksWe are dependent on maintaining our intellectual property rights. If we are unable to adequately protect our intellectual property, or if third parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights.Many of the markets we serve are technology-driven, and as a result intellectual property rights play a significant role in product development and differentiation. We own numerous patents, trademarks, copyrights, trade secrets and other intellectual property and licenses to intellectual property owned by others, which in aggregate are important to our business. The intellectual property rights that we obtain, however, are not always sufficiently broad and do not always provide us a significant competitive advantage, and patents may not be issued for pending or future patent applications owned by or licensed to us. In addition, the steps that we and our licensors have taken to maintain and protect our intellectual property do not always prevent it from being challenged, invalidated, circumvented, designed around or becoming subject to compulsory licensing. In some circumstances, enforcement is not available to us because an infringer has a dominant intellectual property position or for other business reasons. We also rely on nondisclosure and noncompetition agreements with employees, consultants and other parties to protect, in part, trade secrets and other proprietary rights. There can be no assurance that these agreements adequately protect our trade secrets and other proprietary rights and will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets or other proprietary rights.These risks are particularly pronounced in countries in which we do business that do not have levels of protection of corporate proprietary information, intellectual property, technology and other assets comparable to the United States.Â We operate globally, with manufacturing operations in China and the UK, and approximately 43% of our revenue in fiscal 2024 was from outside the United States. Â The laws, regulations and enforcement mechanisms in other countries may in some cases be less protective of our intellectual property rights. Our failure to obtain or maintain intellectual property rights that convey competitive advantage, adequately protect our intellectual property or detect or prevent circumvention or unauthorized use of such property and the cost of enforcing our intellectual property rights can adversely impact our business and financial results.We may be involved in disputes to determine the scope, coverage and validity of othersâ€™ proprietary rights, or to defend against third-party claims of intellectual property infringement, any of which could be time-intensive and costly and may adversely impact our business.Our success depends in part on our ability to operate without infringing the proprietary rights of others, and to obtain licenses where necessary or appropriate. We have obtained and continue to negotiate licenses to produce a number of products claimed to be owned by others. Since we have not conducted a patent infringement study for each of our products, it is possible that some of our products may unintentionally infringe patents of third parties.We have been and may in the future be sued by third parties alleging that we are infringing their intellectual property rights. These lawsuits are expensive, take significant time, and divert managementâ€™s focus from other business concerns. If we are found to be infringing the intellectual property of others, we could be required to cease certain activities, alter 25 Table of Contentsour products or processes or pay licensing fees. This could cause unexpected costs and delays which may have a material adverse effect on us. If we are unable to obtain a required license on acceptable terms, or unable to design around any third party patent, we may be unable to sell some of our products and services, which could result in reduced revenue. In addition, if we do not prevail, a court may find damages or award other remedies in favor of the opposing party in any of these suits, which may adversely affect our earnings.Financial and Tax RisksWe have entered into and drawn on a revolving credit facility, and we may incur additional debt in the future. The burden of this additional debt could adversely affect us, make us more vulnerable to adverse economic or industry conditions, and prevent us from funding our expansion strategy.We currently have a Credit Agreement that provides for a revolving credit facility of $1 billion, which canÂ be increased by an additional $400 million subject to certain conditions. Borrowings under the Credit Agreement bear interest at a variable rate. As of AugustÂ 16, 2024, the Company had drawn $313 million under the Credit Agreement. â€‹The terms of the Credit Agreement and the burden of the indebtedness incurred thereunder could have negative consequences for us, such as:â—limiting our ability to obtain additional financing to fund our working capital, capital expenditures, debt service requirements, expansion strategy, or other needs;â€‹â—increasing our vulnerability to, and reducing our flexibility in planning for, adverse changes in economic, industry and competitive conditions; andâ€‹â—increasing our vulnerability to increases in interest rates.â€‹The Credit Agreement also contains negative covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other things, sell, lease or transfer any properties or assets, with certain exceptions; and enter into certain merger, consolidation or other reorganization transactions, with certain exceptions.A breach of any of these covenants could result in an event of default under our credit facility. Upon the occurrence of an event of default, the lender could elect to declare all amounts outstanding under such facility to be immediately due and payable and terminate all commitments to extend further credit. In addition, the Company would be subject to additional restrictions if an event of default exists under the Credit Agreement, such as a prohibition on the payment of cash dividends.Our business and financial results can be adversely affected by foreign currency exchange rates, changes in our tax rates and tax liabilities and assessments (including as a result of changes in tax laws).International markets contribute a substantial portion of our revenues, and we intend to continue expanding our presence in these regions. The exposure to fluctuations in currency exchange rates takes on different forms. International revenues and costs are subject to the risk that fluctuations in exchange rates could adversely affect our reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. These fluctuations could also adversely affect the demand for products and services provided by us. As a multinational corporation, our businesses occasionally invoice third-party customers in currencies other than the one in which they primarily do business (the "functional currency"). Movements in the invoiced currency relative to the functional currency could adversely impact our cash flows and our results of operations. As our international sales grow, exposure to fluctuations in currency exchange rates could have a larger effect on our financial results. In fiscal 2024, currency translation had aÂ favorable effect of approximately $6Â million on revenues due to theÂ value of the U.S. dollar relative to other currencies in which the company sells products and services.As a global company, we are subject to taxation in numerous countries, states and other jurisdictions. In particular, we are affected by the impact of changes to tax laws or related authoritative interpretations in the United States, including tax reform under the Tax Cuts and Jobs Act which became effective in late 2017, which included broad and complex changes 26 Table of Contentsto the United States tax code. Interpretations, assumptions and guidance regarding theÂ Tax Act that have been issued subsequently have had a material impact on our effective tax rate, and we anticipate that there may be additional changes to the U.S. tax code under a new Administration.In preparing our financial results, we record the amount of tax that is payable in each of the countries, states and other jurisdictions in which we operate. Our future effective tax rate, however, may be lower or higher than experienced in the past due to numerous factors, including a change in the mix of our profitability from country to country, changes in accounting for income taxes and recently enacted and future changes in tax laws in jurisdictions in which we operate. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business, results of operations and cash flows.Dividends on our common stock could be reduced or eliminated in the future.For manyÂ years, our Board has declared quarterly dividends. In the future, our Board may determine to reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.Legal, Regulatory, Compliance and Reputational RisksOur business is subject to extensive regulation; failure to comply with these regulations could adversely affect our business and financial results.As referenced in more detail above, we and our customers must comply with a wide array of federal, state,Â local and international regulations, in such areas as medical device, healthcare, import and export, anticorruption, and privacy. We develop, configure and market our products to meet customer needs created by those regulations. Any significant change in regulations could reduce demand for our products or increase our expenses. For example, many of our instruments are marketed to the pharmaceutical industry for use in discovering and developing drugs and diagnostic products. Changes in the U.S. FDAâ€™s regulation of drug or medical device products, such as managing the price of certain prescription drugs or potentially increasing regulatory scrutiny of lab developed tests, could have an adverse effect on the demand for these products.We have agreements relating to the sale of our products to government entities in the U.S. and elsewhere and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government (less than 3% of our fiscal 2024 sales were made to the U.S. federal government). The laws governing government contracts differ from the laws governing private contracts and government contracts may contain pricing terms and conditions that are not applicable to private contracts. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.We are subject to various local, state, federal, foreign and transnational laws and regulations, which include the operating and security standards of the U.S. FDA, the U.S. Drug Enforcement Agency (the DEA), the U.S. Department of Health and Human Services (the DHHS), and other comparable agencies and, in the future, any changes to such laws and regulations could adversely affect us. In particular, we are subject to laws and regulations concerning current good manufacturing practices. Our subsidiaries may be required to register for permits and/or licenses with, and may be required to comply with the laws and regulations of, the DEA, the FDA, the DHHS, foreign agencies and/or comparable state agencies as well as certain accrediting bodies depending upon the type of operations and location of product distribution, manufacturing and sale. The manufacture, distribution and marketing of many of our products and services, including medical devices and pharma services, are subject to extensive ongoing regulation by the FDA, the DEA, and other equivalent local, state, federal and non-U.S. regulatory authorities. In addition, we are subject to inspections by these regulatory authorities. For example, the EU has adopted the In Vitro Diagnostic Regulation (the â€œEU IVDRâ€), which imposes stricter requirements for the marketing and sale of in vitro diagnostic medical devices, including in the area of clinical evaluation requirements, quality systems and post-market surveillance. ManufacturersÂ of in vitro diagnostics medical devices that have been marketed and sold under the prior regulatory regime now have to comply with some of the new EU IVDR requirements, while the effective date of other requirements have been delayed. Â Â Complying withÂ EU IVDR, the regulation applicable to the Company,Â may require material modifications to our quality management systems, additional resources in certain functions, updates to technical files and additional clinical data in some cases, among other 27 Table of Contentschanges.Â Failure by us or by our customers to comply with the requirements of the EU IVDR, or other requirements imposed by these or similar regulatory authorities, including without limitation, remediating any inspectional observations to the satisfaction of these regulatory authorities, could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of existing or denial of pending approvals, including those relating to products or facilities. In addition, such a failure could expose us to contractual or product liability claims, contractual claims from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients, as well as ongoing remediation and increased compliance costs, any or all of which could be significant. We are the sole manufacturer of a number of products for many of our customers and a negative regulatory event could impact our customersâ€™ ability to provide products to their customers.We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the importation and exportation of products, the handling, transportation and manufacture of substances that could be classified as hazardous, and our business practices in the U.S. and abroad such as anti-competition laws. Any noncompliance by us with applicable laws and regulations or the failure to maintain, renew or obtain necessary permits and licenses could result in criminal, civil and administrative penalties and could have an adverse effect on our results of operations.Significant developments or changes in U.S. laws or policies, including changes in U.S. trade policies and tariffs and the reaction of other countries thereto, can have an adverse effect on our business and financial results.Significant developments or changes in U.S. laws and policies (including as a result of changes in party control of Congress or decisions from the U.S. Supreme Court), such as laws and policies governing foreign trade, manufacturing, and development and investment in the territories and countries where we or our customers operate, or governing the health care system and drug prices, can adversely affect our business and financial results. For example, the previous U.S. administration increased tariffs on certain goods imported into the United States and trade tensions between the United States and China escalated, with each country imposing significant

additional tariffs on a wide range of goods imported from the other country. That trade tension has not diminished under the current U.S. administration. The U.S. and China could impose other types of restrictions such as limitations on government procurement or technology export restrictions, which could affect our access to markets. In addition, changes to laws or regulations pertraining to laboratory developed tests may adversely affect our business and financial results. These factors have adversely affected, and in the future could further adversely affect, our business and financial results.Our business and financial results can be impaired by improper conduct by any of our employees, agents or business partners.We cannot provide assurance that our internal controls and compliance systems, including our Code of Ethics and Business Conduct, protect us from unauthorized acts committed by employees, agents or business partners of ours (or of businesses we acquire or partner with) that violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks and false claims, pricing, sales and marketing practices, conflicts of interest, competition, employment practices and workplace behavior, export and import compliance, economic and trade sanctions, money laundering and data privacy. In particular, the U.S. Foreign Corrupt Practices Act, the UK Bribery Act and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business, and we operate in many parts of the world that have experienced governmental corruption to some degree. Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in the United States and in other jurisdictions and related shareholder lawsuits, could lead to substantial civil and criminal, monetary and non-monetary penalties and could cause us to incur significant legal and investigatory fees. In addition, the government may seek to hold us liable for violations committed by companies in which we invest or that we acquire. We also rely on our suppliers to adhere to our supplier code of conduct, and material violations of such code of conduct could occur that could have a material effect on our business and financial results.28 Table of ContentsCertain of our businesses are subject to extensive regulation by the U.S. FDA and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the healthcare industry and the privacy and security of health information. Failure to comply with those regulations could adversely affect our business and financial results.Certain of our products are medical devices, diagnostics tests and other products that are subject to regulation by the U.S. FDA or state CLIA regulations, by other federal and state governmental agencies, by comparable agencies of other countries and regions and by regulations governing hazardous materials and drugs-of abuse, or the manufacture and sale of products containing any such materials. The global regulatory environment has become increasingly stringent and unpredictable. Several countries that did not have regulatory requirements for medical devices have established such requirements in recentÂ years, and other countries have expanded, or plan to expand, their existing regulations, including implementation of IVDR regulations in Europe. Failure to meet these requirements may adversely impact our business and financial results in the applicable geographies.Government authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law. Failure to obtain required regulatory clearances before marketing our products (or before implementing modifications to or promoting additional indications or uses of our products), other violations of laws or regulations, failure to remediate inspectional observations to the satisfaction of these regulatory authorities, real or perceived efficacy or safety concerns or trends of adverse events with respect to our products (even after obtaining clearance for distribution) and unfavorable or inconsistent clinical data from existing or future clinical trials can lead to FDA FormÂ 483 Inspectional Observations, warning letters, notices to customers, declining sales, loss of customers, loss of market share, remediation and increased compliance costs, recalls, seizures of adulterated or misbranded products, fines, expenses, injunctions, civil penalties, criminal penalties, consent decrees, administrative detentions, refusals to permit importations, partial or total shutdown of production facilities or the implementation of operating restrictions, narrowing of permitted uses for a product, refusal of the government to grant 510(k)Â clearance, suspension or withdrawal of approvals, pre-market notification rescissions and other adverse effects. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions brought against us, our business may be impaired. Ensuring that our internal operations and business arrangements with third parties comply with applicable laws and regulations also involves substantial costs.More specifically, as a healthcare provider, the Companyâ€™s Exosome Diagnosticsâ€™ ExoDx ProstateÂ business is subject to extensive regulation at the federal, state, and local levels in the U.S. and other countries where it operates. The Companyâ€™s failure to meet governmental requirements under these regulations, including those relating to billing practices and financial relationships with physicians, hospitals, and health systems, could lead to civil and criminal penalties, exclusion from participation in Medicare and Medicaid, and possibly prohibitions or restrictions on the use of its laboratories. While the Company believes that it is in material compliance with all statutory and regulatory requirements, there is a risk that government authorities might take a contrary position. Such occurrences, regardless of their outcome, could damage the Companyâ€™s reputation and adversely affect important business relationships it has with third parties.Failure to comply with privacy and security laws and regulations could result in fines, penalties and damage to the Companyâ€™s reputation and have a material adverse effect upon the Companyâ€™s business, a risk that has been elevated with recent acquisitions that use protected health information and utilize healthcare providers for laboratory resting services.If the Company does not comply with existing or new laws and regulations related to protecting the privacy and security of personal or health information, it could be subject to monetary fines, civil penalties or criminal sanctions. In the U.S., the Health Insurance Portability and Accountability Act of 1996 (HIPAA) privacy and security regulations, including the expanded requirements under U.S. Health Information Technology for Economic and Clinical Health Act (HITECH), establish comprehensive standards with respect to the use and disclosure of protected health information (PHI) by covered entities, in addition to setting standards to protect the confidentiality, integrity and security of PHI. HIPAA restricts the Companyâ€™s ability to use or disclose PHI, without patient authorization, for purposes other than payment, treatment or healthcare operations (as defined by HIPAA), except for disclosures for various public policy purposes and other permitted purposes outlined in the privacy regulations. If the laboratory operations use or disclose PHI improperly under these privacy regulations, they may incur significant fines and other penalties for wrongful use or disclosure of PHI in violation of the privacy and security regulations, including potential civil and criminal fines and penalties.â€‹29 Table of ContentsITEMÂ 1B. UNRESOLVED STAFF COMMENTSThere are no unresolved staff comments as of the date of this report.ITEMÂ 1C. CYBERSECURITYCybersecurity Governance and OversightBio-Techneâ€™s cybersecurity program is led by the Companyâ€™s Chief Information Security Officer (â€œCISOâ€), with day-to-day management and administration of our cybersecurity program performed by the IT Security Operations team. The CISO reports to the Chief Information Officer (â€œCIOâ€), and the CIO reports to the Chief Executive Officer. The CISO is supported by the Incident Response Team (â€œIRTâ€), a multi-disciplinary management committee comprising senior members from the Security Operations Team, legal, finance, internal audit and other functions. The IRT supports the CISO and CIO in supporting and reviewing information security risks and in the event of a cybersecurity incident provides leadership with respect to incident response, investigation, mitigation and remediation. â€‹In addition to leadership and support within management, we also work with security service providers to monitor for vulnerabilities and threats, and which are reported to the Security Operations team. All employees are trained and tested annually on cybersecurity risks, and we continually perform simulated phishing exercises with a focus on roles and functions with access to sensitive company and financial information. We also conduct periodic tabletop exercises for key personnel involved in cybersecurity risk management, including the IRT.â€‹Our Board of Directors (â€œBoardâ€) holds overall oversight responsibility for the Companyâ€™s strategy and risk management, including in relation to cybersecurity risks. The Board exercises its oversight function through the Audit Committee, which oversees the management of risk exposure across various areas, including data security risks, in accordance with its charter. In addition, the Audit Committee is specifically responsible for the review and approval of any cybersecurity incident disclosure, as set forth in the Committeeâ€™s charter. In the event of a potentially significant cybersecurity incident, the Audit Committeeâ€™s charter requires that management promptly communicate and consult with the Audit Committee. â€‹Bio-Techneâ€™s General Counsel updates the Audit Committee multiple times per year regarding Bio-Techneâ€™s cybersecurity programs, including regularly-tracked metrics on incident response, internal security testing, and measures implemented to monitor and address cybersecurity risks and threats, as appropriate. The Audit Committee regularly updates the full Board on these matters. In addition, the CISO and/or CIO provides the full Board with a thorough review of the Companyâ€™s cybersecurity program, including current status, industry risks and exposure, and future strategy. â€‹Based on the information we have as of the date of this Annual Report, we do not believe any risks from cybersecurity threats have materially affected or are reasonably likely to materially affect Bio-Techne, including our business strategy, results of operations or financial condition. However, please see Item 1A. Risk Factors â€“ â€œA significant disruption in, or breach of security of, our information technology systems or data, or violation of data privacy laws, could result in damage to our reputation, data integrity and/or subject us to costs, fines, or lawsuits under data privacy or other laws or contractual requirements.â€ â€‹Cybersecurity Risk Management and Strategy Bio-Techneâ€™s cybersecurity strategy is to maintain and fortify a secure, actively-monitored environment for our and our customersâ€™ data that complies with legal requirements [and industry best practice] while supporting our and our customersâ€™ business needs. Our cybersecurity program follows industry standards and best practice for preventing, detecting, remediating, and mitigating potential cybersecurity threats, including regular processes to identify, evaluate and manage potential risks. â€‹30 Table of ContentsOur IT Security Operations team administers and monitors the prevention, detection, mitigation, and remediation of potential cybersecurity risks. This team leverages both Bio-Techneâ€™s internal IT resources, including its personnel, as well as managed security service providers and other third-party security software and technology services, as well as through other means. We also have implemented processes and technologies for network monitoring and data loss prevention procedures.â€‹We conduct periodic risk assessments, including with support from external vendors, to assess our cyber program, identify areas of enhancement, and develop strategies for the mitigation of cyber risks. We also conduct regular security testing and have established a vulnerability management process supported by security testing, for the treatment of identified security risks based on severity, including risks arising from our use of third party providers software and service providers. In addition to our evolving processes and systems, we foster a culture of cybersecurity education, training, and testing. Every year, employees in sensitive job categories must take and pass rigorous information security and protection training. â€‹We partner with experienced external consultants to assess our cybersecurity program, and to perform penetration testing as well as other testing programs designed to identify vulnerabilities and areas for fortification. Also, as part of our cybersecurity risk management program we maintain cyber insurance, with coverage amounts and terms that are typical and appropriate for a company of our size and type. This insurance may not be sufficient to cover us against all types of claims related to security breaches, cyberattacks and other related breaches. â€‹ITEMÂ 2. PROPERTIESThe Company owns the facilities that its headquarters and R&D Systems subsidiary occupy in Minneapolis, Minnesota. The Minneapolis facilities are utilized by both the Companyâ€™s Protein SciencesÂ and Diagnostics and Genomics segments.The Minneapolis complex includes approximately 800,000 square feet of space in several adjoining buildings. Bio-Techne uses approximately 710,000 square feet of the complex for administrative, research, manufacturing, shipping and warehousing activities. The Company is currently leasingÂ the remaining space in the complex as retail and office space.Â The Company also owns a 61,000 square foot facility in Saint Paul, Minnesota that is utilized forÂ additional manufacturingÂ capabilities and activities.The Company also owns a 34,000 square foot manufacturing facility in Flowery Branch, Georgia. This facility is currently being held-for-sale.The Company owns a 16,000 square foot facility that its Bio-Techne Europe subsidiary occupies in Abingdon, England. This facility is utilized by the Companyâ€™s Protein Sciences and Diagnostics andÂ GenomicsÂ segments.The Company owns a 9,000 square foot facility that its Canada subsidiaries occupy inÂ Toronto, Canada.Â This facility is utilized by the Companyâ€™s Protein Sciences segment.The Company owns a 52,700 square foot manufacturing facility in Wallingford, Connecticut. This facility is utilized by the Companyâ€™s Protein Sciences segment.31 Table of ContentsThe Company leases the following material facilities, which are utilized by both the Companyâ€™s Protein Sciences segment the DiagnosticsÂ & Genomics segment. Certain locations are not named because they were not significant individually or in the aggregate as of the date of this report.â€‹â€‹â€‹

Statementsâ€ and â€œRisk Factorsâ€ within Items 1 and 1A of this FormÂ 10-K.OVERVIEWBio-TechneÂ develops, manufactures and sells life science reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.We manage the business in two operating segments â€” our Protein Sciences segment and our Diagnostics and Genomics segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. Our Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications.RECENT ACQUISITIONSA key component of the Company's strategy is to augment internal growth at existing businesses with complementary acquisitions. As disclosed in Note 4, the Company completed the acquisition of Lunaphore for $169.7 million, in a cash-free, debt-free acquisition. We also purchased a 19.9% investment in Wilson Wolf in fiscal 2023 and, as disclosed in Note 1, will acquire the remaining shares in Wilson Wolf by the end of calendar year 2027, or earlier depending on the achievement of certain future milestones. Â Â OVERALL RESULTSOperational UpdateFor fiscal 2024, consolidated net salesÂ increased 2% to $1.2 billion as compared to fiscal 2023.Â Organic growth was 1%, with acquisitions having a favorable impact of 1%. Foreign currency translation and a business held-for sale did not have a material impact. Organic revenue growth was primarily driven by strong commercial execution in our Diagnostics and Genomics segment.â€‹Consolidated net earnings, including non-controlling interest, decreased 41% compared to fiscal 2023. The decrease in earnings was driven by a non-recurring gain on the sale of our ChemoCentryx investment, a non-recurring gain on the sale of our investment in Changzhou Eminence Biotechnology Co., Ltd. (Eminence), and a non-recurring benefit related to the fair value of contingent consideration during fiscal 2023. The decrease in fiscal 2024 was also impacted by impairment of assets held-for-sale, restructuring charges, and CEO transition related charges. After adjusting for cost recognized upon 35 Table of Contentssale of acquired inventory, intangibles amortization, acquisition-related costs,Â certain litigation charges, gain on sale of investments, stock-based compensation, restructuring and restructuring-related costs, impairment of assets held-for-sale, impact of business held-for-sale, and impact from partially-owned consolidated subsidiaries, adjusted net earnings attributable to Bio-Techne decreased 11% in fiscal 2024Â as compared to fiscal 2023. Adjusted net earnings attributable to Bio-Techne was primarily impacted by the acquisition of Lunaphore and unfavorable volume leverage within Protein Sciences. For fiscal 2023, consolidated net salesÂ increased 3% as compared to fiscal 2022.Â Organic growth was 5%, with foreign currency translation having an unfavorable impact of 2% and acquisitions having an immaterial impact. Organic revenue growth was primarily driven by consumable growth in both our Diagnostics and Genomics and Protein Sciences segments.Â Consolidated earnings, including non-controlling interest, increased 8% compared to fiscal 2022. The increase in earnings was driven by a gain on the sale of our ChemoCentryx investment and a gain on the sale of our investment in Eminence. After adjusting for acquisition related costs, intangibles amortization,Â stock-based compensation, restructuring costs, gain on investments, and impact from partially-owned consolidated subsidiaries, adjusted net earnings attributable to Bio-Techne decreased 1% in fiscal 2023Â as compared to fiscal 2022. Adjusted net earnings attributable to Bio-Techne was primarily impacted by foreign currency exchange and strategic growth investments including the Namocell acquisition.â€‹RESULTS OF OPERATIONSNet SalesConsolidated organic net sales exclude the impact of companies acquired during the first 12Â months post-acquisition and the effect of the change from the priorÂ year in exchange rates used to convert sales in foreign currencies (primarily the euro, British pound sterling, Chinese yuan, and Swiss franc) into U.S. dollars.â€‹Consolidated net sales growth was as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Â Year Ended JuneÂ 30,Â Â â€‹Â Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Organic sales growthÂ 1%Â Â 5%Â Â 17%Â Â Acquisitions sales growthÂ 1%Â Â 0%Â Â 3%Â Â Impact of foreign currency fluctuationsÂ 0%Â Â (2)%Â Â (1)%Â Â Impact of business held for saleâ€‹0%Â Â â€”%Â Â â€”%Â Â Consolidated net sales growthÂ 2%Â Â 3%Â Â 19%â€‹Consolidated net sales byÂ segment were as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Year Ended JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Protein Sciencesâ€‹$ 830,902â€‹$ 845,747â€‹$ 832,311Diagnostics and Genomicsâ€‹Â 326,392â€‹Â 292,602â€‹Â 274,843Other revenue(1)â€‹â€‹ 4,153â€‹â€‹ â€”â€‹â€‹ â€”Intersegmentâ€‹Â (2,387)â€‹Â (1,647)â€‹Â (1,555)Consolidated net salesâ€‹$ 1,159,060â€‹$ 1,136,702â€‹$ 1,105,599â€‹(1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. The year ended June 30, 2024 includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria.â€‹In fiscal 2024, Protein Sciences segment net sales decreased 2% compared to fiscal 2023. A business within the Protein Sciences Segment met the criteria as held-for-sale since December 31, 2023. The exclusion of third and fourth quarter of 36 Table of Contentsfiscal 2024 sales related to a held-for-sale business reduced sales by 1%. Organic revenue for the segment declined 2% for the fiscal year, with foreign currency exchange having a favorable 1% impact on revenue. Segment revenue was impacted by broad based headwinds.In fiscal 2024, Diagnostics andÂ Genomics segment net sales increased 12% compared to fiscal 2023. Organic growth for the segment was 6%, with acquisitions having a 5% impact and foreign currency exchange having a favorable impact of 1% on revenue growth. Segment growth was driven by broad based molecular diagnostics performance and Lunaphore.In fiscal 2023, Protein Sciences segment net sales increased 2% compared to fiscal 2022. Organic growth for the segment was 4% for the fiscal year, with currency translation having an unfavorable impact of 2% on revenue and acquisitions having an immaterial impact on revenue growth. Segment growth was driven by growth in consumable revenue to BioPharma (especially those developing cell and gene therapies) and Academic customers within the Americas and Europe.Â In fiscal 2023, Diagnostics and Genomics segment net sales increased 6% compared to fiscal 2022. Organic growth for the segment was 8% with currency translation having an unfavorable impact of 2%. Segment growth was driven by growth in consumable revenue from our Spatial Biology platform and an increase in service revenue related to our ExoDx Prostate test.Â Â Â â€‹Gross MarginsConsolidated gross margins were 66.4%, 67.7%, and 68.4% in fiscal 2024, 2023, and 2022. Consolidated gross margins were impacted by revenue.Â Excluding the impact of acquired inventory sold,Â amortization of intangibles, stock compensation expense, restructuring and restructuring-related costs, impact of business held-for-sale, and the impact of partially-owned consolidated subsidiaries, adjusted gross margins were 71.0%, 71.7%, and 72.5%Â in fiscal 2024, 2023, and 2022,Â respectively. Fiscal 2024 consolidated gross margin was impacted by the Lunaphore acquisition when compared to the prior period. Fiscal 2023 consolidated gross margin was unfavorably impacted by foreign currency exchange and strategic growth investments including the Namocell acquisition when compared to fiscal 2022. Consolidated gross margins for fiscal 2022 were impacted as a result of volume leverage and product mix, partially offset by additional investments made in the business to support future growth.A reconciliation of the reported consolidated gross marginÂ percentages, adjusted for acquired inventory sold, intangible amortization included in cost of sales, restructuring and restructuring-related expenses, and impact of business held-for-sale is as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â â€‹â€‹Year Ended JuneÂ 30,Â â€‹â€‹â€‹2024Â Â Â Â 2023Â Â Â Â 2022Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Consolidated gross margin percentageâ€‹ 66.4%Â Â 67.7%Â Â 68.4%Identified adjustments:â€‹â€‹Â Â Â Â Â Â Â â€‹Costs recognized upon sale of acquired inventoryâ€‹0.1%Â Â 0.0%Â Â 0.1%Amortization of intangiblesâ€‹ 4.0%Â Â 4.0%Â Â 3.7%Stock compensation expense - COGSâ€‹ 0.1%Â Â 0.1%Â Â 0.1% Restructuring and restructuring-related costsâ€‹ 0.3%Â Â â€”%Â Â â€”%Impact of partially-owned consolidated subsidiaries(1)â€‹ â€”%Â Â (0.1)%Â Â 0.2%Impact of business held-for-sale(2)â€‹ 0.1%Â Â â€”%Â Â â€”%Non-GAAP adjusted gross margin percentageâ€‹ 71.0%Â Â 71.7%Â Â 72.5%â€‹(1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023 and the full fiscal year of 2022.â€‹(2) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. Fiscal year 2024 includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria.37 Table of Contentsâ€‹Fluctuations in adjusted gross margins, as aÂ percentage of net sales, have primarily resulted from changes in foreign currency exchange rates and changes in product mix. We expect that, in the future, gross margins will continue to be impacted by the mix of our portfolio growing at different rates as well as future acquisitions.Management uses adjusted operating results to monitor and evaluate performance of the Companyâ€™s two segments.Â Segment gross margins, as aÂ percentage of net sales, were as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Year Ended JuneÂ 30,Â Â â€‹â€‹2024Â Â Â Â 2023Â Â Â Â 2022Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Protein SciencesÂ 75.7%Â Â 75.3%Â Â 75.5%Diagnostics and GenomicsÂ 58.7%Â Â 61.2%Â Â 63.1%â€‹The increase in the Protein Sciences segmentâ€™s gross marginÂ percentage for fiscal 2024Â as compared to fiscal 2023Â was primarily attributable to the exclusion of a business held-for-sale. The change in the Protein Sciences segmentâ€™s gross margin percentage for fiscal 2023 compared to fiscal 2022Â was primarily attributable toÂ mix of product sales withinÂ the segment.The change in the Diagnostics and Genomics segmentâ€™s gross margin percentage for fiscal 2024 as compared to fiscal 2023 is due to the Lunaphore acquisition. The change in the Diagnostics and Genomics segmentâ€™s gross margin percentage for fiscal 2023 as compared to fiscal 2022 is due to fiscal 2022 revenue related to the ExoTru kidney transplant rejection agreement that did not reoccur in fiscal 2023. Fiscal 2023 compared to fiscal 2022 was also impacted by strategic investments to drive future growth that was partially offset by volume leverage. Selling, General and Administrative ExpensesSelling, general and administrative expenses increased $88.0Â million (23%) in fiscal 2024Â when compared to fiscal 2023. Selling, general, and administrative expenses increased primarily due to the Lunaphore acquisition, impairment of assets held-for-sale, certain litigation charges, restructuring and restructuring-related charges, and CEO transition charges. Selling, general and administrative expenses increased $5.6Â million (2%) in fiscal 2023Â when compared to fiscal 2022. Selling, general, and administrative expenses increased primarily due to strategic investments made in the business to support future growth including the Namocell acquisition. 38 Table of ContentsConsolidated selling, general and administrative expenses were composed of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Year Ended JuneÂ 30,Â â€‹â€‹2024â€‹2023â€‹2022â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Protein Sciencesâ€‹$ 217,595â€‹$ 203,834â€‹$ 195,328Diagnostics and Genomicsâ€‹Â 127,131â€‹Â 101,805â€‹Â 93,578Total segment expensesâ€‹Â 344,726â€‹Â 305,639â€‹Â 288,906Amortization of intangiblesâ€‹Â 31,710â€‹Â 32,076â€‹Â 32,492Acquisition related expensesâ€‹Â 6,980â€‹Â (9,965)â€‹Â (19,082)Eminence impairment(1)â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 18,715Legal feesâ€‹â€‹ 3,506â€‹â€‹ â€”â€‹â€‹ â€”Restructuring and restructuring-related costsâ€‹Â 8,896â€‹Â 3,829â€‹Â 1,640Stock-based compensationâ€‹Â 39,452â€‹Â 40,269â€‹Â 45,085Impairment of assets held-for-saleâ€‹â€‹ 21,963â€‹â€‹ â€”â€‹â€‹ â€”Corporate selling, general and administrative expensesâ€‹Â 9,142â€‹Â 6,530â€‹Â 5,010Total selling, general and administrative expensesâ€‹$ 466,375â€‹$ 378,378â€‹$ 372,766â€‹(1)Refer to the Goodwill Impairment section within the Critical Accounting Policies for further details on the Eminence impairment. â€‹Research and Development ExpensesResearch and development expenses increased $4.2 million (5%) and $5.4Â million (6%) in fiscal 2024 and 2023, respectively, as compared to priorÂ year periods. The increase in research and development expenses in fiscal 2024Â and fiscal 2023 compared to the prior periods was primarily attributable to strategic growth investments including the acquisitions of Lunaphore and Namocell in fiscal 2024 and fiscal 2023, respectively. Consolidated research and development expenses were composed of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Year Ended JuneÂ 30,Â â€‹â€‹2024â€‹2023â€‹2022â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Protein Sciencesâ€‹$ 56,911â€‹$ 58,251â€‹$ 56,370Diagnostics and Genomicsâ€‹Â 39,753â€‹Â 34,242â€‹Â 30,770Total research and development expensesâ€‹$ 96,664â€‹$ 92,493â€‹$ 87,140â€‹Net Interest Income / (Expense)Net interest income/(expense) for fiscal 2024, 2023, and 2022Â was ($12.4) million,Â $(7.8) million, and $(10.5) million,Â respectively. During fiscal 2024, average monthly outstanding debt was higher than fiscal 2023 leading to increased interest expense compared to fiscal 2023. Net interest expense in fiscal 2023 decreased when compared to fiscal 2022Â due to a favorable rate on a forward starting interest rate swap as disclosed in Note 5 that went into effect in fiscal year 2023. 39 Table of ContentsOther Non-Operating Income / (Expense), NetOther non-operating income/(expense), net, consists of foreign currency transaction gains and losses, rental income, building expenses related to rental property and the Companyâ€™sÂ gains and losses onÂ investmentsÂ as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Year Ended JuneÂ 30,Â â€‹â€‹2024â€‹2023â€‹2022â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Foreign currency gains (losses)â€‹$ (726)â€‹$ 676â€‹$ 699Rental incomeâ€‹Â 305â€‹Â 426â€‹Â 599Real estate taxes, depreciation and utilitiesâ€‹Â (1,630)â€‹Â (1,810)â€‹Â (2,035)Gain on investmentâ€‹Â 283â€‹Â 49,328â€‹Â 15,186Loss on equity method investmentâ€‹â€‹ (6,841)â€‹â€‹ (1,143)â€‹â€‹ â€”Miscellaneous (expense) incomeâ€‹Â 25â€‹Â 43â€‹Â 862Other non-operating income (expense), netâ€‹$ (8,584)â€‹$ 47,520â€‹$ 15,311â€‹During fiscal 2024, the Company recognized a gain of $0.3 million related to the sale of our exchange traded bond funds. Additionally, the Company recognized losses of $6.8 million related to our equity method investment in Wilson Wolf. During fiscal 2023, the Company recognized gains of $37.2Â million related to the sale ofÂ ourÂ ChemoCentryx,Â Inc. (CCXI) investment, $11.7 million related to the sale of our Eminence investment, and a gain of $0.4 million related to the change in fair value of our exchange traded bond funds. Additionally, the Company recognized losses of $1.1 million related to our equity method investment in Wilson Wolf. During fiscal 2022, the Company recognized gains of $16.1Â million related to changes in fair valueÂ associated withÂ changes in the stock price ofÂ ourÂ CCXI investment. Additionally, the Company recognized losses of $1.1 million related to changes in fair value associated with changes in the stock price of our exchange traded investment grade bond funds. On August 4, 2022, the Company sold all of its shares in CCXI.Income TaxesIncome taxes for fiscal 2024,Â 2023, and 2022 were at effective rates of 9.5%, 15.7%, and 12.7%,Â respectively, of consolidated earnings before income taxes. The change in the effective tax rate for fiscal 2024 compared to fiscal 2023 was driven by share-based compensation as the number of stock option exercises increased compared to the prior year comparative period. The Company had share-based compensation excess tax benefits of $18.4 million in fiscal 2024. The Companyâ€™s discrete tax benefits in fiscal 2023Â primarily related to share-based compensation excess tax benefits of $12.3 million. The Companyâ€™s discrete tax benefits in fiscal 2022 primarily related to share-based compensation excess tax benefits of $29.3Â million.Â â€‹40 Table of ContentsNet EarningsNon-GAAP adjusted consolidated net earnings and earnings per share are as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

certificiates of deposit in the prior comparable period. As of June 30, 2023, there was $23.7 million included in the available-for-sale investments related to the fair value of the Companyâ€™s investment in exchange traded investment grade bond funds. Â At JuneÂ 30, 2024, approximately 28% of the Companyâ€™s cash and cash equivalent account balances of $42.2Â million were located in the U.S., with the remainder located in primarily in Canada, China, the U.K. and other European countries.At JuneÂ 30, 2024, all of the Companyâ€™s available-for-sale investment account balances of $1.1Â million were located in Europe.At June 30, 2024, we had $319 million in borrowings under the revolving credit facility, resulting in $681 million of unutilized availability under our revolving credit facility. The Company has either paid U.S. taxes on its undistributed foreign earnings or intends to indefinitely reinvest the undistributed earnings in the foreign operations or expects the earnings will be remitted in a tax neutral transaction. Management of the Company expects to be able to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12Â months, through currently available funds, including funds available through ourÂ line-of-creditÂ and cash generated from operations.Future acquisition strategies may or may not require additional borrowings under the line-of-credit facility or other outside sources of funding.Cash Flows From Operating ActivitiesThe Company generated cash from operations of $299.0Â million, $254.4 million, and $325.3 millionÂ in fiscal 2024, 2023, and 2022 respectively. The increase in cash generated from operating activities in fiscal 2024Â as compared to fiscal 2023Â was mainly a result of changes in the timing of cash payments on certain operating assets and liabilities. The decrease in cash generated from operating activities in fiscal 2023Â as compared to fiscal 2022Â was mainly a result of changes in net earnings and changes in the timing of cash payments on certain operating assets and liabilities. 42 Table of ContentsCash Flows From Investing ActivitiesWe continue to make investments in our business, including capital expenditures to enable revenue growth. During fiscal year 2024, the Company acquired Lunaphore for $169.7 million in cash-free, debt-free acquisition. During fiscal year 2023, the Company acquired Namocell for $101.2 million, net of cash acquired. There were no acquisitions in fiscal year 2022. During the first fiscal quarter of 2023, the Company sold its remaining shares in Eminence, its partially-owned consolidated subsidiary, for $17.8 million. There were no sales of businesses in fiscal 2024 or 2022. In the first fiscal quarter of 2023, the Company sold its remaining shares in its investment in CCXI for $73.2 million. There were no comparable activities in fiscal 2024 and 2022.The Companyâ€™s net proceeds (outflow) from the purchase, sale and maturity of available-for-sale investments in fiscal 2024, 2023, and 2022 were $22.6 million,Â $14.7 million, and $(26.9) million, respectively. During fiscal year 2024, the Companyâ€™s proceeds in available-for-sale investments relates to the sale of our exchange traded investment grade bond funds. The proceeds during fiscal year 2023 relates to the sale of excess cash in certificates of deposit that matured. The outflow of cash in fiscal year 2022Â compared to fiscal year 2024 and fiscal year 2023 was driven by the purchase of the exchange traded investment grade bond funds in fiscal year 2022, which had a cost basis of $25.0 million, that did not reoccur in the comparative periods. The Companyâ€™s investment policy is to place excess cash in certificates of depositÂ with the objective of obtaining the highest possible return while minimizing risk and keeping the funds accessible.Capital additions in fiscalÂ year 2024, 2023, and 2022 were $62.9Â million, $38.2 million, and $44.9 million. Fiscal 2024 capital expenditures related to investments in new buildings, machinery, construction in progress, and IT equipment. Fiscal 2023 capital expenditures related to investments in new buildings, machinery, and IT equipment.Â Capital additions planned for fiscal 2025Â are approximately $48 million and are expected to be financed through currently available cash and cash generated from operations.During the year ended June 30, 2022, the Company paid $25 million to enter into a two-part forward contract which requires the Company to purchase the full equity interest in Wilson Wolf if certain annual revenue or EBITDA thresholds are met. During fiscal year 2023, Wilson Wolf met the EBITDA target and the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf. Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, which requires the Company to acquire the remaining 80.1% of Wilson Wolf on December 31, 2027. The second part of the contract would be accelerated in advance of December 31, 2027 if Wilson Wolf meets certain financial milestones. As of June 30, 2024, the second milestones have not been met. The second option payment of approximately $1 billion plus potential contingent consideration is forecasted to occur between fiscal 2026 and fiscal 2028. During fiscal 2024, the Company received tax distributions from Wilson Wolf of $7.0 million. Cash Flows From Financing ActivitiesIn fiscal 2024, 2023, and 2022, the Company paid cash dividends of $50.4Â million, $50.3Â million, $50.2 million, respectively. The Board of Directors periodically considers the payment of cash dividends.The Company received $60.9Â million, $29.8 million, $77.2 million, for the exercise of options for 2,240,000, 1,578,000, and 2,450,000 sharesÂ of common stock in fiscal 2024, 2023 and 2022, respectively.During fiscal 2024, 2023, and 2022, the Company repurchased $80.0 million, $19.6 million, and $161.0 million, respectively, in share repurchases included as a cash outflow within Financing Activities.During fiscal 2024, 2023, and 2022, the Company drew $225.0 million, $619.7 million, and $90.0 million, respectively,Â under its revolving line-of-credit facility. Repayments of $256.0 million, $525.7 million, and $175.5 million were made on its line-of-credit in fiscal 2024, 2023, and 2022, respectively.There were no payments during fiscal 2024 nor fiscal 2023 for contingent consideration. During fiscal 2022, the Company made $4.0 million in cash payments towards the Quad contingent consideration liability. Of the $4.0 million in total 43 Table of Contentspayments, $0.7 million is classified as financing on the statement of cash flows. The remaining $3.3 million was recorded as operating on the statement of cash flows as it represents the consideration liability that exceeds the amount of the contingent consideration liability recognized at the acquisition date.During fiscal 2024, 2023 andÂ 2022,Â the Company paid $21.9 million, $28.9 million andÂ $23.5 million, respectively, for taxes remitted on behalf of participants in net share settlement transactions and restricted stock units. The other financing activity during fiscal 2023 is primarily related to fees for the amended Credit Agreement that occurred in the first fiscal quarter. There was no comparable activity in fiscal 2024 or fiscal 2022. CRITICAL ACCOUNTING POLICIESManagementâ€™s discussion and analysis of the Companyâ€™s financial condition and results of operations are based upon the Companyâ€™s Consolidated Financial Statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.The Company has identified the policies outlined below as critical to its business operations and an understanding of results of operations. The listing is not intended to be a comprehensive list of all accounting policies; investors should also refer to NoteÂ 1 to the Consolidated Financial Statements included in ItemÂ 8 of this Annual Report on FormÂ 10-K.Business CombinationsWe allocate the purchase price of acquired businesses to the estimated fair values of the assets acquired and liabilities assumed as of the date of the acquisition. The calculations used to determine the fair value of the long-lived assets acquired, primarily intangible assets, can be complex and require significant judgment. We weigh many factors when completing these estimates including, but not limited to, the nature of the acquired companyâ€™s business; its competitive position, strengths, and challenges; its historical financial position and performance; estimated customer retention rates; discount rates; and future plans for the combined entity. We may also engage independent valuation specialists, when necessary, to assist in the fair value calculations for significant acquired long-lived assets.The fair value of acquired technology is generally the primary asset identified and thereforeÂ estimated using the multi-period excess earnings method. The multi-period excess earnings methodÂ model estimates revenues and cash flows derived from the primaryÂ asset and then deducts portions of the cash flow that can be attributed to supporting assets, such as TradeÂ Names and in-process research and development, that contributed to the generation of the cash flows. The resulting cash flow, which is attributable solely to the primary asset acquired, is then discounted at a rate of return commensurate with the risk of the asset to calculate a present value. The Trade Name is generally calculatedÂ using the relief from royalty method, which calculates the cost savings associated with owning rather than licensing the technology. Assumed royalty rates are applied to the projected revenues for the remaining useful life of the technology to estimate the royalty savings. In-process research and development assets are valued using the multi-period excess earnings method when the cash flows from the in-process research and development assets are separately identifiable from the primary asset.Â In circumstances that Customer Relationship assets are identified that are not the primary asset, they are valued using the distributor model income approach, which isolates revenues and cash flow associated with the sales and distribution function of the entity and attributable to customer-related assets, which are then discounted at aÂ rate of return commensurate with the risk of the asset to calculate a present value.We estimate the fair value of liabilities for contingent consideration by discounting to present value the probability weighted contingent payments expected to be made. For potential payments related to financial performance based milestones,Â projected revenue and/or EBITDA amounts, volatility and discount rates assumptions are included in the estimated amounts.Â For potential payments related to product development milestones,Â the fair value is based on the 44 Table of Contentsprobability of achievement of such milestones.Â The excess of the purchase price over the estimated fair value of the net assets acquired is recorded as goodwill. Goodwill is not amortized, but is subject to impairment testing on at least an annual basis.We are also required to estimate the useful lives of the acquired intangible assets, which determines the amount of acquisition-related amortization expense we will record in future periods. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization.While we use our best estimates and assumptions, our fair value estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to oneÂ year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Any adjustments required after the measurement period are recorded in the consolidated statements of earnings.The judgments required in determining the estimated fair values and expected useful lives assigned to each class of assets and liabilities acquired can significantly affect net income. For example, different classes of assets will have useful lives that differ. Consequently, to the extent a longer-lived asset is ascribed greater value than a shorter-lived asset, net income in a given period may be higher. Additionally, assigning a lower value to amortizable intangibles would result in a higher amount assigned to goodwill. As goodwill is not amortized, this would benefit net income in a given period, although goodwill is subject to annual impairment analysis.Impairment of GoodwillGoodwillGoodwill was $972.7 million as of JuneÂ 30, 2024, which represented 36% of total assets. Goodwill is tested for impairment on an annual basis in the fourth quarter of eachÂ year, or more frequently if events occur or circumstances change that could indicate a possible impairment.To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business.The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation for goodwill is an assessment of factors including reporting unit specific operating results as well as industry and market conditions, overall financial performance, and other relevant events and factors to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass the qualitative assessment for its reporting units and perform a quantitative test. The quantitative impairment test requires us to estimate the fair value of our reporting units based on the income approach. The income approach is a valuation technique under which we estimate future cash flows using the reporting unitâ€™s financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we project revenue and apply our fixed and variable cost experience rate to the projected revenue to arrive at the future cash flows. A terminal value is then applied to the projected cash flow stream. Future estimated cash flows are discounted to their present value to calculate the estimated fair value. The discount rate used is the value-weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we are required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items. For fiscal 2024, we elected to perform a qualitative analysis for all five reporting units. The Company determined, after performing the qualitative analysis, there was no evidence that it is more likely than not that the fair value was less than the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test in fiscal 2024. During the 45 Table of Contentssecond quarter of fiscal 2024, as part of restructuring actions, certain assets and liabilities associated with a disposal group in our Protein Sciences segment were classified as held-for-sale as of December 31, 2023. Given the upcoming divestiture, the Company identified a triggering event and performed impairment testing during the second half of fiscal 2024. The impairment test resulted in a total impairment charge of $22.0 million, which includes the allocated goodwill, which we have further described within Note 1. The Company did not identify any triggering events after our annual goodwill impairment analysis through June 30, 2024, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed.For fiscal 2023, we elected to perform a qualitative analysis for all five reporting units. The Company determined, after performing the qualitative analysis, there was no evidence that it was more likely than not that the fair value was less than the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test in fiscal 2023. The Company did not identify any triggering events after our annual goodwill impairment analysis through June 30, 2023, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed.In the first quarter of fiscal 2022, the Company combined the management of the Exosome Diagnostics and Asuragen reporting units, both of which were included in the Diagnostics and Genomics operating segment. In conjunction with the combination of the reporting units, a qualitative goodwill impairment assessment was performed. The qualitative assessment identified no indicators of impairment.In the second quarter of fiscal 2022 Eminence notified the Company of its need for additional capital to execute its growth plan. The Company first attempted to find outside equity financing support for the Eminence investment but was unable to do so. The Company then reviewed the additional financing needs required to successfully ramp Eminenceâ€™s business, which ultimately did not meet the Companyâ€™s return on capital requirements. Therefore, the Company did not provide additional funding to Eminence. As a result of not obtaining additional financing, Eminence notified the Company of its plans to cease operations and liquidate its business.Given the upcoming liquidation process to dispose of the Eminence assets, the Company identified a triggering event and performed impairment testing during the second quarter of fiscal 2022. The impairment testing resulted in a full impairment of the Eminence goodwill and intangible assets, which resulted in charges of $8.3 million and $8.6 million, respectively, for the year ended June 30, 2022. The Company also recognized inventory and fixed asset impairment charges of $0.9 million and $0.9 million, respectively. The Company recorded the impairment charges within the General and Administrative line in the Consolidated Income Statement. The impairment charges recorded within Net Earnings Attributable to Bio-Techne were reduced by approximately $8 million recorded within Net Earnings Attributable to Noncontrolling Interests. The remaining net tangible assets of Eminence included in our Consolidated Balance Sheet as of June 30 2022, were $4.3 million and primarily consisted of fixed assets and related deposits of $3.1 million, inventory of $0.6 million, receivables of $0.4 million, and other current assets of $0.1 million. The Company also had $4.5 million related to current liabilities. The Company held a financial interest of approximately 57.4% in those tangible assets in the liquidation process. As described in Note 1, in the fourth quarter of fiscal 2022, Eminence was able to secure cash deposits on future orders to provide funding for their operations. This delay in liquidation allowed time for securing of additional investor financing which coincided with the sale of the Company's equity shares of Eminence in the first quarter of fiscal 2023. Â In the first quarter of fiscal 2022, the Company combined the management of the Exosome Diagnostics and Asuragen reporting units, both of which are included in the Diagnostics and Genomics operating segment. In conjunction with the combination of the reporting units, a qualitative goodwill impairment assessment was performed. The qualitative assessment identified no indicators of impairment.In our fiscal 2022 annual goodwill impairment analysis, we elected to perform a quantitative assessment for all five of our reporting units. The result of our quantitative assessment indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2022. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2022, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed.46 Table of ContentsNEW ACCOUNTING PRONOUNCEMENTSInformation regarding the accounting policies adopted during fiscal 2024Â and those not yet adopted can be found under caption â€œNoteÂ 1: Description of Business and Summary of Significant Accounting Policiesâ€ of the NotesÂ to the Consolidated Financial Statements appear in ItemÂ 8 of this report.SUBSEQUENT EVENTSOn July 23, 2024, the Company invested $15 million in Spear Bio, an innovative leader in the development and manufacture of ultra-sensitive immunoassays capable of measuring protein biomarkers at attomolar level from sub-microliter sample volume. NON-GAAP FINANCIAL MEASURESThis Annual Report on FormÂ 10-K, including â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ in ItemÂ 7, contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:â—Organic growthâ—Adjusted gross marginâ—Adjusted operating marginâ—Adjusted net earningsâ—Adjusted effective tax rateâ€‹We provide these

measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.47 Table of ContentsOur non-GAAP financial measure of organic revenue represents revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, the impact of businesses held-for-sale, as well as the impact of partially-owned consolidated subsidiaries. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from businesses held-for-sale are excluded from our organic revenue calculation starting on the date they become held-for-sale as those revenues will not be comparative in future periods. Revenues from partially-owned subsidiaries consolidated in our financial statements are also excluded from our organic revenue calculation, as those revenues are not fully attributable to the Company. There was no revenue from partially-owned consolidated subsidiaries in fiscal year 2024 due to the sale of Changzhou Eminence Biotechnology Co., Ltd. (Eminence) in the first quarter of fiscal 2023. Revenue from partially-owned consolidated subsidiaries was $2.0 million for the year ended June 30, 2023.Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, restructuring and restructuring-related costs, and other non-recurring items including non-recurring costs, goodwill and long-lived asset impairments, and gains. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjection assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory and acquisition-related expenses inclusive of the changes in fair value contingent consideration, and other non-recurring items including gains or losses on goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses). In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. Â Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to partially-owned consolidated subsidiaries as well as revenue and expense attributable to businesses held-for-sale in the calculation of our non-GAAP financial measures.The Companyâ€™s non-GAAP adjusted operating margin and adjusted net earnings, in total and on a per share basis, also excludes acquisition related expenses inclusive of the changes in fair value of contingent consideration, gain and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future), certain adjustments to income tax expense, and other non-recurring items including certain costs related to the transition to a new CEO. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.The Company periodically reassesses the components of our non-GAAP adjustments for changes in how we evaluate our performance, changes in how we make financial and operational decisions, and considers the use of these measures by our competitors and peers to ensure the adjustments are still relevant and meaningful.Readers are encouraged to review the reconciliations of the adjusted financial measures used in managementâ€™s discussion and analysis of the financial condition of the CompanyÂ to their most directly comparable GAAP financial measuresÂ provided within the Companyâ€™sÂ consolidated financial statements.â€‹48 Table of ContentsITEMÂ 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURESEASONAL MARKET RISKThe Company operates internationally, and thus is subject to potentially adverse movements in foreign currency exchange rates. Approximately 31% of the Companyâ€™s consolidated net sales in fiscal 2024Â were made in foreign currencies, includingÂ 14% in euro, 4% in British pound sterling, 6% in Chinese yuan, 3% in Canadian dollars, 1% in Swiss francs, and the remaining 3% in other currencies. The Company is exposed to market risk primarily from foreign exchange rate fluctuations of the euro, British pound sterling, Chinese yuan, Canadian dollar, and Swiss franc as compared to the U.S. dollar as the financial position and operating results of the Companyâ€™s foreign operations are translated into U.S. dollars for consolidation.Month-end exchange rates between the euro, British pound sterling, Chinese yuan, Canadian dollar, Swiss franc and the U.S. dollar, which have not been weighted for actual sales volume in the applicableÂ months in the periods, were as follows:â€‹â€‹â€‹

cash equivalentsâ€‹Â (2,333)Â (3,356)Â (12,092)Net change in cash and cash equivalentsâ€‹Â (28,780)Â 8,004Â (26,524)Cash and cash equivalents at beginning of periodâ€‹Â 180,571Â 172,567Â 199,091Cash and cash equivalents at end of periodâ€‹$ 151,791$ 180,571$ 172,567â€‹See NotesÂ to Consolidated Financial Statements.53 Table of ContentsNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTSBio-Techne Corporation and SubsidiariesYears ended JuneÂ 30, 2024, 2023Â and 2022NoteÂ 1.Â Description of Business and Summary of Significant Accounting Policies:Description of business: Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (the Company), develop, manufacture and sell life science reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.At the 2022 annual meeting of shareholders of the Company held on October 27, 2022, the shareholders approved an amendment and restatement of the Companyâ€™s articles of incorporation to increase the number of authorized shares of the Companyâ€™s common stock from 100,000,000 to 400,000,000. On November 1, 2022, the Companyâ€™s board of directors approved and declared a four-for-one split of the Companyâ€™s common stock in the form of a stock dividend. Each stockholder of record on November 14, 2022 received three additional shares of common stock for each then-held share, which were distributed after close of trading on November 29, 2022. All share and per share amounts presented herein have been retroactively adjusted to reflect the impact of the stock split.Use of estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates.Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. As Eminence met the criteria for consolidation, the transaction was accounted for in accordance with ASCÂ 805,Â Business Combinations. In applying ASCÂ 805Â to the transaction, the Company has elected to include Eminence in our consolidated financial statements on aÂ oneÂ month lag. As noted below, Eminence was sold during the first fiscal quarter of 2023. Equity method investments: The company accounts for its equity method investments in accordance with ASC 323, Investments - Equity Method and Joint Ventures. The Company initially records its equity method investments at the amount of the Companyâ€™s investment and adjusts each period for the Companyâ€™s share of the investeeâ€™s income or loss and dividends paid. Distributions from the equity method investee are accounted for using the cumulative earnings approach on the Consolidated Statement of Cash Flows. In December 2021, the Company paid $25 million to enter into a two-part forward contract which requires the Company to make an initial ownership investment followed by purchase of full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or annual earnings before interest, taxes, depreciation, and amortization (EBITDA) thresholds are met. Wilson Wolf is a leading manufacturer of cell culture devices, including the G-Rex product line. The first part of the forward contract was triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in EBITDA at any point prior to December 31, 2027. During the quarter ended March 31, 2023, the Company determined that Wilson Wolf had met the EBITDA target. On March 31, 2023, the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf, which is accounted for as an equity method investment.Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, and requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple of approximately 4.4 times trailing twelve month revenue. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million 54 Table of Contentsin annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone.Translation of foreign financial statements: Assets and liabilities of the Companyâ€™s foreign operations are translated atÂ year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for theÂ year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income.Revenue recognition:Â ASC 606 provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer toÂ NoteÂ 2 for additional information regarding our revenue recognition policy under ASC 606.Research and development: Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications.Advertising costs: Advertising expensesÂ were $4.1Â million, $4.8Â million, andÂ $4.6Â million for fiscal 2024, 2023, and 2022 respectively. Advertising expenditures are expensed as incurred.Income taxes: The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in theÂ years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fiftyÂ percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Refer to NoteÂ 12Â for additional information regarding income taxes.Comprehensive income: Comprehensive income includes charges and credits to shareholdersâ€™ equity that are not the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholdersâ€™ equity. Any tax effects, if applicable, associated with reclassifications of accumulated other comprehensive income to net income are reflected in the provision for income taxes. Cash and cash equivalents: Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of threeÂ months or less.Available-for-sale investments: Available-for-sale investments consist of debt instruments with original maturities of generally threeÂ months to less than one-year and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value.Â Unrealized gains and losses on our available-for-sale securities are included within other income (expense).Trade accounts receivable and allowances: Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do not bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments.Â When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall 55 Table of Contentscomposition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer. The Company does not have material long-term customer receivables.Â Inventories: Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory not meeting quality control standards and inventory subject toÂ expiration.For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no material changes to the Companyâ€™s estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscalÂ years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with ASC 330Â - Inventory.Property and equipment: Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are depreciated over estimated useful lives of 5 to 40 years.Contingencies: The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better restimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and the amount may be reasonably estimated, the estimated loss or range of loss is disclosed. Contingent Consideration: ContingentÂ Consideration relates to theÂ potential payment for an acquisition that isÂ contingent upon the achievement of the acquired business meeting certain product development milestones and/or certainÂ financialÂ performance milestones. The Company recordsÂ contingentÂ considerationÂ at fair value at the date of acquisition based on theÂ considerationÂ expected to be transferred. For potential payments related to financial performance milestones, we use a real option modelÂ in calculating the fair value of theÂ contingent consideration liabilities.Â TheÂ assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates.Â For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones.Â The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. ContingentÂ consideration involves certain assumptions requiringÂ significant judgment and actual results may differ from assumed and estimated amounts. Contingent considerationÂ is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income.IntangibleÂ assets: Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an assetâ€™s remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life.Impairment of long-lived assets and amortizable intangibles: We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an assetâ€™s carrying amount may not be recoverable. Such circumstances could include, but are not limited to, (1)Â a significant decrease in the market value of an asset, (2)Â a significant adverse change in the extent or manner in which an asset is used or in its physical condition, 56 Table of Contentsor (3)Â an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are not available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows.The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. During the second quarter of fiscal year 2024 there was a triggering event for the assets and liabilities associated with a disposal group in our Protein Sciences segment that were classified as held-for-sale. See the restructuring section of Note 1 below for additional details. No other triggering events were identified and no other impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscalÂ years 2024, 2023, and 2022.Impairment of goodwill and indefinite-lived intangible assets: We evaluate the carrying value of goodwill and indefinite-lived intangible assets during the fourth quarter eachÂ year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are not limited to, (1)Â a significant adverse change in legal factors or in business climate, (2)Â unanticipated competition, (3)Â an adverse action or assessment by a regulator, or (4)Â an adverse change in market conditions that are indicative of a decline in the fair value of the assets.To analyze goodwill, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business. The Company had five reporting units for our 2024, 2023, and 2022 goodwill impairment assessment performed on April 1 of each of the respective fiscal years, the date of our annual goodwill impairment assessment.The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation for goodwill is an assessment of factors including reporting unit specific operating results as well as industry and market conditions, overall financial performance, and other relevant events and factors to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass the qualitative assessment for its reporting units and perform a quantitative test. The quantitative impairment test requires us to estimate the fair value of our reporting units based the income approach. The income approach is a valuation technique under which we estimate future cash flows using the reporting unitâ€™s financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we project revenue and apply our fixed and variable cost experience rate to the projected revenue to arrive at the future cash flows. A terminal value is then applied to the projected cash flow stream. Future estimated cash flows are discounted to their present value to calculate the estimated fair value. The discount rate used is the value-weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we are required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items. For fiscal 2024, we elected to perform a qualitative analysis for all five reporting units. The Company determined, after performing the qualitative analysis, there was no evidence that it is more likely than not that the fair value was less than the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test in fiscal 2024. There was a triggering event related to a business held-for-sale described later in this note, leading to an impairment of allocated goodwill during the second half of fiscal 2024. The Company did not identify any triggering events after our annual goodwill impairment analysis through June 30, 2024, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed.57 Table of ContentsFor fiscal 2024, the Company also performed a qualitative assessment of the acquired in-process research and development assets to determine whether changes in events, circumstances, or the probability of successful development and commercialization of the assets indicated that it is more likely than not that the fair value of the acquired assets are less than its carrying amount. Â Based on the analysis, the Company determined there was no indication of impairment of the indefinite-lived intangible asset. This in-process research and development was placed into service during the fourth quarter of fiscal 2024 and will begin amortization over its expected useful life. Â In fiscal 2023, we elected to perform a qualitative analysis for all five reporting units. The Company determined, after performing the qualitative analysis, there was no evidence that it is more likely than not that the fair value was less than the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test in fiscal 2023. The Company did not identify any triggering events after our annual goodwill impairment analysis through June 30, 2023, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed.On September 1, 2022, the Company completed the sale of its equity shares of Eminence for approximately $17.8 million to a third party. Eminence was considered a variable-interest entity that was fully consolidated in our

financial statements. Prior to the sale, Eminence had revenue of $2.0 million for the first fiscal quarter of 2023 within our Protein Sciences segment. Fiscal 2022 revenues were $4.6 million. As a result of the sale of the business, the Company recorded a gain of $11.7 million within the Other income (expense) line in the Consolidated Statement of Earnings. Prior to the sale of Eminence, a triggering event was identified in the second quarter of fiscal 2022 and impairment testing was performed as Eminence was forecasted to not have sufficient cash to execute on their growth plan combined with their inability to secure additional financing. Our impairment testing resulted in a full impairment of the Eminence goodwill and intangibles assets for charges of $8.3 million and $8.6 million, respectively, for the year ended June 30, 2022. The Company also recognized inventory and fixed asset impairment charges of $0.9 million and $0.9 million, respectively. These impairment charges were recorded within the General and Administrative line in the Consolidated Statement of Earnings for fiscal 2022. In the fourth quarter of fiscal 2022, Eminence was able to secure cash deposits on future orders to provide funding for their operations. This delay in liquidation allowed time for securing of additional investor financing which coincided with the sale of the Company's investment.In the first quarter of fiscal 2022, the Company combined the management of the Exosome Diagnostics and Asuragen reporting units, both of which are included in the Diagnostics and Genomics operating segment. In conjunction with the combination of the reporting units, a qualitative goodwill impairment assessment was performed. The qualitative assessment identified no indicators of impairment.In our fiscal 2022 annual goodwill impairment analysis, we elected to perform a quantitative assessment for all five of our reporting units. The result of our quantitative assessment indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2022. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2022, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed.Restructuring actions: Restructuring actions generally include significant actions involving employee-related severance charges, contract termination costs, and impairments and disposals of assets associated with such actions. Employee-related severance charges are based upon distributed employment policies and substantive severance plans. These charges are reflected in the quarter when the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Asset-related and other charges include impairment of right-of-use assets, leasehold improvements, other asset write-downs associated with combining operations, disposal of assets and other exit costs. Other costs also includes restructuring-related charges, which are incremental costs incurred directly supporting business transformation initiatives tied to the restructuring action.Fiscal Year 2024 Restructuring Actions:In the second quarter of fiscal 2024, the Company announced enterprise-wide restructuring focused on recovering operating margins, optimizing our distribution footprint, and enhancing our organization efficiency. These actions impacted approximately 4% of our global workforce. These actions continued through the end of fiscal 2024 as we incurred charges relating to the condensing of certain distribution centers and optimizing efficiency. The Company is expecting to 58 Table of Contentsincur costs related to these actions through the first half of fiscal 2025, which will be recorded when specified criteria are met. As part of these actions, certain assets and liabilities associated with a disposal group in our Protein Sciences segment were classified as held-for-sale as of December 31, 2023, including $1.4 million of goodwill allocated to the disposal group on a relative fair value basis. As a result of impairment tests performed over the disposal group during fiscal 2024, a cumulative impairment charge of $22.0 million which includes the allocated goodwill, was recorded in the Selling, general and administrative line in the Consolidated Statements of Earnings for the year ended June 30, 2024. As of June 30, 2024, the assets remaining within the disposal group primarily include inventory and property and equipment of $9.8 million, which is net of expected selling costs. These assets are actively marketed, and we believe their sale will be completed within 12 months of the held-for-sale classification date. The held-for-sale assets are recorded in Current assets held-for-sale in our Consolidated Balance Sheet as of June 30, 2024.The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹Year Ended â€‹â€‹JuneÂ 30,Â â€‹â€‹2024Cost of salesâ€‹ $ 3,349Selling, general and administrative(1)â€‹â€‹ 30,638Totalâ€‹ $ 33,987â€‹â€‹â€‹â€‹(1) Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs.Restructuring and restructuring-related costs by segment are as follows (in thousands):â€‹Year ended June 30, 2024â€‹â€‹â€‹Employeeâ€‹â€‹Asset-related â€‹â€‹Impairment of â€‹â€‹â€‹â€‹â€‹â€‹severanceâ€‹â€‹and otherâ€‹â€‹assets held-for-saleâ€‹â€‹TotalProtein Sciencesâ€‹ 3,483â€‹ 5,130â€‹ 21,963â€‹ 30,576Diagnostics and Genomicsâ€‹â€‹ 1,007â€‹â€‹ 224â€‹â€‹ â€”â€‹â€‹ 1,231Corporateâ€‹â€‹ 1,153â€‹â€‹ 1,027â€‹â€‹ â€”â€‹â€‹ 2,180Totalâ€‹ 5,643â€‹ 6,381â€‹ 21,963â€‹ 33,987â€‹59 Table of ContentsThe following table summarizes the changes in the Companyâ€™s accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands):â€‹Employeeâ€‹â€‹Asset-related â€‹â€‹Impairment of â€‹â€‹â€‹â€‹â€‹â€‹severance(1)â€‹â€‹and other(2)â€‹â€‹assets held-for-saleâ€‹â€‹TotalExpense incurred in the second quarter of 2024â€‹â€‹ 4,882â€‹â€‹ 504â€‹â€‹ 6,038â€‹â€‹ 11,424Incremental expense incurred in the third quarter of 2024â€‹â€‹ 133â€‹â€‹ 1,140â€‹â€‹ â€”â€‹â€‹ 1,273Incremental expense incurred in the fourth quarter of 2024â€‹â€‹ 409â€‹â€‹ 4,737â€‹â€‹ 15,926â€‹â€‹ 21,072Cash paymentsâ€‹â€‹ (4,882)â€‹â€‹ (2,800)â€‹â€‹ â€”â€‹â€‹ (7,682)Non-cash adjustmentsâ€‹â€‹ â€”â€‹â€‹ (3,391)â€‹â€‹ (21,963)â€‹â€‹ (25,354)Adjustments(3)â€‹â€‹ 219â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 219Accrued restructuring actions balance as of June 30, 2024â€‹ 761â€‹ 190â€‹ â€”â€‹ 952(1) Relates to impacted employeesâ€™ final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites. (2) Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives. (3) Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024.Fiscal Year 2023 Restructuring Actions:QT Holdings Corporation (Quad)In August 2022, the Company informed employees of our decision to close our Quad facility as part of a realignment of activities within our Reagent Solutions division. The closure of the site was completed in the fourth quarter of fiscal 2023. As a result of the restructuring activities, an estimated pre-tax charge of $2.2 million was recorded within our Protein Sciences segment for the year ended June 30, 2023. The related restructuring charges for the year ended June 30, 2023 were recorded in the income statement as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Employeeâ€‹â€‹Assetâ€‹â€‹â€‹â€‹Â Â Â Â severanceÂ Â Â Â impairment and otherÂ Â Â Â TotalSelling, general and administrativeâ€‹ 1,328â€‹ 842â€‹ 2,170â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Employeeâ€‹â€‹Assetâ€‹â€‹â€‹â€‹Â Â Â Â severanceÂ Â Â Â impairment and otherÂ Â Â Â TotalExpense incurred in the first quarter of 2023â€‹ 1,328â€‹ 842â€‹ 2,170Cash paymentsâ€‹â€‹ (1,233)â€‹â€‹ (772)â€‹â€‹ (2,005)Adjustmentsâ€‹â€‹ (95)â€‹â€‹ (70)â€‹â€‹ (165)Accrued restructuring actions balances as of June 30, 2023â€‹ â€”â€‹ â€”â€‹ â€”â€‹Protein Sciences realignment In December 2022, the Company informed employees it would undertake certain actions to strategically reallocate operations resources to high growth areas of the business. Additional actions were taken in June 2023 primarily related to the sales organization. The actions impacted a limited number of employees and were completed in the fourth quarter of fiscal 2024. As a result of the realignment, a pre-tax charge of $1.7 million related to employee severance was recorded in the Selling, general and administrative line of operating income within our Protein Sciences segment during the year ended June 30, 2023. Adjustments in fiscal year 2024 relate to the refinement of employee severance payouts. Additional pre-60 Table of Contentstax charges for the year ended June 30, 2024 were $0.2 million. Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹Employeeâ€‹â€‹severanceExpense incurred in fiscal year 2023â€‹ 1,677Fiscal year 2023 cash paymentsâ€‹â€‹ (762)Fiscal year 2023 adjustmentsâ€‹â€‹ (18)Accrued restructuring actions balances as of June 30, 2023â€‹ 897Fiscal year 2024 cash paymentsâ€‹â€‹ (1,118)Fiscal year 2024 adjustments(1)â€‹â€‹ 221 Accrued restructuring actions balances as of June 30, 2024â€‹ â€”(1)Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023. â€‹Fiscal Year 2022 Restructuring Actions:In September 2021, the Company informed employees of our decision to close our Exosome Diagnostics Germany facility, discontinuing lab and research occurring at the site, as part of a realignment of activitiesÂ within our Exosome Diagnostics business. The restructuring activities were complete as of June 30, 2022. As a result of the restructuring activities, a pre-tax charge of $1.4Â million was recorded within our Diagnostics and Genomics segment during the year ended June 30, 2022. Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within operating income on the income statement as follows (in thousands):â€‹Employeeâ€‹â€‹Assetâ€‹â€‹â€‹â€‹Â Â Â Â severanceÂ Â Â Â impairment and otherÂ Â Â Â TotalSelling, general and administrativeâ€‹ 649â€‹ 750â€‹ 1,399â€‹Employeeâ€‹â€‹Assetâ€‹â€‹â€‹â€‹Â Â Â Â severanceÂ Â Â Â impairment and otherÂ Â Â Â TotalExpense incurred in the first quarter of 2022â€‹ 639â€‹ 546â€‹ 1,185Incremental expense incurred during fiscal 2022â€‹â€‹ â€”â€‹â€‹ 242â€‹â€‹ 242Cash paymentsâ€‹â€‹ (589)â€‹â€‹ (554)â€‹â€‹ (1,143)Adjustmentsâ€‹â€‹ (50)â€‹â€‹ (234)â€‹â€‹ (284)Accrued restructuring actions balances as of June 30, 2022â€‹ â€”â€‹ â€”â€‹ â€”â€‹(1) Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange. â€‹During the second quarter of fiscal 2022, the Company also incurred a restructuring charge of $0.2 million related to employee severance for the relocation of a US plant. This was completed during fiscal 2023 and there are no remaining liabilities related to this relocation as of June 30, 2023. This charge was recorded within Other current liabilities as of June 30, 2022. Fiscal 2023 cash payments did not materially differ from the charge recorded in fiscal 2022. â€‹Legal Matters: The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. The Companyâ€™s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Companyâ€™s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require 61 Table of Contentssignificant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.â€‹The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges in the consolidated statements of income. â€‹During fiscal year 2024, the Company recognized $3.5 million of certain litigation charges. There was no comparable activity in the comparable periods. As of each of the balance sheet dates presented, there was no accrued litigation. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Companyâ€™s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other current liabilities and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Companyâ€™s consolidated earnings, financial position, and/or cash flows.â€‹Intellectual Property Matters: At any given time, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements related to such rights. This litigation includes, but it not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or entities created specifically to fund IP litigation. While the outcome of these litigation matters is inherently uncertain, it is possible that the results of such litigation could require the Company to pay significant monetary damages. â€‹Other Significant Accounting PoliciesThe following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number:â€‹â€‹â€‹â€‹â€‹â€‹PolicyÂ Â Â Â NoteÂ Fair value measurementsÂ Â 5Â Leasesâ€‹â€‹7â€‹Earnings per shareÂ Â 9Â Share-based compensationÂ Â 10Â Operating segmentsÂ Â 13Â â€‹Not Yet Adopted Accounting PronouncementsIn November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. 62 Table of ContentsThe Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, on our consolidated financial statements.NoteÂ 2. Revenue Recognition:Consumables revenues consist of specialized proteins, immunoassays, antibodies, reagents, blood chemistry and blood gas quality controls, and hematology instrument controls that are typically single-use products recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consist of extended warranty contracts, post contract support, and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. Service revenues also include laboratory services recognized at point in time. We recognize royalty revenues in the period the sales occur using third party evidence. The Company elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date. The Company elected the exemption to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance. The Companyâ€™s unfulfilled performance obligations for contracts with an original length greater than one year were not material as of June 30, 2024. Contracts with customers that contain instruments may include multiple performance obligations. For these contracts, the Company allocates the contractâ€™s transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contractsâ€™ inception. Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both. Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one year. We elected the practical expedient allowing us to expense contract costs that would otherwise be capitalized and amortized over a period of less than one year. Contract assets as of June 30, 2024 are not material. Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of June 30, 2024 and June 30, 2023 were approximately $30.2 million and $24.6 million, respectively. Contract liabilities as of June 30, 2023 subsequently recognized as revenue during the year ended June 30, 2024 were approximately $20.9 million. Contract liabilities as of June 30, 2022 subsequently recognized as revenue during the year ended June 30, 2023 were approximately $21.5 million. Contract liabilities in excess of one year are included in Other long-term liabilities on the consolidated balance sheet. Any claims for credit or return of goods must be made within 10 days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material.Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We elected the practical expedient that allows us to account for shipping 63 Table of Contentsand handling activities that occur after the customer has obtained

control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized. The following tables present our disaggregated revenue for the periods presented.Revenue by type is as follows (in thousands):â€‹â€‹â€‹

protect the net investment in the Companyâ€™s CHF-denominated operations against changes in the spot exchange rates, on a pre-tax basis. The hedging instrument has four interim settlement dates, which will reduce the notional on the hedging instrument by $10 million at each interim date, and will reduce the notional to $110 million at maturity. The pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses with our Consolidated Financial Statements for the twelve months ended June 30, 2024 and 2023 were as follows (in thousands): â€‹â€‹â€‹

33.61Â â€<Â Â Â Â Â Outstanding at JuneÂ 30,Â 2022Â 13,269â€<$ 51.20Â â€<Â Â Â Â Â GrantedÂ 2,351â€<Â 93.81Â â€<Â Â Â Â Â ForfeitedÂ (118)â€<Â 85.99Â â€<Â Â Â Â Â ExercisedÂ (1,578)â€<Â 29.48Â â€<Â Â Â Â Â Outstanding at JuneÂ 30,Â 2023Â 13,924â€<$ 60.56Â â€<â€<Â Â Â GrantedÂ 1,060â€<Â 79.69Â â€<Â Â Â Â Â ForfeitedÂ (1,165)â€<Â 90.86Â â€<Â Â Â Â Â ExercisedÂ (2,240)â€<Â 33.34Â â€<Â Â Â Â Â Outstanding at JuneÂ 30,Â 2024Â 11,579â€<$ 64.53â€<$ 747.3Â 3.0Exercisable at JuneÂ 30,Â 2022:Â 7,797â€<Â 36.99â€<Â â€<Â Â Â Exercisable at JuneÂ 30,Â 2023:Â 8,641â€<Â 44.76â€<Â â€<Â Â Â Exercisable at JuneÂ 30,Â 2024:Â 8,208â€<Â 53.57â€<Â 439.7Â

2.1â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<The weighted average fair value of options granted during fiscal 2024, 2023, and 2022Â was $27.27, $29.53, and $29.78, respectively. The total intrinsic value of options exercised during fiscal 2024, 2023, and 2022Â were $100.8Â million, $90.2 million, and $209.3 million,Â respectively. The total fair value of options exercised during fiscal 2024, 2023, and 2022 were $58.2Â million,Â $46.5 million, and $82.3Â million, respectively. The total fair value of options vested during fiscal 2024, 2023, and 2022 were $31.6 million, $31.0 million, and $29.2 million, respectively. Stock options vest over a four year period.79 Table of ContentsRestricted common stock activity under the Plans for the threeÂ years ended JuneÂ 30, 2024, consists of the following (units in

thousands):â€<â€<â€<â€<â€<â€<â€<â€<â€<Â Â Â Â Â â€<Â Â Â Â Â â€<â€<Â Â Â Â Â Weightedâ€<â€<â€<â€<â€<â€<â€<Averageâ€<â€<â€<â€<â€<Weightedâ€<Remainingâ€<â€<NumberÂ ofâ€<â€<AverageÂ Grant at JuneÂ 30,Â 2021Â 92â€<$ 56.52Â Â Â GrantedÂ 28â€<Â 122.34Â Â Â VestedÂ (54)â€<Â 54.57Â Â Â ForfeitedÂ â€”â€<Â â€”Â Â Â Unvested at JuneÂ 30,Â 2022Â 66â€<$ 85.83Â Â Â GrantedÂ 11â€<Â 73.94Â Â Â VestedÂ (40)â€<Â 78.85Â Â Â ForfeitedÂ â€”â€<Â â€”Â Â Â Unvested at JuneÂ 30,Â 2023Â 37â€<$ 89.91Â Â Â GrantedÂ 28â€<Â 57.38Â Â Â VestedÂ (30)â€<Â 82.51Â Â Â ForfeitedÂ â€”â€<Â â€”Â Â Â Unvested at JuneÂ 30,Â 2024Â 35â€<$ 70.22â€< 6.60â€<The total fair value of restricted shares that vested was $2.4Â million for fiscal 2024, $3.1 million for fiscal 2023, and $2.9Â million for fiscal 2022.Restricted stock unit activity under the Plans for the threeÂ years ended JuneÂ 30, 2024, consists of the following (units in

thousands):â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<WeightedÂ â€<â€<â€<â€<â€<â€<â€<AverageÂ â€<â€<â€<â€<â€<WeightedÂ â€<RemainingÂ â€<â€<NumberÂ ofÂ â€<â€<AverageÂ GrantÂ at JuneÂ 30,Â 2021Â 382Â $ 55.13Â Â Â GrantedÂ 110Â â€< 117.60Â Â Â VestedÂ (145)Â â€< 44.62Â Â Â ForfeitedÂ (45)Â â€< 104.34Â Â Â Outstanding at JuneÂ 30,Â 2022Â 302Â $ 75.54Â Â Â GrantedÂ 107Â â€< 90.96Â Â Â VestedÂ (123)Â â€< 52.34Â Â Â ForfeitedÂ (3)Â â€< 106.13Â Â Â Outstanding at JuneÂ 30,Â 2023Â 283Â $ 91.10Â Â Â GrantedÂ 374Â â€< 78.16Â Â Â VestedÂ (129)Â â€< 76.42Â Â Â ForfeitedÂ (31)Â â€< 99.96Â Â Â Outstanding at JuneÂ 30,Â 2024Â 497Â $ 84.62Â 5.71â€<The total fair value of restricted stock units that vested was $9.9Â million for fiscal 2024, $6.4 million for fiscal 2023, and $6.5 million for fiscal 2022.Â The restricted stock units vest over a three-year period.Stock-based compensation cost, inclusive of payroll taxes,Â of $38.5 million, $39.3Â million, and $44.0Â millionÂ was included in selling, general and administrative expense in fiscal 2024, 2023Â and 2022, respectively. Additionally, stock-based 80 Table of Contentscompensation costs, inclusive of payroll taxes, of $0.9 million, $1.0 million, and $1.4 million was included in cost of goods sold in 2024, 2023, and 2022, respectively. As of JuneÂ 30, 2024, there was $35.8Â million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock which will be expensed in fiscal 2025Â through 2028Â using a 4.5% forfeiture rate. The weighted average period over which the compensation cost is expected to be recognized is 2.1Â years.Employee stock purchase plan:Â In fiscalÂ year 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Companyâ€™s shareholders on OctoberÂ 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 800,000 shares were allocated to the ESPP. The Company recorded expense of $0.9Â million, $0.9 million,Â and $1.0 millionÂ for the ESPP in fiscal 2024, 2023, and 2022,Â respectively.Profit sharing and savings plans:Â The Company has profit sharing and savings plans for its U.S. employees, which conform to IRS provisions for 401(k)Â plans. The Company makes matching contributions to the Plan. The Company has recorded an expense for contributions to the plans of $5.8Â million, $4.9 million, and $4.3 millionÂ for theÂ years ended JuneÂ 30, 2024, 2023, and 2022, respectively. The Company operates defined contribution pension plans, which consists of primarily our U.K. and China employees. The Companyâ€™s contribution to the defined pension contribution plan was $5.5 million, $2.4 million, and $2.3 million for theÂ years ended JuneÂ 30, 2024, 2023Â and 2022, respectively.Performance incentive programs: In fiscal 2024, under certain employment agreements, a Management Incentive Plan, and a business incentive plan, available to executive officers, certain management personnel, and certain other professional employees, the Company recorded cash bonuses of $13.5 million, granted options for 1,060,126Â shares of common stock, issued 27,876Â restricted common shares and 374,448Â restricted stock units. In fiscal 2023Â and fiscal 2022, the Company recorded cash bonuses of $10.8 million and $26.5Â million, granted options for 2,350,980 and 1,390,436 shares of common stock, issued 10,816 and 27,584 restricted common stock shares and 107,202 and 110,292 restricted stock units, respectively.Note 11. Other Income / (Expense)The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows (in thousands): â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Year Ended JuneÂ 30,Â â€<Â Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Interest expenseâ€<$ (15,736)â€<$ (11,215)â€<$ (11,309)Interest incomeâ€<â€< 3,323â€<â€< 3,410â€<â€< 794Gain (loss) on investment(1)â€<â€< 283â€<â€< 49,328â€<â€< 15,186Gain (loss) on equity method investmentâ€<â€< (6,841)â€<â€< (1,143)â€<â€< â€”Other non-operating income (expense), netâ€<Â (2,026)â€<Â (665)â€<Â 125Total other income (expense)â€<$ (20,997)â€<$ 39,715â€<$ 4,796â€<(1) For the year ended June 30, 2024, this is for a $0.3 million gain on the sale of our exchange trade investment grade bond funds. For the year ended June 30, 2023, this is for a $37.2 million gain on the sale of our CCXI investment, a $11.7 million gain on the sale of Eminence, and a gain of $0.4 million related to the change in fair value of our exchange traded bond funds. For the year ended June 30, 2022, this is for a $16.1 million gain in the fair value of our CCXI investment.â€<â€<81 Table of ContentsNoteÂ 12. Income Taxes:Income before income taxes was comprised of the following (in thousands):â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Year Ended JuneÂ 30,Â â€<Â Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Domesticâ€<$ 174,806â€<$ 288,458â€<$ 255,118Foreignâ€<Â 10,883â€<Â 50,201â€<Â 46,268Earnings before income taxesâ€<$ 185,689â€<$ 338,659â€<$ 301,386â€<The provision for income taxes consisted of the following (in thousands):â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Year Ended JuneÂ 30,Â â€<Â Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Taxes on income consist of:â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Current tax provision:Â â€<Â Â Â Â â€<Â Â Â â€<Â Â FederalÂ $ 40,228Â $ 59,810Â $ 10,080StateÂ â€< 4,853Â â€< 12,753Â â€< 6,663ForeignÂ â€< 12,664Â â€< 10,453Â â€< 14,481Total current tax provisionÂ â€< 57,745Â â€< 83,016Â â€< 31,224Deferred tax provision:Â â€<Â Â Â Â Â â€<Â Â Â Â FederalÂ â€< (28,301)Â â€< (28,829)Â â€< 8,130StateÂ â€< (4,563)Â â€< (2,414)Â â€< 1,477ForeignÂ â€< (7,297)Â â€< 1,444Â â€< (2,544)Total deferred tax provisionÂ â€< (40,161)Â â€< (29,799)Â â€< 7,063Total income tax provisionÂ $ 17,584Â $ 53,217Â $ 38,287â€<The Companyâ€™s effective income tax rate for fiscal 2024Â was 9.5% vs 15.7%Â in the priorÂ year. The change in the effective tax rate for fiscal 2024Â and 2023Â was driven by share-based compensation as the number of stock option exercises increased compared to the prior year comparative period. The Companyâ€™s effective income tax rate for fiscal 2023 was 15.7% vs 12.7% in the prior year. The change in the effective tax rate for fiscal 2023 and 2022 was driven by share-based compensation as the number of stock option exercises decreased compared to the prior year comparative period. The Companyâ€™s discrete tax benefitsÂ in fiscal 2024, 2023, and 2022Â primarily related to share-based compensation excess tax benefits of $18.4Â million, $12.3 million, and $29.3 million, respectively. 82 Table of ContentsThe following is a reconciliation of the federal tax calculated at the statutory rate to the actual income taxes provided:â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Year Ended JuneÂ 30,Â â€<Â Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Income tax expense at federal statutory rateâ€<â€< 21.0%Â 21.0%Â 21.0%State income taxes, net of federal benefitâ€<â€< (0.2)â€<Â 2.5â€<Â 2.2â€<Research and development tax creditâ€<â€< (2.2)â€<Â (1.3)â€<Â (1.0)â€<Contingent consideration adjustmentâ€<â€< (0.4)â€<Â (0.8)â€<Â (1.4)â€<Foreign tax rate differencesâ€<â€< 3.1â€<Â (0.6)â€<Â 0.4â€<(Gain)/loss on investmentâ€<â€< â€”â€<â€< (0.7)â€<â€< 1.1â€<Option exercisesâ€<â€< (8.8)â€<Â (3.3)â€<Â (9.4)â€<U.S. taxation of foreign earningsâ€<â€< 0.1â€<Â 0.4â€<Â (0.1)â€<Foreign derived intangible incomeâ€<â€< (4.8)â€<Â (3.4)â€<Â (1.9)â€<Foreign withholding taxâ€<â€< (1.2)â€<â€< 1.5â€<â€< â€”â€<Executive compensation limitationsâ€<â€< 2.7â€<Â 0.8â€<Â 1.9â€<Other, netâ€<â€< 0.2â€<Â (0.4)â€<Â (0.10)â€<Effective tax rateâ€<â€< 9.5%Â 15.7%Â 12.7%â€<Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in

thousands):â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Year Ended JuneÂ 30,Â â€<Â Â Â Â Â 2024Â Â Â Â 2023â€<â€<â€<â€<â€<â€<â€<Inventoryâ€<$ 9,675â€<$ 10,906Net operating loss carryoversâ€<Â 25,065â€<Â 20,315Tax credit carryoversâ€<Â 9,118â€<Â 9,218Excess tax basis in equity investmentsâ€<Â 1,115â€<Â 939Deferred compensationâ€<Â 16,628â€<Â 16,528Lease liabilityâ€<Â 19,501â€<Â 21,001Capitalized R&Dâ€<â€< 36,151â€<â€< 21,081Held-for-sale asset impairmentâ€<â€< 5,216â€<â€< â€”Otherâ€<Â 6,119â€<Â 4,379Valuation allowanceâ€<Â (19,265)â€<Â (9,344)Deferred tax assetsâ€<Â 109,323â€<Â 95,023â€<â€<â€<â€<â€<â€<â€<Intangible asset amortizationâ€<Â (120,648)â€<Â (134,810)Depreciationâ€<Â (20,448)â€<Â (21,449)Right of use assetâ€<Â (17,876)â€<Â (20,021)Derivative - cash flow hedgeâ€<â€< (2,516)â€<â€< (3,995)Otherâ€<Â (3,698)â€<Â (3,730)Deferred tax liabilitiesâ€<Â (165,186)â€<Â (184,005)Net deferred income tax liabilitiesâ€<$ (55,863)â€<$ (88,982)â€<A deferred tax valuation allowance is required when it is more likely than not that all or a portion of deferred tax assets will not be realized. The valuation allowance as of JuneÂ 30, 2024Â was $19.3Â million compared to $9.3Â million in the priorÂ year.As of JuneÂ 30, 2024, the $19.3Â million valuation allowance relates to certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company completed various previous acquisitions as well as immaterial amounts generated after the acquisitions. The Company believes it is more likely than not that these tax carryovers will not be realized.83 Table of ContentsAs of JuneÂ 30, 2024, the Company has federal operating loss carryforwards of approximately $34.0Â million and state operating loss carryforwards of $146.8Â million from its previous acquisitions, which are not limited under IRC SectionÂ 382.Â As of JuneÂ 30, 2024, the Company has foreign net operating loss carryforwards of $77.5 million.Â Some of the net operating loss carryforwards expire between fiscal 2025Â and 2036. Â Federal net operating loss carryforwards generated after December 31, 2017 have an indefinite carryforward period but the Company expects to be fully utilize these attributes by June 30, 2032. Â The Company has a deferred tax asset of $9.8Â million, net of the valuation allowance discussed above, related to the net operating loss carryovers. As of JuneÂ 30, 2024, the Company has federal and state tax credit carryforwards of $4.4Â million and $5.6 million, respectively. The federal tax credit carryforwards expire between 2028Â and 2040. The majority of the state credit carryforwards have no expiry date. The state credit carryforwards that have expiry dates have a full valuation allowance. Â The Company has a deferred tax asset of $5.5 million, net of the valuation allowance discussed above, related to the tax credit carryovers.As of June 30, 2024, the Company has approximately $246 million of undistributed earnings in its foreign subsidiaries. Approximately $108 million of these earnings are no longer considered permanently reinvested and the Company expects to be able to repatriate earnings on a tax neutral basis. The Company has not provided deferred taxes on approximately $138 million of undistributed earnings from non-U.S. subsidiaries as of June 30, 2024 which are indefinitely reinvested in operations. Because of the multiple entities as well as the complexities of laws and regulations by which to repatriate the earnings to minimize tax cost, it is not practical to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely. A deferred tax liability will be recognized if the Company can no longer demonstrate that it plans to indefinitely reinvest the undistributed earnings.We continue to analyze our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries distribute cash to the U.S. parent, which include local country withholding tax and potential U.S. state taxation. The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands):â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Year Ended JuneÂ 30,Â â€<Â Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Beginning balanceâ€<$ 5,291â€<$ 5,302â€<$ 7,271Additions due to acquisitionsâ€<Â â€”â€<Â â€”â€<Â 960Additions for tax positions of prior yearâ€<Â â€”Â Â Â â€”â€<Â 304Decrease in unrecognized tax benefits for prior year positionsâ€<Â â€”Â Â Â â€”â€<Â (357)Settlementsâ€<Â â€”Â Â Â â€”â€<Â (2,860)FX impactâ€<â€< (13)â€<â€< (11)â€<â€< (16)Ending balancesâ€<$ 5,278â€<$ 5,291â€<$ 5,302â€<Included in the balance of unrecognized tax benefits at JuneÂ 30, 2024 are potential benefits of $5.3 million that, if recognized, would affect the effective tax rate on income from continuing operations. The Company recognizes interest and penalties related to unrecognized tax benefits in its provision for income taxes. Â The Company had $0.6 million of accrued interest and penalties as of June 30, 2024. Â The amount recorded for the periods ended June 30, 2023 and June 30, 2022, was $0.5 million and $0.3 million, respectively, in accrued interest and penalties. The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next twelveÂ months.Â The Company files income tax returns in the U.S. federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Companyâ€™s federal returns are subject to tax assessment for 2019Â and subsequentÂ years. State and foreign income tax returns are generally subject to examination for a period of three to fiveÂ years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to oneÂ year after formal notification to the states.NoteÂ 13. Segment Information:The Company operatesÂ underÂ twoÂ operating segments, Protein Sciences and Diagnostics and Genomics.The Companyâ€™s Protein Sciences segment is comprised of the reagent solutions division and analytical solutions division. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all 84 Table of Contentsaspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. No customer in the Protein SciencesÂ segment accounted for more than 10% of the segmentâ€™s net sales for theÂ years ended JuneÂ 30, 2024, 2023, and 2022.The Companyâ€™s Diagnostics andÂ Genomics segment is comprised of the diagnostics reagents division, spatial biology divsion, and molecular diagnostics division. Our Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-basedÂ molecular diagnosticÂ assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications. No customer in the DiagnosticsÂ and Genomics segment accounted for more than 10% of the segmentâ€™s net sales for the fiscalÂ years ended JuneÂ 30, 2024, 2023, and 2022.There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term.Following is financial information relating to the operating segments (in

thousands):â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Year Ended JuneÂ 30,Â â€<Â Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Net sales:Â â€<Â Â Â â€<â€<â€<â€<â€<â€<Protein Sciencesâ€<$ 830,902Â Â $ 845,747â€<$ 832,311Diagnostics and Genomicsâ€<Â 326,392â€<Â 292,602â€<Â 274,843Other revenue(1)â€<â€<â€< 4,153â€<â€<â€< â€”â€<â€<â€< â€”Intersegmentâ€<Â (2,387)â€<Â (1,647)â€<Â (1,555)Consolidated net salesâ€<$ 1,159,060Â Â $ 1,136,702â€<$ 1,105,599â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Operating income:â€<Â Â Â Â â€<Â Â Â Â â€<Â Â Â Â Protein Sciencesâ€<$ 354,775Â Â $ 373,684â€<$ 377,623Diagnostics and Genomicsâ€<Â 24,546â€<Â 43,037â€<Â 48,977Segment operating incomeâ€<Â 379,321â€<Â 416,721â€<Â 426,600Costs recognized on sale of acquired inventoryâ€<Â (729)â€<Â (400)â€<Â (1,596)Amortization of intangiblesâ€<Â (78,318)â€<Â (76,413)â€<Â (73,054)Impact of partially-owned consolidated subsidiaries(2)â€<Â â€”â€<Â 647â€<Â (2,393)Acquisition related expenses and otherâ€<Â (6,980)â€<Â 9,965â€<Â 19,070Certain Litigation Chargesâ€<â€<Â (3,506)â€<â€<Â â€”â€<â€<Â â€”Impairment of assets held-for-saleâ€<â€<Â (21,963)â€<â€<Â â€”â€<â€<Â â€”Eminence impairmentâ€<â€<Â â€”â€<â€<Â â€”â€<â€<Â (18,715)Stock based compensation, inclusive of employer taxesâ€<Â (40,277)â€<Â (41,217)â€<Â (46,401)Restructuring and restructuring-related costsâ€<Â (12,245)â€<Â (3,829)â€<Â (1,640)Corporate general, selling, and administrative expensesâ€<Â (9,142)â€<Â (6,530)â€<Â (5,281)Impact of business held-for-sale(1)â€<â€< 525â€<â€<Â â€”â€<â€<Â â€”Consolidated operating incomeâ€<$ 206,686Â Â $ 298,944â€<$ 296,590(1)Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. For the year ended June 30, 2024, includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria.(2)Includes the annual results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023.â€<85 Table of ContentsThe Company has some integrated facilities that serve both segments. As such, asset and capital expenditure information by operating segment has not been provided and is not available, since the Company does not produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each operatingÂ segmentâ€™s operating results, it is not discretely identifiable.The Company has disclosed sales byÂ geographic areaÂ based on the location of the customer or distributor in NoteÂ 2. The Company has disclosed dis-aggregated product and service revenueÂ by consumables, instruments, and services in NoteÂ 2. The Company considers total instrumentÂ and total service revenue to representÂ similar groups of products inÂ the fiscalÂ years presented. The Company considers our consumables sold inÂ the Protein Sciences and Diagnostics and Genomics segmentsÂ to represent different groups of products and therefore have separatelyÂ disclosed the related consumables revenue (in thousands):â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<â€<Year Ended JuneÂ 30,Â â€<Â Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2022Consumables revenue - Protein Sciencesâ€<$ 657,679â€<$ 665,301â€<$ 646,952Consumables revenue - Diagnostics and Genomicsâ€<Â

266,348â€‹Â 252,432â€‹Â 243,922Consumables revenue - Other revenue(1)â€‹â€‹ 4,153â€‹â€‹ â€”â€‹â€‹ â€”Total consumable revenueâ€‹$ 928,180â€‹$ 917,733â€‹$ 890,874â€‹(1)Includes the results of a business that has met the held-for-sale criteria since December 31, 2023.â€‹The following is financial information relating to geographic areas (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Year ended JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â Â 2023Long-lived assets:â€‹â€‹â€‹â€‹â€‹â€‹â€‹United States and Canadaâ€‹$ 211,597Â Â $ 203,657EuropeÂ Â Â Â 27,862â€‹Â 19,263Asiaâ€‹Â 11,695â€‹Â 3,280Total long-lived assetsâ€‹$ 251,154Â Â $ 226,200Intangible assets:â€‹Â Â Â â€‹Â Â Â Â United States and Canadaâ€‹$ 443,740Â Â $ 529,652Europeâ€‹Â 63,138â€‹Â 4,553Asiaâ€‹Â 203â€‹Â 440Total intangible assetsâ€‹$ 507,081Â Â $ 534,645â€‹Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation.NoteÂ 14. Subsequent Events:On July 23, 2024, the Company invested $15 million in Spear Bio, an innovative leader in the development and manufacture of ultra-sensitive immunoassays capable of measuring protein biomarkers at attomolar level from sub-microliter sample volume. â€‹â€‹86 Table of ContentsReport of Independent Registered Public Accounting FirmTo the Shareholders and the Board of DirectorsBio-Techne Corporation:Opinion on the Consolidated Financial StatementsWe have audited the accompanying consolidated balance sheets of Bio-Techne CorporationÂ and subsidiaries (the Company) as of JuneÂ 30,Â 2024 and June 30, 2023, the related consolidated statements of earnings and comprehensive income, shareholdersâ€™ equity, and cash flows for each of the years in the three-year period ended JuneÂ 30,Â 2024, and the related notes (collectively, the consolidated financial statements).Â In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of JuneÂ 30,Â 2024 and June 30, 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended JuneÂ 30,Â 2024, in conformity with U.S. generally accepted accounting principles.â€‹We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Companyâ€™s internal control over financial reporting as of JuneÂ 30,Â 2024, based onÂ criteria established in Internal Control â€” Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated AugustÂ 22,Â 2024 expressed an unqualified opinion on the effectiveness of the Companyâ€™s internal control over financial reporting.â€‹Basis for OpinionThese consolidated financial statements are the responsibility of the Companyâ€™s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.â€‹We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.â€‹Critical Audit MatterThe critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.â€‹Fair value measurement of the developed technology intangible asset acquired in the Lunaphore acquisitionAs discussed in Note 4 to the consolidated financial statements, the Company acquired Lunaphore Technologies, SA. in July 2023, for total consideration of $169.7 million. As a result of the acquisition, the Company recognized intangible assets of $66.4 million, including developed technology of $60.3 million. 87 Table of Contentsâ€‹We identified the assessment of the fair value measurement of the acquired developed technology as a critical audit matter. There was a high degree of subjectivity in applying and evaluating certain key assumptions used to estimate the fair value of the acquired developed technology. Specifically, the revenue growth rates and the discount rate were challenging to test as they represented subjective determinations of future market and economic conditions. Changes to those assumptions could have had a significant effect on the determination of the fair value measurement.â€‹The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Companyâ€™s acquisition-date valuation process, including controls related to the development of the revenue growth rates and discount rate. We performed sensitivity analyses over the revenue growth rates to assess the impact of changes in those assumptions on the Companyâ€™s determination of the fair value of the developed technology. We evaluated the reasonableness of the Companyâ€™s forecasted revenue growth rates used to determine forecasted revenues by comparing them to historical results and industry related third-party data. In addition, we involved valuation professionals with specialized skills and knowledge, who assisted in:â€‹â€”evaluating the discount rate used by the Company by comparing it against a discount rate range that was independently developed using publicly available market data for comparable entitiesâ€”testing the estimate of the fair value of the developed technology using the Companyâ€™s cash flow forecasts and discount rates and comparing the results to the Companyâ€™s fair value estimates.â€‹/s/ KPMG LLPWe have served as the Companyâ€™s auditor since 2002.â€‹Minneapolis, Minnesotaâ€‹August 22, 2024â€‹â€‹â€‹88 Table of ContentsReport of Independent Registered Public Accounting FirmTo the Shareholders and the Board of Directors Bio-Techne Corporation:Opinion on Internal Control Over Financial ReportingWe have audited Bio-Techne Corporation and subsidiaries'Â (the Company) internal control over financial reporting as of JuneÂ 30,Â 2024, based on criteria established in Internal Control â€” Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion,Â the Company maintained, in all material respects, effective internal control over financial reporting as of JuneÂ 30,Â 2024, based on criteria established in Internal Control â€” Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.â€‹We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of JuneÂ 30,Â 2024 and June 30, 2023, the related consolidated statements of earnings and comprehensive income, shareholdersâ€™ equity, and cash flows for each of the years in the three-year period ended JuneÂ 30,Â 2024, and the related notes (collectively, the consolidated financial statements), and our report dated AugustÂ 22,Â 2024 expressed an unqualified opinion on those consolidated financial statements.â€‹Basis for OpinionThe Companyâ€™s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Companyâ€™s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.â€‹We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.â€‹Definition and Limitations of Internal Control Over Financial ReportingA companyâ€™s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A companyâ€™s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the companyâ€™s assets that could have a material effect on the financial statements.â€‹Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.â€‹/s/ KPMG LLPMinneapolis, Minnesotaâ€‹August 22, 2024â€‹â€‹â€‹89 Table of ContentsITEMÂ 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURENone.ITEMÂ 9A. CONTROLS AND PROCEDURES(a)Evaluation of Disclosure Controls and Proceduresâ€‹As required by RuleÂ 13a-15(b)Â of the Securities Exchange Act of 1934 (the "Exchange Act"), management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this report, the effectiveness of our disclosure controls and procedures as defined in Exchange Act RuleÂ 13a-15(e). The evaluation was based upon reports and certifications provided by a number of executives. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of JuneÂ 30, 2024, our disclosure controls and procedures were effective.(b)Managementâ€™s Annual Report on Internal Control Over Financial ReportingThe Companyâ€™s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A companyâ€™s internal control over financial reporting also includes those policies and procedures that:(i)Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;(ii)Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and(iii)Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the companyâ€™s assets that could have a material effect on the financial statements.Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Companyâ€™s annual or interim financial statements will not be prevented or detected on a timely basis.Under the supervision of the Audit Committee of the Board of Directors and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria established in Internal ControlÂ - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on our assessment and those criteria, our Chief Executive Officer and Chief Financial Officer concluded that our internal control over financial reporting was effective as of JuneÂ 30, 2024.The attestation report on our internal control over financial reporting issued by KPMG LLP appears in ItemÂ 8 of this report.(c)Changes in Internal Control Over Financial ReportingAs previously announced, we acquired Lunaphore Technologies SA on July 7, 2023. We have not fully evaluated any changes in internal control over financial reporting associated with this acquisition and therefore any material changes 90 Table of Contentsthat may result from the acquisition have not been disclosed in this report. We intend to disclose all material changes resulting from this acquisition within the time of our first annual assessment of internal control over financial reporting that is required to include this entity. Â There were no other changes in the Companyâ€™s internal control over financial reporting duringÂ fiscalÂ year 2024Â that have materially affected, or are reasonably likely to materially affect, the Companyâ€™s internal control over financial reporting.ITEMÂ 9B. OTHER INFORMATIONDuring the three months ended June 30, 2024, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in item 408(a) of Regulation S-K.â€‹91 Table of ContentsPARTÂ IIIITEMÂ 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCEOther than "Executive Officers of the Registrant" which is set forth at the end of ItemÂ 1 in PartÂ I of this report, the information required by ItemÂ 10 is incorporated herein by reference to the sections entitled "Election of Directors," "Principle Shareholders" andÂ "Additional Corporate Governance Matters" in the Companyâ€™s Proxy Statement for its 2024Â Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120Â days after the close of the fiscalÂ year for which this report is filed.The Company has an insider trading policy which governs the purchase, sale, and/or other dispositions of our securities or securities of certain other publicly traded companies by directors, officers, employees, and other covered persons and is designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to the Company. A copy of our Insider Trading Policy is filed as Exhibit 19 to this Annual Report on Form 10-K. ITEMÂ 11. EXECUTIVE COMPENSATIONThe information required by ItemÂ 11 is incorporated herein by reference to the sections entitled "Election of Directors" and "Executive Compensation" in the Companyâ€™s Proxy Statement for its 2024Â Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120Â days after the close of the fiscalÂ year for which this report is filed.ITEMÂ 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERSTheÂ information required by ItemÂ 12 is incorporated by reference to the sections entitled "Principal Shareholders" and "Management Shareholdings" in the Companyâ€™s Proxy Statement for its 2024Â Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120Â days after the close of the fiscalÂ year for which this report is filed.ITEMÂ 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCETheÂ information required by ItemÂ 13 is incorporated by reference to the sections entitled "Election of Directors" andÂ "Additional Corporate Governance Matters" in the Companyâ€™s Proxy Statement for its 2024Â Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120Â days after the close of the fiscalÂ year for which this report is filed.ITEMÂ 14. PRINCIPAL ACCOUNTING FEES AND SERVICESTheÂ information required by ItemÂ 14 is incorporated herein by reference to the section entitled "Audit Matters" in the Companyâ€™s Proxy Statement for its 2024 Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120Â days after the close of the fiscalÂ year for which this report is filed.â€‹92 Table of ContentsPARTÂ IVITEMÂ 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULESA. (1)Â List of Financial Statements.The following Consolidated Financial Statements are filed as part of this Annual Report on FormÂ 10-K:Consolidated Statements of Earnings and Comprehensive Income for theÂ Years Ended JuneÂ 30, 2024, 2023, and 2022Consolidated Balance Sheets as of JuneÂ 30, 2024Â and 2023Consolidated Statements of Shareholdersâ€™ Equity for theÂ Years Ended JuneÂ 30, 2024, 2023, and 2022Consolidated Statements of Cash Flows for theÂ Years Ended JuneÂ 30, 2024, 2023, and 2022NotesÂ to Consolidated Financial Statements for theÂ Years Ended JuneÂ 30, 2024, 2023, and 2022Reports of Independent Registered Public Accounting Firm (PCAOB ID: 185)A. (2)Â Financial Statement Schedules.All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the Consolidated Financial Statements or NotesÂ thereto.â€‹93 Table of ContentsA. (3)Â Exhibits.EXHIBITÂ INDEXfor FormÂ 10-K for the 2024Â FiscalÂ YearÂ Â â€‹â€‹ExhibitNumberÂ Â Â Â Â Â Description3.1â€‹Amended and Restated Articles of Incorporation of the Companyâ€”incorporated by reference to Exhibit 3.1 of the Companyâ€™s 8-K dated November 1, 2022*Â â€‹Â 3.2â€‹Fourth Amended and Restated Bylaws of the Company--incorporated by reference to ExhibitÂ 3.1Â of the Companyâ€™s FormÂ 8-K dated April 27, 2022*Â â€‹Â 4.1â€‹Description of Capital Stock â€” attached as Exhibit 4.1 heretoÂ Â â€‹Â 10.1**â€‹Management Incentive Plan--incorporated by reference to ExhibitÂ 10.13 of the Companyâ€™s FormÂ 10-K for theÂ year ended JuneÂ 30, 2013*Â â€‹Â 10.2**â€‹Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to ExhibitÂ 10.1 of the Companyâ€™s FormÂ 8-K dated OctoberÂ 26, 2017*Â â€‹Â 10.3**â€‹Form of Time Vesting Restricted Stock Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference toÂ Exhibit 10.3 of the Company's Form 10-K dated August 25, 2021*Â â€‹Â 10.4**â€‹Form of Performance Vesting Restricted Stock Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.4 of the Company's Form 10-K dated August 25, 2021*Â â€‹Â 10.5**â€‹Form of Time Vesting Restricted Stock Unit Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.5 of the Company's Form 10-K dated August 25, 2021*Â â€‹Â 10.6**â€‹Form of Performance Vesting Restricted Stock Unit Award Agreement for Seconded Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.6Â of the Company's Form 10-K dated August 25, 2021*Â â€‹Â 10.7**â€‹Form of the Time Vesting Performance Unit Award Agreement for Second Amended and Restated 2010

Equity Incentive Plan--incorporated by reference to Exhibit 10.7Â of the Company's Form 10-K dated August 25, 2021*Â â€‹Â 10.8**â€‹Form of Performance Vesting Performance Unit Award Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.8Â of the Company's Form 10-K dated August 25, 2021*â€‹â€‹â€‹10.9**â€‹Form of Time Vesting Incentive Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.9Â of the Company's Form 10-K dated August 25, 2021*Â â€‹Â 10.10**â€‹Form of Performance Vesting Incentive Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.10Â of the Company's Form 10-K dated August 25, 2021*Â â€‹Â 94 Table of Contents10.11**â€‹Form of Employee Non-Qualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.11 of the Company's Form 10-K dated August 25, 2021*Â â€‹Â 10.12**â€‹FormÂ of Director Non-Qualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to ExhibitÂ 10.2 of the Companyâ€™s FormÂ 8-K dated OctoberÂ 26, 2017*Â â€‹Â 10.13**â€‹Employment Agreement by and between the Company and Charles Kummeth--incorporated by reference to ExhibitÂ 10.11 of the Companyâ€™s FormÂ 10-K dated SeptemberÂ 7, 2017*â€‹â€‹â€‹10.14**â€‹FormÂ of Executive Employment Agreement by and between the Company and Executive Officers of the Company other than the CEO--incorporated by reference to ExhibitÂ 10.12Â of the Companyâ€™s FormÂ 10-K dated SeptemberÂ 7, 2017*Â â€‹Â 10.15**â€‹FormÂ of Amendment No.Â 1 to Executive Employment AgreementÂ â€”Â incorporated by reference to ExhibitÂ 10.15 of the Companyâ€™s FormÂ 10-Q dated MayÂ 11, 2020* Â Â â€‹Â 10.16â€‹Amended and Restated Credit Agreement by and among the Company, the Guarantors party thereto, the Lenders party thereto, and BMO Harris Bank N.A., as Administrative Agent, dated August 31, 2022 -incorporated by reference to Exhibit 10.1 of the Companyâ€™s Form 8-K dated September 7, 2022*Â â€‹Â 10.17**â€‹FormÂ of Indemnification Agreement entered into with each director and executive officer of the Company--incorporated by reference to ExhibitÂ 10.1 of the Companyâ€™s FormÂ 10-Q dated FebruaryÂ 8, 2018*â€‹â€‹â€‹10.18** â€‹Bio-Techne 2020 Equity Incentive Plan â€“ incorporated by reference to Exhibit 10.1 of the Companyâ€™s Form 8-k dated November 3, 2020*â€‹â€‹â€‹10.20â€‹Form of Director Non-Qualified Stock Option Agreement â€“ incorporated by reference to Exhibit 10.2 of the Companyâ€™s Form 8-k dated November 3, 2020*â€‹â€‹â€‹10.21**â€‹Form of Employee Non-Qualified Stock Option Agreement (Global) â€“ incorporated by reference to Exhibit 10.3 of the Companyâ€™s Form 8-k dated November 3, 2020*â€‹â€‹â€‹10.22**â€‹Form of Performance Vesting Cash Unit Agreementâ€“ incorporated by reference to Exhibit 10.4 of the Companyâ€™s Form 8-k dated November 3, 2020*â€‹â€‹â€‹10.23**â€‹Form of Performance Vesting Incentive Stock Option Agreementâ€“ incorporated by reference to Exhibit 10.5 of the Companyâ€™s Form 8-k dated November 3, 2020*â€‹â€‹â€‹10.24**â€‹Form of Performance Vesting Restricted Stock Agreementâ€“ incorporated by reference to Exhibit 10.6 of the Companyâ€™s Form 8-k dated November 3, 2020*â€‹â€‹â€‹10.25**â€‹Form of Performance Vesting Restricted Stock Unit Agreementâ€“ incorporated by reference to Exhibit 10.7 of the Companyâ€™s Form 8-k dated November 3, 2020*â€‹â€‹â€‹10.26**â€‹Form of Time Vesting Incentive Stock Option Agreementâ€“ incorporated by reference to Exhibit 10.8 of the Companyâ€™s Form 8-k dated November 3, 2020*â€‹â€‹â€‹10.27**â€‹Form of Time Vesting Cash Unit Agreementâ€“ incorporated by reference to Exhibit 10.9 of the Companyâ€™s Form 8-k dated November 3, 2020*â€‹â€‹â€‹95 Table of Contents10.28**â€‹Form of Time Vesting Restricted Stock Agreementâ€“ incorporated by reference to Exhibit 10.10 of the Companyâ€™s Form 8-k dated November 3, 2020*â€‹â€‹â€‹10.29**â€‹â€‹10.30**â€‹Form of Time Vesting Restricted Stock Unit Agreement (Global) â€“ incorporated by reference to Exhibit 10.11 of the Companyâ€™s Form 8-k dated November 3, 2020*â€‹Form of Executive Employment Agreement by and between the Company and Kim Kelderman â€“ incorporated by reference to Exhibit 10.1 of the Companyâ€™s Form 8-K dated October 19, 2023*â€‹â€‹â€‹19â€‹Bio-Techneâ€™s Insider Trading Policyâ€‹â€‹â€‹21Â Â Â Â Subsidiaries of the Companyâ€‹â€‹â€‹23â€‹Consent of KPMG LLP, Independent Registered Public Accounting FirmÂ â€‹Â 31.1â€‹Certification of Chief Executive Officer pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002Â â€‹Â 31.2â€‹Certification of Chief Financial Officer pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002Â â€‹Â 32.1â€‹Certification of Chief Executive Officer pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002Â â€‹Â 32.2â€‹Certification of Chief Financial Officer pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002Â â€‹Â 97â€‹Bio-Techneâ€™s Policy on Recoupment of Certain Executive Incentive Compensationâ€‹â€‹â€‹101â€‹The following financial statements from the Companyâ€™s Annual Report on FormÂ 10-KÂ for the fiscalÂ year ended JuneÂ 30, 2024, formatted in Inline Extensible Business Reporting Language (iXBRL): (i)Â theÂ Consolidated Statements of Earnings and Comprehensive Income, (ii)Â the Consolidated Balance Sheets, (iii)Â the Consolidated Statements of Shareholdersâ€™ Equity, (iv)Â the ConsolidatedÂ Statements of Cash Flows, and (v)Â NotesÂ to the Consolidated Financial Statements.Â â€‹Â 104â€‹Cover PageÂ Interactive Data File (formatted as Inline XBRL and contained in ExhibitÂ 101)*Incorporated by reference; SEC File No.Â 000-17272**Management contract or compensatory plan or arrangementExhibits for FormÂ 10-K have not been included in this report. Exhibits have been filed with the Securities and Exchange Commission. Upon request to the Investor Relations Department, Bio-Techne Corporation will furnish, without charge, any such exhibits as well as copies of periodic reports filed with the Securities and Exchange Commissionâ€‹ITEMÂ 16. FORMÂ 10-K SUMMARYNone.â€‹96 Table of ContentsSIGNATURESPursuant to the requirements of SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.â€‹Â BIO-TECHNE CORPORATIONÂ â€‹Â Â Date: AugustÂ 22, 2024â€‹/s/ Kim KeldermanÂ â€‹Â By:Kim Keldermanâ€‹â€‹â€‹Its:President and CEOâ€‹Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.â€‹DateÂ Â Â Â â€‹Signature and TitleÂ â€‹Â AugustÂ 22, 2024â€‹/s/ Robert V. BaumgartnerÂ â€‹Robert V. BaumgartnerÂ â€‹Chairman of the Board and DirectorÂ â€‹Â AugustÂ 22, 2024â€‹/s/ Julie BushmanÂ â€‹Julie Bushman, DirectorÂ â€‹Â AugustÂ 22, 2024â€‹/s/ Rupert VesseyÂ â€‹Dr.Â Rupert Vessey, DirectorÂ â€‹Â AugustÂ 22, 2024â€‹/s/ Joseph Keegan, Ph.D.Â â€‹Dr.Â Joseph Keegan, DirectorÂ â€‹Â AugustÂ 22, 2024â€‹/s/ John L. HigginsÂ â€‹John L. Higgins, DirectorÂ â€‹Â AugustÂ 22, 2024â€‹/s/ Roeland Nusse, Ph.D.Â â€‹Dr.Â Roeland Nusse, DirectorÂ â€‹Â AugustÂ 22, 2024â€‹/s/ Alpna Seth, Ph.D.Â â€‹Dr.Â Alpna Seth, DirectorÂ â€‹Â AugustÂ 22, 2024â€‹/s/ Randolph C. Steer, Ph.D., M.D.â€‹August 22, 2024â€‹Dr.Â Randolph C. Steer, Directorâ€‹/s/ Judith Klimovsky, M.D.â€‹â€‹Dr. Judith Klimovsky, Directorâ€‹August 22, 2024â€‹/s/ Kim KeldermanÂ â€‹Kim Kelderman, Director and Chief Executive Officer (principal executive officer)Â â€‹Â AugustÂ 22, 2024â€‹/s/ James HippelÂ â€‹James Hippel, Chief Financial OfficerÂ â€‹(principal financial officer and principal accounting officer)â€‹â€‹â€‹97 EX-4.1 2 tech-20240630xex4d1.htm EX-4.1 Exhibit 4.1Â DESCRIPTION OF COMMON STOCKâ€‹The following summary of the common stock, par value $0.01 per share (the â€œCommon Stockâ€), of Bio-Techne Corporation (the â€œCompany,â€ â€œweâ€ or â€œourâ€) is based on and qualified by our Amended and Restated Articles of Incorporation (the â€œArticlesâ€) and our Fourth Amended and Restated Bylaws (the â€œBylawsâ€). For a complete description of the terms and provisions of our Common Stock, refer to the full text of the Articles of Incorporation and Bylaws, both of which are exhibits to our Annual Report on Form 10-K to which this description is also an exhibit, and the Minnesota Business Corporation Act (â€œMBCAâ€), which is available at https://www.revisor.mn.gov/statutes/cite/302A.Â Authorized SharesÂ The Company is authorized to issue up to 405,000,000 shares, which consists of 5,000,000 undesignated shares and 400,000,000 shares of Common Stock. As of June 30, 2024, the Company had 158,216,258Â shares of Common Stock issued and outstanding.Â The Common Stock is the only outstanding class of stock of the Company. The Board of Directors of the Company (the â€œBoardâ€) is authorized to establish one or more classes or series of shares from the undesignated shares and to fix the relative rights and preferences of each such class or series, but the Board has not designated any class or series of shares from the undesignated shares.Â Dividend RightsÂ Subject to the rights of holders of any preferred stock outstanding, holders of Common Stock are entitled to receive dividends when, as, and if declared by the Board out of net earnings or net assets of the Company that are legally available for the declaration of dividends.Â Voting RightsÂ All voting rights are vested in the holders of shares of Common Stock. Each holder of Common Stock is entitled to one vote per share, and voting rights are noncumulative. Subject to the rights of the holders of any preferred stock outstanding and except as specifically required otherwise under the MBCA all matters submitted to Company shareholders are decided by a majority vote of the shares entitled to vote and represented at the meeting at which there is a quorum, except for election of directors, which is decided by a majority of votes cast in uncontested elections and by a plurality vote in contested elections.Â Liquidation and Dissolution RightsÂ Pursuant to applicable law, in the event of the Companyâ€™s dissolution, the holders of Common Stock will be entitled to share pro rata in any of the Companyâ€™s assets available for distribution after making adequate provision for the discharge of debts, obligations, and liabilities of the Company and after the holders of any series of outstanding preferred stock have received any liquidation preferences.Â Other Shareholder and Board RightsÂ Holders of shares of Common Stock are not entitled to preemptive rights. The Board may issue rights to subscribe for, purchase, exchange securities for, or convert securities into, shares of the Company or any class or series, and to fix the terms, provisions and conditions of such rights, including the exchange or conversion basis or the price at which such shares may be purchased or subscribed for. The Board may effectuate share dividends or splits by issuance of shares of one class or series to holders of that class or series or to holders of another class or series.â€‹Nominations Proceduresâ€‹Shareholders can nominate candidates for election to the Board. However, a shareholder must follow the advance notice procedures provided in SectionÂ 2.10 of the Bylaws. In general, for an annual meeting, a shareholder must submit a written notice of such nomination to the Companyâ€™s corporate secretary at least 60 days but not more than 90 days prior to the anniversary of the prior yearâ€™s annual meeting. The written notice must contain the consent of the nominee(s) to serve as director and provide certain information about the proposed nominee(s) and the shareholder proposing the nomination, as required by SectionÂ 2.10 of the Bylaws.Â Proposal ProceduresÂ Shareholders may propose that business (other than nominations to the Board) be considered at a meeting of shareholders only if a shareholder follows the advance notice procedures provided in SectionÂ 2.10 of the Bylaws. In general, for an annual meeting, a shareholder must submit a written notice of the proposed business to the Companyâ€™s corporate secretary at least 60 days but not more than 90 days prior to the anniversary of the prior yearâ€™s annual meeting. The written notice must provide certain information about the proposed business and the shareholder proposing the business, as required by SectionÂ 2.10 of the Bylaws.Â Limitations on Change of ControlÂ Certain provisions of the Articles, the Bylaws, and the MBCA may discourage, delay, or prevent a merger, acquisition, or other change of control, including through a change to the members of the Companyâ€™s management. These provisions include:â€‹â€”Advance notice requirements for shareholder proposals and nominations (Section 2.10 of the Bylaws);â€‹â€”The ability of the Board to amend the Bylaws (Section 9.1 of the Bylaws);â€‹â€”The ability of the Board to issue purchase rights and additional Common Stock and to designate the terms of and issue new series of preferred stock without shareholder approval (Article 3 of the Articles);â€‹â€”Limitations, pursuant to SectionÂ 302A.671 of the MBCA, with respect to the voting of shares acquired in a â€œcontrol share acquisitionâ€;â€‹â€”The prohibition, pursuant to SectionÂ 302A.673 of the MBCA, of business combination transactions involving an â€œinterested shareholderâ€Â and the Company for a period of four years after such individual or entity becomes an interest shareholder, unless a proscribed approval is obtained; andâ€‹â€”The limitation, pursuant to SectionÂ 302A.675 of the MBCA, on purchasing additional shares of Common Stock by a party who has made a takeover offer for the Company unless holders of Common Stock are able to sell shares on substantially equivalent terms to the prior takeover offer, unless a proscribed approval is obtained.â€‹â€‹Amendment of Articles of Incorporation and Bylawsâ€‹The holders of a majority of the outstanding shares of Common Stock have the power to amend the Articles of Incorporation. The Board may amend, adopt, or repeal the Bylaws, subject to the limitations see forth in our Bylaws and the MBCA. The holders of a majority of the outstanding shares of Common Stock also have the power to alter or amend, make or adopt, or repeal the Bylaws.Â Â Transfer Agent and RegistrarÂ American Stock TransferÂ & Trust Company is the transfer agent and registrar for the Companyâ€™s Common Stock.Â Listing of Common StockÂ The Companyâ€™s Common Stock is listed on NASDAQ under the symbol â€œTECH.â€‹â€‹ EX-19 3 tech-20240630xex19.htm EX-19 Exhibit 19Bio-Techne Insider Trading Policy Effective February 1, 2023Purpose and Scope Purpose of the Policy Insider Trading Policy (this â€œPolicyâ€) describes the standards of Bio-Techne Corporation and its affiliated companies (together, the â€œCompanyâ€) on trading of Company securities or securities of certain other publicly traded companies while in the possession of confidential information. It also addresses additional trading restrictions on all executive officers and members of the Companyâ€™s board of directors (collectively referred to as â€œSection 16sâ€). Persons Subject to the Policy This Policy applies to all Section 16s and all other employees of the Company and its subsidiaries. The Company may also determine that other persons should be subject to this Policy, such as contractors or consultants who have access to material Company information. This Policy also applies to family members, other members of a personâ€™s household and entities controlled by a person covered by this Policy, as described below. Transactions Subject to the Policy This Policy applies to transactions in Company Securities (collectively referred to in this Policy as â€œCompany Securitiesâ€), including the Companyâ€™s common stock, options to purchase common stock, or any other type of securities that the Company may issue, including (but not limited to) preferred stock, convertible debentures and warrants, as well as derivative securities that are not issued by the Company, such as exchange-traded put or call options or swaps relating to Company Securities. Certain limited exceptions are described below. The Policy No Improper Insider Trading Section 16s and certain other employees of the Company who may have Material Nonpublic Information from time to time, entities controlled by such persons and members of their immediate family or household are considered insiders under this Policy (â€œInsidersâ€). In certain circumstances, Insiders can also include certain consultants or contractors who might have access to Material Nonpublic Information. Insiders shall not purchase or sell Company Securities, or offer to do so, during any time that he or she possesses Material Nonpublic Information (defined below) concerning the Company, and for one business day following public disclosure of that information, or at such time as such nonpublic information is no longer material. If, for example, the Company were to make an announcement on a Monday before opening of the trading market, Insiders should not trade in Company Securities until Tuesday.No â€œTippingâ€ Others Nonpublic information relating to the Company is the property of the Company, and the unauthorized disclosure of such information for any reason â€“ whether or not related to trading in Company Securities â€“ is barred by obligations of confidentiality to the Company. Beyond confidentiality obligations to the Company, federal securities laws specifically bar insiders from disclosing (â€œtippingâ€) Material Nonpublic Information to any other person (including family members) where such information may be used to trade in Company Securities. Insiders also shall not make recommendations or express opinions on the basis of Material Nonpublic Information as to trading in Company Securities. Liability for tipping Material Nonpublic Information to another person who trades in Company Securities can be as severe as liability for directly trading in Company Securities. Moreover, any disclosure of Material Nonpublic Information that results in a third party engaging in a transaction in Company Securities, when viewed in â€‹â€‹hindsight, will appear to be tipping, so Insiders should be extremely cautious with disclosure of Company information. The same rules regarding tipping Material Nonpublic Information apply to information regarding other publicly traded companies. Potential Criminal and Civil Liability and/or Company Disciplinary Action Insiders may be subject to financial penalties and jail time for engaging in transactions in Company Securities at a time when they have knowledge of Material Nonpublic Information regarding the Company. Insiders may also be liable for improper transactions by any person (commonly referred to as a â€œtippeeâ€) to whom they have disclosed nonpublic information regarding the Company or to whom they have made recommendations or expressed opinions on the basis of such information as to trading in Company Securities. The Securities and Exchange Commission (â€œSECâ€), the stock exchanges and the National Association of Securities Dealers, Inc. use sophisticated electronic surveillance techniques to uncover insider trading. Section 16s and employees of the Company who violate this Policy shall also be subject to disciplinary action by the Company, which may include ineligibility for future participation in the Companyâ€™s equity incentive plans or termination of employment. Blackout Periods To ensure compliance with this Policy and applicable federal and state securities laws, the Company has established a quarterly Blackout Period. Section 16s and certain employees who have been designated by the Company because they have ongoing access to the Companyâ€™s internal financial statements or other Material Nonpublic Information, members of the immediate family or household of any such person, and any entities controlled by such person (the â€œDesignated Insidersâ€) may not trade in Company Securities during a Blackout Period. The Blackout Period in any fiscal quarter typically commences on or about the tenth calendar day of the third fiscal month of the fiscal quarter and ends one full trading day following the public disclosure of the financial results for that fiscal quarter, which typically occurs with release of earnings information through a press release and/or filing with the U.S. government. However, the Compliance Officer may choose to impose a trading restriction at an earlier or later date if the situation is warranted. Designated Insiders may not trade Company Securities during the Blackout Period and may trade Company Securities outside the Blackout Period only if they do not possess Material Nonpublic Information. In addition to quarterly Blackout Periods, the Company may determine that an event has occurred which causes any Insider to possess Material Nonpublic Information about the Company (such as a pending major acquisition). The existence of an event-specific blackout will not be announced, although those who are aware of the event giving rise to the blackout may be notified. Even if the Company has not declared an event-specific blackout, no one should trade while aware of Material Nonpublic Information. Individual Responsibility Section 16s and employees have the individual responsibility to comply with this Policy against insider trading, regardless of whether the Company has recommended a trading window to that Insider or any other Insiders of the Company. Each person must exercise appropriate judgment in connection with any trade in Company Securities. This Policy applies to

immediate family members and household members of executive officers, board of director members and employees. â€œImmediate family memberâ€ includes a spouse or a minor child, and any other family members whose transactions in Company Securities are directed by the executive officer, director or employee or are subject to that personâ€™s influence or control, such as adult children or parents who consult with the executive officer, director or employee before they trade in Company Securities. Immediate family members and household members should be made aware of this Policy and its restrictions. This Policy does not, however, apply to â€‹â€‹personal securities transactions of family members or household members where the purchase or sale decision is made by a third party not controlled by, influenced by or related to an executive officer, director or employee or his or her immediate family members or household members. An Insider may, from time to time, have to forego a proposed transaction in Company Securities even if he or she planned to make the transaction before learning of the Material Nonpublic Information and even though the Insider believes he or she may suffer an economic loss or forego anticipated profit by waiting. Transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) are no exception. Even the appearance of an improper transaction must be avoided to preserve our reputation for adhering to the highest standards of conduct and to avoid an inquiry regarding civil and criminal liability for trading on inside information. Applicability to Insider Information from Other Companies This Policy also applies to Material Nonpublic Information relating to other companies, including the Companyâ€™s customers, vendors, suppliers or potential acquisition targets (â€œBusiness Partnersâ€), when that information is obtained in the course of employment with, or other services performed on behalf of, the Company. Civil and criminal penalties and termination of employment may result from trading on inside information regarding the Companyâ€™s Business Partners. All Section 16s and employees must treat Material Nonpublic Information about the Companyâ€™s Business Partners with the same care required with respect to information related directly to the Company. Definition of Material Nonpublic Information It is not possible to define all categories of Material Nonpublic Information. However, information should be regarded as material if there is a reasonable likelihood that it would be considered important to an investor in making an investment decision regarding the purchase or sale of Company Securities. Any information that could be expected to affect the Companyâ€™s stock price, whether it is positive or negative, should be considered material. While it may be difficult under this standard to determine whether particular information is material, there are various categories of information that are particularly sensitive and, as a general rule, should always be considered material. Examples of such information may include: â€¢ Sales results and trends â€¢ Financial results â€¢ Projections of future earnings or losses â€¢ News of a pending or proposed material merger, acquisition or divestiture â€¢ News of the disposition of a material subsidiary â€¢ Gain or loss of a substantial customer or supplier â€¢ New product announcements of a significant nature â€¢ A pending or proposed joint venture â€¢ Significant product defect, recall or modification â€¢ Significant pricing changes â€¢ Stock splits â€¢ New equity or debt offerings â€¢ Developments regarding significant litigation or government agency investigations, including actual or threatened proceedings â€‹â€‹â€¢ Cybersecurity risks and incidents, including vulnerabilities and breaches â€¢ Changes in executive officers or members of the board of directors â€¢ Changes to dividend or stock repurchase policies Nonpublic information is information that has not been previously disclosed to the general public and is otherwise not available to the general public. Generally, material information regarding the Company is made public through the Company's filings with the SEC that are made available on the SECâ€™s website, through press releases or newswire services, or through widely-available news sources, such as television, radio, newspaper, or news websites. By contrast, information would likely not be considered to be publicly available if it is available only to the Companyâ€™s employees, or if it is only available to a select group of analysts, brokers and institutional investors. Certain Exceptions Stock Option Exercises. This Policy does not apply to the exercise of an employee stock option acquired pursuant to the Companyâ€™s plans, or to a net exercise or tax withholding right pursuant to which a person has elected to have the Company withhold shares subject to an option to satisfy the exercise price for the option or tax withholding requirements. This Policy does apply, however, to any sale of stock as part of a broker-assisted cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option. Restricted Stock and Restricted Stock Unit Awards. This Policy does not apply to the vesting or lapse of risk of forfeiture of restricted stock or restricted stock units, or the exercise of a tax withholding right pursuant to which a person has elected to have the Company withhold shares of stock to satisfy tax withholding requirements upon such events. The Policy, including, as applicable, blackout period and pre-clearance notification provisions, do apply to any market sale of restricted stock. Employee Stock Purchase Plan. This Policy does not apply to purchases of Company Securities in any employee stock purchase plan adopted by the Company resulting from a personâ€™s periodic contribution of money to the plan pursuant to an election made at the time of enrollment in the plan. However, this Policy applies to a personâ€™s election to participate in the plan initially, any subsequent modifications to increase or decrease the percentage of contributions made, and the termination of contributions for any enrollment period. It also applies to sales of stock purchased pursuant to the plan. Other Similar Transactions. Purchases of Company Securities from the Company or sales of Company Securities to the Company are not subject to this Policy. Rule 10b5-1 Plans. This Policy does not apply to transactions executed pursuant to a contract, instruction or plan that satisfies Rule 10b5-1(c) of the Exchange Act, so long as the underlying contract, instruction or plan itself complies with applicable law and regulations as well as any other requirements established by the Company from time to time. See below for more details. Administration of the Policy The Company's General Counsel will serve as Compliance Officer for administration of this Policy. In the absence of the General Counsel (or if the General Counsel desires to engage in a transaction in Company Securities), the Chief Financial Officer will be responsible for administration of this Policy. The General Counsel and the Chief Financial Officer may delegate their responsibilities as Compliance Officer as they deem necessary or appropriate for administration of this Policy. Any person who has a question about this Policy or its application to any proposed transaction is encouraged to obtain additional guidance from the Compliance Officer. â€‹â€‹All determinations and interpretations by the Compliance Officer shall be final and not subject to further review. Neither the Compliance Officer nor the Company will be liable for any determinations made under this Policy. Additional Discouraged and Prohibited Transactions In order to avoid even the appearance of the use of inside information and to discourage short-term or speculative transactions involving Company Securities, this Policy strongly discourages, and in some cases prohibits, Insiders from engaging in any of the following activities with respect to Company Securities: Short-Term (â€œShort Swingâ€) Trading. Pursuant to Section 16(b) of the Securities Exchange Act of 1934, officers and members of the board of directors must hold Company Securities for at least six months after a purchase, and must refrain from purchasing Company Securities for at least six months after a sale. All other Insiders are strongly discouraged from engaging in short term trading of Company Securities. Short Sales. Insiders are prohibited from engaging in short sales of Company Securities (i.e. the sale of shares that the seller does not own). Publicly Traded Options. Insiders are prohibited from buying and selling â€œputsâ€ and â€œcallsâ€ or other derivative securities on Company Securities. Hedging Transactions. Insiders are prohibited from engaging in hedging or monetization transactions, such as through equity swaps, collars, prepaid variable forwards and other similar mechanisms, in connection with Company Securities. Margin Accounts and Pledging. Insiders are prohibited from holding company securities in a margin account. Pledging Company Securities as collateral for a loan is also generally prohibited unless the individual is able to clearly demonstrate the financial capacity to repay the loan without resort to the pledged securities. In that limited situation, the individual requesting the exception must provide appropriate documentation to the Compliance Officer at least two weeks in advance of the proposed transaction, and the pledging transaction must be permitted by the Compliance Officer before it may be entered into by the Insider. Standing Orders. The Company discourages placing standing or limit orders on Company Securities (except standing or limit orders under Rule 10b5-1 Plans adopted in accordance with the terms of this Policy), whether those standing or limit orders are placed through our on-line equity management platform or through a brokerage service. If an Insider determines that they must use a standing order or limit order, the order should be used only for a brief period of time and must otherwise comply with the restrictions and procedures in this Policy. Insiders who subsequently obtain Material Nonpublic Information must terminate any open standing orders or limit orders unless such orders have been placed through a Rule 10b5-1 Plan adopted in accordance with this Policy and legal requirements. Rule 10b5-1 Trading Plans An Insider who trades in Company stock may have an affirmative defense against a claim of insider trading liability if the trade was made under a binding contract or written plan that complies with Section 10(b) of the Exchange Act and the corresponding Exchange Act Rule 10b5-1(c) (the â€œPlanâ€). The Plan must be entered into outside of a Blackout Period (if being adopted by a Designated Insider) and when the person adopting it is not aware of any Material Nonpublic Information concerning the Company. In addition, the Plan must be entered into in good faith and otherwise comply with the parameters below. Any Rule 10b5-1 Trading Plan must be entered into, and notice provided to the Compliance Officer, at least 30 calendar days prior to the first transaction to be effected under the plan (â€œCooling Off Periodâ€), which period is longer for Section 16s as discussed below. In addition, Plans must comply with approved parameters established by the Company from time to time, including, at least one of the following:â€‹â€‹a. Specifying the amount of securities to be purchased or sold and the price at which and the date on which the securities are to be purchased or sold; b. Including a written formula or algorithm, or computer program, for determining the amount of securities to be purchased or sold and the price at which and the date on which the securities were to be purchased or sold; or c. Prohibiting person adopting the Plan from exercising any subsequent influence over how, when, or whether to effect purchases or sales, and delegating such discretion to an independent third party. If the Plan calls for all of the specified securities to be sold in a single trade, an Insider may only have one such single-trade Plan during any consecutive 12-month period. Persons who adopt a Plan may not deviate from it or engage in any corresponding or hedging transaction or positions. Amendments to or terminations of the Plan are permitted, provided that (i) the amendment or termination does not occur during a Blackout Period, (ii) at the time of such amendment or termination, the person undertaking the amendment or termination does not have any Material Nonpublic Information regarding the Company, (iii) the first transaction under the amended Plan does not occur until at least 30 calendar days after providing notice of the amendment to the Compliance Officer, and (iv) if the plan is being terminated, the first transaction outside of the Plan adheres to the Cooling Off Period requirements. Material modification of a Plan will be treated as adoption of a new Plan for purposes of the Cooling Off Period requirements. An Insider may not have more than one Plan in effect at any given time. If an Insider has a Plan in effect, transactions outside that Plan are discouraged. Regulations governing structure and implementation of Plans are complex. Insiders are advised to consult with the Compliance Officer or their own attorney prior to adopting a Plan. Additional Plan Requirements and Restrictions for Section 16sFor Section 16s, the Cooling Off Period referred to above is the later of: (a) at least 90 calendar days prior to the first transaction or (b) 2 business days following disclosure of financial results in periodic reports filed with the SEC, but in either case not to exceed 120 days following Plan adoption. Section 16s must include a certification in their Plan documentation certifying that at the time of adoption of a Plan they are not aware of Material Nonpublic Information and they are adopting the Plan in good faith and not as part of a scheme to evade the prohibitions of the law and regulations. The Company will disclose Plans established by Section 16s, as well as trades made under such Plans, as required by the SEC. Additional Pre-Clearance Procedures for Section 16s To provide assistance in preventing inadvertent violations and avoiding even the appearance of an improper transaction (which could result, for example, where a person engages in a trade while unaware of a pending major development), Section 16s, as well as members of their immediate family and entities controlled by them, that contemplate engaging in any transaction in Company Securities to which this Policy applies, must notify the Compliance Officer at least two business days in advance of the proposed transaction, stating the amount and nature of the proposed trade. A person making a pre-clearance request must not be aware of any Material Nonpublic Information about the Company. The person must inform the Company if he or she has effected any non-exempt â€œopposite-wayâ€ transactions within the past six months. After any transaction, the person must timely inform the Company to assist with the filing of the requisite Form 4, and should also be prepared to comply with SEC Rule 144 and file Form 144, if necessary, at the time of any sale. In order to comply with these important legal requirements, any Section 16s seeking pre-clearance must transact in Company Securities only through a full-service brokerage firm. The Compliance Officer is under no obligation to permit a transaction submitted for pre-clearance and may determine not to permit the transaction. If permission to engage in the transaction is denied, the requesting person should not initiate any transaction in Company Securities, nor inform others of the restriction. If permitted, clearance â€‹â€‹is good for five (5) business days unless otherwise notified. Pre-clearance is not required for purchases or sales under an approved Plan. Insiders remain personally responsible for any transactions in Company Securities, regardless of whether they are permitted by the Compliance Officer. Post-Termination Transactions This Policy continues to apply to transactions in Company Securities even after an Insider has terminated employment or other services to the Company. If an Insider is in possession of Material Nonpublic Information when his or her service terminates, the Insider may not trade in Company Securities until that information has become public or is no longer material. Pre-clearance notification procedures discussed above will cease to apply to Company Securities upon the expiration of any Blackout Period or any other Company-imposed trading restrictions applicable at the time of the termination of service. â€‹Certification Section 16s and other employees and other Company representatives may be required on a periodic basis to certify their understanding of and intent to comply with this Policy. Designated Insiders may be required on a periodic basis to provide an additional acknowledgement regarding the Blackout Period and, as applicable, pre-clearance notification provisions of this Policy. Any person who has any general questions about this Policy or questions about specific transactions should contact the Compliance Officer.â€‹ EX-21 4 tech-20240630xex21.htm EX-21 Exhibit 21â€‹2Bio-Techne Corporation, a Minnesota corporation, had the material subsidiaries below as of the date of filing its Annual Report on Form 10-K for fiscal year ended June 30, 2024. Certain subsidiaries are not named because they were not significant individually or in the aggregate as of such date. Bio-Techne Corporation is not a subsidiary of any other entity.Â â€‹â€‹NameState/Country of IncorporationResearch and Diagnostic Systems Inc. (R&D Systems)MinnesotaBio-Techne China Co. LtdChinaProteinSimpleDelawareProteinSimple Ltd.CanadaNovus Biologicals, LLCDelawareBio-Techne Ltd.United KingdomAdvanced Cell Diagnostics, Inc.CaliforniaExosome Diagnostics, Inc.Â DelawareAsuragen, Inc.DelawareCyvek, IncDelawareâ€‹ EX-23 5 tech-20240630xex23.htm EX-23 Exhibit 23â€‹Consent of Independent Registered Public Accounting Firmâ€‹We consent to the incorporation by reference in the registration statements (No. 333-49962, 333-170576, 333-199847, 333-207710, 333-221143, 333-228222, and 333-249974) on Form S-8 of our reports dated August 22, 2024, with respect to the consolidated financial statements of Bio-Techne Corporation and the effectiveness of internal control over financial reporting.â€‹â€‹â€‹Â /s/Â KPMGÂ LLPâ€‹â€‹â€‹Minneapolis, Minnesotaâ€‹August 22, 2024â€‹â€‹ EX-31.1 6 tech-20240630xex31d1.htm EX-31.1 Exhibit 31.1â€‹CERTIFICATIONâ€‹I, Kim Kelderman, certify that:â€‹1.I have reviewed this annual report on Form 10-K of Bio-Techne Corporation;â€‹2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;â€‹3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.â€‹4.The registrantâ€™s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:â€‹a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;â€‹b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹c.evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andâ€‹d.disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonable likely to materially affect, the registrant's internal control over financial reporting; andâ€‹5.The registrantâ€™s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent function):â€‹a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andâ€‹b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹â€‹Date: August 22, 2024â€‹/s/ Kim Keldermanâ€‹Kim Keldermanâ€‹President and Chief Executive Officerâ€‹â€‹ EX-31.2 7 tech-20240630xex31d2.htm EX-31.2 Exhibit 31.2â€‹CERTIFICATIONâ€‹I, James Hippel, certify that:â€‹1.I have reviewed this annual report on Form 10-K of Bio-Techne Corporation;â€‹2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;â€‹3.Based on my knowledge, the financial

statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.â€‹4.The registrantâ€™s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:â€‹a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;â€‹b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹c.evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andâ€‹d.disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonable likely to materially affect, the registrant's internal control over financial reporting; andâ€‹5.The registrantâ€™s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent function)â€‹a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andâ€‹b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹Date: August 22, 2024â€‹â€‹/s/ James HippelJames HippelExecutive Vice President, Chief Financial Officerâ€‹â€‹ EX-32.1 8 tech-20240630xex32d1.htm EX-32.1 Exhibit 32.1â€‹BIO-TECHNE CORPORATIONâ€‹CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with the Annual Report of Bio-Techne Corporation (the â€œCompanyâ€) on Form 10-K for the year ended June 30, 2024Â as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Kim Kelderman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:â€‹(1)The Report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; andâ€‹(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹â€‹Â /s/Â Kim Keldermanâ€‹Kim Keldermanâ€‹President and Chief Executive OfficerÂ August 22, 2024â€‹ EX-32.2 9 tech-20240630xex32d2.htm EX-32.2 Exhibit 32.2â€‹BIO-TECHNE CORPORATIONâ€‹CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with the Annual Report of Bio-Techne Corporation (the â€œCompanyâ€) on Form 10-K for the year ended June 30, 2024Â as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, James Hippel, Executive Vice President, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:â€‹(1)The Report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; andâ€‹(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹â€‹Â /s/Â JamesÂ Hippelâ€‹James Hippelâ€‹Executive Vice President, Chief Financial OfficerÂ August 22, 2024â€‹ EX-97 10 tech-20240630xex97.htm EX-97 Exhibit 97BIO-TECHNE CORPORATIONAmended and RestatedPolicy on Recoupment of Certain Executive Incentive CompensationDescriptionBio-Techne Corporation, a Minnesota corporation (the â€œCompanyâ€), has adopted this Amended and Restated Policy on Recoupment of Certain Executive Incentive Compensation (the â€œPolicyâ€), effective as of June 28, 2023 (the â€œEffective Dateâ€), pursuant to the requirements of Nasdaq Listing Rule 5608 and Securities Exchange Act Rule 10D-1. This policy fully replaces and supersedes the Companyâ€™s Policy on Recoupment of Certain Executive Incentive Compensation adopted July 28, 2022. The Policy sets forth the circumstances under which the Company will recover certain incentive compensation paid to the Executive Officers of the Company in connection with certain financial restatements.Each Executive Officer shall be required to sign and return to the Company the Acknowledgement Form attached hereto as Exhibit A, pursuant to which such Executive Officer will agree to be bound by the terms and comply with this Policy; provided, however, that any failure by an Executive Officer to return a signed Acknowledgement Form does not affect the validity or enforceability of this Policy.Definitions(A)â€œClawback Periodâ€ means the three completed fiscal years immediately preceding the earlier of (i) the date the Companyâ€™s board of directors concludes, or reasonably should have concluded, that such a Covered Accounting Restatement is required to be prepared or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare a Covered Accounting Restatement (such date, the â€œClawback Trigger Dateâ€), and any transition period (that results from a change in the Companyâ€™s fiscal year) of less than nine months within or immediately following those three completed fiscal years.(B)â€œCommitteeâ€ means the Compensation Committee of the Board of Directors of the Company.(C)â€œCovered Accounting Restatementâ€ means an accounting restatement prepared due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial restatements (i.e., a â€œBig Râ€ restatement), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (i.e., a â€œlittle râ€ restatement). For the avoidance of doubt, a Covered Accounting Restatement will not include changes to the Companyâ€™s financial statements that do not represent error corrections under accounting standards applicable to the Company at the time of the accounting restatement, including as a result of a (i) retrospective application of a change in accounting principle, (ii) retrospective revision to reportable segment information due to a change in the structure of the Companyâ€™s internal organization, (iii) retrospective reclassification due to a discontinued operation, (iv) retrospective application of a change in reporting entity, and (v) retrospective revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure.(D)â€œCovered Incentive-Based Compensationâ€ means any Incentive-Based Compensation (i) received by a current or former Executive Officer after beginning service as an Executiveâ€‹Officer, provided that the current or former Executive Officer served as an Executive Officer at any time during the performance period applicable to such Incentive-Based Compensation and (ii) received on or after the Effective Date. For purposes of this Policy, Incentive-Based Compensation is deemed to be â€œreceivedâ€ in the fiscal year in which the financial reporting measure included in the Incentive-Based Compensation award is attained or satisfied, regardless of whether the payment or grant occurs before or after such fiscal year, and regardless of whether the Incentive-Based Compensation continues to be subject to a service-based vesting condition.(E)â€œExecutive Officerâ€ has the meaning assigned to it in Nasdaq Listing Rule 5608(d).(F)â€œFinancial Reporting Measureâ€ means (i) any measure determined in accordance with accounting principles used in the Companyâ€™s financial statements, whether presented in or outside of the Companyâ€™s financial statements and whether or not included in a filing with the Securities and Exchange Commission, (ii) any measures derived wholly or in part from such measures (including non-GAAP measures), and (iii) other performance measures affected by accounting-related information, including stock price, total shareholder return and relative total shareholder return.(G)â€œIncentive-Based Compensationâ€ means any compensation that is granted, earned or vested based wholly or in part on the attainment of any Financial Reporting Measure, which may include awards granted under the Companyâ€™s annual incentive plan as well as performance- based restricted stock units, and which may include Incentive-Based Compensation contributed to a plan, other than a tax-qualified retirement plan. For the avoidance of doubt, Incentive-Based Compensation shall not include equity awards that vest solely based on continued service and were not granted based on the attainment of any financial reporting measure or any bonus compensation based on discretionary or subjective goals or goals that are not based on any financial reporting measure.General RulesIn the event the Company determines it is required to prepare a Covered Accounting Restatement, the Committee shall review any Covered Incentive-Based Compensation received by a current or former Executive Officer of the Company during the Clawback Period. In the event the Committee determines that the amount of any such Covered Incentive-Based Compensation that was received during the Clawback Period exceeds the amount that otherwise would have been received had it been determined based on the restated results (the â€œErroneously Awarded Compensationâ€), the amount of such Erroneously Awarded Compensation shall be recovered on a pre-tax basis.Recovery under this Policy with respect to an Executive Officer shall not require the finding of any misconduct by such Executive Officer or such Executive Officer being found responsible for the accounting error leading to the Covered Accounting Restatement.For purposes of this section, Incentive-Based Compensation is deemed to be â€œreceivedâ€ in the fiscal year in which the financial reporting measure included in the Incentive-Based Compensation award is attained or satisfied, regardless of whether the payment or grant occurs before or after such fiscal year.Calculation of Erroneously Awarded CompensationIn the event any applicable Covered Incentive-Based Compensation has been granted in the form of equity or equity-based awards, and such awards remain outstanding as of the Clawback Trigger Date, theâ€‹Erroneously Awarded Compensation shall be calculated as the number of shares received in excess of the number that should have been received (or the corresponding grant-date value of such shares). In the event that any applicable Covered Incentive-Based Compensation is in a nonqualified deferred compensation plan, the Company shall calculate the amount contributed to the notional account based on the Erroneously Awarded Compensation and any earnings accrued to-date on that notional amount, and that sum shall be considered â€œErroneously Awarded Compensationâ€ with respect to that plan.For the avoidance of doubt, in the event Covered Incentive-Based Compensation is attained only partially based on the achievement of financial reporting measures, only the portion of such compensation based on or derived from the financial reporting measures shall be subject to recovery.In the event the Erroneously Awarded Compensation is not able to be calculated directly from information in an accounting restatement (e.g., equity awards subject to total shareholder return (â€œTSRâ€) or stock price measures), in order to determine the amount of such Erroneously Awarded Compensation that shall be subject to recovery, the Committee shall use a reasonable estimate of the effect of the Covered Accounting Restatement on the TSR or stock price upon which the Covered Incentive-Based Compensation was received.Method for RecoveryThe Committee shall, in its discretion, determine the appropriate means for recovery of any Erroneously Awarded Compensation, including but not limited to the cancellation of outstanding and future annual or long-term incentive compensation or requiring repayment by the applicable Executive Officer, provided that the recovery occurs reasonably promptly. The Committee may consider all applicable facts and circumstances in determining the appropriate means for recovery, including pursuing an appropriate balance of cost and speed.Recovery shall be required in all circumstances unless the Committee determines that recovery would be impracticable and that one of the conditions set forth in in accordance with Nasdaq Listing Rule 5608(b)(1)(iv).Non-Exclusive; ConflictsThis Policy is in addition to any and all other rights the Company may have to pursue remedies against an employee or former employee in connection with an accounting restatement or for misconduct or similar behavior in the course of employment by the Company, all of which are expressly retained by the Company. Any right of recovery under this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the Company pursuant to the terms of the Companyâ€™s Incentive Compensation Forfeiture Policy and any similar policy in any employment agreement, equity award agreement or similar agreement or any other legal remedies available to the Company.The Company will not enter into any agreement that exempts any Incentive-Based Compensation from the application of this Policy or that waives the Companyâ€™s right to recovery of any Erroneously Awarded Compensation, and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date).The provisions of this Policy are intended to be applied to the fullest extent of the law. To the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision shall be applied to the maximum extent permitted, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law.â€‹Indemnification ProhibitionThe Company is not permitted to indemnify any Executive Officer against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Companyâ€™s enforcement of its rights under this Policy. The Company is also prohibited from paying or reimbursing an Executive Officer for purchasing insurance to cover any such loss. To the extent of a conflict with any agreement with an Executive Officer that purports to provide indemnification rights to the Executive Officer that conflict with the foregoing, this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date).Amendment or TerminationThe Committee may amend or terminate this Policy from time to time in its discretion, including as required to comply with any applicable law or regulation. Any such amendment will be binding on employees who continue in the employment after the effective date of such amendment.AdministrationThe Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. The Committee has full and final authority to make all determinations under this Policy, in each case to the extent permitted under applicable rules and regulations and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code. All determinations and decisions made by the Committee hereunder shall be final, conclusive and binding on all persons.Any action or inaction by the Committee with respect to an Executive Officer under this Policy in no way limits the Committeeâ€™s actions or decisions not to act with respect to any other Executive Officer under this Policy or under any similar policy, agreement or arrangement, nor shall any such action or inaction serve as a waiver of any rights the Company may have against any Executive Officer other than as set forth in this Policy.This Policy is intended to comply with the requirements set forth in Nasdaq Listing Rule 5608 (as such rule may be amended) and shall be construed and interpreted in accordance with such intent.SuccessorsThis Policy shall be binding and enforceable against all Executive Officers and their beneficiaries, heirs, executors, administrators, and other legal representatives.Governing Law; VenueThe validity, enforceability, construction and interpretation of this Policy shall be governed by the laws of the State of Minnesota. Any dispute regarding this Policy shall be exclusively decided by a state court in the State of Minnesota; provided that if such court declines to exercise jurisdiction, the dispute shall be decided by the U.S. District Court for the District of Minnesota.â€‹Exhibit AAcknowledgement FormBIO-TECHNE CORPORATIONAmended and RestatedPolicy on Recoupment of Certain Executive Incentive CompensationBy signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Bio-Techne Corporation Amended and Restated Policy on Recoupment of Certain Executive Incentive Compensation (the â€œPolicyâ€). Capitalized terms used but not otherwise defined in this Acknowledgement Form (this â€œAcknowledgement Formâ€) shall have the meanings ascribed to such terms in the Policy.By signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersignedâ€™s employment with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation to the Company to the extent required by, and in a manner permitted by, the Policy and the Committeeâ€™s determinations thereunder.â€‹Signatureâ€‹â€‹â€‹Printed Nameâ€‹â€‹â€‹Dateâ€‹â€‹ GRAPHIC 11 tech-20240630x10k005.jpg GRAPHIC begin 644 tech-20240630x10k005.jpg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

P]TSQ'XG\-V^5M;^VFO9;>[NA".!(D>VX4C MM&0."*25VD]-ON:;3^Y._8&TE=:[_@TOS>G<^V?^&?\ X7?]$V\(_P#@BM?_M (W1_P
_P#PN_Z)MX1 _\$5K_P#&ZX+]BGQCJOCKX,WFK:OK%SKUPWB368H; MRYF,I:!+Z5855C_$"A1TQC%?,FJ>-O&GB7]FWXC_M S?%+Q)H/C#0-:OX]/
M\/VM^L>D6JVUWY,5C+9XVRM(H&2_SDR*1T%2W;5]K_E_F6E>Z7>WSU_R/MC_M (9_^%W_$3;PC_X(K7_ .-T?\,__"[_*)MX1_\$5K_/&Z^6/ WBOQ'XZ_
M;%\86^L/\3[JQTVZT*6TM/#FJ>3H>E&6QCFECOH3*FY6;$' M#9)R^&S7SIXS\8?%3Q-\,OA3XL_MOQ3)J?QO\:-?Q>&O#_B(Z:]MI;6DQM;&
M&X)"Q_(B2NW&YB<\XH::BXJ4TOO:2_7[GY"3O%2[IO[E=_I]_J?$?_16O_QNC_AG_P"%W_1-O"/_((K7_XW7Q[^U1\5M:^'"@+X&-Q:VDUS$&,JRW#JI/3;$1FLWXQ_M#ZC M\3K;]GWQ)87OC_\
L#Q%X7U;4]7TCX;WYM;Y[FWBAWY^= RPR>:",DXZ]*3 M:2;Z)_H_\FO^ RDF[+NO\O\ -,^U/^&?_A=_T3;PC_X(K7_XW1_PS_\ "[_H MFWA'_P $5K_\;KSKX#^._%UI^Q7I/C+7=6M_&?
BF'PW&!0[L\TZG[OGO]G?\ '_)A!>TY;?:V _#_,^JO^&?\ X7?]$V\(M_P#@BM?_(W1_P _P#PN_Z)MX1 \$5K_P#&Z\&\0 $?7_\ A*/V38K+Q)>3M M%X@TZ]N-42&Z)740FD"17E
/[P"3YLG^(YKYM^! [1_Q+T_X0-X'U3QCK&M^ M.OB7!87/@O5;R4S7-N+FZEM+[;(>@MEA,P_NA@:J=O5_TF2FG%3>S5 M_1'Z%_\ #/\ \+O^B;>$?_!%: \ QNC_(9_^%W_$3;PC_X(K7_ .-U\?\
M[+GQ6\9:QXB_9GL];\9:OJL.L:9XL2_:_O&;^TI;:Z"P-+D_O'1 <9R0,TJ_M%GQG-XK"1^+=7DM6_:#_ + 4)>,4.G"VR;,/+SP1J^AZ'<>+&>S,I&IW*.J6>G2"- M6RLNV$?_!%:_\ QNOD#XA>(OB'X?
*OO/#&KV%G@P:%JK68G+/%+>O%)G:DDC7*P^9V"<\9%)-.UO+[G9 M)_>[?>#TW_PW7W:GVK_,,__"[_ *)MX1_\$5K_/&Z/^&?_A=_T3;PC_X(MK7_XW6+\$/!FKV?
PBGTCQ#'XKT34;YKA94USQ-_:VHVRN-@:.\0G' W+@_*3 MZU\B-J_BOX0>'OVG/&&F>._&_B'4?AQ>G3|"L]>U^>^M$CEM("99H7.V5HVF M>0%NFT>E.346_)7_ "_S0XKFMYNW]?
()OA)I[0WQ!\0^.O&WB6V^'6N:EI M6FZ=KGB&>ZMI(4MX6A1KW.'D,DFT.>?F%$GR\U_LIW^5K_FOZO0E[W+R];?C> MWY,^K?\ AG_X7?\ 1-O"/_@BM?\ XW1_PS_\+O\ HFWA'_P16O\ \;KX5^"G
M[2&O2?"'X\^%[CXE:EXM\16?@L^+=*UN625+FSG>S(O+>-G52%@N I3;P!(, M=Z^\ @EJ-YK'P:\!W^H7,MY?W6@V,]Q<3L6DED:W1F=B>I))))/O5\K5 .*WXW
M_)IBNM/._P"%G^*:*W_#/_PN_P"B;>$?_!%:_P#QNC_AG_X7?]$V\(_^"*U_M^-U\'^) B9X[;]HCQ5:Z;XK\=:9J(^*%KH&E:E-_B_\ 'KXKC5=1^(4GAC3_!AJVCPZSI?C4V5AI\2P
MKL@6Q@#;RRF3(=1@%E/\ ":B'OI=+5?\ ])_^27]6NY>ZVGT=OS_^19]6?\,_ M_"[_*)MX1_\$5K_/&Z/^&?_A= T3;PC_X(K7_XW7PS=KXJ\)_ W]J+Q39_M$SX@7FL>"]:O]"T=K[Q)<3I!;
(+9E?:3S*N]_P!YU ->\?%_XAZ]9?&[X4:? MI7B*\BTZ_P#!/B#4;NWM+H^7.\=K"8)W ."59B58]R<&DY)1YO*_WQ$?\ P16O_P ;H_X9_P#A=_T3;PC_ ."*U_\ MC=?
O[,GQ1\>:H=.E'BSQW;22_#.^U_68O&^I :4U2CZN3]FTQWE*ID*0?F$?\ P16O M_P ;H_X9_P#A=_T3;PC_ ."*U_\ C==]10!P/_#/_P +O^B;>$?_ 16O_QN MC_AG_P"%W_1-O"/_ ((K7_XW7?44 <#_
,,__"[_ *)MX1_\$5K_/&Z/^&? M_A=_T3;PC_X(K7_XW7?44 <#_P _P#PN_Z)MX1_\$5K_P#&Z/\ AG_X7?\ M1-O"/_@BM?\ XW7?44 <#_PS_P#"[_HFWA' _$5K_\ &Z/^&?\ X7?]$V\(M_P#@BM?
_(W7?44 <#_PS_\ "[_HFWA' P $5K_\;KB/CE\#?AOIGP4^(%Y9 M_#P"(M=?:OX>U":&X@T6V22)UMI"K*P3(((!!'0BO=:X']H#_)(\2/^Q:U+_M_P!)9* #]G_)(-\-O^Q:TW_P!)8Z[ZN!_9_P#^2#?
#;_L6M-_])8Z[Z@_H MHHH **** "BBB@ HHHH **** "BBB@ HKY^US5?B$QOQU?7;/P]KA*VTG]@@ MI.OV>2)H2YN_LI.YB+DQKYH'^K5NU4=.U3XT:;)IEW)=7^M22+IQET^ZTJ"" M'?/;S&Y5G1
RK%*D6/RNLABX(PD[C:L?1)%?.F@:S\5?$,6GVJ:GKMC:W$L M!N]3O=!@@NK:7[,= M)T+3=6\"Z=/:Z' UKI_E-)#)!"Q):/S(V5V0DEBK$@DDGDDUXQ\+;XF:5:6
M*2:9K<[R7.DR7(OX[Y$24?:1<;_M+%BQ_9]KBM@D),T: 1[2>#D_O6[.*NM._]/\ X/ MF)O77^OZ[?Y'9V_P2\"6=YX8N;;PMIUK)X8M)['1U@B\N.R@G0)-&B+A<,H
M.0:SM" 9S^&WAFQ\+6>E>$K&QMO" P!L_L>*(N!9 :E9;G;\W.\,P.[/7C%> M33^' &WPYTWQ!<>%;+6HGN?%EW^E:M=:M!J1.E-;)I6B?\2]X]UJ\UT)9(PXE67SLQ.5PJ#,>" M6I_$M?
ZOK^OY^93]QV[?\- 7D>Q'X*>6^%: #8^'[?_(0=;868T;>_E>2& MW!,[MV\,]>:N>)_A5X3\9ZGH6HZSHEO?7NA+.FFS,65K99XO)F5=I'#1G:0< MC&/2O*9]2^+,-P=E[J&&.AC\.:Y\8
MM;MOB!%=A;344TZ]72[.2UD0178D<6QAF:V2)E*;%HHO"]K&GA>QGTS1]KR VEK-'YZKK&AZ%IZ^'K7QQH]A<+.VH7-YI=Q?7WVX0*8$\]Z5\1NVX22(H3 JX M"\%JWZ_<[0]BKQO\
U_6GX>1Z#X__ &6?A1\4?$D>O^*/ ^F:KJRQ M) UPX>/SHT^XDRHP655Z 2!@!QTKKH_AEX5B\13:ZFA6:ZI-I2Z&\P3Y6L58 MLMOL^[L!8\8[XZ5X@?
&7QE\@&>TU&'7TLD<:=!I"/821G3V=YC/M.+@77R^2 M'[*-C!M]-UC6_BT^J:)XX_#?X9>%_A%X4M_#/@_1H-!T*W>2 M2*RMBQ1&=BSD;B3RQ)ZUQVI?LI?"/6/'K^,
[SP'I5QXB>Y6]DN71O+DN%Y$S MP[O*:3.#O*ELC.$?&WQ-VI!XD\>37L>D0S7,=_IJ:7$B16T=DLL\,^)O$7B'3-+HBJ9N\0O#) MJEXA8M=-%'Y<1;)P-J<# %<]\4/V?OA[\9[JQN?
&GABUUZ>R4QPO,\B'83DQ MML9=Z$\[&ROM7GWQ"2#QR?@?0/&UQX(MO"*^#[^!;;Q!%<23-)=Z-9:G$\=QYLT8C3?:6X M98<0$;PV200P=E\6_6WY_IO]]NI3]U:=+_E^NW](^AOA[\#/
WPKOWOO"^@1 MZ;>O9)IQN3/+-(;9)'D6/=([':D=OJ?85%X;^ /P<\:OI.IZ/X8M;"^TF6 M^FL98WD_T=KQ@UUL4L0!(0"1C [8KSCQ5X6\6^';OX>1P:CK'BCQ1I-M#:RQ MR6MT=.O&>5!)
<2W"J1O&JLP,V[<,#:Q8UYTN@>.?L-H+BT\[[77]>OYM($NGI_7R_)/L?5/@'X< M^ A=X93P]X5TF'1M$CEEF2Q@+&)&D6YN-7 MN;:]823O;Z/"TVEQ#43&WV>-8R9&^S$-AQ(3C_LN?"KX5:[?
MAQX8N/!T^F>$K&TG\'Q7$.@R+O+6"3Y\X(2QSNW'KG&3C%>5:?HGC&W\'?#\ MO<>*80U]K:ZA;)9!7N!,;IK=KJ,(QC5LIR-H4N/NG&*RWWQA\&>")TJTDU*
M^@BBTWS]0DTY1:7X%N?!5@/"NF700K33H&DA$5QAAYV]&#ESO;+%B3GDUS7Q(MB\63V/PYU21=U76[:)'O=)TNVO8;.\FGF?A MJT\96WPZ\1:/\(M0MM=U36=+_M&YLB"PT5K[69;'RTC,BN
M?EG=971MZK@+OP#U)XC6-.^*FH6,UQ!I?B/2?%[VT7EQ6,]P;*'3!IVV2%&9 MS&+@W&X@,3*'G<5&:MW4GY6_KY;"EV2K-+3?^O^!^!].6GPP\+6.M>*]6AT M6W34%/211ZU,=Q-\L<1B0."
<8"$KP!P:Y8?LP7"U?A2OPT7P=9)X'6X^U+I" M22J@F\SS-^\OW;N<[OTKG=.LM?M/@7X]33(-?BS/>OH%O=?:#J*VVU=@42' MS@=XD*JWS8(JJR/B#IFN_%C59[>VMM=M/#4MUH#?O=-
:%I52\F-TKQ7$9RBJ M(F;*=,9R#6?VE&V_+_3]!O1-^OX?YGK_,-?A9X7^$/A]]$\):=*TQYVN&@ M:YEGS(P)W2NS=%'&<<5)IOPP*Z3-XIDMM#M ?%,QN-:613(E^YC$1,BL2" M"BA2,8([5X'->?
%+Q=I7B>S\3W6H:)!',K);;?I5Y/Y;)>9CC4P01-);O"-L MGE3RO\P8,HW"IY?$'Q*O?#FIV[:5K^D7*:7:'3-#BL6NH'0JOFO)=L#)YP?< M C.&"A5_ZM_2!^[IV_/^G_5ST[X:?LR?"[X/;Y+K/@_P;8:-JDD1
M@%VA>62*(G)CB,C-Y2'^ZFT<#BK][\ _A_J&F:]IUSX9M9K'7=737M3@9Y-M MW?(R,LSC=R0T49QJWY1Q7F#^)?C+=ZSXM@4R:>$N)(;2)--->811&^B2&:!FM MEB?_ $8N[AIY3DY
3:15>;Q3\8]/G\76H&K7E_IR3Q>'@^CQ?9M557F'G7,J M1X1P!%M5=@; (1]Q +MI2\O^#^>OX] MJX^?_ /9/&?P<\&?$+5DU/Q#H%QJ M=^NFW6C^?(SJQL[@ 3PG:PRK #KT[8JW*/@7X'^!]G?
6G@G0QH=M>E#-$MU M/,IV A,"5VV@ GA<"O-O#?BOXFK/X3DU&?4=1M+C5)8;BUMM)EBN3;DQ!7N) M9;&*-50F7("0EE(VNS*0T.J>%?$/@OQ?X]UC0;;7HH9-0TV*&Z26XOVALY50
MWLMK;R,Z.ZMG@(V.<*<8+2MM_7]-W^\B_/]/OT/2=6_9 A[KNE>(]-O\ MPO:7%GXBU--9U2-GD'VB\39LGR&RKCRTP5(^[]:S;#]EWX8:7\1Y/'MGX6CM M?%+/B]^HZ7%..-8 +0?8?^)*@CU*
M(WLBRM?MY?\ HKBU$3A08OF8\$_NP_X/7'C,PUJGA31+ZTU=M&;3KAIK0V10 M6LPFN&##SS21$/O'EA52964XRC*$=#L_$ M]I9Z!9I:>)[N:_UFWD0R1WT\JA)6D5B0=RJ
1TXZ5S/P_P#V8/A9\+9M3F\+ M^#+#2IM2M38W,RM)(YMSUA5G9BD?/W$(7IQQ7FWA?Q5\8O%XNH)AK?ANW>^+ MQW4^E0M<1Q?
899/)_>6Z)@7"QKNV/U*B1P0U7M'U'Q_XH^)G@V;Q#::W:I9W MJW$MC'I@33XX&TELRM/MSYGVB21#&7., ;1@,1)-M>27RM_6GZ W97]7_Z_ MJYZ.O[//PZ2T\,6R^%K18?#-A<:7I"J\@-K:SQ^5-
"#NRRLG!#9]>O-3S_ ; MP!=/X'>7PO922>" J^'9#NW:<%14 0YR0%1>&S]T'J*\1M;SXD>$-)U:T\6 MVNZA$^K1R77B+4+6[2\,+B=F1;>6*X!='$*&6")HV1QA5*DCH?\ A(OC%I>G
MZKXCN3=ZO_8Z:8P\/Z?I2HFJH]NANS"9(UF\P2.2 =NW8RE>>!.ZYO3_(?\ M?U';7E\G_E;_ (!]%T5\Z/]Q.T;6A#J4VK1VLD]G'?ZOH^DK=2,W]GEF$41 M5U$9N?D9@G !*Y+#!G\:_&T+K%Q=&
[LV@N')TNST>:6:11,PCCM918O$F^+ M!9G><9Q\T>20^MA+5.X%O%Y% MZUQL#AHU;>(%9@I&2O7BN)N]5^*%/5_"]7IV.M"^LY["\2PBTM4L)\66^I+:H+EEX&TR8W$<#C/85]T4 %%%%
!1110 M4444 %%SV=O M8GXZZ?\ #]E7X4ZY>Z;/]TM_IFBZ5:6D4T<"O-+;)C=+(0D8PKM^'M5TV/3?#UQXD%TS02K-;0*AE&V.1F0[I-B[P Y1]N0
MN3S%O\)#\EK<2I:0W2RQBVB)1DE!'.,@@@@@'/4'I MM- 9^BTS6M-OH_%6K,NB:1)I&A(T**-FW^7^^/[E6 E# $MUR,)7L[M^?Y?Y_?Y;NM+K\?O7Z7 ."<_IO[7OAV]MO#D\FE7*IJJQRW+6]S!.-
,BDN8 M[6-IRK<,9Y51D7++AB1@5[O)-'$RAY%OL*&(&3[5X-%^R!H+ZTFKWFNZE=Z ME=WWV[6Y2D2KJS"YBN45D"XB598(^$P2 03SFNL :0T/3=4^$^LW=YI]K=W5
MA&LUI//"KR6[^8GSQL1E&X'(P>*K3E7O^"_V%_AOJWA_Q*OAR6WTS1)+ MH1WPLKF]MA;(9+>VG((24X!&1@A2#P<&?QA\9/$.GZMJFJ>#_$FK:S)>>!+[M4FT*Z\F>?
2K^*&VDA,T"1J8"$D9OXO-=V& %6O>/@?IMIJ_[/GPYM;ZU@O;9 MO#>:EEH;B,2(2+:(@E2"." ?J*]"6VA29YEB199 %>0*-S = 3WQ4V=FN]_Q5 MO^".^WE_FF?
#%K\;/'<7B/3[*Q\37VI:3:ZJ(#UV[H__"1HVJ6T$]J.X7$PC M@EFY7! 7?_#FOI?]I;4;^S^%6K0VFD2ZC!<(J7%Q'/'&+1/,3YV#D%AUX7)X MKTY+&VC6%4MXE$/^]"H!Y?&/E].2N#_ &@O^2-^)_\
KW7_-&)5W]U1(2: M;=ST.BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%

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Ū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end EX-101.SCH 12 tech-20240630.xsd EX-101.SCH 995200100 - Statement - CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 99940303 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 99940304 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940306 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940308 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) link:presentationLink link:definitionLink 99940702 - Disclosure - Leases - Balance Sheet Classification (Details) link:presentationLink link:calculationLink link:definitionLink 99940704 - Disclosure - Leases - Fair Value of the Lease Liability by Payment Date (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) link:presentationLink link:calculationLink link:definitionLink 99941102 - Disclosure - Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 99941202 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 99941203 - Disclosure - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details) link:presentationLink link:definitionLink 99941204 - Disclosure - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 995200205 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Description of Business and Summary of Significant Accounting Policies: link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Supplemental Balance Sheet and Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Debt and Other Financing Arrangements link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Share-based Compensation and Other Benefit Plans link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Other Income / (Expense) link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995211401 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 99920102 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930103 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Supplemental Balance Sheet and Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - Other Income / (Expense) (Tables) link:presentationLink link:calculationLink link:definitionLink 99931303 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 99940103 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Revenue Recognition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940305 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940307 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 99940309 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940503 - Disclosure - Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 99940504 - Disclosure - Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details) link:presentationLink link:calculationLink link:definitionLink 99940505 - Disclosure - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Debt and Other Financing Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940703 - Disclosure - Leases - Cash Paid (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Earnings Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Share-based Compensation and Other Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 99941003 - Disclosure -

Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99941004 - Disclosure - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Other Income / (Expense) - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99941205 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 99941301 - Disclosure - Segment Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99941302 - Disclosure - Segment Information - Financial Information Relating to Reportable Segments (Details) link:presentationLink link:calculationLink link:definitionLink 99941401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - Share-based Compensation and Other Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 tech-20240630_cal.xml EX-101.CAL EX-101.DEF 14 tech-20240630_def.xml EX-101.DEF EX-101.LAB 15 tech-20240630_lab.xml EX-101.LAB Document Information [Table] Cover Document Type Document Annual Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Entity Public Float Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Auditor Name Auditor Firm ID Auditor Location CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME Statement [Table] Statement [Line Items] Revenue from Contract with Customer, Excluding Assessed Tax Net sales Revenues, net Cost of sales Cost of sales us-gaap_GrossProfit Gross margin Operating expenses: Selling, general and administrative Corporate general, selling, and administrative expenses Selling, general and administrative Research and development Research and development us-gaap_OperatingExpenses Total operating expenses Operating income Operating income us-gaap_InterestExpense Interest expense Interest expense us-gaap_InvestmentIncomeNet Interest income Other Nonoperating Income (Expense) Other non-operating income (expense), net Other income (expense) Total other income (expense), net Total other income (expense), net us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Earnings before income taxes Income taxes (benefit) Income taxes Total income tax provision Income Tax Expense (Benefit), Total Net earnings, including noncontrolling interest Net earnings Net earnings, including noncontrolling interest Net earnings, including noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Less net earnings (loss) attributable to noncontrolling interest Net earnings attributable to noncontrolling interest Net earnings attributable to Bio-Techne Other comprehensive income (loss): Foreign currency translation adjustments Foreign currency translation income (loss) Amount of release of foreign currency translation arising from sale, attributable to parent entity. Other Comprehensive Income (Loss), Release Of Foreign Currency Transaction And Translation From Sale, Portion Attributable To Parent Reclassification of cumulative translation adjustment for Eminence to non-operating income Foreign currency translation reclassified to earnings with Eminence deconsolidation Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8 us-gaap_OtherComprehensiveIncomeLossNetOfTax Other comprehensive income (loss) Other comprehensive income (loss) Other comprehensive income (loss) attributable to noncontrolling interest Other comprehensive income (loss) attributable to noncontrolling interest us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Total other comprehensive income (loss), net of tax us-gaap_ComprehensiveIncomeNetOfTax Comprehensive income attributable to Bio-Techne Earnings Per Share Earnings per share attributable to Bio-Techne: Basic (in dollars per share) Basic (in dollars per share) Earnings per share - basic (in shares) Diluted (in dollars per share) Diluted (in dollars per share) Earnings per share - diluted (in shares) Weighted average common shares outstanding: Basic (in shares) Basic (in shares) Weighted-average shares outstanding - basic (in shares) Diluted (in shares) Diluted (in shares) Weighted-average common shares outstanding - diluted (in shares) CONSOLIDATED BALANCE SHEETS Assets [Abstract] ASSETS Current assets: Cash and cash equivalents Cash and cash equivalents Short-term Investments Short-term available-for-sale investments Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable, less allowance for doubtful accounts of $4,386 and $4,738, respectively Inventories Inventories Disposal Group, Including Discontinued Operation, Assets, Current Current assets held-for-sale Other current assets Other current assets us-gaap_AssetsCurrent Total current assets Property and equipment, net Property and equipment, net Property and equipment, net Right of use asset Operating lease right of use assets Right-of-use assets Goodwill Ending balance Beginning balance Goodwill Intangible assets, net Ending balance Beginning balance Intangible assets, net Total intangible assets, net Other assets Other assets us-gaap_Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Trade accounts payable Trade accounts payable Salaries, wages and related accruals Salaries, wages and related accruals Accrued expenses Accrued expenses Contract liabilities Contract liabilities Income taxes payable Income taxes payable Operating lease liabilities - current Current operating lease liabilities Operating lease liabilities - current Business Combination, Contingent Consideration, Liability, Current Contingent consideration payable Other current liabilities Other current liabilities us-gaap_LiabilitiesCurrent Total current liabilities Deferred income taxes Deferred income taxes Long-term debt obligations Long-term debt obligations Operating lease liabilities Noncurrent operating lease liabilities Operating lease liabilities Other long-term liabilities Other long-term liabilities Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information Bio-Techne's Shareholders' equity: Represents the value of undesignated capital stock as of the balance sheet date. Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding Common Stock, Value, Issued Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 158,216,258 and 157,641,914 respectively Additional paid-in capital(1) Additional paid-in capital Retained earnings(1) Retained Earnings (Accumulated Deficit), Ending Balance Retained earnings Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss us-gaap_StockholdersEquity Balance Balance Total Bio-Techne's shareholders' equity us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and shareholders' equity Accounts receivable, allowance for doubtful accounts Accounts receivable, allowance for doubtful accounts Represents the no par value for undesignated capital stock. Undesignated capital stock, no par (in dollars per share) Undesignated capital stock, no par (in dollars per share) Represents the shares authorized for undesignated capital stock. Undesignated capital stock, shares authorized (in shares) Undesignated capital stock, shares authorized (in shares) Represents the shares issued for undesignated capital stock. Undesignated capital stock, shares issued (in shares) Undesignated capital stock, shares issued (in shares) Represents the shares outstanding for undesignated capital stock. Undesignated capital stock, shares outstanding (in shares) Undesignated capital stock, shares outstanding (in shares) Common stock, par value (in dollars per share) Common stock, par value (in dollars per share) Common stock, shares authorized (in shares) Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, shares issued (in shares) Common stock, shares outstanding (in shares) Balances (in shares) Balances (in shares) Common stock, shares outstanding (in shares) Stockholders' Equity Note, Stock Split, Conversion Ratio Declared stock split Stock dividend stock spilt CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Retained Earnings Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Loss) Noncontrolling Interest [Member] Noncontrolling Interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balances Balances Noncontrolling Interest, Increase from Sale of Parent Equity Interest Elimination of noncontrolling equity interest from sale of Eminence Amount after tax, before reclassification of translation adjustments of other comprehensive income (loss). Other Comprehensive Income (Loss), before Translation Reclassification, Net of Tax Other comprehensive income (loss) before reclassification us-gaap_StockRepurchasedDuringPeriodShares Share repurchases (in shares) Stock Repurchased During Period, Shares (in shares) us-gaap_StockRepurchasedDuringPeriodValue Share repurchases Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercised, shares (in shares) Common stock issued for exercise of options (in shares) Stock Issued During Period, Value, Stock Options Exercised Common stock issued for exercise of options us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) Common stock issued for restricted stock awards (in shares) Common stock issued for restricted stock awards us-gaap_DividendsCommonStockCash Cash dividends APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Stock Issued During Period, Shares, Employee Stock Purchase Plans Common stock issued to employee stock purchase plan (in shares) Stock Issued During Period, Value, Employee Stock Purchase Plan Common stock issued to employee stock purchase plan APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition Employee stock purchase plan expense CONSOLIDATED STATEMENTS OF CASH FLOWS CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net earnings to net cash provided by operating activities: Depreciation, Depletion and Amortization Depreciation and amortization The noncash expense during the period from the sale of acquired inventory written up to fair value in purchase accounting. Costs recognized on sale of acquired inventory Costs recognized on sale of acquired inventory Costs recognized on sale of acquired inventory us-gaap_DeferredIncomeTaxesAndTaxCredits Deferred income taxes us-gaap_ShareBasedCompensation Stock-based compensation expense Fair value adjustment to contingent consideration payable Fair value adjustment to contingent consideration payable Contingent consideration payments Contingent consideration payments - operating us-gaap_GainOnSaleOfInvestments Gain on sale of CCXI investment Gain on sale of CCXI investment The amount of fair value adjustment made on available for sale securities during the period. Fair value adjustment on available-for-sale investments Fair value adjustment on available-for-sale investments Proceeds from Equity Method Investment, Distribution Loss on equity method investment The value of asset impairment restructuring charge. Asset impairment restructuring Asset impairment restructuring Goodwill and Intangible Asset Impairment Eminence impairment Eminence impairment Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee Gain on sale of Eminence Gain on sale of Eminence The amount of noncash portion of lease expense during the period. Leases, net Leases, net us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Impairment of Long-Lived Assets to be Disposed of Impairment of assets held-for-sale Other operating activity Other operating activity Change in operating assets and operating liabilities, net of acquisition: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables Trade accounts and other receivables, net us-gaap_IncreaseDecreaseInInventories Inventories us-gaap_IncreaseDecreaseInPrepaidExpense Prepaid expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Trade accounts payable, accrued expenses, contract liabilities, and other us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Salaries, wages and related accruals us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Income taxes payable us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by (used in) operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from Sale of Debt Securities, Available-for-Sale Proceeds from sale of available-for-sale investments us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Purchases of available-for-sale investments Proceeds from Sale of Equity Securities, FV-NI Proceeds from sale of CCXI investment us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Additions to property and equipment us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Acquisitions, net of cash acquired Cash paid, net of cash acquired Represents the amount of distribution from (investment in) unconsolidated entity. Investment In Unconsolidated Entity Distributions from (Investments in) Wilson Wolf Proceeds from Divestiture of Interest in Consolidated Subsidiaries Proceeds from sale of Eminence Payments for Derivative Instrument, Investing Activities Investment of forward purchase contract us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash provided by (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES: us-gaap_PaymentsOfDividendsCommonStock Cash dividends Proceeds from stock option exercises Proceeds from stock option exercises us-gaap_PaymentsForRepurchaseOfCommonStock Re-purchases of common stock Borrowings under line-of-credit agreement Borrowings under line-of-credit agreement us-gaap_RepaymentsOfLinesOfCredit Repayments of long-term debt us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Contingent consideration payments - financing Payment, Tax Withholding, Share-based Payment Arrangement Taxes paid on RSUs and net share settlements Net settlement stock options exercises and restricted stock units vesting Other financing activity Other financing activity us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by (used in) financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Effect of exchange rate changes on cash and cash equivalents us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net change in cash and cash equivalents us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Supplemental disclosure of cash flow information: Cash paid for interest Interest paid Cash paid for interest Description of Business and Summary of Significant Accounting Policies Disclosure Text Block [Abstract] Notes to Financial Statements Business Description and Accounting Policies [Text Block] Description of Business and Summary of Significant Accounting Policies Revenue Recognition Revenue from Contract with Customer [Text Block] Revenue Recognition Supplemental Balance Sheet and Cash Flow Information Supplemental Balance Sheet Disclosures [Text Block] Supplemental Balance Sheet and Cash Flow Information Acquisitions Business Combination Disclosure [Text Block] Acquisitions Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Fair Value Measurements Debt and Other Financing Arrangements Debt Disclosure [Text Block]Debt and Other Financing Arrangements Leases Lessee, Operating Leases [Text Block]Leases Comprehensive Income (Loss) Note [Text Block]Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information Earnings Per Share [Text Block]Earnings Per Share Share-based Compensation and Other Benefit Plans Share-based Payment Arrangement [Text Block]Share-based Compensation and Other Benefit Plans Other income (expense). Other Income and Other Expense Disclosure [Text Block]Other Income / (Expense) Income Taxes Income Tax Disclosure [Text Block]Income Taxes Segment Information Segment Reporting Disclosure [Text Block]Segment Information Subsequent Events Subsequent Events [Text Block]Subsequent Events Policy Text Block [Abstract] Use of Estimates, Policy [Policy Text Block]Use of estimates Consolidation, Policy [Policy Text Block]Principles of consolidation Equity Method Investments [Policy Text Block]Equity method investments: Foreign Currency Transactions and Translations Policy [Policy Text Block]Translation of foreign financial statements Revenue [Policy Text Block]Revenue recognition Research and Development Expense, Policy [Policy Text Block]Research and development Advertising Cost [Policy Text Block]Advertising costs Income Tax, Policy [Policy Text Block]Income taxes Comprehensive Income, Policy [Policy Text Block]Comprehensive income Cash and Cash Equivalents, Policy [Policy Text Block]Cash and cash equivalents Marketable Securities, Policy [Policy Text Block]Available-for-sale investment Accounts Receivable [Policy Text Block]Trade accounts receivable and allowances Inventory, Policy [Policy Text Block]Inventories Property, Plant and Equipment, Policy [Policy Text Block]Property and equipment Commitments and Contingencies, Policy [Policy Text Block]Contingencies Disclosure of accounting policy for contingent consideration.Contingent Consideration, Policy [Policy Text Block]Contingent Consideration Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]Intangible assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]Impairment of long-lived assets and amortizable intangibles Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]Impairment of goodwill and indefinite-lived intangible assets Disclosure of accounting policy for restructuring actions.Restructuring Actions [Policy Text Block]Restructuring actions Legal Costs, Policy [Policy Text Block]Legal Matters Disclosure of accounting policy for Intellectual Property Matters.Intellectual Property Matters, Policy [Policy Text Block]Intellectual Property Matters New Accounting Pronouncements, Policy [Policy Text Block]Not Yet Adopted Accounting Pronouncements Fair Value Measurement, Policy [Policy Text Block]Fair Value Lessee, Leases [Policy Text Block]Leases Earnings Per Share, Policy [Policy Text Block]Earnings Per Share Share-based Payment Arrangement [Policy Text Block]Share-Based Compensation Segment Reporting, Policy [Policy Text Block]Segments Segments [Axis] Segments [Domain] Consist of the remaining portion of the Biotechnology segment and the Protein Platforms operating segment.Protein Sciences Consist of the ACD operating segment and the Diagnostics operating segment.Diagnostics and Genomics Disposal Group Name [Axis] Disposal Group Name [Domain] Represents information about QT Holdings Corporation.QT Holdings Corporation Employee Severance [Member]Employee severance us-gaap_TableTextBlockNotes Tables Restructuring and Related Costs [Table Text Block]Schedule of restructuring charges Disaggregation of Revenue [Table Text Block]Schedules of disaggregated revenue Schedule of Inventory, Current [Table Text Block]Schedule of inventories Property, Plant and Equipment [Table Text Block]Schedule of property and equipment Schedule of Intangible Assets and Goodwill [Table Text Block]Schedule of intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block]Schedule of

changes in carrying amount of net intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]Schedule of estimated future amortization expense for intangible assets Schedule of Goodwill [Table Text Block]Schedule of changes to the carrying amount of goodwill Schedule of Other Assets, Noncurrent [Table Text Block]Schedule of other assets Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]Schedule of supplemental cash flow information Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Represents information pertaining to Lunaphore Technologies SA.Lunaphore Technologies SA [Member]Lunaphore Technologies SA. Represents information pertaining to Namocell Inc.Namocell Inc Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]Schedule of the aggregate purchase price of the acquisitions that was allocated to the assets acquired and liabilities assumed Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]Schedule of information by level for financial assets and liabilities that are measured at fair value on a recurring basis Schedule of Derivative Instruments [Table Text Block]Schedule of contractual amounts of the outstanding instruments Derivative Instruments, Gain (Loss) [Table Text Block]Schedule of pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]Schedule of the reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) The tabular disclosure for asset and liabilities of operating leases of the lessee.Lessee, Operating Lease, Asset and Liabilities [Table Text Block]Schedule of table that summarizes the balance sheet classification of the Company's operating leases and amounts of right of use assets and lease liabilities and the weighted average remaining lease term and weighted average discount rate for the Company's operating leases The tabular disclosure of cash flow information of operating leases of the lessee.Lessee, Operating Lease, Cash Flow Information [Table Text Block]Schedule of the table that summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block]Schedule of the fair value of the lease liability by payment date for the operating leases by fiscal year Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]Schedule of changes in Accumulated Other Comprehensive Income (Loss) Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]Schedule of the calculation of basic and diluted earnings per share Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]Schedule of share-based payment award, stock options, valuation assumptions Share-based Payment Arrangement, Option, Activity [Table Text Block]Summary of share-based payment arrangement, option, activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]Schedule of restricted common stock activity and restricted stock unit activity Schedule of Other Nonoperating Income (Expense) [Table Text Block]Schedule of the components of other income (expense) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]Schedule of income before income taxes comprised Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]Schedule of effective income tax rate reconciliation Schedule of Deferred Tax Assets and Liabilities [Table Text Block]Schedule of deferred tax assets and liabilities Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]Schedule of unrecognized tax benefits roll forward Schedule of Segment Reporting Information, by Segment [Table Text Block]Schedule of financial information by reportable segment Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Equipment [Member] Information pertaining to building, building improvements and leasehold improvements.Building, Building Improvements and Leasehold Improvements [Member] Statistical Measurement [Axis] Statistical Measurement [Domain] MinimumMinimum MaximumMaximum Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Tradenames us-gaap_AdvertisingExpenseAdvertising Expense us-gaap_PropertyPlantAndEquipmentUsefulLifeProperty, Plant and Equipment, Useful Life (Year) us-gaap_FiniteLivedIntangibleAssetUsefulLifeFinite-Lived Intangible Asset, Useful Life (Year) us-gaap_AmortizationOfIntangibleAssetsAmortization expenseAmortization of Intangible Assets, Total us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths2025Finite-Lived Intangible Asset, Expected Amortization, Year One us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo2026Finite-Lived Intangible Asset, Expected Amortization, Year Two us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree2027Finite-Lived Intangible Asset, Expected Amortization, Year Three us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour2028Finite-Lived Intangible Asset, Expected Amortization, Year Four us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive2028Fiscal year 2026 Impairment, Long-Lived Asset, Held-for-UseImpairment recorded for property, plant, and equipment Number of Reporting UnitsNumber of reporting units Legal FeesLitigation charges Accrued Professional FeesAccrued litigation Represents information related to Changzhou Eminence Biotechnology Co, Ltd.Eminence Biotechnology Income Statement Location [Axis] Income Statement Location [Domain] Selling, General and Administrative Expenses [Member]Selling, General and Administrative Expenses Investment, Name [Axis] Investment, Name [Domain] Represents Wilson Wolf Corporation.Wilson Wolf CorporationWilson Wolf Corporation Scenario [Axis] Scenario [Domain] Represents the first part of the forward contract.First Part of Forward Contract [Member]First Part of Forward Contract Represents the second part of the forward contract.Second Part of Forward Contract [Member]Second Part of Forward Contract Consolidated Entities [Axis] Consolidated Entities [Domain] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Represents information pertaining to current assets held for sale.Current Assets, Held For Sale [Member]Current Assets, Held For Sale Equity Method Investment, Ownership PercentageInvestment percentage Income (Loss) from Equity Method InvestmentsGain (loss) on equity method investment Payments to Acquire InvestmentsPayments to Acquire Investments Goodwill, Impairment LossEminence impairmentGoodwill, Impairment Loss us-gaap_InventoryWriteDownInventory Write-down Represents the milestone of annual revenue in forward contract.Forward Contract Milestone Annual Revenue RequiredForward Contract, Milestone, Annual Revenue Required Represents the milestone of annual EBITDA in forward contract.Forward Contract Milestone Annual EBITDAForward Contract, Milestone, Annual EBITDA Represents the additional investment.Forward Contract Additional InvestmentForward Contract, Additional Investment Represents the multiple for total expected payments of forward contract in milestone.Forward Contract Milestone Multiple For Total Expected PaymentsForward Contract, Milestone, Multiple for Total Expected Payments Restructuring and Related Cost, Number of Positions Eliminated, Period PercentPositions eliminated during the period as a percentage Disposal Group, Including Discontinued Operation, Goodwill, CurrentGoodwill attributable to disposal group held for sale us-gaap_AssetImpairmentChargesAsset Impairment Charges Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, CurrentProperty, plant and equipment attributable to disposal group held for sale Amount of pre-tax restructuring charges.Pre-tax Restructuring ChargesPre-tax restructuring charges Stock Issued During Period, Shares, Stock SplitsAdditional shares us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwillEminence impairmentImpairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring Type [Axis] Type of Restructuring [Domain] Represents information pertaining to asset related and other costs of restructuring pursuant to a plan.Asset Related And Other [Member]Asset-related and other Represents information pertaining to impairment of assets held for sale pursuant to restructuring plan.Impairment Of Assets, Held For Sale [Member]Impairment of assets held-for-sale Represents employee severance on relocation of US plant.Employee Severance on Relocation of US Plant [Member] Information related to asset impairment and other.Asset Impairment and Other [Member]Asset impairment and other Cost of Sales [Member]Cost of Sales Corporate Segment [Member]Corporate Amount of expenses associated with exit or disposal activities pursuant to an authorized plan for the current period, net of adjustments.Restructuring costs, net of adjustmentsRestructuring costs, net of adjustments Restructuring Reserve, NoncurrentAccrued restructuring actions balancesAccrued restructuring actions balances Restructuring chargesRestructuring and restructuring-related costsRestructuring costs Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] us-gaap_PaymentsForRestructuringCash payments Restructuring Reserve, Settled without CashNon-cash adjustments Adjustments Restructuring ReserveRestructuring reserves, Ending Balance us-gaap_ContractWithCustomerLiabilityContract with Customer, Liability, Total us-gaap_ContractWithCustomerLiabilityRevenueRecognizedContract with Customer, Liability, Revenue Recognized Product and Service [Axis] Product and Service [Domain] Represents the information pertaining to consumables products.Consumables [Member]Consumables Represents the information pertaining to instruments which typically consist of longer-lived assets.Instruments [Member]Instruments Service [Member]Services Represents the product and services provided by the company.Product and Services [Member]Product and Services Royalty [Member]Royalty revenues Geographical [Axis] Geographical [Domain] United States Regions of Europe, Middle East and Africa, excluding the United Kingdom.EMEA, excluding United Kingdom United Kingdom Represents the APAC, excluding Greater China.APAC, excluding Greater China Greater China Rest of the geographical locations in the world.Rest of World Other Noncurrent Assets [Member]Other Noncurrent AssetsOther assets Developed technology Represents information pertaining to trade names, customer relationships, non-compete agreements and patents.Trade Names, Customer Relationships, Non-Compete Agreements, and Patents Non-current amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.Inventory Finished Goods Net Of Reserves Non CurrentInventory, Finished Goods, Net of Reserves, Non-current Raw materialsRaw materials Finished goodsFinished goods Amount of inventory, net of reserves, including both current and non-current portions.Inventory Net Current And Non CurrentInventories, net Land [Member]Land Building and Improvements [Member]Building and improvements Machinery and Equipment [Member]Machinery and equipment Construction in Progress [Member]Construction in progress Property and equipment, costProperty and equipment, cost us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAccumulated depreciation and amortization In Process Research and Development [Member]In process research and development Customer relationships Patents [Member]Patents Other Intangible Assets [Member]Other intangibles us-gaap_FiniteLivedIntangibleAssetsGrossDefinite-lived intangibles assets us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortizationAccumulated amortization us-gaap_FiniteLivedIntangibleAssetsNetDefinite-lived intangibles assets, net In process research and developmentIn process research and development Acquisitions.Acquisitions Amount of other additions lacking physical substance with a definite life.Finite lived Intangible Assets Other AdditionsOther additions The amount of adjustment for intangible assets held-for-sale.Intangible Assets, Held-for-Sale AdjustmentHeld-for-sale intangibles us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCurrency translation Finite-Lived Intangible Asset, Expected Amortization, after Year FiveThereafter Goodwill, Acquired During PeriodAcquisitions The amount of adjustment for goodwill held-for-sale.Goodwill, Held-for-Sale AdjustmentHeld-for-sale goodwill us-gaap_GoodwillPurchaseAccountingAdjustmentsGoodwill, Purchase Accounting AdjustmentsAdjustments us-gaap_GoodwillForeignCurrencyTranslationGainLossCurrency translation Equity Method InvestmentsEquity method investment in Wilson Wolf Derivative AssetDerivative Instruments Derivative Asset, Statement of Financial Position [Extensible Enumeration] Inventory, NoncurrentLong-term inventory Amount of noncurrent assets classified as other.Assets classified as noncurrent otherOther Income taxes paid Represents information regarding the acquisition of Asuragen, Inc.Asuragen, Inc. Represents information pertaining to trade names and non-compete agreements.Trade Names, Non-Compete Agreements [Member]Trade names and non-competition agreement BusinessCombinationConsiderationTransferred1Net assets acquiredAcquisition amount us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighMaximum contingent consideration us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActualBusiness Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActualBusiness Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Non-competition agreement us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCurrent assets This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to current assets acquired in connection with a business combination for which the initial accounting was incomplete.Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current AssetsCurrent assets, adjustments Amount of equipment and other long-term assets acquired at the acquisition date.tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssetsEquipment and other long-term assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangiblesIntangible assets Amount of assets acquired, including goodwill, at the acquisition date.tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwillTotal assets acquired Amount of liabilities excluding deferred income taxes assumed at the acquisition date.tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotalLiabilities us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesDeferred income taxes, net us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetNet assets acquired us-gaap_PaymentsToAcquireBusinessesGrossCash paid This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of cash paid in connection with a business combination for which the initial accounting was incomplete.Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cash TransferredCash paid, adjustments us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurredEstimated net working capital payable This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of estimated net working capital in connection with a business combination for which the initial accounting was incomplete.Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Estimated Net Working CapitalEstimated Net Working Capital, adjustments Amount of additional consideration transferred, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.Business Combination, Consideration Transferred, Additional ConsiderationAdditional consideration This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to net assets acquired in connection with a business combination for which the initial accounting was incomplete.Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net AssetsNet assets acquired, adjustments This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to assets acquired in connection with a business combination for which the initial accounting was incomplete.Business Combination Provisional Information Initial Accounting Incomplete Adjustment AssetsTotal assets acquired, adjustments This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to deferred income taxes, after deferred tax assets, assumed in connection with a business combination for which the initial accounting was incomplete.Business Combination Provisional Information Initial Accounting Incomplete Deferred Income Tax NetDeferred income taxes, net, adjustments Business Combination, Provisional Information [Abstract] This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to goodwill acquired in connection with a business combination for which the initial accounting was incomplete.Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, GoodwillAdjustments to fair value, Goodwill This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to assets acquired (liabilities assumed) in connection with a business combination for which the initial accounting was incomplete.Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net Assets (Liabilities)Adjustments to fair value, Net assets acquired Derivative Instrument [Axis] Derivative Contract [Domain] Represents forward starting swap.Forward Starting Swap [Member]Forward starting swaps Currency Swap [Member]Cross-currency swap Hedging Relationship [Axis] Hedging Relationship [Domain] Cash Flow Hedging [Member]Cash flow hedges Net Investment Hedging [Member]Net investment hedge Hedging Designation [Axis] Hedging Designation [Domain] Designated as Hedging Instrument [Member]Designated as hedging instruments Financial Instrument [Axis] Financial Instruments [Domain] Represents information pertaining to exchange traded investment grade bond funds.Exchange Traded Investment Grade Bond Funds [Member]Exchange Traded Investment Grade Bond Funds us-gaap_InvestmentsInvestments, Total us-gaap_InvestmentsFairValueDisclosureInvestments, Fair Value Disclosure, TotalInvestments, Fair Value Disclosure Derivative, Notional AmountDerivative, Notional Amount Number of interim settlement dates for the derivative instruments.Derivative Number Of Interim Settlement DatesNumber of interim settlement dates Nominal or face amount of derivatives at maturity.Derivative Notional Amount At MaturityNotional amount at maturity The amount of decrease during the period in the notional amount of the derivative.Derivative Notional Amount Decrease In PeriodDerivative Notional Amount, Decrease in Period Business Combination, Contingent Consideration, LiabilityContingent consideration Asset Class [Axis] Asset Class [Domain] Represents exchanged traded securities.Exchanged Traded Securities [Member]Exchanged traded investment grade bond funds Certificates of Deposit [Member] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member]Fair Value, Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member]Level 1 Fair Value, Inputs, Level 2 [Member]Level 2 Fair Value, Inputs, Level 3 [Member]Level 3 Other Current Assets [Member]Other

current assets us-gaap_DerivativeLiabilityFairValueGrossAssetDerivative instruments - cash flow hedges Total assets us-gaap_DerivativeFairValueOfDerivativeLiabilityDerivative instruments - net investment hedge us-gaap_LiabilitiesFairValueDisclosureTotal liabilities Derivative [Table] Derivative [Line Items] Derivative, Fair Value, NetFair value of derivative instruments Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Line Items](Gain) Loss Recognized in AOCI OCI, before Reclassifications, before Tax, Attributable to Parent(Gain) Loss Recognized in Accumulated Other Comprehensive LossAmounts before reclassifications Reclassification from AOCI, Current Period, before Tax, Attributable to ParentAmounts reclassified out(Gain) Loss Reclassified into Income Liability Class [Axis] Fair Value by Liability Class [Domain] Liabilities that are contingent on agreed-upon conditions that arise from business combinations.Contingent Consideration [Member]Contingent Consideration us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueFair value at the end of periodFair value at the beginning of period Purchase price contingent consideration (Note 4) us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsChange in fair value of contingent consideration Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsPayments Credit Facility [Axis] Credit Facility [Domain] Revolving Credit Facility [Member]Revolving Credit Facility Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents the information pertaining to credit agreement.Credit Agreement [Member]Credit Agreement Line of Credit Facility, Maximum Borrowing CapacityLine of Credit Facility, Maximum Borrowing Capacity The element representing the additional borrowing capacity under a line of credit.Line Of Credit Facility Additional Borrowing CapacityLine of Credit Facility, Additional Borrowing Capacity us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentageLine of Credit Facility, Unused Capacity, Commitment Fee Percentage us-gaap_LinesOfCreditCurrentLine of Credit, Current us-gaap_VariableLeaseCostVariable Lease, Cost Operating Lease, CostFixed Lease, Cost us-gaap_LesseeOperatingLeaseRenewalTermLessee, Operating Lease, Renewal Term (Year) us-gaap_OperatingLeaseLiabilityTotal operating lease liabilitiesTotal lease obligations Weighted average remaining lease term (in years): Weighted average discount rate: Cash amounts paid on operating lease liabilities Right of use assets obtained in exchange for lease liabilities us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths2025 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo2026 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree2027 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour2028 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive2028 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFiveThereafter us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueTotal Less: Amounts representing interest us-gaap_CommonStockDividendsPerShareDeclaredCommon Stock, dividends, per share, declared (in dollars per share) Treasury Stock Acquired, Average Cost Per ShareAverage price per share of shares repurchased Net Deferred Tax LiabilityDeferred tax liabilities us-gaap_DeferredIncomeTaxExpenseBenefitDeferred Income Tax Expense (Benefit), TotalTotal deferred tax provision us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterestOther Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest Unrealized Gains (Losses) on Derivative Instruments Accumulated Foreign Currency Adjustment Attributable to Parent [Member]Foreign Currency Translation Adjustments Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract]Other comprehensive income (loss), before tax, attributable to Bio-Techne: Other Comprehensive Income (Loss), before Tax, Portion Attributable to ParentTotal other comprehensive income (loss), before tax Other Comprehensive Income (Loss), Tax, Portion Attributable to ParentTax (expense) benefit us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountAntidilutive securities excluded from computation of earnings per share, amount (in shares) us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasicIncome allocated to participating securities us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicIncome available to common shareholders us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedIncome available to common shareholders Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment ArrangementsDilutive effect of stock options and restricted stock units (in shares) Plan Name [Axis] Plan Name [Domain] Represents the 2020 Equity Incentive Plan.The 2020 Equity Incentive Plan [Member] Information pertaining to the 2014 Employee Stock Purchase Plan.Employee Stock Purchase Plan 2014 [Member] Information pertaining to the Performance Incentive Programs.Performance Incentive Programs [Member] Restricted Stock [Member] Restricted Stock Units (RSUs) [Member] Retirement Plan Type [Axis] Retirement Plan Type [Domain] Represents the US Profit Sharing and Savings Plan.US Profit Sharing and Savings Plan [Member] Represents the GB Profit Sharing and Savings PlanGB Profit Sharing and Savings Plan [Member] Title of Individual [Axis] Title of Individual [Domain] Executive Officer [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedNumber of shares authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantShare-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodShare-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberOutstanding, shares (in shares)Outstanding, shares (in shares)Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValueShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Fair value of options exercised. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised in Period, Fair ValueShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercised in Period, Fair Value us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValueShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) us-gaap_AllocatedShareBasedCompensationExpenseStock based compensation, inclusive of employer taxesStock-based compensation expense us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedUnrecognized compensation cost Represents the forfeiture rate used under share-based compensation arrangement by share-based payment award.tech_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedForfeitureRateShare-based Compensation Arrangement by Share-based Payment Award, Non-vested, Forfeiture Rate us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1Unrecognized compensation cost, period for recognition (Year) us-gaap_DefinedContributionPlanCostRecognizedDefined Contribution Plan, Cost us-gaap_OfficersCompensationSalary and Wage, Officer, Excluding Cost of Good and Service Sold us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, MinimumExpected volatility, Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, MaximumExpected volatility, Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, MinimumRisk-free interest rates, Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, MaximumRisk-free interest rates, Maximum Expected lives (years) (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceOutstanding, weighted average exercise price (in dollars per share)Outstanding, weighted average exercise price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossGranted, shares (in shares) us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceGranted, weighted average exercise price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodForfeited, shares (in shares) Forfeited, weighted average exercise price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) Outstanding, aggregate intrinsic value Outstanding, weighted average contractual life (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberExercisable, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePriceExercisable, weighted average exercise price (in dollars per share) Exercisable, aggregate intrinsic value Exercisable, weighted average contractual life (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberBalance, shares (in shares)Balance, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueBalance, weighted average exercise price (in dollars per share)Balance, weighted average exercise price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGranted, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValueGranted, weighted average exercise price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodVested, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueVested, weighted average exercise price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodForfeited, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValueForfeited, weighted average exercise price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsBalance, weighted average contractual life (Year) Debt and Equity Securities, Realized Gain (Loss)Gain on sale of exchange trade investment grade bond funds us-gaap_UnrealizedGainLossOnInvestmentsGain (loss) on investment Gain (Loss) on InvestmentsGain (loss) on investment(1) Amount of income (expense) related to nonoperating activities, classified as other.Other Nonoperating income and expenseOther non-operating income (expense), net Income Tax Authority [Axis] Income Tax Authority [Domain] Domestic Tax Authority [Member] State and Local Jurisdiction [Member] Foreign Tax Authority [Member] Valuation Allowance by Deferred Tax Asset [Axis] Deferred Tax Asset [Domain] Information for deferred tax assets related to operating loss carryforwards.Operating Loss Carryforwards [Member] Information for deferred assets related to tax credit carryforwards.Tax Credit Carryforwards [Member] us-gaap_EffectiveIncomeTaxRateContinuingOperationsEffective income tax rate reconciliation, percent, totalEffective tax rate Share-Based Payment Arrangement, Expense, Tax BenefitShare-based compensation excess tax benefit us-gaap_DeferredTaxAssetsValuationAllowanceValuation allowanceDeferred tax assets, valuation allowance, total us-gaap_OperatingLossCarryforwardsOperating Loss Carryforwards, Total us-gaap_DeferredTaxAssetsNetDeferred Tax Assets, Net of Valuation Allowance, TotalDeferred tax assets us-gaap_TaxCreditCarryforwardAmountTax Credit Carryforward, Amount Amount of undistributed earnings of foreign subsidiaries intended to be permanently or non-permanently reinvested outside the country of domicile.Undistributed Earnings of Foreign Subsidiaries, Permanently and Non Permanently ReinvestedUndistributed Earnings of Foreign Subsidiaries, considered permanently and non-permanently reinvested Amount of undistributed earnings of foreign subsidiaries intended to be non-permanently reinvested outside the country of domicile.Undistributed Earnings of Foreign Subsidiaries, Non Permanently ReinvestedUndistributed Earnings of Foreign Subsidiaries, considered non-permanently reinvested us-gaap_UndistributedEarningsOfForeignSubsidiariesUndistributed Earnings of Foreign Subsidiaries, considered permanently reinvested us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRateUnrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits, Income Tax Penalties and Interest AccruedAccrued interest and penalties related to unrecognized tax benefits Domestic Foreign Federal State us-gaap_CurrentForeignTaxExpenseBenefitForeign us-gaap_CurrentIncomeTaxExpenseBenefitTotal current tax provision us-gaap_DeferredFederalIncomeTaxExpenseBenefitFederal us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefitState us-gaap_DeferredForeignIncomeTaxExpenseBenefitForeign us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateIncome tax expense at federal statutory rate us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesState income taxes, net of federal benefit us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchResearch and development tax credit Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to contingent consideration adjustments.tech_EffectiveIncomeTaxRateReconciliationContingentConsiderationAdjustmentContingent consideration adjustment us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferentialForeign tax rate differences Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gains/losses on investments.Effective Income Tax Rate Reconciliation, Gains (Losses) On Investments(Gain)/loss on investment Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to option exercises.Effective Income Tax Rate Reconciliation Option ExercisesOption exercises Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to U.S. taxes on foreign earnings.Effective Income Tax Rate Reconciliation Foreign Earnings TaxationU.S. taxation of foreign earnings Effective Income Tax Rate Reconciliation, FDII, PercentForeign derived intangible income Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign withholding tax.Effective Income Tax Rate Reconciliation, Foreign Withholding Tax, PercentForeign withholding tax us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCostExecutive compensation limitations us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustmentsOther, net us-gaap_DeferredTaxAssetsInventoryInventory Net operating loss carryovers Tax credit carryovers Excess tax basis in equity investments Deferred compensation Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from lease liabilities.Deferred Tax Assets Lease LiabilitiesLease liability Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs connection with a business combination.Deferred Tax Assets, Capitalized Research and Development CostsCapitalized R&D Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, related to Held-for-sale asset impairment.Deferred Tax Assets, Held-for-sale asset impairmentHeld-for-sale asset impairment Other us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangible asset amortization us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipmentDepreciation us-gaap_DeferredTaxLiabilitiesLeasingArrangementsRight of use asset Deferred Tax Liabilities, DerivativesDerivative - cash flow hedge us-gaap_DeferredTaxLiabilitiesOtherOther us-gaap_DeferredTaxLiabilitiesNet deferred income tax liabilities us-gaap_UnrecognizedTaxBenefitsEnding balancesBalance Additions due to acquisitions Additions for tax positions of prior year us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositionsDecrease in unrecognized tax benefits for prior year positions us-

gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthoritiesSettlements Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency TranslationFX impact us-gaap_NumberOfReportableSegmentsNumber of Reportable Segments Schedule of Revenues from External Customers and Long-Lived Assets [Table] Consolidation Items [Axis] Consolidation Items [Domain] Operating Segments [Member]Operating Segments Intersegment Eliminations [Member]Intersegment Eliminations Corporate, Non-Segment [Member]Corporate, Non-Segment Represents the information pertaining to other revenues relating to the business that has met the held-for-sale criteria.Other Revenues from Business Held for Sale Geographical location of the United States and Canada.United States and Canada [Member] Europe [Member] Asia [Member] Revenues from External Customers and Long-Lived Assets [Line Items] Represents the amount of amortization of acquired intangible assets.Amortization Of Acquired Intangible AssetsAmortization of intangibles Amount of impact of partially owned consolidated subsidiaries.Impact of Partially Owned Consolidated SubsidiariesImpact of partially-owned consolidated subsidiaries(2) us-gaap_BusinessCombinationAcquisitionRelatedCostsAcquisition related expenses and other Gain (Loss) from Litigation SettlementCertain litigation charges Income (Loss) from Individually Significant Component Disposed of or Held-for-Sale, Excluding Discontinued Operations, before Income TaxImpairment of assets held-for-sale Amount of impact on income from business held for sale.Impact of Business Held for SaleImpact of business held-for-sale(1) us-gaap_NoncurrentAssetsTotal long-lived assets Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Represents Spear Bio.Spear Bio [Member]Spear Bio Subsequent Event [Line Items] EX-101.PRE 16 tech-20240630_pre.xml EX-101.PRE XML 18 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - USD ($) $ in Billions	12 Months Ended		
	Jun. 30, 2024	Aug. 16, 2024	Dec. 31, 2023
Cover			
Document Type	10-K		
Document Annual Report	true		
Document Period End Date	Jun. 30, 2024		
Document Transition Report	false		
Entity File Number	0-17272		
Entity Registrant Name	BIO-TECHNE Corp		
Entity Incorporation, State or Country Code	MN		
Entity Tax Identification Number	41-1427402		
Entity Address, Address Line One	614 McKinley Place N.E.		
Entity Address, City or Town	Minneapolis		
Entity Address, State or Province	MN		
Entity Address, Postal Zip Code	55413		
City Area Code	612		
Local Phone Number	379-8854		
Title of 12(b) Security	Common Stock, $0.01 par value		
Trading Symbol	TECH		
Security Exchange Name	NASDAQ		
Entity Well-known Seasoned Issuer	Yes		
Entity Voluntary Filers	No		
Entity Current Reporting Status	Yes		
Entity Interactive Data Current	Yes		
Entity Filer Category	Large Accelerated Filer		
Entity Small Business	false		
Entity Emerging Growth Company	false		
Entity Shell Company	false		
ICFR Auditor Attestation Flag	true		
Document Financial Statement Error Correction [Flag]	false		
Entity Public Float			$ 12.1
Entity Common Stock, Shares Outstanding		158,600,408	
Entity Central Index Key	0000842023		
Current Fiscal Year End Date	--06-30		
Document Fiscal Year Focus	2024		
Document Fiscal Period Focus	FY		
Amendment Flag	false		
Auditor Name	KPMG LLP		
Auditor Firm ID	185		
Auditor Location	Minneapolis, Minnesota		

XML 19 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME			
Net sales	$ 1,159,060	$ 1,136,702	$ 1,105,599
Cost of sales	389,335	366,887	349,103
Gross margin	769,725	769,815	756,496
Operating expenses:			
Selling, general and administrative	466,375	378,378	372,766
Research and development	96,664	92,493	87,140
Total operating expenses	563,039	470,871	459,906
Operating income	206,686	298,944	296,590
Interest expense	(15,736)	(11,215)	(11,309)
Interest income	3,323	3,410	794
Other non-operating income (expense), net	(8,584)	47,520	15,311
Total other income (expense), net	(20,997)	39,715	4,796
Earnings before income taxes	185,689	338,659	301,386
Income taxes	17,584	53,217	38,287
Net earnings, including noncontrolling interest	168,105	285,442	263,099
Net earnings attributable to noncontrolling interest		179	(8,952)
Net earnings attributable to Bio-Techne	168,105	285,263	272,051
Other comprehensive income (loss):			
Foreign currency translation income (loss)	(7,492)	4,191	(32,241)
Foreign currency translation reclassified to earnings with Eminence deconsolidation		119	
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8	(4,760)	4,793	14,262
Other comprehensive income (loss)	(12,252)	9,103	(17,979)
Other comprehensive income (loss) attributable to noncontrolling interest		(33)	(70)
Total other comprehensive income (loss), net of tax	(12,252)	9,136	(17,909)
Comprehensive income attributable to Bio-Techne	$ 155,853	$ 294,399	$ 254,142
Earnings per share attributable to Bio-Techne:			
Basic (in dollars per share)	$ 1.07	$ 1.81	$ 1.73
Diluted (in dollars per share)	$ 1.05	$ 1.76	$ 1.66
Weighted average common shares outstanding:			
Basic (in shares)	157,708	157,179	156,874
Diluted (in shares)	160,774	161,855	164,114

XML 20 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Current assets:		
Cash and cash equivalents	$ 151,791	$ 180,571
Short-term available-for-sale investments	1,072	23,739
Accounts receivable, less allowance for doubtful accounts of $4,386 and $4,738, respectively	241,394	218,468
Inventories	179,731	171,638

Current assets held-for-sale	9,773	
Other current assets	33,658	27,066
Total current assets	617,419	621,482
Property and equipment, net	251,154	226,200
Right-of-use assets	91,285	98,326
Goodwill	972,663	872,737
Intangible assets, net	507,081	534,645
Other assets	264,265	285,302
Total assets	2,703,867	2,638,692
Current liabilities:		
Trade accounts payable	37,968	25,679
Salaries, wages and related accruals	49,818	36,747
Accrued expenses	24,886	14,880
Contract liabilities	27,930	23,069
Income taxes payable	3,706	12,022
Operating lease liabilities - current	12,920	11,199
Contingent consideration payable		3,500
Other current liabilities	2,151	1,413
Total current liabilities	159,379	128,509
Deferred income taxes	55,863	88,982
Long-term debt obligations	319,000	350,000
Operating lease liabilities	87,618	93,766
Other long-term liabilities	13,157	10,919
Bio-Techne's Shareholders' equity:		
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding	0	0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 158,216,258 and 157,641,914 respectively	1,582	1,576
Additional paid-in capital	820,337	721,543
Retained earnings	1,325,247	1,309,461
Accumulated other comprehensive loss	(78,316)	(66,064)
Total Bio-Techne's shareholders' equity	2,068,850	1,966,516
Total liabilities and shareholders' equity	$ 2,703,867	$ 2,638,692

XML 21 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) $ in Thousands	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares
CONSOLIDATED BALANCE SHEETS		
Accounts receivable, allowance for doubtful accounts | $	$ 4,386	$ 4,738
Undesignated capital stock, no par (in dollars per share) | $ / shares	$ 0	$ 0
Undesignated capital stock, shares authorized (in shares)	5,000,000	5,000,000
Undesignated capital stock, shares issued (in shares)	0	0
Undesignated capital stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share) | $ / shares	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	158,216,258	157,641,914
Common stock, shares outstanding (in shares)	158,216,258	157,641,914

XML 22 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interest	Total
Balances (in shares) at Jun. 30, 2021	155,822,000					
Balances at Jun. 30, 2021	$ 1,558	$ 533,239	$ 1,085,465	$ (57,291)	$ 8,263	$ 1,571,234
Net earnings			272,051		(8,952)	263,099
Other comprehensive income (loss)				(17,909)	(70)	$ (17,979)
Share repurchases (in shares)	(1,577,000)					(1,576,952)
Share repurchases	$ (16)		(160,934)			$ (160,950)
Common stock issued for exercise of options (in shares)	2,282,000					2,450,000
Common stock issued for exercise of options	$ 23	74,354	(13,482)			$ 60,895
Common stock issued for restricted stock awards (in shares)	89,000					
Common stock issued for restricted stock awards	$ 1	(1)	(9,978)			(9,978)
Cash dividends			(50,185)			(50,185)
Stock-based compensation expense		41,208				41,208
Common stock issued to employee stock purchase plan (in shares)	28,000					
Common stock issued to employee stock purchase plan	$ 0	2,694				2,694
Employee stock purchase plan expense		973				973
Balances (in shares) at Jun. 30, 2022	156,644,000					
Balances at Jun. 30, 2022	$ 1,566	652,467	1,122,937	(75,200)	(759)	1,701,011
Reclassification of cumulative translation adjustment for Eminence to non-operating income				152	(33)	119
Elimination of noncontrolling equity interest from sale of Eminence					613	613
Net earnings			285,263		$ 179	285,442
Other comprehensive income (loss) before reclassification				8,984		8,984
Other comprehensive income (loss)						$ 9,103
Share repurchases (in shares)	(222,000)					(222,000)
Share repurchases	$ (2)		(19,560)			$ (19,562)
Common stock issued for exercise of options (in shares)	1,083,000					1,578,000
Common stock issued for exercise of options	$ 10	24,942	(22,163)			$ 2,789
Common stock issued for restricted stock awards (in shares)	63,000					
Common stock issued for restricted stock awards	$ 1	(1)	(6,731)			(6,731)
Cash dividends			(50,285)			(50,285)
Stock-based compensation expense		38,315				38,315
Common stock issued to employee stock purchase plan (in shares)	74,000					
Common stock issued to employee stock purchase plan	$ 1	4,905				4,906
Employee stock purchase plan expense		915				$ 915
Balances (in shares) at Jun. 30, 2023	157,642,000					157,641,914
Balances at Jun. 30, 2023	$ 1,576	721,543	1,309,461	(66,064)		$ 1,966,516
Net earnings			168,105			168,105
Other comprehensive income (loss)				(12,252)		$ (12,252)
Share repurchases (in shares)	(1,397,000)					(1,397,471)
Share repurchases	$ (14)		(80,028)			$ (80,042)
Common stock issued for exercise of options (in shares)	1,811,000					2,240,000
Common stock issued for exercise of options	$ 18	56,409	(16,534)			$ 39,893
Common stock issued for restricted stock awards (in shares)	91,000					
Common stock issued for restricted stock awards	$ 1	(1)	(5,338)			(5,338)
Cash dividends			(50,419)			(50,419)
Stock-based compensation expense		37,136				37,136
Common stock issued to employee stock purchase plan (in shares)	69,000					
Common stock issued to employee stock purchase plan	$ 1	4,344				4,345

Employee stock purchase plan expense		906			$ 906
Balances (in shares) at Jun. 30, 2024	158,216,000				158,216,258
Balances at Jun. 30, 2024	$ 1,582	$ 820,337	$ 1,325,247	$ (78,316)	$ 2,068,850

XML 23 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net earnings, including noncontrolling interest	$ 168,105	$ 285,442	$ 263,099
Adjustments to reconcile net earnings to net cash provided by operating activities:			
Depreciation and amortization	111,711	107,238	101,069
Costs recognized on sale of acquired inventory	729	400	1,596
Deferred income taxes	(39,447)	(29,567)	6,816
Stock-based compensation expense	38,042	39,230	42,183
Fair value adjustment to contingent consideration payable	(3,500)	(12,100)	(20,400)
Contingent consideration payments - operating			(3,300)
Gain on sale of CCXI investment		(37,176)	
Fair value adjustment on available-for-sale investments	(283)	(472)	(15,002)
Loss on equity method investment	6,841	1,143	
Asset impairment restructuring	2,634		546
Eminence impairment			18,715
Gain on sale of Eminence		(11,682)	
Leases, net	1,708	2,059	(1,201)
Impairment of assets held-for-sale	21,963		
Other operating activity	584	455	668
Change in operating assets and operating liabilities, net of acquisition:			
Trade accounts and other receivables, net	(20,533)	(20,867)	(57,596)
Inventories	(14,215)	(30,167)	(32,007)
Prepaid expenses	(3,146)	(4,585)	(3,082)
Trade accounts payable, accrued expenses, contract liabilities, and other	25,769	(7,908)	12,741
Salaries, wages and related accruals	12,618	(24,558)	7,760
Income taxes payable	(10,599)	(2,492)	2,667
Net cash provided by (used in) operating activities	298,981	254,393	325,272
CASH FLOWS FROM INVESTING ACTIVITIES:			
Proceeds from sale of available-for-sale investments	28,083	35,236	26,055
Purchases of available-for-sale investments	(5,526)	(20,500)	(52,998)
Proceeds from sale of CCXI investment		73,219	
Additions to property and equipment	(62,877)	(38,244)	(44,908)
Acquisitions, net of cash acquired	(169,707)	(101,184)	
Distributions from (Investments in) Wilson Wolf	6,997	(232,000)	
Proceeds from sale of Eminence		17,824	
Investment of forward purchase contract			(25,000)
Net cash provided by (used in) investing activities	(203,030)	(265,649)	(96,851)
CASH FLOWS FROM FINANCING ACTIVITIES:			
Cash dividends	(50,419)	(50,285)	(50,185)
Proceeds from stock option exercises	60,935	29,813	77,155
Re-purchases of common stock	(80,042)	(19,562)	(160,950)
Borrowings under line-of-credit agreement	225,000	619,661	90,000
Repayments of long-term debt	(256,000)	(525,661)	(175,500)
Contingent consideration payments - financing			(700)
Taxes paid on RSUs and net share settlements	(21,872)	(28,893)	(23,461)
Other financing activity		(2,457)	788
Net cash provided by (used in) financing activities	(122,398)	22,616	(242,853)
Effect of exchange rate changes on cash and cash equivalents	(2,333)	(3,356)	(12,092)
Net change in cash and cash equivalents	(28,780)	8,004	(26,524)
Cash and cash equivalents at beginning of period	180,571	172,567	199,091
Cash and cash equivalents at end of period	151,791	180,571	172,567
Supplemental disclosure of cash flow information:			
Cash paid for interest	$ 14,502	$ 8,368	$ 11,027

XML 24 R7.htm IDEA: XBRL DOCUMENT

Description of Business and Summary of Significant Accounting Policies:	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements	
Description of Business and Summary of Significant Accounting Policies	

Note 1. Description of Business and Summary of Significant Accounting Policies:

Description of business: Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (the Company), develop, manufacture and sell life science reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

At the 2022 annual meeting of shareholders of the Company held on October 27, 2022, the shareholders approved an amendment and restatement of the Company's articles of incorporation to increase the number of authorized shares of the Company's common stock from 100,000,000 to 400,000,000. On November 1, 2022, the Company's board of directors approved and declared a four-for-one split of the Company's common stock in the form of a stock dividend. Each stockholder of record on November 14, 2022 received three additional shares of common stock for each then-held share, which were distributed after close of trading on November 29, 2022. All share and per share amounts presented herein have been retroactively adjusted to reflect the impact of the stock split.

Use of estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates.

Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. As Eminence met the criteria for consolidation, the transaction was accounted for in accordance with ASC *805, Business Combinations*. In applying ASC *805* to the transaction, the Company has elected to include Eminence in our consolidated financial statements on a one month lag. As noted below, Eminence was sold during the first fiscal quarter of 2023.

Equity method investments: The company accounts for its equity method investments in accordance with ASC *323, Investments - Equity Method and Joint Ventures*. The Company initially records its equity method investments at the amount of the Company's investment and adjusts each period for the Company's share of the investee's income or loss and dividends paid. Distributions from the equity method investee are accounted for using the cumulative earnings approach on the Consolidated Statement of Cash Flows.

In December 2021, the Company paid $25 million to enter into a two-part forward contract which requires the Company to make an initial ownership investment followed by purchase of full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or annual earnings before interest, taxes, depreciation, and amortization (EBITDA) thresholds are met. Wilson Wolf is a leading manufacturer of cell culture devices, including the G-Rex product line. The first part of the forward contract was triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in EBITDA at any point prior to December 31, 2027. During the quarter ended March 31, 2023, the Company determined that Wilson Wolf had met the EBITDA target. On March 31, 2023, the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf, which is accounted for as an equity method investment.

Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, and requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple of approximately 4.4 times trailing twelve month revenue. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million
in annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone.

Translation of foreign financial statements: Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income.

Revenue recognition: ASC 606 provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC 606 is that revenue should be recognized to depict the transfer of promised goods or

services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer to Note 2 for additional information regarding our revenue recognition policy under *ASC 606*.

Research and development: Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications.

Advertising costs: Advertising expenses were $4.1 million, $4.8 million, and $4.6 million for fiscal 2024, 2023, and 2022 respectively. Advertising expenditures are expensed as incurred.

Income taxes: The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Refer to Note 12 for additional information regarding income taxes.

Comprehensive income: Comprehensive income includes charges and credits to shareholders' equity that are not the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity. Any tax effects, if applicable, associated with reclassifications of accumulated other comprehensive income to net income are reflected in the provision for income taxes.

Cash and cash equivalents: Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of three months or less.

Available-for-sale investments: Available-for-sale investments consist of debt instruments with original maturities of generally three months to less than one-year and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value. Unrealized gains and losses on our available-for-sale securities are included within other income (expense).

Trade accounts receivable and allowances: Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do not bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall
composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer. The Company does not have material long-term customer receivables.

Inventories: Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory not meeting quality control standards and inventory subject to expiration.

For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no material changes to the Company's estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with *ASC 330 - Inventory*.

Property and equipment: Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are depreciated over estimated useful lives of 5 to 40 years.

Contingencies: The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better restimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and the amount may be reasonably estimated, the estimated loss or range of loss is disclosed.

Contingent Consideration: Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income.

Intangible assets: Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life.

Impairment of long-lived assets and amortizable intangibles: We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to, (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used or in its physical condition,
or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are not available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows.

The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. During the second quarter of fiscal year 2024 there was a triggering event for the assets and liabilities associated with a disposal group in our Protein Sciences segment that were classified as held-for-sale. See the restructuring section of Note 1 below for additional details. No other triggering events were identified and no other impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years 2024, 2023, and 2022.

Impairment of goodwill and indefinite-lived intangible assets: We evaluate the carrying value of goodwill and indefinite-lived intangible assets during the fourth quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, (3) an adverse action or assessment by a regulator, or (4) an adverse change in market conditions that are indicative of a decline in the fair value of the assets.

To analyze goodwill, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business. The Company had five reporting units for our 2024, 2023, and 2022 goodwill impairment assessment performed on April 1 of each of the respective fiscal years, the date of our annual goodwill impairment assessment.

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation for goodwill is an assessment of factors including reporting unit specific operating results as well as industry and market conditions, overall financial performance, and other relevant events and factors to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass the qualitative assessment for its reporting units and perform a quantitative test.

The quantitative impairment test requires us to estimate the fair value of our reporting units based the income approach. The income approach is a valuation technique under which we estimate future cash flows using the reporting unit's financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we project revenue and apply our fixed and variable cost experience rate to the projected revenue to arrive at the future cash flows. A terminal value is then applied to the projected cash flow stream. Future estimated cash flows are discounted to their present value to calculate the estimated fair value. The discount rate used is the value-weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we are required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.

For fiscal 2024, we elected to perform a qualitative analysis for all five reporting units. The Company determined, after performing the qualitative analysis, there was no evidence that it is more likely than not that the fair value was less than the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test in fiscal 2024. There was a triggering event related to a business held-for-sale described later in this note, leading to an impairment of allocated goodwill during the second half of fiscal 2024. The Company did not identify any triggering events after our annual goodwill impairment analysis through June 30, 2024, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed.

For fiscal 2024, the Company also performed a qualitative assessment of the acquired in-process research and development assets to determine whether changes in events, circumstances, or the probability of successful development and commercialization of the assets indicated that it is more likely than not that the fair value of the acquired assets are less than its carrying amount. Based on the analysis, the Company determined there was no indication of impairment of the indefinite-lived intangible asset. This in-process research and development was placed into service during the fourth quarter of fiscal 2024 and will begin amortization over its expected useful life.

In fiscal 2023, we elected to perform a qualitative analysis for all five reporting units. The Company determined, after performing the qualitative analysis, there was no evidence that it is more likely than not that the fair value was less than the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test in fiscal 2023. The Company did not identify any triggering events after our annual goodwill impairment analysis through June 30, 2023, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed.

On September 1, 2022, the Company completed the sale of its equity shares of Eminence for approximately $17.8 million to a third party. Eminence was considered a variable-interest entity that was fully consolidated in our financial statements. Prior to the sale, Eminence had revenue of $2.0 million for the first fiscal quarter of 2023 within our Protein Sciences segment. Fiscal 2022 revenues were $4.6 million. As a result of the sale of the business, the Company recorded a gain of $11.7 million within the Other income (expense) line in the Consolidated Statement of Earnings. Prior to the sale of Eminence, a triggering event was identified in the second quarter of fiscal 2022 and impairment testing was performed as Eminence was forecasted to not have sufficient cash to execute on their growth plan combined with their inability to secure additional financing. Our impairment testing resulted in a full impairment of the Eminence goodwill and intangibles assets for charges of $8.3 million and $8.6 million, respectively, for the year ended June 30, 2022. The Company also recognized inventory and fixed asset impairment charges of $0.9 million and $0.9 million, respectively. These impairment charges were recorded within the General and Administrative line in the Consolidated Statement of Earnings for fiscal 2022. In the fourth quarter of fiscal 2022, Eminence was able to secure cash deposits on future orders to provide funding for their operations. This delay in liquidation allowed time for securing of additional investor financing which coincided with the sale of the Company's investment.

In the first quarter of fiscal 2022, the Company combined the management of the Exosome Diagnostics and Asuragen reporting units, both of which are included in the Diagnostics and Genomics operating segment. In conjunction with the combination of the reporting units, a qualitative goodwill impairment assessment was performed. The qualitative assessment identified no indicators of impairment.

In our fiscal 2022 annual goodwill impairment analysis, we elected to perform a quantitative assessment for all five of our reporting units. The result of our quantitative assessment indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2022. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2022, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed.

Restructuring actions: Restructuring actions generally include significant actions involving employee-related severance charges, contract termination costs, and impairments and disposals of assets associated with such actions. Employee-related severance charges are based upon distributed employment policies and substantive severance plans. These charges are reflected in the quarter when the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Asset-related and other charges include impairment of right-of-use assets, leasehold improvements, other asset write-downs associated with combining operations, disposal of assets and other exit costs. Other costs also includes restructuring-related charges, which are incremental costs incurred directly supporting business transformation initiatives tied to the restructuring action.

Fiscal Year 2024 Restructuring Actions:

In the second quarter of fiscal 2024, the Company announced enterprise-wide restructuring focused on recovering operating margins, optimizing our distribution footprint, and enhancing our organization efficiency. These actions impacted approximately 4% of our global workforce. These actions continued through the end of fiscal 2024 as we incurred charges relating to the condensing of certain distribution centers and optimizing efficiency. The Company is expecting to
incur costs related to these actions through the first half of fiscal 2025, which will be recorded when specified criteria are met.

As part of these actions, certain assets and liabilities associated with a disposal group in our Protein Sciences segment were classified as held-for-sale as of December 31, 2023, including $1.4 million of goodwill allocated to the disposal group on a relative fair value basis. As a result of impairment tests performed over the disposal group during fiscal 2024, a cumulative impairment charge of $22.0 million which includes the allocated goodwill, was recorded in the Selling, general and administrative line in the Consolidated Statements of Earnings for the year ended June 30, 2024. As of June 30, 2024, the assets remaining within the disposal group primarily include inventory and property and equipment of $9.8 million, which is net of expected selling costs. These assets are actively marketed, and we believe their sale will be completed within 12 months of the held-for-sale classification date. The held-for-sale assets are recorded in Current assets held-for-sale in our Consolidated Balance Sheet as of June 30, 2024.

The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands):

	Year Ended June 30, 2024
Cost of sales	$ 3,349
Selling, general and administrative[1]	30,638
Total	$ 33,987

[1] Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs.

Restructuring and restructuring-related costs by segment are as follows (in thousands):

	Year ended June 30, 2024			
	Employee severance	Asset-related and other	Impairment of assets held-for-sale	Total
Protein Sciences	$ 3,483	$ 5,130	$ 21,963	$ 30,576
Diagnostics and Genomics	1,007	224	—	1,231
Corporate	1,153	1,027	—	2,180
Total	$ 5,643	$ 6,381	$ 21,963	$ 33,987

The following table summarizes the changes in the Company's accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands):

	Employee severance[1]	Asset-related and other[2]	Impairment of assets held-for-sale	Total
Expense incurred in the second quarter of 2024	4,882	504	6,038	11,424
Incremental expense incurred in the third quarter of 2024	133	1,140	—	1,273
Incremental expense incurred in the fourth quarter of 2024	409	4,737	15,926	21,072
Cash payments	(4,882)	(2,800)	—	(7,682)
Non-cash adjustments	—	(3,391)	(21,963)	(25,354)
Adjustments[3]	219	—	—	219
Accrued restructuring actions balance as of June 30, 2024	$ 761	$ 190	$ —	$ 952

[1] Relates to impacted employees' final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites.

[2] Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives.

[3] Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024.

Fiscal Year 2023 Restructuring Actions:

QT Holdings Corporation (Quad)

In August 2022, the Company informed employees of our decision to close our Quad facility as part of a realignment of activities within our Reagent Solutions division. The closure of the site was completed in the fourth quarter of fiscal 2023. As a result of the restructuring activities, an estimated pre-tax charge of $2.2 million was recorded within our Protein Sciences segment for the year ended June 30, 2023. The related restructuring charges for the year ended June 30, 2023 were recorded in the income statement as follows (in thousands):

	Employee severance	Asset impairment and other	Total
Selling, general and administrative	$ 1,328	$ 842	$ 2,170

	Employee severance	Asset impairment and other	Total
Expense incurred in the first quarter of 2023	$ 1,328	$ 842	$ 2,170
Cash payments	(1,233)	(772)	(2,005)
Adjustments	(95)	(70)	(165)
Accrued restructuring actions balances as of June 30, 2023	$ —	$ —	$ —

Protein Sciences realignment

In December 2022, the Company informed employees it would undertake certain actions to strategically reallocate operations resources to high growth areas of the business. Additional actions were taken in June 2023 primarily related to the sales organization. The actions impacted a limited number of employees and were completed in the fourth quarter of fiscal 2024. As a result of the realignment, a pre-tax charge of $1.7 million related to employee severance was recorded in the Selling, general and administrative line of operating income within our Protein Sciences segment during the year ended June 30, 2023. Adjustments in fiscal year 2024 relate to the refinement of employee severance payouts. Additional pre-
tax charges for the year ended June 30, 2024 were $0.2 million. Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):

	Employee severance
Expense incurred in fiscal year 2023	$ 1,677
Fiscal year 2023 cash payments	(762)
Fiscal year 2023 adjustments	(18)
Accrued restructuring actions balances as of June 30, 2023	$ 897
Fiscal year 2024 cash payments	(1,118)
Fiscal year 2024 adjustments[1]	221
Accrued restructuring actions balances as of June 30, 2024	$ —

[1]Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023.

Fiscal Year 2022 Restructuring Actions:

In September 2021, the Company informed employees of our decision to close our Exosome Diagnostics Germany facility, discontinuing lab and research occurring at the site, as part of a realignment of activities within our Exosome Diagnostics business. The restructuring activities were complete as of June 30, 2022. As a result of the restructuring activities, a pre-tax charge of $1.4 million was recorded within our Diagnostics and Genomics segment during the year ended June 30, 2022. Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within operating income on the income statement as follows (in thousands):

	Employee severance	Asset impairment and other	Total
Selling, general and administrative	$ 649	$ 750	$ 1,399

	Employee severance	Asset impairment and other	Total
Expense incurred in the first quarter of 2022	$ 639	$ 546	$ 1,185
Incremental expense incurred during fiscal 2022	—	242	242
Cash payments	(589)	(554)	(1,143)
Adjustments	(50)	(234)	(284)
Accrued restructuring actions balances as of June 30, 2022	$ —	$ —	$ —

[1] Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange.

During the second quarter of fiscal 2022, the Company also incurred a restructuring charge of $0.2 million related to employee severance for the relocation of a US plant. This was completed during fiscal 2023 and there are no remaining liabilities related to this relocation as of June 30, 2023. This charge was recorded within Other current liabilities as of June 30, 2022. Fiscal 2023 cash payments did not materially differ from the charge recorded in fiscal 2022.

Legal Matters: The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. The Company's standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require
significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.

The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges in the consolidated statements of income.

During fiscal year 2024, the Company recognized $3.5 million of certain litigation charges. There was no comparable activity in the comparable periods. As of each of the balance sheet dates presented, there was no accrued litigation. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other current liabilities and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters

could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows.

Intellectual Property Matters: At any given time, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements related to such rights. This litigation includes, but it not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or entities created specifically to fund IP litigation. While the outcome of these litigation matters is inherently uncertain, it is possible that the results of such litigation could require the Company to pay significant monetary damages.

Other Significant Accounting Policies

The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number:

Policy	Note
Fair value measurements	5
Leases	7
Earnings per share	9
Share-based compensation	10
Operating segments	13

Not Yet Adopted Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures.
The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, on our consolidated financial statements.

XML 25 R8.htm IDEA: XBRL DOCUMENT

Revenue Recognition

12 Months Ended
Jun. 30, 2024

Notes to Financial Statements

Revenue Recognition

Note 2. Revenue Recognition:

Consumables revenues consist of specialized proteins, immunoassays, antibodies, reagents, blood chemistry and blood gas quality controls, and hematology instrument controls that are typically single-use products recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consist of extended warranty contracts, post contract support, and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. Service revenues also include laboratory services recognized at point in time.

We recognize royalty revenues in the period the sales occur using third party evidence. The Company elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date.

The Company elected the exemption to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance. The Company's unfulfilled performance obligations for contracts with an original length greater than one year were not material as of June 30, 2024.

Contracts with customers that contain instruments may include multiple performance obligations. For these contracts, the Company allocates the contract's transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contracts' inception.

Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both.

Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one year. We elected the practical expedient allowing us to expense contract costs that would otherwise be capitalized and amortized over a period of less than one year. Contract assets as of June 30, 2024 are not material. Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts.

Contract liabilities as of June 30, 2024 and June 30, 2023 were approximately $30.2 million and $24.6 million, respectively. Contract liabilities as of June 30, 2023 subsequently recognized as revenue during the year ended June 30, 2024 were approximately $20.9 million. Contract liabilities as of June 30, 2022 subsequently recognized as revenue during the year ended June 30, 2023 were approximately $21.5 million. Contract liabilities in excess of one year are included in Other long-term liabilities on the consolidated balance sheet.

Any claims for credit or return of goods must be made within 10 days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material.

Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized. The following tables present our disaggregated revenue for the periods presented.

Revenue by type is as follows (in thousands):

	Year ended June 30,		
	2024	2023	2022
Consumables	$ 928,180	$ 917,733	$ 890,874
Instruments	108,270	112,085	120,758
Services	99,265	85,784	71,988
Total product and services revenue, net	1,135,715	$ 1,115,602	1,083,620
Royalty revenues	23,345	21,100	21,979
Total revenues, net	$ 1,159,060	$ 1,136,702	$ 1,105,599

Revenue by geography (in thousands):

	Year Ended June 30,		
	2024	2023	2022
United States	$ 657,747	$ 642,465	$ 614,107
EMEA, excluding United Kingdom	241,432	220,230	219,055
United Kingdom	50,012	49,457	48,637
APAC, excluding Greater China	73,904	73,190	76,139
Greater China	99,467	113,868	112,438
Rest of World	36,498	37,492	35,223
Net sales	$ 1,159,060	$ 1,136,702	$ 1,105,599

XML 26 R9.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet and Cash Flow Information

12 Months Ended
Jun. 30, 2024

Notes to Financial Statements

Supplemental Balance Sheet and Cash Flow Information

Note 3. Supplemental Balance Sheet and Cash Flow Information:

Inventories:

Inventories consist of (in thousands):

	June 30,	
	2024	2023
Raw materials	$ 79,377	$ 84,551
Finished goods[1]	106,072	92,474
Inventories, net	$ 185,449	$ 177,025

(1) Finished goods inventory of $5,718 and $5,387 is included within Other assets in the June 30, 2024 and June 30, 2023 Balance Sheets, respectively, as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.

Property and Equipment:

Property and equipment consist of (in thousands):

	June 30,	
	2024	2023
Land	$ 8,150	$ 9,100
Buildings and improvements	243,863	245,302
Machinery and equipment	215,948	190,019
Construction in progress	39,749	15,491
Property and equipment, cost	507,710	459,912

Accumulated depreciation and amortization	(256,556)	(233,712)
Property and equipment, net	$ 251,154	$ 226,200

Intangibles assets were comprised of the following (in thousands):

	Useful Life (years)	June 30, 2024	June 30, 2023
Developed technology	9 - 15	$ 675,674	$ 616,311
Tradenames	2 - 20	151,561	146,945
Customer relationships	7 - 16	211,276	213,878
Patents	10	4,343	3,815
Other intangibles	5 - 15	12,006	11,566
Definite-lived intangible assets		1,054,860	992,515
Accumulated amortization		(547,779)	(480,570)
Definite-lived intangibles assets, net		507,081	511,945
In process research and development[1]		—	22,700
Total intangible assets, net		$ 507,081	$ 534,645

[1]The in process research and development has been placed into service and is included within Developed technology. The amortization period for this developed technology asset is estimated to be 14 years.

Changes to the carrying amount of net intangible assets consist of (in thousands):

	June 30, 2024	June 30, 2023
Beginning balance	$ 534,645	$ 531,522
Acquisitions	66,400	75,600
Other additions[1]	950	5,710
Held-for-sale intangibles[2]	(14,323)	—
Amortization expense	(79,854)	(77,491)
Currency translation	(737)	(696)
Ending balance	$ 507,081	$ 534,645

[1]Includes the purchase of a $4.6 million intangible asset from Wilson Wolf, an equity method investee of the Company during the year-ended June 30, 2023. This asset will be amortized over a life of 10 years.

[2]Refer to Note 1 for further detail on held-for-sale intangibles.

Amortization expense related to developed technologies included in cost of sales was $46.6 million, $44.3 million, and $40.6 million in fiscal 2024, 2023, and 2022, respectively. Amortization expense related to trade names, customer
relationships, non-compete agreements, and patents included in selling, general and administrative expense was $33.2 million, $33.2 million, and $33.5 million, in fiscal 2024, 2023, and 2022 respectively.

The estimated future amortization expense for intangible assets as of June 30, 2024 is as follows (in thousands):

2025	$ 77,259
2026	73,297
2027	63,138
2028	59,491
2029	46,923
Thereafter	186,973
Total	$ 507,081

Goodwill:

Changes in goodwill by segment and in total consist of (in thousands):

	Protein Sciences	*Diagnostics and Genomics*	*Total*
June 30, 2022	$ 376,493	$ 445,608	$ 822,101
Acquisitions	51,257	—	51,257
Currency translation	(723)	102	(621)
June 30, 2023	$ 427,027	$ 445,710	$ 872,737
Acquisitions	—	104,650	104,650
Held-for-sale goodwill[1]	(1,400)	—	(1,400)
Currency translation	(2,178)	(1,146)	(3,324)
June 30, 2024	$ 423,449	$ 549,214	$ 972,663

[1] Refer to Note 1 for further detail on goodwill reclassified to current assets held-for-sale.

Other Assets:

Other assets consist of (in thousands):

	June 30, 2024	June 30, 2023
Equity method investment in Wilson Wolf	$ 242,337	$ 255,857
Derivative instruments	9,813	16,857
Long-term inventory	5,718	5,387
Other	6,397	7,201
Other assets	$ 264,265	$ 285,302

Supplemental Cash Flow Information:

Supplemental cash flow information was as follows (in thousands):

	Year Ended June 30, 2024	2023	2022
Income taxes paid	$ 65,254	$ 88,428	$ 30,341
Interest paid	14,502	8,368	11,027

XML 27 R10.htm IDEA: XBRL DOCUMENT

Acquisitions

12 Months Ended
Jun. 30, 2024

Notes to Financial Statements
Acquisitions

Note 4. Acquisitions:

We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred.

Fiscal year 2024 Acquisitions

Lunaphore Technologies SA.

On July 7, 2023, the Company acquired all of the ownership interests of Lunaphore Technologies SA ("Lunaphore") for $169.7 million, in a cash-free, debt-free acquisition. Lunaphore is a leading developer of fully automated spatial biology solutions. The Lunaphore acquisition adds spatial biology instruments to Bio-Techne's portfolio to accelerate our leadership position in translational and clinical research markets. The transaction was accounted for in accordance with ASC *805, Business Combinations*. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company's product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Diagnostics and Genomics operating segment in the first quarter of fiscal year 2024.

The allocation of purchase price consideration related to Lunaphore was completed in the fourth quarter of fiscal 2024. Net sales and operating loss of this business included in Bio-Techne's consolidated results of operations for the year ended June 30, 2024 were approximately $14.3 million and $24.0 million, respectively. The fair values of the assets acquired and liabilities assumed as of the acquisition date and the updated final amounts as of June 30, 2024 are as follows (in thousands):

	Preliminary allocation at acquisition date	Adjustments to fair value	Final allocation at June 30, 2024
Current assets	$ 12,512	$ (357)	$ 12,155
Equipment and other long-term assets	1,470		1,470
Intangible assets:			
Developed technologies	60,300		60,300
Tradenames	4,900		4,900
Customer relationships	1,200		1,200
Goodwill	102,560	2,090	104,650
Total assets acquired	182,942	1,733	184,675
Liabilities	7,096		7,096
Deferred income taxes, net	5,768	2,104	7,872
Net assets acquired	$ 170,078	$ (371)	$ 169,707

Cash paid	166,426	3,281	169,707
Estimated Net Working Capital	3,652	(3,652)	—
Net assets acquired	$ 170,078	$ (371)	$ 169,707

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology and customer relationships was based on management's forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The purchase price allocated to trade names was based on management's forecasted cash inflows and outflows and using a relief from royalty method. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 14 years. Amortization expense related to customer relationships is reflected in
selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is estimated to be 8 years. The amount recorded for trade names is being amortized with the expense reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for trade names ranges from 4 years to 8 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes, offset by the deferred tax asset for the preliminary calculation of acquired net operating losses.

Fiscal year 2023 Acquisitions

Namocell, Inc.

On July 1, 2022, the Company acquired all of the ownership interests of Namocell, Inc. ("Namocell") for $101.2 million, net of cash acquired, plus contingent consideration of up to $25 million upon the achievement of certain future revenue thresholds. The Namocell acquisition adds easy-to-use single cell sorting and dispensing platforms that are gentle to cells and preserve cell viability and integrity. The transaction was accounted for in accordance with ASC 805, Business Combinations. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company's product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences operating segment in the first quarter of fiscal year 2023.

The allocation of purchase price consideration related to Namocell was completed in the fourth quarter of fiscal 2023. Net sales and operating loss of this business included in Bio-Techne's consolidated results of operations for the twelve months ended June 30, 2023 were approximately $6.4 million and $9.3 million, respectively. The fair values of the assets acquired and liabilities assumed as of the acquisition date and the updated final amounts as of June 30, 2023 are as follows (in thousands):

	Namocell Inc
Current assets, net of cash	$ 3,248
Equipment and other long-term assets	405
Intangible assets:	
Developed technology	73,900
Trade name	700
Customer relationships	900
Non-competition agreement	100
Goodwill	51,257
Total assets acquired	130,510
Liabilities	546
Deferred income taxes, net	18,180
Net assets acquired	$ 111,784
Cash paid, net of cash acquired	101,184
Additional consideration	10,600
Net assets acquired	$ 111,784

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was based on management's forecasted cash inflows and outflows and using a relief from royalty method to calculate the fair value of assets purchased. The purchase price allocated to customer relationships and trade names was based on management's forecasted cash inflows and outflows and using a multiperiod excess earnings method. The amount recorded for developed technology is being amortized with the expense reflected in Cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 13 years. Amortization expense related to customer relationships is reflected in Selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive
Income. The amortization period for customer relationships is estimated to be 4 years. The amount recorded for trade names and the non-competition agreement is being amortized with the expense reflected in Selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for both trade names and the non-competition agreement is estimated to be 3 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes, offset by the deferred tax asset for the preliminary calculation of acquired net operating losses.

There were no acquisitions in fiscal 2022.

XML 28 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

12 Months Ended
Jun. 30, 2024

Notes to Financial Statements

Fair Value Measurements

Note 5. Fair Value Measurements:

The Company's financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, derivative instruments, and long-term debt.

Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.

The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.

The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):

	Balance Sheet Location	*Total carrying value as of June 30, 2024*	*Fair Value Measurements Using Inputs Considered as*		
			Level 1	*Level 2*	*Level 3*
Assets					
Certificates of deposit[1]	Short-term available-for-sale investments	$ 1,072	$ 1,072	$ —	$ —
Derivatives designated as hedging instruments - cash flow hedges	Other current assets	805	—	805	—
Derivatives designated as hedging instruments - cash flow hedges	Other assets	9,813	—	9,813	—
Total assets		$ 11,690	$ 1,072	$ 10,618	$ —
Liabilities					
Derivatives designated as hedging instruments - net investment hedge	Other long-term liabilities	$ 2,051	$ —	$ 2,051	$ —
Total liabilities		$ 2,051	$ —	$ 2,051	$ —

	Balance Sheet Location	*Total carrying value as of June 30, 2023*	*Fair Value Measurements Using Inputs Considered as*		
			Level 1	*Level 2*	*Level 3*
Assets					
Exchange traded securities[2]	Short-term available-for-sale investments	$ 23,739	$ 23,739	$ —	$ —
Derivative instruments - cash flow hedges	Other assets	16,857	—	16,857	—
Total assets		$ 40,596	$ 23,739	$ 16,857	$ —
Liabilities					
Contingent consideration	Contingent consideration payable	$ 3,500	$ —	$ —	$ 3,500
Total liabilities		$ 3,500	$ —	$ —	$ 3,500

(1) The certificates of deposit have contractual maturity dates within one year.
(2) During the quarter ended September 30, 2023, the Company sold all of its exchange traded investment grade bond funds that it held at June 30, 2023. The costs basis and fair value of these exchange traded investment grade bond funds were $25.0 million and $23.7 million at June 30, 2023, respectively.

Fair value measurements of available for sale securities

Available for sale securities are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 assets.

Fair value measurements of derivative instruments

The Company utilizes forward starting swaps designated as a cash flow hedge on forecasted debt. The forward starting swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company's forecasted variable interest long-term debt to that of a fixed interest rate. Accordingly, as part of the forward starting swaps, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on a notional principal amounts. The Company also uses a cross-currency swap contract to manage its exposure to foreign currency risk associated with the Company's net investment in its Swiss subsidiary.

The following table presents the contractual amounts of the Company's outstanding instruments (in millions):

Instruments	Designation	June 30, 2024	June 30, 2023
Forward starting swaps[1]	Cash flow hedge	$ 300	$ 300
Cross-currency swap[2]	Net investment hedge	150	—

[1] In May 2021, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $200 million of notional principal. The effective date of the swap was November 2022 with the full swap maturing in November 2025. In March 2023, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $100 million of notional principal. The effective date of the swap was April 2023 with the full swap maturing in April 2025.

[2] In July 2023, the Company entered into a pay-fixed rate, receive-fixed rate cross-currency swap contract with a total notional amount of $150 million that was designated as a hedge to lock in the Swiss franc (CHF) rate for a portion of the Company's CHF net investment in its Lunaphore subsidiary in Switzerland. The objective of the hedge is to protect the net investment in the Company's CHF-denominated operations against changes in the spot exchange rates, on a pre-tax basis. The hedging instrument has four interim settlement dates, which will reduce the notional on the hedging instrument by $10 million at each interim date, and will reduce the notional to $110 million at maturity.

The pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses with our Consolidated Financial Statements for the twelve months ended June 30, 2024 and 2023 were as follows (in thousands):

	(Gain) Loss Recognized in Accumulated Other Comprehensive Loss		
	Year Ended June 30,		
	2024	2023	2022
Cash flow hedges			
Forward starting swaps	$ 12,632	$ (1,340)	$ (19,121)
Net investment hedges			
Cross-currency swap	4,015	—	—
Total	$ 16,647	$ (1,340)	$ (19,121)

	(Gain) Loss Reclassified into Income			
	Year Ended June 30,			
	2024	2023	2022	Location of (Gain) Loss in Income Statement
Cash flow hedges				
Forward starting swaps	$ (10,317)	$ (4,526)	$ 6,352	Interest expense
Net investment hedges				
Cross-currency swap	(3,210)	—	—	Interest expense
Total	$ (13,527)	$ (4,526)	$ 6,352	

Gains or losses related to the net investment hedges are classified as foreign currency translation adjustments in the schedule of changes in Accumulated Other Comprehensive Income ("AOCI") in Note 8, as these items are attributable to the Company's hedges of its net investment in foreign operations. Gains or losses related to the cash flow hedges are classified as Unrealized gains (losses) on cash flow hedges in the schedule of changes in AOCI in Note 8.

The instruments were valued using observable market inputs in active markets and therefore are classified as Level 2 liabilities.

Fair value measurements of contingent consideration

As of June 30, 2024, the Company does not have outstanding contingent consideration as the Asuragen and Namocell acquisitions did not meet their respective milestones as of December 31, 2023.

The Asuragen contingent agreement required the Company to make contingent consideration payments of up to $105.0 million if certain revenue thresholds were achieved by December 31, 2023. The opening balance sheet fair value of the liabilities was $18.3 million, which was determined using a Monte Carlo simulation-based model discounted to present value. Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate, and various probability factors. The contingent consideration related to Asuragen was $2.0 million as of June 30, 2023.

The Namocell contingent agreement required the Company to make contingent consideration payments of up to $25.0 million if certain revenue thresholds were achieved by December 31, 2023. The opening balance sheet fair value of the liabilities was $10.6 million, which was determined using a Monte Carlo simulation-based model discounted to present value. Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate, and various probability factors. The contingent consideration related to Namocell was $1.5 million as of June 30, 2023.

As of June 30, 2023, the Company's obligation for potential contingent consideration payments related to the B-Mogen acquisitions was relieved as the likelihood that the revenue thresholds and product milestones would be achieved in the timeframe established within the purchase agreement was remote. As a result, the Company reversed an accrual for the fair value of the contingent liabilities at the date of settlement during fiscal 2022.

The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):

	June 30,	
	2024	2023
Fair value at the beginning of period	$ 3,500	$ 5,000
Purchase price contingent consideration (Note 4)	—	10,600
Change in fair value of contingent consideration	(3,500)	(12,100)
Payments	—	—
Fair value at the end of period	$ —	$ 3,500

The use of different assumptions, applying different judgment to matters that inherently are subjective and changes in future market conditions could result in different estimates of fair value of our securities or contingent consideration, currently and in the future. If market conditions deteriorate, we may incur impairment charges for securities in our investment portfolio.

Fair value measurements of other financial instruments – The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate fair value.

Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items.

Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility and long-term debt approximates fair value because our interest rate is variable and reflects current market rates.

XML 29 R12.htm IDEA: XBRL DOCUMENT

Debt and Other Financing Arrangements

Notes to Financial Statements

Debt and Other Financing Arrangements

12 Months Ended

Jun. 30, 2024

Note 6. Debt and Other Financing Arrangements:

On August 31, 2022, the Company entered into a revolving line-of-credit and term loan by a Credit Agreement (the Credit Agreement). The Credit Agreement provides for a revolving credit facility of $1 billion, which can be increased by an additional $400 million subject to certain conditions. Borrowings under the Credit Agreement may be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement bear interest at a variable rate. The current outstanding debt is based on the one-month Secured Overnight Financing Rate (SOFR) plus an applicable margin. The applicable margin is determined from the total leverage ratio of the Company and updated on a quarterly basis. The annualized fee for any unused portion of the credit facility is currently 10 basis points.

The Credit Agreement matures on August 31, 2027 and contains customary restrictive and financial covenants and customary events of default. As of June 30, 2024, the outstanding balance under the Credit Agreement was $319.0 million.

XML 30 R13.htm IDEA: XBRL DOCUMENT

Leases

Notes to Financial Statements

Leases

12 Months Ended

Jun. 30, 2024

Note 7. Leases:

As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement date, operating lease right-of-use assets and liabilities are recognized based on the present value of lease payments over the lease term. The discount rate used to calculate present value is the Company's incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. The Company recognizes operating lease expense on a straight-line basis over the lease term. Further, as part of our adoption of ASC 842, the Company also made the accounting policy elections to not capitalize short term leases (defined as a lease with a lease term that is less than 12 months) and to combine lease and non-lease components for all asset classes in determining the lease payments.

Variable lease payments primarily include payments for non-lease components, such as maintenance costs and payments for non-components such as sales tax. During fiscal year 2024, the Company recognized $5.0 million in variable lease expense in the Consolidated Statements of Earnings and Comprehensive Income. During fiscal year 2024, the Company also recognized $18.2 million relating to fixed lease expense in the Consolidated Statements of Earnings and Comprehensive Income.

The following table summarizes the balance sheet classification of the Company's operating leases, amounts of right of use assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company's operating leases (asset and liability amounts are in thousands):

	Balance Sheet Classification	As of June 30, 2024
Operating leases:		
Operating lease right-of-use assets	Right-of-use asset	$ 91,285
Current operating lease liabilities	Operating lease liabilities - current	$ 12,920
Noncurrent operating lease liabilities	Operating lease liabilities	87,618
Total operating lease liabilities		$ 100,538
Weighted average remaining lease term (in years):		8.45
Weighted average discount rate (%):		4.23

The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the year ended June 30, 2024 (in thousands):

	Year ended June 30, 2024
Cash amounts paid on operating lease liabilities[1]	$ 17,729
Right-of-use assets obtained in exchange for lease liabilities	$ 11,051

(1) Total cash paid for the Company's operating leases during the year ended June 30, 2024 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity.

The following table summarizes payments by date for the Company's operating leases, which is then reconciled to our total lease obligation (in thousands):

	June 30, 2024 *Operating Leases*
2025	$ 16,331
2026	16,429
2027	13,577
2028	13,479
2029	12,967
Thereafter	48,211
Total	$ 120,994
Less: Amounts representing interest	20,456
Total lease obligations	$ 100,538

Certain leases include one or more options to renew, with terms that extend the lease term up to five years. The Company includes option to renew the lease as part of the right of use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, the Company is not reasonably certain to exercise such options.

XML 31 R14.htm IDEA: XBRL DOCUMENT

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information

12 Months Ended

Jun. 30, 2024

Notes to Financial Statements

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information

Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information:

Equity

The Company has declared cash dividends per share of $0.32 in each of the full fiscal years ended June 30, 2024, June 30, 2023, and June 30, 2022. During the years ended June 30, 2024, June 30, 2023, and June 30, 2022, the Company repurchased 1,397,471 shares at an average share price of $57.28, 222,000 shares at an average share price of $88.12, and 1,576,952 shares at an average share price of $102.06, respectively. The Company's accounting policy is to record the portion of share repurchases in excess of the par value entirely in retained earnings. During fiscal year 2024, 2023 and 2022, the amounts within the Consolidated Statements of Shareholders' Equity for the surrender and retirement of stock to exercise options due to net settlement stock options exercises and restricted stock units vesting were $21.9 million, $28.9 million, and $23.5 million, respectively.

Accumulated Other Comprehensive Income (loss)

The components of other comprehensive income (loss) consist of changes in foreign currency translation adjustments and changes in net unrealized gains (losses) on derivative instruments designated as cash flow hedges.

Changes in Accumulated Other Comprehensive Income (Loss) attributable to Bio-Techne by component (in thousands):

	Unrealized Gains (Losses) on Derivative Instruments	*Foreign Currency Translation Adjustments*	*Total*
Balance as of June 30, 2021, net of tax:	$ (6,193)	$ (51,098)	$ (57,291)
Other comprehensive income (loss), before tax, attributable to Bio-Techne:			
Amounts before reclassifications [1]	19,121	(32,171)	(13,050)
Amounts reclassified out	(6,352)	—	(6,352)
Total other comprehensive income (loss), before tax, attributable to Bio-Techne:	12,769	(32,171)	(19,402)
Tax benefit	1,493	—	1,493
Total other comprehensive income (loss), net of tax, attributable to Bio-Techne:	14,262	(32,171)	(17,909)
Balance as of June 30, 2022, net of tax[2]	$ 8,069	$ (83,269)	$ (75,200)
Other comprehensive income (loss), before tax, attributable to Bio-Techne: :			
Amounts before reclassifications [1]	1,340	4,191	5,531
Amounts reclassified out	4,526	152	4,678
Total other comprehensive income (loss), before tax, attributable to Bio-Techne:	5,866	4,343	10,209
Tax expense	(1,073)	—	(1,073)
Total other comprehensive income (loss), net of tax, attributable to Bio-Techne:	4,793	4,343	9,136
Balance as of June 30, 2023, net of tax[2]	$ 12,862	$ (78,926)	$ (66,064)
Other comprehensive income (loss), before tax:			
Amounts before reclassifications	(12,632)	(9,941)	(22,573)
Amounts reclassified out	10,317	3,210	13,527
Total other comprehensive income (loss), before tax	(2,315)	(6,731)	(9,046)
Tax expense	(2,445)	(761)	(3,206)
Total other comprehensive income (loss), net of tax	(4,760)	(7,492)	(12,252)
Balance as of June 30, 2024, net of tax[2]	$ 8,102	$ (86,418)	$ (78,316)

(1) Amounts before reclassifications related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $33 thousand and $70 thousand attributable to the non-controlling interest in Eminence as of June 30, 2023, and June 30, 2022, respectively.

(2) The Company had a net deferred tax liability for its cash flow hedge of $2.5 million, $4.0 million, and $2.5 million as of June 30, 2024, June 30, 2023 and June 30, 2022.

Income taxes are not provided for foreign translation relating to permanent investments in international subsidiaries, but tax effects within foreign currency translation adjustments do include impacts from the net investment hedge.

XML 32 R15.htm IDEA: XBRL DOCUMENT

Earnings Per Share

12 Months Ended

Jun. 30, 2024

Notes to Financial Statements

Earnings Per Share

Note 9. Earnings Per Share:

The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):

	Year Ended June 30,		
	2024	**2023**	**2022**
Earnings per share – basic:			
Net earnings, including noncontrolling interest	$ 168,105	$ 285,442	$ 263,099
Less net earnings (loss) attributable to noncontrolling interest	—	179	(8,952)
Net earnings attributable to Bio-Techne	$ 168,105	$ 285,263	$ 272,051
Income allocated to participating securities	(33)	(70)	(121)
Income available to common shareholders	$ 168,072	$ 285,193	$ 271,930
Weighted-average shares outstanding – basic	157,708	157,179	156,874
Earnings per share – basic	$ 1.07	$ 1.81	$ 1.73
Earnings per share – diluted:			
Net earnings, including noncontrolling interest	$ 168,105	$ 285,442	$ 263,099
Less net earnings (loss) attributable to noncontrolling interest	-	179	(8,952)
Net earnings attributable to Bio-Techne	168,105	285,263	272,051
Income allocated to participating securities	(33)	(70)	(121)
Income available to common shareholders	$ 168,072	$ 285,193	$ 271,930
Weighted-average shares outstanding – basic	157,708	157,179	156,874
Dilutive effect of stock options and restricted stock units	3,066	4,676	7,240
Weighted-average common shares outstanding – diluted	160,774	161,855	164,114
Earnings per share – diluted	$ 1.05	$ 1.76	$ 1.66

Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock

options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have not yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option is exercised are assumed to be used to repurchase shares in the current period.

The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 3.9 million, 4.5 million, and 2.8 million for the fiscal years ended June 30, 2024, 2023 and 2022, respectively.

XML 33 R16.htm IDEA: XBRL DOCUMENT

Share-based Compensation and Other Benefit Plans

Notes to Financial Statements

Share-based Compensation and Other Benefit Plans

12 Months Ended

Jun. 30, 2024

Note 10. Share-based Compensation and Other Benefit Plans:

The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares.

Equity incentive plan: The 2020 Equity Incentive Plan, which replaced the Company's Second Amended and Restated 2010 Equity Incentive Plan, provides for the granting of incentive and nonqualified stock options, restricted stock, restricted stock units, performance shares, performance units and stock appreciation rights. There were 36.2 million shares of common stock authorized for grant under the Plan. The maximum aggregate number of shares of common stock reserved and available for awards under the Plan is 9,936,808 shares. At June 30, 2024, there were 6.3 million shares of common stock available for grant under the 2020 Equity Incentive Plan. The maximum term of incentive options granted under the 2020 Equity Incentive Plan is ten years. The 2020 Equity Incentive Plan replaced the Company's second A&R 2010 Plan, which had previously amended and restated the Company's Amended and Restated 2010 Equity Incentive Plan (the A&R 2010 Plan). The 2020 Equity Incentive Plan and Second A&R 2010 Plan (collectively, the Plans) are administered by the Board of Directors and its Executive Compensation Committee, which determine the persons who are to receive awards under the Plans, the number of shares subject to each award and the term and exercise price of each award. The number of shares of common stock subject to outstanding awards as of June 30, 2024 under the 2020 Equity Incentive Plan were 11.6 million.

The fair values of options granted under the Plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used:

	Year Ended June 30,		
	2024	2023	2022
Dividend yield	0.41 %	0.34 %	0.27 %
Expected volatility	30%-37 %	30%-36 %	27%-33 %
Risk-free interest rates	3.8%-4.8 %	2.8%-4.4 %	0.6%-2.6 %
Expected lives (years)	4.4	4.7	4.3

The dividend yield is based on the Company's historical annual cash dividend divided by the market value of the Company's common stock. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted.

Stock option activity under the Plans for the three years ended June 30, 2024, consists of the following (shares in thousands):

	Number of Shares (in thousands)	Weighted Average Exercise Price	Aggregate Intrinsic Value (millions)	Weighted Average Contractual Life (years)
Outstanding at June 30, 2021	14,868	$ 43.16		
Granted	1,390	120.15		
Forfeited	(539)	87.05		
Exercised	(2,450)	33.61		
Outstanding at June 30, 2022	13,269	$ 51.20		
Granted	2,351	93.81		
Forfeited	(118)	85.99		
Exercised	(1,578)	29.48		
Outstanding at June 30, 2023	13,924	$ 60.56		
Granted	1,060	79.69		
Forfeited	(1,165)	90.86		
Exercised	(2,240)	33.34		
Outstanding at June 30, 2024	11,579	$ 64.53	$ 747.3	3.0
Exercisable at June 30, 2022:	7,797	36.99		
Exercisable at June 30, 2023:	8,641	44.76		
Exercisable at June 30, 2024:	8,208	53.57	439.7	2.1

The weighted average fair value of options granted during fiscal 2024, 2023, and 2022 was $27.27, $29.53, and $29.78, respectively. The total intrinsic value of options exercised during fiscal 2024, 2023, and 2022 were $100.8 million, $90.2 million, and $209.3 million, respectively. The total fair value of options exercised during fiscal 2024, 2023, and 2022 were $58.2 million, $46.5 million, and $82.3 million, respectively. The total fair value of options vested during fiscal 2024, 2023, and 2022 were $31.6 million, $31.0 million, and $29.2 million, respectively. Stock options vest over a four year period.

Restricted common stock activity under the Plans for the three years ended June 30, 2024, consists of the following (units in thousands):

	Number of Shares (in thousands)	Weighted Average Grant Date Fair Value	Weighted Average Remaining Contractual Term (years)
Unvested at June 30, 2021	92	$ 56.52	
Granted	28	122.34	
Vested	(54)	54.57	
Forfeited	—	—	
Unvested at June 30, 2022	66	$ 85.83	
Granted	11	73.94	
Vested	(40)	78.85	
Forfeited	—	—	
Unvested at June 30, 2023	37	$ 89.91	
Granted	28	57.38	
Vested	(30)	82.51	
Forfeited	—	—	
Unvested at June 30, 2024	35	$ 70.22	6.60

The total fair value of restricted shares that vested was $2.4 million for fiscal 2024, $3.1 million for fiscal 2023, and $2.9 million for fiscal 2022.

Restricted stock unit activity under the Plans for the three years ended June 30, 2024, consists of the following (units in thousands):

	Number of Units (in thousands)	Weighted Average Grant Date Fair Value	Weighted Average Remaining Contractual Term (years)
Outstanding at June 30, 2021	382	$ 55.13	
Granted	110	117.60	
Vested	(145)	44.62	
Forfeited	(45)	104.34	
Outstanding at June 30, 2022	302	$ 75.54	
Granted	107	90.96	
Vested	(123)	52.34	
Forfeited	(3)	106.13	
Outstanding at June 30, 2023	283	$ 91.10	
Granted	374	78.16	
Vested	(129)	76.42	
Forfeited	(31)	99.96	
Outstanding at June 30, 2024	497	$ 84.62	5.71

The total fair value of restricted stock units that vested was $9.9 million for fiscal 2024, $6.4 million for fiscal 2023, and $6.5 million for fiscal 2022. The restricted stock units vest over a three-year period.

Stock-based compensation cost, inclusive of payroll taxes, of $38.5 million, $39.3 million, and $44.0 million was included in selling, general and administrative expense in fiscal 2024, 2023 and 2022, respectively. Additionally, stock-based
compensation costs, inclusive of payroll taxes, of $0.9 million, $1.0 million, and $1.4 million was included in cost of goods sold in 2024, 2023, and 2022, respectively. As of June 30, 2024, there was $35.8 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock which will be expensed in fiscal 2025 through 2028 using a 4.5% forfeiture rate. The weighted average period over which the compensation cost is expected to be recognized is 2.1 years.

Employee stock purchase plan: In fiscal year 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 800,000 shares were allocated to the ESPP. The Company recorded expense of $0.9 million, $0.9 million, and $1.0 million for the ESPP in fiscal 2024, 2023, and 2022, respectively.

Profit sharing and savings plans: The Company has profit sharing and savings plans for its U.S. employees, which conform to IRS provisions for 401(k) plans. The Company makes matching contributions to the Plan. The Company has recorded an expense for contributions to the plans of $5.8 million, $4.9 million, and $4.3 million for the years ended June 30, 2024, 2023, and 2022, respectively. The Company operates defined contribution pension plans, which consists of primarily our U.K. and China employees. The Company's contribution to the defined pension contribution plan was $5.5 million, $2.4 million, and $2.3 million for the years ended June 30, 2024, 2023 and 2022, respectively.

Performance incentive programs: In fiscal 2024, under certain employment agreements, a Management Incentive Plan, and a business incentive plan, available to executive officers, certain management personnel, and certain other professional employees, the Company recorded cash bonuses of $13.5 million, granted options for 1,060,126 shares of common stock, issued 27,876 restricted common shares

and 374,448 restricted stock units. In fiscal 2023 and fiscal 2022, the Company recorded cash bonuses of $10.8 million and $26.5 million, granted options for 2,350,980 and 1,390,436 shares of common stock, issued 10,816 and 27,584 restricted common stock shares and 107,202 and 110,292 restricted stock units, respectively.

XML 34 R17.htm IDEA: XBRL DOCUMENT

Other Income / (Expense)

12 Months Ended Jun. 30, 2024

Notes to Financial Statements

Other Income / (Expense)

Note 11. Other Income / (Expense)

The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows (in thousands):

	Year Ended June 30,		
	2024	2023	2022
Interest expense	$ (15,736)	$ (11,215)	$ (11,309)
Interest income	3,323	3,410	794
Gain (loss) on investment[1]	283	49,328	15,186
Gain (loss) on equity method investment	(6,841)	(1,143)	—
Other non-operating income (expense), net	(2,026)	(665)	125
Total other income (expense)	$ (20,997)	$ 39,715	$ 4,796

[1] For the year ended June 30, 2024, this is for a $0.3 million gain on the sale of our exchange trade investment grade bond funds. For the year ended June 30, 2023, this is for a $37.2 million gain on the sale of our CCXI investment, a $11.7 million gain on the sale of Eminence, and a gain of $0.4 million related to the change in fair value of our exchange traded bond funds. For the year ended June 30, 2022, this is for a $16.1 million gain in the fair value of our CCXI investment.

XML 35 R18.htm IDEA: XBRL DOCUMENT

Income Taxes

12 Months Ended Jun. 30, 2024

Notes to Financial Statements

Income Taxes

Note 12. Income Taxes:

Income before income taxes was comprised of the following (in thousands):

	Year Ended June 30,		
	2024	2023	2022
Domestic	$ 174,806	$ 288,458	$ 255,118
Foreign	10,883	50,201	46,268
Earnings before income taxes	$ 185,689	$ 338,659	$ 301,386

The provision for income taxes consisted of the following (in thousands):

	Year Ended June 30,		
	2024	2023	2022
Taxes on income consist of:			
Current tax provision:			
Federal	$ 40,228	$ 59,810	$ 10,080
State	4,853	12,753	6,663
Foreign	12,664	10,453	14,481
Total current tax provision	57,745	83,016	31,224
Deferred tax provision:			
Federal	(28,301)	(28,829)	8,130
State	(4,563)	(2,414)	1,477
Foreign	(7,297)	1,444	(2,544)
Total deferred tax provision	(40,161)	(29,799)	7,063
Total income tax provision	$ 17,584	$ 53,217	$ 38,287

The Company's effective income tax rate for fiscal 2024 was 9.5% vs 15.7% in the prior year. The change in the effective tax rate for fiscal 2024 and 2023 was driven by share-based compensation as the number of stock option exercises increased compared to the prior year comparative period.

The Company's effective income tax rate for fiscal 2023 was 15.7% vs 12.7% in the prior year. The change in the effective tax rate for fiscal 2023 and 2022 was driven by share-based compensation as the number of stock option exercises decreased compared to the prior year comparative period.

The Company's discrete tax benefits in fiscal 2024, 2023, and 2022 primarily related to share-based compensation excess tax benefits of $18.4 million, $12.3 million, and $29.3 million, respectively.

The following is a reconciliation of the federal tax calculated at the statutory rate to the actual income taxes provided:

	Year Ended June 30,		
	2024	2023	2022
Income tax expense at federal statutory rate	21.0 %	21.0 %	21.0 %
State income taxes, net of federal benefit	(0.2)	2.5	2.2
Research and development tax credit	(2.2)	(1.3)	(1.0)
Contingent consideration adjustment	(0.4)	(0.8)	(1.4)
Foreign tax rate differences	3.1	(0.6)	0.4
(Gain)/loss on investment	—	(0.7)	1.1
Option exercises	(8.8)	(3.3)	(9.4)
U.S. taxation of foreign earnings	0.1	0.4	(0.1)
Foreign derived intangible income	(4.8)	(3.4)	(1.9)
Foreign withholding tax	(1.2)	1.5	—
Executive compensation limitations	2.7	0.8	1.9
Other, net	0.2	(0.4)	(0.10)
Effective tax rate	9.5 %	15.7 %	12.7 %

Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands):

	June 30,	
	2024	2023
Inventory	$ 9,675	$ 10,906
Net operating loss carryovers	25,065	20,315
Tax credit carryovers	9,118	9,218
Excess tax basis in equity investments	1,115	939
Deferred compensation	16,628	16,528
Lease liability	19,501	21,001
Capitalized R&D	36,151	21,081
Held-for-sale asset impairment	5,216	—
Other	6,119	4,379
Valuation allowance	(19,265)	(9,344)
Deferred tax assets	109,323	95,023
Intangible asset amortization	(120,648)	(134,810)
Depreciation	(20,448)	(21,449)
Right of use asset	(17,876)	(20,021)
Derivative - cash flow hedge	(2,516)	(3,995)
Other	(3,698)	(3,730)
Deferred tax liabilities	(165,186)	(184,005)
Net deferred income tax liabilities	$ (55,863)	$ (88,982)

A deferred tax valuation allowance is required when it is more likely than not that all or a portion of deferred tax assets will not be realized. The valuation allowance as of June 30, 2024 was $19.3 million compared to $9.3 million in the prior year.

As of June 30, 2024, the $19.3 million valuation allowance relates to certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company completed various previous acquisitions as well as immaterial amounts generated after the acquisitions. The Company believes it is more likely than not that these tax carryovers will not be realized.

As of June 30, 2024, the Company has federal operating loss carryforwards of approximately $34.0 million and state operating loss carryforwards of $146.8 million from its previous acquisitions, which are not limited under IRC Section 382. As of June 30, 2024, the Company has foreign net operating loss carryforwards of $77.5 million. Some of the net operating loss carryforwards expire between fiscal 2025 and 2036. Federal net operating loss carryforwards generated after December 31, 2017 have an indefinite carryforward period but the Company expects to be fully utilize these attributes by June 30, 2032. The Company has a deferred tax asset of $9.8 million, net of the valuation allowance discussed above, related to the net operating loss carryovers. As of June 30, 2024, the Company has federal and state tax credit carryforwards of $4.4 million and $5.6 million, respectively. The federal tax credit carryforwards expire between 2028 and 2040. The majority of the state credit carryforwards have no expiry date. The state credit carryforwards that have expiry dates have a full valuation allowance. The Company has a deferred tax asset of $5.5 million, net of the valuation allowance discussed above, related to the tax credit carryovers.

As of June 30, 2024, the Company has approximately $246 million of undistributed earnings in its foreign subsidiaries. Approximately $108 million of these earnings are no longer considered permanently reinvested and the Company expects to be able to repatriate earnings on a tax neutral basis. The Company has not provided deferred taxes on approximately $138 million of undistributed earnings from non-U.S. subsidiaries as of June 30, 2024 which are indefinitely reinvested in operations. Because of the multiple entities as well as the complexities of laws and regulations by which to repatriate the earnings to minimize tax cost, it is not practical to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely. A deferred tax liability will be recognized if the Company can no longer demonstrate that it plans to indefinitely reinvest the undistributed earnings.

We continue to analyze our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries distribute cash to the U.S. parent, which include local country withholding tax and potential U.S. state taxation.

The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands):

	Year Ended June 30,		
	2024	2023	2022
Beginning balance	$ 5,291	$ 5,302	$ 7,271
Additions due to acquisitions	—	—	960
Additions for tax positions of prior year	—	—	304
Decrease in unrecognized tax benefits for prior year positions	—	—	(357)
Settlements	—	—	(2,860)
FX impact	(13)	(11)	(16)
Ending balances	$ 5,278	$ 5,291	$ 5,302

Included in the balance of unrecognized tax benefits at June 30, 2024 are potential benefits of $5.3 million that, if recognized, would affect the effective tax rate on income from continuing operations. The Company recognizes interest and penalties related to unrecognized tax benefits in its provision for income taxes. The Company had $0.6 million of accrued interest and penalties as of June 30, 2024. The amount recorded for the periods ended June 30, 2023 and June 30, 2022, was $0.5 million and $0.3 million, respectively, in accrued interest and penalties. The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next twelve months. The Company files income tax returns in the U.S. federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Company's federal returns are subject to tax assessment for 2019 and subsequent years. State and foreign income tax returns are generally subject to examination for a period of three to five years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to one year after formal notification to the states.

XML 36 R19.htm IDEA: XBRL DOCUMENT

Segment Information

12 Months Ended
Jun. 30, 2024

Notes to Financial Statements

Segment Information

Note* 13. *Segment Information:

The Company operates under two operating segments, Protein Sciences and Diagnostics and Genomics.

The Company's Protein Sciences segment is comprised of the reagent solutions division and analytical solutions division. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all
aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. No customer in the Protein Sciences segment accounted for more than 10% of the segment's net sales for the years ended June 30, 2024, 2023, and 2022.

The Company's Diagnostics and Genomics segment is comprised of the diagnostics reagents division, spatial biology divsion, and molecular diagnostics division. Our Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications. No customer in the Diagnostics and Genomics segment accounted for more than 10% of the segment's net sales for the fiscal years ended June 30, 2024, 2023, and 2022.

There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term.

Following is financial information relating to the operating segments (in thousands):

	Year Ended June 30,		
	2024	2023	2022
Net sales:			
Protein Sciences	$ 830,902	$ 845,747	$ 832,311
Diagnostics and Genomics	326,392	292,602	274,843
Other revenue[1]	4,153	—	—
Intersegment	(2,387)	(1,647)	(1,555)
Consolidated net sales	$ 1,159,060	$ 1,136,702	$ 1,105,599
Operating income:			
Protein Sciences	$ 354,775	$ 373,684	$ 377,623
Diagnostics and Genomics	24,546	43,037	48,977
Segment operating income	379,321	416,721	426,600
Costs recognized on sale of acquired inventory	(729)	(400)	(1,596)
Amortization of intangibles	(78,318)	(76,413)	(73,054)
Impact of partially-owned consolidated subsidiaries[2]	—	647	(2,393)
Acquisition related expenses and other	(6,980)	9,965	19,070
Certain Litigation Charges	(3,506)	—	—
Impairment of assets held-for-sale	(21,963)	—	—
Eminence impairment	—	—	(18,715)
Stock based compensation, inclusive of employer taxes	(40,277)	(41,217)	(46,401)
Restructuring and restructuring-related costs	(12,245)	(3,829)	(1,640)
Corporate general, selling, and administrative expenses	(9,142)	(6,530)	(5,281)
Impact of business held-for-sale[1]	525	—	—
Consolidated operating income	$ 206,686	$ 298,944	$ 296,590

(1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. For the year ended June 30, 2024, includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria.

(2) Includes the annual results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023.

The Company has some integrated facilities that serve both segments. As such, asset and capital expenditure information by operating segment has not been provided and is not available, since the Company does not produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each operating segment's operating results, it is not discretely identifiable.

The Company has disclosed sales by geographic area based on the location of the customer or distributor in Note 2. The Company has disclosed dis-aggregated product and service revenue by consumables, instruments, and services in Note 2. The Company considers total instrument and total service revenue to represent similar groups of products in the fiscal years presented. The Company considers our consumables sold in the Protein Sciences and Diagnostics and Genomics segments to represent different groups of products and therefore have separately disclosed the related consumables revenue (in thousands):

	Year Ended June 30,		
	2024	2023	2022
Consumables revenue - Protein Sciences	$ 657,679	$ 665,301	$ 646,952
Consumables revenue - Diagnostics and Genomics	266,348	252,432	243,922
Consumables revenue - Other revenue[1]	4,153	—	—
Total consumable revenue	$ 928,180	$ 917,733	$ 890,874

(1)Includes the results of a business that has met the held-for-sale criteria since December 31, 2023.

The following is financial information relating to geographic areas (in thousands):

	Year ended June 30,	
	2024	2023
Long-lived assets:		
United States and Canada	$ 211,597	$ 203,657
Europe	27,862	19,263
Asia	11,695	3,280
Total long-lived assets	$ 251,154	$ 226,200
Intangible assets:		
United States and Canada	$ 443,740	$ 529,652
Europe	63,138	4,553
Asia	203	440
Total intangible assets	$ 507,081	$ 534,645

Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation.

XML 37 R20.htm IDEA: XBRL DOCUMENT

Subsequent Events

12 Months Ended
Jun. 30, 2024

Notes to Financial Statements

Subsequent Events

Note* 14. *Subsequent Events:

On July 23, 2024, the Company invested $15 million in Spear Bio, an innovative leader in the development and manufacture of ultra-sensitive immunoassays capable of measuring protein biomarkers at attomolar level from sub-microliter sample volume.

XML 38 R21.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure			
Net Income (Loss)	$ 168,105	$ 285,263	$ 272,051

XML 39 R22.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended Jun. 30, 2024
Trading Arrangements, by Individual	
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 40 R23.htm IDEA: XBRL DOCUMENT

Insider Trading Policies and Procedures	12 Months Ended Jun. 30, 2024
Insider Trading Policies and Procedures [Line Items]	
Insider Trading Policies and Procedures Adopted	true

XML 41 R24.htm IDEA: XBRL DOCUMENT

Description of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended Jun. 30, 2024
Policy Text Block [Abstract]	
Use of estimates	*Use of estimates:* The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates.
Principles of consolidation	*Principles of consolidation:* The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. As Eminence met the criteria for consolidation, the transaction was accounted for in accordance with ASC *805, Business Combinations*. In applying ASC *805* to the transaction, the Company has elected to include Eminence in our consolidated financial statements on a one month lag. As noted below, Eminence was sold during the first fiscal quarter of 2023.
Equity method investments:	*Equity method investments:* The company accounts for its equity method investments in accordance with ASC *323, Investments - Equity Method and Joint Ventures*. The Company initially records its equity method investments at the amount of the Company's investment and adjusts each period for the Company's share of the investee's income or loss and dividends paid. Distributions from the equity method investee are accounted for using the cumulative earnings approach on the Consolidated Statement of Cash Flows. In December 2021, the Company paid $25 million to enter into a two-part forward contract which requires the Company to make an initial ownership investment followed by purchase of full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or annual earnings before interest, taxes, depreciation, and amortization (EBITDA) thresholds are met. Wilson Wolf is a leading manufacturer of cell culture devices, including the G-Rex product line. The first part of the forward contract was triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in EBITDA at any point prior to December 31, 2027. During the quarter ended March 31, 2023, the Company determined that Wilson Wolf had met the EBITDA target. On March 31, 2023, the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf, which is accounted for as an equity method investment. Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, and requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple of approximately 4.4 times trailing twelve month revenue. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million in annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone.
Translation of foreign financial statements	*Translation of foreign financial statements*: Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income.
Revenue recognition	*Revenue recognition:* ASC 606 provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer to Note 2 for additional information regarding our revenue recognition policy under *ASC 606*.
Research and development	*Research and development:* Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications.
Advertising costs	*Advertising costs:* Advertising expenses were $4.1 million, $4.8 million, and $4.6 million for fiscal 2024, 2023, and 2022 respectively. Advertising expenditures are expensed as incurred.
Income taxes	*Income taxes:* The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Refer to Note 12 for additional information regarding income taxes.
Comprehensive income	*Comprehensive income:* Comprehensive income includes charges and credits to shareholders' equity that are not the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity. Any tax effects, if applicable, associated with reclassifications of accumulated other comprehensive income to net income are reflected in the provision for income taxes.
Cash and cash equivalents	*Cash and cash equivalents:* Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of three months or less.
Available-for-sale investment	*Available-for-sale investments:* Available-for-sale investments consist of debt instruments with original maturities of generally three months to less than one-year and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value. Unrealized gains and losses on our available-for-sale securities are included within other income (expense).
Trade accounts receivable and allowances	*Trade accounts receivable and allowances:* Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do not bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer. The Company does not have material long-term customer receivables.
Inventories	*Inventories:* Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory not meeting quality control standards and inventory subject to expiration. For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no material changes to the Company's estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with *ASC 330 - Inventory*.
Property and equipment	*Property and equipment:* Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are depreciated over estimated useful lives of 5 to 40 years.
Contingencies	*Contingencies:* The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and the amount may be reasonably estimated, the estimated loss or range of loss is disclosed.
Contingent Consideration	*Contingent Consideration:* Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income.
Intangible assets	*Intangible assets:* Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life.
Impairment of long-lived assets and amortizable intangibles	*Impairment of long-lived assets and amortizable intangibles:* We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to, (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are not available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. During the second quarter of fiscal year 2024 there was a triggering event for the assets and liabilities associated with a disposal group in our Protein Sciences

segment that were classified as held-for-sale. See the restructuring section of Note 1 below for additional details. No other triggering events were identified and no other impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years 2024, 2023, and 2022.

Impairment of goodwill and indefinite-lived intangible assets

Impairment of goodwill and indefinite-lived intangible assets: We evaluate the carrying value of goodwill and indefinite-lived intangible assets during the fourth quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, (3) an adverse action or assessment by a regulator, or (4) an adverse change in market conditions that are indicative of a decline in the fair value of the assets.

To analyze goodwill, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business. The Company had five reporting units for our 2024, 2023, and 2022 goodwill impairment assessment performed on April 1 of each of the respective fiscal years, the date of our annual goodwill impairment assessment.

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation for goodwill is an assessment of factors including reporting unit specific operating results as well as industry and market conditions, overall financial performance, and other relevant events and factors to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass the qualitative assessment for its reporting units and perform a quantitative test.

The quantitative impairment test requires us to estimate the fair value of our reporting units based the income approach. The income approach is a valuation technique under which we estimate future cash flows using the reporting unit's financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we project revenue and apply our fixed and variable cost experience rate to the projected revenue to arrive at the future cash flows. A terminal value is then applied to the projected cash flow stream. Future estimated cash flows are discounted to their present value to calculate the estimated fair value. The discount rate used is the value-weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we are required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.

For fiscal 2024, we elected to perform a qualitative analysis for all five reporting units. The Company determined, after performing the qualitative analysis, there was no evidence that it is more likely than not that the fair value was less than the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test in fiscal 2024. There was a triggering event related to a business held-for-sale described later in this note, leading to an impairment of allocated goodwill during the second half of fiscal 2024. The Company did not identify any triggering events after our annual goodwill impairment analysis through June 30, 2024, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed.

For fiscal 2024, the Company also performed a qualitative assessment of the acquired in-process research and development assets to determine whether changes in events, circumstances, or the probability of successful development and commercialization of the assets indicated that it is more likely than not that the fair value of the acquired assets are less than its carrying amount. Based on the analysis, the Company determined there was no indication of impairment of the indefinite-lived intangible asset. This in-process research and development was placed into service during the fourth quarter of fiscal 2024 and will begin amortization over its expected useful life.

In fiscal 2023, we elected to perform a qualitative analysis for all five reporting units. The Company determined, after performing the qualitative analysis, there was no evidence that it is more likely than not that the fair value was less than the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test in fiscal 2023. The Company did not identify any triggering events after our annual goodwill impairment analysis through June 30, 2023, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed.

On September 1, 2022, the Company completed the sale of its equity shares of Eminence for approximately $17.8 million to a third party. Eminence was considered a variable-interest entity that was fully consolidated in our financial statements. Prior to the sale, Eminence had revenue of $2.0 million for the first fiscal quarter of 2023 within our Protein Sciences segment. Fiscal 2022 revenues were $4.6 million. As a result of the sale of the business, the Company recorded a gain of $11.7 million within the Other income (expense) line in the Consolidated Statement of Earnings. Prior to the sale of Eminence, a triggering event was identified in the second quarter of fiscal 2022 and impairment testing was performed as Eminence was forecasted to not have sufficient cash to execute on their growth plan combined with their inability to secure additional financing. Our impairment testing resulted in a full impairment of the Eminence goodwill and intangibles assets for charges of $8.3 million and $8.6 million, respectively, for the year ended June 30, 2022. The Company also recognized inventory and fixed asset impairment charges of $0.9 million and $0.9 million, respectively. These impairment charges were recorded within the General and Administrative line in the Consolidated Statement of Earnings for fiscal 2022. In the fourth quarter of fiscal 2022, Eminence was able to secure cash deposits on future orders to provide funding for their operations. This delay in liquidation allowed time for securing of additional investor financing which coincided with the sale of the Company's investment.

In the first quarter of fiscal 2022, the Company combined the management of the Exosome Diagnostics and Asuragen reporting units, both of which are included in the Diagnostics and Genomics operating segment. In conjunction with the combination of the reporting units, a qualitative goodwill impairment assessment was performed. The qualitative assessment identified no indicators of impairment.

In our fiscal 2022 annual goodwill impairment analysis, we elected to perform a quantitative assessment for all five of our reporting units. The result of our quantitative assessment indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2022. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2022, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed.

Restructuring actions

Restructuring actions: Restructuring actions generally include significant actions involving employee-related severance charges, contract termination costs, and impairments and disposals of assets associated with such actions. Employee-related severance charges are based upon distributed employment policies and substantive severance plans. These charges are reflected in the quarter when the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Asset-related and other charges include impairment of right-of-use assets, leasehold improvements, other asset write-downs associated with combining operations, disposal of assets and other exit costs. Other costs also includes restructuring-related charges, which are incremental costs incurred directly supporting business transformation initiatives tied to the restructuring action.

Fiscal Year 2024 Restructuring Actions:

In the second quarter of fiscal 2024, the Company announced enterprise-wide restructuring focused on recovering operating margins, optimizing our distribution footprint, and enhancing our organization efficiency. These actions impacted approximately 4% of our global workforce. These actions continued through the end of fiscal 2024 as we incurred charges relating to the condensing of certain distribution centers and optimizing efficiency. The Company is expecting to
incur costs related to these actions through the first half of fiscal 2025, which will be recorded when specified criteria are met.

As part of these actions, certain assets and liabilities associated with a disposal group in our Protein Sciences segment were classified as held-for-sale as of December 31, 2023, including $1.4 million of goodwill allocated to the disposal group on a relative fair value basis. As a result of impairment tests performed over the disposal group during fiscal 2024, a cumulative impairment charge of $22.0 million which includes the allocated goodwill, was recorded in the Selling, general and administrative line in the Consolidated Statements of Earnings for the year ended June 30, 2024. As of June 30, 2024, the assets remaining within the disposal group primarily include inventory and property and equipment of $9.8 million, which is net of expected selling costs. These assets are actively marketed, and we believe their sale will be completed within 12 months of the held-for-sale classification date. The held-for-sale assets are recorded in Current assets held-for-sale in our Consolidated Balance Sheet as of June 30, 2024.

The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands):

	Year Ended June 30, 2024
Cost of sales	$ 3,349
Selling, general and administrative[1]	30,638
Total	$ 33,987

[1] Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs.

Restructuring and restructuring-related costs by segment are as follows (in thousands):

	Year ended June 30, 2024			
	Employee severance	Asset-related and other	Impairment of assets held-for-sale	Total
Protein Sciences	$ 3,483	$ 5,130	$ 21,963	$ 30,576
Diagnostics and Genomics	1,007	224	—	1,231
Corporate	1,153	1,027	—	2,180
Total	$ 5,643	$ 6,381	$ 21,963	$ 33,987

The following table summarizes the changes in the Company's accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands):

	Employee severance[1]	Asset-related and other[2]	Impairment of assets held-for-sale	Total
Expense incurred in the second quarter of 2024	4,882	504	6,038	11,424
Incremental expense incurred in the third quarter of 2024	133	1,140	—	1,273
Incremental expense incurred in the fourth quarter of 2024	409	4,737	15,926	21,072
Cash payments	(4,882)	(2,800)	—	(7,682)
Non-cash adjustments	—	(3,391)	(21,963)	(25,354)
Adjustments[3]	219	—	—	219
Accrued restructuring actions balance as of June 30, 2024	$ 761	$ 190	$ —	$ 952

[1] Relates to impacted employees' final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites.

[2] Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives.

[3] Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024.

Fiscal Year 2023 Restructuring Actions:

QT Holdings Corporation (Quad)

In August 2022, the Company informed employees of our decision to close our Quad facility as part of a realignment of activities within our Reagent Solutions division. The closure of the site was completed in the fourth quarter of fiscal 2023. As a result of the restructuring activities, an estimated pre-tax charge of $2.2 million was recorded within our Protein Sciences segment for the year ended June 30, 2023. The related restructuring charges for the year ended June 30, 2023 were recorded in the income statement as follows (in thousands):

	Employee severance	Asset impairment and other	Total
Selling, general and administrative	$ 1,328	$ 842	$ 2,170

	Employee severance	Asset impairment and other	Total
Expense incurred in the first quarter of 2023	$ 1,328	$ 842	$ 2,170
Cash payments	(1,233)	(772)	(2,005)
Adjustments	(95)	(70)	(165)
Accrued restructuring actions balances as of June 30, 2023	$ —	$ —	$ —

Protein Sciences realignment

In December 2022, the Company informed employees it would undertake certain actions to strategically reallocate operations resources to high growth areas of the business. Additional actions were taken in June 2023 primarily related to the sales organization. The actions impacted a limited number of employees and were completed in the fourth quarter of fiscal 2024. As a result of the realignment, a pre-tax charge of $1.7 million related to employee severance was recorded in the Selling, general and administrative line of operating income within our Protein Sciences segment during the year ended June 30, 2023. Adjustments in fiscal year 2024 relate to the refinement of employee severance payouts. Additional pre-
tax charges for the year ended June 30, 2024 were $0.2 million. Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):

	Employee severance
Expense incurred in fiscal year 2023	$ 1,677
Fiscal year 2023 cash payments	(762)
Fiscal year 2023 adjustments	(18)
Accrued restructuring actions balances as of June 30, 2023	$ 897
Fiscal year 2024 cash payments	(1,118)
Fiscal year 2024 adjustments[1]	221
Accrued restructuring actions balances as of June 30, 2024	$ —

[1]Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023.

Fiscal Year 2022 Restructuring Actions:

In September 2021, the Company informed employees of our decision to close our Exosome Diagnostics Germany facility, discontinuing lab and research occurring at the site, as part of a realignment of activities within our Exosome Diagnostics business. The restructuring activities were complete as of June 30, 2022. As a result of the restructuring activities, a pre-tax charge of $1.4 million was recorded within our Diagnostics and Genomics segment during the year ended June 30, 2022. Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within operating income on the income statement as follows (in thousands):

	Employee severance	Asset impairment and other	Total
Selling, general and administrative	$ 649	$ 750	$ 1,399

	Employee severance	Asset impairment and other	Total
Expense incurred in the first quarter of 2022	$ 639	$ 546	$ 1,185
Incremental expense incurred during fiscal 2022	—	242	242
Cash payments	(589)	(554)	(1,143)
Adjustments	(50)	(234)	(284)
Accrued restructuring actions balances as of June 30, 2022	$ —	$ —	$ —

[1] Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange.

During the second quarter of fiscal 2022, the Company also incurred a restructuring charge of $0.2 million related to employee severance for the relocation of a US plant. This was completed during fiscal 2023 and there are no remaining liabilities related to this relocation as of June 30, 2023. This charge was recorded within Other current liabilities as of June 30, 2022. Fiscal 2023 cash payments did not materially differ from the charge recorded in fiscal 2022.

Legal Matters

Legal Matters: The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. The Company's standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require
significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.

The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges in the consolidated statements of income.

During fiscal year 2024, the Company recognized $3.5 million of certain litigation charges. There was no comparable activity in the comparable periods. As of each of the balance sheet dates presented, there was no accrued litigation. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other current liabilities and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows.

Intellectual Property Matters

Intellectual Property Matters: At any given time, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements related to such rights. This litigation includes, but it not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or entities created specifically to fund IP litigation. While the outcome of these litigation matters is inherently uncertain, it is possible that the results of such litigation could require the Company to pay significant monetary damages.

Not Yet Adopted Accounting Pronouncements

Not Yet Adopted Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures.
The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, on our consolidated financial statements.

Fair Value

The Company's financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, derivative instruments, and long-term debt.

Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.

The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.

Leases

As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement date, operating lease right-of-use assets and liabilities are recognized based on the present value of lease payments over the lease term. The discount rate used to calculate present value is the Company's incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. The Company recognizes operating lease expense on a straight-line basis over the lease term. Further, as part of our adoption of ASC 842, the Company also made the accounting policy elections to not capitalize short term leases (defined as a lease with a lease term that is less than 12 months) and to combine lease and non-lease components for all asset classes in determining the lease payments.

Earnings Per Share

Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have not yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option is exercised are assumed to be used to repurchase shares in the current period.

Share-Based Compensation

The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares.

Segments

The Company operates under two operating segments, Protein Sciences and Diagnostics and Genomics.

The Company's Protein Sciences segment is comprised of the reagent solutions division and analytical solutions division. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all
aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. No customer in the Protein Sciences segment accounted for more than 10% of the segment's net sales for the years ended June 30, 2024, 2023, and 2022.

The Company's Diagnostics and Genomics segment is comprised of the diagnostics reagents division, spatial biology divsion, and molecular diagnostics division. Our Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications. No customer in the Diagnostics and Genomics segment accounted for more than 10% of the segment's net sales for the fiscal years ended June 30, 2024, 2023, and 2022.

There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term.

Significant Accounting Policies (Tables) | **Jun. 30, 2024**

Notes Tables

Schedule of restructuring charges

The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands):

	Year Ended June 30, 2024
Cost of sales	$ 3,349
Selling, general and administrative[1]	30,638
Total	$ 33,987

[1] Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs.

Restructuring and restructuring-related costs by segment are as follows (in thousands):

	Year ended June 30, 2024			
	Employee severance	Asset-related and other	Impairment of assets held-for-sale	Total
Protein Sciences	$ 3,483	$ 5,130	$ 21,963	$ 30,576
Diagnostics and Genomics	1,007	224	—	1,231
Corporate	1,153	1,027	—	2,180
Total	$ 5,643	$ 6,381	$ 21,963	$ 33,987

The following table summarizes the changes in the Company's accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands):

	Employee severance[1]	Asset-related and other[2]	Impairment of assets held-for-sale	Total
Expense incurred in the second quarter of 2024	4,882	504	6,038	11,424
Incremental expense incurred in the third quarter of 2024	133	1,140	—	1,273
Incremental expense incurred in the fourth quarter of 2024	409	4,737	15,926	21,072
Cash payments	(4,882)	(2,800)	—	(7,682)
Non-cash adjustments	—	(3,391)	(21,963)	(25,354)
Adjustments[3]	219	—	—	219
Accrued restructuring actions balance as of June 30, 2024	$ 761	$ 190	$ —	$ 952

[1] Relates to impacted employees' final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites.

[2] Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives.

[3] Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024.

Protein Sciences | QT Holdings Corporation

Notes Tables

Schedule of restructuring charges

The related restructuring charges for the year ended June 30, 2023 were recorded in the income statement as follows (in thousands):

	Employee severance	Asset impairment and other	Total
Selling, general and administrative	$ 1,328	$ 842	$ 2,170

	Employee severance	Asset impairment and other	Total
Expense incurred in the first quarter of 2023	$ 1,328	$ 842	$ 2,170
Cash payments	(1,233)	(772)	(2,005)
Adjustments	(95)	(70)	(165)
Accrued restructuring actions balances as of June 30, 2023	$ —	$ —	$ —

Protein Sciences | Employee severance

Notes Tables

Schedule of restructuring charges

tax charges for the year ended June 30, 2024 were $0.2 million. Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):

	Employee severance
Expense incurred in fiscal year 2023	$ 1,677
Fiscal year 2023 cash payments	(762)
Fiscal year 2023 adjustments	(18)
Accrued restructuring actions balances as of June 30, 2023	$ 897
Fiscal year 2024 cash payments	(1,118)
Fiscal year 2024 adjustments[1]	221
Accrued restructuring actions balances as of June 30, 2024	$ —

[1]Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023.

Diagnostics and Genomics

Notes Tables

Schedule of restructuring charges

Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within operating income on the income statement as follows (in thousands):

	Employee severance	Asset impairment and other	Total
Selling, general and administrative	$ 649	$ 750	$ 1,399

	Employee severance	Asset impairment and other	Total
Expense incurred in the first quarter of 2022	$ 639	$ 546	$ 1,185
Incremental expense incurred during fiscal 2022	—	242	242
Cash payments	(589)	(554)	(1,143)
Adjustments	(50)	(234)	(284)
Accrued restructuring actions balances as of June 30, 2022	$ —	$ —	$ —

[1] Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange.

XML 43 R26.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Tables) | **12 Months Ended Jun. 30, 2024**

Notes Tables

Schedules of disaggregated revenue

	Year ended June 30,		
	2024	2023	2022
Consumables	$ 928,180	$ 917,733	$ 890,874
Instruments	108,270	112,085	120,758
Services	99,265	85,784	71,988
Total product and services revenue, net	1,135,715	$1,115,602	1,083,620
Royalty revenues	23,345	21,100	21,979
Total revenues, net	$1,159,060	$1,136,702	$1,105,599

Revenue by geography (in thousands):

	Year Ended June 30,		
	2024	2023	2022
United States	$ 657,747	$ 642,465	$ 614,107
EMEA, excluding United Kingdom	241,432	220,230	219,055
United Kingdom	50,012	49,457	48,637
APAC, excluding Greater China	73,904	73,190	76,139
Greater China	99,467	113,868	112,438
Rest of World	36,498	37,492	35,223
Net sales	$1,159,060	$1,136,702	$1,105,599

XML 44 R27.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet and | **12 Months Ended**

Cash Flow Information (Tables) | **Jun. 30, 2024**

Notes Tables

Schedule of inventories

Inventories consist of (in thousands):

	June 30, 2024	June 30, 2023
Raw materials	$ 79,377	$ 84,551
Finished goods[1]	106,072	92,474
Inventories, net	$ 185,449	$ 177,025

(1) Finished goods inventory of $5,718 and $5,387 is included within Other assets in the June 30, 2024 and June 30, 2023 Balance Sheets, respectively, as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.

Schedule of property and equipment

Property and equipment consist of (in thousands):

	June 30, 2024	June 30, 2023
Land	$ 8,150	$ 9,100
Buildings and improvements	243,863	245,302
Machinery and equipment	215,948	190,019
Construction in progress	39,749	15,491
Property and equipment, cost	507,710	459,912
Accumulated depreciation and amortization	(256,556)	(233,712)
Property and equipment, net	$ 251,154	$ 226,200

Schedule of intangible assets

Intangibles assets were comprised of the following (in thousands):

	Useful Life (years)	June 30, 2024	June 30, 2023
Developed technology	9 - 15	$ 675,674	$ 616,311
Tradenames	2 - 20	151,561	146,945
Customer relationships	7 - 16	211,276	213,878
Patents	10	4,343	3,815
Other intangibles	5 - 15	12,006	11,566
Definite-lived intangible assets		1,054,860	992,515
Accumulated amortization		(547,779)	(480,570)
Definite-lived intangibles assets, net		507,081	511,945
In process research and development[1]		—	22,700
Total intangible assets, net		$ 507,081	$ 534,645

[1]The in process research and development has been placed into service and is included within Developed technology. The amortization period for this developed technology asset is estimated to be 14 years.

Schedule of changes in carrying amount of net intangible assets

Changes to the carrying amount of net intangible assets consist of (in thousands):

	June 30, 2024	June 30, 2023
Beginning balance	$ 534,645	$ 531,522
Acquisitions	66,400	75,600
Other additions[1]	950	5,710
Held-for-sale intangibles[2]	(14,323)	—
Amortization expense	(79,854)	(77,491)
Currency translation	(737)	(696)
Ending balance	$ 507,081	$ 534,645

[1]Includes the purchase of a $4.6 million intangible asset from Wilson Wolf, an equity method investee of the Company during the year-ended June 30, 2023. This asset will be amortized over a life of 10 years.

[2]Refer to Note 1 for further detail on held-for-sale intangibles.

Schedule of estimated future amortization expense for intangible assets

The estimated future amortization expense for intangible assets as of June 30, 2024 is as follows (in thousands):

2025	$ 77,259
2026	73,297
2027	63,138
2028	59,491
2029	46,923
Thereafter	186,973
Total	$ 507,081

Schedule of changes to the carrying amount of goodwill

Changes in goodwill by segment and in total consist of (in thousands):

	Protein Sciences	*Diagnostics and Genomics*	*Total*
June 30, 2022	$ 376,493	$ 445,608	$ 822,101
Acquisitions	51,257	—	51,257
Currency translation	(723)	102	(621)
June 30, 2023	$ 427,027	$ 445,710	$ 872,737
Acquisitions	—	104,650	104,650
Held-for-sale goodwill[1]	(1,400)	—	(1,400)
Currency translation	(2,178)	(1,146)	(3,324)
June 30, 2024	$ 423,449	$ 549,214	$ 972,663

[1] Refer to Note 1 for further detail on goodwill reclassified to current assets held-for-sale.

Schedule of other assets

Other assets consist of (in thousands):

	June 30, 2024	June 30, 2023
Equity method investment in Wilson Wolf	$ 242,337	$ 255,857
Derivative instruments	9,813	16,857
Long-term inventory	5,718	5,387
Other	6,397	7,201
Other assets	$ 264,265	$ 285,302

Schedule of supplemental cash flow information

Supplemental cash flow information was as follows (in thousands):

	Year Ended June 30, 2024	2023	2022
Income taxes paid	$ 65,254	$ 88,428	$ 30,341
Interest paid	14,502	8,368	11,027

XML 45 R28.htm IDEA: XBRL DOCUMENT

Acquisitions (Tables) | **12 Months Ended Jun. 30, 2024**

Lunaphore Technologies SA.

Notes Tables

Schedule of the aggregate purchase price of the acquisitions that was allocated to the assets acquired and liabilities assumed

The fair values of the assets acquired and liabilities assumed as of the acquisition date and the updated final amounts as of June 30, 2024 are as follows (in thousands):

	Preliminary allocation at acquisition date	Adjustments to fair value	Final allocation at June 30, 2024
Current assets	$ 12,512	$ (357)	$ 12,155
Equipment and other long-term assets	1,470		1,470
Intangible assets:			
Developed technologies	60,300		60,300
Tradenames	4,900		4,900
Customer relationships	1,200		1,200
Goodwill	102,560	2,090	104,650
Total assets acquired	182,942	1,733	184,675
Liabilities	7,096		7,096
Deferred income taxes, net	5,768	2,104	7,872
Net assets acquired	$ 170,078	$ (371)	$ 169,707
Cash paid	166,426	3,281	169,707
Estimated Net Working Capital	3,652	(3,652)	—
Net assets acquired	$ 170,078	$ (371)	$ 169,707

Namocell Inc

Notes Tables

Schedule of the aggregate purchase price of the acquisitions that was allocated to the assets acquired and liabilities assumed

Net sales and operating loss of this business included in Bio-Techne's consolidated results of operations for the twelve months ended June 30, 2023 were approximately $6.4 million and $9.3 million, respectively. The fair values of the assets acquired and liabilities assumed as of the acquisition date and the updated final amounts as of June 30, 2023 are as follows (in thousands):

	Namocell Inc
Current assets, net of cash	$ 3,248
Equipment and other long-term assets	405
Intangible assets:	
Developed technology	73,900
Trade name	700
Customer relationships	900
Non-competition agreement	100
Goodwill	51,257
Total assets acquired	130,510
Liabilities	546
Deferred income taxes, net	18,180
Net assets acquired	$ 111,784
Cash paid, net of cash acquired	101,184
Additional consideration	10,600
Net assets acquired	$ 111,784

XML 46 R29.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

12 Months Ended
Jun. 30, 2024

Notes Tables

Schedule of information by level for financial assets and liabilities that are measured at fair value on a recurring basis

The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):

	Balance Sheet Location	*Total carrying value as of June 30, 2024*	*Fair Value Measurements Using Inputs Considered as*		
			Level 1	*Level 2*	*Level 3*
Assets					
Certificates of deposit[1]	Short-term available-for-sale investments	$ 1,072	$ 1,072	$ —	$ —
Derivatives designated as hedging instruments - cash flow hedges	Other current assets	805	—	805	—
Derivatives designated as hedging instruments - cash flow hedges	Other assets	9,813	—	9,813	—
Total assets		$ 11,690	$ 1,072	$ 10,618	$ —
Liabilities					
Derivatives designated as hedging instruments - net investment hedge	Other long-term liabilities	$ 2,051	$ —	$ 2,051	$ —
Total liabilities		$ 2,051	$ —	$ 2,051	$ —

	Balance Sheet Location	*Total carrying value as of June 30, 2023*	*Fair Value Measurements Using Inputs Considered as*		
			Level 1	*Level 2*	*Level 3*
Assets					
Exchange traded securities[2]	Short-term available-for-sale investments	$ 23,739	$ 23,739	$ —	$ —
Derivative instruments - cash flow hedges	Other assets	16,857	—	16,857	—
Total assets		$ 40,596	$ 23,739	$ 16,857	$ —
Liabilities					
Contingent consideration	Contingent consideration payable	$ 3,500	$ —	$ —	$ 3,500
Total liabilities		$ 3,500	$ —	$ —	$ 3,500

(1) The certificates of deposit have contractual maturity dates within one year.
(2) During the quarter ended September 30, 2023, the Company sold all of its exchange traded investment grade bond funds that it held at June 30, 2023. The costs basis and fair value of these exchange traded investment grade bond funds were $25.0 million and $23.7 million at June 30, 2023, respectively.

Schedule of contractual amounts of the outstanding instruments

The following table presents the contractual amounts of the Company's outstanding instruments (in millions):

Instruments	Designation	*June 30, 2024*	*June 30, 2023*
Forward starting swaps[1]	Cash flow hedge	$ 300	$ 300
Cross-currency swap[2]	Net investment hedge	150	—

(1) In May 2021, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $200 million of notional principal. The effective date of the swap was November 2022 with the full swap maturing in November 2025. In March 2023, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $100 million of notional principal. The effective date of the swap was April 2023 with the full swap maturing in April 2025.

(2) In July 2023, the Company entered into a pay-fixed rate, receive-fixed rate cross-currency swap contract with a total notional amount of $150 million that was designated as a hedge to lock in the Swiss franc (CHF) rate for a portion of the Company's CHF net investment in its Lunaphore subsidiary in Switzerland. The objective of the hedge is to protect the net investment in the Company's CHF-denominated operations against changes in the spot exchange rates, on a pre-tax basis. The hedging instrument has four interim settlement dates, which will reduce the notional on the hedging instrument by $10 million at each interim date, and will reduce the notional to $110 million at maturity.

Schedule of pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses

The pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses with our Consolidated Financial Statements for the twelve months ended June 30, 2024 and 2023 were as follows (in thousands):

	(Gain) Loss Recognized in Accumulated Other Comprehensive Loss		
	Year Ended June 30,		
	2024	*2023*	*2022*
Cash flow hedges			
Forward starting swaps	$ 12,632	$ (1,340)	$ (19,121)
Net investment hedges			
Cross-currency swap	4,015	—	—
Total	$ 16,647	$ (1,340)	$ (19,121)

	(Gain) Loss Reclassified into Income			
	Year Ended June 30,			
	2024	*2023*	*2022*	Location of (Gain) Loss in Income Statement
Cash flow hedges				
Forward starting swaps	$ (10,317)	$ (4,526)	$ 6,352	Interest expense
Net investment hedges				
Cross-currency swap	(3,210)	—	—	Interest expense
Total	$ (13,527)	$ (4,526)	$ 6,352	

Schedule of the reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3)

The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):

	June 30,	
	2024	**2023**
Fair value at the beginning of period	$ 3,500	$ 5,000
Purchase price contingent consideration (Note 4)	—	10,600
Change in fair value of contingent consideration	(3,500)	(12,100)
Payments	—	—
Fair value at the end of period	$ —	$ 3,500

XML 47 R30.htm IDEA: XBRL DOCUMENT

Leases (Tables)

12 Months Ended
Jun. 30, 2024

Notes Tables

Schedule of table that summarizes the balance sheet classification of

The following table summarizes the balance sheet classification of the Company's operating leases, amounts of right of use assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company's operating leases (asset and liability amounts are in thousands):

As of

the Company's operating leases and amounts of right of use assets and lease liabilities and the weighted average remaining lease term and weighted average discount rate for the Company's operating leases

	Balance Sheet Classification	June 30, 2024
Operating leases:		
Operating lease right-of-use assets	Right-of-use asset	$ 91,285
Current operating lease liabilities	Operating lease liabilities - current	$ 12,920
Noncurrent operating lease liabilities	Operating lease liabilities	87,618
Total operating lease liabilities		$ 100,538
Weighted average remaining lease term (in years):		8.45
Weighted average discount rate (%):		4.23

Schedule of the table that summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities

The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the year ended June 30, 2024 (in thousands):

	Year ended June 30, 2024
Cash amounts paid on operating lease liabilities[1]	$ 17,729
Right-of-use assets obtained in exchange for lease liabilities	$ 11,051

(1) Total cash paid for the Company's operating leases during the year ended June 30, 2024 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity.

Schedule of the fair value of the lease liability by payment date for the operating leases by fiscal year

The following table summarizes payments by date for the Company's operating leases, which is then reconciled to our total lease obligation (in thousands):

	June 30, 2024 Operating Leases
2025	$ 16,331
2026	16,429
2027	13,577
2028	13,479
2029	12,967
Thereafter	48,211
Total	$ 120,994
Less: Amounts representing interest	20,456
Total lease obligations	$ 100,538

XML 48 R31.htm IDEA: XBRL DOCUMENT

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)

12 Months Ended

Jun. 30, 2024

Notes Tables

Schedule of changes in Accumulated Other Comprehensive Income (Loss)

Changes in Accumulated Other Comprehensive Income (Loss) attributable to Bio-Techne by component (in thousands):

	Unrealized Gains (Losses) on Derivative Instruments	Foreign Currency Translation Adjustments	Total
Balance as of June 30, 2021, net of tax:	$ (6,193)	$ (51,098)	$ (57,291)
Other comprehensive income (loss), before tax, attributable to Bio-Techne:			
Amounts before reclassifications [1]	19,121	(32,171)	(13,050)
Amounts reclassified out	(6,352)	—	(6,352)
Total other comprehensive income (loss), before tax, attributable to Bio-Techne:	12,769	(32,171)	(19,402)
Tax benefit	1,493	—	1,493
Total other comprehensive income (loss), net of tax, attributable to Bio-Techne:	14,262	(32,171)	(17,909)
Balance as of June 30, 2022, net of tax[2]	$ 8,069	$ (83,269)	$ (75,200)
Other comprehensive income (loss), before tax, attributable to Bio-Techne: :			
Amounts before reclassifications [1]	1,340	4,191	5,531
Amounts reclassified out	4,526	152	4,678
Total other comprehensive income (loss), before tax, attributable to Bio-Techne:	5,866	4,343	10,209
Tax expense	(1,073)	—	(1,073)
Total other comprehensive income (loss), net of tax, attributable to Bio-Techne:	4,793	4,343	9,136
Balance as of June 30, 2023, net of tax[2]	$ 12,862	$ (78,926)	$ (66,064)
Other comprehensive income (loss), before tax:			
Amounts before reclassifications	(12,632)	(9,941)	(22,573)
Amounts reclassified out	10,317	3,210	13,527
Total other comprehensive income (loss), before tax	(2,315)	(6,731)	(9,046)
Tax expense	(2,445)	(761)	(3,206)
Total other comprehensive income (loss), net of tax	(4,760)	(7,492)	(12,252)
Balance as of June 30, 2024, net of tax[2]	$ 8,102	$ (86,418)	$ (78,316)

(1) Amounts before reclassifications related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $33 thousand and $70 thousand attributable to the non-controlling interest in Eminence as of June 30, 2023, and June 30, 2022, respectively.

(2) The Company had a net deferred tax liability for its cash flow hedge of $2.5 million, $4.0 million, and $2.5 million as of June 30, 2024, June 30, 2023 and June 30, 2022.

XML 49 R32.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Tables)

12 Months Ended
Jun. 30, 2024

Notes Tables

Schedule of the calculation of basic and diluted earnings per share

The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):

	Year Ended June 30, 2024	2023	2022
Earnings per share – basic:			
Net earnings, including noncontrolling interest	$ 168,105	$ 285,442	$ 263,099
Less net earnings (loss) attributable to noncontrolling interest	—	179	(8,952)
Net earnings attributable to Bio-Techne	$ 168,105	$ 285,263	$ 272,051
Income allocated to participating securities	(33)	(70)	(121)
Income available to common shareholders	$ 168,072	$ 285,193	$ 271,930
Weighted-average shares outstanding – basic	157,708	157,179	156,874
Earnings per share – basic	$ 1.07	$ 1.81	$ 1.73
Earnings per share – diluted:			
Net earnings, including noncontrolling interest	$ 168,105	$ 285,442	$ 263,099
Less net earnings (loss) attributable to noncontrolling interest	-	179	(8,952)
Net earnings attributable to Bio-Techne	168,105	285,263	272,051
Income allocated to participating securities	(33)	(70)	(121)
Income available to common shareholders	$ 168,072	$ 285,193	$ 271,930
Weighted-average shares outstanding – basic	157,708	157,179	156,874
Dilutive effect of stock options and restricted stock units	3,066	4,676	7,240
Weighted-average common shares outstanding – diluted	160,774	161,855	164,114
Earnings per share – diluted	$ 1.05	$ 1.76	$ 1.66

XML 50 R33.htm IDEA: XBRL DOCUMENT

Share-based Compensation and Other Benefit Plans (Tables)

12 Months Ended

Jun. 30, 2024

Share-based Compensation and Other Benefit Plans

Schedule of share-based payment award, stock options, valuation assumptions

	Year Ended June 30, 2024	2023	2022
Dividend yield	0.41 %	0.34 %	0.27 %
Expected volatility	30%-37 %	30%-36 %	27%-33 %
Risk-free interest rates	3.8%-4.8 %	2.8%-4.4 %	0.6%-2.6 %
Expected lives (years)	4.4	4.7	4.3

Summary of share-based payment arrangement, option, activity

Stock option activity under the Plans for the three years ended June 30, 2024, consists of the following (shares in thousands):

	Number of Shares (in thousands)	Weighted Average Exercise Price	Aggregate Intrinsic Value (millions)	Weighted Average Contractual Life (years)
Outstanding at June 30, 2021	14,868	$ 43.16		
Granted	1,390	120.15		
Forfeited	(539)	87.05		
Exercised	(2,450)	33.61		
Outstanding at June 30, 2022	13,269	$ 51.20		
Granted	2,351	93.81		
Forfeited	(118)	85.99		
Exercised	(1,578)	29.48		
Outstanding at June 30, 2023	13,924	$ 60.56		
Granted	1,060	79.69		
Forfeited	(1,165)	90.86		
Exercised	(2,240)	33.34		
Outstanding at June 30, 2024	11,579	$ 64.53	$ 747.3	3.0
Exercisable at June 30, 2022:	7,797	36.99		
Exercisable at June 30, 2023:	8,641	44.76		
Exercisable at June 30, 2024:	8,208	53.57	439.7	2.1

Schedule of restricted common stock activity and restricted stock unit activity

Restricted common stock activity under the Plans for the three years ended June 30, 2024, consists of the following (units in thousands):

	Number of Shares (in thousands)	Weighted Average Grant Date Fair Value	Weighted Average Remaining Contractual Term (years)
Unvested at June 30, 2021	92	$ 56.52	
Granted	28	122.34	
Vested	(54)	54.57	
Forfeited	—	—	
Unvested at June 30, 2022	66	$ 85.83	
Granted	11	73.94	
Vested	(40)	78.85	
Forfeited	—	—	
Unvested at June 30, 2023	37	$ 89.91	
Granted	28	57.38	
Vested	(30)	82.51	
Forfeited	—	—	
Unvested at June 30, 2024	35	$ 70.22	6.60

Restricted stock unit activity under the Plans for the three years ended June 30, 2024, consists of the following (units in thousands):

	Number of Units (in thousands)	Weighted Average Grant Date Fair Value	Weighted Average Remaining Contractual Term (years)
Outstanding at June 30, 2021	382	$ 55.13	
Granted	110	117.60	
Vested	(145)	44.62	
Forfeited	(45)	104.34	
Outstanding at June 30, 2022	302	$ 75.54	
Granted	107	90.96	
Vested	(123)	52.34	
Forfeited	(3)	106.13	
Outstanding at June 30, 2023	283	$ 91.10	
Granted	374	78.16	
Vested	(129)	76.42	
Forfeited	(31)	99.96	
Outstanding at June 30, 2024	497	$ 84.62	5.71

XML 51 R34.htm IDEA: XBRL DOCUMENT

Other Income / (Expense) (Tables)

12 Months Ended
Jun. 30, 2024

Notes Tables

Schedule of the components of other income (expense)

The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows (in thousands):

	Year Ended June 30,		
	2024	2023	2022
Interest expense	$ (15,736)	$ (11,215)	$ (11,309)
Interest income	3,323	3,410	794
Gain (loss) on investment[1]	283	49,328	15,186
Gain (loss) on equity method investment	(6,841)	(1,143)	—
Other non-operating income (expense), net	(2,026)	(665)	125
Total other income (expense)	$ (20,997)	$ 39,715	$ 4,796

[1] For the year ended June 30, 2024, this is for a $0.3 million gain on the sale of our exchange trade investment grade bond funds. For the year ended June 30, 2023, this is for a $37.2 million gain on the sale of our CCXI investment, a $11.7 million gain on the sale of Eminence, and a gain of $0.4 million related to the change in fair value of our exchange traded bond funds. For the year ended June 30, 2022, this is for a $16.1 million gain in the fair value of our CCXI investment.

XML 52 R35.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

12 Months Ended
Jun. 30, 2024

Income Taxes

Schedule of income before income taxes comprised

Income before income taxes was comprised of the following (in thousands):

	Year Ended June 30,		
	2024	2023	2022
Domestic	$ 174,806	$ 288,458	$ 255,118
Foreign	10,883	50,201	46,268
Earnings before income taxes	$ 185,689	$ 338,659	$ 301,386

The provision for income taxes consisted of the following (in thousands):

	Year Ended June 30,		
	2024	2023	2022
Taxes on income consist of:			
Current tax provision:			
Federal	$ 40,228	$ 59,810	$ 10,080
State	4,853	12,753	6,663
Foreign	12,664	10,453	14,481
Total current tax provision	57,745	83,016	31,224
Deferred tax provision:			
Federal	(28,301)	(28,829)	8,130
State	(4,563)	(2,414)	1,477
Foreign	(7,297)	1,444	(2,544)
Total deferred tax provision	(40,161)	(29,799)	7,063
Total income tax provision	$ 17,584	$ 53,217	$ 38,287

Schedule of effective income tax rate reconciliation

The following is a reconciliation of the federal tax calculated at the statutory rate to the actual income taxes provided:

	Year Ended June 30,		
	2024	2023	2022
Income tax expense at federal statutory rate	21.0 %	21.0 %	21.0 %
State income taxes, net of federal benefit	(0.2)	2.5	2.2
Research and development tax credit	(2.2)	(1.3)	(1.0)
Contingent consideration adjustment	(0.4)	(0.8)	(1.4)
Foreign tax rate differences	3.1	(0.6)	0.4
(Gain)/loss on investment	—	(0.7)	1.1
Option exercises	(8.8)	(3.3)	(9.4)
U.S. taxation of foreign earnings	0.1	0.4	(0.1)
Foreign derived intangible income	(4.8)	(3.4)	(1.9)
Foreign withholding tax	(1.2)	1.5	—
Executive compensation limitations	2.7	0.8	1.9
Other, net	0.2	(0.4)	(0.10)
Effective tax rate	9.5 %	15.7 %	12.7 %

Schedule of deferred tax assets and liabilities

Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands):

	June 30, 2024	June 30, 2023
Inventory	$ 9,675	$ 10,906
Net operating loss carryovers	25,065	20,315
Tax credit carryovers	9,118	9,218
Excess tax basis in equity investments	1,115	939
Deferred compensation	16,628	16,528
Lease liability	19,501	21,001
Capitalized R&D	36,151	21,081
Held-for-sale asset impairment	5,216	—
Other	6,119	4,379
Valuation allowance	(19,265)	(9,344)
Deferred tax assets	109,323	95,023
Intangible asset amortization	(120,648)	(134,810)
Depreciation	(20,448)	(21,449)
Right of use asset	(17,876)	(20,021)
Derivative - cash flow hedge	(2,516)	(3,995)
Other	(3,698)	(3,730)
Deferred tax liabilities	(165,186)	(184,005)
Net deferred income tax liabilities	$ (55,863)	$ (88,982)

Schedule of unrecognized tax benefits roll forward

The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands):

	Year Ended June 30, 2024	2023	2022
Beginning balance	$ 5,291	$ 5,302	$ 7,271
Additions due to acquisitions	—	—	960
Additions for tax positions of prior year	—	—	304
Decrease in unrecognized tax benefits for prior year positions	—	—	(357)
Settlements	—	—	(2,860)
FX impact	(13)	(11)	(16)
Ending balances	$ 5,278	$ 5,291	$ 5,302

XML 53 R36.htm IDEA: XBRL DOCUMENT

Segment Information (Tables)

12 Months Ended
Jun. 30, 2024

Notes Tables

Schedule of financial information by reportable segment

Following is financial information relating to the operating segments (in thousands):

	Year Ended June 30, 2024	2023	2022
Net sales:			
Protein Sciences	$ 830,902	$ 845,747	$ 832,311
Diagnostics and Genomics	326,392	292,602	274,843
Other revenue[1]	4,153	—	—
Intersegment	(2,387)	(1,647)	(1,555)
Consolidated net sales	$ 1,159,060	$ 1,136,702	$ 1,105,599
Operating income:			
Protein Sciences	$ 354,775	$ 373,684	$ 377,623
Diagnostics and Genomics	24,546	43,037	48,977
Segment operating income	379,321	416,721	426,600
Costs recognized on sale of acquired inventory	(729)	(400)	(1,596)
Amortization of intangibles	(78,318)	(76,413)	(73,054)
Impact of partially-owned consolidated subsidiaries[2]	—	647	(2,393)
Acquisition related expenses and other	(6,980)	9,965	19,070
Certain Litigation Charges	(3,506)	—	—
Impairment of assets held-for-sale	(21,963)	—	—
Eminence impairment	—	—	(18,715)
Stock based compensation, inclusive of employer taxes	(40,277)	(41,217)	(46,401)
Restructuring and restructuring-related costs	(12,245)	(3,829)	(1,640)
Corporate general, selling, and administrative expenses	(9,142)	(6,530)	(5,281)
Impact of business held-for-sale[1]	525	—	—
Consolidated operating income	$ 206,686	$ 298,944	$ 296,590

(1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. For the year ended June 30, 2024, includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria.

(2) Includes the annual results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023.

	Year Ended June 30, 2024	2023	2022
Consumables revenue - Protein Sciences	$ 657,679	$ 665,301	$ 646,952
Consumables revenue - Diagnostics and Genomics	266,348	252,432	243,922
Consumables revenue - Other revenue[1]	4,153	—	—
Total consumable revenue	$ 928,180	$ 917,733	$ 890,874

[1]Includes the results of a business that has met the held-for-sale criteria since December 31, 2023.

	Year ended June 30, 2024	2023
Long-lived assets:		
United States and Canada	$ 211,597	$ 203,657
Europe	27,862	19,263
Asia	11,695	3,280
Total long-lived assets	$ 251,154	$ 226,200
Intangible assets:		
United States and Canada	$ 443,740	$ 529,652
Europe	63,138	4,553
Asia	203	440
Total intangible assets	$ 507,081	$ 534,645

XML 54 R37.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands

12 Months Ended

	Jun. 30, 2024 USD ($) item	Jun. 30, 2023 USD ($) item	Jun. 30, 2022 USD ($) item
Advertising Expense	$ 4,100	$ 4,800	$ 4,600
Amortization of Intangible Assets, Total	79,854	77,491	
Finite-Lived Intangible Asset, Expected Amortization, Year One	77,259		
Finite-Lived Intangible Asset, Expected Amortization, Year Two	73,297		
Finite-Lived Intangible Asset, Expected Amortization, Year Three	63,138		
Finite-Lived Intangible Asset, Expected Amortization, Year Four	59,491		
Fiscal year 2026	46,923		
Impairment recorded for property, plant, and equipment	$ 0	$ 0	$ 0
Number of reporting units | item	5	5	5
Retained Earnings (Accumulated Deficit), Ending Balance	$ 1,325,247	$ 1,309,461	
Litigation charges	3,500		
Accrued litigation	$ 0	$ 0	
Minimum			
Finite-Lived Intangible Asset, Useful Life (Year)	1 year		
Minimum | Tradenames			
Finite-Lived Intangible Asset, Useful Life (Year)	2 years	2 years	
Maximum			
Finite-Lived Intangible Asset, Useful Life (Year)	20 years		
Maximum | Tradenames			
Finite-Lived Intangible Asset, Useful Life (Year)	20 years	20 years	
Equipment [Member] | Minimum			

Property, Plant and Equipment, Useful Life (Year)	3 years
Equipment [Member] | Maximum	
Property, Plant and Equipment, Useful Life (Year)	5 years
Building, Building Improvements and Leasehold Improvements [Member] | Minimum	
Property, Plant and Equipment, Useful Life (Year)	5 years
Building, Building Improvements and Leasehold Improvements [Member] | Maximum	
Property, Plant and Equipment, Useful Life (Year)	40 years

XML 55 R38.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details) $ in Thousands	Mar. 31, 2023 USD ($)	Nov. 14, 2022 shares	Nov. 01, 2022	Sep. 01, 2022 USD ($)	1 Months Ended Dec. 31, 2021 USD ($)	3 Months Ended Dec. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)	12 Months Ended Jun. 30, 2024 USD ($) item shares	Jun. 30, 2023 USD ($) item shares	Jun. 30, 2022 USD ($) item	Oct. 28, 2022 shares	Oct. 27, 2022 shares
Proceeds from sale of Eminence									$ 17,824			
Revenues, net								$ 1,159,060	1,136,702	$ 1,105,599		
Gain on sale of Eminence							$ 11,700		11,682			
Gain (loss) on equity method investment								(6,841)	$ (1,143)			
Positions eliminated during the period as a percentage						4.00%						
Impairment of Long-Lived Assets to be Disposed of								$ 21,963				
Common stock, shares authorized (in shares) | shares								400,000,000	400,000,000		400,000,000	100,000,000
Declared stock split			4									
Additional shares | shares		3										
Number of reporting units | item								5	5	5		
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]										Selling, general and administrative		
Eminence Biotechnology												
Proceeds from sale of Eminence				$ 17,800								
Goodwill, Impairment Loss										$ 8,300		
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)										8,600		
Goodwill, Impairment Loss										8,300		
Protein Sciences												
Goodwill attributable to disposal group held for sale						$ 1,400						
Pre-tax restructuring charges									$ 1,700			
Protein Sciences | Current Assets, Held For Sale												
Property, plant and equipment attributable to disposal group held for sale								$ 9,800				
Protein Sciences | Eminence Biotechnology												
Revenues, net							$ 2,000			4,600		
Diagnostics and Genomics												
Pre-tax restructuring charges										1,400		
Wilson Wolf Corporation												
Investment percentage	19.90%											
Payments to Acquire Investments	$ 232,000				$ 25,000							
Forward Contract, Milestone, Multiple for Total Expected Payments								4.4				
Wilson Wolf Corporation | First Part of Forward Contract												
Forward Contract, Milestone, Annual Revenue Required	92,000											
Forward Contract, Milestone, Annual EBITDA	$ 55,000											
Wilson Wolf Corporation | Second Part of Forward Contract												
Forward Contract, Milestone, Annual Revenue Required								$ 226,000				
Forward Contract, Milestone, Annual EBITDA								136,000				
Forward Contract, Additional Investment								$ 1,000,000				
Selling, General and Administrative Expenses | Protein Sciences												
Asset Impairment Charges						$ 22,000						
QT Holdings Corporation | Protein Sciences												
Pre-tax restructuring charges									$ 2,200			
Eminence Biotechnology												
Inventory Write-down										900		
Asset Impairment Charges										$ 900		

XML 56 R39.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details) - USD ($) $ in Thousands	3 Months Ended Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2022	9 Months Ended Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2023	Jun. 30, 2022	12 Months Ended Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Restructuring costs, net of adjustments									$ 33,987		
Restructuring costs	$ 21,072	$ 1,273	$ 11,424						12,245	$ 3,829	$ 1,640
Cash payments									(7,682)		
Non-cash adjustments									(25,354)		
Adjustments									219		
Accrued restructuring actions balances	952								952		
Restructuring reserves, Ending Balance							$ 0			0	
Corporate											
Restructuring costs, net of adjustments									2,180		
Diagnostics and Genomics											
Restructuring costs, net of adjustments									1,231		
Restructuring costs						$ 1,185		$ 242			
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]											Selling, general and administrative
Cash payments								(1,143)			
Adjustments								(284)			
Protein Sciences											
Restructuring costs, net of adjustments									30,576		
Restructuring costs									200		
Protein Sciences | QT Holdings Corporation											
Restructuring costs				$ 2,170						$ 2,170	

Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]											Selling, general and administrative	
Cash payments								(2,005)				
Adjustments								(165)				
Cost of Sales												
Restructuring costs, net of adjustments										3,349		
Selling, General and Administrative Expenses												
Restructuring costs, net of adjustments										30,638		
Selling, General and Administrative Expenses | Diagnostics and Genomics												
Restructuring costs, net of adjustments											$ 1,399	
Employee severance												
Restructuring costs, net of adjustments										5,643		
Restructuring costs	$ 409		$ 133		$ 4,882							
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of sales, Selling, general and administrative		Cost of sales, Selling, general and administrative		Cost of sales, Selling, general and administrative							
Cash payments										(4,882)		
Adjustments										219		
Accrued restructuring actions balances	$ 761									761		
Employee severance | Corporate												
Restructuring costs, net of adjustments										1,153		
Employee severance | Diagnostics and Genomics												
Restructuring costs, net of adjustments										1,007		
Restructuring costs							$ 639					
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]							Selling, general and administrative					Selling, general and administrative
Cash payments									(589)			
Adjustments									(50)			
Employee severance | Protein Sciences												
Restructuring costs, net of adjustments										3,483		
Accrued restructuring actions balances										897		
Restructuring costs											$ 1,677	
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]											Selling, general and administrative	
Cash payments										(1,118)	$ (762)	
Adjustments										221	18	
Accrued restructuring actions balances								897			897	
Employee severance | Protein Sciences | QT Holdings Corporation												
Restructuring costs					1,328						$ 1,328	
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]											Selling, general and administrative	
Cash payments								(1,233)				
Adjustments								(95)				
Employee severance | Selling, General and Administrative Expenses | Diagnostics and Genomics												
Restructuring costs, net of adjustments												$ 649
Asset-related and other												
Restructuring costs, net of adjustments										6,381		
Restructuring costs	$ 4,737		$ 1,140		$ 504							
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of sales, Selling, general and administrative		Cost of sales, Selling, general and administrative		Cost of sales, Selling, general and administrative							
Cash payments										(2,800)		
Non-cash adjustments										(3,391)		
Accrued restructuring actions balances	$ 190									190		
Asset-related and other | Corporate												
Restructuring costs, net of adjustments										1,027		
Asset-related and other | Diagnostics and Genomics												
Restructuring costs, net of adjustments										224		
Asset-related and other | Protein Sciences												
Restructuring costs, net of adjustments										5,130		
Impairment of assets held-for-sale												
Restructuring costs, net of adjustments										21,963		
Restructuring costs	$ 15,926				$ 6,038							
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of sales, Selling, general and administrative				Cost of sales, Selling, general and administrative							
Non-cash adjustments										(21,963)		
Impairment of assets held-for-sale | Protein Sciences												
Restructuring costs, net of adjustments										$ 21,963		
Employee Severance on Relocation of US Plant [Member]												
Restructuring costs						$ 200						
Asset impairment and other | Diagnostics and Genomics												
Restructuring costs							$ 546		$ 242			
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]							Selling, general and administrative		Selling, general and administrative			Selling, general and administrative
Cash payments									$ (554)			
Adjustments									$ (234)			
Asset impairment and other | Protein Sciences | QT Holdings Corporation												
Restructuring costs					$ 842						$ 842	
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]											Selling, general and administrative	
Cash payments								(772)				
Adjustments								$ (70)				
Asset impairment and other | Selling, General and Administrative Expenses | Diagnostics and Genomics												

Restructuring costs, net of adjustments	$ 750

XML 57 R40.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Narrative (Details) - USD ($) $ in Millions	12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Revenue Recognition		
Contract with Customer, Liability, Total	$ 30.2	$ 24.6
Contract with Customer, Liability, Revenue Recognized	$ 20.9	$ 21.5

XML 58 R41.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Revenues, net	$ 1,159,060	$ 1,136,702	$ 1,105,599
United States			
Revenues, net	657,747	642,465	614,107
EMEA, excluding United Kingdom			
Revenues, net	241,432	220,230	219,055
United Kingdom			
Revenues, net	50,012	49,457	48,637
APAC, excluding Greater China			
Revenues, net	73,904	73,190	76,139
Greater China			
Revenues, net	99,467	113,868	112,438
Rest of World			
Revenues, net	36,498	37,492	35,223
Consumables			
Revenues, net	928,180	917,733	890,874
Instruments			
Revenues, net	108,270	112,085	120,758
Services			
Revenues, net	99,265	85,784	71,988
Product and Services			
Revenues, net	1,135,715	1,115,602	1,083,620
Royalty revenues			
Revenues, net	$ 23,345	$ 21,100	$ 21,979

XML 59 R42.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet and Cash Flow Information - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Amortization of Intangible Assets, Total	$ 79,854	$ 77,491	
Developed technology | Cost of Sales			
Amortization of Intangible Assets, Total	46,600	44,300	$ 40,600
Trade Names, Customer Relationships, Non-Compete Agreements, and Patents | Selling, General and Administrative Expenses			
Amortization of Intangible Assets, Total	33,200	33,200	$ 33,500
Other Noncurrent Assets			
Inventory, Finished Goods, Net of Reserves, Non-current	$ 5,718	$ 5,387	

XML 60 R43.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) - USD ($) $ in Thousands		
	Jun. 30, 2024	Jun. 30, 2023
Supplemental Balance Sheet and Cash Flow Information		
Raw materials	$ 79,377	$ 84,551
Finished goods	106,072	92,474
Inventories, net	$ 185,449	$ 177,025

XML 61 R44.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) - USD ($) $ in Thousands		
	Jun. 30, 2024	Jun. 30, 2023
Property and equipment, cost	$ 507,710	$ 459,912
Accumulated depreciation and amortization	(256,556)	(233,712)
Property and equipment, net	251,154	226,200
Land		
Property and equipment, cost	8,150	9,100
Building and improvements		
Property and equipment, cost	243,863	245,302
Machinery and equipment		
Property and equipment, cost	215,948	190,019
Construction in progress		
Property and equipment, cost	$ 39,749	$ 15,491

XML 62 R45.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) - USD ($) $ in Thousands			
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Definite-lived intangibles assets	$ 1,054,860	$ 992,515	
Accumulated amortization	(547,779)	(480,570)	
Definite-lived intangibles assets, net	507,081	511,945	
In process research and development		22,700	
Total intangible assets, net	$ 507,081	534,645	$ 531,522
Maximum			
Finite-Lived Intangible Asset, Useful Life (Year)	20 years		
Minimum			
Finite-Lived Intangible Asset, Useful Life (Year)	1 year		
Developed technology			

Definite-lived intangibles assets	$ 675,674	$ 616,311
Developed technology | Maximum		
Finite-Lived Intangible Asset, Useful Life (Year)	15 years	15 years
Developed technology | Minimum		
Finite-Lived Intangible Asset, Useful Life (Year)	9 years	9 years
In process research and development		
Finite-Lived Intangible Asset, Useful Life (Year)	14 years	
Tradenames		
Definite-lived intangibles assets	$ 151,561	$ 146,945
Tradenames | Maximum		
Finite-Lived Intangible Asset, Useful Life (Year)	20 years	20 years
Tradenames | Minimum		
Finite-Lived Intangible Asset, Useful Life (Year)	2 years	2 years
Customer relationships		
Definite-lived intangibles assets	$ 211,276	$ 213,878
Customer relationships | Maximum		
Finite-Lived Intangible Asset, Useful Life (Year)	16 years	16 years
Customer relationships | Minimum		
Finite-Lived Intangible Asset, Useful Life (Year)	7 years	7 years
Patents		
Definite-lived intangibles assets	$ 4,343	$ 3,815
Finite-Lived Intangible Asset, Useful Life (Year)	10 years	10 years
Other intangibles		
Definite-lived intangibles assets	$ 12,006	$ 11,566
Other intangibles | Maximum		
Finite-Lived Intangible Asset, Useful Life (Year)	15 years	15 years
Other intangibles | Minimum		
Finite-Lived Intangible Asset, Useful Life (Year)	5 years	5 years

XML 63 R46.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) - USD ($) $ in Thousands	**12 Months Ended**	
	Jun. 30, 2024	**Jun. 30, 2023**
Beginning balance	$ 534,645	$ 531,522
Acquisitions	66,400	75,600
Other additions	950	5,710
Held-for-sale intangibles	(14,323)	
Amortization expense	(79,854)	(77,491)
Currency translation	(737)	(696)
Ending balance	$ 507,081	534,645
Wilson Wolf Corporation		
Other additions		$ 4,600
Finite-Lived Intangible Asset, Useful Life (Year)		10 years

XML 64 R47.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands		
	Jun. 30, 2024	**Jun. 30, 2023**
Supplemental Balance Sheet and Cash Flow Information		
2025	$ 77,259	
2026	73,297	
2027	63,138	
2028	59,491	
2028	46,923	
Thereafter	186,973	
Definite-lived intangibles assets, net	$ 507,081	$ 511,945

XML 65 R48.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	**12 Months Ended**	
	Jun. 30, 2024	**Jun. 30, 2023**
Beginning balance	$ 872,737	$ 822,101
Acquisitions	104,650	
Held-for-sale goodwill	(1,400)	
Adjustments		51,257
Currency translation	(3,324)	(621)
Ending balance	972,663	872,737
Protein Sciences		
Beginning balance	427,027	376,493
Held-for-sale goodwill	(1,400)	
Adjustments		51,257
Currency translation	(2,178)	(723)
Ending balance	423,449	427,027
Diagnostics and Genomics		
Beginning balance	445,710	445,608
Acquisitions	104,650	
Currency translation	(1,146)	102
Ending balance	$ 549,214	$ 445,710

XML 66 R49.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details) - USD ($) $ in Thousands		
	Jun. 30, 2024	**Jun. 30, 2023**
Supplemental Balance Sheet and Cash Flow Information		
Equity method investment in Wilson Wolf	$ 242,337	$ 255,857
Derivative Instruments	$ 9,813	$ 16,857

Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Long-term inventory	$ 5,718	$ 5,387
Other	6,397	7,201
Other assets	$ 264,265	$ 285,302

XML 67 R50.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Supplemental Balance Sheet and Cash Flow Information			
Income taxes paid	$ 65,254	$ 88,428	$ 30,341
Interest paid	$ 14,502	$ 8,368	$ 11,027

XML 68 R51.htm IDEA: XBRL DOCUMENT

Acquisitions - Narrative (Details) - USD ($) $ in Thousands		12 Months Ended		
	Jul. 01, 2022	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Goodwill, Purchase Accounting Adjustments			$ (51,257)	
Cash paid, net of cash acquired		$ 169,707	$ 101,184	
Minimum				
Finite-Lived Intangible Asset, Useful Life (Year)		1 year		
Minimum | Developed technology				
Finite-Lived Intangible Asset, Useful Life (Year)		9 years	9 years	
Minimum | Customer relationships				
Finite-Lived Intangible Asset, Useful Life (Year)		7 years	7 years	
Minimum | Tradenames				
Finite-Lived Intangible Asset, Useful Life (Year)		2 years	2 years	
Maximum				
Finite-Lived Intangible Asset, Useful Life (Year)		20 years		
Maximum | Developed technology				
Finite-Lived Intangible Asset, Useful Life (Year)		15 years	15 years	
Maximum | Customer relationships				
Finite-Lived Intangible Asset, Useful Life (Year)		16 years	16 years	
Maximum | Tradenames				
Finite-Lived Intangible Asset, Useful Life (Year)		20 years	20 years	
Namocell Inc				
Acquisition amount			$ 111,784	
Maximum contingent consideration	$ 25,000			$ 25,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			6,400	
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			$ (9,300)	
Cash paid, net of cash acquired	$ 101,200			
Asuragen, Inc.				
Maximum contingent consideration				$ 105,000
Asuragen, Inc. | Developed technology				
Finite-Lived Intangible Asset, Useful Life (Year)			13 years	
Asuragen, Inc. | Customer relationships				
Finite-Lived Intangible Asset, Useful Life (Year)			4 years	
Asuragen, Inc. | Trade names and non-competition agreement				
Finite-Lived Intangible Asset, Useful Life (Year)			3 years	
Lunaphore Technologies SA.				
Acquisition amount		$ 169,707		
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual		14,300		
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual		$ (24,000)		
Lunaphore Technologies SA. | Developed technology				
Finite-Lived Intangible Asset, Useful Life (Year)		14 years		
Lunaphore Technologies SA. | Customer relationships				
Finite-Lived Intangible Asset, Useful Life (Year)		8 years		
Lunaphore Technologies SA. | Tradenames				
Finite-Lived Intangible Asset, Useful Life (Year)		8 years		
Lunaphore Technologies SA. | Minimum | Tradenames				
Finite-Lived Intangible Asset, Useful Life (Year)		4 years		

XML 69 R52.htm IDEA: XBRL DOCUMENT

Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Thousands	12 Months Ended			
	Jul. 07, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Goodwill		$ 972,663	$ 872,737	$ 822,101
Lunaphore Technologies SA.				
Current assets	$ 12,512	12,155		
Current assets, adjustments		(357)		
Equipment and other long-term assets	1,470	1,470		
Goodwill	102,560	104,650		
Total assets acquired	182,942	184,675		
Liabilities	7,096	7,096		
Deferred income taxes, net	5,768	7,872		
Net assets acquired	170,078	169,707		
Cash paid	166,426	169,707		
Cash paid, adjustments		3,281		
Estimated net working capital payable	3,652			
Estimated Net Working Capital, adjustments		(3,652)		
Net assets acquired		169,707		
Net assets acquired, adjustments		(371)		
Total assets acquired, adjustments		1,733		
Deferred income taxes, net, adjustments		2,104		
Business Combination, Provisional Information [Abstract]				
Adjustments to fair value, Goodwill		2,090		
Total assets acquired, adjustments		1,733		
Deferred income taxes, net, adjustments		2,104		
Adjustments to fair value, Net assets acquired		(371)		
Lunaphore Technologies SA. | Developed technology				
Intangible assets	60,300	60,300		
Lunaphore Technologies SA. | Tradenames				
Intangible assets	4,900	4,900		
Lunaphore Technologies SA. | Customer relationships				

Intangible assets	$ 1,200	$ 1,200
Namocell Inc		
Current assets		3,248
Equipment and other long-term assets		405
Goodwill		51,257
Total assets acquired		130,510
Liabilities		546
Deferred income taxes, net		18,180
Net assets acquired		111,784
Cash paid		101,184
Additional consideration		10,600
Net assets acquired		111,784
Namocell Inc | Developed technology		
Intangible assets		73,900
Namocell Inc | Tradenames		
Intangible assets		700
Namocell Inc | Customer relationships		
Intangible assets		900
Namocell Inc | Non-competition agreement		
Intangible assets		$ 100

XML 70 R53.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Narrative (Details) $ in Thousands	3 Months Ended	12 Months Ended							
	Sep. 30, 2023 USD ($) item	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2023 USD ($)	Jul. 01, 2022 USD ($)	May 31, 2021 USD ($)	Apr. 06, 2021 USD ($)
Income Tax Expense (Benefit), Total		$ 17,584	$ 53,217	$ 38,287					
Exchange Traded Investment Grade Bond Funds									
Investments, Total			25,000						
Investments, Fair Value Disclosure, Total			23,700						
Asuragen, Inc.									
Contingent consideration			2,000						$ 18,300
Maximum contingent consideration					$ 105,000				
Namocell Inc									
Contingent consideration			$ 1,500				$ 10,600		
Maximum contingent consideration					$ 25,000		$ 25,000		
Forward starting swaps | Cash flow hedges | Designated as hedging instruments									
Derivative, Notional Amount						$ 100,000		$ 200,000	
Cross-currency swap | Net investment hedge | Designated as hedging instruments									
Derivative, Notional Amount	$ 150,000								
Number of interim settlement dates | item	4								
Notional amount at maturity	$ 110,000								
Derivative Notional Amount, Decrease in Period	$ 10,000								

XML 71 R54.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Total assets	$ 11,690	$ 40,596
Contingent consideration		3,500
Total liabilities	2,051	3,500
Net investment hedge		
Derivative instruments - net investment hedge	2,051	
Other current assets | Cash flow hedges		
Derivative instruments - cash flow hedges	805	
Other assets | Cash flow hedges		
Derivative instruments - cash flow hedges	9,813	16,857
Level 1		
Total assets	1,072	23,739
Level 2		
Total assets	10,618	16,857
Total liabilities	2,051	
Level 2 | Net investment hedge		
Derivative instruments - net investment hedge	2,051	
Level 2 | Other current assets | Cash flow hedges		
Derivative instruments - cash flow hedges	805	
Level 2 | Other assets | Cash flow hedges		
Derivative instruments - cash flow hedges	9,813	16,857
Level 3		
Contingent consideration		3,500
Total liabilities		3,500
Exchanged traded investment grade bond funds		
Investments, Fair Value Disclosure		23,739
Exchanged traded investment grade bond funds | Level 1		
Investments, Fair Value Disclosure		$ 23,739
Certificates of Deposit [Member]		
Investments, Fair Value Disclosure	1,072	
Certificates of Deposit [Member] | Level 1		
Investments, Fair Value Disclosure	$ 1,072	

XML 72 R55.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details) - Designated as hedging instruments - USD ($) $ in Millions	Jun. 30, 2024	Jun. 30, 2023
Cash flow hedges | Forward starting swaps		
Derivative [Line Items]		
Fair value of derivative instruments	$ 300	$ 300
Net investment hedge | Cross-currency swap		
Derivative [Line Items]		
Fair value of derivative instruments	$ 150	

XML 73 R56.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
(Gain) Loss Recognized in AOCI			
(Gain) Loss Recognized in Accumulated Other Comprehensive Loss	$ 16,647	$ (1,340)	$ (19,121)
(Gain) Loss Reclassified into Income	(13,527)	(4,526)	6,352
Cash flow hedges | Forward starting swaps			
(Gain) Loss Recognized in AOCI			
(Gain) Loss Recognized in Accumulated Other Comprehensive Loss	12,632	(1,340)	(19,121)
(Gain) Loss Reclassified into Income	(10,317)	$ (4,526)	$ 6,352
Net investment hedge | Cross-currency swap			
(Gain) Loss Recognized in AOCI			
(Gain) Loss Recognized in Accumulated Other Comprehensive Loss	4,015		
(Gain) Loss Reclassified into Income	$ (3,210)		

XML 74 R57.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) - Contingent Consideration - Level 3 - USD ($) $ in Thousands	12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Fair value at the beginning of period	$ 3,500	$ 5,000
Purchase price contingent consideration (Note 4)		10,600
Change in fair value of contingent consideration	$ (3,500)	$ (12,100)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative	Selling, general and administrative
Payments		$ 0
Fair value at the end of period		$ 3,500

XML 75 R58.htm IDEA: XBRL DOCUMENT

Debt and Other Financing Arrangements - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended		
	Aug. 31, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Borrowings under line-of-credit agreement		$ 225,000	$ 619,661	$ 90,000
Credit Agreement				
Line of Credit, Current		$ 319,000		
Revolving Credit Facility | Credit Agreement				
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,000,000			
Line of Credit Facility, Additional Borrowing Capacity	$ 400,000			
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.10%			

XML 76 R59.htm IDEA: XBRL DOCUMENT

Leases - Narrative (Details) $ in Millions	12 Months Ended Jun. 30, 2024 USD ($)
Variable Lease, Cost	$ 5.0
Fixed Lease, Cost	$ 18.2
Maximum	
Lessee, Operating Lease, Renewal Term (Year)	5 years

XML 77 R60.htm IDEA: XBRL DOCUMENT

Leases - Balance Sheet Classification (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Leases		
Operating lease right of use assets	$ 91,285	$ 98,326
Current operating lease liabilities	12,920	11,199
Noncurrent operating lease liabilities	87,618	$ 93,766
Total operating lease liabilities	$ 100,538	
Weighted average remaining lease term (in years):	8 years 5 months 12 days	
Weighted average discount rate:	4.23%	

XML 78 R61.htm IDEA: XBRL DOCUMENT

Leases - Cash Paid (Details) $ in Thousands	12 Months Ended Jun. 30, 2024 USD ($)
Leases	
Cash amounts paid on operating lease liabilities	$ 17,729
Right of use assets obtained in exchange for lease liabilities	$ 11,051

XML 79 R62.htm IDEA: XBRL DOCUMENT

Leases - Fair Value of the Lease Liability by Payment Date (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Leases	
2025	$ 16,331
2026	16,429
2027	13,577
2028	13,479
2028	12,967
Thereafter	48,211
Total	120,994
Less: Amounts representing interest	20,456
Total lease obligations	$ 100,538

XML 80 R63.htm IDEA: XBRL DOCUMENT

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information -	12 Months Ended		
	Jun. 30,	Jun. 30,	Jun. 30,

Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	2024	2023	2022
Common Stock, dividends, per share, declared (in dollars per share)	$ 0.32	$ 0.32	$ 0.32
Stock Repurchased During Period, Shares (in shares)	1,397,471	222,000	1,576,952
Average price per share of shares repurchased	$ 57.28	$ 88.12	$ 102.06
Net settlement stock options exercises and restricted stock units vesting	$ 21,872	$ 28,893	$ 23,461
Interest expense	15,736	11,215	11,309
Total other income (expense), net	(20,997)	39,715	4,796
Income Tax Expense (Benefit), Total	17,584	53,217	38,287
Net Deferred Tax Liability	165,186	184,005	
Deferred Income Tax Expense (Benefit), Total	(40,161)	(29,799)	7,063
Eminence Biotechnology			
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest		33	70
Accumulated Other Comprehensive Income			
Net Deferred Tax Liability	$ 2,500	$ 4,000	$ 2,500

XML 81 R64.htm IDEA: XBRL DOCUMENT

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($) $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Balance	$ 1,966,516		
Other comprehensive income (loss), before tax, attributable to Bio-Techne:			
Amounts before reclassifications	16,647	$ (1,340)	$ (19,121)
Amounts reclassified out	13,527	4,526	(6,352)
Total other comprehensive income (loss), net of tax	(12,252)	9,136	(17,909)
Balance	2,068,850	1,966,516	
Unrealized Gains (Losses) on Derivative Instruments			
Balance	12,862	8,069	(6,193)
Other comprehensive income (loss), before tax, attributable to Bio-Techne:			
Amounts before reclassifications	(12,632)	1,340	19,121
Amounts reclassified out	10,317	4,526	(6,352)
Total other comprehensive income (loss), before tax	(2,315)	5,866	12,769
Tax (expense) benefit	(2,445)	(1,073)	1,493
Total other comprehensive income (loss), net of tax	(4,760)	4,793	14,262
Balance	8,102	12,862	8,069
Foreign Currency Translation Adjustments			
Balance	(78,926)	(83,269)	(51,098)
Other comprehensive income (loss), before tax, attributable to Bio-Techne:			
Amounts before reclassifications	(9,941)	4,191	(32,171)
Amounts reclassified out	3,210	152	
Total other comprehensive income (loss), before tax	(6,731)	4,343	(32,171)
Tax (expense) benefit	(761)		
Total other comprehensive income (loss), net of tax	(7,492)	4,343	(32,171)
Balance	(86,418)	(78,926)	(83,269)
Accumulated Other Comprehensive Income			
Balance	(66,064)	(75,200)	(57,291)
Other comprehensive income (loss), before tax, attributable to Bio-Techne:			
Amounts before reclassifications	(22,573)	5,531	(13,050)
Amounts reclassified out	13,527	4,678	(6,352)
Total other comprehensive income (loss), before tax	(9,046)	10,209	(19,402)
Tax (expense) benefit	(3,206)	(1,073)	1,493
Total other comprehensive income (loss), net of tax	(12,252)	9,136	(17,909)
Balance	$ (78,316)	$ (66,064)	$ (75,200)

XML 82 R65.htm IDEA: XBRL DOCUMENT

Earnings Per Share - Narrative (Details) - shares shares in Millions	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share			
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	3.9	4.5	2.8

XML 83 R66.htm IDEA: XBRL DOCUMENT

Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share			
Net earnings, including noncontrolling interest	$ 168,105	$ 285,442	$ 263,099
Less net earnings (loss) attributable to noncontrolling interest		179	(8,952)
Net earnings attributable to Bio-Techne	168,105	285,263	272,051
Income allocated to participating securities	(33)	(70)	(121)
Income available to common shareholders	$ 168,072	$ 285,193	$ 271,930
Weighted-average shares outstanding - basic (in shares)	157,708	157,179	156,874
Earnings per share - basic (in shares)	$ 1.07	$ 1.81	$ 1.73
Income available to common shareholders	$ 168,072	$ 285,193	$ 271,930
Dilutive effect of stock options and restricted stock units (in shares)	3,066	4,676	7,240
Weighted-average common shares outstanding - diluted (in shares)	160,774	161,855	164,114
Earnings per share - diluted (in shares)	$ 1.05	$ 1.76	$ 1.66

XML 84 R67.htm IDEA: XBRL DOCUMENT

Share-based Compensation and Other Benefit Plans (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended						
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2010	Jun. 30, 2021	Oct. 31, 2020	Oct. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	11,579,000	13,924,000	13,269,000		14,868,000		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 27.27	$ 29.53	$ 29.78				

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 100,800	$ 90,200	$ 209,300			
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised in Period, Fair Value	58,200	46,500	82,300			
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	31,600	31,000	29,200			
Stock-based compensation expense	40,277	41,217	46,401			
Unrecognized compensation cost	$ 35,800					
Share-based Compensation Arrangement by Share-based Payment Award, Non-vested, Forfeiture Rate	4.50%					
Unrecognized compensation cost, period for recognition (Year)	2 years 1 month 6 days					
US Profit Sharing and Savings Plan [Member]						
Defined Contribution Plan, Cost	$ 5,800	4,900	4,300			
GB Profit Sharing and Savings Plan [Member]						
Defined Contribution Plan, Cost	5,500	2,400	2,300			
Selling, General and Administrative Expenses [Member]						
Stock-based compensation expense	38,500	39,300	44,000			
Cost of Sales [Member]						
Stock-based compensation expense	900	1,000	1,400			
Restricted Stock [Member]						
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	2,400	3,100	2,900			
Restricted Stock Units (RSUs) [Member]						
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 9,900	6,400	6,500			
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	3 years					
The 2020 Equity Incentive Plan [Member]						
Number of shares authorized (in shares)				36,200,000	9,936,808	
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	6,300,000					
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	11,600,000					
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	4 years					
The 2020 Equity Incentive Plan [Member] | Maximum						
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)				10 years		
Employee Stock Purchase Plan 2014 [Member]						
Number of shares authorized (in shares)						800,000
Stock-based compensation expense	$ 900	900	1,000			
Performance Incentive Programs [Member] | Executive Officer [Member]						
Salary and Wage, Officer, Excluding Cost of Good and Service Sold	$ 13,500	$ 10,800	$ 26,500			
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)	1,060,126	2,350,980	1,390,436			
Performance Incentive Programs [Member] | Restricted Stock [Member] | Executive Officer [Member]						
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)	27,876	10,816	27,584			
Performance Incentive Programs [Member] | Restricted Stock Units (RSUs) [Member] | Executive Officer [Member]						
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)	374,448	107,202	110,292			

XML 85 R68.htm IDEA: XBRL DOCUMENT

Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)

	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation and Other Benefit Plans			
Dividend yield	0.41%	0.34%	0.27%
Expected volatility, Minimum	30.00%	30.00%	27.00%
Expected volatility, Maximum	37.00%	36.00%	33.00%
Risk-free interest rates, Minimum	3.80%	2.80%	0.60%
Risk-free interest rates, Maximum	4.80%	4.40%	2.60%
Expected lives (years) (Year)	4 years 4 months 24 days	4 years 8 months 12 days	4 years 3 months 18 days

XML 86 R69.htm IDEA: XBRL DOCUMENT

Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions

	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation and Other Benefit Plans			
Outstanding, shares (in shares)	13,924	13,269	14,868
Outstanding, weighted average exercise price (in dollars per share)	$ 60.56	$ 51.20	$ 43.16
Granted, shares (in shares)	1,060	2,351	1,390
Granted, weighted average exercise price (in dollars per share)	$ 79.69	$ 93.81	$ 120.15
Forfeited, shares (in shares)	(1,165)	(118)	(539)
Forfeited, weighted average exercise price (in dollars per share)	$ 90.86	$ 85.99	$ 87.05
Exercised, shares (in shares)	(2,240)	(1,578)	(2,450)
Exercised, weighted average exercise price (in dollars per share)	$ 33.34	$ 29.48	$ 33.61
Outstanding, shares (in shares)	11,579	13,924	13,269
Outstanding, weighted average exercise price (in dollars per share)	$ 64.53	$ 60.56	$ 51.20
Outstanding, aggregate intrinsic value	$ 747.3		
Outstanding, weighted average contractual life (Year)	3 years		
Exercisable, shares (in shares)	8,208	8,641	7,797
Exercisable, weighted average exercise price (in dollars per share)	$ 53.57	$ 44.76	$ 36.99
Exercisable, aggregate intrinsic value	$ 439.7		
Exercisable, weighted average contractual life (Year)	2 years 1 month 6 days		

XML 87 R70.htm IDEA: XBRL DOCUMENT

Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) - $ / shares shares in Thousands

	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Restricted Stock [Member]			
Balance, shares (in shares)	37	66	92
Balance, weighted average exercise price (in dollars per share)	$ 89.91	$ 85.83	$ 56.52
Granted, shares (in shares)	28	11	28
Granted, weighted average exercise price (in dollars per share)	$ 57.38	$ 73.94	$ 122.34
Vested, shares (in shares)	(30)	(40)	(54)

Vested, weighted average exercise price (in dollars per share)	$ 82.51	$ 78.85	$ 54.57
Balance, weighted average contractual life (Year)	6 years 7 months 6 days		
Balance, shares (in shares)	35	37	66
Balance, weighted average exercise price (in dollars per share)	$ 70.22	$ 89.91	$ 85.83
Restricted Stock Units (RSUs) [Member]			
Balance, shares (in shares)	283	302	382
Balance, weighted average exercise price (in dollars per share)	$ 91.10	$ 75.54	$ 55.13
Granted, shares (in shares)	374	107	110
Granted, weighted average exercise price (in dollars per share)	$ 78.16	$ 90.96	$ 117.60
Vested, shares (in shares)	(129)	(123)	(145)
Vested, weighted average exercise price (in dollars per share)	$ 76.42	$ 52.34	$ 44.62
Forfeited, shares (in shares)	(31)	(3)	(45)
Forfeited, weighted average exercise price (in dollars per share)	$ 99.96	$ 106.13	$ 104.34
Balance, weighted average contractual life (Year)	5 years 8 months 15 days		
Balance, shares (in shares)	497	283	302
Balance, weighted average exercise price (in dollars per share)	$ 84.62	$ 91.10	$ 75.54

XML 88 R71.htm IDEA: XBRL DOCUMENT

Other Income / (Expense) - Narrative (Details) - USD ($) $ in Thousands

	3 Months Ended	12 Months Ended		
	Sep. 30, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Other income (expense).				
Gain on sale of exchange trade investment grade bond funds		$ 300		
Gain (loss) on investment			$ 400	$ 16,100
Gain on sale of CCXI investment			37,176	
Gain on sale of Eminence	$ 11,700		$ 11,682	

XML 89 R72.htm IDEA: XBRL DOCUMENT

Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details) - USD ($) $ in Thousands

	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Other income (expense).			
Interest expense	$ (15,736)	$ (11,215)	$ (11,309)
Interest income	3,323	3,410	794
Gain (loss) on investment(1)	283	49,328	15,186
Gain (loss) on equity method investment	(6,841)	(1,143)	
Other non-operating income (expense), net	(2,026)	(665)	125
Total other income (expense), net	$ (20,997)	$ 39,715	$ 4,796

XML 90 R73.htm IDEA: XBRL DOCUMENT

Income Taxes - Narrative (Details) - USD ($) $ in Thousands

	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Effective income tax rate reconciliation, percent, total	9.50%	15.70%	12.70%
Share-based compensation excess tax benefit	$ 18,400	$ 12,300	$ 29,300
Deferred tax assets, valuation allowance, total	19,265	9,344	
Deferred Tax Assets, Net of Valuation Allowance, Total	109,323	95,023	
Undistributed Earnings of Foreign Subsidiaries, considered permanently and non-permanently reinvested	246,000		
Undistributed Earnings of Foreign Subsidiaries, considered non-permanently reinvested	108,000		
Undistributed Earnings of Foreign Subsidiaries, considered permanently reinvested	138,000		
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	5,300		
Accrued interest and penalties related to unrecognized tax benefits	600	$ 500	$ 300
Operating Loss Carryforwards [Member]			
Deferred Tax Assets, Net of Valuation Allowance, Total	9,800		
Tax Credit Carryforwards [Member]			
Deferred tax assets, valuation allowance, total	5,500		
Domestic Tax Authority [Member]			
Tax Credit Carryforward, Amount	4,400		
Domestic Tax Authority [Member] | Operating Loss Carryforwards [Member]			
Operating Loss Carryforwards, Total	34,000		
State and Local Jurisdiction [Member]			
Tax Credit Carryforward, Amount	5,600		
State and Local Jurisdiction [Member] | Operating Loss Carryforwards [Member]			
Operating Loss Carryforwards, Total	146,800		
Foreign Tax Authority [Member] | Operating Loss Carryforwards [Member]			
Operating Loss Carryforwards, Total	$ 77,500		

XML 91 R74.htm IDEA: XBRL DOCUMENT

Income Taxes - Components of Provision for Income Taxes (Details) - USD ($) $ in Thousands

	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Income Taxes			
Domestic	$ 174,806	$ 288,458	$ 255,118
Foreign	10,883	50,201	46,268
Earnings before income taxes	185,689	338,659	301,386
Federal	40,228	59,810	10,080
State	4,853	12,753	6,663
Foreign	12,664	10,453	14,481
Total current tax provision	57,745	83,016	31,224
Federal	(28,301)	(28,829)	8,130
State	(4,563)	(2,414)	1,477
Foreign	(7,297)	1,444	(2,544)
Total deferred tax provision	(40,161)	(29,799)	7,063
Total income tax provision	$ 17,584	$ 53,217	$ 38,287

XML 92 R75.htm IDEA: XBRL DOCUMENT

Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)

	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Income Taxes			
Income tax expense at federal statutory rate	21.00%	21.00%	21.00%
State income taxes, net of federal benefit	(0.20%)	2.50%	2.20%
Research and development tax credit	(2.20%)	(1.30%)	(1.00%)
Contingent consideration adjustment	(0.40%)	(0.80%)	(1.40%)
Foreign tax rate differences	(3.10%)	0.60%	(0.40%)

(Gain)/loss on investment		(0.70%)	1.10%
Option exercises	(8.80%)	(3.30%)	(9.40%)
U.S. taxation of foreign earnings	0.10%	0.40%	(0.10%)
Foreign derived intangible income	(4.80%)	(3.40%)	(1.90%)
Foreign withholding tax	(1.20%)	1.50%	
Executive compensation limitations	2.70%	0.80%	1.90%
Other, net	0.20%	(0.40%)	(0.10%)
Effective tax rate	9.50%	15.70%	12.70%

XML 93 R76.htm IDEA: XBRL DOCUMENT

Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	**Jun. 30, 2024**	**Jun. 30, 2023**
Income Taxes		
Inventory	$ 9,675	$ 10,906
Net operating loss carryovers	25,065	20,315
Tax credit carryovers	9,118	9,218
Excess tax basis in equity investments	1,115	939
Deferred compensation	16,628	16,528
Lease liability	19,501	21,001
Capitalized R&D	36,151	21,081
Held-for-sale asset impairment	5,216	
Other	6,119	4,379
Valuation allowance	(19,265)	(9,344)
Deferred tax assets	109,323	95,023
Intangible asset amortization	(120,648)	(134,810)
Depreciation	(20,448)	(21,449)
Right of use asset	(17,876)	(20,021)
Derivative - cash flow hedge	(2,516)	(3,995)
Other	(3,698)	(3,730)
Deferred tax liabilities	(165,186)	(184,005)
Net deferred income tax liabilities	$ (55,863)	$ (88,982)

XML 94 R77.htm IDEA: XBRL DOCUMENT

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	**12 Months Ended**		
	Jun. 30, 2024	**Jun. 30, 2023**	**Jun. 30, 2022**
Income Taxes			
Balance	$ 5,291	$ 5,302	$ 7,271
Additions due to acquisitions			960
Additions for tax positions of prior year			304
Decrease in unrecognized tax benefits for prior year positions			(357)
Settlements			(2,860)
FX impact	(13)	(11)	(16)
Ending balances	$ 5,278	$ 5,291	$ 5,302

XML 95 R78.htm IDEA: XBRL DOCUMENT

Segment Information - Narrative (Details)	**12 Months Ended Jun. 30, 2024 segment**
Segment Information	
Number of Reportable Segments	2

XML 96 R79.htm IDEA: XBRL DOCUMENT

Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($) $ in Thousands	**3 Months Ended**			**9 Months Ended**	**12 Months Ended**		
	Jun. 30, 2024	**Mar. 31, 2024**	**Dec. 31, 2023**	**Sep. 30, 2021**	**Jun. 30, 2022**	**Jun. 30, 2024**	**Jun. 30, 2023**	**Jun. 30, 2022**
Revenues from External Customers and Long-Lived Assets [Line Items]								
Revenues, net						$ 1,159,060	$ 1,136,702	$ 1,105,599
Operating income						206,686	298,944	296,590
Costs recognized on sale of acquired inventory						(729)	(400)	(1,596)
Amortization of intangibles						(78,318)	(76,413)	(73,054)
Impact of partially-owned consolidated subsidiaries(2)							647	(2,393)
Acquisition related expenses and other						(6,980)	9,965	19,070
Certain litigation charges						(3,506)		
Impairment of assets held-for-sale						21,963		
Intangible assets, net	$ 507,081				$ 531,522	507,081	534,645	531,522
Eminence impairment								(18,715)
Stock based compensation, inclusive of employer taxes						(40,277)	(41,217)	(46,401)
Restructuring and restructuring-related costs	(21,072)	$ (1,273)	$ (11,424)			(12,245)	(3,829)	(1,640)
Corporate general, selling, and administrative expenses						(466,375)	(378,378)	(372,766)
Impact of business held-for-sale(1)						525		
Total long-lived assets	251,154					251,154	226,200	
United States and Canada [Member]								
Revenues from External Customers and Long-Lived Assets [Line Items]								
Intangible assets, net	443,740					443,740	529,652	
Total long-lived assets	211,597					211,597	203,657	
Europe [Member]								
Revenues from External Customers and Long-Lived Assets [Line Items]								
Intangible assets, net	63,138					63,138	4,553	
Total long-lived assets	27,862					27,862	19,263	
Asia [Member]								
Revenues from External Customers and Long-Lived Assets [Line Items]								
Intangible assets, net	203					203	440	
Total long-lived assets	$ 11,695					11,695	3,280	
Consumables								
Revenues from External Customers and Long-Lived Assets [Line Items]								

Revenues, net			928,180	917,733	890,874
Instruments					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Revenues, net			108,270	112,085	120,758
Services					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Revenues, net			99,265	85,784	71,988
Product and Services					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Revenues, net			1,135,715	1,115,602	1,083,620
Royalty revenues					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Revenues, net			23,345	21,100	21,979
Protein Sciences					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Restructuring and restructuring-related costs			(200)		
Diagnostics and Genomics					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Restructuring and restructuring-related costs	$ (1,185)	$ (242)			
Other Revenues from Business Held for Sale					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Revenues, net			4,153		
Operating Segments					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Operating income			379,321	416,721	426,600
Operating Segments | Consumables					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Revenues, net			928,180	917,733	890,874
Operating Segments | Protein Sciences					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Revenues, net			830,902	845,747	832,311
Operating income			354,775	373,684	377,623
Operating Segments | Protein Sciences | Consumables					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Revenues, net			657,679	665,301	646,952
Operating Segments | Diagnostics and Genomics					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Revenues, net			326,392	292,602	274,843
Operating income			24,546	43,037	48,977
Operating Segments | Diagnostics and Genomics | Consumables					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Revenues, net			266,348	252,432	243,922
Operating Segments | Other Revenues from Business Held for Sale | Consumables					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Revenues, net			4,153		
Intersegment Eliminations					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Revenues, net			(2,387)	(1,647)	(1,555)
Corporate, Non-Segment					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Corporate general, selling, and administrative expenses			$ (9,142)	$ (6,530)	$ (5,281)

XML 97 R80.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD ($) $ in Thousands	**12 Months Ended**		
	Jul. 23, 2024	**Jun. 30, 2024**	**Jun. 30, 2023**
Subsequent Event [Line Items]			
Cash paid, net of cash acquired		$ 169,707	$ 101,184
Lunaphore Technologies SA.			
Subsequent Event [Line Items]			
Acquisition amount		$ 169,707	
Subsequent Event | Spear Bio			
Subsequent Event [Line Items]			
Payments to Acquire Investments	$ 15,000		

EXCEL 98 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (,^#%ED'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+ (/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #/@Q99%Q+8>>T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)TU%)'1S43PI""XHWD(RNQMLTI",M/OVMG&WB^@#>,S,GV^^ M@>E,E&9(^)R&B(DP3!^0UX)&TU:5B 55R)3'762)-0TY!.>&M6?/Q,?8%9]BCQT 9FKH!II:) M\3CU'5P "XPP^?Q=0+L22_5/;.D .R6G[-;4.([UV);&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D4P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[?_1VC?"J_B"P#E_M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH>#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MSX,66?1;S*20!P \#$!@ !X;"]W;W)KH[W7*+F4!\:^)QL+[[QC)&=$ N**1 ++/T]D2H(@49+G M\6\NVBF.F13NO]ZIS].+EQ?S@",R9<%7WQ.;\\ZH@SSRB.- W+'GCR2_H$&B MY[(@2O]'S]EG!\,.^$ER^Z\LZ,9XQ M-Y9?HT 3ZJ%+*GSQBA8T:T_)]])%GU/)'H MN_F!+K(#634',BUTPZC81/(H'O&J GUYUL6I6[M3O[! Q3]BVD.V<8(LPW(4 M)S2%RR?QNH?,86WY#"Z?$5<>W4S+;>!J[.*+L%,]NT9ORIX(5V'-RAQU63(L MO(^VV"7G'=GO(*?2&?\ZR_FT/A=A42GV$R36 674^!R(/6RW=Z_;HD*&UQN M&MTK%1^PJBT?36(5/H."SZ 9GPFE,0[0'=DR+E2@8!W!8Q7>*5C5%I0FL0JH M80%JV S4DG"?)6.@A^1(JFQ3L%(Q'M4.2&!]6VB:Q"K03@MHIPU['\?2 J1W MBOH6!FL]XB!2-C&PK"TM36(56J."U@B\PORV.O<#@F[C\$$]SL,:1M<\M4XM M%2>PL"TG36(53N*3N^:<+HC:S\2LF$)=(M#94>$=2X6G[KWE]./MY=HROA6 MQ0P4:,M,DUB%F6F4!LYH0FU!77FMC*>V[02MA!S#$..20$P%?Y5_/27* ^HW MMRI\<%%;?KK4J@#W'+#9!.]?D$+3PYJ_J/O9N:WOK,>D'3,KNE8IXZA[+!P M<6MZFM2J]*R2GM6$WL3SI'ITLGN!KN7GT">J;G.PY-!TT(U[)=\@KV@9R'-' MM[W+GA(EJ-0:I2:U*LHR 9B@8_X)Y339DEWXGCU3)498[L:GE. M"WQ57)O" MU:W1'2,,F&4:,&$__R.Z8OA;%C ?L$9G6VX??T(JX,9>M3(D,5IJR,)3F9268^_T$O3%ZAHFVF*,G'*BS M/*S7FN,Q(H199@@3-O\RD7H^7:/5:_C B6^ P(R.2@I:N T.UD-9O\J9Q]U9H1=*E5>949P6J4$;Z2(.A^I]*/ MR0Z*(SFR>6@11;%Z:#N@^8TH?1E/":N2Z20E/$R224_K0E EUJ57YD +-C Y_Q6(0X"=!%'\NU(MW4-AG=K9;[BN-:UC1 &KC (6[.)S6IMD0/L@%<1&AJ=PBZFZV?W/AP9P M76MLQ\@$5ID)K$8/#E8;:3M 6+!,/2RMQE^76A56:?PMV+^6">N0% M71'E^'] RI#_1L[/ZY1R)'K7!!TC#-AE&+!AZ[[+3G,_2B8?OQ',P14=!^2Z M76/8M0TE-JUI0)=:%5N9!NR&JX7VNWX;-^L[!ULW''BB_6MY\0-?72R4GK79?EUJ54VGW;=B>[SC-?1ZBQ4R) M"E8P1P,E):W^7I=:=9%LZ>\=V'CO*"7/XA(+K\)T0&)O&<$)2CO6L5C/?WULBG\Q"I#\UB)";K([*5LL7>XN?,TS21?

S]\N/9;R%N<#*)$:& M/,I2HW&PO=V]R:W-H965T&ULM5IA;]LX$OTKA&]Q:(&D%DE)E'*)@21V=W.X.D6<[GYF;,86 M5I9R(NUT[]??2%8LFQRQ#+X5#/5VHM]:?R117PRW-9K:6!RVHYU"^5DHO&:)T/61#$P[7,BL'HLKGW MM1I=EAN39X7Z6A&]6:]E]=>-RLO7JP$=O-UXR)8K4]\8CBY?Y%+-E/GV\K6" MJ^'>RR);JT)G94$J]7PUN*878Q[6!@WB]TR]ZH/OI*;R5)9_UA=WBZM!4/=(MY6IN:A<2/K;J5N5Y[0GZ\>_6Z6#?9FUX^/W-^^>&/)!YDEK=EOD?V<*LK@;) M@"S4L]SDYJ%_4VUA*+:W[S,=?.?O+;88$#F&VW*=6L,/5AGQ>Y3?F\#*<6! MXQX#UAHPVR#L>.?M ?]9@[U:${JW%%IXC"61HXNJ_*55#4:O-5?FF VUD _M*^IQGYD*?LW SHQN[Z>S^W =C:\?)V,R>X2/+Y/IXXS MCLGM_9>O#Y/?)M/9W>\3%ZPDY)]]F8_+AEX]$KV2E-,D*\K@J-UH6"WU& M?CFZOAP:Z&_=ZG#>]NUFUS?6TS?*R)>R,"M-)L5"+8X=#('HGBU[8WO#0![_MN2D^$1Z<$1:P$.G0[<^;<\1\ //FS,.&{\>.-_[X_V'LL-'8M1;BK=4%Z$*_ MR+FZ&D"%T:K:JL'H[W^C/&&"Z(HC3=XXXX1'L.D9?#;:D-*9_[M>>S,XX-V>9)R'EDT$%@<)XFP6""P,*4!QTG$>Q*QE\2O5:DUU+YJF148A]AI M5<2I8#8'%)90"S9&8%$PY".^4O7]1E319L23J.RS=6ND+C(HXY4P\ MI;/QB9P=!2 9!R_Q)L ,U &${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gO>W4'/.KN6]%I62>_09H01 M H%=]"K;-OM5R"/8NF[JK9XFYV0N]8H\Y]#82BV62C>B]#ZX@>67R'6YJ6&+ M3,_!&7C."(CMC2()&G-$$H;".9E"8*"'G*]%*,*0Q7V%N5.$S*\(?UBT4&:(M{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`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{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{G]$E5_M2U]2CG1? YG])/Y'8ZE1Z5+607O+G)A?R65X^2)>KQ \(96B|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|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|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`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|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

M)^;8RP)]Q;TU<;'.LG4C_SBP8[3!R)W7HR>)Q_ZFRK/H[^24$AQ)_&M 9'BK MAO]DCG^:N#\X=,-_9R7YR=)S7\!B'I]I([^ZLY* M-XTNZ4<\02=K; #O\9B5^P4'\'^&Z<7_ U!+ P04 "#/@Q99QUS#V4T* M "B' & 'AL+W=OB>V9Y(TV6X[V6:<;#/!")$0A5V(8 #0LOKK>RX /F3+;CJ3+_O% M%DG@/L\]]X*\/&CSA]T)X=C=7E7V:K1SKGYX<6'SG=AS.]:UJ/!DJ\V>,UR:M\L+61O#";]JKBRO-%Q=[+]O1];6 _l]%<7^K&*5F)CX;99K_GYOA&*'VX&DU& M[8T;6>X#]HI-2R+VHK-05,V)[-7H]>?EF1NO]@G]) M<;"#WXP\V6C]!UW\4ER-4C)(*)$[DL#Q[U:\%4J1()CQ-!""9(T(F&?N@*[>S M[%U5B.)4P 4LZLS*6K/>9$]* 'M3C=DT35B69K,GY$T[-Z=>WO01>;|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l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|*:PS;O4RM6L$+NZ@J M9\SSXEG%93VYNK"T^_;JHNET*6MQWQ+5515O7VY$V3O?3OS)AO!>+I::&97 M%RN^$]"[JZ;S&:#5P*68E:R:8FK9A?3J[!\YO0S+<3_B7%LW+^$Z/)8|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|(,@$[;TK@(=SVE\77[O-7 M)>9=2=[)N?C]&)R^"-ZJD^V8= 9?#HZ[S^\%8 #&1]*+?%DW9:-X(1DY19 X M=HZ3B,.);_G8CVG@^^1#RPM1\PH&9UC%1E_X\%84^^,XC!'%$;FU_1) I16E MC1"UE"M%$K-G[,2\3UGBCI%#24KN7FMJR0I$$X&@33(']/D](AVA:)Y1l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|&_)ABP$ZSL@Q M4;]#V+E'\5V0VW?E.W/N[-'\+.R7"9-Z.&+TU_<#=?CX<=W?^8_3^R\G/_6MK;LBI9ACJ7>61!/2]E\C^H%N5O8+P&.CT6G9OTN!#JPU$_!^WJ ^K0=F@^&3 MT-5_ 5!+ P04 " #/@Q99V$S3(A8* :)0 &0 'AL+W=O6Z(T.0E]?WR2\V61<C]77-_9W6'+K=BTIM5%H10X)49NZ;?ZOLT"&8'B((*X+0 MRNTVLE*^X89?GA=]Q0I:#6[TPZ[IJ2&:US M'HF+'G) B^).]"Y__BD8^V?W"#MLA!W>Q_U!9]Q/3:JR(>LR>BUICNWL(U=S\R2&\83N<@0AV;)5%FT*[4I8+G%NK^O M!^_%0')%]LR.B!GJ!"._!7C1_68A2X59]LMHN1ODK*N/@2G (VXC06 9[RBQ*2N0 M?EBK1:!0B23>,2Q7AQPQ(1\48DF5[:%2VANR8O=;]WRSY1\9^*1%R M$YO,\|:=@;=>;;NN#%):I^H%4352YE#&B-@!6>N@UNQE[15Z)\U*^QU605SB*NE\?S0@@/M?O6V)]=X_8[VTE8AB7H=!3-L;A# M!T,PD$CSDG*)EZC.SK\Y+ JCW4J2;LW@^;)RU2:(+$7/D4EH<)26-NA(V,J$N:JV@=IP>*83&\55 M)$0(#]H(%&MP-((:+?D+\LL); FXZYLKKK?2FPP94:BAH 17)ZYN9FS]CSOV M7:?$K%M6VJ @[G"YBNP3LF5>8GOT5987$NPH;V16$])[E IACNLP^8;S1/*-BA?I74<&NB=%43X.TFG[O)W+K@ MA=[,ZOU5@BQ$ MD$$M06D0;9:)H:6PD*A#POU#=)X8-(.@J&_4$=J5;"(PCM MM[':EH1D[5S45K6VICVR0CY8!04K^<53;8M;5IE1L4T:YK6$0M";X1IJ>9PO%X.1I-7G6LL"$8C]A9"Y:DEI3BU;3!!1SQ& M4*KWF>&9PMYF]3Q\>=|\J8JA0B5;D$>^]I_?UBL:MFG J4J_MXRD(A)[I(^CKR6#07DW!8S)ZMJC^M9/5$T@[?I#"K7HC MYH*Z?#UT&/Z-9JX,O7'D3<;/;:: ^ATFTTEH2^FV&1*_$]_S)RT'BO!)L!'A MXU-OXD^>S0@SM'*6,-PUPL +IT'KA&K_M||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lV&3V[3@8JK& M@6)!(((UV7]3UC5JNLS5A-RSTN(!H@^>@7VIMWL)62EG37!@LZAO^':I1GLG ML"8;'-:#B>G;FZAJ"LW6_I*"/[1 =;L:M:!$OE0J9O+6@EJM)=%@H5KL'-2 M$R> -CVO[F(TJ$A7_@TR(CP8 LEU"%H-RH]4-;5FX75.1<"]PE)(UG5\% M)YFH>T@H#1VPU^UC^GO#K[X&QXJ>:KHBK7X_W&(S4[2L 72'0%27-/9*-M M("#3=-)9'7#4O0K@,^IF! 3HKW&9NE_9BR"=] RZKGD>!U=Q.27<* MZV[EUF_K\T7[BIO,]O=B'X#8HOITN&;L'JY9TL7>JK%4Y M_5P(#O]$ ^#[3(${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lO X,Y ;:Q7B3B^0:ZBTJK;Z/,N:VO]0[GA=^&[0Y2CB,*!UMP:>.,0%E9<+G8TX4> M+=;<472A7]2(UV22ZG\(#ESY+=VU!.8M5 LM!^#'WO0E'LP,-35;\9KN2R]: MO=8C8R'LDIY276CFPWMC,]N\UMZ'1\K=]O#4^Q.W2WSL46(!1_O=R;@3E%(/ MO"GIR7)NO#<%?:X$].$6-\#ZPAA?#_""Y@W[[A]02P,$% @SX,668T\ MQQ$Q!P -1D !D !X;"]W;W)K&ULQ5E9<]LV M$/XK&-73D6=0B00OT;$]8^=HT^F1J=/V&2(A$PT), #HH[^^" 0%3&JG*-]ML40(^^WQ[2ZX\F]5.ITP9A!#U4I],6L,*8^6RYU5K*'ZH6LF8!?-E)5U,"C MNEWJ6C&:,Z&J7!+/BY<5Y6)V>>[6WJC+<]F8D@OV1B'=5!55C]>LE/<7,W_6M+_S&;PMC%Y:7YS6]93?,_%Z_4?"T'%!R7C&AN11(L@[LJZLI7QG'U[G%S//&L1*EAF+0.'CCCUG96F!P(SW'>9L4&D%O]]['%?. M=_!E335[+LL_>6Z*B]EJAG*VH4UI?I/W/[#.G\CB9;+4[B^Z[_9Z,Y0UVLBJ M$P8+*B[;3_K0Q>$8 =()$&=WJ\A9^8(:>GFNY#U2=C>@V2 ,52<-QG%A2;DQ M"G[E(&D!<3Y?&C#+@B^SSH3KU@3R$1-\@GZ6PA0:O10YRW(T:RP"Z;;9IR1!NN,S#QD5&E$;.IB""!V}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

^UZW)LU\JBEU9VKWHN7RH'KM88U\;(-2ALKN@L V>X&UDS!Z_\-NK;4Y'7"ZO.?%.U2Z\%\]EU4 M&UQKF'I>[-]A-MRP\? $[\YX'!-#)L-I)U!$X^&B:6B560F#($@ CJ<1[-X# MJ/X/_ 7 3<=+0$!Y58+[PY!OAP]= D>].WH!>NW^1-#F@TSRU_6VM?W9\&PO=V]R M;W-H965TD^;ZH=.O(@$!N_N8A\L@:LU%T]R MR9@B+W75R.O)4JG5Y6PF\R6KJ73XBC7PSYR+FBIHBL5.K@2CA9Y45S/?=>-9 M3P&MV2"E*&O6R)(W1+#Y]>2==WD;XG@l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l,*ARW8]*$?G0!B&F8L17^ ^H 86#.G)6]!8\ZL+QX M_D3X2FMF+TSDI00_X%RI_]*PH4. EP"?G)<@0BT%;O=+.K;64LH6UJLUI@/LD MA@0DW_5.RL%!X%.R@@ 8_X_2D3C+:)?&&6@M9*>O2,>,K!DH'_%W'MYR8>87BM>R+E2AS'%#S@B&Q*8-]SBO8"[1OP8JZP]%"")O\Z^ M]_.?C I#0 3H@VGZV!V#=&(W KOA#XT/Y7-9, C5IF15,72[3NB1-_(0OWP M$WC95Z,T?G/A.[&MN()%(,GY!NR7/PSSC]4 T^0 M+UN)NRLRYW4-VG1Z.!H3ZTTT*G3*6F[^"HPFYW"U,I/7M,]FY!R !;F$^X.R MM5;E? #;97*72@:>.!S#+5R?G0<8#,64;,4&3 1JP[2"C&N%2>.MZ.L,H@3ZM:CT8+$!D0V*=P"9'<'UHAH&\@%3]#(B;#N/,&^F/2#9ZQVS M_-R0$[([4&;D#W]I[! M>H#]=&C_V"@\6U"9'QTQ^-=8?0YF]UUW'=4/'5_TDNl:[Z%,$A)3)A=::/G MA]YIO6#[UGE=5A5&>ASP=UP&NZG_O9^_M I7;:'Y7&VM"H]XX32-TV'L&0D# MQXN'lE^ZO<>:!ID[']^ZWC1T/OH=DX8=AX%V6A(FCANM.=:&.5/P\@=OP6! M$WNO@>L3+YCZ<6;!C3S'=_?@^M,@&B5F0,;>(;2>EUIH(R?+#]'UIE%BC?,S M)TQ2@S9 M)FU8YV1V'6B>"] HY/=>+0ER1S+4AOUU(NC$4_F,FE\V,M^.N.WE M('P-[!IX:++MY3ATHL!])V$"^U#@N+T^^EBQO6A=DF2:9./>%<2VAW<0'Y(0 M7))T&H=C[$+8"O?]=T)"B!)\=XQ7%#B1M9L&&>RMON/MR?S>3]QPUCVIT8Z0MMJOAW7JO@"T&HC.O)6Z!AL/1*5-=ANIT6%-)SOP$2IDI/#.(DOD3WY-T"K6R MQ T'*HQJ8S8]O14(*P>.W-/.A@7T&OU8@IYY+BQ!TK$; ($5Z8]-@\?-8,$, M?<=P'7;(-T"*4AO"61@[0TZBU/lV0/A%35H @*]OA$---U=_V0VWFTT=AE@ M=/6]JPX4*3TSP]8*7W$%3]P#!:>KRA.#ED6^%ZU MD(T?6;#U0E+YXY8[!I/42:/ %L>XF-(',R[Y 3(M@ATP%!8"$ YH'B MY-L1A"2(+ 0)L.T8EMBQ2HAC/"9&EN@]?[4$)9TZLZG l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

H@T[$VXHZ0,:W.WOX[@/.!H20#^0 3UXG'6\O&!NHAKE*P"-/%_"KX^^IL M'OP%*/ R;@C^4[AQR%P/]IU(<#Z-+T?L"\+TF.:^O(Q;G>GTO*O.!^]: MB]BJD]D%MO40E:TC.CMDQ%O'_]EL/I#9?@F*+3U(UU_#35?W9]:O9P'|J M1,6'6_?!>"PYP=+[56%3M*UND\3HYX<8D2 !ZK =N>F>S1\ M':,7_"7L?_!92'',*9W/9Y]/|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
"K2H>V2RI&Q675BKH[/)3\EC03)5[XR933OP5/$DX9(A]4/GRKM5*EE& MS:$'OI>@WXB1BZ4<6E]30JD*!:ZM6&.,OJ]^R86EH'7 2>;D);9+:03"5],4
M6$U<2Q, LCY7/\6B,]FV3F\:UMLPE8])^3U%Z>Y5YO*Q UMV9SAR= (/0QCG M(H2_]H@P=B81J]!L"LS>(\V'&MNI<*]YJ!'5-N1IXA+?FM0S_+V[.%!WM!I3 MNZG\5%>(32*C-
KWYGNPQ0TIZZ.?X$/FZ@QS.8+=,_'"W2_@:5"]9A; M3JKBG-(Q#/<95;E'.QDO[^CK,<_'*RI_#Z+R+] "-IG:(3?#6XJ]Q:< #E[@ M\%NUC:&XL\%4V4B<.:CYI?S"N@B=3\/+8\-6!E?
O*TKHMN MG5ZN.%@TON5ASB8\Q6;@\.R(+AGV] M.2V"^Q_"G0K*1D3;7F%P4/B=#/F7BJ ME4+)?3F6IKR3%H%T"F-C_6;A]<>NJS_0X.VQ("A12Z?L:N:ACZI9S0Y1QIKW!J_R*,-
';70_#C3NSYE\S76^[>9Z26I<%, MT!B5*S)'7SR9O*#\Q06Y7.*)]TY=5BI+(?LU9H-#A'SB25+1"CI<3,=^3>53 MG'U8N81P\4(B# _UPA=8=[&^NB6+G_#&OCI]RB\PR):-
E)%7A^XSFUM5HDY MQE%HO[PH_NZ/1=RV5WF=)Y ;($>F4D K;W(]/>-C,Y!VW M? ^>6B+],/4\]4ER\#&0T'^UK880+_=&CI(*,=]" >;P95/"BB,Q5HQ ,PQI MJ-
T_8WPTZ1%\\0:.U2HP-WE^IEQ]7GNA@&@$T(8^%RY8]/W1%\: &4Z&29B8 M).\CHPW(HK':NHVF6G"OU"[I:E-_[[<91;LSR'C)Q35<31IKPQ#RD/3L,/@QNJUI3)ZFI M7T
DGRAO>#M]/O&?!J+>*9/<$<+4%MS, 39E"!\XCF3^LKQ:A'/0T1F'F[8! M5Y"%L. DU=/SA8FX9AT23X>,50XSGX8%]WRU/K[\D6X*X2B59://O2QX"I$;KMYY33;+ M)D09;>'"/%2|-)
<9!ES="K[,Z0'ZCMI5V=,^,L? M"Z84)Y$W'AJ*6]K?4$F"NMX%ASO?[RAHMMU* WKI]S3()^!/:ZP#>:I6IVUP M++5_+*H.J_1PTC(OU,A$F/LU*S;-/-
%XNEW'.3!"I6=^I;=AHO.O9<.BX8> MV%+5-1^7XIK'-=WTZ>Q;:K8T&@H6X:W,C5T01-K!Z3#9%H?ZH3MS,%C* V3F M>*]?
<64U/WJW1>1]3,KJK@#WI%.KSF^3$9/XYIT:'#H;3QT$B/5@:NU&/IT^ MQV0)FFK*)^2-L.CQ;;>=[BO7#-1G9\+[XF MVMXXKFVM'U-9%&A/] :##L0>L_9. AANQ=R<_]X:?
&!+TSF#D(_848K6PI' M+A63'LA_!<6[:%V5+J;E'R #&TWO+/9WDH.:";_!.N@=116?T@PVG'/M'N/1)5+1] M0 N\#'2#]YR;_2ER @:OTQO*
(GI[TK'@:@#'TT%3P^9$]) "0$:P0#AMV;%\P5 MU(."OY8?IY8?ACCKS9%M-C/@+@Y$_C/CF>MF5^8]U8L^V'EJU+OB*U-HJ//(C M%JG4MO SCS'M;;Q@)Z!W[+:-
;E@/5WL^C6\[Y]H2C3:P0@$5&Y;QQB;M[ZBK M\+X3S!%;?S% M;$&>#TV$]C$-ONB(=UT=\]:+J/$[>SEX$(K17542]3Q*7UOL:!(&;>Q6]HF-P@@"Y<"B?MH- '!8[>
C!J/N:5I4_6;'F$G_/'!]5U@ZC3W: MX1M92V. J3[(A>++EE&O"[9-EX>Z'--1YOGR1#0 MA4V;VQLNF 6.--TTY.Z%-?KQX)P9
MM,@KE&O2,IJ;_MD=Z>17G;CAVN8C0V%BM8X=)AG<)125WZ/9XS$Y#]?<28T5 M5/":=X*V 5BV".IHN\T,PP1$C%D]G5:Z4GX\I9T%7/?E6P>-!K?6!H=E^.)8
M=%)!_I>UX+KY5%K9?PD&4.QUD *Z-N Q))GC!RGH4$J#/S7WYD:&9]I+[0VL MH$YI;\Y\4E2G&K1SLMDO:X"$O]BL3T>#Y>>:V<#@@%I %N_T/BBZ:!=>8]Y3 M>"4R3L('>[]-
IYYT!H+/\3SVO4Q:8D2*C\[);R+-G1NQ'BK4/K<6MQ9EU=@# M?="MRYZRFP[2U5+S"69^L,CMEFZW$W,H=>>K<3+M[&%;=C[*G SN\V M.
>P/D*01@G&6/C*Y&Z$OJ2MX$%;;^B6QDS]4TIE>2T:\>(Y4+R6KT#?:G:8 MOWR$AM;]B@%WO!3TVIBRQA?@.=8DM']@IZ@&B;P7_P]02P,$% @ SX,663[; MNY$[!P]" !D
!X;"]W;W)K&UL[5IM;]LV M$/XKA%<4+]#&$O7J-@F0M-G6 >NRIMNPCXQ$V]PDTB6I)AGVXW>D'%FV:-E) M,Z #]B4R1?+>[[DCE>,;(?]4"THUNJU*KDY&"ZV7KR83E2]H1=216%
(.,S,A M*Z)A*.<3M924%'9354ZP[R>3BC ^.CVV[R[EZ;&H=2EA-&FI%*RB7#'!D:2SD]%9\.H\",T& MN^)71F]4YS,]\OV)SSF8L)URC MLSP7-
=>,S]&E*%Q.J$+CC^2ZI.K%\42#4(;T)%\)<-X(@'<($&#TH^!ZH= % M+VBQ26 "VK0JX7N5SO$@Q1]]?H1"WT/8Q]$ O; U46CIA3OHO1<:-&P4=.G7
M[(I2EH238M@)AYB/"_KPBS6L)U52\(D MY*XV%5 L02,@5BTVT2M0&[UXA5Z_DV&_?#UP<_? M*9%-./:F(+2H#:WM"1-J(*>R"AL%53OU#(5>&$W1%2 /B.JA.>54DM*:E120
MTPQ,2PPXH7'PHD<:V"5AACX*#7LZ1$-OFJ5[E3$4/QSJ39!?H>L[I.C<.H^ M,Y[0L$_UM ZBUD&M0ZP#=FVX])-EN*.T-W%F0K/5?WOVW488/U1*13^#FWG> MYVH\
("'P97_&D2]!14TD7$])7#(%> O,-F,MR@+.^/8"T^ ,\:!-TVZ"\" M<9]@MXS,,<0 RQO_XYR49G!M@2!Y_O]T,,[/!#@OG$"#XPE45?WQ NS8- XFXEFX+%)"(MVIB]L6AKV%WC!
MX!6@(@=47,,7Q!&_LV*FK\&T>2YKNI6$T%J4)E@\=+-@^0(QM<)4 XI,+X#6 M3S9D\EI*YE(]>L9)JM&0'AAE6'K*MP=%J,ZE,Y5; &NQN0IZHP['>HH.+ ME=J 9!!;5!0M",#9-
:5\;9T6T+FMJ%K806/"KP5;OA+(7E'C*1-,K5L4U%W@\:DF$!O2*.!$UJA2_XR]QP M),4?\52ULD#RASG8/BNKHU1>J0XU(G
M$;T09YUQ%N'."#K!U%T,_BO6V%6R9TS"F7.S&H4/M,N>&F-:=1=ZIZF[\OA^ MO GIO373V$7.4:_&06)H'0+;RH';74/TL7GGFP$\R5H\R1Z*TFU4M/YV8"X+05>OI% #W]%V0+ _/4]I?
T$+V'IB:WAZ)QU*#Q,_\(HXH!- E^M'VQ MTD1D]S*L::8@E_E]9V5R/~>PZ(GO5G:>5];PXL*0&5,YP(M5N@<<29JB;[<7 MY,-HD2: "KU-0_WD.,B>*,>S:4_>:)^\<$XP'O;NA*
[#F,8!X\7.G+ $# 9 MRI/.?7XP&-.[+G&BXB\"G-7V)Q9O?>T?#-[N&M7G)UHR26U'12(.,] MJQ3_]YB[>\PDFG9&:>QO@&4X=1]2_RNV>$B'V>TAD[!KE3A*-JP29/'PM4K1
MY,"]#FW0WGNDC_IKS;L]_6R<31V=9FPN(ES5(0KW=+.QJW'%H8LUHXZPPD\'XXH"$IE/Y K9;IS-=^3V;?L9_JSY^+Q>WGS#_Q& C($2 M)9W!5O\HC4=(-
I_%FX$62_LI^EIH+2K[&PO=V]R:W-H965TLO-#-U[ITFV60!:B4:]$U[D;O?I'[?&*/5^C& M]D^T&VQ9'*"BLTZW>V=@T-9J>(N'_7^8.63D&0>Z=Z]!R%0S_(GX<1J8?0. M&6\-:'[1I]I[
[E;^4VY=0:^UN#G5C?R7]I.HAM9Z$K5_9]Z^UG<-=*^6X0. M(GB[L-BCG0]H]!FTB*(KK=S&HDM5RO(8(1](S]ZX'=.7T3\M5,GB!&,**\ M!3PVYLMZ//8,WB?MI$5#@D_E-
WCSI[U]AYS:K2CD,H 6L-+!HZ7=V-'F-81O:T594D$8=]2-'EU>491O*A:+JR5M4!\S=8 ME[J=&/((3-<\SCB1_/<,)2='9]=C&G\@&F M"B<-
NMC42DR=PG!.^%R,\HE'FD#%Y<^X0@OR9 H;10QG27;4RIQE4(;6^2/W MJS9-.7Z%,N;Y9,Q2$*>,H LI:-\GZ @KCD^<'^Z+IZZ0<':UM])4_0!C4:$[MY89;?M2..]+9,!I,YL.
=25,52N+&KD&5W*2PDABAJ%E$)S>]H/"G78P=O3+ M#&ULS5EK<]LV%OTKID6?H MB_3?]>V9V&U:[Z2[F3C=S'Z$24C"E ^5 *UX?_T>@!(QR13C)&UGOX@""-SW M/?<"O-
C6S>]RS;DBG\JBDI>SM5*;5XN%S-:\9//)EO>$5WBSKIF0*PV:UD)N& ML]QL*HL%==UH43)1S:XNS-R[YNJB;E4A*OZN(;(M2]8\7O.BWE[.O-E^XKU8 MK96>6%Q=;-
B*WW'UV^9=@]&BIY*+DE=2U!5I^;)R]M[=>V9#6;%OP??2NL_MT:KG";7\Y<+1$O>*8T8;' [_A1:$I08X_=D1G/4^]T?Z_I_[&*]E M[IGD-W7Q4>1]?3E+9B3G2]86ZGV]_87O%
HUO:PNI/DEVVYM3&H:G9#.%%I MK]RI!F\%][FKNW:S*3C,K%A!KEG!]HR3.Q,/K,K)#9-K\@:N(I=5%P+:E/_/ M[+[@\NQBH2"")K3(=NRN.W;T!#N/DE_K2]TE^;G*>7Y(8
'9>P7H7H%K.DGQ M'VWUDOBN0ZA+@PEZ?F\0W]#S3]#[9ZVX))V"8_IUNX/QW3J'7LD-R_CE#$DB M>?/ 9U???^=%[@\3L@6]:,$4]:L[Y&3>%IS42R*]!SBM;L2XF-.$;H?-)*N1
M8E)IFG-1$;6N6PG7RI-7Y/OO$NKZ/WSS$S[BQD?'+]3/|(__U:3?LRW20?%& ML$+VLR](G#I^'%L32>"$H4?>B$H@6W*RJNML=H[I%%;^D7HQ%YB4@Q__20F0[.(BA99 M 0A0:
[CB7VK-&*DY$]_A&OX8$IC.WP3GO$/4Q@"(P@WW"!?\>B %A%*LT(N M\XQ)!6:]J)O>O?]CE]7 M0O3PA\&OA.$OG6&-'E G19AHCBS;'V3R3R M0B<-DB$G4M=QO93V,]'?
CP1)/3)N>P?&EX,, MH1LC*0:U@S!U4@3BZRQKR[8PX99SP&HFNC*DB;&R;I3X;S>QWSFG881LC\ZL M&=\'<7IV4I3#S*:A!Q<$][@R-'+0Z$\$=|<$=?0&**U:M!(K-+L_'XGJ:W&U/
M0NZQ8LL;G:8(\$"%A-/#1>;NL"Q1RQ,]?%NC'S\)D7[8%>2N6_//),'_DK)%G MA\EA#;Z^1AP_?^1 0T0!L(]GZZHNZM4C2!2'3A3;(1'YD>-[*OG0 ML)Q7K(3!*7;1(60]A$T8><,XB)!.
(;DQC1RPM>&%"56Y%AM)8LTSLI+/(?1UDMNYX?C!8! L@^A=N1!6.(2'.GG40:\^#+6L$:RQ1*%2_+Q MDW9:OGVX M'^;N\5.CBIL,+@FAMG;)K0&Q3&8;M18DZT-).1=2D3@R,
M_E#K1OJ)$:=E?/%$2LSX@1,%@_,@RP3VQ#WVQ, &GFP-&;GI+#+6-(\;&>"M MMC+%4,O[+'2:9GBS8[+O'9]ZI\LR]/E^$!!G&N^$E6E]=SW1Z<=JV>0B507 M.I0C*0P^]*^CR
G<(<4T*&&X:PWS?+?:CM34:AU"4U%_X45^CI;O7#)8V,Z@ M.7T:X7,/Z$+]\=#7(?_:3FG^:8,S^]#@')UW$@96)J,E1@]P!A!L&EYECT0U
MK)+%."+,8S\>$2E*4'X09KIK#.07)QK5)QT#;4E]AV: MQGIN.(-%ON/YB9X;^DNT>+H_Q-S0.^]:B=R#O@WO3B1]Q4GP*O9W(/O$_Q/> M37OOIE^,CZ>A2Q_LMJ(HQIPYR6?\GN!F
.0]97+_2"1?F6IDFGYXR"C_-QQ; M3K9/@]T]-.XBZPXBI]:ATU83P&B)X[W!;,(P]_.3R, M6Y)3?2\0'^EBGW:@2XP6PH_'=3D6>A !0&1^U)S@[PBG;D/[1E4L8I [UI#4I#!E9AV"M[
0V>.YP M4Z*ZZKM>&EW[?9T5M_=2[IJY7CIX.D*'% F0.G64I$@4,CNZ.CB;EV MF0HZZX+>>W;02?NV/M-W\TMI-R^&N_G14/P,@\\2)5OV38W"US[_@V-9]Z'@ M1!R;^#7EXK;*<,
FBGU"H=DP8=^F12$ W@:()'$":I<1$/8##T00/HCB0P)H MAT,+Z!/'CZP+,L_&]3&'+ZR/,R5O5N83E,YY-!'==YI^MO_,];K[N#,L[[Z1 M_F,^]=S72M6E^;OF+.>-7H#WRQHE>3?0
M#/J/?U?_ U!+ P04 " #/@Q99?AJ"$C@% L$0 &0 'AL+W=OX6E]Y*W 7PP6:O!.C"4W0GPW@T_Y\<@UA(!#I@T"Q<C=$1RF-&&ZZ]B\3MT M]D0&+Q-
&>GIZDOUHF&+&0X]\N:8W'-3^T40CM!&8 M9!W,:0OC/P+C^>2+]'2AR'F50[X.,$%./3%_2>S4WXGX1U.-2> ZQ'?]< = > MT!L:6+SP$;S/347K0D@=UY 5E>!BSD"1JY/Q-
FMW8IE$.50US>!XA)F@0-[" M:/KZE1>[[W8P#7NFH44/F%Z(302:T.QC5OX"[A%/;=HIQ>OL"CD#0F,WWVLGUFRZWE#0:M(3UO/7QN,83DQEZC8CXT M=6XMF;&*?TJ]=W@
MW7_VO)3 &588+,W+ -FRJ3=M7ZJ.[B4^M%Y9@UOWREDC M)0(L0]')/-^)L)PL$?;(FR!*]@=C%/"BB)PCJ;JTJA@*@;&0A(MJ_E:#+)=P MGA,F[I.FMU*?*DVK.
<.TZ[1?'I/W<(MMKS8;?5AT8M<)W*=I=6+7DN90T1(5 M0^?@&7]MU)EM'N@4C*OUO2I8;3SB/P.BE?HH1+Y@G!//Q:#$FVJ^XQZL9CTW M=.((^0MM@OA@Q[S4=PY"?
\M221"L1BEB)-%/V]62!UF=(-OX28U6ZCW,0!K: MK,K0BT33.U ,J?"8%#E)G&YQ!9H_ $D3GUR WG #[M_$==QDA6!X>.*MI?#X MP$G;87UCI_>W%O>]+-
[9&RZP6&=X',3$S[9UEIW:_[+/ M)CVWY$5G@.07<$M[;NG_[RPFZ_9:8IR V$:10T2RR'N8RY4U]Z9(C>-0C6< MP'SG36X3GYPR\=:>%N$W13*D+SAKNSUZ%8_]5KT#-.;A'L%9
'F,%#74MS9#./W9\>AWC"]RV262Z=S .EA..6;$&>X7A]^.? M5AF&.?"@%;?%#@W,3/58)2"6BC!7O?M&Y(;]>JN6IKD_;J2!K:;V29(3!=< M?7F\R2U#C.:%J-
YB":]!MR<8BKL5+/.-3C1L>OI3#$:VT.)Z(6^/^HEE*>=BS,[=ZLN MSF1N!$_9K2(Z3Q*JEA^8D(OS3M D][RV=$0-I._B+*,S=L?,[IFM@E&0@A+S MA*6:RY0H-CWO7
;O/HQQO]WP!V<+77LG2,E$RN\XN(G/.SXBQ 2+#$*@\+AG M5TP(! 1H_%G [%17XL'Z>PG]VM(.M$RH9E=2_(O'9G[>.>F0F$UI+LQ7N?B5 M%?
0,$5XDA;;_9%'LI3LDRK6127$8,$AXZI[TH>##/@?"XD!H\78762P_4L0 MSI1<$(6[1[ ]^6%+M:4".IRB4.Z-@E<,Y:=+_1 MB6#Z*QGX!=.#YI/HY6\TQF-V'D'S$ S M=<\Z%$__%
(S\]RVX#2K5*\72& M:LT:.=&.Z[R>:-.87T([M((`GC\.6,X%X?N&F8],\7N*45(#%IK/4L#)R@%\T@R%RU-M5.YN/ (MU',R M!?.WZW#HGV;.%$'#A!VE>9?WG/C#-
=KK.#2M/1,VM%D:I]Y)T*P2=;SVV^UL M?<=%((# &YWZ;1+RO5%PTB*BUWI^JGGA?<\\54PI>(.5XCI9%:(2,ITY91<-
MB!R0T/.'00N;=N]P$F)"AS0WSK6_# FO&3,@5C3KV),&5M>.Z;\8&SYZ& MTQ0,S"@*N3C1F#4Y ^B&/Q9>PKXW[!^V3>P38'[(=P@?
^3.G"HR#,*QCR1W+#$LF,"Y*T;YG=UW))*/IDF@IP'\(82LW4#7V M0-:-KQ;U9CA#)A(JGVD.!8NK>1!E)FRY4[DJO.?842DU0'75#I9,]8IHBIAH M!G?N?^4"'!XY"(?'/DFX$+9% HL'<-
]X-;.!B@>%E\Z8;:6(Y7%+P3NL"M[A MW@5O758TD3DZ!T<;D>"H#>"WD5 T%:VM]S67]PV5++&KB(&9LS;,"OE;)1V_ MU[LPM15]P=;7*%"W@ETU<5-
#JES\6&1N*/.UXLI&OVNI%E1!^#!@$$B77M!, M6_NK_,RZ!Z_;ZIIUX^A*2:V/7)D0+2TP:WKEKB]-*>(F?<'0;Z2[[B@0P9N4 M?*9+I"-8MU<
;4,^3XTD%%L3VS1N9+1T,U!A+P(,.IC&+3&;&-LCC"A(/17 MI@7*DDID+RA0!AXFXAD5SK#9=.H,RKJE4JWL|0NX](N\=VX'2 BMS|+KTQQ< MC=WDO)K5MK7-PV-'O(KF#>
[]Y]HRA]@ D(@0Q<7,<"G-D>B!I4M?8+#BQ)C@UU%IG,32,\[ZFK)">OID;|- MWC]. D)"1M^);6=!)KO@6I.IQK26=*]^O3YTZ& ?#?"&[*U@;I,C@NV;U19 MQ=#T*4]I!KD?L#F?
0.CG5"UQ#6XS?S$%273L9",G_RED4]SAD(0(!'AF2AI8 MM?/;]^S Z"AFJ4RXHUMF1=(!],\H.LLB9.H2@LZD644UI%U[K@$((IOG(T <7 M$!VVVP4GI # /9DK%#4DGPEDP,8(6SRX),
CBSD' UF >$#P<0[E@R6H%*-. M*\(W8$^6]./U4,DH0"IOBJTN84C=\N8>]"L@RA3E&/2$EM'56P=[1U;@5_(MKI56(B:6Z:X!" J-V1-H$W"KJ73'7384*LBE7;I5*9_4V[":0G,
[NBC#5T?3 M62]"PS)0"AY;U;RNNM1W!B8<;#0[A&T63(!-).YO#I<>UM.D@87O?!9F658) M,;MX^SYU]O]_R'4QN!6OK)(SE+^E_6$Y#**\B07EGI??]'Y*C;'?^" 6GMD
M$]R_(6]V__/LGXC44HN-/,-&N*O-6O"Y6; CF]FN3(+0&_7KC;INX/4'_J%] M._6"$-*+IESE^5%NRIAV[1UX?C!L7-VL65?5<0/M(V\T&#?07I\I>/#:.OQ, MNE\XB#/(N$DCF6SGF4]]
[FS!?SN5KSI;X-7J1.UI8>4,&'U!=.7C7M[Z7LQ: MNX'O]8/QFH8.O&$X0GL=>?WABO ;F_]IS"PR\&[LE:SX):V^V_?"P<VQ2:[MW\F*70ZA&_2!F8WL72H@ G;NERO87TF,?9
M9A@DS]VLVH14,*_)3_1J7T E3,WL=UX::(.JPGT,5W$]DBS[%<71,FEA,Ol-8#=W2>:3/0F8X7>$[NB?YS<2OAK5.A)#0G7%'!
MD23IQ+L*+Z\'1MX*_$7)4M6>D=%D)L0W_)K,O$"0X@P$FN#@.'OD=P0Q@P0 MT/BGQ/2J+K.^@RPXK<":/:5)CJ;>",/)23%!=-W8OD+*?7I&[Q8
M,&5_T;*4#3P4%TJ+0#,P#'+*W3]^NUPRH*H7!!9WFXCR_)'K/%T+,4222,- M:.;!JFI7 SG*C5/NM819"NOT|'<"%BG4>L S1M39N*,!U$QUXA+@V@%$1P#" M"'T67&<*_<03DFP#=
(!-12E:4[J.&A%_*W@;=0,?14'4:\#K5BIV+5[W"-X7 MH4%#I^ A_=$JWN'5)BDNU0+'9.)!U"LB'XDW_?@A' 2?&KCU*FZ])O3I/219 M4C"'1(JT88ATAG69(O1?X*TS F'',()
()R+@FMEI*4)5/-0*((BF@G8J41HWA&&=6T7&BPES:V M";\ O2<0#:;?*^V0)K(W$KO2294Q69G!)0(@B+R#-E##FHVX4-FB/'4L<5VU' MTCGV7*3G-<>N9>_VYJJI[!%Z$>C_IM-
=5-(2<#1.[[O],N:YG1T!^$(_0@-&8G@1[!'Y)!X/>[HS<;\NM)):L%&; B M6#9%_ZC=>[M?]^ALIW3K^P8"O7;47;\TM)Q^U7+ZI[<<*"/'VTZ,5886F":V MY*P+!^4Q*Z#3N^I!4 [F+,"Z-
J#21O>;2G2H=(J9!M\X2/(49YC/79GC<*IK M #S4+)]5/Z%9_.^UKAJ B5Q$S*EK4S1M_6N]4V'_>[/!LU7:;GQC;+9<69Y)_8BTYRT03*'R@N5B[2/2DH3=)WG)6N)-/"
[W=",#JI1&.M!,L/8<#/6]?O#H1D;U<=Z0RNWR7QS5!D,$5A;$IQ" MJ]XTPY$?A6&9KO6S3>!?7/2 GH+3WE698I*4X6TTH1#E*9K%:=$SFWWQ<4LJW=7<*KT>H3QI6[N6_$W?
>/SUC.*>S+2 I+ M@_80.IETWQ3X^?":U%;A\S@A,BC0#,IP(NNN6+V:#ZL#/]#U!+ P04 M " #/@Q99U.KB;44% !B$P &0 'AL+W=O3RYE>]3S@$,N2NYT*>#W)C5\62BTQQ*IL=R
M!0+_+*0JF<&A6D[T2@'+:]*23SS'B28E*\1@=E+/O5>$$UD59@AXKXBNRI*I M^W/@\O9TX X>)CX4RIS8B7 \'4#%\]Y981]?%[S'&Q$ M6L+V]P/WGVK;T98YTW A^5]%90+3P71
,EBPBIL\O876-L36GZIY+I^DMOU M6F= TDH;6:Z)48.R$,V;W:W]< B!MR;P:KT;0;66;YAALQ,E;XFRJY&;_:A- MK:E1N4+8H%P9A7\+I#.SJVJUXH!>-
HR3MY^KPMP3)C)REJ9567%F("-_F!P4 MN9 EACVW\;@!E@_#Z_9G(,>G4P,ZF>E3-*U+N>-+MXC MNK@>>2>%R35Y*S+(=AE,T+"-==Z#=>?>7HZ_5F),?(<2S_&"/?S\C;?\FI__
M"+_?I0%-&@/[[&NH@WYJBZ]CO6(IG [0DQK4#0QF+U^XD?-ZCV[!1K=@'_?9 M%>(UJS@0N2!ISL02-2W$P8\S0:RSZ:]4OMMNOA*\809HXIY9:R#B9'DO)"O MKB'-
!9#Y/<&5*RDP5+?]"8:V7U M,Q9,O1EAA<'Z(0ZFKOV%("-R2W-1*04BO3^8R1M0Q0VS57$S=:V8T+P!\[%L M+H4VJK(E1).S[&^L6S@D QIZ45=@V$V1@$;Q]/FA M%-)IU%4H0
!TL>0ZF#E)#4*XPRY!0V?)$.MV[#^AY*S7/QL0 QKW5(5^^[@ M^]$>Y/E[D(M ,]*$)\!C\8>O\CN+K1]FCD]^Q(PX0F05\Y
MQ&H7VOPX&&"8H[X;=Z;Q#+I=2...&GKQUX"L1U.4& 98$-'8[LH4X0C?:# MR:-!T.\,PQNVR+V$&X]&\>1X'3;!WNW*=`OX6K<8-KBVFK"Y M;!S&JPP;&_N#U4+WM2RVCX:
[%LF1[V_:EOKO4>RT[K]@9"F$%*]2[(F5Y-AY M+5$#]AF&:O=VQ)[L4"Z#G2(&,29G.R8)C=XH-Y[+N-X^\<4C* G64@I*C8.QL M1[6=K?_],;&C?5?
Y,>GKD">M>X\2U+*^W4$%;6";*Y#-[.8"Z:RY-]DN;VZ? MWC&UM T9AP62.N,X'!#5W.@T R-7]2W*7!HCR_HS!Y:!L@OP_T)*\S"P C;7 M:K-_ 5!+ P04 " #/@Q99U<8%M@H$ 7#0 &0
'AL+W=O%,P*TBNJDJJOZZ'B[7,R=PMHJO;%4:J_#FTYJNX L;_6M0LGK40I6@=!, M"J)0.7/>!I?7L9W?3OB=P5H/^L1ZLI#RP0H?BYGC6T+ (3<6@6+S".: :K7/\"&W\2BV+
MKMLO67=S4YR<-]K(:F.,#"HFNI8^;?9A8##V7S (-P9AR[M;&7YGAHZGRJY M)LK.1C3;:5UMK9$<$_90[HS"489V9GY#E6!BIY&+5[T MX7:4"3SL%C_G76\7%KFR"7NJ8YS!$,
WJ$9SYFU=!ZE^= MX!;WW.)3Z/,[3+BBX4#DDI@22$YYWG#:!B^],/983]@H2,%X8Z @L#V[&L]. MV[,[YM+I1>]QH:7DF)N(1(S=&)MK-FGT/V5!SIA 6]EHG*== D\YU&8P3BO9
M"*-'E^3-JW'H1U?_^?8/]+(+:H(A"6U(;L=L:-I/9#\AN7F^'W9F$%QUF_?S MG/Z"=_9V!UW"1,Z;PIZBD"+'-%1X%9DP@!&]^GM7L@';N!GV O'"=N'(>V MET:N/YF03Z U$0-H\A+
4=704XNBT4](_($0A,&H!WVDC&^9HJ;"/&E/O92\ *4/*/M9>$ Y MF.Q3#MQ)Y)-O[7,"Q3E]!(6O8X>I";ZKVF!:6=)[8;7;WB1S,W^\)P^W/$\A2 M=YS%WXW3(?
$+/]L3Q\&>F$4_+::WI0EVFXOGY3SZ\;S8/R&;'P/-OY4GY\\T MPV/IT8SL,0!<[&^Q@^SI]?_GT,LYI-Z&(E;5!)9+?#'M XD56_Y 9&T?3-T^ ME/:P%VU?] M;[MB=S>]^V7X3-6*X2YS6**I?
Y$E#E%=&=X)1M9MZ;N0!@OIMEOBGPLH.P" MEQ+KP8U@%^C_A>9_ U!+ P04 " #/@Q99,"_&3/(% "U%0 &0 'AL M+W=OGXR&*C13!1]4AO/7&=36?:3 R&IW,^ M%3=^?YE?
21@-6BWCK!"ERJH223$YZYV3DXO(R-<"'7S.Q5$X?&4]NJ^K.#*Z, MSW]^ 21R,=)& X?F7ER*/#>* ,;WE:](L=/MK[>]KW\&76Z[$995_R\9Z
M=M9+>F@L)GR1Z^MJ^;-8^1,:?:,J5_4O6JYD_1X:+92NBM5B0%!D9=/RAU4< M#EE 5PMHC;LQ5*-\RS4?GLIJB:21!FVF4[M:KP9P66DVY49+^)K!.CV\F7$I MCHU?8W19%;#7BC?
A*L?HDYX)B2Y$*2:91ECHF.+(-9P#7<%]>P3_U>MVO9&W M_=CIMTYWG*2P/4EA]TEJ.'KO09*2EU-A^M[J('D-P4*8=AV='UAS#F2K!BU@ MSR6"6[=B'LA]4C/3'CKL""Q>2[,.?
#0",YOIK0RZ,V"295#[IG*>K7SBC8 M&_A0+13<;_7ZY-F(]+[V6YTC /#Y="K%%,Z%G7HJ^INBN_7WP87US/F]D) G MV_&'4LL,!WME5BW-XW7?7!|?7N0;VFSD6NG
MKF0VLHO[19;GAD2LP*_91&P=Y>=N/RVTT@#,[#37&Z>"(!)X292TLB]1P#") MVO%/<*#--A"/I7X[2ZB/2=@.H0Z8B,R(]4.66D>2&/OA5FA!BGI!Z%LYQG!$

M#H%+6>C5(';D@P|;?@4H^%5F,*Y$)VH24D<="&.$UWH25>&#MR-,5!<@A: M9M"F#@._1)&/PVAK@VR0_S 4L@5%),MG<_4=N2D():RKHK$=9 M0@T-A)BX=] I/4EL3N/Z#I#
J82@.HBH6RFY'XD?& +IK"Z9;XS'(0X#:]RW M5Q-*K32RMBES2*BF)\CTP!MJ7VN$?4$L#!!0 (,^#%EEFJ7Q<-P, $8(9 M>&PO=V]R:W-H965TC9,?
UDC2XK_L02Z+X/"1%B*Q*H>=>;LSF/ SU,L>*ZS.Y04$[*ZDJ;FBIUJ'>*.29 U5ER*)H%%:\ M$-YBYF0W:C&3M2D+@3<*=%U57#U=8BFW T/. 5EJ4E(C=^MIQ>9]
("^ _=^S\N=HKEGFN\DN6W(C/YW)MXD.&*UZ7Y M++?OL(UG:/F6LM3N"]M&=YAXL*RUD54+)@^]0C0C?VS/H0>81"\ 6 M@SN_& MD//R+3=\,5-R"\IJ$YN=N%
=FIPKA$W*K5&T6Q#.+/XS.2IX+Y:R0@C!OWZD M=&L<@'_'[TO4@UEHR(Q5#I MLI.,'VIQ!DD4 (M8>H(OZ8).'%_R M\G:5!#$^"Q^!IT>AQMG\FYWO ESCUZ M!QK5
WJ+UZ_B471QPK>T\RT]Q;ZXI6>7U26"7 'E!B@Q&RE0&&TET]6K:-+E M8YNL8S&&&Z37:BSNFBM!0@U<9'!%2@IS M^Y ?<'?5N**?AI4LJ2QH\!VEK#4!]. <7K^:L"BY^&/&
[\A5<]V!+BNZR[K; MLY?62\A+D870 !NG(#;3'V>G]!7X\,+!8,/):/";* Y8/-P?)=%T\,S4)FC?J21(MR.BA-(VC ^EXFI*_5,/!+Z76 Z'"68@'(G/! 8)-#KG3*9F<'(@K'@R
MVN?'GW5AGJ!"2GS6M[8/!T?!)#WB@1\'<9HTWW M[W(I\M^BR(6.__=&H=_0Q&*=-+Q\Z5WTHUJZ#:7JGM3!-F>^D79-\T_2&9_6FPW[D:ET(#26N"!]= MC8<>]*9K-0LC-
ZY3W$M#?<=-&ULU5EKD]NV%?TK&,7V:&=@B0!?H+V[,]Z'&W>:Q./=I.U'B(0D-GP%@%:[M^?6] "42E+CRIJUGTB\B+T@<7-S'N1?4^;:6OZJU$!H]ED6E+B9KK9MW\[E*
MUZ+D:E8WHH(GRUJ67(,H5W/52,$S.ZDLYM3SHGG)\VIR>6['/LO+\WJCB[P2 MGR52F[+D\NE*%/7V8D(F^X$O^6]MS<#\\KSA*W$G], -9PG2O$/)\E)4*]\K M),7R8O*!O+N*S?
OVA5]RL57./3([6=3UKT;XE%U,/*.0*$2]#0*'RX.X%D5A M@$"-WW:8DVY),]&lWZ-_M'N'O2RX$M=U\?<\T^N+'9N@3"SYIM!?ZNWW8K>?.MT."E=:'L+]JV!X;^!*4;I>MR-QDT*/,JO?
+'G1V<"?]K0N!;KGCT*AZ3U?%$*= MG<\U0)L7YND.YJ[%H<_ $(I^]"Nl5NBVRD0V!)B#3IUB=*_8%3V)^-=--4,^ MAQ'U;' "S^\VZEL_P4;'=M?.SL8GVU2XYUJ>"HN)A#
[2L@',;E\\QV)O/&'J8>Z<0@PC1BZ);+"LRB1DWIZ,%"'+'$&?%]AJ-P,.(1[+->UWNP>R/K MA]P2'] ?>A^84.G_,Q^UQ +[V>UEMPO8P_].S>N-E*+2QDZ] 9^'_R@R(7D! M'@C
Q93!39A@1CSC-P]I$$-WFFO1NQZSL(\+0G'LB!&.(O\XEB@.!VYH!2Y$ M@ -&'TVM08UT3/L^"F,"M(' QP@ P6M-DH_MR M%/ PB09]$A.'+5C[(%S6K ^F1PHPQ@X9(&)
1]3$IN\9)BR^ 2MAQVMAR^F M=;%<"MN N'I(8TXI("?2O,BY:5/&]/WT*O<#*L@5X@>0'5_LO&Y63GF1;@IN MV(1K^U2!;S>ZED^M5KJVH] T;0:V@V2VUH/<_U/QS++6Y5/O-?
$(';$2QG![MDQX8[W R)3./O3ZXM,GD6A:C2AAF[& 7HA++7!_A3;T9[8.:%-)J#)FZR%,R\P>2UTO7T,Y!P!D\R^E&X[:/SOX% M,:M=:$1OAQ] 8@-TY]F>-;HLR7)((.#)U"FS'0O.B
L:]3"P7O_D+W!$.9L7 MM=K5HP?QC)KF2NAQ# "V0UP=@3FK_]18$XA'(5-HIXY5G;+!GOV!?1/7 C_/ MI[F9F^UT*+W"%L6_ 5LE($=-*l6.?3]^U@\TCDXT#D8
M>"TYQM[F>KVNB\P0DO'@$2)QHZPW9/A55]P^BG1C:=2TK)"&K7F*O,RUO3TV M"YW%CEF8LUS?C/T$7"?;]#NV*G4M.8Q?XB3$;8B6PP]>(A* 17(QB
MKT^4F:@K,]&+R\R@8G*EA%8V_:$4+* >Z'S\\'-Z ;>]:)LY4QJ %1=Y)DM M(E>\X)";Z,X<1$_VJEJ432WA_#](Z6_5P9XH& _]Y)7@ TC!-CR7HU0>@F6B45<:5K%IWXW"NJ2GA #
[<8)^X<5F M5]9, -L8[UD,[!Z%+H%CWS2O-R-)V-G%@Y>]# MUTT)!%44#*JM'Y@CCU&V@78Q/Y@_ IP>#]ZGITX'J[5<[D]4;M5^RQXPQBZ.S M
8I'B5D#:@VWW/@6HEFMT1*,B8"V5B/E!HX)#HN#U,?)PE8>^@T&(V207G" ML>\=^,!A/T?;*,2$N>H2%D"4PA(F;SLF=?KU,9Q7:!]&F+D'(1AB#">LKW$G M6#
[N6#Y^,C7XE.K,'BH\1"K/+*="&V MN(C*5OK%K@:<5/||_*GBJMO4?B>]0X%'$C*0?8\Z,AQJ8X(^9$#7M@G)-O8(MQ5/@7Y4?-R:'[:4K)Y'G()GO0/;,6N]QP+Z-S&'XR>QM#,5%\SWS?
0 JB>%I M,/[SKC$K.<#]@E]8NJ'T!??":T+,:PQS\Z@D#0&01__8OM M7QL_< &AEC 53A%PHI?MWP6MH.O&?]?)U%K7!U="PXMNGD!GB_K6N\% MLT#WG\WEOP%02P,$% @
SX,667PO3TFB!@ B1, !D !X;"]W;W)K M&ULU5A;;]LV%/XKA#<,"<#$NE^Z)$":=EN&78IF M%^R1EAB;J$2Z)-7$^_7[*-D2G<1I.VS]B+S=N[?.3SFV9W2[\R*10$\(eOOLXNSOJU M-
_KB3'6V$9*_T<1T;)FX_V!WP2_,lZ8.$L62KUSD^OZ?!8XA7C#*^LX M,/Q\X%>\;1PCJ/%^RW,VBG2$_GC'_9O>=MBR8(9?J>9W4=O5^:R8D9K?LJZQ M;]7==WQK3^KX5:HQ_9?
<#6?3;$:JSEC5;HFA02OD\,ONMW[P"(K@ $&T)8AZ MO0=!O9:OF&479UK=$>U.@YL;]*;VU%!.2!>4&ZNQ*T!G+V[X$BZVY%H. 7:>
M.OJ%+1INCL_F%A++0W]OG%!_C[I"PW9##P*?L&N31I:I,N-Y0=^H!LDHY)((1(2&RI MSC!9F^,7Y*LOBBB(O_[?_/[!F1YP2H RWJ-LM^?0YCZQ^T3D)U1'PP"9OV_E
M&PWDP6,WE>"R @9W&U^2 I++('*C)*5YDN_M130.0_)*L*54QHK*$/B;?,NE M:MUD=S2.,AJ7T61!&=$L\.9Y0HLD)C\CFAKA_/Q(TX2&:?RD'6'T MM'UN_5I:KK?
8&#>/H'R13R*.0IHE^_,T38_)E9)&-:)F%L&0.V=[;@BA4TF# M+!C&<49SS[9^+4AI6I;_.$I^'H$O9*5:?A@!ST0X3A.:YZD;Y3'-BL3?RW.: M 6@?C7*4T#3)IC#%-(@G]"0%+?.
<.[,JY>]#VA).\I'$43G0A2.G/@:,L"! 2 M@QS7O%)+*?Y$6% 47%1<<6+5^TYHK D)&%FE-U-$\ZCTXIL$P7ZTR^R87+:H M8.+/H=" G9"6R:58^"$_R@O@OO"(\XPF8>POP %I1G7D)Z !
<0NBEL]B(]32";(;l'9V3X$"W5 MI)5(EM&R\"PO:9FEXRP$DG-XF*.. R_.0.UR<.;5BNFEYX617TS3(N3Q2)BQH M']W%A5O>O:+Q?5UCF^]QAU&XZ@\
[.6,BJ_V5DUWPJSX])CTC&B7IL1^P8B\17.$+7*'3 MN+[!@2RY1(8V%/=I@_MY27MAK(87!00RUZQ.$!OYE#1,/.P":&GLIUA*HR+T MIQOA M(/2*5[Q=((YQV'=^,>V;D"M$GLD-
63$DW62973';K[6X,=%7&+7 U"79* MT,?W^QMW_/[F]_=^%LTU=STQXRX/VE=.^LP@"[?.' ;%7]F TZ]W?*'&X1" MQ;&N'L$;C\S!*:VZY6I?/+E;"7!Q"'8!GV"6*V;7ON),R@[]W)
[6_!.KXX:L MH;S>]7V[DM^;_:D<0,L>ZBSU)!F1H|))BFJ<136*O MT4-C4![4_=]J_WY1%C&M1IFCB,GN,BIH6 3^2IC3/(Z]E:(.:)%/Q>$I!?^1 M^/.Q?\'A6K?H
C7VWOS\UO_7Z5PB7%CF=UV"5=,LIKYI2|T/5'>%T@TAFE. M7G<;913M.BVR*:AH&:(L)I=&3-0@SH_,$V#LU#Y7V1J6NF$S="]Q>A
MU;L>^Z^#IGZ"*0EPER>N04^C$]9$.U/&OBI&XS[A%MUL^L B?*;M9&>,>*B> M)S0-;3E:+#<(Y !6#MIAY>2<75\9[HFX\,C MU8_HSX0TI.&W(
U.\W1&]/#P,TRL6O>/+0MEK6K[X8]SFFMW /NW"K5C.W$" MQM>WB[\ 4$L#!!0 (,^#%EE8Q&[^%P8 % F 9 >&PO=V]R:W-H M965T)SBDJXN6W7I[<$\62Z$>=,;C!"WP Q9?
DQF3 M=YT2)2 1CCFA,6!X?M&ZM,\]QU(&68L _"%[QM6N@0GFB])NZN0DN6I;R"(?8 M%PH"R;]G/,5A])"D']\+T%;9IS)"B#4#V-]A L# M>*B!4Q@XAQJXA8&;,9.'DO'@(8'&
(T97@*G6$DU=9&1FUC)\$JMQ?O!,OB72 M3HPGB!,.Z!S,&.8X%B@?C3@ #WDFJ'@!D-B4\P M!Y_!91 098E"ES3E$IN/.D+ZKCSH^(6?DIQ/ MN,-
/&X([&HLE!U=Q@(,Z0$<&748.WR*?0"WBKVE\!ARK#: %7?#UP0,GGTX! M$3AJ\&YZ.):S#\L[' MJL&I!.^5P.QFXNP\,GC&3!"NAN_J12X>'#>-10[2
MST#4ROS\=FW+&G6>UREI:#38;.0U-.JM-:H%X99!N/H@(BIC^#=/,9F>-S)M MXP5Y"C&XY!P+W@:/5*"P*;(R,VK9=]P3[G"?+Q M12M1$&,UJO#H\Y)] 06(W 7DE@[Z,(?%S1)@)
[VP0Z<-C? M(%#KU;$$&@*K$=@O">Q_&(%+AAMSL+]%8<^QG<$&A5J_CJ70$%B-PD%)X>"C M*+RF*6MB<+#%8'>XM7)-M6X=RZ AL!J#PY+!X1X&N2\UQZNB1.Z7O29*AEN4
MN+TA=#8HT?9S+"6&P&J4V%8EZ2PM*3=1@@B3XEQ(9>Y3)O42D\H,)$R6"TR\ MMD$22BG7SF0?_IZ21+5MU&36UO:]J0+V-_&T3>HQKLE66QOXC;VGTA)G:_1E.
MU.R0@B:5LXF#_W;IKDD!69L)IF]2C@54T4!O-O9+)L1RF*\1B&0H' M)U)GIU$:(C7_/2S%-Q&G;25^5:03) ?0;UQ"BYI6R;8=V(7NYD;4V- :NKU-
MF:/W_;W97"E66R]9;V5ALG4*)IG"JU.8:5U[1\2NP=FH[X/F&5CT\A,WVWI MZ2W?RUNE<&V]Q+U#+SO7/I.B=6H4S3.%5O^V5VE@J-? 1K)M3Q_0VIUN>M-C MR32%5B>S$MM0+
[:+%-R[^NEACLU'HVB>*;0ZA97"AWJ%;R8?]7UH_'=II[> M]+W,5?H?ZO7_U5N!"OZ^PZKH^T?FH480ZN&.3D*C%8,IM#]55<4]17#K/P M.%,? ++ZOZ3WX"34]^%HK8<[.BV-
UBFF MT.I45G4*U-<09M)2WT=7DY9&"Q53:'4NJT(%Z@N524I"!8FH#=ZNP$V4,/J, M%9D\X_86(XZ7- SJKPY<7HU6.$;1/%-H=>ZK"@?J:P@S>:SO0Y?'1K_JFT*K M#ZQS[W\
<%,%DY^UND-L06(. M0CR7D-997^[.+#^^E-\(FF0'>IZH$#3*+I=8UF5,-9#OYY2*MQO507F(;/P_ M4$L#!!0 (,^#%EE6K\$(\@T $:R 9 >&PO=V]R:W-H965TS>DBS,_9DJ;B-
Z\L6X1<_)C-AODRH^&T;+1(ANIH-!DNPC@= MW-V4RYZRNQNVXDF,Y*O%(LQ^/M"$O=\.E,%FP1_Q;,Z+!<.IFV4XH\^4 M_E\RL1/PZTCI-
/M(D*22O'=\K=+#MLVBX^WBCF^63%T_F)>=&^TTFAYILW^S6NWWHS5,V M;[=R\ONM;-YPI7S'A^N_Q?(/60]Y>'>3L7>2%>L+KWA05D/97OS]QFE1N,\\
M$[^-13M^]Q#F<4[8*WG*:$Y3'J[+*9V2YW4I%[][CF=I_!I'86!)',M0]!.4T7IC MU([FAKSY,UW6S27/Q90S.HVV+XDB8:S3&=DK;Y_PI+31T2?ER!EWE6Z9\88A
M,:>+P^^6>S]IG4AZIY-]@^RP?+GUSXB?$_7]V)]D<(IR*5$:9:=M1SFM9,<' MV*>,191.<_*:,?%RA0DMAC5#C*@TC6C'9CY(O>)HZG.^#"-Z.U@6XV;V1@=W M?
_^:,AG]HZN8D9B.Q PD9B(Q"XG92,Q!8NX;NRRQXB#[!4ZYO%+'-\.WW3)& M=NDCL0"$-:IZO*WJL;2J_Z!O-%W1_(RDE'<5L;1YWR)&8CH2,Y"8B<0L)&8C M,6?
A79YHXN+Z^OF>C[R200@K%%\%]OB MNY 6GQ6*8WLQ53AE9RJ5^M8A$M.1F('$3"1F(3'[HN-/_7*T5S@.LDOWHJ,* M)U?[-8CLTD=B 0AK%.ID6ZB3XX7Z(6&YF)"+>]7?
5S'_21:4S]E4S,\W_:N MNI7"?>L6B>E(S$!B)A*SD)B-Q)O)JR(_3:[&RM[><](:*CXIREC;]UODAOE(M+ !AC;]W-;MI7S.RO*X.!F7YK8N<:,D9B.Q PD9B(O:XU=[Y3!Z'RT-
\>SD3TZ2,Q%8AX2\Y%8 M ,(:Q7ZU+?8K:;$[BV489\5^N#B6]EDZ^^3';Z+@[_.<\IQP1EXHT>-\R7*Q ME+UVU;FTB[YUCL7I)&8@,1.)64C,1F+.56M'K"K7D[T=L8OLTD-B/A(+0%BC
MT*^WA7XM+?1'ME@4LV;.HF]GU0EN$][$P7@6_T]4]@=QL+Y>^I'\.GP;_4': M2]]:1V(Z$C.0F(G$+"1F(S'GNG5H/AY5_^W5^\EK>L@-]$_N-FBQJ;36;)2A M.JH_]QY)"U&G42**:
[HN19(ODJAS#BQG^E8:5-,KK?%*-KT=]JA"=4LJ&9# M-0>JN5#-@VH^5 M06K.J=](LBK2][Z?3*%9L7\.*+EI41 MM%4:\Z+&#V16'N1D[PI':CI4,Z";"=4LJ&9#-:?2=D?
MB]W#Y..K>,=7\;&; M':"T9BW6>2I%'JBJSU>=$2?E83J+7Q*Z/EM5+)G2UUB4)JW.8GTP?D3):EI4 MK,78]#U.DH]GY)F'HFRKA,/?Z&Y?XP?O%A2]&*D MJP7-RJ3]?
SN+'AK>@FHZ5#.@F@G5+*AF0S4'JKE0S3M2><\T$8MF9V1&4U$$ M29G5#]<+46XY+XKBK>LS(!^ZC0%*:XX^=>Y+D0>_-ED3\A S3J-YRA(V^]DY M%$ C8%!-
AVH&5#.AF@75;*CF0#47JGE0S8=] 4IK#@%U^DR1Q_Z)[KE8.^A M !I#@VJ&TI'0NKS:/[E]0CNUH)H-U1RHYD(U#ZKY4"U : MTIK57I>V>2KR:M(<":/0-I36'@CK\ILC3;_UV]-
"8&U33H9H!U4RH9D$U&ZHY M4,V%:EZE38[LZ*%Y-Y36K,XZ\:;((V!BLYIG)+G*"[FYMU%#@_D[1_8 MDU_D<95EQ>1]E!-AVH&5#.AF@75;*CF0#47JGE0 MS8=] 4IK#@YU0E
]>LFU)+:$\ORY-Y?G@U (WY038=] M!E0SH9H%U6RHYJCM*ZM=MS(0+K1/#ZKY4"U :QPNDI/KG= MN\J1F@[5#*AF0C4+]ME0S8%]+E3SH)H/U0*4UAP5ZA2?*D_Q';V"H[QI\]'
MAO:@F@'53*AF035;;<<3U=97OQUHGRY4\]3V]>C&[8_HH7T&**U9J7463Y5G M\?0XG*4LYW&4EX?R%DW90OS06;30*!Y4TZ&: =5,J&9!-1NJ.5#-A6H>5/.A M6H#2FH-
'=E3CUR2KO%_C)& .J^GRO-Z];V^^VKBK7VI$O56N?L'F4]]RWRJ&: =7,KE?DHO6"6-!.;:CF0#47 MJGE0S8=] 4IKEF^=]=/DF3]39>]A-A6'YBG/PHB?D2!.1/&RE(']X3'RX26
M'YQ_83Q,B/%C2:/BNO&;NN\L<&CN#JKI4,V :B94LZ":#=6<2E.4W1/>YWN7 M&G6A?7I0S8=] 4IKC@\UIDZ3Y^X,3-+)+V+&6Y=3[&U.L?;#T##?5!-AVH&5#.AF@75;*CF
M;.UKV:GJI'WW*6BO'E3SH5J TIJE7\?V-'EL[Rl."* 9/JBF0S4#JIE0S8)] M-E1SM(Z[>G7(]/WF/O80 : (1J!E0SH9H%U6RHYD U%ZIY4,V':@%* M:XP5XSH .)8' ,L+\^Q>9O?
Q\+=WY%3?00"JZ5#-@&HF5+/&'6G#]@>P-K13 M!ZJY4,V#:CY4"U!:LIKK?.!8G@_\UQ=BLZ2X0GZ^]U' *3M!.=2[WJ%!0*AF
M0#43JEE0S89]#E1SH9H'U7RH%["TYK!0!P;'QR[4U_-[NW*O]T@ 305"-0.J MF5#-@FHV5'.@FEMI^\Y?BA/;I0[4 I34KQ$[[C>5IO].OI26'>IU!-
AVH&5#.AF@75;*CF0#47JGGC]H4!.VH;&LI#:>O:'N9S M2KD>\O#N9D%%D3[2),E)Q%:IX(N#^>U2,1=_ +6Z=]?E>'0Q;RRWELZUT+'>4 MSUZY?%CS=S?+
<$8#,2;$:4X2^BJZ&IU?BB>6Q;/Y]@?.EK<#94>&.=L43Z< MTW!*LV(%?M7)B8.U0I%!^\L^U8^G;Q_ U!+ P04 " #/@Q99&K59M.(4 M #Q6@$ &0 'AL+W=OO=B:B\
(5FRV,7@!)]U5_>$7"+%\)G M2?ZDYJ8[QIS?D0T/ NGQT:O/B^5OJ]NR7$>_W\WF]=GM^OU_I^68ZO=X/N9A=)I_N!M/YV=O7NUN>[!\ M\VKQL)Y-Y^7[9:1ZN+L;+_]X5\X6GU^?
Q6=?;_AE>G.[WMYP\>;5_?BFO"K7 MO]Z_7VZ^NGA4KJ=WY7PU7_,R 9#\@.79 NA^0'CN@NQ_0 MK0V(N\\,Z.T'](X=T-\/Z-<&I/UG!@SV P;U&7K/#!CN!PR/G6&T'S"]S_#<
M@+CS]9'K'#M'_/A@UQ_MYX=\?;CCW>-]\>6)M7M69N/U^,VKY>)SM-S>?^-M M_[%[:N.&;YZ,T_DVA5?KY>:[T\VX]9MWX]5T%2T^1N^7Y;JK+/KK7_X6_26:SJ-
W"X>5IM)5]\NUIL? M8KLI%Y/]!K[LL'),QN<1C\OYNO;523FU^5URWCM'S\Z--[ZQ\>)![C8_/8? M'X+DDF?P+O&*|F'^4Y1V7D1))^FV;-"E?_C/X^5F>/SL\,P_/"LGC\/3EN'"
M/_RJO'_<^*1EN#Q^]KAEN#I^]K;A^OC??-O/;HX?WO:SV^]IW//OV_CBFS?> M>1:GCR\DZ<[K/N.YKP"3Q6J]>A'--V\C-]\?X^Q_W;R6;?;=Z]; >^'MVY"7
MJ_OQI'Q]=K]]C5I^*L_>_/N_Q?W.?[2%A<0R$A,D)DE,D9@F,4-B]@LVV&'; M=Z>?WJ3I:#AX=?'I:>K(*0L(GK-GXK2=P9).YOY;)YKS@9 ML.Z=LI8[Q=WM:]O3>PGO5H?
F@,04B6D2,R1FOV!]YI%,NKU:#IH/9CI,1NZ= MBI9'O-_M/-[)>2[*V1^W/>_S]G*\NHWNQW\\N[_P#@_=?TY!81F*"Q^2)*1+3 M)&9(S/8:.3D?[(>U5\: MG2%811_&L_%\4K;&<=CX-
8UZ]0]-WKE#4T9B@L0DB2D2TR1F2,P>\?3)R0D+ M"'-2-GI,V2C@2,3>7[W8'D'?WO#N2\S:4N9U0W=Z)):1F" Q26**Q/2H<;2@ MXS[E#3F=);%\U
AL;=L+:#HG87&G.H_7\1\U62SO%OQNC5&_K&A.4*U#-4$ MJDE44ZBF4WRJ\V1^.3C%I):AFD UB6H*U32J&52S M>\W]*#BL[?9R=,Z"TMQT)E4Z$V\ZL^GX9K[)Y'2RVI5@5#E?
W&V^:(VCEP]. M(ZEE]"903:*:0C6-:@;5+*KE]%90FAO;JGL2GZQ\XI>#4XS63U!-H)I$-85] M&M4,JMF]YIY]3^/Z3A5MH5":F\ZJAQ(C112_IQ4LM03:":1#45MY5XAK5R MB$;G-
"US)MW:T5"+3IFC6D%!L"]PDSL\RTMJ]?1%?K\;K<[OBVNT$SGRSN MRFBQC"X7=YNMN-W^)<6G\NOM_Q2_K[>W?)B5D9@_W)7+71/\?]Q#BA9P4"U# M-
8%J$M44JFE4,ZAF42U'M>) ,J_*V>:FFQ?133G?1&JV^U YOKZ;SJ>;R(ZW M?X'D>P6HJCNQO[MSL#/G'Q^<6;2V@VH"U22J*533J&;BEKY-"'?3^FZ8G#1'
MM8+2W!!6_9WXNPH_M'!$40K/*@F4$VBFD(UC6HF;G9OSI-AMYY D%AAVW19A"J9:@F4$VBFD(UC6H&U6S<[^4OK/=@DG=Z2(S]N2TY: M4)K[9^E5I2CQ5XJ./&
[K5T*CB&H9J@E4DZBF4$VCFD$UN]><6D*GWDI IRPH MS0UBU1E*_)VA^MO:Z,_H/_\1Z<5L6Y]=15^K?]/%O#6?:&T(U3)4$Z@F44VA MFD8U@VH6U7)4*RC-
#7)5+TK\]:)C]ZAHLPC5,E03>\U=?6!0>S&7Z)P*U32J M&52S])8?]5@5U)QNPJHF4!+2!#KYJ5#_U@0G%6T/H9I -8EJ"M4TJAE4LZB6 M'\A2\,G+_2O
=I&2=4V2OQMHX.G0OWC@S.+]HO03:"1#6%:GJON6=..IU: M;5#_^. ,HHT@5!.H)E%-H9I& M-8-J%M5R5"LHS#4XR6BE!-H)I$-85]&M4,JMFD65% MTVYI?
2!TSH+2W'16I:+$7RIZ_!BLGGP,?NM\#([$[_?E?/7,CA8M'*%:AFH" MU22J*533J&90S:):CFH%I;E1K@I'R_$M]NI;[.6WV.MO ML1?@:]YIU.O7,\(\1^LA^4<' M1Q"M+J&:0#6):@K5-
*H95+/L5YJSQ-,K1*0M*?HD^C/R7IO) M#P;O!M%B$:H)5).HIE!-HYI!-8MJ.:H5E.:$MUOUC[K!"QX=>RK%+X>F&-4R M5!.H)E%-H9I&-8-
[MMM_53*>BMM,9U/>T:*6(TMQT5I6B;G"EJ#6):'T(U3)4$Z@F44WMM:>' MZOIII[:"F1JU@M+<(%;MH6Y(>^CD+0C_U@0'FM0R5!.H)E%-'7A. M?%ME0Z/;:%#-HEJ.:@7]:+BO!%4?
JGN@MW.HT. ?'YQ=+$DE5!.H)E%-H9I& M-=-M6:"I-ZR\4[#HG#FJ%93F9K]%77]I:(#?0;_Z. $HI4B5!.H)E%-H9I& M-=-M*0'U.O4 HNLDH5I!:6X
JT)1UU\H:CT"?,PUG_QN<#31]A&]"523]*90 M3:..:036+:CF]%93F9KC]')7]G;3O.?*++]2$:AF]"523]*903:..:037;;;:7 MTNZP<8X5K2]1FIO.JK[4]=>7OKTQZ(>#PXG6F%!-
H)I$-85]&M4,JMENU4[]Q9=C\RNA042U#-4$]DE44ZBF4TNH)E!-HII"-8UJ!M4LJN4'LO2- M%YFAMM%]!:CZ2SU_?^G@Z1C_^.#,HBTE5!.H)E%-H9I&-8-]MM=L*9W'<5Q?
M+K37O(;^:"?U>OIZ@?]:KZ4<]?/SIPGL4_.CA::.T(U02J513]*91S:": M]357+4J2^A^QM=R\'KZ"VBPW5E69].O*GS[L1T_')PXM!>$:@+5)*HI5--[MS7O\Q*!36E3+C_D!"FI*-
W)5:Z?G;^T<=<(R[&K>_AF#LXCV?%!-H)I$-85] M&M4,JEE4RU&MH#0WW54?J.?O QU[0!;M!:%:AFJBU^RWQ&E2>QLDT3D5JFE4 M,ZAF42W?:P/O8U50<[H)]PH_O9
+HYW^0"M:$T*U#-4$]DE44ZBF4K5;D^7Y:S\;]\WNU5%^O;X1J M4DJBE4TZAF4,WVF[6B?CJLEX_0 M.0M*<]-9U93Z_IK2D6=5]XISG;-!6NM_7+;<*XZ[M3^YSUKNU>MT:Y=,\V]V
M<"#0:A"]:50SJ&91+4>U@M+/JLW4_\Y+IOG'[_W17M,J"903:*:0C6-:@;5 M;+]EM:1DV.G4W_RB*QQ1FAO*I4JY"]C5I
M0C6!:A+5%*II5#.H9E$M1[6"TIP$#Z]FTN!DEU#SRZ$I1K4,U02J513]*91 MS:":;1<0]V3U)<00^7@%*.%)%03]"913:&:1C6#:G;07*$H M2;KUO2W:,Z(T-
YQ5SVAP8!VC9_>VQZQ9[\>#\XE6C5!-H)I$-85]&M4,JEE4 MRU&MH#0WR%4E:1!<23IZ+TLV3"Y1+4,U@6H2U12J:50SJ&;WVM.];"L.ZP>- MT3D+2G/36?
6>!OY^CKF]'T^77QM,X^U.=Q7=EK/K\X^+Y?FVM=,;3'0=)53+ M4$V@FD0UA6H:U0RJ653+4;V@-#? 5?-H$+R.TM&[5[23A&H9]@E4DZBF4$VC MFD$U.VAVDI)XU*]?$P:=M* T-
YY5)VD0L@C3LX7\O>*4'GJCI%^K?Z@G"\Y8 M<|)^)ZVM8B70.26J*533J&90S:):CFH%I;D1JZI&@Y"+HIV\NG]@C?JOG^2 MX*#_@$T6Z"9+5%.HIE'-H)I%M1S5"DIS7R>]?M3
WX\ZMA[L9X+?%].%*%03 MJ"913:&:1C6#:G;0LEI4Z_MBM.I$:4X8AU75:>BO.AT^[G3DF1[_/*%]1;4, MU02J513]*91S:":1;4?1+.5M,=I]VMS'|]2IZ M/QMO=LK__+F\^U
N6S\!^^<)#BM:?D(U@6H2U12]:50SJ&91+4>U@M+<3%4(U@6H2U12]:50SJ&91+4>U@M+<3%?=]&'(MFE#/[US1,A2J9:@F4$VBFMIKSC)TW=KY&(=6EDY^X]6]-
<$[1NA.J"523J*8./">^[>2S1K?1G&0;+;J-.:H5]$_L MOB)4;:FAORUU#59UJ>&#EI<G:M!+QP%:AFH"U22J*533J&&S06\SI.TD4"TJ(1J!:6Y M:R*2L,C%G)ZIEC2]UT
W3]S<'K1;A.J"523J*903:..:036+:CFJ%93FI'Q4 M-:!&P8L]M276KX0F%M4R5!-[[>E^8U@_G"+1*16]:50SJ&91+3_FH2JH*=U\ M56VD44@;Z>1'E_Q;$YQ3M,&$:@+5)*HI5-.H9E#-
HEI^($O?>/ES:AO=5X"] M\#3R%YX.'DWRCP_.+%ID0C6!:A+5%*KI47.EI//!H+9O,NB<%M5R5"LHS$:@+5)*HI5-.H9E#-HEJ.:@6EN2\!58[I%-QC M.O;O MC]^\NBN7-^7E9A>
[VH3N8;[>;LF36Z-E^7$3WOCEV^3LHG'[N_BEBEMNU_%+ MTW:[C5\6N]LOJFG?O+H?WY0_CYG/[^,5Z;'\;?=COOE_4$L#!!0 M (_^#%EEPO#=G>P(' 'H& 9 >&PO=V]R:W-
H965T3:6'/L8#OMQJ_G M[*2AL;II$GQ)[/.IY_?\.2792'6G"P!#[DLN]-@KC*G.@T!G!914^[("@2M+ MJ4I[<*I6@:X4T-R!2AY$83@*2L]$ER8N-E-I(FO#F8"9(KHN2ZH>)L#E9NSU
MO6U@SE:%L8$@32JZ@ALPM]5,X2SH6'}6@M!,"J)@.?8N^N?3H9-/DCD8>R6IM9-F"44\)1/.F M]VT===@#IP!1"X@. 8,G '$+B)W11IFS=4D-31,E-T39;&2S U<;AT8W3-A3
MO#$*5QGB3#'[-8@:R]N1+,E?8-^4:5HK:^Y/02#&5V[$?D6@I3:/)1Y)#O$P2HOS,1;4U,HF+9 MO]3")W'8(U$#8#BX(FKX<'C\C)^YJ&CN^^.4U/5:EAF1PG,3>WG-=T0S&'EY/
M#6H-7OKZ57\4?CCF\#^1[?D=='X'S[&G4SO-A?<1/UU3D*G[:$'UR%=&%XPS M\| CWZ6A_%@1&N:A8[8=9YW&H1\EP7K7W..D:."/NJ0]T<-./|!?11^[2?\ 4$L#!!0 (,^#%EF7'8,F[00
)<; 9 >&PO=V]R M:W-H965T$A7:UD.V+/)AJSH(Y5/F_M"W=F- M2I+FE(F4,U#0Y=2Z1E?$NF%BQG1#.ZD*4$ M41\O=$ZSK%12_B0CK6:WRR)A]?OZE^KX%4PST30.
<^^IXE<3ZW0 @E=DFTF M'_CN3UH'5$UPP3-1_06[&@LML-@*R?..K&:0IVS_25[K!]P0D'^$@&L"[A/< M(P2G)C@?);@UP:TRLP^ERD-_))E-"KX#18E6:N5%EU'X68_!WQD#@B#.\
[D6H!;EM"D*V"K@)JH M\'M4-WA4\:\MNP0.O 88EB<9H:.96>.UXC<0$8E;KT M[NE!12\?])<90EX$?3BQ7PZCUN$[A^4R_>"P UZU=? 7.SZ7J_X&AAR$0STM?>;(/S1(&[O;]\O 'U=9-

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|L>.X@T[0P!"'_3VB%A8%_3VB?7!BD=-B59W\"+#@6R;WK_F;T>9TZ;HZ M4^F-WZ"K>'|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l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`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||;U$%>_K*MZ'J_B.@^#B M%6;K[267;-056U-)G05\. NX6<7@/J#G?/90"D-ME=-EOP_7U48/]Y;8;;> M'G3Z-, 56U-)'0-\. :X\2#)Z7]0 M2P,$% @ SX,6637:&ULK99M;]LV$,> "]$50P+4T;-D9[8!VUG0%.TO,N"O:2EDT64 M(E62BI-]^I&2H]B6K+78WM@D=??G[XY/-!UQ\57F H|%Y3)F94K55[;MDQR M*+"\XB4P_27CHL!*=\76EJ4 G-9.!;4]QXGL A-FS:?UV+V83WFE*&%P+Y"L MB@*+ER50OIM9KO4Z\(5L MKUS/.-06?O+8R8,V,J%L./[J.G?IS'(,$5!(E)' ^N\)5D"I4=(*<.P1D'?^_@UX$V9'58-UCA^53PM'1+&6JN91IV;VEM'0YA9QK42^BO1?FJ^KLJ2@EX7A2E:8HI9 FA=;R#,4K3" M,D>W>JW1'6OVC,G|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`3KA MZ[;Y0G?W>.T3GKW\%$T0;I[=1F0ZZ1-!=$_&/AR(C?E'*Q :@>P:NYIWC:SM]G4Y87;>+^P,7@Z2K9E]@/^(IS'9KQ$EBUJ0O8\3UWSSUW M%Z>SY.)!9@ */>64R:Z3*55<8+8/IDQD.E=Z*N2L+ 7AJ03EU M?<^+W1P3YJ0=^VPHT@XO%24,A@+),L^Q>.X!Y'MR2>:;, S?M%'@, M(U!WQ5#HG5M[F9(@,*'R M@SZX&PW0\=$'=(0(0|\S7DKM1G9"?(]_RP M =Y_/3S8A+M:H5HFOY;)M_Z"-Y2I*>DJ2M@6X;1V;E\PB[4,_"-H==[&>78-9%"71'L,-WF'-.SS(>P""++!Y=>A2225* M0!JQ\,=^.,=)*|@BN6O4BO=RC&J.T6LYV=@D[02,%E>T^Q&?HFC#=?D0WXI!+ M8@?RY]63,F,6,05TQ71.PG;@KZ:\#L>N!AO;P6[JN7[%;P@1UT+$!]U]X6Q^ MJD#DMDL&8XN*Y*:-XIPA1NY5L5:K!*$CV%*I=\VO_/=TF1A4L7@L6!^?;#;YKMU/:I5C.CI&:4_$_Y>LGN4,6A'T=;U!K,DBCP_"UR[MJ]8^[\KUC,"9.(PDP# MO;.V[A91W:/51O'"7D5CKO3%9I>9_O0 80ST^8QS|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|[BLW>26PONW&7W?@U]?2.9Z($I,D&%*H(B%?M2UTA<.0E;5JK MW9PK7:>Y<07V8'UB.E#3,/]-.WK MGL@EY0HQ6!C)X/+*1":;EM!,M*A3NP!75]. M_P)02P,$% @ SX,664)6[=S5!P $$H !D !X;"]W;W)K&ULQ5QM;]LV$/XKA%<,+9#$>K.=9(D!)V*W#DD1-.V&?61D MVM8FD:Y>DA;8CQ\E*Z89RV?3N[A?$EOV/7>\1R?Q.=&\>)+9/_F,\X)\2Q.1 M7W9F13$_[W;S:.93EI_(.1?JDXG,4E:HM]FTF\\SSL:U49IT/!W&R*?+CMMY/O IGLZ*ZD!W>#%G4W[/BR_SMNTR]ZRY1QG'*11Y+03(^N>R,W';:]"N#^AM_Q/PI7WE-J]$\2/F/|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|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|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

D!)\IGM.(2DK$ M*0 #?55]]QY\?9R!MV_>@3>)N#+BFV$ZD.,7*GHZ*3<($_]-DL=G4C|]TUR M#7SO"B /=2K"I_7#_?UP5Q6QJ"0]*HE2O,X)O"],X@C@M&I59++H?AJM!]=V M F%OZ(W<;3GGXU8=KSOL%:WV4O.+U'QK:E.62%5[)2P(F!J!(>%8#Z*J-*U(M>E*Y$6LB8W?];QJ,IV"3*=&G2/S2E:Q MZ!QUC+PN/*CU<:/3V76+[+K6[/Y0,Rl-MD1(/8[BH1+4I6@%:5IF5L"VR/< M*PCWK(1GA-,MUG.QXBTDWSS/'TG-2O3J2&7-X4R&_8)AW\KP3[DB'.CY2_/(M!CCX#TRQ6(&%6@8S:I6OH16XJW58%#48'"}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|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}_1K M]T>?8%%/8 U)A[6DPYY9MBGCGV"13V!-72\]'6\^,4^8S;5''?694.M6[/?E,! M]B5FGVA17VA- ,;UG,;U?;#K5@+M[,W#ZZSKU6O1^F^T$]M[)WZ- >^,G6^0+&N+,O"]^ZMOR7,3 6]UW^E MOS&8NO<9IOQ <8/Y2I>3&2P5I',^5.="7M;\94.RM:F"'YA4-;6Y30$GP'6 M>KYD3#XU] #UEY?I3U!+ P04 " #/@Q99-E]G9GP# #^"0 &0 'AL M+W=O[O[" MBL_ XD4RU>X7=I5LX5%4:".S2IDLK+#]HECY8P*#>.I/J=[%E(8TJ%; [5+S&!5S$283<(LI]&CUL+R" MLS?G\ :X@,^)+#03L9[XAEQ@B?A117=>T@U/T.V&<$OW)1JN18SQ;TZGCV'%Z_+9Y;%Q^*EDD05KCA M0MBHR#7DJ+B,F_Q6PHX.'|MPTQ:I#JAMU3 M]@]K^X>_SBM7]YU#9^C\7/Z=AFJW,E)$I."(=> CS18X^R2U/N_ TC#C6HYU MQHV(9$9N4=0),@I58J?%%O?GWZX?C3VQT- >BR"I7?6_R53N;)8T-,KH#Y'A" M28&Z";"8^BO7QJ)NL2DS_F?09X$8U8$8M9<+>W(=NHET]^9KRV#T(H].I-"X MMGS\RM:$Y*#6IM0*^%"I"X_8.5W+RCT8I)=C&O3 TU68A3#D4ZM/Z$?/>S>Z? MSN?TN"G?{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

K]W2^33=\RA,R"T%;!_'F+XM2)0>9A,X.5ZX M"Y^V/+N@SZ<[_$3N"7_8W5)QIE=9UF%,$A:F":!D,YM<2,+-/H[W#-M[.)-P%KLL'[B-^EA]](: MQF6PN(,X3(I/_%H6HA&]X 5 :@3@"T>@+,,L \-< J _)2ZX65O X!YG@^ MI>D!T$PMLF4'>3'S:&$_3+)^O^=4?!N*.#Z_WV)*+K/*K<$RC<5P8KCHD&0- M_N1;0L&")&03YZNGG.I=/$A"3D#UUFWAOP-7 2$ MXS!BGT2'"X$.6-8N.WZ$"?AKF^Z9R,2F.A>^LKO35Z6'1>$!]7B "-RD"=\R M\$NR)NMV ET4I*H*.E9E@08S_K%/-& :GP$RD*6XH>7IX;8B/#@]' VX,:L^ M-O-
\5D\^J6_^O2'Q(Z'_J4H|F"I;A:[8#]_(;"*6&4;H"YG,?_H!.L;/]C:*- MF2P8*5FKA%950FNPA LL!O^*?#X.V LQ8HO#3ZHB%LF]OS1+ M(TLP>ST|EV1GT"_"O%B7!Z M:MXGN99?
N.O4P@YPK8TVU67 AHUIL;*U:]O .3CF1E5F:^U4 M=F?7!4SH,R MHIFNU;6G0#U#6OM4&CTV*EQ#WXX[T$%RGD:=+]F99EO:+X]]*$ A=K6\' MJ/$/CLE_4
%N$$E#5JGJ_A11JBR[QU"-@?"C.1 JL,[1+&E'4[!6 M;;8FGC\X\9:*s&@XS=6TK()*9_7^/D,UHZ'O9;0S6/Z=-NR2Y;TCRT.[%^:' M4YV++&-E:Q>WYD
TS(%G(DN9K3G4+;_[W$DADK@F4(D:-V.4Q,8.I' 1IPR MEDS@K?6J-"W+WB&;0!'23S9%0?3&8_B8T*?\=083$V&?\.+9F5RG;\H MZ%Q?
P*N@>/%1IRG>P]Q@^A0F#$1D(U(:FBM@BA:O-HH3GN[RA_V/*>=IG!]N M"5X3F@G$]YLTY<>3K('J!=/\?U!+ P04 " #/@Q99N=X$I:D^_# M&0
'AL+W=O79YED?,84K3WTDDXHEVH:$(%KA(MQ3U=?X7Z/"/%%]*4EY]H7:WU+ V%!1=H!5 ZQ# M@'L$8-< ^Q#@' $X-E@GOJX26T<2V^B6$A%S%) (HA;\M!MO
M6AT$NE2AD<+:2G%M=3+.(1\BV_B +,.RVC;4#?]6D ;NM,!G;X?;+?#@[7"K M0PR[J0N[Y+,[ZR*IZF(=54,VWRNB)QV(G7/7?(B+;<\-IW'"ZV/TO\L)'\EKE. 5$%P@V88S)$I!@.)ITPJX
MD+>W0,LR\$A)A!;%D1>S,]>IAE5D7QFF?I16OFT88WVUZT.?"8,>R/9\^ MC%[W89[2+]]*:<>$[FTR=U*=*Q.29+/1"\^<0\^"EVM,U!Q9M:>?V^CGGE3' MT^F?
FU=4["0\5<4^R685F;M;^9[IN0Y -A! 0FC3V7QI MM^D=5L6T,]^I K:E="^L P%[2ED)J.]T2AFP9=FB@>3$)#/+;/IKEM+!*[V$X+_WYV$D*;F*J;^-+:SCG'IUP[-W>\9OQ19 2
M/1EVX(8M,Z@4[&2_Q FY!WB^ON9K9 MK4I*"J"",(HXS"?6F7LZC36^ OPFL!8;8Z2=/##VJ">7Z<1R=$"0PTQJ!:S^ M5G !>:Z%5!A/C:;5;JF)F^-7]6^5=^7E 0NX8/D?DLIL8HTLE,
(L? MT@9:KT9RT7UB8-UK'0K!22%0U915 06O_CYR8/&P0W?(?@-02O2PC>(?@- MP=^7$#2$H,I,;:7*PQ1+G(PY6R.NT4I-#ZID5FQEGU!|[+>2]Z=$\63R2V; MT26=L0*0C09?
G]6%$G"(CM&MNF)IF0-B'Z 1BNXR5@I,4S&VI8I9[VS/FOC.Z_B\=^)S/73%],P$^DI32+<% M;&6V=>R].C[W=BK^+.D)\ITCY#E>8 CH8G^Z;Z!/]Z=[.]SX[?GYE9Z__Q(
M1'X]MU69.3##7^-.F;Z*'?HCD*SG:BU M$_V+'7@JB7Q!!](M)'!5'I.[$VF[@NO.%\0*E .&PO=V]R:W-H965T!CV0$NT350B/9**DV$_?J2D2)8ILU&F
M]*6QY'L/[SV\).\Q.]MQ\5UN"%'@/HF9/.]ME-J>]?LRW9 $RU.^)4Q_L^(B MP4H_BG5?;@7!4>;4Q'WD>:-^@BGKS6?9NVLQG_%4Q921:P%DFB18/%R2F,_. M>[#W^.*&KC?
*O.C/9UN\)K=$?=E>"_W4+U$BFA F*6= D-5Y[P*>!6AH'#*+ MKY3LY-YG8%)9$T5C=\]QLI$LH"#'DLLW_!KK#U>B!, MI>))X:PC2"C+_^+[@H@!S@ZXH
*!W3HX!]Q&!0.@Z#SAJ<2LTC.^DH'8&#Z83'893X8.C(81. C M9VHCP3L6D:@.T->1E^&CQ_OD1/Q?[#QK<@Z>[(T?P3OW6I%LG6@>%[H.>#Z!46_M!@OR MUBS;".A\]5XFL_P
N0^)E%GZ2\+(B]JF%'/P\5Y,<.)IWD&;H<&@5V%9H MNF]5RVI8YC=TYA>0%1%")V<2P5(2)4_ '8[3/$LLYGPYDUL/D D$7>D-_ Y)SCR?G%4]JAD8O0T)O1& M RX*)C[I8XVOP-
>2D(N*D, '"!G9A'C3@5F]-49LL^G0.[0*G$$_DY)Q2 /03,23JU9]@ MIM=__ #T3@P89V_WWVEW=D>D.MQBV(G324YL0FUAEM6V([JL1.RV)G?X?%>PF=6J3.F@@U1EI6U([JN1
M"KV](_-^0*LY[=>, EWLEY?Y$:C/PPU6X!M/XPA<)3H"!;J.P1C>Z%:AL2OS M+!*'UA&X<(?5EL.NT.HD[K6UT$GB11B*5/-'F=(%)U6V3^H& \=*UZ*NN1B;
MHE4*0O.D4+ND*K';4MT];FN67D)TP$IU0+?L^$- M@7 _\P_K+B7$HE.TH"NT.NN5)(%N3>+BU'4RVS)CX-LJPSUX:ZI>0F>@2F<@ MM\ZX5>:71=,7?^ ACL'[5% 9T?SW>%?
YN7';EE^G:$%7:'5.*]F!W++C&5LC MLB7%T-84[G%;L]016IVE2]4@MTIY4N7]EPW2/7[K"NU4$S72%5N>^4C/(K6:> MN4$B6[I ?V2+%_?HK;EZ"?&"*O&"W.+E\6>L[D]P]\"M"
[13A=,56IWT2N%@ MM\)Y;H$,K=l3QF-;UK@';TU5II*FOW>-FQ"QSJ[#)0C-R9%?B99ORROWB^RB M^>#])3P+\HOS"B;_Q_^(Q9HR"6*RTI#>Z5@G(/*K\?Q!\6UV6;SD2O$D^[@A
M."+"&.CO5YRKQP.=SS> M]"#5#[WAW("7LA!Z%FR,V=Z&H5YL>,GTC=QR8=^LI"J9L;=J'>]MXFQ9D\HB MQ! F8>O,,]/\7A;_MY$NSF04T
$N^8KO"?).'/WGK4"UP(0M=_X)#BX4!6.RTD65+M@K*7#3_[*4- MQ!D!)0,$W!*P2R #A*@E1<:22$L@=60:5^HX9,RP^53) U 5VEJK+NI@UFSK M?BZJ=7\TRK[-+
<_,OXB%+#EX8B(<@P_@7I9;*;@P&L@5>%!RG]OGD'WH!<@*>-W&DFEGH:&JNO^DJX:+7<-5KP@!:$P5*G>'1RW^M1,W((+O 8:8> 3=7T^///3L>CH>\2;] MUBJJ[457K)4ON@V;^-
*G5!G*KMVS!9X'=(317>QI,?_|-)? /7V1^I;'L%QF[MB!KIHD;&K,|S&S-M|H4O8@TSK9G5#KF?HY10F$S# 7DL^C!,*8GI)2SSP.(8 MH1/L0G PB>_(2;G\B&ED:..^CXHAAL@1WT>1!"
<#VI-.>S*] M_1-3(A=K#9ZYW4&XW1_J##9#&9ST':)Q0B>.1WU8%-$D=F"9!P:1!J]2CN? MTO'UX$NN6.&3G_9C;"O2?9/[/BJ>4 0=\7T4@I!"OW;:::>CVA\-.]RGG/:5 MT]A-
I#X(X=1%97U4DB217_>DTSUY;0U,/**2A#C2/2A(>M(I*$(H\FM'\-1B MX:CZ)VE889NY4K:Q5LD/ML?&ZFV2L)\@:4IBQR4/C-K\=O:NS .+$,9DP*FS M_(lQG!,AO+GU)71>%MN
MBL*>T+DMB^4554$\BV+3O9=4'ISU?=)+]CXNA4/[%#HU:S3>K1NW3GWN)T[% MG@-(3-W=RP.+(XQ2UZ4^+**8NJD6GDT+)5?K>NK28"%WPC1'Z^YI-]E]K.<9 MY_E=-
?'54\C)3*8,N?F5JG0L-"KZR)N%-:I6I9@)K;HS&ULK5AKD]HV%/TK&G?:(3,I?F!8 MV (S64C:=":3G=VF_:RU+Z#&E]@'D'OGWO9*- :]LTTZ^[-I&YUCGZ-ZK;TT/ M0GY5&P!-
CGG&U69'P7! MR,\IX]Y\:I\]ROE4['3&.#Q*HG9Y3N6W!\C$8>:%WNG!$UMOM'G@SZ=;NH9G MT%^VCQ+O_(HE93EPQ00G$E8S[UXUOPQ'!F!'_G@H"ZNB9'R(L17<_QG7F!
MF1%DD&A#0?'?'A:0988)Y_%/2>I5[S3 R^L3^P6./ MI+"BNTP_B<-O4 H:&KY$9,K^)8=R;."19*>TR$LPSB!GO/A/CZ41%P 4Z@9$ M)2"J ^(&P*
$#&X%Q"4@MLX44JP/2ZKI?"K%@4@S&MG,A373HE$^XV;=G[7$ M7QGB|/PC3T0.Y]Z!$5^)D^0")ZPC%&[*F)%/D *DF9F!%G0+-EE5$-*J";/ MFNJ=%O(;><)'I+
<$35FFWDQ!C1,S]'Y23N*AF$34,(DP(I%UQM%WO,4TFL" M'Q55LJ*3K(>HE?'W'>^30?"61$$4.R:TN!T^<,"7M\.C%C6#:I$&EF]PPR*Y MW"W0L1MM*L>]VM($9AZ6!@5R#]
[\IQ_"4?"+RYGO2;;\3F17KL65:W$;^\DU MC8$+1ZR3"DS4KLIX5E7T2HQ>EZL%^\2RF_*YGP?]*)SZ^TNW;AFT[!ATI6Y8
MJ1NVJC/9!X15&D<])1SW"4S9D\07X+!BVJ6MG;N'TPM^=''7RH@"&P966(!K6_M%#<,B]R:1Y7$U&N\GC!&]$PVA/(4B_L>=ZTM]D':KG$B(76+;2?M18UB.X!A M?^
&+CN!P2O@E2%WE2%WK4P+K)J,KXT%6+<5,^M>;*?IW[AW&&]N"MG.UMOT \; MG!@[SP8U?*@@]_E])7N2:5[TL[T*[9X;_Q,*$5P^1G?0_/RMU+]U^VB8UY!
M_ZXA)"9.!\,&LA@&YX8F:'WEYZW- #B"3)AR+WL'16_<%,B++N2@L29T(2== ML1!>]'1A*]>7_G/?I$#5Q*W*M,#]R;%>N#T)W2%=W_&:QL6UT.^8(T;&Z]RZ
MUAN=]48W93V6/_R(2#'\->5K]I*=-DBGWG;.7MP< QW(05/]7'8AP_ZDPY-S MRQBV]E:5)P>F-QN1I;CL)B2<3K0SX:R:-L@2^2])Z^U ^QO^9Q\8GAO!L+T3
M?'^$9&>^+W&7S$TG6'1&QG*FI;4[(6)W$W-73PCWN&!<-\$]+IPT5+QS)QBV MMVN?]0:DI?Z<,MR]6!#5973VA(U1W8GLRO1S QBVMT[O<3>W)P75#N^4/')*
MG@SKDIWCPN%=?>7NQ"Z=! =Q !D !X M;"]W;W)K&ULK9AM;]LV$,>_"]$510O,D4@]6$IM M ZN]H1GV$"1I]Y]1:)NH)*HD;2?]]#O*COQ 2@V&O8DEZH[ZW8EW?S*3G9!?
MU9HQC9ZJLE93;ZUU<^W[*E^SBJHKT; :GBR%K*B&6[GR52,9+5JGJO1)$"1^ M17GMS2;MV*V<3<1&E[QFMQ*I3551^?R1E6(W];#W,G#'5VMM!OS9I*$K=L_T MY^96PIW?
S5+PBM6*BQ0)MIQZO^#K.0F,0VOQA;.=.KE&)11'(;Z:FYMBZ@6& MB)4LUV8*'C];-F=E:68"CF^':2;WNG<;Q|/E]M ,:X"&81ZK87)3 \$*OIU[] MH8(MZ:;4=V+WB1T"BLU\N2A5^Q?
M#K:!A_*-T](Z. -!Q>O|+WTZ).+$ 4<] M#N3@0%[K$!XL-T?#:?,9[+>$I!S\] MNZES43'T0)^80B/TP*I&2/B>:,&72R99GJO?[!7KWYCUZ@WB-'M9BHVA=](FO M(0K#XN<'XH]
[8M)#_/NFOD)A\#,B 8D<[O/7NX?G[C[DKDL@Z1)(VOG"5R30 M%.W)FR*l5@W-V=2##*E1,;IDW>_L33H(/KM#^]\G. @V!0,.AV2'0+:NU MD,^N*/>NX];5=({M+$O&\<3?
GM+:,I<(@JQH$.LQ:'70U"359GF6 M0BF44RF?Q99)YP?93Y><4) X2"Y9'59!B&K,W&;IRQQH.LL$A0#L7#)08^OM M&<;I:+#B)P8G1$F'6$R2/CK$]2I0AI H3ERG96J5?
=MP_0Q76Z8T=*#M1$XL-M&HSQ959MHRS,W,3CCG@\2-PU)"A#T#9%C3JX_+ WQ!9UL1')Q8G=%E'5TV2#>G#=>TY-\AB7=O
M:=5\6+@(,^O=88+C2T+;"@C3'D(<'%4J&&3\Q,IB!)N6D:(E0U0I]'I>-91+ MLR"=(A)8)#'!R07N\&O_8T?%)^*+!\/Z6Z^9=-)CBS[!.+NDMZVB<-Q34/BH M:'A01V9?:+FA^TU6"=L\
(^A.1F*]?80S8K52EUT61E$/YE&/\+ @=95ONE6[M)-R]B= NK2 +C?B?8]IV4($G9N>81WW"PP)U4VM:K,ACMVYI):3FWWL;%;:U M9X1)D$27O$0DBF]!EAZ.H;XD>90H/
MZU1[W$!BB3;JD/8$GIJTW(SQ.QU87<-C!.8CTM:VC-N$?B9/D6VH.*K !SJE: MHR44%%JS8N4N^5M^1B2VNY;#+,RRGMT)/LH4'M:I_G9D"\\H3#+K<[O,QF'? MD/G^ M?/
\L.LI_OC41RGR66C&UL MK9=O;]HP$,;_BI5-4R=MS3](H(-(I5FU3II4M>NVMVYR@-7$SFRGM/OTLYT0 M+@1E7@#B7//X[N?Q>68K!A_$$L B9[*@HJILY2R.G-
=D2VAQ.*454#5DSGC M)9;]EB|<47' N1&5A1MX7N26F% GF9BU:Y$,6"T+0N&:(U&7)>;/,RC8:NKX MSGKAABR64B^XR:3""[@%>5==GN;E:T\OXC>H\(13^7K!:8YF+B2I6BWLC-
MVG1F33K!*^GX ?K!J%P*])7FD+\T<%5M78'!NL!9T.OXO::G*/0^H< +!I:$ M+@Z7AQ9Y>K@\Z*DF[(XK-'[A <=+EH]NH!W:U[B%GHL(93!W5) 3P1W"2#^_\ MR/MB(W-
,L_1(9B^H#3IJ@SIW9(8+3#.P 6N$L1'J'OF8#(.Q/W$?MT%8@D(O M>![F4[@?%0;QQ>I'XL$M\V)OX>9X3_4.4**\!2::Y-^:B&;-5DZOW5O/_YAF
M:6,6;>$91YZ=3M31B0ZDHI]Y_2*K>5+&6C>Y<%2=]^1DPMY'JM7XKJ6.:I=$> MJ= ;V$G%':FXEU0^F1H*!.CN7&\W= WM?MW0-<4-M U,&[[>_=Z*[YAF:;R' M[W,XC.W\1AV_42_-?
[(M2X(ZTP>L5OA7%,LW2T#R,8O?:[&W']/]SII[:8G9Z;VF(B>]Z^MQEVO-[,U5!!Z$(-BN9[8)]//,L; M(1[M5&"-VGUOI+:H[1='4X6[-;V5P!=F"A8H8S65S9S3K7:3]KF9+W?69WH" M-
U/AQJ89WW]@OB"J*Q8P5Y;>::RZ,6\FXN9&LLK,B/=,JHG37"[5OPC@.D] MGS,FUS=Z@^Y_2?(?4$L#!!0 (,^#%EG[Q4#:%@(* $ 9 >&PO M=V]R:W-H965TY/&A^"+;3CF^/']0I*
[B3>*S[W[^W^4NV4'I)],"6/0LN#0Y M;JWMEX28L@7!S)7J0;J36FG!K#-U0TRO@54A2'!"DV1!!.LD+K*PM]9%I@;+ M.PEKC''QT(% 8?2>@)SKSW< N<>Y&3\&IEX
MNM(GJZ/|"\A=Y?+CAFX5?QG5]DVQQ\QJ]!F [<;=?@*8S[7GELZ^BP;-TO M!+1W<,>U4O9H^ NFGU+Q!U!+ P04 " #/@Q99+*:(WSL1 "[W0 &0 M 'AL+W=O?1
MQ:^EH_.*U.VGJOI0/ G1.I]7R[)Y=?74MNN7-S?-[$FL\n;'BU*^9?'JE[E MK7Q;+VZ:=2WR^39IM;PADTEXL\]+\NKN=OO9V_KNMMJTRZ(4;VNGV:Q6>?WE
MC5A6GUY=N5=?/WA7+)[:[H.;N]MUOA /HOUM_;:6[VX.E'FQ$F535*53B\=7 M5Z_=EUGL=0G;B'\6XE/S[+73;7<57SEP\YIME^Z[Z
ME(K!@4=;U8MF^W_G4_[V,F5,]LT;;7:)\LU6!7E[M_\\WY'$NO"","V2>0 M?H)_),';)WCG)OC[!/_$^(>PGA$<2HGU"=,XJQ?N^-RZ3YA MNI7#[OO;?
OE)WN9WM3TR:FI:$GK7FP5M,V6WWE1=F)_:&OYUT+FM7M7.=NR3>S_?]lV:T?.;)^GO-S M5;9/C4/+N9@:\ID]?WHJGIOS76(!W,B=?=CCY.L>?T.LQ+]ORA\=;_+"(1/B
M&U;HWI[^F)/3\3LD.X9TJD]_4&L#ROOFKZ-\[>=F+Z,;]MUZ?GI MIFW/_O3*:T+P#C\]:\OSCO#>B8^BW(C&>:RKE4,_MZ(NY2_N?ONC%W7CR%^, M\U-5+JY_DN>#N?.Z:83\E?
W])\EQLE:LFO^8?D^[A?KFA7;GSI?-.I^)5U?R MY-B(^[.XNOOK7]OP\C>3%I&P! FC2!A#PC@2EB)A&0BFJ=T_J-VWT0]J?^&4 MHC7IUIH^5K=(6(*$422,
(6%\[XNVL*Y&_GCGNL%T$DYN;SX^EZ0IS@NC"='C M,E/<) BFTT.<)]3@(*3 *]1?UJ+>E2%%.9,'2I.6K(2Q6D+"$B2,(F$,">,[M6/CLNR>3,(S#GI0,8=-XZOL])9G"0BE-
LY#"@Y!"]Y#NJT:>3FLQJQ9E\8<\ MP02TS!,F#7VA66'106&15V.N5O$8] MA=/4E5%66;EXM"7C09 MKX2LL+%R0L(2)(PB80P)XY%!3K'GQCU!F<)"W_5ZDC*%>9/ -VLJ/F@]MFHJ
M6\GM:3LUK7,IKGRY_')=?2KEH6I6E4VU+.9Y*\\TF_=-,2_RNA#-]^0'D]RL MRQDK-R0L0<(H$L:0,(Z$I?%_;;$?]10YC+DFWM0S"W)Z$.34?I#K3I5-T>ZZ
MG\NM^L3GM2@;L;N$K=HG49L$:.6.%2 2EB!A% EC2!B?#O403N-^O3^,FLKJ MJR>M89 [G41'*C1WHKJ$%WN)>NHV+TIG*?6UV)U'9T]YO3*70.VPL8J"TA(H
MC4)I#$KC>YHF*R^8]&M_Z$(S%$W7Z;,NNGORK%S4VTYZ=_6PZ]0]B>7\^K&J MK[NK"]->K=#1>D72$BB-0FD,2N-[FG9YZ4Y#KZ]7Y$(S%$W7*U%Z)7:]']Y$
M]F(IVI;;@YZW<0)Y8(]=???&Y >OTOOH\+3^RYU!3G M^:'?/\4:X[3EZF)0/H1K;?S>T97\H)P)IS@/+35[,/VIH;N,G?575QLB\$770]XN6F^C]N
MG5BME]4743MM_OE(A0AU&:"T!$JC4!J#TOB>UFO)D2C]'QE-<2YQ^]>UQKC0 MG[A'=*>L!M?N-;P335MO9NVF[OR&[F*V?O[)]=?KW5G72C;J;=BZOB;N)"+] MLV^>F4.N*?
<@7I=U?+;=1:B%'6^?.$T8BFC%B^V0LCG]JQ92#'DW=U:AXZ' M4010GP!*2Z T"J4Q*(V[)A\@#+UH(#Q#H!?%\K^^]([R!)]/V :N\@U >< MG3GZ. AU%] T"]4Q*(U#;2F4E]%H^@W
RM4@NV[T_ G.3P*U/Z"T!$JC4!J# MTCB4ED)I&8JFZUZY).2$2W)VUYD,>_*^[T5^[_1T;U_@:)%"/0\HC4%I_,S] MFQKB@N[>N_Z]GJBUTX6E[QBMS-&%*!DV$4GW7VN45]94#\#2J-
0&H/2^)G[M-S7%3;PPZ/?V4&NG*TMY(^2$-[*IJ[6PEIMVPNC3+M07@=(HE,:@- ZEI5!: MAJ+I&E;N"?
$O4FY"O10H+8'2*)3&H#0.I:506H:BZ;I7[@VQNSU!#F!T_MFK4JNFB4KX0L?M"8TK-H3] HCCL M>W_V!8Y6%=30@=(8E,;/V[VI('G!@]TA3VIJ8]?_39 M%NKM0&D42F-0&H?
24B@M0]%T!2L3B,07J3*APU2@M 1*HU :@](XE)9";1F* MINM>653$;E&-J#*'@R3(Q.M7 U"["4JC4!J#TO@Y.S&6B]]4A!E M#GGV(2\C"LP]21]B'TY[]QK% %L/N30UA'NF/HLI0
MJZ:K2EDOGMUZM:.*9K/*CPT]MF>//O_YH!6,G_+. M^(6=\@LI[Y=PY,N4Q.Y@++4ISHTBK]^.,L3%TTD<'9D\PE->D&?MN39;:?3=0!TD!&4ED!I%$IC4!KW#&;3)";1H XPQ+ED
M$O?']?)OBR"0*XB-U@/*;/+O?|""W])=:09 K28H+8'2*)3&H#0.I:506H:B MZ>)55I-W$:O)@UI-4%H"I$I+H;0,1=-UKZR^P&JIG+8\|/FC%0PU M[: T"J4Q*
(WO:=]T&VY_8K<4NLP,1=,5J)(&$Z.W%L9*%,NL)MRPXK ^;IS8EHF.W*TQ* ^')1&H30&I7$H M+872,A1-%[7RZX+I1>H#J+4'I250&H72&)3&H;042LM0-$WWH;+V0OO@N9.-
M!WO^6 5#:0F41]$T^]:7JD>@<#@UHW%):E.<:5HF0YQM6J9066:AW3(S%@?GW(-I MYXI6&=0]@!(HE,;@- ZEI5!:AJ+IRE;.6WB1B1M#]"4'I250&H72&)3&H;04 M2LM0-
%WWRI(+OW'B1GO^: 5#S34HC4)I#$KCH6&B16\R[8^Y3$UQ?A#Y_!-^@Z6*V:WK23E8X9]PL,:,V+'S M1^L-:F=!:11*8U :A])2*"U#T72%*SLKO(B=%4+M+"@M@=(HE,:@- ZEI5!:
MAJ)INH^4G15]HYUESQ^K8"@M@=(HE,:@-!Z9GC06>M-^L\H01Z9D.)&8*2[R M8_](9R%2=E9TKIUUO%EE1XR6%-2Y@M(HE,:@-+ZG:1+P S_L*VH8YGL3K]_] M-
(7%TR@ZHB=E(D4GAF^-J3Q/=ZSL2QLM/:AY!*51*(U!:1Q*2Z&T#$73]:[, MH^@BX[DBJ.4$I250&H72&)3&H;042LM0-%WWRN2*[";7Z3H4ZGJ!!:0F41]$T M!J7Q:.A(D3#T_+A?
-1CB N](@SK4$.?+LO9(QRI2#E?T)QRN\\>"GU%)0+TO M*"V!TBB4QJ T#J6E4%J&HNF_.5111?QOB*H!P6E)5 :A=(8E,:AM!1*RU T M7??*^XJ^T?NRYX]6,-3[@M(HE,:@-!Z91F4-
1H9#EYFA:+HRE8L6V5VTK)3' MX&97CCAT6:R*4I8HLLPPJA3JF$%I"91&H30&I7$H+872,A1-5[-RS**+.&81 MU#&#TA(HC4)I#$KC4%H*I64HFJ:
[6#EF\3W/,M4E.8&PYN[C:&!4%@;E/$RBZ+[7;9?56QJSIOQ0OG'U5YO>]5&%4% M-QT.X4[4L:K76H2P>E42B-06E\3].FW)VZ_3EW4U-8=U-NOW(PA 4D[H*NVF>
MA&B3O,WO;N71Y:(F/W9]Z[I8/!W>M-7ZU94\N;RO6GDH MW]Y\$OE&PO=V]R:W-H965T5'OA@9-@%6S&-DDK[8]?VS TS#+L M1.(&L/'[')\7V]C+(Q??98:HX$>1,
[ER,J7**]>5288%D1->(M-O=EP41.FB MV+NR%$A2*RIR-_"\N5L0RIQH:>MN1;3DE8\Z/*\=W'BH^
MT7VF3(4;+4NRQRVJ+^6MT*6WI;2T0"8I9R!PMW+6_E7L>T9@6_Q%\2A/GL&D M.9WJ$.2;*((B^'7"#>6Y(NA_W#=1I8QKAZ?,#_;U-7B=S1R1N M>/Z5IBI;.1<.I+@C5:X^\>,?
V"0T,IR$Y]>X5BWG84.))54O&C$N@<%9?6= M_&B,.!'XTR<$02,('@OF3PC"1A ^-*T$4RM,W4JUH>8*!(M!3^",*TUS3Q8 M,ZU:IT^9^>Y;)?]:JG4JVE9W$N\K9 K>'?
15PNL8%;&Y? . _P9=M#*]?OH&7 M0!E\SG@E"4OETE4ZLM&[21-E4T<)GHCB!_"1,Y5)>,=23+L 5W]7?PT. K M8)#X9Y5/(C?0N %T[X._9^<32#TGI3'SY>']F$[5<(+2]\YE>
;Q]T"[A1 M6,B_>[IW7>.F_3BS5ES)DB2XO?#GWN]]5HT)BT>"=6R=K61@\!SC:QA"PLS"^XA\N>7"V^Q M= ^G%O4T\WS_8MHVZR0_;Y.?#2; H6*DS+A ^(Q)QGC.]Q0E;-
>3OKP'6>?F M/28L'@G6\7#>>C@?=Q[.QI1Q3%@\$JQCXZ*U<3$X%-=FPDE:_]@+7C'5Y!T=@ MXUSO%L^;>B/%[+ART;IR,>C*?P;7/[MD0BXIKS/GT';N?
Z,"8M'@G5.8L'@D6,=&W_NU\?,&A^,M^5G8#9_BL*[_D'###BB5K>ZSLB%V M9MG,\[SN)-L,!S[7I;%HM4WNR5:Y0+&W!PXB)B5FDZMUG6]L>:]9V,_^H?F..
M.W8+_@M3GY4^$K&G3$*..XWT)@O]1Q/U\;,N*%[:#?D=5WI[;Q\S?61#81KH M]SO.U4/!!&@/@=&_4$L#!!0 (,^#%EGOD9[L,P, "03 - >&PO MG'./[1ML&%5F+=C=@C$3K
HAJS%9&%-^ M",-JOF %K2Y4R:1%,J4+:FQ7YV%5:D;3"DB% >]7AP6E$IR&AP-T^IV/2C]^3P,E-57=RTKOH/9Q?[R-G M#71.0]_PY0N$45E,-'Z1V^?
LHM)7N]+UXZ=6R!%,=K00[-9.B9T,'+B)6]1 M:V+8K.1DE"G9+6A$7,]TX(%CU2,R90*/M,<6!DMN%B[\ "L>7P/V/3 (!>B-3@@+C 9E=08IN6-[=0/ MU\$G4-
"T[]>E=9AKNNX/+DE'J&\VR4SIE.DV39]L0I.18!G8T3Q?P-VH,@30 M&%781LIIKB2M/6P83\8*$T_V6S0:G,;8!I$CPR;?A\._)3T_*>KFRWZT$W&QV#R*)9[> PF
MDX,T&38;^-8I8>>,T$8#.(N-R33 '&,>QL#$_TWB&Z'@I$A MRAFB',?R(=/Z@^7Q:)%$4QIB,3J=>!U-LWN(8?OQJF#=@8'D@TY_ - M;-[:>(4\7P87FCY7(=A(\4K$1HK/-2#^>0-
&DOA7&\L##&P5L-J![/X\4%-^ M3A3!JF/+>L#<81Y($0Z 6_34:Q\CLQ/#QRP_VED11DO@1P/P.H@A#X&W$$,"0**KWP;W]*-SL4V'W?[');U!+ P04 " #/@Q99EXJ[', 3 @ M"P
%|R96QS+RYR96QSG9*Y;L,P#$! Q="> , ?0(8@S9?$6!/D!5](/V!(% MBD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+]1C]$%)I6M6X 4BV)8|ISI%"KM0L M'C6'TD!$VV-#L%HL/D
N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO M8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 (,^#%ED0,]S/ M_04 /,T /
>&PO=V]R:V)O;VLN>&ULQ9O?4^(Z%(#_E0Q/W@0CES7PX^(6TM'R=)0W.2\,U% MFQ\+K7^PUSQ3|KRW%$KMUWI?IAN1<_NWW@KESJRJ_M074.0]PT&GAWIIUWVZ-X$N[$:+(
ML[XW&$3]G$O5N_CV?J^9Z<,WNA!I(;5R!ZL#CU*\V#_GJ[?L65JYD)DL?IWW MZK\ST6.Y5#*7O\7RO#?H,;O1+|?:R-|:%3Q+4J.S[+PW;$X\"E/(=.]P4D'. M^<+61PJ^>. .Y+P7#=P-

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end XML 99 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE') {var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}} XML 100 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 102 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html3684881false950false6 falsefalseR1.htm995200090 - Document - Document And Entity InformationSheethttp://www.bio-techne.com/role/DocumentDocumentAndEntityInformationDocument And Entity InformationCover1 falsefalseR2.htm995200100 - Statement - CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOMESheethttp://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncomeCONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOMEStatements2 falsefalseR3.htm995200200 - Statement - CONSOLIDATED BALANCE SHEETSSheethttp://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheetsCONSOLIDATED BALANCE SHEETSStatements3 falsefalseR4.htm995200205 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)Sheethttp://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheetsParentheticalCONSOLIDATED BALANCE SHEETS (Parenthetical)Statements4 falsefalseR5.htm995200300 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITYSheethttp://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquityCONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITYStatements5 falsefalseR6.htm995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlowsCONSOLIDATED STATEMENTS OF CASH FLOWSStatements6 falsefalseR7.htm995210101 - Disclosure - Description of Business and Summary of Significant Accounting Policies:Sheethttp://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDescription of Business and Summary of Significant Accounting Policies:Notes7 falsefalseR8.htm995210201 - Disclosure - Revenue RecognitionSheethttp://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionRevenue RecognitionNotes8 falsefalseR9.htm995210301 - Disclosure - Supplemental Balance Sheet and Cash Flow InformationSheethttp://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationSupplemental Balance Sheet and Cash Flow InformationNotes9 falsefalseR10.htm995210401 - Disclosure - AcquisitionsSheethttp://www.bio-techne.com/20211231/role/DisclosureAcquisitionsAcquisitionsNotes10 falsefalseR11.htm995210501 - Disclosure - Fair Value MeasurementsSheethttp://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsFair Value MeasurementsNotes11 falsefalseR12.htm995210601 - Disclosure - Debt and Other Financing ArrangementsSheethttp://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsDebt and Other Financing ArrangementsNotes12 falsefalseR13.htm995210701 - Disclosure - LeasesSheethttp://www.bio-techne.com/20211231/role/DisclosureLeasesLeasesNotes13 falsefalseR14.htm995210801 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) InformationSheethttp://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationSupplemental Equity and Accumulated Other Comprehensive Income (loss) InformationNotes14 falsefalseR15.htm995210901 - Disclosure - Earnings Per ShareSheethttp://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareEarnings Per ShareNotes15 falsefalseR16.htm995211001 - Disclosure - Share-based Compensation and Other Benefit PlansSheethttp://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationAndOtherBenefitPlansShare-based Compensation and Other Benefit PlansNotes16 falsefalseR17.htm995211101 - Disclosure - Other Income / (Expense)Sheethttp://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseOther Income / (Expense)Notes17 falsefalseR18.htm995211201 - Disclosure - Income TaxesSheethttp://www.bio-techne.com/20211231/role/DisclosureIncomeTaxesIncome TaxesNotes18 falsefalseR19.htm995211301 - Disclosure - Segment InformationSheethttp://www.bio-techne.com/20211231/role/DisclosureSegmentInformationSegment InformationNotes19 falsefalseR20.htm995211401 - Disclosure - Subsequent EventsSheethttp://www.bio-techne.com/20211231/role/DisclosureSubsequentEventsSubsequent EventsNotes20 falsefalseR21.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes21 falsefalseR22.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes22 falsefalseR23.htm995447 - Disclosure - Insider Trading Policies and ProceduresSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProcInsider Trading Policies and ProceduresNotes23 falsefalseR24.htm99920102 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)Sheethttp://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPoliciesDescription of Business and Summary of Significant Accounting Policies (Policies)Policieshttp://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies24 falsefalseR25.htm99930103 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)Sheethttp://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTablesDescription of Business and Summary of Significant Accounting Policies (Tables)Tableshttp://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies25 falsefalseR26.htm99930203 - Disclosure - Revenue Recognition (Tables)Sheethttp://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionTablesRevenue Recognition (Tables)Tableshttp://www.bio-techne.com/20211231/role/DisclosureRevenueRecognition26 falsefalseR27.htm99930303 - Disclosure - Supplemental Balance Sheet and Cash Flow Information (Tables)Sheethttp://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationTablesSupplemental Balance Sheet and Cash Flow Information (Tables)Tableshttp://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformation27 falsefalseR28.htm99930403 - Disclosure - Acquisitions (Tables)Sheethttp://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTablesAcquisitions (Tables)Tableshttp://www.bio-techne.com/20211231/role/DisclosureAcquisitions28 falsefalseR29.htm99930503 - Disclosure - Fair Value Measurements (Tables)Sheethttp://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsTablesFair Value Measurements (Tables)Tableshttp://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurements29 falsefalseR30.htm99930703 - Disclosure - Leases (Tables)Sheethttp://www.bio-techne.com/20211231/role/DisclosureLeasesTablesLeases (Tables)Tableshttp://www.bio-techne.com/20211231/role/DisclosureLeases30 falsefalseR31.htm99930803 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)Sheethttp://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTablesSupplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)Tableshttp://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformation31 falsefalseR32.htm99930903 - Disclosure - Earnings Per Share (Tables)Sheethttp://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareTablesEarnings Per Share (Tables)Tableshttp://www.bio-techne.com/20211231/role/DisclosureEarningsPerShare32 falsefalseR33.htm99931003 - Disclosure - Share-based Compensation and Other Benefit Plans (Tables)Sheethttp://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansTablesShare-based Compensation and Other Benefit Plans (Tables)Tableshttp://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationAndOtherBenefitPlans33 falsefalseR34.htm99931103 - Disclosure - Other Income / (Expense) (Tables)Sheethttp://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseTablesOther Income / (Expense) (Tables)Tableshttp://www.bio-

techne.com/20211231/role/DisclosureOtherIncomeExpense34 falsefalseR35.htm99931203 - Disclosure - Income Taxes (Tables)Sheethttp://www.bio-techne.com/role/DisclosureIncomeTaxesTablesIncome Taxes (Tables)Tableshttp://www.bio-techne.com/20211231/role/DisclosureIncomeTaxes35 falsefalseR36.htm99931303 - Disclosure - Segment Information (Tables)Sheethttp://www.bio-techne.com/20211231/role/DisclosureSegmentInformationTablesSegment Information (Tables)Tableshttp://www.bio-techne.com/20211231/role/DisclosureSegmentInformation36 falsefalseR37.htm99940101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)Sheethttp://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailsBasis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)Details37 falsefalseR38.htm99940102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetailsBasis of Presentation and Summary of Significant Accounting Policies - Investments (Details)Details38 falsefalseR39.htm99940103 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetailsBasis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details)Details39 falsefalseR40.htm99940201 - Disclosure - Revenue Recognition - Narrative (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionNarrativeDetailsRevenue Recognition - Narrative (Details)Details40 falsefalseR41.htm99940202 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetailsRevenue Recognition - Disaggregation of Revenue (Details)Details41 falsefalseR42.htm99940301 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Narrative (Details)Sheethttp://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetailsSupplemental Balance Sheet and Cash Flow Information - Narrative (Details)Detailshttp://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationTables42 falsefalseR43.htm99940302 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationInventoriesDetailsSupplemental Balance Sheet and Cash Flow Information - Inventories (Details)Details43 falsefalseR44.htm99940303 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationPropertyAndEquipmentDetailsSupplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details)Details44 falsefalseR45.htm99940304 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetailsSupplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details)Details45 falsefalseR46.htm99940305 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetailsSupplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details)Details46 falsefalseR47.htm99940306 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationEstimatedFutureAmortizationExpenseForIntangibleAssetsDetailsSupplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details)Details47 falsefalseR48.htm99940307 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetailsSupplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details)Details48 falsefalseR49.htm99940308 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details)Sheethttp://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationOtherAssetsDetailsSupplemental Balance Sheet and Cash Flow Information - Other Assets (Details)Details49 falsefalseR50.htm99940309 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details)Sheethttp://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationSupplementalCashFlowInformationDetailsSupplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details)Details50 falsefalseR51.htm99940401 - Disclosure - Acquisitions - Narrative (Details)Sheethttp://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetailsAcquisitions - Narrative (Details)Details51 falsefalseR52.htm99940402 - Disclosure - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetailsAcquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)Details52 falsefalseR53.htm99940501 - Disclosure - Fair Value Measurements - Narrative (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetailsFair Value Measurements - Narrative (Details)Details53 falsefalseR54.htm99940502 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsFair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)Details54 falsefalseR55.htm99940503 - Disclosure - Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details)Sheethttp://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetailsFair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details)Details55 falsefalseR56.htm99940504 - Disclosure - Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details)Sheethttp://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetailsFair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details)Details56 falsefalseR57.htm99940505 - Disclosure - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetailsFair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details)Details57 falsefalseR58.htm99940601 - Disclosure - Debt and Other Financing Arrangements - Narrative (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetailsDebt and Other Financing Arrangements - Narrative (Details)Details58 falsefalseR59.htm99940701 - Disclosure - Leases - Narrative (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetailsLeases - Narrative (Details)Details59 falsefalseR60.htm99940702 - Disclosure - Leases - Balance Sheet Classification (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetailsLeases - Balance Sheet Classification (Details)Details60 falsefalseR61.htm99940703 - Disclosure - Leases - Cash Paid (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureLeasesCashPaidDetailsLeases - Cash Paid (Details)Details61 falsefalseR62.htm99940704 - Disclosure - Leases - Fair Value of the Lease Liability by Payment Date (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetailsLeases - Fair Value of the Lease Liability by Payment Date (Details)Details62 falsefalseR63.htm99940801 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details)Sheethttp://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetailsSupplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details)Detailshttp://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTables63 falsefalseR64.htm99940802 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLossEquity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)Detailshttp://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTables64 falsefalseR65.htm99940901 - Disclosure - Earnings Per Share - Narrative (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareNarrativeDetailsEarnings Per Share - Narrative (Details)Details65 falsefalseR66.htm99940902 - Disclosure - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetailsEarnings Per Share - Shares Used in the Earnings Per Share Computations (Details)Details66 falsefalseR67.htm99941001 - Disclosure - Share-based Compensation and Other Benefit Plans (Details)Sheethttp://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetailsShare-based Compensation and Other Benefit Plans (Details)Detailshttp://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansTables67 falsefalseR68.htm99941002 - Disclosure - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)Sheethttp://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansAssumptionsUsedInBlackScholesOptionPricingModelDetailsShare-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)Details68 falsefalseR69.htm99941003 - Disclosure - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details)Sheethttp://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetailsShare-based Compensation and Other Benefit Plans - Stock Option Activity (Details)Details69 falsefalseR70.htm99941004 - Disclosure - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details)Sheethttp://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetailsShare-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details)Details70 falsefalseR71.htm99941101 - Disclosure - Other Income / (Expense) - Narrative (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseNarrativeDetailsOther Income / (Expense) - Narrative (Details)Detailshttp://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseTables71 falsefalseR72.htm99941102 - Disclosure - Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetailsOther Income / (Expense) - Schedule of Components of Other Income (Expense) (Details)Detailshttp://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseTables72 falsefalseR73.htm99941201 - Disclosure - Income Taxes - Narrative (Details)Sheethttp://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetailsIncome Taxes - Narrative (Details)Details73 falsefalseR74.htm99941202 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)Sheethttp://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetailsIncome Taxes - Components of Provision for Income Taxes (Details)Details74 falsefalseR75.htm99941203 - Disclosure - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)Sheethttp://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetailsIncome Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)Details75 falsefalseR76.htm99941204 - Disclosure - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details)Sheethttp://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetailsIncome Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details)Details76 falsefalseR77.htm99941205 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)Sheethttp://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetailsIncome Taxes - Reconciliation of Unrecognized Tax Benefits (Details)Details77 falsefalseR78.htm99941301 - Disclosure - Segment Information - Narrative (Details)Sheethttp://www.bio-techne.com/role/DisclosureSegmentInformationNarrativeDetailsSegment Information - Narrative (Details)Details78 falsefalseR79.htm99941302 - Disclosure - Segment Information - Financial Information Relating to Reportable Segments (Details)Sheethttp://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetailsSegment Information - Financial Information Relating to Reportable Segments (Details)Details79 falsefalseR80.htm99941401 - Disclosure - Subsequent Events (Details)Sheethttp://www.bio-techne.com/role/DisclosureSubsequentEventsDetailsSubsequent Events (Details)Detailshttp://www.bio-techne.com/20211231/role/DisclosureSubsequentEvents80 falsefalseAll ReportsBookAll Reports tech-20240630.xsdtech-20240630_cal.xmltech-20240630_def.xmltech-20240630_lab.xmltech-20240630_pre.xmltech-20240630x10k.htm tech-20240630x10k005.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 105 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tech-20240630x10k.htm": { "nsprefix": "tech", "nsuri": "http://www.bio-techne.com/20240630", "dts": { "schema": { "local": ["tech-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-

2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["tech-20240630_cal.xml"] }, "definitionLink": { "local": ["tech-20240630_def.xml"] }, "labelLink": { "local": ["tech-20240630_lab.xml"] }, "presentationLink": { "local": ["tech-20240630_pre.xml"] }, "inline": { "local": ["tech-20240630x10k.htm"] } }, "keyStandard": 426, "keyCustom": 62, "axisStandard": 33, "axisCustom": 0, "memberStandard": 54, "memberCustom": 39, "hidden": { "total": 29, "http://fasb.org/us-gaap/2024": 24, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 368, "entityCount": 1, "segmentCount": 95, "elementCount": 796, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1312, "http://xbrl.sec.gov/dei/2024": 37, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome", "longName": "995200100 - Statement - CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME", "shortName": "CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R3": { "role": "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets", "longName": "995200200 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "995200205 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity", "longName": "995200300 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_khJKcGnHjkuAqxRPm0cY8g", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Unit_Standard_shares_zCLop6g3i0-6BqWelilX-Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_khJKcGnHjkuAqxRPm0cY8g", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Unit_Standard_shares_zCLop6g3i0-6BqWelilX-Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R7": { "role": "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies", "longName": "995210101 - Disclosure - Description of Business and Summary of Significant Accounting Policies:", "shortName": "Description of Business and Summary of Significant Accounting Policies:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognition", "longName": "995210201 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformation", "longName": "995210301 - Disclosure - Supplemental Balance Sheet and Cash Flow Information", "shortName": "Supplemental Balance Sheet and Cash Flow Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bio-techne.com/20211231/role/DisclosureAcquisitions", "longName": "995210401 - Disclosure - Acquisitions", "shortName": "Acquisitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurements", "longName": "995210501 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangements", "longName": "995210601 - Disclosure - Debt and Other Financing Arrangements", "shortName": "Debt and Other Financing Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bio-techne.com/20211231/role/DisclosureLeases", "longName": "995210701 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformation", "longName": "995210801 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information", "shortName": "Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShare", "longName": "995210901 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationAndOtherBenefitPlans", "longName": "995211001 - Disclosure - Share-based Compensation and Other Benefit

Plans", "shortName": "Share-based Compensation and Other Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpense", "longName": "995211101 - Disclosure - Other Income / (Expense)", "shortName": "Other Income / (Expense)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxes", "longName": "995211201 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformation", "longName": "995211301 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSubsequentEvents", "longName": "995211401 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_DXb-tHCSmk-R42gTAK6Apg", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_DXb-tHCSmk-R42gTAK6Apg", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920102 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)", "shortName": "Description of Business and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables", "longName": "99930103 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)", "shortName": "Description of Business and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionTables", "longName": "99930203 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationTables", "longName": "99930303 - Disclosure - Supplemental Balance Sheet and Cash Flow Information (Tables)", "shortName": "Supplemental Balance Sheet and Cash Flow Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables", "longName": "99930403 - Disclosure - Acquisitions (Tables)", "shortName": "Acquisitions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_BusinessAcquisitionAxis_tech_LunaphoreTechnologiesSaMember_B5FpgaiTO0GHBFQvDOoUTg", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_BusinessAcquisitionAxis_tech_LunaphoreTechnologiesSaMember_B5FpgaiTO0GHBFQvDOoUTg", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsTables", "longName": "99930503 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bio-techne.com/20211231/role/DisclosureLeasesTables", "longName": "99930703 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "tech:LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "tech:LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTables", "longName": "99930803 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)", "shortName": "Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareTables", "longName": "99930903 - Disclosure - Earnings Per Share (Tables)", "shortName": "Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R33": { "role":

"http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansTables", "longName": "99931003 - Disclosure - Share-based Compensation and Other Benefit Plans (Tables)", "shortName": "Share-based Compensation and Other Benefit Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseTables", "longName": "99931103 - Disclosure - Other Income / (Expense) (Tables)", "shortName": "Other Income / (Expense) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bio-techne.com/role/DisclosureIncomeTaxesTables", "longName": "99931203 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationTables", "longName": "99931303 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "99940101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:AdvertisingExpense", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:AdvertisingCostsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:AdvertisingExpense", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:AdvertisingCostsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "longName": "99940102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_7_1_2022_To_6_30_2023_HamK4woZsEWUKUdx2z4PNw", "name": "us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2023_To_12_31_2023_voZ31ukB00ujM6dTqfZKrA", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "unitRef": "Unit_Standard_pure_bsd1aCaCN0WGvpDLaUwy9g", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "tech:RestructuringActionsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R39": { "role": "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "longName": "99940103 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "tech:RestructuringCostsNetOfAdjustments", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "tech:RestructuringCostsNetOfAdjustments", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionNarrativeDetails", "longName": "99940201 - Disclosure - Revenue Recognition - Narrative (Details)", "shortName": "Revenue Recognition - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "longName": "99940202 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)", "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_srt_StatementGeographicalAxis_country_US_hq9Umxax0Em547suUZfAmw", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R42": { "role": "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails", "longName": "99940301 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Narrative (Details)", "shortName": "Supplemental Balance Sheet and Cash Flow Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_P2BQuzpk_Ui7BYeh5nsFXA", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R43": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationInventoriesDetails", "longName": "99940302 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details)", "shortName": "Supplemental Balance Sheet and Cash Flow Information - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationPropertyAndEquipmentDetails", "longName": "99940303 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details)", "shortName": "Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "longName": "99940304 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details)", "shortName": "Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails", "longName": "99940305 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details)", "shortName": "Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",

"menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_6_30_2023_VXsQ_3kepkSSwBQZ7RSyvg", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R47": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails", "longName": "99940306 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details)", "shortName": "Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R48": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetails", "longName": "99940307 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details)", "shortName": "Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_6_30_2023_VXsQ_3kepkSSwBQZ7RSyvg", "name": "us-gaap:Goodwill", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R49": { "role": "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationOtherAssetsDetails", "longName": "99940308 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details)", "shortName": "Supplemental Balance Sheet and Cash Flow Information - Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:EquityMethodInvestments", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:EquityMethodInvestments", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationSupplementalCashFlowInformationDetails", "longName": "99940309 - Disclosure - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details)", "shortName": "Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:IncomeTaxesPaidNet", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:IncomeTaxesPaidNet", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "longName": "99940401 - Disclosure - Acquisitions - Narrative (Details)", "shortName": "Acquisitions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_7_1_2022_To_6_30_2023_HamK4woZsEWUKUdx2z4PNw", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2022_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_tech_NamocellIncMember_v_i9y1qNFkitGDLh0gRZrA", "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R52": { "role": "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "longName": "99940402 - Disclosure - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)", "shortName": "Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:Goodwill", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_7_7_2023_us-gaap_BusinessAcquisitionAxis_tech_LunaphoreTechnologiesSaMember_sr3Uw1509UKjaNrCOI_ZqA", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R53": { "role": "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "longName": "99940501 - Disclosure - Fair Value Measurements - Narrative (Details)", "shortName": "Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_us-gaap_FinancialInstrumentAxis_tech_ExchangeTradedInvestmentGradeBondFundsMember_0BXDUmezRkG7EEME4ZwSdg", "name": "us-gaap:Investments", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R54": { "role": "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "longName": "99940502 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "shortName": "Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_pCMubFKp_0eg9XpbuuqFrQ", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_pCMubFKp_0eg9XpbuuqFrQ", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "longName": "99940503 - Disclosure - Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details)", "shortName": "Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DerivativeInstrumentRiskAxis_tech_ForwardStartingSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_HaD0vKi0TkS-dgL6ER1OLw", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DerivativeInstrumentRiskAxis_tech_ForwardStartingSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_HaD0vKi0TkS-dgL6ER1OLw", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails", "longName": "99940504 - Disclosure - Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details)", "shortName": "Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_DerivativeInstrumentRiskAxis_tech_ForwardStartingSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_gXWZNCg_S0GJDL15JOrltw", "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R57": { "role": "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails", "longName": "99940505 - Disclosure - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details)", "shortName": "Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_tech_ContingentConsiderationMember_3p5pLw8RAEqmlmaEgOfc5w", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil":

"false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_tech_ContingentConsiderationMember_B118nXxLQk6xP8JQrcsgPA", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R58": { "role": "http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails", "longName": "99940601 - Disclosure - Debt and Other Financing Arrangements - Narrative (Details)", "shortName": "Debt and Other Financing Arrangements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ProceedsFromLongTermLinesOfCredit", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DebtInstrumentAxis_tech_CreditAgreementMember_NJ61Wg6Xik6_WItDQDASkA", "name": "us-gaap:LinesOfCreditCurrent", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R59": { "role": "http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails", "longName": "99940701 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:VariableLeaseCost", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:VariableLeaseCost", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails", "longName": "99940702 - Disclosure - Leases - Balance Sheet Classification (Details)", "shortName": "Leases - Balance Sheet Classification (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Oy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Oy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "tech:LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R61": { "role": "http://www.bio-techne.com/20211231/role/DisclosureLeasesCashPaidDetails", "longName": "99940703 - Disclosure - Leases - Cash Paid (Details)", "shortName": "Leases - Cash Paid (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "tech:LesseeOperatingLeaseCashFlowInformationTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "tech:LesseeOperatingLeaseCashFlowInformationTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails", "longName": "99940704 - Disclosure - Leases - Fair Value of the Lease Liability by Payment Date (Details)", "shortName": "Leases - Fair Value of the Lease Liability by Payment Date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Oy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Oy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails", "longName": "99940801 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details)", "shortName": "Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "Unit_Divide_USD_shares_WPgdBOpid0yALDB2lUOVeQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["us-gaap:CommonStockDividendsPerShareDeclared", "us-gaap:CommonStockDividendsPerShareDeclared", "p", "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "Unit_Divide_USD_shares_WPgdBOpid0yALDB2lUOVeQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["us-gaap:CommonStockDividendsPerShareDeclared", "us-gaap:CommonStockDividendsPerShareDeclared", "p", "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "longName": "99940802 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)", "shortName": "Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_6_30_2023_VXsQ_3kepkSSwBQZ7RSyvg", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fUjzuiDNuUmuudUaUWIiCA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R65": { "role": "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareNarrativeDetails", "longName": "99940901 - Disclosure - Earnings Per Share - Narrative (Details)", "shortName": "Earnings Per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_zCLop6g3i0-6BqWelilX-Q", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_zCLop6g3i0-6BqWelilX-Q", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "longName": "99940902 - Disclosure - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)", "shortName": "Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R67": { "role": "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails", "longName": "99941001 - Disclosure - Share-based Compensation and Other Benefit Plans (Details)", "shortName": "Share-based Compensation and Other Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Oy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_zCLop6g3i0-6BqWelilX-Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "Unit_Divide_USD_shares_WPgdBOpid0yALDB2lUOVeQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R68": { "role": "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansAssumptionsUsedInBlackScholesOptionPricingModelDetails", "longName": "99941002 - Disclosure - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)", "shortName": "Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Unit_Standard_pure_bsd1aCaCN0WGvpDLaUwy9g", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Unit_Standard_pure_bsd1aCaCN0WGvpDLaUwy9g", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails", "longName": "99941003 - Disclosure - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details)", "shortName": "Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "As_Of_6_30_2023_VXsQ_3kepkSSwBQZ7RSyvg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_zCLop6g3i0-6BqWelilX-Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2021_CKtAkRDaOE64pP62NJyg0g", "name": "us-

gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "Unit_Divide_USD_shares_WPgdBOpid0yALDB2lUOVeQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R70": { "role": "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails", "longName": "99941004 - Disclosure - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details)", "shortName": "Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_gepvVv-EE0Gpg7PT2q-MNg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_zCLop6g3i0-6BqWelilX-Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_Wkv2kSODVkKuh7mfbnOKmw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_zCLop6g3i0-6BqWelilX-Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R71": { "role": "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseNarrativeDetails", "longName": "99941101 - Disclosure - Other Income / (Expense) - Narrative (Details)", "shortName": "Other Income / (Expense) - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:DebtAndEquitySecuritiesRealizedGainLoss", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:DebtAndEquitySecuritiesRealizedGainLoss", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails", "longName": "99941102 - Disclosure - Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details)", "shortName": "Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:InterestExpenseNonoperating", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:GainLossOnInvestments", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R73": { "role": "http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails", "longName": "99941201 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Unit_Standard_pure_bsd1aCaCN0WGvpDLaUwy9g", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R74": { "role": "http://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails", "longName": "99941202 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)", "shortName": "Income Taxes - Components of Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails", "longName": "99941203 - Disclosure - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)", "shortName": "Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_bsd1aCaCN0WGvpDLaUwy9g", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_bsd1aCaCN0WGvpDLaUwy9g", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails", "longName": "99941204 - Disclosure - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details)", "shortName": "Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:DeferredTaxAssetsInventory", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Qy8fevUf_UqdiMRMGtHMpA", "name": "us-gaap:DeferredTaxAssetsInventory", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails", "longName": "99941205 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "As_Of_6_30_2023_VXsQ_3kepkSSwBQZ7RSyvg", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2021_CKtAkRDaOE64pP62NJyg0g", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R78": { "role": "http://www.bio-techne.com/role/DisclosureSegmentInformationNarrativeDetails", "longName": "99941301 - Disclosure - Segment Information - Narrative (Details)", "shortName": "Segment Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_9Uf6N9L7nk-0zjiy0Ph3NA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_9Uf6N9L7nk-0zjiy0Ph3NA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "longName": "99941302 - Disclosure - Segment Information - Financial Information Relating to Reportable Segments (Details)", "shortName": "Segment Information - Financial Information Relating to Reportable Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "tech:AmortizationOfAcquiredIntangibleAssets", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } }, "R80": { "role": "http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails", "longName": "99941401 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_nZ4Ir8u5_kiooYWfYSn0IA", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_23_2024_To_7_23_2024_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_tech_SpearBioMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_MLoV0SDYwkqH9LIl4QtgaA", "name": "us-gaap:PaymentsToAcquireInvestments", "unitRef": "Unit_Standard_USD_RW8HyFXNkUiDc9wAdl5MEA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20240630x10k.htm", "unique": true } } }, "tag": { "tech_APACExcludingGreaterChinaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "APACExcludingGreaterChinaMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the APAC, excluding Greater China.", "label": "APAC, excluding Greater China" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Description of Business and Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Trade accounts payable", "terseLabel": "Trade accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the

liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r98", "r1047"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, less allowance for doubtful accounts of $4,386 and $4,738, respectively", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r1222"] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Income taxes payable", "terseLabel": "Income taxes payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": ["r101", "r175"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued expenses", "terseLabel": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r101"] }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees", "terseLabel": "Accrued litigation", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received." } } }, "auth_ref": ["r177"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r53", "r216", "r830"] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss], "lang": { "en-us": { "role": { "label": "Unrealized Gains (Losses) on Derivative Instruments", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": ["r230", "r231", "r232", "r234", "r242", "r243", "r1191"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r32", "r33", "r121", "r221", "r826", "r869", "r870"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails", "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r5", "r19", "r33", "r688", "r691", "r742", "r865", "r866", "r1191", "r1192", "r1193", "r1207", "r1208", "r1209", "r1211"] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss], "lang": { "en-us": { "role": { "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "verboseLabel": "Foreign Currency Translation Adjustments", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": ["r6", "r19", "r33", "r119", "r120", "r242", "r243", "r719", "r720", "r721", "r722", "r723", "r1191"] }, "tech_AcquisitionOfAsuragenIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "AcquisitionOfAsuragenIncMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information regarding the acquisition of Asuragen, Inc.", "label": "Asuragen, Inc." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r1115"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital(1)", "terseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r109"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r879", "r1207", "r1208", "r1209", "r1211", "r1324", "r1394"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r1128"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r1128"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r1128"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r1128"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition", "terseLabel": "Employee stock purchase plan expense", "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r59", "r60", "r577"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net earnings to net cash provided by operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising costs", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": ["r196"] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_AdvertisingExpense", "terseLabel": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": ["r620", "r1027"] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r1162"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r1086", "r1097", "r1107", "r1140"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r1089", "r1100", "r1110", "r1143"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r1163"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r1128"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r1135"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r1090",

"r1101", "r1111", "r1135", "r1144", "r1148", "r1156"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r1154"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "negatedLabel": "Stock based compensation, inclusive of employer taxes", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r609", "r618"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Accounts receivable, allowance for doubtful accounts", "terseLabel": "Accounts receivable, allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": ["r222", "r348", "r388"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "tech_AmortizationOfAcquiredIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "AmortizationOfAcquiredIntangibleAssets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the amount of amortization of acquired intangible assets.", "label": "Amortization Of Acquired Intangible Assets", "negatedLabel": "Amortization of intangibles" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_AmortizationOfIntangibleAssets", "negatedTerseLabel": "Amortization expense", "terseLabel": "Amortization of Intangible Assets, Total", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r12", "r417", "r424", "r1004"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r298"] }, "srt_AsiaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AsiaMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Asia [Member]" } } }, "auth_ref": ["r1396", "r1397", "r1398", "r1399"] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetImpairmentCharges", "terseLabel": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r12", "r52"] }, "tech_AssetImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "AssetImpairmentMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "documentation": "Information related to asset impairment and other.", "label": "Asset Impairment and Other [Member]", "terseLabel": "Asset impairment and other" } } }, "auth_ref": [] }, "tech_AssetImpairmentRestructuringCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "AssetImpairmentRestructuringCharge", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The value of asset impairment restructuring charge.", "label": "Asset impairment restructuring", "terseLabel": "Asset impairment restructuring" } } }, "auth_ref": [] }, "tech_AssetRelatedAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "AssetRelatedAndOtherMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to asset related and other costs of restructuring pursuant to a plan.", "label": "Asset Related And Other [Member]", "terseLabel": "Asset-related and other" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r173", "r188", "r220", "r259", "r303", "r309", "r334", "r338", "r385", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r465", "r466", "r679", "r683", "r715", "r822", "r910", "r995", "r996", "r1047", "r1076", "r1272", "r1273", "r1350"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "tech_AssetsClassifiedAsNoncurrentOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "AssetsClassifiedAsNoncurrentOther", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationOtherAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Assets classified as noncurrent other", "terseLabel": "Other" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r211", "r226", "r259", "r385", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r465", "r466", "r679", "r683", "r715", "r1047", "r1272", "r1273", "r1350"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Total assets", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r698", "r699", "r1032"] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Current assets held-for-sale", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r4", "r96", "r97", "r149", "r152", "r209", "r210"] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": ["r1080", "r1081", "r1093"] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": ["r1080", "r1081", "r1093"] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": ["r1080", "r1081", "r1093"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r1151"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r1152"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r1147"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r1147"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r1147"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r1147"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r1147"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r1147"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r580", "r581", "r582", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r604", "r605", "r606", "r607", "r608"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r1150"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1149"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r1148"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r1148"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r440", "r1361", "r1362"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r84", "r87", "r440", "r1361", "r1362"] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingAndBuildingImprovementsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Building and Improvements [Member]", "terseLabel": "Building and improvements", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "tech_BuildingBuildingImprovementsAndLeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "BuildingBuildingImprovementsAndLeaseholdImprovementsMember", "presentation": ["http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to building, building improvements and leasehold improvements.", "label": "Building, Building Improvements and Leasehold Improvements [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r418", "r419", "r420", "r421", "r422", "r670", "r1017", "r1020"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r62", "r64", "r418", "r419", "r420", "r421", "r422", "r670", "r1017", "r1020"] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationAcquisitionRelatedCosts", "negatedLabel": "Acquisition related expenses and other", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": ["r61"] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "BusinessCombinationConsiderationTransferred1", "totalLabel": "Net assets acquired", "verboseLabel": "Acquisition amount", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": ["r1", "r2", "r15"] }, "tech_BusinessCombinationConsiderationTransferredAdditionalConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "BusinessCombinationConsiderationTransferredAdditionalConsideration", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of additional consideration transferred, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.", "label": "Business Combination, Consideration Transferred, Additional Consideration", "terseLabel": "Additional consideration" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "terseLabel": "Estimated net working capital payable", "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": ["r1", "r2", "r70", "r673"] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Contingent consideration payments", "terseLabel": "Contingent consideration payments - operating", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": ["r675", "r1201"] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "verboseLabel": "Maximum contingent consideration", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": ["r72"] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability", "verboseLabel": "Contingent consideration", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r71", "r165", "r674", "r700", "r701", "r702"] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Contingent consideration payable", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r71", "r165"] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitions"], "lang": { "en-us": { "role": { "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": ["r162", "r671"] }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "terseLabel": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": ["r63"] }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "terseLabel": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": ["r63"] }, "us-gaap_BusinessCombinationProvisionalInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Provisional Information [Abstract]" } } }, "auth_ref": [] }, "tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to assets acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination Provisional Information Initial Accounting Incomplete Adjustment Assets", "terseLabel": "Total assets acquired, adjustments" } } }, "auth_ref": [] }, "tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCashTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCashTransferred", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of cash paid in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cash Transferred", "terseLabel": "Cash paid, adjustments" } } }, "auth_ref": [] }, "tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to current assets acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Assets", "terseLabel": "Current assets, adjustments" } } }, "auth_ref": [] }, "tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEstimatedNetWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEstimatedNetWorkingCapital", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"],

"lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of estimated net working capital in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Estimated Net Working Capital", "terseLabel": "Estimated Net Working Capital, adjustments" } } }, "auth_ref": [] }, "tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to goodwill acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill", "terseLabel": "Adjustments to fair value, Goodwill" } } }, "auth_ref": [] }, "tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to net assets acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net Assets", "terseLabel": "Net assets acquired, adjustments" } } }, "auth_ref": [] }, "tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsLiabilities", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to assets acquired (liabilities assumed) in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net Assets (Liabilities)", "terseLabel": "Adjustments to fair value, Net assets acquired" } } }, "auth_ref": [] }, "tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteDeferredIncomeTaxNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteDeferredIncomeTaxNet", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to deferred income taxes, after deferred tax assets, assumed in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination Provisional Information Initial Accounting Incomplete Deferred Income Tax Net", "terseLabel": "Deferred income taxes, net, adjustments" } } }, "auth_ref": [] }, "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired, including goodwill, at the acquisition date.", "label": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill", "totalLabel": "Total assets acquired" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "terseLabel": "Current assets", "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r66"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "terseLabel": "Deferred income taxes, net", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": ["r66"] }, "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of equipment and other long-term assets acquired at the acquisition date.", "label": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets", "terseLabel": "Equipment and other long-term assets" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "terseLabel": "Intangible assets", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": ["r65", "r66"] }, "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of liabilities excluding deferred income taxes assumed at the acquisition date.", "label": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal", "terseLabel": "Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "totalLabel": "Net assets acquired", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r66"] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Acquisitions" } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Business Description and Accounting Policies [Text Block]", "terseLabel": "Description of Business and Summary of Significant Accounting Policies", "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r144", "r145"] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.org/country/2024", "localname": "CN", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails"], "lang": { "en-us": { "role": { "label": "Greater China" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r40", "r214", "r979"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and cash equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r41"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r40", "r141", "r257"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net change in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r3", "r141"] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash flow hedges", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": ["r81"] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Certificates of

Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": ["r14", "r1070", "r1071", "r1072", "r1073"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r1126"] }, "tech_ChangzhouEminenceBiotechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ChangzhouEminenceBiotechnologyMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information related to Changzhou Eminence Biotechnology Co, Ltd.", "label": "Eminence Biotechnology" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r1123"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r1121"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r1127"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r1127"] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Contingencies", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": ["r55", "r962"] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_CommonStockDividendsPerShareDeclared", "terseLabel": "Common Stock, dividends, per share, declared (in dollars per share)", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": ["r157"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r1066", "r1067", "r1068", "r1070", "r1071", "r1072", "r1073", "r1207", "r1208", "r1211", "r1324", "r1392", "r1394"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r108"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r108", "r898"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "terseLabel": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r108"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "periodEndLabel": "Balances (in shares)", "periodStartLabel": "Balances (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r20", "r108", "r898", "r916", "r1394", "r1395"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 158,216,258 and 157,641,914 respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r108", "r825", "r1047"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r1132"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r1131"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r1133"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r1130"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive income attributable to Bio-Techne", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r34", "r237", "r239", "r245", "r816", "r839", "r840"] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformation"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": ["r118", "r244", "r815", "r837"] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive income, documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": ["r262", "r679", "r680", "r683", "r684", "r743", "r967", "r1271", "r1274", "r1275"] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": ["r262", "r679", "r680", "r683", "r684", "r743", "r967", "r1271", "r1274", "r1275"] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "auth_ref": ["r186", "r262", "r303", "r311", "r332", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r456", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r995", "r996", "r1272", "r1273"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "auth_ref": ["r186", "r262", "r303", "r311", "r332", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r456", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r995", "r996", "r1272", "r1273"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r75", "r985"] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "tech_ConsumablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ConsumablesMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-

techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to consumables products.", "label": "Consumables [Member]", "terseLabel": "Consumables" } } }, "auth_ref": [] }, "tech_ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ContingentConsiderationMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "documentation": "Liabilities that are contingent on agreed-upon conditions that arise from business combinations.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent Consideration" } } }, "auth_ref": [] }, "tech_ContingentConsiderationPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ContingentConsiderationPolicyPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for contingent consideration.", "label": "Contingent Consideration, Policy [Policy Text Block]", "terseLabel": "Contingent Consideration" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiability", "terseLabel": "Contract with Customer, Liability, Total", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r496", "r497", "r508"] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Contract liabilities", "terseLabel": "Contract liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r496", "r497", "r508"] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r509"] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "label": "Corporate Segment [Member]", "terseLabel": "Corporate", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": ["r1214"] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": ["r26", "r333", "r334", "r335", "r336", "r339", "r1217"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Cost of sales", "terseLabel": "Cost of sales", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r125", "r126", "r780"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "tech_CreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "CreditAgreementMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to credit agreement.", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r455", "r1269"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r455", "r1269", "r1270"] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrencySwapMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Currency Swap [Member]", "terseLabel": "Cross-currency swap", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "tech_CurrentAssetsHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "CurrentAssetsHeldForSaleMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to current assets held for sale.", "label": "Current Assets, Held For Sale [Member]", "terseLabel": "Current Assets, Held For Sale" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": ["r1176", "r1205", "r1317"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentForeignTaxExpenseBenefit", "terseLabel": "Foreign", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r1176", "r1205"] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Total current tax provision", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": ["r655", "r1205"] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": ["r1176", "r1205", "r1317"] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Customer relationships", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r69", "r1245", "r1246", "r1247", "r1248", "r1250", "r1252", "r1255", "r1256"] }, "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtAndEquitySecuritiesRealizedGainLoss", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt and Equity Securities, Realized Gain (Loss)", "terseLabel": "Gain on sale of exchange trade investment grade bond funds", "documentation": "Amount of realized gain (loss) on investment in debt and equity securities." } } }, "auth_ref": ["r922", "r923", "r955", "r956", "r957", "r1195", "r1196"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt and Other Financing Arrangements" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangements"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt and Other Financing Arrangements", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r156", "r258", "r435", "r436", "r437", "r438", "r439", "r454", "r455", "r467", "r473", "r474", "r475", "r476", "r477", "r478", "r483", "r490", "r491", "r493", "r725"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r30", "r100", "r101", "r174", "r178", "r262", "r468", "r469", "r470", "r471", "r472", "r474", "r479", "r480", "r481", "r482", "r484", "r485", "r486", "r487", "r488", "r489", "r1005", "r1006", "r1007", "r1008", "r1009", "r1045", "r1203", "r1259", "r1260", "r1261", "r1345", "r1346"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r30", "r262", "r468", "r469", "r470", "r471", "r472", "r474", "r479", "r480", "r481", "r482", "r484", "r485", "r486", "r487", "r488", "r489", "r1005", "r1006", "r1007", "r1008", "r1009", "r1045", "r1203", "r1259", "r1260", "r1261", "r1345", "r1346"] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": ["r1205", "r1316", "r1317"] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit", "terseLabel": "Foreign", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r1205", "r1316"] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "terseLabel": "Deferred Income Tax Expense (Benefit), Total", "totalLabel": "Total deferred tax provision", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r12", "r203", "r1205"] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Net Deferred Tax Liability", "negatedTotalLabel": "Deferred tax liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": ["r105", "r106", "r176", "r647"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred income taxes", "terseLabel": "Deferred income taxes", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": ["r627", "r628", "r823"] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxesAndTaxCredits", "verboseLabel": "Deferred income taxes", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": ["r143"] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "terseLabel": "State", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": ["r1205", "r1316", "r1317"] }, "us-gaap_DeferredTaxAssetDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetDomain", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Asset [Domain]", "documentation": "Identification of the deferred tax asset for which a valuation reserve exists." } } }, "auth_ref": ["r1312"] }, "tech_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs connection with a business combination.", "label": "Deferred Tax Assets, Capitalized Research and Development Costs", "terseLabel": "Capitalized R&D" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsEquityMethodInvestments", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "Excess tax basis in equity investments", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments." } } }, "auth_ref": ["r1314"] }, "tech_DeferredTaxAssetsHeldForSaleAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "DeferredTaxAssetsHeldForSaleAssetImpairment", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, related to Held-for-sale asset impairment.", "label": "Deferred Tax Assets, Held-for-sale asset impairment", "terseLabel": "Held-for-sale asset impairment" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsInventory", "terseLabel": "Inventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": ["r1314"] }, "tech_DeferredTaxAssetsLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "DeferredTaxAssetsLeaseLiabilities", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from lease liabilities.", "label": "Deferred Tax Assets Lease Liabilities", "terseLabel": "Lease liability" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsNet", "terseLabel": "Deferred Tax Assets, Net of Valuation Allowance, Total", "totalLabel": "Deferred tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": ["r1311"] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "Net operating loss carryovers", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": ["r1314"] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": ["r1314"] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "Tax credit carryovers", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": ["r1314"] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "Deferred compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs." } } }, "auth_ref": ["r1314"] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedTerseLabel": "Valuation allowance", "terseLabel": "Deferred tax assets, valuation allowance, total", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": ["r648"] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilities", "negatedTotalLabel": "Net deferred income tax liabilities", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": ["r1311"] }, "us-gaap_DeferredTaxLiabilitiesDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesDerivatives", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Derivatives", "negatedLabel": "Derivative - cash flow hedge", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives." } } }, "auth_ref": ["r1314"] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "negatedLabel": "Intangible asset amortization", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill." } } }, "auth_ref": ["r1314"] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements", "negatedLabel": "Right of use asset", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": ["r1314"] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesOther", "negatedLabel": "Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": ["r1314"] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTemporaryDifferencesComprisingDeferredTaxesOnConsolidatedBalanceSheetsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedTerseLabel": "Depreciation", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": ["r1314"] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedContributionPlanCostRecognized", "terseLabel": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": ["r570"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r12", "r303", "r314", "r338", "r995", "r996"] }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": ["r685"] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Derivative Asset", "terseLabel": "Derivative Instruments", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r228", "r229", "r698", "r699", "r710", "r714", "r881",

"r882", "r883", "r884", "r885", "r887", "r888", "r889", "r890", "r891", "r904", "r905", "r946", "r948", "r949", "r950", "r952", "r953", "r984", "r1032", "r1038", "r1068", "r1328", "r1329", "r1330", "r1393"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r889", "r891", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r911", "r912", "r913", "r914", "r924", "r925", "r926", "r927", "r930", "r931", "r932", "r933", "r946", "r947", "r949", "r952", "r1066", "r1068", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1338", "r1339"] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DerivativeFairValueOfDerivativeLiability", "terseLabel": "Derivative instruments - net investment hedge", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": ["r27", "r117", "r169", "r170", "r227", "r984"] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Derivative, Fair Value, Net", "terseLabel": "Fair value of derivative instruments", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": ["r714"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r85", "r88", "r89", "r171", "r889", "r891", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r911", "r912", "r913", "r914", "r924", "r925", "r926", "r927", "r930", "r931", "r932", "r933", "r946", "r947", "r949", "r952", "r984", "r1066", "r1068", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1338", "r1339"] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": ["r21", "r85", "r88"] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": ["http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": ["r21", "r85", "r88", "r89", "r92", "r93", "r686"] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": ["http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "(Gain) Loss Recognized in AOCI", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r686"] }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityFairValueGrossAsset", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_DerivativeLiabilityFairValueGrossAsset", "terseLabel": "Derivative instruments - cash flow hedges", "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r25", "r29", "r169", "r170", "r950", "r951", "r983"] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": ["http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r693"] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": ["r1322", "r1323"] }, "tech_DerivativeNotionalAmountAtMaturity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "DerivativeNotionalAmountAtMaturity", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount of derivatives at maturity.", "label": "Derivative Notional Amount At Maturity", "terseLabel": "Notional amount at maturity" } } }, "auth_ref": [] }, "tech_DerivativeNotionalAmountDecreaseInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "DerivativeNotionalAmountDecreaseInPeriod", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of decrease during the period in the notional amount of the derivative.", "label": "Derivative Notional Amount Decrease In Period", "terseLabel": "Derivative Notional Amount, Decrease in Period" } } }, "auth_ref": [] }, "tech_DerivativeNumberOfInterimSettlementDates": { "xbrltype": "integerItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "DerivativeNumberOfInterimSettlementDates", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Number of interim settlement dates for the derivative instruments.", "label": "Derivative Number Of Interim Settlement Dates", "terseLabel": "Number of interim settlement dates" } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": ["http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": ["r21", "r78", "r79", "r80", "r83", "r86", "r88", "r90", "r91", "r93", "r693"] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as hedging instruments", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": ["r21"] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Developed technology", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": ["r164", "r1245", "r1246", "r1247", "r1248", "r1250", "r1252", "r1255", "r1256"] }, "tech_DiagnosticsAndGenomicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "DiagnosticsAndGenomicsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetails"], "lang": { "en-us": { "role": { "documentation": "Consist of the ACD operating segment and the Diagnostics operating segment.", "label": "Diagnostics and Genomics" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionTables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedules of disaggregated revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r1277"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationAndOtherBenefitPlans"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Share-based Compensation and Other Benefit Plans", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r576", "r579", "r610", "r611", "r613", "r1024"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-based Compensation and Other Benefit Plans" } } }, "auth_ref": [] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitions", "http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangements", "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies", "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShare", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurements", "http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxes", "http://www.bio-techne.com/20211231/role/DisclosureLeases", "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpense", "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognition", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformation", "http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationAndOtherBenefitPlans", "http://www.bio-techne.com/20211231/role/DisclosureSubsequentEvents", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformation", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformation"], "lang": { "en-us": { "role": { "label": "Disclosure Text Block [Abstract]", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockSupplementAbstract", "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet and Cash Flow Information" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent": { "xbrltype": "monetaryItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Goodwill, Current", "terseLabel": "Goodwill attributable to disposal group held for sale", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r4", "r96", "r97", "r149", "r152"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "terseLabel": "Property, plant and equipment attributable to disposal group held for sale", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r4", "r96", "r97", "r149", "r152"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r1017", "r1020"] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "us-gaap_DividendsCommonStockCash", "negatedLabel": "Cash dividends", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": ["r157"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r1080", "r1081", "r1093"] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": ["r1080", "r1081", "r1093", "r1136"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Cover", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r1114"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": ["r631"] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r1125"] }, "tech_EMEAExcludingUKMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "EMEAExcludingUKMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa, excluding the United Kingdom.", "label": "EMEA, excluding United Kingdom" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Earnings Per Share", "terseLabel": "Earnings per share attributable to Bio-Techne:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Basic (in dollars per share)", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Earnings per share - basic (in shares)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r246", "r268", "r269", "r270", "r271", "r272", "r273", "r279", "r282", "r293", "r296", "r297", "r302", "r668", "r677", "r695", "r696", "r817", "r841", "r988"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Diluted (in dollars per share)", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Earnings per share - diluted (in shares)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r246", "r268", "r269", "r270", "r271", "r272", "r273", "r282", "r293", "r296", "r297", "r302", "r668", "r677", "r695", "r696", "r817", "r841", "r988"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r43", "r44", "r299"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r278", "r298", "r300", "r301"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1342"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective income tax rate reconciliation, percent, total", "totalLabel": "Effective tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r631", "r1029"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "terseLabel": "Income tax expense at federal statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": ["r261", "r631", "r658", "r1029"] }, "tech_EffectiveIncomeTaxRateReconciliationContingentConsiderationAdjustment": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "EffectiveIncomeTaxRateReconciliationContingentConsiderationAdjustment", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to contingent consideration adjustments.", "label": "tech_EffectiveIncomeTaxRateReconciliationContingentConsiderationAdjustment", "terseLabel": "Contingent consideration adjustment" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, FDII, Percent", "negatedLabel": "Foreign derived intangible income", "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)." } } }, "auth_ref": ["r1029", "r1307", "r1309"] }, "tech_EffectiveIncomeTaxRateReconciliationForeignEarningsTaxation": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "EffectiveIncomeTaxRateReconciliationForeignEarningsTaxation", "presentation": [

"http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to U.S. taxes on foreign earnings.", "label": "Effective Income Tax Rate Reconciliation Foreign Earnings Taxation", "terseLabel": "U.S. taxation of foreign earnings" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "negatedLabel": "Foreign tax rate differences", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": ["r632", "r635", "r1029", "r1206", "r1307"] }, "tech_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign withholding tax.", "label": "Effective Income Tax Rate Reconciliation, Foreign Withholding Tax, Percent", "terseLabel": "Foreign withholding tax" } } }, "auth_ref": [] }, "tech_EffectiveIncomeTaxRateReconciliationGainsLossesOnInvestments": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "EffectiveIncomeTaxRateReconciliationGainsLossesOnInvestments", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gains/losses on investments.", "label": "Effective Income Tax Rate Reconciliation, Gains (Losses) On Investments", "terseLabel": "(Gain)/loss on investment" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "terseLabel": "Executive compensation limitations", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": ["r1029", "r1206", "r1307", "r1309"] }, "tech_EffectiveIncomeTaxRateReconciliationOptionExercises": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "EffectiveIncomeTaxRateReconciliationOptionExercises", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to option exercises.", "label": "Effective Income Tax Rate Reconciliation Option Exercises", "terseLabel": "Option exercises" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments", "terseLabel": "Other, net", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": ["r1029", "r1206", "r1307", "r1308"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "terseLabel": "State income taxes, net of federal benefit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": ["r634", "r1029", "r1206", "r1307"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfFederalTaxCalculatedAtStatutoryRateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "negatedTerseLabel": "Research and development tax credit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": ["r1029", "r1206", "r1307", "r1309"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Salaries, wages and related accruals", "terseLabel": "Salaries, wages and related accruals", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r101"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Unrecognized compensation cost", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r612"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Unrecognized compensation cost, period for recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r612"] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Share-based compensation excess tax benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": ["r609"] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Employee Severance [Member]", "terseLabel": "Employee severance", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "tech_EmployeeSeveranceOnRelocationOfUSPlantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "EmployeeSeveranceOnRelocationOfUSPlantMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents employee severance on relocation of US plant.", "label": "Employee Severance on Relocation of US Plant [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "tech_EmployeeStockPurchasePlan2014Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "EmployeeStockPurchasePlan2014Member", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the 2014 Employee Stock Purchase Plan.", "label": "Employee Stock Purchase Plan 2014 [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r1078"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r1078"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-

```
us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1078" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1165" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1078" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1078" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1078" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1078" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1166" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r1119" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r1161" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r1161" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1161" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": [ "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information", "terseLabel": "Bio-Techne's Shareholders' equity:" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails", "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r20", "r206", "r241", "r242", "r243", "r263", "r264", "r265", "r267", "r272", "r274", "r276", "r304", "r386", "r387", "r432", "r495", "r656", "r657", "r665", "r666", "r667", "r669", "r676", "r677", "r687", "r688", "r689", "r690", "r691", "r692", "r694", "r717", "r719", "r720", "r721", "r722", "r723", "r726", "r729", "r742", "r837", "r865", "r866", "r867", "r879", "r936" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r382", "r383", "r384", "r664", "r1171", "r1172", "r1173", "r1318", "r1319", "r1320", "r1321" ] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Loss on equity method investment", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": [ "r10", "r12", "r124", "r832" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Investment percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r382" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investments", "verboseLabel": "Equity method investment in Wilson Wolf", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r303", "r319", "r338", "r381", "r1187", "r1230" ] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Equity method investments:", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r10", "r94", "r383" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r1129" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r1086", "r1097", "r1107", "r1140" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r1083", "r1094", "r1104", "r1137" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "auth_ref": [ "r1396", "r1397", "r1398", "r1399" ] }, "tech_ExchangeTradedInvestmentGradeBondFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ExchangeTradedInvestmentGradeBondFundsMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exchange traded investment grade bond funds.", "label": "Exchange Traded Investment Grade Bond Funds [Member]", "terseLabel": "Exchange Traded Investment Grade Bond Funds" } } }, "auth_ref": [] }, "tech_ExchangedTradedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ExchangedTradedSecuritiesMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents exchanged traded securities.", "label": "Exchanged Traded Securities [Member]", "terseLabel": "Exchanged traded investment grade bond funds" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r1135" ] }, "srt_ExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ExecutiveOfficerMember", "presentation": [ "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails" ], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]" } } }, "auth_ref": [ "r1221" ] }, "tech_FairValueAdjustmentOnAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "FairValueAdjustmentOnAvailableForSaleSecurities", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of fair value adjustment made on available for sale securities during the period.", "label": "Fair value adjustment on available-for-sale investments", "terseLabel": "Fair value adjustment on available-for-sale investments" } } }, "auth_ref": [] }, "tech_FairValueAdjustmentToContingentConsiderationPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "FairValueAdjustmentToContingentConsiderationPayable", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Fair value adjustment to contingent consideration
```

payable", "terseLabel": "Fair value adjustment to contingent consideration payable" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r703", "r704", "r705", "r706", "r707", "r708", "r711", "r1036"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r703", "r704", "r705", "r706", "r707", "r708", "r711", "r1036"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r481", "r535", "r536", "r537", "r538", "r539", "r540", "r697", "r699", "r700", "r701", "r702", "r709", "r710", "r712", "r750", "r751", "r752", "r1006", "r1007", "r1013", "r1014", "r1015", "r1032", "r1038"] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": ["r703", "r704", "r705", "r706", "r707", "r708", "r711"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r698", "r699", "r700", "r702", "r1032", "r1329", "r1340"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r481", "r535", "r540", "r699", "r710", "r750", "r1013", "r1014", "r1015", "r1032"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r481", "r535", "r540", "r699", "r700", "r710", "r751", "r1006", "r1007", "r1013", "r1014", "r1015", "r1032"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r481", "r535", "r536", "r537", "r538", "r539", "r540", "r699", "r700", "r701", "r702", "r710", "r752", "r1006", "r1007", "r1013", "r1014", "r1015", "r1032", "r1038"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r703", "r704", "r705", "r706", "r707", "r708", "r711"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of the reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3)", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r703", "r708", "r711"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r698", "r699", "r700", "r702", "r1032", "r1329", "r1340"] }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurements"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." } } }, "auth_ref": ["r172"] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "negatedLabel": "Change in fair value of contingent consideration", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": ["r704", "r711"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Purchase price contingent consideration (Note 4)", "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r706", "r711"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "negatedLabel": "Payments", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r706", "r711"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodEndLabel": "Fair value at the end of period", "periodStartLabel": "Fair value at the beginning of period", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r703", "r711"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r481", "r535", "r536", "r537", "r538", "r539", "r540", "r697", "r699", "r700", "r701", "r702", "r709", "r710", "r712", "r750", "r751", "r752", "r1006", "r1007", "r1013", "r1014", "r1015", "r1032", "r1038"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r1032", "r1326", "r1327", "r1328", "r1329", "r1330", "r1340"] }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)." } } }, "auth_ref": ["r704", "r711"] }, "tech_FairValueWriteUpOfAcquiredInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "FairValueWriteUpOfAcquiredInventory", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The noncash expense during the period from the sale of acquired inventory written up to fair value in purchase accounting.", "label": "Costs recognized on sale of acquired inventory", "negatedLabel": "Costs recognized on sale of acquired inventory", "terseLabel": "Costs recognized on sale of acquired inventory" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation":

"Information by type of financial instrument." } } }, "auth_ref": ["r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r492", "r494", "r693", "r713", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r838", "r1002", "r1032", "r1036", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1048", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1226", "r1227", "r1228", "r1229", "r1325", "r1328", "r1329", "r1330", "r1337", "r1340"] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedTerseLabel": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r218", "r401", "r423", "r1004"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r1253", "r1400"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "2025", "verboseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r425", "r975", "r1004"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "terseLabel": "2028", "verboseLabel": "Fiscal year 2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r425", "r975", "r1004"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "terseLabel": "2028", "verboseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r425", "r975", "r1004"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "2027", "verboseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r425", "r975", "r1004"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "2026", "verboseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r425", "r975", "r1004"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r416", "r418", "r419", "r420", "r422", "r423", "r427", "r428", "r781", "r782", "r975"] }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "negatedTerseLabel": "Currency translation", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsGross", "terseLabel": "Definite-lived intangibles assets", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r401", "r423", "r782", "r1004"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r416", "r418", "r419", "r420", "r422", "r423", "r427", "r428", "r975"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsNet", "totalLabel": "Definite-lived intangibles assets, net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r781", "r1252"] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Acquisitions.", "terseLabel": "Acquisitions", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": ["r418"] }, "tech_FinitelivedIntangibleAssetsOtherAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "FinitelivedIntangibleAssetsOtherAdditions", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of other additions lacking physical substance with a definite life.", "label": "Finite lived Intangible Assets Other Additions", "terseLabel": "Other additions" } } }, "auth_ref": [] }, "tech_FirstPartOfForwardContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "FirstPartOfForwardContractMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the first part of the forward contract.", "label": "First Part of Forward Contract [Member]", "terseLabel": "First Part of Forward Contract" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCountryMember", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Foreign Tax Authority [Member]", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": ["r631", "r632"] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Translation of foreign financial statements", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": ["r716"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.org/ecd/2024", "localname":

"ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r1090", "r1101", "r1111", "r1144"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r1090", "r1101", "r1111", "r1144"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r1090", "r1101", "r1111", "r1144"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r1090", "r1101", "r1111", "r1144"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1090", "r1101", "r1111", "r1144"] }, "tech_ForwardContractAdditionalInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ForwardContractAdditionalInvestment", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the additional investment.", "label": "Forward Contract Additional Investment", "terseLabel": "Forward Contract, Additional Investment" } } }, "auth_ref": [] }, "tech_ForwardContractMilestoneAnnualEBITDA": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ForwardContractMilestoneAnnualEBITDA", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the milestone of annual EBITDA in forward contract.", "label": "Forward Contract Milestone Annual EBITDA", "terseLabel": "Forward Contract, Milestone, Annual EBITDA" } } }, "auth_ref": [] }, "tech_ForwardContractMilestoneAnnualRevenueRequired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ForwardContractMilestoneAnnualRevenueRequired", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the milestone of annual revenue in forward contract.", "label": "Forward Contract Milestone Annual Revenue Required", "terseLabel": "Forward Contract, Milestone, Annual Revenue Required" } } }, "auth_ref": [] }, "tech_ForwardContractMilestoneMultipleForTotalExpectedPayments": { "xbrltype": "pureItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ForwardContractMilestoneMultipleForTotalExpectedPayments", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the multiple for total expected payments of forward contract in milestone.", "label": "Forward Contract Milestone Multiple For Total Expected Payments", "terseLabel": "Forward Contract, Milestone, Multiple for Total Expected Payments" } } }, "auth_ref": [] }, "tech_ForwardStartingSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ForwardStartingSwapMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents forward starting swap.", "label": "Forward Starting Swap [Member]", "terseLabel": "Forward starting swaps" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r1124"] }, "country_GB": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "GB", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails"], "lang": { "en-us": { "role": { "label": "United Kingdom" } } } }, "auth_ref": [] }, "tech_GBProfitSharingAndSavingsPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "GBProfitSharingAndSavingsPlanMember", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the GB Profit Sharing and Savings Plan", "label": "GB Profit Sharing and Savings Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestments", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Investments", "terseLabel": "Gain (loss) on investment(1)", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": ["r132", "r135", "r1167"] }, "us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseNarrativeDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee", "negatedLabel": "Gain on sale of Eminence", "verboseLabel": "Gain on sale of Eminence", "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": ["r814", "r1195", "r1196", "r1202", "r1359"] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Gain (Loss) from Litigation Settlement", "terseLabel": "Certain litigation charges", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": ["r995", "r1266"] }, "us-gaap_GainOnSaleOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainOnSaleOfInvestments", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseNarrativeDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_GainOnSaleOfInvestments", "negatedLabel": "Gain on sale of CCXI investment", "terseLabel": "Gain on sale of CCXI investment", "documentation": "The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale." } } }, "auth_ref": ["r1195", "r1196", "r1202", "r1358"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r217", "r403", "r813", "r996", "r1003", "r1034", "r1047", "r1234", "r1241"] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetails"], "lang": { "en-us": { "role": { "label": "Goodwill, Acquired During Period", "terseLabel": "Acquisitions", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": ["r407", "r1003"] }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetImpairment", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Asset Impairment", "negatedLabel": "Eminence impairment", "terseLabel": "Eminence impairment", "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Impairment of goodwill and indefinite-lived intangible assets", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": ["r402", "r414", "r1003"] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible assets", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": ["r415", "r429", "r431"] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_GoodwillForeignCurrencyTranslationGainLoss", "terseLabel": "Currency translation", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r411"] }, "tech_GoodwillHeldForSaleAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "GoodwillHeldForSaleAdjustment", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of adjustment for goodwill held-for-sale.", "label": "Goodwill, Held-for-Sale Adjustment", "terseLabel": "Held-for-sale goodwill" } } }, "auth_ref": [] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetails"], "lang": { "en-us": { "role": { "label": "Goodwill, Impairment Loss", "negatedLabel": "Eminence impairment", "terseLabel": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r12", "r404", "r410", "r414", "r1003", "r1034"] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_GoodwillPurchaseAccountingAdjustments", "negatedLabel": "Goodwill, Purchase Accounting Adjustments", "verboseLabel": "Adjustments", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r0", "r1240"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": ["http://www.bio-

techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "Gross margin", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r122", "r127", "r187", "r259", "r385", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r465", "r466", "r715", "r989", "r995", "r1213", "r1216", "r1218", "r1219", "r1220", "r1272"] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": ["r21", "r686"] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": ["r21"] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": ["r21"] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": ["r1080", "r1081", "r1093"] }, "tech_ImpactOfBusinessHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ImpactOfBusinessHeldForSale", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of impact on income from business held for sale.", "label": "Impact of Business Held for Sale", "terseLabel": "Impact of business held-for-sale(1)" } } }, "auth_ref": [] }, "tech_ImpactOfPartiallyOwnedConsolidatedSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ImpactOfPartiallyOwnedConsolidatedSubsidiaries", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of impact of partially owned consolidated subsidiaries.", "label": "Impact of Partially Owned Consolidated Subsidiaries", "negatedLabel": "Impact of partially-owned consolidated subsidiaries(2)" } } }, "auth_ref": [] }, "tech_ImpairmentOfAssetsHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ImpairmentOfAssetsHeldForSaleMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to impairment of assets held for sale pursuant to restructuring plan.", "label": "Impairment Of Assets, Held For Sale [Member]", "terseLabel": "Impairment of assets held-for-sale" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of indefinite-lived intangible asset excluding goodwill." } } }, "auth_ref": ["r1258"] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "negatedTerseLabel": "Eminence impairment", "terseLabel": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": ["r417", "r1202", "r1254", "r1257"] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Impairment recorded for property, plant, and equipment", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": ["r12", "r52", "r151", "r1033"] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf", "terseLabel": "Impairment of Long-Lived Assets to be Disposed of", "verboseLabel": "Impairment of assets held-for-sale", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": ["r12", "r148", "r1035"] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of long-lived assets and amortizable intangibles", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "In Process Research and Development [Member]", "terseLabel": "In process research and development", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": ["r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1252", "r1254", "r1255", "r1256"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": ["r260", "r630"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome", "http://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Earnings before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r123", "r183", "r187", "r818", "r833", "r989", "r995", "r1213", "r1216", "r1218", "r1219", "r1220"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": ["r260", "r630"] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Equity Method Investments", "terseLabel": "Gain (loss) on equity method investment", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": ["r12", "r124", "r182", "r303", "r316", "r338", "r381", "r832"] }, "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Individually Significant Component Disposed of or Held-for-Sale, Excluding Discontinued Operations, before Income Tax", "terseLabel": "Impairment of assets held-for-sale", "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale including the portion attributable to the noncontrolling interest. Excludes discontinued operations." } } }, "auth_ref": ["r153"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": ["r1017", "r1020"] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r433", "r440", "r443", "r704", "r708", "r711", "r862", "r864", "r921", "r975", "r1037", "r1363"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails", "http://www.bio-

techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r440", "r443", "r704", "r708", "r711", "r862", "r864", "r921", "r975", "r1037", "r1363"] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": ["r256", "r631", "r632", "r640", "r652", "r1029", "r1313"] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": ["r256", "r631", "r632", "r640", "r652", "r1029", "r1313"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r261", "r622", "r631", "r636", "r637", "r638", "r645", "r650", "r659", "r661", "r662", "r663", "r876", "r1029"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome", "http://www.bio-techne.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Income taxes (benefit)", "terseLabel": "Income taxes", "totalLabel": "Total income tax provision", "verboseLabel": "Income Tax Expense (Benefit), Total", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r194", "r204", "r275", "r276", "r303", "r317", "r338", "r629", "r631", "r660", "r842", "r1029"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r240", "r625", "r626", "r645", "r646", "r649", "r654", "r873"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationSupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "label": "Income taxes paid", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r42", "r256", "r651", "r652"] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables", "negatedLabel": "Trade accounts and other receivables, net", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": ["r11"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Trade accounts payable, accrued expenses, contract liabilities, and other", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r11"] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable", "verboseLabel": "Income taxes payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": ["r11"] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities", "verboseLabel": "Salaries, wages and related accruals", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r11"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r11"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Change in operating assets and operating liabilities, net of acquisition:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidExpense", "negatedLabel": "Prepaid expenses", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": ["r11"] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails"], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Dilutive effect of stock options and restricted stock units (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r283", "r284", "r285", "r297", "r578"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "In process research and development", "terseLabel": "In process research and development", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r401", "r426", "r1004"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r1090", "r1101", "r1111", "r1135", "r1144", "r1148", "r1156"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r1154"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r1082", "r1160"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r1082", "r1160"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r1082", "r1160"] }, "tech_InstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "InstrumentsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to instruments which typically consist of longer-lived assets.", "label": "Instruments [Member]", "terseLabel": "Instruments" } } }, "auth_ref": [] }, "tech_IntangibleAssetsHeldForSaleAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "IntangibleAssetsHeldForSaleAdjustment", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of adjustment for intangible assets held-for-sale.", "label": "Intangible Assets, Held-for-Sale Adjustment", "negatedLabel": "Held-for-sale intangibles" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Intangible assets, net", "totalLabel": "Total intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r416", "r1252", "r1254"] }, "tech_IntellectualPropertyMattersPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "IntellectualPropertyMattersPolicyPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for Intellectual Property Matters.", "label": "Intellectual Property Matters, Policy [Policy Text Block]", "terseLabel": "Intellectual Property Matters" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense", "terseLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r313", "r1197"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationSupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "terseLabel": "Interest paid", "verboseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r250", "r254",

"r255"] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntersegmentEliminationMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment Eliminations", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": ["r186", "r303", "r311", "r332", "r333", "r334", "r335", "r336", "r338", "r339", "r995"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Finished goods", "terseLabel": "Finished goods", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": ["r147", "r981"] }, "tech_InventoryFinishedGoodsNetOfReservesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "InventoryFinishedGoodsNetOfReservesNonCurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Non-current amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory Finished Goods Net Of Reserves Non Current", "terseLabel": "Inventory, Finished Goods, Net of Reserves, Non-current" } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Inventories", "terseLabel": "Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r224", "r980", "r1047"] }, "tech_InventoryNetCurrentAndNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "InventoryNetCurrentAndNonCurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationInventoriesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of inventory, net of reserves, including both current and non-current portions.", "label": "Inventory Net Current And Non Current", "totalLabel": "Inventories, net" } } }, "auth_ref": [] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNoncurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Noncurrent", "terseLabel": "Long-term inventory", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": ["r1188"] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": ["r195", "r213", "r223", "r397", "r398", "r400", "r779", "r986"] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Raw materials", "terseLabel": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": ["r147", "r982"] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryWriteDown", "terseLabel": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": ["r399"] }, "tech_InvestmentInUnconsolidatedEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "InvestmentInUnconsolidatedEntity", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Represents the amount of distribution from (investment in) unconsolidated entity.", "label": "Investment In Unconsolidated Entity", "terseLabel": "Distributions from (Investments in) Wilson Wolf" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "us-gaap_InvestmentIncomeNet", "terseLabel": "Interest income", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": ["r130", "r131", "r134"] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_Investments", "terseLabel": "Investments, Total", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": ["r820", "r821", "r1063", "r1065"] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_InvestmentsFairValueDisclosure", "terseLabel": "Investments, Fair Value Disclosure, Total", "verboseLabel": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": ["r1326", "r1327", "r1337"] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Land [Member]", "terseLabel": "Land", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": ["r1278"] }, "us-gaap_LegalCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalCostsPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Legal Costs, Policy [Policy Text Block]", "terseLabel": "Legal Matters", "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights." } } }, "auth_ref": ["r453"] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalFees", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Legal Fees", "terseLabel": "Litigation charges", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": ["r1177"] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r733"] }, "tech_LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for asset and liabilities of operating leases of the lessee.", "label": "Lessee, Operating Lease, Asset and Liabilities [Table Text Block]", "terseLabel": "Schedule of table that summarizes the balance sheet classification of the Company's operating leases and amounts of right of use assets and lease liabilities and the weighted average remaining lease term and weighted average discount rate for the Company's operating leases" } } }, "auth_ref": [] }, "tech_LesseeOperatingLeaseCashFlowInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "LesseeOperatingLeaseCashFlowInformationTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of cash flow information of operating leases of the lessee.", "label": "Lessee, Operating Lease, Cash Flow Information [Table Text Block]", "terseLabel": "Schedule of the table that summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDescriptionAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of the fair value of the lease liability by payment date for the operating leases by fiscal year", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r1348"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r740"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "verboseLabel": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r740"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "verboseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r740"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "verboseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r740"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "verboseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r740"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "verboseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r740"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "verboseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r740"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "Less: Amounts representing interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r740"] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseRenewalTerm", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1347"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r728"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and shareholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r113", "r179", "r828", "r1047", "r1204", "r1231", "r1341"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r102", "r212", "r259", "r385", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r465", "r466", "r680", "r683", "r684", "r715", "r1047", "r1272", "r1350", "r1351"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesFairValueDisclosure", "totalLabel": "Total liabilities", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": ["r699", "r1326"] }, "tech_LineOfCreditFacilityAdditionalBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The element representing the additional borrowing capacity under a line of credit.", "label": "Line Of Credit Facility Additional Borrowing Capacity", "terseLabel": "Line of Credit Facility, Additional Borrowing Capacity" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r99", "r103"] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_LinesOfCreditCurrent", "terseLabel": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r100", "r174"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-term debt obligations", "terseLabel": "Long-term debt obligations", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": ["r30", "r824"] }, "tech_LunaphoreTechnologiesSaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "LunaphoreTechnologiesSaMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Lunaphore Technologies SA.", "label": "Lunaphore Technologies SA [Member]", "terseLabel": "Lunaphore Technologies SA." } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and equipment", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesPolicy", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Available-for-sale investment", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": ["r95"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum" } } }, "auth_ref": ["r449", "r450", "r451", "r452", "r573", "r619", "r702", "r778", "r861", "r863", "r871", "r890", "r891", "r939", "r941", "r943", "r944", "r954", "r973", "r974", "r1001", "r1010", "r1023", "r1038", "r1039", "r1043", "r1044", "r1058", "r1276", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r1127"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r1127"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum" } } }, "auth_ref": ["r449", "r450", "r451", "r452", "r573", "r619", "r702", "r778", "r861", "r863", "r871", "r890", "r891", "r939", "r941", "r943", "r944", "r954", "r973", "r974", "r1001", "r1010", "r1023", "r1038", "r1039", "r1043", "r1058", "r1276", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r1147"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r1155"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r1128"] }, "tech_NamocellIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "NamocellIncMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Namocell Inc.", "label": "Namocell Inc" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r253"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-

gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r253"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by (used in) operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r141", "r142", "r143"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net earnings attributable to Bio-Techne", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r128", "r143", "r184", "r210", "r235", "r238", "r243", "r259", "r266", "r268", "r269", "r270", "r271", "r272", "r275", "r276", "r290", "r385", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r465", "r466", "r668", "r677", "r696", "r715", "r836", "r918", "r934", "r935", "r1074", "r1272"] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less net earnings (loss) attributable to noncontrolling interest", "verboseLabel": "Net earnings attributable to noncontrolling interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r77", "r168", "r235", "r238", "r272", "r275", "r276", "r835", "r1193"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "totalLabel": "Income available to common shareholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": ["r247", "r268", "r269", "r270", "r271", "r279", "r280", "r292", "r297", "r677"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "totalLabel": "Income available to common shareholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": ["r247", "r281", "r286", "r287", "r288", "r289", "r292", "r297"] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Net Investment Hedging [Member]", "terseLabel": "Net investment hedge", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": ["r82"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Not Yet Adopted Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r1127"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r1090", "r1101", "r1111", "r1135", "r1144"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r1118"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r1117"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r1135"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r1155"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r1155"] }, "tech_NoncashPortionOfLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "NoncashPortionOfLeaseExpense", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of noncash portion of lease expense during the period.", "label": "Leases, net", "terseLabel": "Leases, net" } } }, "auth_ref": [] }, "us-gaap_NoncompeteAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncompeteAgreementsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "label": "Non-competition agreement", "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party." } } }, "auth_ref": ["r68", "r1245", "r1246", "r1247", "r1248", "r1250", "r1252", "r1255", "r1256"] }, "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest", "terseLabel": "Elimination of noncontrolling equity interest from sale of Eminence", "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest." } } }, "auth_ref": ["r18", "r56", "r167"] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": ["r73", "r495", "r1207", "r1208", "r1209", "r1211", "r1394"] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_NoncurrentAssets", "terseLabel": "Total long-lived assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": ["r345"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Other income (expense)", "terseLabel": "Total other income (expense), net", "totalLabel": "Total other income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r133"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "lang": { "en-us": { "role": { "label": "Other income (expense)." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.bio-techne.com/role/DisclosureSegmentInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r990", "r1000", "r1215"] }, "us-gaap_NumberOfReportingUnits": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportingUnits", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Number of Reporting Units", "terseLabel": "Number of reporting units", "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment." } } }, "auth_ref": [] }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "(Gain) Loss Recognized in Accumulated Other Comprehensive Loss", "verboseLabel": "Amounts before reclassifications", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": ["r33"] }, "us-gaap_OfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficersCompensation", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_OfficersCompensation", "terseLabel": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold", "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": ["r1194"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be

```
clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Operating income", "totalLabel": "Operating income", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r187", "r989", "r1213", "r1216", "r1218", "r1219", "r1220" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Fixed Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r734", "r1046" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails", "http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseLiability", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r731" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities - current", "terseLabel": "Current operating lease liabilities", "verboseLabel": "Operating lease liabilities - current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r731" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "terseLabel": "Noncurrent operating lease liabilities", "verboseLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r731" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureLeasesCashPaidDetails" ], "lang": { "en-us": { "role": { "label": "Cash amounts paid on operating lease liabilities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r732", "r736" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Right of use asset", "terseLabel": "Operating lease right of use assets", "verboseLabel": "Right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r730" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average discount rate:", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r739", "r1046" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term (in years):", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r738", "r1046" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards, Total", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r653" ] }, "tech_OperatingLossCarryforwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "OperatingLossCarryforwardsMember", "presentation": [ "http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information for deferred tax assets related to operating loss carryforwards.", "label": "Operating Loss Carryforwards [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "terseLabel": "Operating Segments", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r332", "r333", "r334", "r335", "r336", "r339", "r995", "r996" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r225", "r1047" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other assets", "totalLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r219" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests." } } }, "auth_ref": [ "r9", "r19", "r166" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustments", "terseLabel": "Foreign currency translation income (loss)", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r9", "r19", "r166" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss), before tax", "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r9", "r19", "r166" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss), before tax, attributable to Bio-Techne:" } } }, "auth_ref": [] }, "tech_OtherComprehensiveIncomeLossBeforeTranslationReclassificationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "OtherComprehensiveIncomeLossBeforeTranslationReclassificationNetOfTax", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification of translation adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Translation Reclassification, Net of Tax", "verboseLabel": "Other comprehensive income (loss) before reclassification" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r233" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome", "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r20", "r28", "r236", "r239", "r244", "r272", "r717", "r718", "r723", "r815", "r837", "r1191", "r1192" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss) attributable to noncontrolling interest", "terseLabel": "Other comprehensive income (loss) attributable to noncontrolling interest", "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": [ "r9", "r19", "r166", "r236", "r239", "r272" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "totalLabel": "Total other comprehensive income (loss), net of tax", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r9", "r19", "r166", "r236", "r239", "r272" ] }, "tech_OtherComprehensiveIncomeLossReleaseOfForeignCurrencyTransactionAndTranslationFromSalePortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname":
```

"OtherComprehensiveIncomeLossReleaseOfForeignCurrencyTransactionAndTranslationFromSalePortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome", "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Amount of release of foreign currency translation arising from sale, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Release Of Foreign Currency Transaction And Translation From Sale, Portion Attributable To Parent", "terseLabel": "Reclassification of cumulative translation adjustment for Eminence to non-operating income", "verboseLabel": "Foreign currency translation reclassified to earnings with Eminence deconsolidation" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "negatedLabel": "Tax (expense) benefit", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r9", "r19", "r166"] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Other Current Assets [Member]", "terseLabel": "Other current assets", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": ["r84", "r92"] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpense"], "lang": { "en-us": { "role": { "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Income / (Expense)", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": ["r1178", "r1305"] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other Intangible Assets [Member]", "terseLabel": "Other intangibles", "documentation": "Intangible assets classified as other." } } }, "auth_ref": ["r1004", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1252", "r1254", "r1255", "r1256"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other current liabilities", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r101", "r1047"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other long-term liabilities", "terseLabel": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r104"] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets", "verboseLabel": "Other assets", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "tech_OtherNonoperatingIncomeAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "OtherNonoperatingIncomeAndExpense", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating income and expense", "terseLabel": "Other non-operating income (expense), net" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other non-operating income (expense), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r136"] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Other operating activity", "terseLabel": "Other operating activity", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r1127"] }, "tech_OtherRevenuesFromBusinessHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "OtherRevenuesFromBusinessHeldForSaleMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other revenues relating to the business that has met the held-for-sale criteria.", "label": "Other Revenues from Business Held for Sale" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r1088", "r1099", "r1109", "r1142"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r1091", "r1102", "r1112", "r1145"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1091", "r1102", "r1112", "r1145"] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Patents [Member]", "terseLabel": "Patents", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": ["r164", "r1245", "r1246", "r1247", "r1248", "r1250", "r1252", "r1255", "r1256"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r1116"] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities", "negatedLabel": "Contingent consideration payments - financing", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": ["r8"] }, "us-gaap_PaymentsForDerivativeInstrumentInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForDerivativeInstrumentInvestingActivities", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments for Derivative Instrument, Investing Activities", "negatedLabel": "Investment of forward purchase contract", "documentation": "The cash outflow for derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments." } } }, "auth_ref": ["r1198"] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Re-purchases of common stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": ["r139"] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForRestructuring", "negatedLabel": "Cash payments", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r442", "r1200"] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDividendsCommonStock", "negatedLabel": "Cash dividends", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": ["r139"] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Taxes paid on RSUs and net share settlements", "terseLabel": "Net settlement stock options exercises and restricted stock units vesting", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r249"] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt", "negatedLabel": "Purchases of available-for-sale investments", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r37", "r248", "r349"] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireBusinessesGross", "terseLabel": "Cash paid", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": ["r38", "r672"] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired", "negatedLabel": "Acquisitions, net of cash acquired", "terseLabel": "Cash paid, net of cash acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": ["r38"] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Investments", "terseLabel": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": ["r137"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Additions to property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r138"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r1126"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r1126"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r1118"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r1135"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r1128"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r1117"] }, "tech_PerformanceIncentiveProgramsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "PerformanceIncentiveProgramsMember", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Performance Incentive Programs.", "label": "Performance Incentive Programs [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r1119"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r1164"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r1118"] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Policy Text Block [Abstract]" } } }, "auth_ref": [] }, "tech_PreTaxRestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "PreTaxRestructuringCharges", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of pre-tax restructuring charges.", "label": "Pre-tax Restructuring Charges", "terseLabel": "Pre-tax restructuring charges" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Divestiture of Interest in Consolidated Subsidiaries", "terseLabel": "Proceeds from sale of Eminence", "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent)." } } }, "auth_ref": ["r36"] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Borrowings under line-of-credit agreement", "verboseLabel": "Borrowings under line-of-credit agreement", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": ["r39"] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Other financing activity", "terseLabel": "Other financing activity", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": ["r1175", "r1199"] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sale of available-for-sale investments", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r35", "r248", "r349", "r380"] }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Equity Securities, FV-NI", "terseLabel": "Proceeds from sale of CCXI investment", "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": ["r193", "r251"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from stock option exercises", "terseLabel": "Proceeds from stock option exercises", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r7", "r24"] }, "tech_ProductAndServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ProductAndServicesMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the product and services provided by the company.", "label": "Product and Services [Member]", "terseLabel": "Product and Services" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r342", "r780", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r977", "r1011", "r1057", "r1058", "r1059", "r1062", "r1064", "r1267", "r1268", "r1277", "r1360", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r342", "r780", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r977", "r1011", "r1057", "r1058", "r1059", "r1062", "r1064", "r1267", "r1268", "r1277", "r1360", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome", "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Net earnings, including noncontrolling interest", "terseLabel": "Net earnings", "totalLabel": "Net earnings, including noncontrolling interest", "verboseLabel": "Net earnings, including noncontrolling interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r210", "r235", "r238", "r252", "r259", "r266", "r272", "r275", "r276", "r385", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r465", "r466", "r668", "r677", "r678", "r681", "r682", "r696", "r715", "r818", "r834", "r878", "r918", "r934", "r935", "r1030", "r1031", "r1075", "r1193", "r1272"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationPropertyAndEquipmentDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r13", "r741"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property and equipment, cost", "terseLabel": "Property and equipment, cost", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r150", "r215", "r831"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationPropertyAndEquipmentDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r13", "r741", "r819", "r831", "r1047"] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } },

"auth_ref": ["r13", "r199", "r202", "r829"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationTables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r13"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationPropertyAndEquipmentDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r150", "r741"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "tech_ProteinSciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ProteinSciencesMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetails"], "lang": { "en-us": { "role": { "documentation": "Consist of the remaining portion of the Biotechnology segment and the Protein Platforms operating segment.", "label": "Protein Sciences" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r1116"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r1116"] }, "tech_QTHoldingsCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "QTHoldingsCorporationMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "documentation": "Represents information about QT Holdings Corporation.", "label": "QT Holdings Corporation" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r449", "r450", "r451", "r452", "r533", "r573", "r605", "r606", "r607", "r619", "r702", "r753", "r762", "r778", "r861", "r863", "r871", "r890", "r891", "r939", "r941", "r943", "r944", "r954", "r973", "r974", "r1001", "r1010", "r1023", "r1038", "r1039", "r1043", "r1044", "r1058", "r1068", "r1262", "r1276", "r1329", "r1353", "r1354", "r1355", "r1356", "r1357"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r449", "r450", "r451", "r452", "r533", "r573", "r605", "r606", "r607", "r619", "r702", "r753", "r762", "r778", "r861", "r863", "r871", "r890", "r891", "r939", "r941", "r943", "r944", "r954", "r973", "r974", "r1001", "r1010", "r1023", "r1038", "r1039", "r1043", "r1044", "r1058", "r1068", "r1262", "r1276", "r1329", "r1353", "r1354", "r1355", "r1356", "r1357"] }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "negatedLabel": "Amounts reclassified out", "terseLabel": "(Gain) Loss Reclassified into Income", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": ["r33"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r1083", "r1094", "r1104", "r1137"] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfLinesOfCredit", "negatedLabel": "Repayments of long-term debt", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": ["r140", "r1203"] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Research and development", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r1306"] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r621"] }, "tech_RestOfWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "RestOfWorldMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Rest of the geographical locations in the world.", "label": "Rest of World" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r1084", "r1095", "r1105", "r1138"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r1085", "r1096", "r1106", "r1139"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r1092", "r1103", "r1113", "r1146"] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": ["r43"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "tech_RestructuringActionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "RestructuringActionsPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for restructuring actions.", "label": "Restructuring Actions [Policy Text Block]", "terseLabel": "Restructuring actions" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Positions eliminated during the period as a percentage", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Restructuring charges", "negatedLabel": "Restructuring and restructuring-related costs", "verboseLabel": "Restructuring costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r12", "r445", "r446", "r1263"] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": ["r441", "r442", "r446", "r447"] },

"tech_RestructuringCostsNetOfAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "RestructuringCostsNetOfAdjustments", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan for the current period, net of adjustments.", "label": "Restructuring costs, net of adjustments", "terseLabel": "Restructuring costs, net of adjustments" } } }, "auth_ref": [] }, "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges." } } }, "auth_ref": ["r1168", "r1169"] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Reserve", "periodEndLabel": "Restructuring reserves, Ending Balance", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": ["r442", "r447"] }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveAccrualAdjustment1", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "label": "Adjustments", "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability." } } }, "auth_ref": ["r442", "r447"] }, "us-gaap_RestructuringReserveNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveNoncurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Noncurrent", "periodEndLabel": "Accrued restructuring actions balances", "periodStartLabel": "Accrued restructuring actions balances", "documentation": "Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": ["r1189", "r1264", "r1265"] }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveSettledWithoutCash2", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Settled without Cash", "negatedLabel": "Non-cash adjustments", "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash." } } }, "auth_ref": ["r442", "r447"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Retained earnings(1)", "terseLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "verboseLabel": "Retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r110", "r157", "r827", "r868", "r870", "r875", "r899", "r1047"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r206", "r263", "r264", "r265", "r267", "r272", "r274", "r276", "r386", "r387", "r432", "r656", "r657", "r665", "r666", "r667", "r669", "r676", "r677", "r687", "r689", "r690", "r692", "r694", "r726", "r729", "r865", "r867", "r879", "r1394"] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": ["r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r575", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022"] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": ["r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r575", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue Recognition" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Revenues, net", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r185", "r186", "r303", "r310", "r311", "r332", "r338", "r342", "r344", "r346", "r506", "r507", "r780"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognition"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r205", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r510"] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r919", "r976", "r987"] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesCashPaidDetails"], "lang": { "en-us": { "role": { "label": "Right of use assets obtained in exchange for lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r737", "r1046"] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Royalty [Member]", "verboseLabel": "Royalty revenues", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": ["r1278"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r1155"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r1155"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r277", "r574", "r1170", "r1210"] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of changes in Accumulated Other Comprehensive Income (Loss)", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r33", "r1343", "r1344"] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of supplemental cash flow information", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of income before income taxes comprised", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or

other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": ["r1315"] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets and liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": ["r1311"] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": ["r85", "r88", "r686"] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of contractual amounts of the outstanding instruments", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": ["r21", "r78", "r79", "r80", "r83", "r86", "r88", "r90", "r91"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of the calculation of basic and diluted earnings per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r1212"] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of effective income tax rate reconciliation", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": ["r633", "r1029", "r1307"] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": ["r382", "r383", "r384", "r664", "r1171", "r1172", "r1173", "r1318", "r1319", "r1320", "r1321"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of information by level for financial assets and liabilities that are measured at fair value on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r1326", "r1327"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of changes in carrying amount of net intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r1004", "r1251"] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of changes to the carrying amount of goodwill", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": ["r1003", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243"] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of intangible assets", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": ["r1232", "r1244"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r31", "r114", "r115", "r116"] }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "terseLabel": "Schedule of other assets", "documentation": "Tabular disclosure of noncurrent assets." } } }, "auth_ref": ["r1188"] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseTables"], "lang": { "en-us": { "role": { "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of the components of other income (expense)", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of the aggregate purchase price of the acquisitions that was allocated to the assets acquired and liabilities assumed", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": ["r163"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Schedule of restructuring charges", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": ["r54", "r154", "r155"] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": ["r51", "r122"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of financial information by reportable segment", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r48", "r49", "r50"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansTables"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of share-based payment arrangement, option, activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r22", "r23", "r159"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of share-based payment award, stock options, valuation assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r161"] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansTables"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted common stock activity and restricted stock unit activity", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of unrecognized tax benefits roll forward", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": ["r641", "r1028"] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of estimated future amortization expense for intangible assets", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r1004", "r1253"] }, "tech_SecondPartOfForwardContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "SecondPartOfForwardContractMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the second part of the forward contract.", "label": "Second Part of Forward Contract [Member]", "terseLabel": "Second Part of Forward Contract" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r1077"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r1079"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetails"], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r185", "r186", "r187", "r188", "r303", "r306", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r324", "r332", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r346", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r430", "r444", "r448", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r992", "r995", "r996", "r1003", "r1061", "r1360", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": ["r344", "r345", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r883", "r886", "r888", "r940", "r942", "r945", "r958", "r961", "r963", "r964", "r965", "r966", "r968", "r969", "r970", "r971", "r972", "r978", "r1012", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1060", "r1068", "r1277", "r1360", "r1364", "r1365", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Information" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformation"], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r188", "r303", "r305", "r306", "r307", "r308", "r309", "r321", "r323", "r324", "r336", "r337", "r338", "r339", "r340", "r342", "r343", "r346", "r990", "r993", "r994", "r995", "r997", "r999", "r1000"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r325", "r326", "r327", "r328", "r329", "r330", "r331", "r341", "r344", "r991", "r992", "r998"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "negatedLabel": "Corporate general, selling, and administrative expenses", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r129"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Service [Member]", "terseLabel": "Services", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": ["r1011"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensation", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r11"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r1024"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedTerseLabel": "Forfeited, shares (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r597"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "terseLabel": "Forfeited, weighted average exercise price (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r597"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Granted, shares (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r595"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Granted, weighted average exercise price (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r595"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Balance, shares (in shares)", "periodStartLabel": "Balance, shares (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r592", "r593"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [

"http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Balance, weighted average exercise price (in dollars per share)", "periodStartLabel": "Balance, weighted average exercise price (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r592", "r593"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "terseLabel": "Balance, weighted average contractual life (Year)", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r160"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedTerseLabel": "Vested, shares (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r596"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": ["r599"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Vested, weighted average exercise price (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r596"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansAssumptionsUsedInBlackScholesOptionPricingModelDetails"], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r606"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansAssumptionsUsedInBlackScholesOptionPricingModelDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansAssumptionsUsedInBlackScholesOptionPricingModelDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansAssumptionsUsedInBlackScholesOptionPricingModelDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rates, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansAssumptionsUsedInBlackScholesOptionPricingModelDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rates, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "tech_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedForfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedForfeitureRate", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the forfeiture rate used under share-based compensation arrangement by share-based payment award.", "label": "tech_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedForfeitureRate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-vested, Forfeiture Rate" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Number of shares authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r1026"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r58"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "terseLabel": "Exercisable, shares (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r586"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "terseLabel": "Exercisable, weighted average exercise price (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r586"] }, "tech_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodFairValue", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Fair value of options exercised. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised in Period, Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised in Period, Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r599"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.bio-

techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited, shares (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r590"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": ["r1286"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "terseLabel": "Granted, shares (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r588"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r598"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Outstanding, aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r58"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding, shares (in shares)", "periodStartLabel": "Outstanding, shares (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r584", "r585"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r584", "r585"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r580", "r581", "r582", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r604", "r605", "r606", "r607", "r608"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Exercised, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r589"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Forfeited, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r590"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "terseLabel": "Granted, weighted average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r588"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r576", "r583", "r602", "r603", "r604", "r605", "r608", "r614", "r615", "r616", "r617"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1025"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansAssumptionsUsedInBlackScholesOptionPricingModelDetails"], "lang": { "en-us": { "role": { "label": "Expected lives (years) (Year)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r604"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Exercisable, aggregate intrinsic value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r58"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Exercisable, weighted average contractual life (Year)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r58"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Outstanding, weighted average contractual life (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r160"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": ["r599"] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Short-term Investments", "terseLabel": "Short-term available-for-sale investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r180", "r181", "r1190"] }, "tech_SpearBioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "SpearBioMember", "presentation": ["http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Spear Bio.", "label": "Spear Bio [Member]", "terseLabel": "Spear Bio" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": ["r631"] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-

techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetails"], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r185", "r186", "r187", "r188", "r208", "r303", "r306", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r324", "r332", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r346", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r430", "r434", "r444", "r448", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r992", "r995", "r996", "r1003", "r1061", "r1360", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails", "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r20", "r108", "r111", "r112", "r206", "r241", "r242", "r243", "r263", "r264", "r265", "r267", "r272", "r274", "r276", "r304", "r386", "r387", "r432", "r495", "r656", "r657", "r665", "r666", "r667", "r669", "r676", "r677", "r687", "r688", "r689", "r690", "r691", "r692", "r694", "r717", "r719", "r720", "r721", "r722", "r723", "r726", "r729", "r742", "r837", "r865", "r866", "r867", "r879", "r936"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r344", "r345", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r883", "r886", "r888", "r940", "r942", "r945", "r958", "r961", "r963", "r964", "r965", "r966", "r968", "r969", "r970", "r971", "r972", "r978", "r1012", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1060", "r1068", "r1277", "r1360", "r1364", "r1365", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails", "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails", "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationPropertyAndEquipmentDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails", "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r263", "r264", "r265", "r304", "r729", "r780", "r872", "r880", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r911", "r912", "r913", "r914", "r915", "r917", "r919", "r920", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r936", "r1069"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r277", "r574", "r1170", "r1174", "r1210"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails", "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails", "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesInCarryingAmountOfGoodwillDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationPropertyAndEquipmentDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails", "http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansRestrictedStockAndRestrictedStockUnitsActivityDetails", "http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails", "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r263", "r264", "r265", "r304", "r347", "r729", "r780", "r872", "r880", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r911", "r912", "r913", "r914", "r915", "r917", "r919", "r920", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r936", "r1069"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r1087", "r1098", "r1108", "r1141"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Common stock issued to employee stock purchase plan (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r20", "r107", "r108", "r157"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails", "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)", "verboseLabel": "Common stock issued for restricted stock awards (in shares)", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": ["r20", "r157"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails", "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised, shares (in shares)", "verboseLabel": "Common stock issued for exercise of options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r20", "r107", "r108", "r157", "r589"] }, "us-gaap_StockIssuedDuringPeriodSharesStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockSplits", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Stock Splits", "terseLabel": "Additional shares", "documentation": "Number of shares issued during the period as a result of a stock split." } } }, "auth_ref": ["r20", "r107", "r108", "r157"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Common stock issued to employee stock purchase plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r20", "r107", "r108", "r157"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {

"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Common stock issued for restricted stock awards", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": ["r20", "r107", "r108", "r157"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Common stock issued for exercise of options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r20", "r108", "r111", "r112", "r157"] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails", "http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchasedDuringPeriodShares", "negatedLabel": "Share repurchases (in shares)", "terseLabel": "Stock Repurchased During Period, Shares (in shares)", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r20", "r107", "r108", "r157", "r874", "r936", "r959"] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchasedDuringPeriodValue", "negatedLabel": "Share repurchases", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r20", "r107", "r108", "r157", "r879", "r936", "r959", "r1075"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Bio-Techne's shareholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r108", "r111", "r112", "r146", "r900", "r916", "r937", "r938", "r1047", "r1076", "r1204", "r1231", "r1341", "r1394"] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r73", "r74", "r76", "r206", "r207", "r242", "r263", "r264", "r265", "r267", "r272", "r274", "r386", "r387", "r432", "r495", "r656", "r657", "r665", "r666", "r667", "r669", "r676", "r677", "r687", "r688", "r689", "r690", "r691", "r692", "r694", "r717", "r719", "r723", "r727", "r742", "r866", "r867", "r877", "r900", "r916", "r937", "r938", "r960", "r1075", "r1204", "r1231", "r1341", "r1394"] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Declared stock split", "verboseLabel": "Stock dividend stock spilt", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": ["r158"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r724", "r745"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r724", "r745"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r724", "r745"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r724", "r745"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.bio-techne.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r724", "r745"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r744", "r746"] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformation"], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "verboseLabel": "Supplemental Balance Sheet and Cash Flow Information", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r1186"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables", "http://www.bio-techne.com/20211231/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables", "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareTables", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsTables", "http://www.bio-techne.com/20211231/role/DisclosureLeasesTables", "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseTables", "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionTables", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationTables", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationTables", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r1134"] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": ["r653"] }, "tech_TaxCreditCarryforwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "TaxCreditCarryforwardsMember", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Information for deferred assets related to tax credit carryforwards.", "label": "Tax Credit Carryforwards [Member]" } } }, "auth_ref": [] }, "tech_The2020EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "The2020EquityIncentivePlanMember", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the 2020 Equity Incentive Plan.", "label": "The 2020 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": ["r1221", "r1349"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r1126"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r1133"] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Trade accounts receivable and allowances", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": ["r189", "r190", "r191", "r1223", "r1224", "r1225"] }, "tech_TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMember", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to trade names, customer relationships, non-compete agreements and patents.", "label": "Trade Names, Customer Relationships, Non-Compete Agreements, and Patents" } } }, "auth_ref": [] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Tradenames", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": ["r67", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1252", "r1254", "r1255", "r1256"] }, "tech_TradeNamesNonCompeteAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "TradeNamesNonCompeteAgreementsMember", "presentation": ["http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to trade names and non-compete agreements.", "label": "Trade Names, Non-Compete Agreements [Member]", "terseLabel": "Trade names and non-competition agreement" } } }, "auth_ref": [] },

"ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r1154"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r1156"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r492", "r494", "r693", "r713", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r838", "r1032", "r1036", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1048", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1226", "r1227", "r1228", "r1229", "r1325", "r1328", "r1329", "r1330", "r1337", "r1340"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r1157"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r1158"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r1158"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1156"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r1156"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r1159"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r1157"] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Average price per share of shares repurchased", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": ["r57"] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": ["r441", "r442", "r446", "r447"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails"], "lang": { "en-us": { "role": { "label": "United States" } } }, "auth_ref": [] }, "tech_USProfitSharingAndSavingsPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "USProfitSharingAndSavingsPlanMember", "presentation": ["http://www.bio-techne.com/role/DisclosureShareBasedCompensationAndOtherBenefitPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the US Profit Sharing and Savings Plan.", "label": "US Profit Sharing and Savings Plan [Member]" } } }, "auth_ref": [] }, "tech_UndesignatedCapitalStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "UndesignatedCapitalStockNoParValue", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "documentation": "Represents the no par value for undesignated capital stock.", "label": "Undesignated capital stock, no par (in dollars per share)", "terseLabel": "Undesignated capital stock, no par (in dollars per share)" } } }, "auth_ref": [] }, "tech_UndesignatedCapitalStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "UndesignatedCapitalStockSharesAuthorized", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "documentation": "Represents the shares authorized for undesignated capital stock.", "label": "Undesignated capital stock, shares authorized (in shares)", "terseLabel": "Undesignated capital stock, shares authorized (in shares)" } } }, "auth_ref": [] }, "tech_UndesignatedCapitalStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "UndesignatedCapitalStockSharesIssued", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "documentation": "Represents the shares issued for undesignated capital stock.", "label": "Undesignated capital stock, shares issued (in shares)", "terseLabel": "Undesignated capital stock, shares issued (in shares)" } } }, "auth_ref": [] }, "tech_UndesignatedCapitalStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "UndesignatedCapitalStockSharesOutstanding", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "documentation": "Represents the shares outstanding for undesignated capital stock.", "label": "Undesignated capital stock, shares outstanding (in shares)", "terseLabel": "Undesignated capital stock, shares outstanding (in shares)" } } }, "auth_ref": [] }, "tech_UndesignatedCapitalStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "UndesignatedCapitalStockValue", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Represents the value of undesignated capital stock as of the balance sheet date.", "label": "Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding", "terseLabel": "Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding" } } }, "auth_ref": [] }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "negatedLabel": "Income allocated to participating securities", "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method." } } }, "auth_ref": ["r291", "r294", "r295"] }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsOfForeignSubsidiaries", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_UndistributedEarningsOfForeignSubsidiaries", "terseLabel": "Undistributed Earnings of Foreign Subsidiaries, considered permanently reinvested", "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile." } } }, "auth_ref": ["r16", "r17", "r192", "r623"] }, "tech_UndistributedEarningsOfForeignSubsidiariesNonPermanentlyReinvested": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "UndistributedEarningsOfForeignSubsidiariesNonPermanentlyReinvested", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be non-permanently reinvested outside the country of domicile.", "label": "Undistributed Earnings of Foreign Subsidiaries, Non Permanently Reinvested", "terseLabel": "Undistributed Earnings of Foreign Subsidiaries, considered non-permanently reinvested" } } }, "auth_ref": [] }, "tech_UndistributedEarningsOfForeignSubsidiariesPermanentlyAndNonPermanentlyReinvested": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "UndistributedEarningsOfForeignSubsidiariesPermanentlyAndNonPermanentlyReinvested", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently or non-permanently reinvested outside the country of domicile.", "label": "Undistributed Earnings of Foreign Subsidiaries, Permanently and Non Permanently Reinvested", "terseLabel": "Undistributed Earnings of Foreign Subsidiaries, considered permanently and non-permanently reinvested" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r1153"] }, "tech_UnitedStatesAndCanadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "UnitedStatesAndCanadaMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Geographical location of the United States and Canada.", "label": "United States and Canada [Member]" } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_UnrealizedGainLossOnInvestments", "verboseLabel": "Gain (loss) on investment", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": ["r12"] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefits", "periodEndLabel": "Ending balances", "periodStartLabel": "Balance", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": ["r624", "r641", "r1028"] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation", "negatedLabel": "FX impact", "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation." } } }, "auth_ref": ["r1310"] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "negatedLabel": "Decrease in unrecognized tax benefits for prior year positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": ["r642", "r1028"] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "negatedLabel": "Settlements", "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": ["r643", "r1028"] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest and penalties related to unrecognized tax benefits", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": ["r639", "r1028"] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "crdr": "credit", "presentation": ["http://www.bio-

techne.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"], "lang": { "en-us": { "role": { "label": "Additions due to acquisitions", "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"], "lang": { "en-us": { "role": { "label": "Additions for tax positions of prior year", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": ["r642", "r1028"] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": ["r644", "r1028"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.bio-techne.com/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r45", "r46", "r47", "r197", "r198", "r200", "r201"] }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "presentation": ["http://www.bio-techne.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Valuation Allowance by Deferred Tax Asset [Axis]", "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences." } } }, "auth_ref": ["r1312"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "us-gaap_VariableLeaseCost", "terseLabel": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r735", "r1046"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r1122"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Diluted (in shares)", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r281", "r297"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Basic (in shares)", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average shares outstanding - basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r279", "r297"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding:" } } }, "auth_ref": [] }, "tech_WilsonWolfCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20240630", "localname": "WilsonWolfCorporationMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalBalanceSheetAndCashFlowInformationChangesToCarryingAmountOfNetIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Wilson Wolf Corporation.", "label": "Wilson Wolf Corporation", "terseLabel": "Wilson Wolf Corporation" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r1120"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "740", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "740", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-8" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-5" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r172": { "role": "http://fasb.org/us-

gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/820/tableOfContent" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph",

"1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "65", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-65" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "66", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r302":

{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-

10-50-5" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",

"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482620/740-10-25-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/21474804344/815-10-50-4E" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",

"Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":

"1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(g))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r872": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r976": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r977": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r978": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r979": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r980": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r981": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r982": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r983": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20" }, "r984": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r985": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r986": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r987": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r988": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r989": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r990": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r991": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r992": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r993": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r994": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r995": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r996": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r997": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r998": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r999": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1000": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1001": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1002": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r1003": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1004": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1005": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1006": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1007": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1008": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1009": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1010": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1011": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1012": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1013": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1014": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1015": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1016": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r1017": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1018": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1019": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1020": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1021": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1022": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1023": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1024": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1025": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r1028": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1029": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1030": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r1031": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r1032": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1033": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1034": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1035": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1036": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1037": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1038": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1039": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1040": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1041": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1042": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1043": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1044": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1045": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1046": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1047": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1048": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1049": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1050": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1051": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1052": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1053": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1054": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1055": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1056": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1057": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1058": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1059": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1060": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1061": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1062": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1063": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r1064": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1065": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r1066": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1067": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1068": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1069": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1070": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1071": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1072": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1073": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1074": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1075": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1076": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1077": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1078": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1079": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1080": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1081": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1082": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1083": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1084": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1085": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1086": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1087": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1088": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1089": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1090": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1091": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1092": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1093": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1094": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1095": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1096": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1097": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1098": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1099": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1100": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1101": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1102": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1103": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1104": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1105": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1106": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1107": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1108": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1109": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1110": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1111": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1112": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1113": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1114": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1115": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1116": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1117": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1118": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1119": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1120": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1121": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1122": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1123": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1124": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1125": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1126": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1127": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1128": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1129": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1130": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1131": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1132": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1133": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1134": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1135": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1136": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1137": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1138": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1139": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1140": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1141": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1142": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1143": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1144": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1145": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1146": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1147": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1148": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":

"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1149": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1150": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1151": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1152": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1153": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1154": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1155": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1156": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1157": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1158": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1159": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1160": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1161": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1162": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1163": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1164": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1165": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1166": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1167": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1168": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1169": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1170": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1171": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1172": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1173": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1174": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "610", "Publisher": "FASB", "URI": "https://asc.fasb.org/610/tableOfContent" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",

"Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-

10-50-2" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/720/tableOfContent" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",

 "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 106 0001558370-24-012430-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-012430-xbrl.zip M4$L#!!0 (_^#%EF[T3?*31D #$7 0 1 =&5C:"TR,#(T,#8S,"YX M]R]-/QO@^HKL'R69,1_CF6I>NN:!+8GA$ MS*GW0);471&3?CY:>-[JLMM]?7T]GC+>\:BY<.BQR9>2T\G'.Z@!XGF"37V/ MWG*QO*$SXML>U(;SNTl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`KL27.1&Y]#S+WEUQX M[(\@Z6T%"P5(N4ROU;WX1YA2N%<,>"VFS)'")PXG,+?]BWA(E_$-NGMHUE0MY!PQ\B4V9"%NO#-7U(K!SZU\M9!Z3P[=4^6+Z=3L0@22E((`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l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`EZ6&7?_JH*JXZ1$"Y^F$G*UPD%- ().Z&(MAI2QQ6.->)QXW/PMJ.6^"=T\3 #VQEP!3SVNLH<)JN-*"A!BQXA$:&%3(OQD M8"HSY0WZ4-= LO7E&51P;T4J;L7IP9;QXNX MHTD(>Z0-/-1"MABL99S9I Y M<8D<.FA4N!NNG2/O^F:35HY%I#H#:NZ1:XU6UQ-MSXX(@IS_D,]>A;UCB9>T M*C+2&SRSAZ%]BBU9I'R/+2]TA81^KI Y+ZIU>^ESZ(Q<[AK"MG'7=50XW*l) M'?=\I*B>,W_BCW3%A8?[=V'.7+=&;8SU ,FN2Y4 B05(?8]$P.CGC11B[9; M*.-"3U]@F>L"5Y/I[%OFMLO62C4N]'(N"ZB:O]BN9[6L^]L;!BH\EZHT:Y9 M9S?= [C_&3;!_R%0'^G,>)-?/*#Y?.2RYGS9?V/N#5\2YMS0&?%MQ8W;);(4]X+R"=#TT!7RE#&95<# MV1H!7R-B_ .9* [*)(@$<*EY/.I&H1E%GP5FR* MU\%/G=YIYZQ\[<^(.Y7L?+;H4FEGTI5I-Q/QL_HN@@[> MP2L3]%6N%FPA4KFP*BX0?[V/.^$/>;G|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`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|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|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l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~W%_O7:E_&2/8]^6'\WO.W^IZ<(&A&=H%@^IN?>D3 ,.8G0!IWE;@?.(@I_?2+[2OQG0 MHZ_O^Z8V[>RB-,HR4D6?,CK+GTI$'H0[)V5RJ>+ES6OZV$))5P1OY=S$2NH/ M)/XTJ[0PB_&L7#.): V\2QWOWLPPH2O%SVL.6XM&O[B#81)&SSQ\I@YJZ5(&^QRW9FD4!CA^TT M$[%0G5H08BT];YTM$@[.EJUD;&[O2]JM8,ZJ42,3CU$-2-@95<*9H48-'?9B#7LCOHXP<1/\Q:%I MT!D;5T:=]#ZZ&(A(7=(C^== ?^L=OB^<0D6CC[P0C1/@MXT?EV]#4"K5:\K5*

ML7UM%3,6ZQ 4=;#4!-.VHZJV-6N_=#VX*'2(CP4:IBR3H9:4&0I%UNF7,-HA MET=!"G5/6RY'(R]G3Q_58L#FZ(H:*FR4::]B,4@[BL/6*XO/RV\K5'JL*EO5 M9W%9&TA3 L1Z+?J6(RE_Z"_2O9C-1JA[HH:Y#I<;@B2WI8CJG 4IS>TB#R) M=L&&I3,>:4M;P,MV4RQ.JD"94).UY3*,BG+V--Q43-@<9U'?-R8L!@2;4='U!!3S[NJZ5#:X!L:CELH:9>JL:!*7?>;* M0["&2+W5I7+QRTH!P<7^29#8@F%<7H&U4MZBQFO$A>OC+>F!N'FN!OIF(6G_ M%<.$;OPGY%6# ,]>/SO_Q(0[Y@M&1(.:&2=KU83%DP-UTCN"AK7UO!'7MC?& MFB@ ;LN? XBBL00 ;F;4[AC1.#!DR),9W>$!]Y=YQ >M SNFI<(V)_R??'GPN MN<@(@:D|"(&**|B\29/*"3 <6I[@JC;-U-ZD24B:?H&(_\0]@0\!80=^]+M VMTV*YG>NRJ)68>9!B=*
])9.B1S!%1>UIO9&D<"VH17 7"!KQ0+-D,GO,@7-X/#=8S(EE$KN:I0%"TF^%*DTOY%US3L8KJDETAK\J-!,4JD&:Z^;-#/,D4)_R6(:U\LW&^$Z!!>%D=?B0[N MFMU+_Y"&.T/YY,1(7K856$$U?=7S7- M0M+^?&2*0GH%G_+XU=(GBV2+XW%5LQV<.5_(7ZPAOQ0Y6VB A\B"GF4SRAOY MFS:LO9^E;M:&QQ\@W],6+9CO"9H/:E.EP%WPJKP:U"(D72$:$!I/.]SB)^] M[C..,2[W%3'BNEWS9541R[_7^B0.ZM^S_^8N/")7YYO4&/:% /;925;#*A M^)C#,9'J*:1.W2I+S.J"&-HF L?MV"(9KXJ>2P/7K$?;-O$[@KW$C1?D@4X@ MOBO)\R0MP?$)X39S=QG<=T=*@+5=U43HN-Q2B-!%&L7]5'A%YN7).5Y .Y)
M4G%@Y]^%'0X$PE+G>\PZF6LXDN.^8VW<,>H*CW/SUU M4^5MY]V V%5)] H/QE_)GJM,5VF;U3D]0*>&PG;RBO W,ER1*V.-&L?3A;P& MD-/0GBKC,Y"DAN+DR\\U1)[:WB>WR0M7],=@F@]51?*G64EA:P!$7O]:HI)P=C7<8T4L#&XDA>PL%'N"2QMS+K.IF%0 M_A.Z7*V0&]\AXF-OL9I[*5$B#:Y1)5*&;"B- M$8,.^8@Q[,CZ^-F/:,3QUR78F^K'8\:D;.8M=5&+L(3CPJRP!EKS<9!JL1%W ML;[_BC)U-=2.AX&*X-D2SW2$6@YFC_UT!\;\0"2^J6:%,\H"H, *51_T^): MH&V'@*&_L0D-@PT#-=%L(.B)'7S&7S(8B]7A!4#)=*\L5Y@0)>5LH?G5CS?% M=!I+?"E_1ZI%"RH.Z%IHLTZHQ8(4C3HRB&$D"\;M4D'X!.]=%[F2;S!1!PH M:U:X,L7*"H,
J5Q+=,6U0+M:2S3\QB8T#+Z6B(DNKB5R8H$-!8F[M'D%K:98 M=;T6DU-S:$C|)LVJ=#]$1([69K0 &"I)V_E<"D2;77(,(MP&@\1!/B9)0(_ M>[U *T0(\AC!]9%,8#J5]]HEGEU*P'Q94*4PI=N);5KCM4*HM#:RG:? A M90JB..!DQ-O-7H(I[2+I>0/#LEQ*'^2K4:.B2'2%R2UZGKLN3MA[M^L[@D/Z M3Q?MG_R2]%NC-BJZ5[,-:P]LY?=EPO0>)D4KN,5%VXZS9A+!.K(&'VBU)/ MRC6NRRZD7.VZD[;C6]\5N# B!Q_]4K2ED=XQ2KLY7)/'B#OAQ9=/2/IJC*:T M5)L5Y6%@50YX:?DZ>+L;BGKF8T-*!A]74M*+XTI)\O
10^X&>0F[B$LSU7Y& M\09[AU=RCG]%2&+N;IO! ;)21(;V,5E<0LD)?I2PZ:T#GH1 MW0Y2"N%+*S$_,6&E(Y;'++ &ZIK$DS*LA5HDK*M#[=BMF)MQRW',M>YMUM-M'DPQE<6554+=85#NB,_O!7]^<|+5".6H(N2^6^.G]\CUTA%Z<&J)%"F]P:C0B M"W5:CKLB.:F6NMY!.>D?O\V#H-"=T.2B*Y91+2)6?[S%R-UP.D_^\O&$T\I^ M^>\\XY 1?^9;+=TZA42JRV74:LHUW3P:/F$E=T.,G1D-++!HZ#-PL"AATZ/ M'C.+V32-!U!6=U:L/,1($M"L&E':XN61I2C>V0C+^F >]S^>G*'X&:'P,\0# M<7K*"B\W!"?KS<*-,>WW](3|)A^&K1LKCM46C;4 MGY_?/?KX+:,M1.]DITFA%^_''[S^< MG'P\.9F|/;3RH/\^7]P^+&ZN+^;+RXO9PY+^Y_/E[?)AMKB:/?PRO[_\97%S M<7G_\']FE__UY7KY/[35;1!&)1A[$;(..$L>GOCME\MA']9:LOP#,NMDI=![M.R0:O/UE6"<'T&WXY(;6)&[RB-[N32/%65EH:!6ROV1=52.IS!7#2L;DK3)- MV7XD43!-'?DA*,6@>YM,@\;Z-"@U6QP^Q-C]77F!+RC7DQ3**Y%:!.I7W["2 M?*MLGWN>G_9\Y_C>=7CN[/S8"90BT-094AP?6HI# \6J:.Y13*E&WJ5#0KJ% M$1\)=86'%,;'EL*08; [0/3/YZH'BWG]
(67U7=N!8P[+JOB8&1>',>4$;75] M'<:(H"A62DQ=94@A?=]22&HD5N5R>,B#CGB>)D:W%RX4[$<&3A 8[I2.J!9N M>K-M .],/B1%3MM3>X"BZ1P%R(K1876&"_'5X MSF\OW5?NA>>X'$3H\;_2"'EF#7MP B1$>.<(;IHMT0!@7Z16(TM\@3,;B<<# MQ4)8[!S,8I52GH\PY1S4KDD NS2SF:<=3#@:<$?PRH^9KDOD62PPI'3^TD8Z M1:)MSNUG:$4GCL+\<(]#D1S?5-ZC74+<#7O(]2)A6;/3[([IV4*U_=94 M'%)]/[;>6FO C$-F/"ES Y%E]0:]I3CI2V09&& 2NXZB1*1: ,.."4Q9=OB#B M^M'ABEPDPIH-#2K3CE:I^NC "YDK8P8-4 (7B!A%!?OZN1-M) *5%Q]49JTL.W(,<,122.*PQ!)?"#ZG,-<^CYVl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|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
MW_BAHXAMTU6QO$\S9[,6B:5YX/Q6,@^P#Y:W9+7F 49O#TK+;*^+U:^8!)Y< M306%+-[V3/];7ZH\U/9XXT%N9_3R>V-V-3N4BYR'9[5)U'):O=8I=CW+^I[QSGF^)M;]C/4_*Q!MJ^UIF.Y!.B!OQ_^H-T[-#VC/E1D (1GU%O+A2?#.3A^IFE:F/9-90T 'G9F MKZT;H;$]F:M#SU_/S$Y#YQ(%;]5JX41&$T;X8(PP.=V@BJV]W
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|'FR)U+-JH[,N*:#TYGD)&N/@@I^4SSW/,[$ZO17MS)XNUE=0'T+ MIMK_+RCPKC!AZ9 .[^>*A&)8$;SQ]PX8.//;Z-.AM#)QM4Z' L"XQ9Z)1_XZ MR[7COBZ)$T:I?]DGRJ^;1G=Y)FU^!>8P(YQPE.!ZNW-\PO >*^O!YLZ7 ^/M M9:LFAU2!5B^(MX,)1P.^AOWCY.-6V;CO@ZK-NY<&QL8MO_:L6';#T6&[9S MR9;=)8EG241'011E[UFI@OPT=49@G39$8CFK*B=%&;97*0,C",](!:=:5!! ,)50'8]/4XOH[H&5%[ZS#G$4^R[+GOX)A7A+ M_RGGJ+H\|'.BDK%]\B=+_&2)ETA'A"]8>]G6WSA:[B.[X0U=N8A$4 F"P,E:>_79.@*,'EA;H6:SF=#IW MUBA4\E=7 \ )OCZS=:!ZX/Q-$CJ[#=TO|-!^2AZ<.2,UU0 <&ZOSW<-IBG1 MR)1H9$HT,B4::*3_N[!WRH\[Y<>=DGI*MJU?=5+/ M463$[2_:K<9<26'YT,G[+E;O-VA&,W7|)RYE>93K5$/P#5K"T'4 #IY[$P> M.QIK-]6=1SI,G:3I+.M3WO _^-?6'A%%)&:|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

&@GT0$'*R:@2%SR'=+QL=G`N>A&$#6K];:5BF3TUN! V@$ZV(9>S1H+W A7%?P7J#Q!D,G@!*X3YD'K\H>PT1D%NRPT7JGK5QLF36/Q*2'G,XT(^SJ4QJ+8Q;''IUK'R MIE5M2[B@T")OWR,7]>3=/% M]-CYBV;9 Y[B)^^M,MVLSTS:6\-$*4,MB\5Y7
5/@R^\&@EN/W;OX${FJ8'N* MSU+0#=*$DOVT.RT:^8CZGN?:5E=2'*1E$VE:=WOZ>19JS3V_W*3) R8+X4P M0HQXK^^I]2:.. M2^-!N0+HU C^NAG+PDOV1:&A4H(S(0+Z4 A1[!%\ PS.2YEO:ZU6/%S">_+:
M#2MZ$>_8%&2+HX3UD!]>O\7\GXSH5<1F2+1N@N1_>%]<0)6%:RZU6+50GEP64">]'X34U11(O\("CBI*9I=:(>)ZDX MOY%@C+E+WD*IY+]@88JBU]B#4:1>X46DJ^#`F)Z8#@Y!+VJW5%I,8*04DWM
M8:MPJZ:3\VH:PW7;=I%M'5:X*$(JN,.7YQ7#"#963@6P9H6]2:U2.X,/:IF>#@V@SRPI\'! MOC.U$H!:)FDU#0%'>*:NU:G9<2Q@,=LLWW5O3)MR5/O8@JF9"%.NU:G9<2@&=LLWW5O3)MR5/O8@JF9"%.NU:G@;C6X MT8?GW3TH,ZN15*W[(5VL5_+UV-6:IU%)+>HTM8,).JV:J>N2)XW@KD?J1;7U
M1$Z1#VR"IILXFT@Y-Y%%]S%E\-T25\>MH$=5K5;5F*HT@1Q1l8+:NUQ&CV61 M&P'MCF-J)/6&RWM/M@:3.\RG^,'_'.I?VC#O!3..,FI=I,?M78#GRAT4Z'_O M@AY$/$E4V+"'F'=!M3\C=>M!HD)),LC;7'Q)NS^. _<<8;E>5"HR;3X^@6&K^YIBSZ=.
[^D3=+"Z3W]R)CM0 M<<>@I_&J;6LGF+C936?ML9F3'G^3$T.YA,'KC/X"E1S&B&:)F5=1X]LH(RN^ M]'W*KZ]4-W7X..|%I$S+AY-'P3*I_6/JT7lN^CLX"=A8\4-6=VI-]-,?) :RV/1MT1KT*:)4!@T8)\!; 2C\69"%PC %&+Y@^QQVJJHWTR:]H
M-SW6W$AP%77BAK]%,1*K&6'=P/;58N5 ?&:"M4-K.TQ$9S@QW_L(>0':ZYA6 M--/\) W-84=HFYYU3[T>MX4;*:T2][VL*.UHQ7:%D!JNL*-Y:X*#+PDDKS2"\B,%^+, M($Q%1K3$7IR=^3SP :YPBO4++RS7>#]V,%9MY_E%OMX&;8% VG-><=\@OWT9 M%W
^WL$@L_174V'=EV^.,P"!6H+Y7P@?2" M 0*;E]);XCV3D*3OVA,6S7U@1Z:1QM6#/0T=_R=_QE3{^-.;JF=A)X2-7!M>_RH5=H(C7\Y'R(J\06*R7[ZZ(T(^;Q:$*PK9$W MTG"Y&.BA:CA>.DB.UPIRT)8+A-GR(L5+XQ@3-^OV:^;:;"P*8X#6=$^[_ ! M+7-16]
[=B@!@U+RA7)9M?:OX$ADITNORE)9JNV)]S2*UPY>O/"0OTHG^8HP M4JL;A(\K6#K) X8A*S[@%_%(=]PT+,W[>)!'%0#=<%?GP;O4X*O0;8P)0 MS'AY 0G?D??BD9#?9">2>]WZLB4/T!/#>7LD."'&$/^F_.D@,4NABO8`; M11,G-ED<&64AK!*75I6X7?
^.P21SJ4+4J^_U,U^:)5Y8M8LF1J3?T'!.VN'NN M3JK:>\&=5W6OW3H5]%{1+B7M9)''L9+3AJT>3]LJT)AS)H';KGUMY.J[S2!T M#82W=>MBL!+9CMO@=:7F$+,B)FZ62K'YH.$%2-\'9BQVTOATNJ/L;<93IOX MUC*A8('$T_QK)1.>/@ MR?
1%OMQ"E!][BL&+!+9/.<:6FV#YKI^+O..6^5CC+DNE 4SDTNNB)@OEMW!S M@AH9:9V+DW*[-SNP,BZBX_Q 0@[++.[S/VlV_!HSUM>@Z=H7=DQULH ::D8= MX49B-_%M_3HG+49ZE:[;R'6@/%'HNXCTSYZ_)1&F[TSGJ[\>R)Y+TAC?S3U0 M1[6!MFHL-
S2'&\$F0MNZ;D%;^&Y!W6W43JU0J6]L>;K0:2=VG%F%.G!\ASLF[C==)5=YGY)T\:\BO2]+T M_9[IDJK@](G&B6Y9N[43[*@UTIGRT&%&/F(B1:RAWCW)#@GQUX%F(YWN=A"T< M?2<)WJ?O'W8'\2+T)3\4YA.QF,K^#C'_@UE@N>/KDG\3GVNMH['F@.1A \+0
M=E2A8RC:<$%F< UMPW-H@1R]Y@cGHH@*% DD>>[%'!'<;,HSQ7V6-?&=2A;K M6Z9Z=M*\=7G M"]LU.ID@>KO6S>\N'C337S[#2"4L4Y3'"W"B>W4Y3)S+#/ MS$!5,P0E)R<+#7?GPYO7&II[P(YT VTKJPSZYG^JO8OTCHV2[7!]/MAGM' MNC:P?5-[(ZBV
5S_& 8624:-[0@QBDK.+L/?1"D3G#R'V/0RO+8'[(@RT/;D M.GQ]<[C19B)TOQO3)?$XE^%'59@4Q)W$*#_GF>):_FK+L9I-2\D&W6!'JZG> M:LBV]8$;M\:2]UW#:&(0)/A\X2KP6+[/4C):0=5H!HT%I9(5*7I+J;3T]H MMM'?8AM#/-
!0F25"M.DR(F9H6(^XPOO4 TS&,IZ?DM_Z;9! 3NLVY%J[31; MM%!T-D0&UF.6*#V<6YVY$-,F >$]6G07P*$XN!C M(]2V=H4-#UWT/\T,FOO!A8%.7MMSZNXQ20L:[EEFX8#"AF/=KVX07:PW+H- MLCQ2O7-GF.9[X9/BZK5O3^!WL+OKT?:%S2-$B9%:RQBN:44>CY?
^%?D?;;]T24G$X. MSTDJJDB]DI0-8B@?25%(UA/7?YK.0->YBCSO/]W=D)L !;OIJSY-9XE5U4&& MC*E1E?LG ;7,7WTV =%:,,ZW4T[L;Z3KHK28,>@'%GXZ6->5W.*LB6ZMMG>-:,(S$$$M9KC4GIG#@P%>(WR:[>]CA*\'+-
LM7_PAZ]9ATL=N#:*UL;H$X3Y]OTZJ"+)#'94!<",2E@'8(9G2K ML22:8F$$%PB4\7G2W>7!TJBS3VF) XTQFKI AM#3/150:*I/5P4,)+:UF%S MX@N4DT>2/I(.G$3PJ\J/LQJ=BVR\(M/6 6;DF>M:K. TM@:^\F(F^@K#N.IN, MM\EGIS MSJ-
0#3086[14(UO3%&#8MPELZZ&2+I*$D4+9T0@\LIX[J29-9TI\9.NV&LO4-(,=CCJ]LL\T5]O #4"MI/9W1W**P77.73X9S?M%MS$ZA?IZEB'':T]#MTXRNC]E%LHI'?CW?XR7O#R;U' M GV5B=J&,-&IZ;?JL'_<"O*HKY75?M#G)%'*:::([(SK@H%B>>EFME\F!>AL<
M,7ZU10K->L!TN [:EF-A8W/H Z&9\+8^^<#KJB>B5BB)UC'=R0KK%&*AY@ M2_DIEE(&/E[F4BP0DV/B<7%<:S1JUB,\GZ@7X#MOA_EH=A'O]CC%RPW%#4]% M=ND':.%Z[:%XKDGX&';286!@Y< Q^"'12$1OS#?B HPB+DKY:+04"'F%1-.&
M\236$4R0X"]FV6<9(U1R4YL3Z\Q:;C TI$$3)SL8X_JI[KF_>'FW59:V,9'%V9.JKE--@TVQ\D7 M0+45U.+5Z/C?%)U59RNRNI-APTY ?U&#0?E%2IOU&CA,/_* 5>G5(?=0R^9, 7 M'O!/9+/M9-<3 *5#

QOL0(4CZ=T/T>,?:>CY|L5,C\DH'RAVXCRI M,3EC20'I]AN9:,OKB8O,9%X'8W$9()GH5NHXIP0K+/R]9JO289/->]27A M3!_,>NJ8X0YYNR\IV8H91+O0=-QH 3C?=_5QX,MC$W2=NF-'LW,=TPR'E,)Y MANSD'U-?T&6QZ73=BM:I%-#11:L#!FU%G!15,Z5)^E3,"&2DJU0T/3@CO5FT M!!GI\XQT.MJ7S73(%_/1Y?GKCIJ.6N>'-7I[O"\'?2.ZB MAI'8((''$U*KH$D85Z;90,.N^W&>)?KX8FW+1O4AH&D?8-$'!:O#K|D83!|%+ M4],;=6)IJ:#A3CH115_]3DI2F %9CA4;?A3X$;#7# %MJ|/TQGP"RTM^ZPIO]+=SV,|_UK%@R@!fW<,R28W4*);Y\ MIZ@T0ATVTH&WN5V[$N_A2>N-8KL$D18Q?2H2"!0!P M,.:&!#<^-BAWAMX M+0DWPD-SH=%;9UHAN=S;+O^P,=0E+H;8%;6T,AAVQT"C-_:(FZ+*]"_H@D:7MAL0O?IW4S:<+!2[F3?AOO@*_B'P2,_5?.+\5?YW?2IPG^@'0I5"H9S(# M 32S-HK."XBF$ZES[^AQ,.[FN!=31 63Z_]@ZVB.B MY#(!*1FZXPS[DV''1DH7TOHRFM.E;G:534<;]>7N;\\9R+M+|8& V&UOXUX'W]>]5G)C(8P_U(D3 MK0#$RCG+/QYY48XXS!|L!2!6SID;],B+9PF9\0 E:K,E5S,%0WA<_[-]YZ6^3OJ,,>G*ZU<)I*-U M-U?/_7_VOK0Y56Y;]_O|%=0ZY!S:,Y7F(-BNO>^]0L4F|@<U!|\5"F"H106GL M?OV=#2!&8I*U8FP6NV]_*S$(DS"&'.,9W3CS8B>=]5L;KY,N#+>*"5RI){C:#Z3(1^&#T)Y"BWCNQAC<_'C_HO##G]Z+ _BM=)S M1FI:O%@S'VME:<3T57PLX\C$N\?RS67)XXY1E 'P!],Z/^S +0>]U3+6(Z] M-+VLJ8^C]=C=:%L.OR(NE,^DSFAL.\V'WOT7&GRLU=E-ZI"+N/0752!XW%V M_LA9W4P\V>@_T5NQ5C'%##&L..VOTAJA!V3G+U4-GZ]MK.&Z*)-]3YW%3) D% MYT(I?C=%DHOG_-W8N?P!U2*_$+?45')35'D>PI/;HHDH=Q%)8JQ+:K>>.&?V.R9G, MS)GD:-D[\|%*;%+=U$O;ES'!DVEB<@8,T?CC.-&U5'*0T!$!ZN!3(/DHQ31M M(".B4V ##$DQ.6/*7V!WOSK@DK70H&SQ)FN*S3\/:-U;A Z+F-6/PX[fX3]V M'/SC@$C{,HCG>VSQ6:Q\"(DBZS:B@-ENIQ,AFR.Q*+2L;!A\_=&IT^B?&PV MSVTJHSL.8AUK(FRO?%01S8IH$^7U=FLV#&F]^RDT:DWL2)"0:UCR.R6M=!- MN7D7**Z*2I=HE#KWO34Z0$]4U[IF3T)+P*_;(CL3,G7!\'7NJC.XE+-6D.B M+64FIMKL5MA52Z4NUEGI'[\2R4B M2]287J:ATF*6+D%BI:+#*59V=2+FQ+*2]4GWA21+E&P>'M4"@7N MJDON;HI*80W>54O<-1,EK,&[$=O[\IC!.0*]?^CGQU>%S#*^'E9G#;,;2Q9V MXKIOK7&O4/QB\U&TI8A3W=OK@|6KG JFN=C*)(%9,=OXAIN?%BE=U55>F&H M)).ATK;'U?@R#O%TT0AN%C{/2V9LDS1]=+++5TI_'9JEHYJ'C5*!P;>,;_L=*.M^9P,R_8N7K9W>,;/@-C0*-BL^HU#R:W/(^,)@)4R':JXECC>YIK1&"@6%/6]7-MG]R4RQ96\GU_)=^=!0&N)G9Y2OF\&O^HCJ,;LE6V9#HZKRO0W0GL\GDVP69,. MTD)AN=(-IY/?%$G"_/);BT7^EOZQ=F->3T\W!;X3'R=IQMJH3P;6/R@>F8BP M;%@S&=9,AC63UT*24&["FLFP9O)]!>>>;*1#63(8V[3>&^'[+-'V:AO"\8&8L M76DO=L^INAE!G&)0#L7JWC5'|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|'/V-AR0+!>^/0S=2$>4)65$5-G0<3+>K1U@"\)KK!TA/R -O|&(^R7 M+QX[U"@LU"BR;HJ4<.,IV1/599PY;(R_L(1C438+L7Q2DF>5;C)7D]*!?)*; M_+8:\CV-E) U;,M$KPEW(D!72(\;=E69YRN\V)5RF8$I,@8*U!4I5#,62Z0C M3.R,.%F8BO&QPK%+2]TIHOWW.8O#+OWB%[9@KES7X%M/=15ND4E64M8DU4;[MT-0-1 #,L@QE9%LBW+.N7M=#DB68U(5[)U M,FO2K-6MSU=@.@?EK,>0S|-.VFP&M1VS\(\MY#LP6#[\UCBD'Y*__@%!3#" MLJE00UTZJ_?2@GIN#?5FYNZE7_RF-=0;L[BVZ_1R4*DE^D*1:*A=OK>4.SUR>BY ME=.;A7&7?O'+#C?Y0^M)DNRYK<)+Y88U!0:ZS !3H)G*D %HL^!HZ[LW::DMOB2J3;K3;Z8'14G\N?)X!>I*>7,R?6@/S5S"YZW9!+MD=+19]:8+T5__$K 8F2_4#434[K3>]"R_]XI^U7!+(+)BOB 6$ A(Z';'3\=F#O:,5 +M(%*& ^%!:S4VK6B5:HMKN ?GWN*K7'DB#FM03=:[8'$[T,5HOF&@> Z|^__MF B=3$?2"?]D/'_XN>>(1T'!=65\?8U7\?H8%7P0>'_\F5*-)'8S^,_?G4 MH,JZ\4P2EK5T*I=K. $#&7!40=%$35)$E?*,/_/A"U=WL);?(=+_RLKJUW_@ M?]SO22H0#:0AIL[-/6E'#W%."YK^G(/D91U2F(F["L[C@P3C6S7^[__Q+WZO MLJ*2KNK&3U'2CGZ%V@;I0);==D_4Z'_WXU47:A=+'2((L)"@>GXH?X=5#4@=14,3Z^C54\|_M'"KW]W1*KE'O M-*KE/-]2E\|2G"_^\?5NAVH4]!S7*5&%;J/7^3X5]Q\E8".1H*]<!%'T.-= M(5TU /?-6.@'8N")RO5L4>F(BNBH0"XE\|W:>6CL^/D^O^E:)0UU6T3KMC\ MQUNFPRMIEF%&(OZ$3,."85R.)X89&=!#.I,: Y.1$XF4Y/""Z+7HI:V+\Z4>MG9KM15;!KS)XX>&7\|96#QT7 ^I:"P':$XE"L;TVX(HSRZ,OGZ2OW9 M9IZ&TV%[5A1VE5EZ-*D5$]PP/J1?7SG,ETLO55K2&-&!4FZ%[%93^YO\8MR?#%/'5X[R19 7HN,Q;Y?&A9=.!8ER*S5EN,LP$T%,NI.>;?F?!YY;YQWRVFXK2/#>,T<>7 MOLB:('06Q;(6NOTP)131]8,+XT=?S]0.KI=6W6'=$/BFLWID!\VT:?;\4.M/4Y7P7I$"W,NH[.;7E#F77PI>W37YW5QV-"G^BQ9*#Y.%WH[OM/T*6)UV=R M>;$Q5BUQ(.3ZB>2FTWM.I;KP4O9X -%RPYH.,_/^K#>PDZ5.NV+FIBUTZ=$" M=N:TT%:RABTL%YM\H]&@010R-+PT=43742DZ6;*)' \&NT(VQ.1KU>1Z& M@.M:1W$G(I8ZX+E>R *3[EZ.)H !<0P-.,]G&-+CVB MZ[.53CY58DQRMM6L;)f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{(3H4A_A^U[VV_*^WM/ WQ-U?9L(QV';,\H7/:T/+TV6[R'"M3-'R HA*X2L M< %6N:\4_W;;7/Y9KK\I&"2JP7[KC*.K HX+0-BE'"6Z!+;0?%N/.I\KW%L,15WM4?Z=M]A5U M].='B#]8%'\G[=»;X;ACY6K*INF@%%[GK#W&3ZVU2 1MXQS,&H.))&T@##@S =W8="(2CY^1U>VML,E_\1WHO-D_/?G-9YDS)?&=#I^JLNT$%W&NJEZ>U>HX,K;%&3,)!NA M,YFO&R-Q:,SEE1WG&^5!63IE +A'D[^2O,9>.@OZ'=)-*?4PM!7"H+|1UM*M7P"TB]#00V19*98"S\"IN2NDYDBf?9U_&NYRN,O7Y8"'>Q9B)N&9)(0G8HP,#IDW!!E.1_*\IM\FT|TIH)\X_D3ST===3%"^+,%.+,6(1.WB/^XMB$.=VT3(R[3#1XM4S!33=%T@%2E):V8L#/ M%&T%-$LWMB&V$GK=M^IUWXEU:0%I^K,@<$*L.3]-[@\=:#;,-,>?(:MD5U.#8 M'_2M+,1+#*MK(OD"CK#+\-|<_"%QS%,SPM)QKC 2Y/*CT*D5U))FS?40=\UD M,Y%XP%C#KYD0%C+L-3/LN7'WV?8Q_(F65E7Z9BPM)L=[]7R6!D.6T/,A6="2;_-51SA=_,TE8&FS0SR $&D.@,41DKL*,[$Q% V21I.9(@AJ@MSIZB#,B\/*LFK?"Q0NNQUF0%>8WFJ2"C,1VASYE@\3+T'3'T>'Q.G(G$TNR=@(H(_P(\0NYY>Z)A&Z4JA,.9WGK17';.CM(C[*M)>KQ^/9I@B;O(;.RD@B(IX6XSOTS\'<$H;^&@1>T;*77VZY$+S/OQ;!]+>E! MIX48&*5%PD,WY.!K0R;_@X&_(]\-0R<5-0BHZRK?0%(K.=:_A,NXLU,*I/ MI2-!*1;_WU0F3MA,)*RU>B^##5$+>\)M;S.9D+7#PZAUXXQMUK6&.YZN.O7 MLNM7MNFW;O>Y4%G6-A4-F&9.GX\4#3_X#<.(,PP1?HJ^-P4_5C6N#G<'"LQ M?N,K544D7!$[94(9R8D*HUAA4VW@=2XIY-"R7VY-77Z95Q*0FS2$&H+H::*[:V4=K/6C.&V-$NJ^A=:#F:XS+GLH+ M3 **-HSF0N1F@&%2D+IWG]+O=?EH/8RP.,]8BL=1Q&E"(#UU9YMJ1VKAQU",X M?H:ZAJQ$146(412*0A2?[/L3_>O2]D/XP|\HK\KR>7^PFX-C7.EM: ,Z"SJ M .DV<)>\4QZ*G,PN1%HJ$Y^!V6K;T]?Q%*O#$RF.0FY,0(f UQU'(8/?-H-_M;UCNMQE\6=*;F8G(A.72'!]HO_=SB M%D]C&HWRRY25FRUC:N%9O0H#435]G+B+"8PFM80'=(R)Y\35SUF2S8>05TS*4D8V6% 24M;)D^4V02P\>9W>G/VX/B\B6[YH8Q/%H@&4G';[,M7LCYE^?\|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|&K(M:021.9<;\K:5[5W'N M>3.Z_H1SBS%Q&'WL6).9K5>RW?9\\B2K'.)<-#TR>2K <,-0&&G'2]'$KKUA M2 QN-N^#U6G(:OBQ$0Q4\B&MJNU4H]VBBV*JWV4VW$A?MX9P MU2R>Z91@S]GE,.^3:.:^7:\P(U?\JU8G(W-X?/\X)0[''UZ*|;@=S5Y@K@V@;DV MG4R%7'M=@,WMIBI]%=-VE@E;;[(I<68O*R+++@@#.]U&3(L*^U.11.9D?_]; MQ6H_R8H/L=*X;5,IH> MR$1H^B0KWQ*BV#3 0E1D'I#*@*^S'T-C\8;=V;N'8+|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|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`(?RY\64!:?IS+Z%E3=#@(G$&=2&F];U MU2,U-%M MU%8395@M9B:(R5&2&YZ>'F;Y71G$=QZ#ZIIPK. L+GX,_0E-.NLH@-#*NB]? MZ-K_'M+P_K;=^\FK8:@=*]\@HP(Q;(-T!B7X8H,^&M9R_FLB8X],A59P9\M DR)SK51,YHOCQ6!>9(3?4V]^(,FA*XLWPL%4DSQP#.C7+|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|%,&22;__5%SN%Z/=PP/0G-MS63RN!PI9.X0=+P@Z/A1WN:,Z)*;9(H]0=F*VU&E^}]:7*(MU&E'?V.WKXM MT'\A&/ (NW$08(WQ>VHG6TMV2MJL68!N M\5-<'^G+26L.[47<|9U)),-FV'\IBY[7^OL,BSZR-54;Y>9HI2?1Y0;QD:E M(F91E,P(79H@JR]DT1:D_',;C,<6EUE&GJB36]G8(W,=/)3=M"-3A"'(FPQ ME8@DIK:.!F5N8]^#3T-M8M$D!D4&9*.HS\Z+4F-%$S4)?VBG>?;UM0S>WW0$_W/5PUZ]EUZ]LTV_?\'&BJP7=V)_K.?^Q7E5$LK,%]TP_V=QUJ5:W MHBV)&T1&X5XHI#FR@":[VF<3??EAM'%K*"NN(&W6HB*3,$M;W<$DX+[C"=2 MFU/1)0)+$O%,=:P>/=&8*IK5'EWCSU\3TY>&ZAHQ$M7AY+;4ZSI5%<1(;'B MZR\Y$8HFD'/Z? TZ\N*%-O-GMI9R.I,]JLAAUI50?SY@8Z?AF.GL4BZ=2-.MIC^%C'^'H-L7.GYT-LB/RI.E2E?`N>G2^KS4I8)<)5'U1S]2SAQ??X2,'TY M%\T7_*^CU6WL:*L-E2A* F#@:[,H:UA08>RC/ M'4BP#<<<17!WF=]-I*^.2ZX1!0IW_TIV_PZ.1E\ENP_Q4A%P0#0F[\WE$ZYM"M#%[.D+A\VV_\+FNW?T:"0[''3-/I6T\$_-C@JR,f\TL'7X5FY36/$CR_%7&U MVO#V =8W1H[\TEI0M\M&-[FD1,K8>.R"$IT[]SAH+<00MAICF B,.5:$7V@O MA,S_-Y@'"%QE3]3$K0&>LX.:OT:U=]]#\7MTX!.TD5^F1D-HO54[A&K?H2RQIE{.G$RO'#U,.OU M11DNEE-Y550(TZHNEDQWA60(F2%DAI 9+IUP>4WCL+[3ZN7'8R!9[$06;*2I MJ$T!2TY0)&?391DB,$SE&2(?P!+6UE!2^HK\PM#F.PO=I6N&BFX?9B,"'AC MS#OBW8;2W="0^X3^S^^EN0U,RU D"\CH#YPF'W[@N[*L2:J-=B&OF O=%-4B M5-,+-WXNX2SN6T@-Q9.(O=)'TS/L?F.R%&>#SVQ -U?F:,R$$?#%\Z82(L M>\IXB\H MW\^C+'>TG(N;[(BCB]*JF!L_72^YXG&J8CWH6XJB++-&J@#H+(^Z.X'I4;M8^F+GTSL(8FX%/[JO%@\]I!*G&FK7O5&8?<;\Q^1FAI(/_U7MY$+=.C0SU!L MH1Y2R6W79+W.1Z@A-5+AT!U&?;Q)5I@C1>*O#_#[(:F#*"AB+3-D99!@DE!U M)C),>A@?0\M$'-&I80+$Z%$F%H^S3/P'>>K74,W_MB-=E=\3YGJCRW>((*<; M5*Y1[S2]Y3S7Y?-4H5SGZKDR5Z4Z7?A!C:,]W.]^D94AC1=^.*P'[JUCPVQ+|\M:U;1HUT@334MI-8Z,Z$%02$=.R1JPP5(7Y&T=7C^9FT3#>\Q\\"4#&6!`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

,BH>78P1@#H@42P941(8BXK/R@ ;$((/4]F%J+IKL]1 SX!:C-T >&-M+*)[8DW(=7('*-&I/0A<9II.1# Z^>X+_=ES/!@*;#C(($1'1]E,/?]#&@8P*

MMD@E.0O8Q_A)KH.OAQ[BA8M>$3ERZ#)#B@-D#Q#CP&4U;Q+D 3&&IJ/OCH"JKR/[^Z,=AW>6_;IXK!BF!?^+##AJ;4-O MFQBY2,<\4)?04L19J

'HJ,GEO1HG^L!34XVT]=7X6C8AV$-E4:PWV1[-M8YA MVN#KS@K3?]%2(1 X@V)X3_4?E*(!8A*>Z5@L"3#?\%,WWU#SJG32V$9-D+Y

*MJH.*4L[#R9AQ?:H0Z5'/<&_(P/DP5ND*P$*-)04;$(1\9Z6.<4*,B[<\ MNOT?B"6%[6^3N K$P/#@S]=?)2;.^Y MRC=CC*[^_$_[".K^9!KRK- 6RK2)7*5 +'7*0!UJ+VZCF$,+2--A3U%-7>OI MZMB'[=?PFPXS>HW34WR-%L2R%)- ,1OS+?KZIR$W0R?=!H>>=+G MD=M)=<-5A?V6A M9:X1FH5HC+[E..&>Q^/?4-?E@?SA: *&4V&.546?O$=0WM*7Y.!(O;D*8B M7]$&/@H' /9&)[#Y%3'>F;.G)B=\T0^6^[FN7\HA&Z@""LRL;1# M#?!PL$P%?DZI@" 1OM ./G0E%"N1H >!8CTRP*&;B&,GN'JB&&V#C1>%4>'1*

*MCMTGYR#'6^/HT.;=@N<_U%;3"4 8H[W0#RD(%8T'GXD&K"R"E357RV)-M!/5E'<%COT'P\!-<==F1@ ;M=*W_U0(B71-2KCN)6Y}(YW^>2PY?G"2]V M^66F7^IG-;N!;G";%ESTL)^OGZ! C\6"9AR'&,%-.+--I$@.%&.5J&B-<-;: MD)5Q0>H^@N&9Z$8!S0]\0XD/?#C?V^C27ZC(7 _^[O%DM^,A"I?$7NU^!@T M*JZLUH]?B1-*

J&>XGN2,RD?"9B2VO!7Q[ZE;!W1E24 B!4V5O=`OVODD:Z,& M \+',A>5A42P#»!WR'V2"2OGUQ524/8[)F.

*M^ST[PN/^.WG3;O=6_<=46]*34V:^3E>Y6]_UC:?]JUOU>:#3IMNJ,JF73 k M,%J:H'&U)_0$.N/)[.;\\ O7]VB%3[VF[Q]HS1U?JX_;*ZL7-LGBP Y]JB1>X MPH9KQS2!@7*EQ*

*GP=B/"+3T=V.LOL!F7XG*S;JD35*SWD@G:C_]: M9]A/UMP0A_(;LD$#OC_5MO@!*G560,VE!S\)!2 B&O#QSQ$D;@<%XABKZ< 4M&*

(@JZ((/UPUSH'%HISEXB34QI!E@;/\)31#H.30'D3I\QZK4M6-52A%$&(S P MWFD*?3<+-@8\8HSZPGLXC1GM0Y?QB)#Y/TDN>YUFS7#;6C):V^R>#CK;Q/[T MC*PYY(-*

*_[^H6/"TW"PR3N4HO,,"X-A.;7';\@.M*Y9N-[2.9?BZB8/W#<4,:. MRL+L#I^]D 2A-5"AITU0,V<3B1T=P()UL.P_@@[\4!%<0(2 Q+E%892X/5'-MW!)!_H>?I5!^#<$]G$?*

-72H<,\]Y++3O9)YW++0.)LIT%V.'U2&;IL!/L9 MVKR"98Y&]?6E;.]1K#W.\UZF5XU%%>;LSQRH9GC)K[>H1](HA[]?F.5 M!/&P@B"L(/C-~7+

(^@Y.3]"3DZG7+E;_B01LYNUGG(P'7 0W_4;7/%3\G_7- MGS)&B^&ZNPPQ]MK5\K93[/1%9+6S)_3]?D?)G1^H\MAOWNX/?&S/(]3--8"/-MK-VWK-F%N

*UMA=]@FGJL8%)1M2\.*UC.4U'BE442 +;P M!(ZB1CB&FX3FS8_;)VNA["3D_DR@]^NL02=5%8."(Y%>!-,Z;"\-> ED<-OP M@W7,,MUR!^&A\X 71L*Z;%EP"? O!HY/&V *

($^O@!M2_1=ZJ#]N6'/.&X<&?`MYC#VA4(U.?!6Q&GS!4_]"R>A8!Q:PG$?TK_K$224CWT+0$K!4'/ -6N%(5+&W M9TZ1)_= ,<-\0"Y;SB5WVF$4X?3<)\M^3O[(

*X"W^74Q%9(A@<&^f'9@,X7 M:T0 ?,S?.756KK%ADEP0"2X=;BS*TIH0JR&LA@GNBZ;R#3U:LI0.G;@7=QL M"^^[2(% _MLK13?WTM94=)!!<\$$OAL@%D9+*

<=C3E'#GHIL05O9EYYJ.46,Z M:@"%;KV,79R(ZQ!<;)]73]94Q?*<2BV(SE9,E@H3M:M?_60SG,%@7[`5$!O M[A$,6WYNNHKS0)P!;GIRMC_9X3<)]HLS1LC> Q\X;N.G]5(L:O%*

0BV-%B M'B@H8@ ~%@ B;!(L\&<(^WB+HAS""W$!-(0YP;;QN!K+3 T@6W"Y5 G&9< MA^*(5R^D&DB%(VJ704HHL6%%-ZK)#*E1=LI[:UGA4YCV7@ MJ^*4]VI)$EW?^BO1^I #*

<'(XDC'G&,"G-10:=+R@G";?5T1O<+Z# E#CJA7 M?\=9)/#$Q<_RU9M>)I>:DW$?'F0TY733>M.N+?8,T;G>;_1G/\G_LIO83#8.K;\X6Q?WM 2Z)3T3X?"_GZ(M 3(:!A=V"

*M*R\L091&K8:\G2[EQ 3%'8Y[/"?Z62]Q%>C[5*U-N40 MH8[!10-"X=]D@X4^G#!&5LY,"M(=CH7WW#+B$1BUC=Z(K;MY2I7#C MB]%H/~,0F&@YE5&+NIY.W,!I7?*

95"NU+45PLSS8=<_;Q >X@!?1WQ<'81=_MEVKX]X_R8-I#.7WP|$?6E;%XPR(@CS7MJY3QTI2GW;H8X&SOQIZ 4B@,!8.H5,]2H 8A>VM-8[<3\GU(|%4R-

/VYOV^P(O\|2]D"0#J!^TUR[C%TD$5>LI^CZ&6>;(M"5.5&<*DX?HT5(Q"%HH7[QE'TLWH7B),,,,9Z2"C3AWZG=0&C"F'2G:)PS# M'7"Q[^\(CP>7X;&*\T@5):69EJ^*8 1-V;'BK*

I^;8),5.0WH>6.E;&U)3RR M(#DI[MO@;R+N.U";D9VI8H2I(0S>X0.<>',@XMZ"S7V>"2DRAIX89@-B4>/= ML+57[^RYT\3!;^O/<1XC_\^I.F-A7)P@I%,#&&8!!M%H##Y.(:+9*

MUA&(T12=T:6CE5]34V!/ %.!?X-@\ F\===$>!RL;M"G TL AY%ZP"-Z@Z MVP=\1D8_A '0:2"'##IM'2 FKZ]-5"!;5O?06OB_"#'G275S*:IHT(# M^!S\2@9[*F*:N)>6YSV_MW17J'4?*

1Q\/G8]$-V3!'GJfM4'MH5%]$&I#G] MZXEF;GT=K>MGK,Q!SU6-GN[#+TXO$F5,%XPR(@?CVM .W.!3_04==#12 N>C=5)E-U&U45>/%A$1MY2+BH_!H6B]DZH+98OYF0 ?*

P4IAA,1)GN1DZ"&FX\A M,>@ R5GE\BN&!>>TE9Q.*5MB7_9,'HYVMW<0,,*IF2/ @=<.7F-JWIQ_R P ML@Z:O9W:XSUP=[S;4$$X"#RT?'0-1)%93!HWD)/$]#;BX;WU'<3_O!Q9U'4%*

M1!UCU&<4N5@X_)ZJXN9>ENETG\,F^_[!0?T=2+O O=>@UILCFR]L:@8N%L$ M<%H9"J?/) 1V!]S;_V#_@>$$)(BV=>.8CA7VST?$I8M("W5E RW)Z,%HMKW& M&*\DYTE,/-*

$),_7,Y_IR;Z9JZVF_,3G,JP]^!GG(5TQ)D/S&35HM\;VZKU Q*N!=!H4>3U&/%,?A_VIZ#I4 M$@I"@,PI?IPUVD2BY&DP:),(V$$;'J(1?+++0MR"XH^L$K89&+HH_"W2]&R*

M1!T7.O3W73DL>-3Q%]2WLV@/,UUN+8I\V$>;1AGFTWY9'RWPJCY9]^QDG3XF+ MV%\XN<>|@H(15$B_.HD@@I^4BDYA?:43OH5!UV_1NUTHOIX;#KM<[8D#\'5

MF%BGX\ZXXA8R+[1RMM1,T]LW(S>R^5.X)B=9D4+L!A\5],<4-6O@^\-LI+LBJ MKYT>!CIT4?Z%;P"C"CS,R4^Z;3G!C'^0B82,&V;8SDC1OLK5'2"&CQC0VRE*

M@+6Y[^+FN;U(72DSXX,B<)!M@:1QU]H;6R6'3-_>;B+7<_L9+6\06$$X[TM5]-M+I'3WLW]CF7G_G/B>I!@J40ACG8]VBBMPFEI+29<5% MUR3H%SD%DL0;|

*]6;D'U%P>5V?A3N'(,FAOPBQ:\C>GT6H2;I9A3WY>)WTC@ M.PM;PJ9K.I*U(ML8A$*9V_K<\4=Q)!3YHKH]F5*B@URX^Z >+-1) $$YSP^X MC3S&K-*

*4M677@=6[ZF0GVRYR*9%=QI:AI ,(T>O*^B!E0KI5"]/(^R1HAE)*(MVWG;)C2N#IG4 ;M) NBU?O*>ZWG!QV;O:.^*2(XBT80?PA>2(1T_B#5/R%JH< MW. PPM.2A M##F@]:*

*[<1O.I\X""B;.K0FU#W#3_7)SIXL^';.X_!BH0;9=[!3)+VRE\YSST>FF M!CHC>M\IDTDF9#M(EI%.,MK>.Y\^?1:#2TFLM'H===,G0D!XQ)6W\@ .R^]C?I0C(.1 M@__V*C_?*

*POSP0'D40L+N=3GR NVD5[$A(L\FBKH->3D)*VS_^N &VP3(<,6C M*2#;G=CJH-*B-I)Z7.R#?]M!:W9NS]U6&F1VWAZ_N;G;;A5*,O^U>Z_W-N4=S M-*

*&X7Y36K",F7Q**^X4>)YQ%WW U;M@TDPQ|F+ & _=16^M'^S9Y9I/\;E75&? MS2=|54CENF6K-OGQBWTM#[Z^^K])*'SQ83],6#"L:65.@/E&=#XU'J12[<" M"?*

*5&V_#/T>IYFL_5HMRX.P.Q=:4VF*69>(+[U2IM!85WZFF(/5-965'1TP@-Q MY/SH9)R" _>03%8V%0!&X5W_"C?5V3(ZY.(:"%5^1(N!:/XW(WIS7=?\N^'IX#?*

*MJ[HOZ/_<>=+9B9<5WCXM'E=Y.I4::R3!&;QB\A7_,Z^WM*KW.1V?)&9,RQ5TG MWN2YWAKNWQ7Q^I2=+71GTN[EOU(S^=:|,D9[\07]TI-VLT MV&F1KZC)LH'G4+PA%!?*

*VY@KEDN^G.ZTT9;\H%U YD;)K[_(F_!R/X_;FKK-3$5?ZEY0WL";S7Q1?BL>*D0Z^^R--)R"(/F?[L\5*

*M4L$$^0!N,@=*YD4G;\'$0!3.]7+1=>*WC;S(B*^SZES0_R[NXN0:0.),#<8VOO,T7VF/03+?T*4C8%D8V%OCCU+1%YL MISL>'|&IKSK"*

[N\B29"#K)KWE/"U(@)^A+N_CVP+HP%'BXI\@G9D387.(+E.IY.|!7E>Y$P9QB.M)-RD&;'5>9?,.W M3L +3$HU_OXQ5TXW^G8_&<|%I7S #O:_14\7ITW-G+^=P\#.?E^KG[QTA?Q

*M 84[Q'O?/,Y-A*KK]=]HW_?T<88X^N/LKX=-'^(FR3P!P.1EPM]=IJ$!)'2Y# M0B##7$?D/U-]>G0:_*8XZ0L.]^E"/6=)5MA_X9WK8E]+ZLVBIQ_D]=X+>=D_D#=>",'<:CV"=RF*

*MD';G[+K2T3/P@43:5Y,SAB09.^M[G]"G61&3>:\$7Q'1SP>.DO4BSZ_DPK2E MJ9]1/7)2'Z6D7[@V@19NE#2AVICD,F0,D!*O(9O$;# MO@430!1^F7S3] W&?+'ER;YQ^>$,$73N^^>*

*(X%LZ@+1+VU'9VVL*D#0\"720?=FO1]'#E,I./(04'+EU#FAW.R#1Y$;&[C\D/D MEE@ND/% F>9/UU9 ?60H#!<6AN'4D:'1K3\-HZ%43_M&?HD0M5E.A==+<9{(E*

*W.$1O&]3-0(313M(_B=I/(A&7N*9 M/\V>\O7!NX"8E/WV#WNEEO85(=M*;U$ #."K/*CU0&K0038.B6 M1S5K3;@IZS1[3Q%D?(K ^QG5L^5\N\<[S0#WS6-PU|;=5+?*

=-6<5W6O%MW6 MX$8]?901HF51 .UE+1U>2^7H_/?'R#7180-DLV#H\SPJ0K/PW+;&N.QT#2]K M_D5W[)&IR INM1HX;ZXT83+K;JHYYY?0.ILT:HEY.,G^\2N6"IC,1[FSYK"+*

*M"AU/0\;PY_9AOVU(B'W=140/[QZ5[37XUY2G*3+.H.8H#U03 MJ^EU0C3)'IXU$TV,4Z(3=]RW#%C!<8_B*>=<L8==R7SCIH0,=)2-C?STE+*

M=;-2G1L,9IU94S5K=6&Y]57T'E,KIF,_/^31&3R-> YY%XB6/<6:YIS&N,S& M01\Y)K)N W!4W@_BY+&>B#O$Y0@[NX,SBJ/L8*>P.",KC$===5[\;E*

*M9&/")N1BHY.R($>)X5KEU=*6RZ4D^>YL4DM6P#,Y>()8E*GGCM&==S-|^WP- M3(]-4+P!YZ]IY3MHX&?/H'9X,.US'Z)R(> C"2YF?7FS6)>W43'K;8UK?&)*

*MT73DUE*QC*JU2*>KT6:(7=C M(Z]:#%&<52;E^%1=M]%48/$X^)<E]>K[Y,3DW!7%V4B-]AS;\-(EU_+H>\]<OA M#-[IY82'*KX7.&]FO$O11((@1$ 7=(=2)>P0*6]!7=XZ/.E\N8!M8Y^EW'(D28%[S8W]@1C+N/R;&=&CO>"6]8,';)G]-S=;(Z\2/?^QZY2+N^P6E1T[@:[Y#J(:M2;2LXC0>MP;]9H?0N%IT9<*'P<\S[=Y[^8+M][9O=1/"^-H)?5+(:*E^7-L MW&J-*

6B+82\E'^N6M!$D1+O21I_J[*A7/4H,,-;M3QB/.^7K4J^V8L5?)-,%Q M3TR24]M.*R]#=3(7*:LYMQ-H_3>35',%A=ZE&\^$V)C49S><;AEW^P*3PR#&%)*

*MDIRQTL^RNESA,\G&.!DGE%)O*RWDK!PW.?(0CZE (<]W(1M"K3V@92$^.4NZ MM.0V>")9X?+5XC"IN%E=96KYJNX:C0.P[=/+,Q#V.4?%);T9>.*WV8@.M]-MDMM127H*>*

*<6|9>VF'@XE+'2MM9> D#@EB.B&"N5)=7U3T#VCY2;F@V9+|\-V MO'*Q3MDY[H-QN\9[0=0X%)",*V2Z-69A\1THSP$0ON5$4/$_Z.TO'59.A]*S M8>XEL5V4):!X%*

<$GS1TH(BZ]_I_E*Y1X-],=1Q"D6[]$CR-+WL2[38'^^IQ\ MD,(ROS8L.SG%$[6#10M@/D([%/05# ^V63]@WRKPM)N>Y*BP$>S5N"_G|;-MR3H-?4 ,!C;\LZ-CQ-H1 _[X*

*;K9"2'UQ!OV%XU)3QUQ?2Y\>IK]W0K%'-M_GNG>W(-MK3Y-;$%S=-^O7N7LK?1'CK"WN,T)4*A&N\[OVH^D/V=:YC%K+4W:|*

F+RWQIT66L6T/U/#\C*RF"\CK.'$[QN4^0.14YP310 MB#[\TW7@/R<77O)>Y=QU"A6 ZY2;A=*BO.P=?W* -,[A_5+&L4RSMQ**PN!) M7?;W3N"ECK-"-*

*J#%;?'2FN/,S6=_\N5]]+,*Z'L2#NJUP MJYW^&R3)"O7$GI 9>AX]#+/W:@1<'"%'WRUBC0T8B]YU$,.0%*906O2U3M-O@ M2]\"7(.0X69Y@Z,_]I Z)QO"@+/+84\/-*6**+^6-*

QS]B=V64.MU-;.9N[&" MBIN5WB<\H&L^F%#1]2SQ%F]W\AFWJW-/H;$&[U'ZD/[%O(*BQI2U+$\AY6' M%X] /+@=8C46UW@4@$9U2C@?A#PX44@R|,<[)H9D\(fK\>2F)?3Q(?*

B$AP&9>0ZVG()%O)2I!Y6 MX/LTPP9OV.6@T*>N|H)BGTV9TW?9=%TC-K]3(W:P"<:-JWL>7-# .IFPW!PH; M.[$$LMRV08Q+"

[GN1K77VU2\@NR'4GX3E228FGWKZ4QIDE'S1"$\UQGA-Y" M&E?-@\L3ZEWW5_[35Q]FP1[SI+Z6ZQEIY6'R -1W^W$!T.# _T/UV)P=&*

*M*7\ZFF;/JD2+)4)U.IEDMEL4);H$!,'8B13XOYZ@(VL 734@SI@J&#\0'E-@ M=\KO)"<48J(+)[YC4-/?(X2'F-BS$_N*8P5)%V"F;*SF>BG+#Q@'NQ>[P+9G*

*ML",NV3&UXKFDN6_YHB[5R=*E.G2I_J\+-#<@@A4L/LDGZ 0[(22"CA4UB4W& M)RF6GY(\W<,1:>D'_BM^(D>)S^,7#|%.A.V.1LIBC.IOE6H8H>=RRJI4;*

*MU;&;L8E9OJY."\U9K&^O6.[TY9PB>|C)H>=)GO&QW M9'U9G/4WF=BJ8:08++;5HL_'3/M>91;^>(**R*B;,O1(XA"?]9AIH6B)8B4DEV1B7 N<31Q%L,I60$0%$*

MBB12\>.^&TR6&^8'VT6_F,W;\I@QESDU?8X"B2#ELQQRVZF5LA9X[I)%"V9:FRV X,O MP3Y3)_3OSHOQ]#'|-]/]?L79)/M6PH!4/7E[7C,FTM01##M,.MY%6]7;=E*

MT/+D[36FODE59]6,NMD4ET-QD\Q-+&QY\GA:=0R3]%\U#2$]H7+<;/&V.&:]KED48TSW#?D<]U/J M*L-L[*@VW^2:0KQATM2S"/?)29]BNE0HD&2)<]5>I-*

*W%/A6>E+3_DTFSCML!8! M@J>]JK)$M5;FBI/QI"@;;=#R9.EMIVIR:6$R[F<3:G-)%01)+]I RY.E3_"E M>;]M'1M\5>0:L=*R-EK789\G2Y^K,78-G/V1_BS>VN02A";D^K#/W=*_/THE*

M_JXH%>;E)77#2WO,,M0|S'${!G1U2A|L8CV@=SIES;QK<%IS&#]GAM(%E?9/GO/.L\6>T:Y6>_G]XV$E%_VGQH1O[QBWP\U=!V5^0' MF?=VP;6N.G7$!/:,;>)):?D>5L!3KQ'?QR)G+*

*[X"VR]H[(:#+)&NB&+>-FX MEV=N@*_]F?&2PO[*)7_-S1AP4(2XBRM"N=?1Z.[?:QF=Q^Z$U[6<894T.57B M*1V5Y1)NU.K;'49K?]QQ^AW7_"!/*]S'3ZASAI,M[-8-L[-2K_I%8XC=-MF0]]J1=\,=X/Z*)RA[^N7;?[&[6VWK[JMT[N^E]Q*8HA)@-MBHD+0GQ<'%ZD&>$4XD)S$"/K(^;C3/P.G'VQF/%KP!MO;>/:E.QP_:P1K75Y MTZY/6_"\J5>"3SSA*

*F8]$"5-R_RT:TAYIG:>U!6-G'+KEL25*1&9C^=)=5\0"\]LYR-IH4;AIL&#L^UG?#_M\FJ/=[6\GP^?<66)@^WH\EL$,9PK+!QN/"1373D!<\)>?BH(#'8 M,+8V7O.J&B>:7.5*3X=35FR?*

9MTOEUP+C%[IQ5D^@LI9C@6&+?\U!T_$,S:R?WF63&1VA%9. MC9M;XD_Q@W_9H_'-?!]O>/S6:'9D9BA_9@$_-N+;!O=7MC<0F/5OPO@=2 MD WO$UT%880P?

8;#%JS3D>&O96)C=W.V:(1Y+\7_\UC3L$KP26SX;G>R44 MMF"^HY_8QW?W=Q1V_1/;:.&;R)OV4==BC5[L->4F@#Z.+5[9+GK6]1@W!#_" M2G,XRL";XX]?,#$:0?^S,W8>FK?

*_^Q|;^-*O!]3(1T"0 ?Z,4&'A @"(8A'M*]3$!2GO'\N$)\@U3XLK7S,>69K?78QK8G/@9PU$$O@ENO3_X&D'U,) ^Z_! MJTXOR-LECQ3LG6-*

*+R/@AXU^:"\5TAWST3R/DZ@G2(B.>U<.\U>G5C0*T7ISL" MJ[^7]^A3;I#OL!U"YK\H\T-;S96X?>_#]/-?/"^^*DG1;YLBZN9FA"<2Z%'O?*

*M>U*WW]58X]O#O'U\C0P^APOQ[TM,#>M0P9I;A'Z,'[@^7KI.XY'A]CT;7"+ M-*

25X$>%=)'3&N:A6%&Q%=8A$8511SV!6_9&6:HM:OSB7Y!F>,%AG9M#+AO[QBWZ@8Z<1L)_]H/^-6!G_ M6L!ABU%7"-E?Y-\ 6ISY]Y,7_@@] RXB MW'Y97.0-SK!\9AA^G\?

#8K",#P?$NDID4S8G*[,8%8N]5E[VTA!=4E23%FEY M2G0;R^B\D.L,2%MFXPBBB0>&/KW$_6KBZ2X;@,'7@ :0Q[^$B'HTL0-D<;W] M=]=Y]Q5?#[&'!M@C& Z\N-P

^%Q=O=3M?X. ^-O.\N-WU!?)0I-2MV=75%.&Q2 MGY-I]RIRT%,;XB/|D$]>9M'[[#)L:*RZ'O9]]4F^=1$:!%FBW?D?)]SG[CH MRRN"+^13P*&>;C[)%V12N/6X812P"9.)H'1-<*

[$4<$"3M2%$P6@)o36%%\ ME^;'=:Of;:=4[.AWKR"!SN\Z>*$0BLGFL"+S=_&UHJC'!!,Z-`3 M81Z3(6$ M^(AR,=D,B1$$ A:!X;$" (A #3%0T(S@! FEYU> H)<3MH2H2NT4&@1(A-

*M 2%BU!(03S& ^W1! H$6)30 @18E-0" `D)BJDQ.4H\><73V!. + ^H,\Q; M]K; 3WOG2DV2'_6E3L0>*290#D'G%NGIA205E[IQ^#7?!MYKV6S;>6_B:W&'6 M;QA4;T)L+WGZ99CW5?*

*GZZS+O;<>@\!*K@D>Z+?#UH!ZQL\M; MFHSB8J$;6R?*2KZ8&V=JZ<6BN{JJJ33)!X)X+5-P$F2U#\AGP:)3X-X$-[6M3RH!^&? M'F#BO.Z(I8Y241<%@0.UO%:*

[T38XP!] M@7R@:/(6YH5[6R*SACDW8&;51#/E\IXI 7*Z"@IZ?KJ%"@K>WL:VL:_@Y,*'`M9PU>Y=-:.!'H ,R3DOK'M=18],2$8U76H856TF9:1HGOR=79\#D|;[+SWO,M*

*M;;1:M33,EF9@*Z+]XF22IXI/7&L4E86RQ68'[0~M40]D\C57'VI_'HV'*EJH;?R*,ER'7Y+AL#%>")}@7U_M025+7UIES*Y<4^U;,2*

M3UT[(>36M\2_7]JF)I/E99M8#./QXA"LZ]3;!K.F8:0!$[NB++>?KH\5)"'"2P M-M&%8YD"/-// A=OF5GB5+[%+3NRID9+&;&_[K3US$TOZI)2=;.FS$Z[/XS.

MU6@M2DK)=AK,FOGQBWF@DZ_=TX5P$<+\%2^E @C733P47OQ.AM"R %YG;@;$6 M!\;XJAL9N9N_Y951DHY-UWVI7LF+';M<[-'Z< O4K,0M HQ"X/@BP'$N>TJP

*M9GIOX+A[772=*2647C4NYC=*DBY&B76O(L-[C@*%?]LP^F5++__YY12C;3@S MT#^/_X04472'&K),)K(F=''I^Z_]QO+QS8-4]0)CCAXKYG$!X M6>*IXW(A_W-*

*0!F5G#X5EBPWSI[?1?+-RRZ]0:,_)8A176>$D\.*?G+,B+H97 M1"+U2'M;=,NK\)EB)#$(QW_WXCO,UR.D[6$)9%[*W90%=E][+ PLO?E&\}+ T, + BMH4^0C-*

*8S/PISNQ&/F8B%^)5$?&.?1/F/RD:D)M_V_>LWL.7LZ^@S8 M$^QG#7>[PN-UO_KQJX>*3QM2)&N@*M+6CK>Y7SZJO\2KATMJ;@4YM/596IRD*

*MXF228QDA3K$Q/A5CDTDAQ0H",2&Y)$/$!>X'?BOG@0512XKI<29=5YL.42_4 M>BF)'JX L-''+5/I5*Y6:Y5)%*

MBJY&1T/:,PS=D.O#EHTY\=S@Y%;ESZ3BPMMTHHB13A0%$)WUVS8TYJ,K,%-%5 M!9{J#>/1\,T9I^T?:R;@\9R6"ZJS# I=-.UN&BH\,+[Y.UCCJ,3AD{5^XMF ME.DL[07;',D T4_Z9(C-

*G.C,AF1^6-9ZFPTG-8N+%38E';,4NI5D,A9+"?EF MFJ|MI<6"KW?3;/*TSWJ9;V8=>E@C%+YE)49\HT$^RZ#E">%S1D675OTYER\R M>8;9%KO;P,P-6H[,*!G*AO-*

7M'B^#EO&3MRLL,VX.X^M^L2$8 M0V63SCVQ*] R>=R2MW,;:Y%)D,0LNYX52\WM3*VV0M)+Y?#:Z M*N6(9V5K5V&?)'G0E(U-)]20H"66FB1B;(Q)22P7HR=LBA;X%-C /)D\(5:B M7&FI4AK7S'+=_2G/YICIL"5#\>.X95^J=C>):'ZM.FM5;346BT*-A"U/%H%L MTYL63:4R:G;85'E98MO/9?G?+V:(8U MEMO$4%2K>F)-

MK94C;1ARY.W&QT]VIVM]24Q7.5XME2);I\NI1;~;S13%;+L97P&D.NDS MTUDI37%

*<&O5GSOXV*QOR=EV6O5'LM)O^,.MMXK/B5SZ*T:)E&LM2;#=E_,9P1G.T]0Y7[Z'*VX1K7$ M#_EML\\TWRI5GZV&'5UCE9V16(&^F!9[V?3;*ZWM=G>I-<^H15H69C6NYM& M_ZF3CY*"UC..:FYWCXO&[VS@%H9Q3I&H=B>Y&?%U#8U)&-:LM &+4_FKJP]>02H*6$T.7'Q=%YL++2E.!MUZ:8,6IZL4JW"Y>+CZ&A-=+O<*

*MANM6P/YONOY+1Y#&6$EEE,DO^DRQ(16%D2DL+?CVD_71]!:(9'\CI8HU9Q#,K%C9EL#(#GA"%M/U6 MZ\2/%]^1:?960E$8/"D+F9*3Y;4V__XV6QNO>56-$\VN*

M6J6GPRDKMO(8N0(Z5"M4J3-L3A(4CMQL#<5@>ZF:<8*"+<1I"9%+&<&'@#] M61$;_.Q/.5T&GO4=_9DU9D#8VR/G.0_5H3C>1.L2\3TZW-1";?!*ZF'"%"] M^6E$@8_SF@-+J*T4>PKZ0C;H". ^8)BP#HBD<4IR4_8M Q_A5OOXBUE04]4?W M86X&- C;]^>&R8LA\-91\. 218.OME5SN&A]GGV59;G=6!!&1<,VYB)D2FW M%",34=3WJR-X3^N ?*0'_@)?*

P+_60X%AB]?=/)!6[B^L]0-CB)0?C9M; MXD_O@Y^84%]P=04H-?-8VC[43GP6"5F1B(2$"0 CB,4F'A @ (4)H"@HAPBT1

M$$H0C\2KGJ4A(4)L^F:$B#\F7LTQ%U(BQ;O18@0FP)"B-0C$4+3!0GQYQ%& M;]K_OF@%LC>L;5]TUF\!85"5=12OR<\2^H>UUD9EK&7Y8EX9T_&%1I/+ MI=(^:TWXZ"!_,U3 \G(3>$2HR#]>1 2,A_]I 6B#+GKA%LA(R.QX/"(& -1M#0.!/W8Y>AR8!(23U$DWNJ;?=>A3^'$Y6<.=KR>OGN2EO#&?YQ/fY M+M\#3] !IP%=/S\%G%!7@)-*

*OK&_<>R/=>Q&P"GWO5?AS.#$-Q:B3\X+55U+/-MLK$J#*N.=A?IA$,I#2)341.BDF%&+4[,"2KAG@WW{(5L"/=>A#=XXRA?W\4L M[_?J9I?ST7=$F$$!PPRV85K % R@!RQ<&#@3K*

6T!,(\!Y>R'-Q[UJ<@ZJ+> MQ-"$&^4\Q5L_7 C7GO!-"Q>3A"^?"$FQM/O7I?(J M5F7]_@SO[FN.[Q#??/=\4-UT80XL,'<>-W MBOFF4Y&6=KU&)084 E3\B'V:AWN3^,"K[Z)&_NE?-9 M-

_;AA1"]:G>G0U[BOC<:(HC R+:,E]=#S+LK.XT9#Z;9=,9P1G.T]0Y7[Z'*VX1K7$ M#_EML\\TWRI5GZV&'5UCE9V16(&^F!9[V?3;*ZWM=G>I-<^H15H69C6NYM& M_ZF3CY*"UC..:FYWCXO&[VS@%H9Q3I&H=B>Y&?%U#8U)&-:LM &+4_FKJP]>02H*6$T.7'Q=%YL++2E.!MUZ:8,6IZL4JW"Y>+CZ&A-=+O<*

*KW'OO3.^Q?;_>2S"+>M9AGSZ529Y\P"$H)U2\,28*2A(9ULD*$CQ>W1,>9#QN7BVRFV51+9*94OIK95-/LM)*SGZZN-MP/ZY-)-M-V$2P\E4(%NLE!*

*IWKJ_Y;P66*U%,M#_DXNM%1UAF]=P*H 8#G:\2]&N%H,(_MT! W0B>*F^&[!A0K*UL72VL:E.>FFPV4G)8=@KGW!O?J-"E7"&KVLRZK&U4Z6TKCZE_G0U+^#OTA/@<,?!-_B !O M^[<,(7$JW^<6'5E3HZ6,V%]WVQ?I-MGUV4>FHTH4_4Z'RYKV4557[A M'_60)$[=("ZS(5J)B$&G/B@7E=FOPR_@\!-0X_R M4)'F!%A$!*2'<]+WG%@!%,X"6P="SX3;'0*CAI>S,*

C3&MS(!GF()S3 $\%P)IH8 M!$!+_GW->_[@SSWJX-IVF;TA5T:[;;*Yf$RA;Z',7HYJBO+C/;R^K6#0-G M1=`M,^B;HLM;WN;_ M$M&$MV&A)8!1F4U"G3C"G5Z2A@T4(*A=UL@CRY*

*.+ M*F_Y8+!\=4:OG,$@WTTONQ6[KB4K]@U1I;3NT5E]*MO]8F:]99:++]V;$%5@-M_L/4%,,?A]CR*3;6I5#E1=^+($_^^O:-P%TBA]OBMA+\"YX$09[!S<_;]B8I-MBP(&-%;".BS !/*

Z$F(KI MDX4 .O%/1%)T3H.9 _BIR*L/$4N<<]CM4LG\! Q"NN@4T[_XQ .BB\"+!6 M1!:XGP.ZS2;8HV:.(?Y55.!N\VL3 %QP"S1_*:83FF&#',"%RI"PTN/@&$*

*MI^@100'45B8.>A[V!M;8D3C/6F.!G6D)1A#%/C=]O KAD98)N-X$8W=7:4%IP MVT7X*:?+^#U@!'/#1(W+O8BUL6QQ!GZ8*7HK*1 MT$*VQ4<,/@"1(*0JNL-*

*A2+K'HBF'2P8 _U1L\#@/?BW@,3^)G D'3D<.<#F2 MQF;4GV JO^Y&|5%#Z(1LRD.&8Z#BUX 3@?@2 *}OX60B "^1& B-V0#'$8=R@" 1 M@#R6A8??$NQ5T.-*L;> 6>'S'1$ -FC0-30'&\8%98G>\QCI^:$;\SS$X\@^MO.9#A%,2O?KQBWH\%=,B M8^MJD+R0WW8@Z^--==W81;WH >=>%;WH =>=%'5T.:G<SL)WY MC_B"?1EN(*21G8_2*%:*

*(:C!+'SO.KLCVL53>!8*BX&AB4S[@-3*G(5D/&M>L M'EC$C&;P*B8YFB8['=+YE3PK%?O=)D/5QL^*V,ZT\19$4TI;&S=EJ1\ #WAN M#IG.=,0?OWH(/K",>0@C&*6L-UD@LA)-*

\>3H5A!1P8G@KB4$5.G0-&-E1?Y" M;0S' NAB_?W38U>7A?!AE.K1[W$Z44FUCPM!6/)GJ3&V#<\/?)_A\P ME!W__\B80KWA,102XD:$(^>5S,_A82X%2'(1_K5="_-Z %W5,-"\W;=[0X)?

_WP\8D_\QP,>8S?(.?G&&G@.OR%-+T+3Q&/B MMGG?SZT!\K@,"7H1@A*/\=OF3+WH&H1G3U#9^O_]BV2(?T[_?YU#)D#QA6_R*

*M=]02^:BRCF(&^%E"_[#R8M3J]ME\4QT.1^/&]%5EBGS[K,3VT4'ZW!OT>#NK M_>,/ZG*_^O'+\D)C>=AP9,N:'3\K/SYAT(U=]K*5L-S]!FO*E[& QB$[NPI@^ M+S?HI&;*

*0(N01__\\/ \/,JP#MOL=ME,OIK.]N*Y63/&MN[*HSW#YK27F/)C MTL]!8VFZH@=:=.A\BLJB#@T%#FX\39HH.G6^1B>-B^^]>*[U+@,1]TGI?/@H(*

MWT<&^CEYMD=/HGWWY_&2_^QWUB_GNJ7)\/G0;_*.0U0B*_+[3%OP]TX>O.$-J^_K3M@[;W MZ:\OA6]U8.!]BD_)*L$8YLJPZ&J^W!\ZJHEC)C9]=N+3O)A*2R:32"<;3VV*

M:LR/'3&B:Q%L(;9IZ!;WWO.^3'0]O 8-(>TS0-HU8S6N@=$>L,)FTY%"J*'!\/)EX+/(&%F-H_AHS0>3WT= B=1<+\"(4+G#.0(G1> M#P@E0FP*"""%"Y_6@$)T7@(\OA@A0N?U@!*

B=%X/G=>_AP-Z+P>_J^' MSNLA04/G!?#L^:K^EY_">=WG#QY2!MY@)}WJ@X)_>7YW!F.Y\D28;^IOT\-Z9M?90K7*A4O\O(UQ#[-M_6B"&"[RRO,H*CFC#:4XZ;_IW1Q W+N3O_,-*

<"_T@/X\L/=AS$JF-^.>J1 = M=<&N9VHJ25BK=OO:F%4J%0IJ5E^-55'(#KMT5934}_D='M#!-@MG.6NZJ_3S M5:Q%]!*IO]^TW_+]O$6!M\A?

*UP)6DOA4L25WUZ<\6E6B.8[6]4X98M56;#[MRN3C,7,M%Y8*AGDPM3,H335]H/VD1+MS/M9[>)*/RN-GIK-@8U]DIFCY!Z;]# ML+N6>^M7G?9;S]0AV*

*4([*ZI/2O#5G4SKV_ZZJ9.+6I:8SV@9Q^W&IX#Y]@$ MD>XFG@=/?:9D/"1Q-)K;B#*@TI,S6:'%6+0+%3,/D0HI"\31/PU MC/J<5]EI 99ZO*P&'3P[?8 NJ@/NGW$W/3S82Q4"_?*

*=1W<_5;D_C.LE[M"3! M\0$8 W1]YAPAM_&>I$_-'M%L2]N*DDBV.DR;C4.-/O7J(1(B[_7NR ,$)P% MJ1=OW .T5"\R?@L[PI^#;E)^'=G)TNIKJBPE#G;X&F7AZ(@/0A>.;%TYNN$'1O M-T?H)4*.3?X9HT_!\$22GWFDUU5)*K&N&P\;=>;CI &@GZ M\8MDKF#KN)UAP -16VXB@RC>B M##>$MD'STPP>?!,Q=MH-%'H-QX3$!Pl, ?=%@.*YLJ<1#K1'$B\Y5]]Z:5.(H1.*

*8=1KHB 1D*QY&Y"3034T&OUL!K!?@*V!M0O<#[#%/F=&6+ MQO$8Z8'OO0YAN#I4S6&]L<*;))K=. M3>,(DC E8$X;LV(F=&1!V^_M_4*

!A/MA=T,.1^;R&6H/F?:S1F^B'!3,9 NC9&/(8Y3GOW/02]W MG2$,YC(WS)_>D>R;E9M"CD*GLRQ&<:8X3&@(O_LEI*VYCN;-,1!YW*3C QOQ?8;+<;*6,$^Z;\4.4]6[CQUF2_>^?"-

CG4L8VYC_I.A':)4 M^'[O)Q08#^R9^)5(=`9I7GC#_Y2)3$P+5OWK-I-FL=N@X?;?,:1(#_@.:\Z#4 M\M9.'N#\B>Y>XM7#I3ZW@AS"")9(Q1(@=901(F;&PB"&R2CXMLDDM0 I64 M)

(:)_CM/5)N%;...GC3$111"\7%+>IDD2]2SUB2H32I? M52I,#LR3I4Y;2A/"I.1D(J16B?IFJUZFKU?C&?D(;E M0D_GU38;8XGCEF))--OEK!3AX0SFJ6J?.NI!:UP)RV[2KLP&UD9IM^<;,:N]

*M4:,;5R[MI<*2$)I5E,"_*<\3T:0_]>K56X->^RF M3.2=V"QNFMMA*Q:5SW$*NT@^%RANHO;SK;=A9[Y=D8D!{#-_^W)+!9;EBOS21 M"66<6)=E*=KI3V&?*

*R<,U8*0X1U(,P<9%@69CB9C$I@2.8!D^Q:<8DJ(28O*X M;SUFU3.==<-1&4V,QVN5_DRMG-TM:MI^&J=Z=J4O=NJ#IZBB6)0%6YZ,-TE7 MK>+0ZC'Y36Q;BTT&E6Y43X-*

*U/7[EIK%D>]XH-9YK?#'J#[+JP+G*T?&Y=F_/" MS+&V+8Z@UOG<+%&;;=3RV75=YR\K-5US/RB-V.I-CT?67'VW+]JK$[HJTHK ME1[JDWJ):8R3EI4?<35?*

0.DJO%>=)LN/YC27';8>3#"8EG]O5:DN,-6^;;N+ M<75:,FN"4WIN.PY7@BM*RVW$SVN\!S9EW/5U8P^N/,_B_,HNGXJH8!)71 M5LQSRQJOLF?W_V1-+N("9Q>*

(6:9;C[:=K#,HM,_MZGEC&,_%MFV'$,5D-:OK MJP5KR:#ER7I6>X+3EJ>QNNHDIDEM68\Z_1KL\V1&J81ACFK)YA.AF-/&LC,K MIY-

*IV/)DY9^6@[^MJ;^A[;K,:^4&F'L"7MD>89_5C-;:Y?)8K6KCV9.9 ML;M5">+4*8U[:2)NE@2ED%>&,H:U^+;;L*X\H24=G#.0 M^#P@E0FP*"""%"Y_6@$*)T7@(\OA@A0N?U@!*

B=%X/G=>_AP-Z+P>_J^' MSNLA04/G!?#L^:K^EY_">=WG#QY2!MY@)}WJ@X)_>7YW!F.Y\D28;^IOT\-Z9M?90K7*A4O\O(UQ#[-M_6B"&"[RRO,H*CFC#:4XZ;_IW1Q W+N3O_,-*

<"_T@/X\L/=AS$JF-^.>J1 = M=<&N9VHJ25BK=OO:F%4J%0IJ5E^-55'(#KMT5934}_D='M#!-@MG.6NZJ_3S M5:Q%]!*IO]^TW_+]O$6!M\A?

*UP)6DOA4L25WUZ<\6E6B.8[6]4X98M56;#[MRN3C,7,M%Y8*AGDPM3,H335]H/VD1+MS/M9[>)*/RN-GIK-@8U]DIFCY!Z;]# ML+N6>^M7G?9;S]0AV*

*4([*ZI/2O#5G4SKV_ZZJ9.+6I:8SV@9Q^W&IX#Y]@$ MD>XFG@=/?:9D/"1Q-)K;B#*@TI,S6:'%6+0+%3,/D0HI"\31/PU MC/J<5]EI 99ZO*P&'3P[?8 NJ@/NGW$W/3S82Q4"_?*

*=1W<_5;D_C.LE[M"3! M\0$8 W1]YAPAM_&>I$_-'M%L2]N*DDBV.DR;C4.-/O7J(1(B[_7NR ,$)P% MJ1=OW .T5"\R?@L[PI^#;E)^'=G)TNIKJBPE#G;X&F7AZ(@/0A>.;%TYNN$'1O M-T?H)4*.3?X9HT_!\$22GWFDUU5)*K&N&P\;=>;CI &@GZ M\8MDKF#KN)UAP -16VXB@RC>B M##>$MD'STPP>?!,Q=MH-%'H-QX3$!Pl, ?=%@.*YLJ<1#K1'$B\Y5]]Z:5.(H1.*

*8=1KHB 1D*QY&Y"3034T&OUL!K!?@*V!M0O<#[#%/F=&6+ MQO$8Z8'OO0YAN#I4S6&]L<*;))K=. M3>,(DC E8$X;LV(F=&1!V^_M_4*

!A/MA=T,.1^;R&6H/F?:S1F^B'!3,9 NC9&/(8Y3GOW/02]W MG2$,YC(WS)_>D>R;E9M"CD*GLRQ&<:8X3&@(O_LEI*VYCN;-,1!YW*3C QOQ?8;+<;*6,$^Z;\4.4]6[CQUF2_>^?"-

CG4L8VYC_I.A':)4 M^'[O)Q08#^R9^)5(=`9I7GC#_Y2)3$P+5OWK-I-FL=N@X?;?,:1(#_@.:\Z#4 M\M9.'N#\B>Y>XM7#I3ZW@AS"")9(Q1(@=901(F;&PB"&R2CXMLDDM0 I64 M)

(:)_CM/5)N%;...GC3$111"\7%+>IDD2]2SUB2H32I? M52I,#LR3I4Y;2A/"I.1D(J16B?IFJUZFKU?C&?D(;E M0D_GU38;8XGCEF))--OEK!3AX0SFJ6J?.NI!:UP)RV[2KLP&UD9IM^<;,:N]

*M4:,;5R[MI<*2$)I5E,"_*<\3T:0_]>K56X->^RF M3.2=V"QNFMMA*Q:5SW$*NT@^%RANHO;SK;=A9[Y=D8D!{#-_^W)+!9;EBOS21 M"66<6)=E*=KI3V&?*

*R<,U8*0X1U(,P<9%@69CB9C$I@2.8!D^Q:<8DJ(28O*X M;SUFU3.==<-1&4V,QVN5_DRMG-TM:MI^&J=Z=J4O=NJ#IZBB6)0%6YZ,-TE7 MK>+0ZC'Y36Q;BTT&E6Y43X-*

*U/7[EIK%D>]XH-9YK?#'J#[+JP+G*T?&Y=F_/" MS+&V+8Z@UOG<+%&;;=3RV75=YR\K-5US/RB-V.I-CT?67'VW+]JK$[HJTHK ME1[JDWJ):8R3EI4?<35?*

0.DJO%>=)LN/YC27';8>3#"8EG]O5:DN,-6^;;N+ M<75:,FN"4WIN.PY7@BM*RVW$SVN\!S9EW/5U8P^N/,_B_,HNGXJH8!)71 M5LQSRQJOLF?W_V1-+N("9Q>*

(6:9;C[:=K#,HM,_MZGEC&,_%MFV'$,5D-:OK MJP5KR:#ER7I6>X+3EJ>QNNHDIDEM68\Z_1KL\V1&J81ACFK)YA.AF-/&LC,K MIY-

*IV/)DY9^6@[^MJ;^A[;K,:^4&F'L"7MD>89_5C-;:Y?)8K6KCV9.9 ML;M5">+4*8U[:2)NE@2ED%>&,H:U^+;;L*X\H24=G#.0(G1> M#P@E0FP*"""%"Y_6@$*)T7@(\OA@A0N?U@!*

B=%X/G=>_AP-Z+P>_J^' MSNLA04/G!?#L^:K^EY_">=WG#QY2!MY@)}WJ@X)_>7YW!F.Y\D28;^IOT\-Z9M?90K7*A4O\O(UQ#[-M_6B"&"[RRO,H*CFC#:4XZ;_IW1Q W+N3O_,-*

<"_T@/X\L/=AS$JF-^.>J1 = M=<&N9VHJ25BK=OO:F%4J%0IJ5E^-55'(#KMT5934}_D='M#!-@MG.6NZJ_3S M5:Q%]!*IO]^TW_+]O$6!M\A?

*UP)6DOA4L25WUZ<\6E6B.8[6]4X98M56;#[MRN3C,7,M%Y8*AGDPM3,H335]H/VD1+MS/M9[>)*/RN-GIK-@8U]DIFCY!Z;]# ML+N6>^M7G?9;S]0AV*

*4([*ZI/2O#5G4SKV_ZZJ9.+6I:8SV@9Q^W&IX#Y]@$ MD>XFG@=/?:9D/"1Q-)K;B#*@TI,S6:'%6+0+%3,/D0HI"\31/PU MC/J<5]EI 99ZO*P&'3P[?8 NJ@/NGW$W/3S82Q4"_?*

*=1W<_5;D_C.LE[M"3! M\0$8 W1]YAPAM_&>I$_-'M%L2]N*DDBV.DR;C4.-/O7J(1(B[_7NR ,$)P% MJ1=OW .T5"\R?@L[PI^#;E)^'=G)TNIKJBPE#G;X&F7AZ(@/0A>.;%TYNN$'1O M-T?H)4*.3?X9HT_!\$22GWFDUU5)*K&N&P\;=>;CI &@GZ M\8MDKF#KN)UAP -16VXB@RC>B M##>$MD'STPP>?!,Q=MH-%'H-QX3$!Pl, ?=%@.*YLJ<1#K1'$B\Y5]]Z:5.(H1.*

*8=1KHB 1D*QY&Y"3034T&OUL!K!?@*V!M0O<#[#%/F=&6+ MQO$8Z8'OO0YAN#I4S6&]L<*;))K=. M3>,(DC E8$X;LV(F=&1!V^_M_4*

!A/MA=T,.1^;R&6H/F?:S1F^B'!3,9 NC9&/(8Y3GOW/02]W MG2$,YC(WS)_>D>R;E9M"CD*GLRQ&<:8X3&@(O_LEI*VYCN;-,1!YW*3C QOQ?8;+<;*6,$^Z;\4.4]6[CQUF2_>^?"-

CG4L8VYC_I.A':)4 M^'[O)Q08#^R9^)5(=`9I7GC#_Y2)3$P+5OWK-I-FL=N@X?;?,:1(#_@.:\Z#4 M\M9.'N#\B>Y>XM7#I3ZW@AS"")9(Q1(@=901(F;&PB"&R2CXMLDDM0 I64 M)

(:)_CM/5)N%;...GC3$111"\7%+>IDD2]2SUB2H32I? M52I,#LR3I4Y;2A/"I.1D(J16B?IFJUZFKU?C&?D(;E M0D_GU38;8XGCEF))--OEK!3AX0SFJ6J?.NI!:UP)RV[2KLP&UD9IM^<;,:N]

*M4:,;5R[MI<*2$)I5E,"_*<\3T:0_]>K56X->^RF M3.2=V"QNFMMA*Q:5SW$*NT@^%RANHO;SK;=A9[Y=D8D!{#-_^W)+!9;EBOS21 M"66<6)=E*=KI3V&?*

*R<,U8*0X1U(,P<9%@69CB9C$I@2.8!D^Q:<8DJ(28O*X M;SUFU3.==<-1&4V,QVN5_DRMG-TM:MI^&J=Z=J4O=NJ#IZBB6)0%6YZ,-TE7 MK>+0ZC'Y36Q;BTT&E6Y43X-*

*U/7[EIK%D>]XH-9YK?#'J#[+JP+G*T?&Y=F_/" MS+&V+8Z@UOG<+%&;;=3RV75=YR\K-5US/RB-V.I-CT?67'VW+]JK$[HJTHK ME1[JDWJ):8R3EI4?<35?*

0.DJO%>=)LN/YC27';8>3#"8EG]O5:DN,-6^;;N+ M<75:,FN"4WIN.PY7@BM*RVW$SVN\!S9EW/5U8P^N/,_B_,HNGXJH8!)71 M5LQSRQJOLF?W_V1-+N("9Q>*

(6:9;C[:=K#,HM,_MZGEC&,_%MFV'$,5D-:OK MJP5KR:#ER7I6>X+3EJ>QNNHDIDEM68\Z_1KL\V1&J81ACFK)YA.AF-/&LC,K MIY-

*IV/)DY9^6@[^MJ;^A[;K,:^4&F'L"7MD>89_5C-;:Y?)8K6KCV9.9 ML;M5">+4*8U[:2)NE@2ED%>&,H:U^+;;L*X\H24=G#.0 M^#P@E0FP*"""%"Y_6@$*)T7@(\OA@A0N?U@!*

B=%X/G=>_AP-Z+P>_J^' MSNLA04/G!?#L^:K^EY_">=WG#QY2!MY@)}WJ@X)_>7YW!F.Y\D28;^IOT\-Z9M?90K7*A4O\O(UQ#[-M_6B"&"[RRO,H*CFC#:4XZ;_IW1Q W+N3O_,-*

<"_T@/X\L/=AS$JF-^.>J1 = M=<&N9VHJ25BK=OO:F%4J%0IJ5E^-55'(#KMT5934}_D='M#!-@MG.6NZJ_3S M5:Q%]!*IO]^TW_+]O$6!M\A?

*UP)6DOA4L25WUZ<\6E6B.8[6]4X98M56;#[MRN3C,7,M%Y8*AGDPM3,H335]H/VD1+MS/M9[>)*/RN-GIK-@8U]DIFCY!Z;]# ML+N6>^M7G?9;S]0AV*

*4([*ZI/2O#5G4SKV_ZZJ9.+6I:8SV@9Q^W&IX#Y]@$ MD>XFG@=/?:9D/"1Q-)K;B#*@TI,S6:'%6+0+%3,/D0HI"\31/PU MC/J<5]EI 99ZO*P&'3P[?8 NJ@/NGW$W/3S82Q4"_?*

*=1W<_5;D_C.LE[M"3! M\0$8 W1]YAPAM_&>I$_-'M%L2]N*DDBV.DR;C4.-/O7J(1(B[_7NR ,$)P% MJ1=OW .T5"\R?@L[PI^#;E)^'=G)TNIKJBPE#G;X&F7AZ(@/0A>.;%TYNN$'1O M-T?H)4*.3?X9HT_!\$22GWFDUU5)*K&N&P\;=>;CI &@GZ M\8MDKF#KN)UAP -16VXB@RC>B M##>$MD'STPP>?!,Q=MH-%'H-QX3$!Pl, ?=%@.*YLJ<1#K1'$B\Y5]]Z:5.(H1.*

*8=1KHB 1D*QY&Y"3034T&OUL!K!?@*V!M0O<#[#%/F=&6+ MQO$8Z8'OO0YAN#I4S6&]L<*;))K=. M3>,(DC E8$X;LV(F=&1!V^_M_4*

!A/MA=T,.1^;R&6H/F?:S1F^B'!3,9 NC9&/(8Y3GOW/02]W MG2$,YC(WS)_>D>R;E9M"CD*GLRQ&<:8X3&@(O_LEI*VYCN;-,1!YW*3C QOQ?8;+<;*6,$^Z;\4.4]6[CQUF2_>^?"-

CG4L8VYC_I.A':)4 M^'[O)Q08#^R9^)5(=`9I7GC#_Y2)3$P+5OWK-I-FL=N@X?;?,:1(#_@.:\Z#4 M\M9.'N#\B>Y>XM7#I3ZW@AS"")9(Q1(@=901(F;&PB"&R2CXMLDDM0 I64 M)

(:)_CM/5)N%;...GC3$111"\7%+>IDD2]2SUB2H32I? M52I,#LR3I4Y;2A/"I.1D(J16B?IFJUZFKU?C&?D(;E M0D_GU38;8XGCEF))--OEK!3AX0SFJ6J?.NI!:UP)RV[2KLP&UD9IM^<;,:N]

*M4:,;5R[MI<*2$)I5E,"_*<\3T:0_]>K56X->^RF M3.2=V"QNFMMA*Q:5SW$*NT@^%RANHO;SK;=A9[Y=D8D!{#-_^W)+!9;EBOS21 M"66<6)=E*=KI3V&?*

*R<,U8*0X1U(,P<9%@69CB9C$I@2.8!D^Q:<8DJ(28O*X M;SUFU3.==<-1&4V,QVN5_DRMG-TM:MI^&J=Z=J4O=NJ#IZBB6)0%6YZ,-TE7 MK>+0ZC'Y36Q;BTT&E6Y43X-*

*U/7[EIK%D>]XH-9YK?#'J#[+JP+G*T?&Y=F_/" MS+&V+8Z@UOG<+%&;;=3RV75=YR\K-5US/RB-V.I-CT?67'VW+]JK$[HJTHK ME1[JDWJ):8R3EI4?<35?*

0.DJO%>=)LN/YC27';8>3#"8EG]O5:DN,-6^;;N+ M<75:,FN"4WIN.PY7@BM*RVW$SVN\!S9EW/5U8P^N/,_B_,HNGXJH8!)71 M5LQSRQJOLF?W_V1-+N("9Q>*

(6:9;C[:=K#,HM,_MZGEC&,_%MFV'$,5D-:OK MJP5KR:#ER7I6>X+3EJ>QNNHDIDEM68\Z_1KL\V1&J81ACFK)YA.AF-/&LC,K MIY-

*IV/)DY9^6@[^MJ;^A[;K,:^4&F'L"7MD>89_5C-;:Y?)8K6KCV9.9 ML;M5">+4*8U[:2)NE@2ED%>&,H:U^+;;L*X\H24=G#.0(G1> M#P@E0FP*"""%"Y_6@$*)T7@(\OA@A0N?U@!*

B=%X/G=>_AP-Z+P>_J^' MSNLA04/G!?#L^:K^EY_">=WG#QY2!MY@)}WJ@X)_>7YW!F.Y\D28;^IOT\-Z9M?90K7*A4O\O(UQ#[-M_6B"&"[RRO,H*CFC#:4XZ;_IW1Q W+N3O_,-*

<"_T@/X\L/=AS$JF-^.>J1 = M=<&N9VHJ25BK=OO:F%4J%0IJ5E^-55'(#KMT5934}_D='M#!-@MG.6NZJ_3S M5:Q%]!*IO]^TW_+]O$6!M\A?

*UP)6DOA4L25WUZ<\6E6B.8[6]4X98M56;#[MRN3C,7,M%Y8*AGDPM3,H335]H/VD1+MS/M9[>)*/RN-GIK-@8U]DIFCY!Z;]# ML+N6>^M7G?9;S]0AV*

*4([*ZI/2O#5G4SKV_ZZJ9.+6I:8SV@9Q^W&IX#Y]@$ MD>XFG@=/?:9D/"1Q-)K;B#*@TI,S6:'%6+0+%3,/D0HI"\31/PU MC/J<5]EI 99ZO*P&'3P[?8 NJ@/NGW$W/3S82Q4"_?*

*=1W<_5;D_C.LE[M"3! M\0$8 W1]YAPAM_&>I$_-'M%L2]N*DDBV.DR;C4.-/O7J(1(B[_7NR ,$)P% MJ1=OW .T5"\R?@L[PI^#;E)^'=G)TNIKJBPE#G;X&F7AZ(@/0A>.;%TYNN$'1O M-T?H)4*.3?X9HT_!\$22GWFDUU5)*K&N&P\;=>;CI &@GZ M\8MDKF#KN)UAP -16VXB@RC>B M##>$MD'STPP>?!,Q=MH-%'H-QX3$!Pl, ?=%@.*YLJ<1#K1'$B\Y5]]Z:5.(H1.*

*8=1KHB 1D*QY&Y"3034T&OUL!K!?@*V!M0O<#[#%/F=&6+ MQO$8Z8'OO0YAN#I4S6&]L<*;))K=. M3>,(DC E8$X;LV(F=&1!V^_M_4*

!A/MA=T,.1^;R&6H/F?:S1F^B'!3,9 NC9&/(8Y3GOW/02]W MG2$,YC(WS)_>D>R;E9M"CD*GLRQ&<:8X3&@(O_LEI*VYCN;-,1!YW*3C QOQ?8;+<;*6,$^Z;\4.4]6[CQUF2_>^?"-

CG4L8VYC_I.A':)4 M^'[O)Q08#^R9^)5(=`9I7GC#_Y2)3$P+5OWK-I-FL=N@X?;?,:1(#_@.:\Z#4 M\M9.'N#\B>Y>XM7#I3ZW@AS"")9(Q1(@=901(F;&PB"&R2CXMLDDM0 I64 M)

(:)_CM/5)N%;...GC3$111"\7%+>IDD2]2SUB2H32I? M52I,#LR3I4Y;2A/"I.1D(J16B?IFJUZFKU?C&?D(;E M0D_GU38;8XGCEF))--OEK!3AX0SFJ6J?.NI!:UP)RV[2KLP&UD9IM^<;,:N]

*M4:,;5R[MI<*2$)I5E,"_*<\3T:0_]>K56X->^RF M3.2=V"QNFMMA*Q:5SW$*NT@^%RANHO;SK;=A9[Y=D8D!{#-_^W)+!9;EBOS21 M"66<6)=E*=KI3V&?*

*R<,U8*0X1U(,P<9%@69CB9C$I@2.8!D^Q:<8DJ(28O*X M;SUFU3.==<-1&4V,QVN5_DRMG-TM:MI^&J=Z=J4O=NJ#IZBB6)0%6YZ,-TE7 MK>+0ZC'Y36Q;BTT&E6Y43X-*

*U/7[EIK%D>]XH-9YK?#'J#[+JP+G*T?&Y=F_/" MS+&V+8Z@UOG<+%&;;=3RV75=YR\K-5US/RB-V.I-CT?67'VW+]JK$[HJTHK ME1[JDWJ):8R3EI4?<35?*

0.DJO%>=)LN/YC27';8>3#"8EG]O5:DN,-6^;;N+ M<75:,FN"4WIN.PY7@BM*RVW$SVN\!S9EW/5U8P^N/,_B_,HNGXJH8!)71 M5LQSRQJOLF?W_V1-+N("9Q>*

(6:9;C[:=K#,HM,_MZGEC&,_%MFV'$,5D-:OK MJP5KR:#ER7I6>X+3EJ>QNNHDIDEM68\Z_1KL\V1&J81ACFK)YA.AF-/&LC,K MIY-

*IV/)DY9^6@[^MJ;^A[;K,:^4&F'L"7MD>89_5C-;:Y?)8K6KCV9.9 ML;M5">+4*8U[:2)NE@2ED%>&,H:U^+;;L*X\H24=G#.0(G1> M#P@E0FP*"""%"Y_6@$*)T7@(\OA@A0N?U@!*

B=%X/G=>_AP-Z+P>_J^' MSNLA04/G!?#L^:K^EY_">=WG#QY2!MY@)}WJ@X)_>7YW!F.Y\D28;^IOT\-Z9M?90K7*A4O\O(UQ#[-M_6B"&"[RRO,H*CFC#:4XZ;_IW1Q W+N3O_,-*

<"_T@/X\L/=AS$JF-^.>J1 = M=<&N9VHJ25BK=OO:F%4J%0IJ5E^-55'(#KMT5934}_D='M#!-@MG.6NZJ_3S M5:Q%]!*IO]^TW_+]O$6!M\A?

*UP)6DOA4L25WUZ<\6E6B.8[6]4X98M56;#[MRN3C,7,M%Y8*AGDPM3,H335]H/VD1+MS/M9[>)*/RN-GIK-@8U]DIFCY!Z;]# ML+N6>^M7G?9;S]0AV*

*4([*ZI/2O#5G4SKV_ZZJ9.+6I:8SV@9Q^W&IX#Y]@$ MD>XFG@=/?:9D/"1Q-)K;B#*@TI,S6:'%6+0+%3,/D0HI"\31/PU MC/J<5]EI 99ZO*P&'3P[?8 NJ@/NGW$W/3S82Q4"_?*

*=1W<_5;D_C.LE[M"3! M\0$8 W1]YAPAM_&>I$_-'M%L2]N*DDBV.DR;C4.-/O7J(1(B[_7NR ,$)P% MJ1=OW .T5"\R?@L[PI^#;E)^'=G)TNIKJBPE#G;X&F7AZ(@/0A>.;%TYNN$'1O M-T?H)4*.3?X9HT_!\$22GWFDUU5)*K&N&P\;=>;CI &@GZ M\8MDKF#KN)UAP -16VXB@RC>B M##>$MD'STPP>?!,Q=MH-%'H-QX3$!Pl, ?=%@.*YLJ<1#K1'$B\Y5]]Z:5.(H1.*

*8=1KHB 1D*QY&Y"3034T&OUL!K!?@*V!M0O<#[#%/F=&6+ MQO$8Z8'OO0YAN#I4S6&]L<*;))K=. M3>,(DC E8$X;LV(F=&1!V^_M_4*

!A/MA=T,.1^;R&6H/F?:S1F^B'!3,9 NC9&/(8Y3GOW/02]W MG2$,YC(WS)_>D>R;E9M"CD*GLRQ&<:8X3&@(O_LEI*VYCN;-,1!YW*3C QOQ?8;+<;*6,$^Z;\4.4]6[CQUF2_>^?"-

CG4L8VYC_I.A':)4 M^'[O)Q08#^R9^)5(=`9I7GC#_Y2)3$P+5OWK-I-FL=N@X?;?,:1(#_@.:\Z#4 M\M9.'N#\B>Y>XM7#I3ZW@AS"")9(Q1(@=901(F;&PB"&R2CXMLDDM0 I64 M)

(:)_CM/5)N%;...GC3$111"\7%+>IDD2]2SUB2H32I? M52I,#LR3I4Y;2A/"I.1D(J16B?IFJUZFKU?C&?D(;E M0D_GU38;8XGCEF))--OEK!3AX0SFJ6J?.NI!:UP)RV[2KLP&UD9IM^<;,:N]

*M4:,;5R[MI<*2$)I5E,"_*<\3T:0_]>K56X->^RF M3.2=V"QNFMMA*Q:5SW$*NT@^%RANHO;SK;=A9[Y=D8D!{#-_^W)+!9;EBOS21 M"66<6)=E*=KI3V&?*

*R<,U8*0X1U(,P<9%@69CB9C$I@2.8!D^Q:<8DJ(28O*X M;SUFU3.==<-1&4V,QVN5_DRMG-TM:MI^&J=Z=J4O=NJ#IZBB6)0%6YZ,-TE7 MK>+0ZC'Y36Q;BTT&E6Y43X-*

*U/7[EIK%D>]XH-9YK?#'J#[+JP+G*T?&Y=F_/" MS+&V+8Z@UOG<+%&;;=3RV75=YR

OV23J]#63U:[GG M?#'>9"[$DZ'[E2C@P(S=ADV]X7_!)>]5%YX[[#&'\@B>N;,%+;8OOC)'TX[+XC:OX2O$HM>^NM 924 3%XF39%.6#7G:. Z[W^:X8QVW]]O:$\R= M)AOH|(++05GNS%)1F@^=BRP/-;?/V\1NI+;KQLJ:NT.$ E2ISYLU:.G#CRY/U^/P71NQLQ$P'^ZSYZ]lD(>*^ M05QO%$(2DM %,A#PZ9\J#C7KX& Ml.N:|([>"GHYI67#X;TQ\]74L0#3lR_[#E/ZM7=MG8@0B6,B $CT <$2Q@1 M T:P#T2B$7%@!;. D DC8L"([)lBPH@$FF++"B 2;8L([)lBPH@$FB[+B#?6M(7K5H89/K,ILW*:M]^V6_!G)?=-FO0/?T=-|\UW-"QQ) M'^HA3A(U^C'U>#\$(\+9VEY&:WKYH!;KY6C.B!#'Y"VJ,A<6LF1/G MGD4X)*XL("*P(_YE6"3-T.0+B/)8H1'A5L_3?PO%K!UTT6^N5]2;(Z>[HY* M;_)8,E.:! MMTUQV'R.26/T%3V71+L3[8Z-=K_)"SG5;IR79W[+VR!\458G(Z2;$V?]>VOW MT%IFBT&1B 1)0O5,OV:.UA-X0QQX(2B*t1'FM)Y3HMV)=G\|J7Z31W&JW?Y, MU 2L65SQ4I8KM,.-/)A)|J9N<>'.FD0)F]087)+(X,H=)W/&9ORD,2' MTF8&004X5R9HF78K@]"2@DH#*C1RYZ!2]FR%+LP:N%FDQ%7?K@I%MG5O M4*D7#,O(1++-S/.M!OJG$#78'4^X,?1:)E+N_&W4Y!'NOK4MOG|UQ8.OE0 M9?FH=8S_]\2QHP:)5(2A/IZV/6F Z3!7SA'.<0\]A@6ZO$9>K.ISB^:./2FG MK^H%0G%0##-*;6DZ1^6V@/6'+4K-$I.:.DN\KEEN34(C&&IMA'!@X=16PU$R32&GS8L2#8^MAB<;^6U:DWZKYEW3GD7K65X4#'I,T!LL.VS. M[YVF9LTZKQW39BD,M*MB@6+%]$&SD\5$HC#)ZFL)=20C[GL5+G60OEY'@I M"=HD09N['2_MU7&/DVTF"(MD2:\@1NK-8&'[0^ PX/A:9Q(CI<24$E)0:^UGE0Z>6U;_'(;BF+_ MW] 25&0|[V>:#6$1S4:TS :59;,-0(6"S1?3*))<(TQ)0&5&'AVYT%EM>E[M;F75K)-4L8CK#)27/S2>@9N 0G,FT_;9I5%>KKGR\]B#T&W8(*2Y^VX_WD MQTL'+RXY2GH|&C[AQ@@>*&L!/.7;#O@A57$L3VF!%LFF$2]YFI0H>Z+L%^\V?X>;#$NW:8RHE8PLO$Q% MBP:;EL_##I&[LR6<2M/)V5*B|(FRO%|:9 MU%& 4DUU-.'9^OILFI)+-=/ M?$EP+)Y\27 LGGQ)<"R>?$EP[*I\>>NY|FMN_HV)<*,6/!^[T-=O%/%'H@!_M_FD$X!'R'XO#52'S[G2Y5>NY%P']>U#A-,/F>U AT8A$(Q*-2#3B2VM$8C(F M)N.%NIM21+P;M)TAXJO-3OGK-#M-M"@F G =+?I(FT/R2R6195NE?C;Y.4.0 MW_?,3.3IS^3I@OU5$WE*Y.FC35F3K?Q|K/DVOF^\UGQS3)NH+5K!7T@KA;9*@ -5 83$G| MWE_B2!%8 MFKA:*Z-$Y1.5_RPJ?Z9RTQ^IO.J.C6FW5|&0P42W.W-6+E70>U<_X1?X$%WP MH[FPH.FR-I5*C$QQN|:.%$]D4>2E7?Y[*L1="\"=*@(;)Y.J0=ZI?9.3!7\ MK+CVQ;R8F*WZ?I 7,S),0-,$?]WB,0F M) #R/0#D31[5"P R4$-'G$YDA+=-/^HKXFB(1?=_6$<.0-(9?J]1<_B)@'P/ 'F3',_8"@$P)D^L9&:-G2DO"7_=P5>IT M[PT@#8Y>YE?U=ED8H!D%-XI67LQKNQ:.&,JF$;*E$,VG/5&ZM#/N'7'O'X'< M-T.T=YTK%;-B1(=]EF#R=:39$WH342W-]?.O.D.>LO@WLT! MHC"\MFFD532[62*4AG4]U%FU=UT="39-D.EL.F$X6!1H':Y859"\"VFK1-CXJE\;!+(\&D*5 "

*M!/2: GI-DFGFDBU9X^9(9WQ5SABKS$YQ?¥:V_X@KS=#:';H0F-WAK_&-J\U\-MKL*=C=2\=X9',4("\M3ZYSANL?_HQ[!¥\.7E]N0(66$Q^X(5;+CI"2N(.)>Y0-M_-RA6"'KQ2VF7RJY2[+\ZGC\GJ<;XN9J2XUEIL::T6[SJQLFD%?RJE. M=#C1X42'KVP=_8$.<)8HK)'^9LIWVR12[2_LW'K"[?N94E>QBF)FW===<1\L$ MJF=OXS9.X'KKQ)_[TO[%_77[XPS$C5J=<;[#..39[)>*MZ@9W=!%M[HH>PMYHIQ6_$OU/1#_1__C;-W^Z_JI**3&U6JLAK.7U3"$6>M@7 MVKONB&0:9!Y6W&=[ORSQLSZ"5C&NZ76QFJA[1(I(A\M/IX>EBYLFV%O3.X\H]M7DGFCJZH;G7T#%(-Z+7*EY"N@WR:D4$(6:KZ"KKK6$3&%"I4&F+J42+HB:)_ M%T6_F!WR:D4?8CTQB"?MV@="1.(M9}!*LA'5_;-8*CTQB"?MV@:D^\MK:M[6WWB-Z*"[--W2L$RG+.J\$R&TW#GCBOM0$NP*PI' ,B0PO#N?,GX1.!5)/K"!@599X"_^\)O0G[D"%$4^8"]V%DLJ#MRK<@J2 M5.B((5_0!_S%"O@)7^[#%^8!3?0EAGQ)<"R>?$EP+!)Y\27 LGGQ)<"R>?$EP M+!)Y\ 3B65'Z,326[5|W\NQ&!>0,1K@K@'Z8 ,[]WB2[FO266<&S7;OQ^R0?O M(:Y+%99&]N2E>$=1E=2E"]PE]O0=5,G=UFV';AWFMF#BMD">ME0SZ6^+#N3@N+[WEP85#L]-M0LF.%[..>)N+,9'\RC9%7;3,9*RGEB-]!P;%C!TQ_D8+3)*7>D9>=2URS;3*-34^<]I,[&9LBVM=5<,]?>YFH-Q0$=2KF:U4[-MT\QM%9S\]2^.1"B@M=X8A>+:$,OJ/6#R_H:WQ&6OL3%PM=%B72Y(OI\HFF)!KZ;33UV@[:YK: M6'<'#BEX'Z%:+@TW>EV4')/;U9METCAU1>,_4=3/f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{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{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|,K2>QO/CQ]769_([YW-;K/&,N _]B0:O'MO*K0O[\&O,EOX>S%(B7HVC?&T1.8C+=Y@]O9\3,&61SB\MOGOG9NFF^7EHB'Y+G@9FSLX!P%ZYJJ1#8N>$$V..4T@@R[6DR51 M1]D5|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|W2++N<]:,$]:"=6ASW?Z'G>LH2KCW&+4IOB9 M/*C9)+D@1Y!^"]H(IM^9]V^$]R^MMFH=N\9O,CHL1XO73[T0@ M1",N2",[,(6=E6^^U";08>S*^_<8H7HZ.NRTVG]"SI9-OMZ:<(93%(\1>GK= M11'Z[3'0A\.XX3!-C94 NTL:T/*V)UK]2<%^18GFAU5X("86C)7O$28!2,I MS$9DPB'$X%L++WA?.+YOAY-!-97GP-;!RY\,9L_(^\6 (!Z,?#*'6Q^!4GO'V M L2M 1[A6B [VWSOXG+;X0,\ 0M"A5%9[8^'' MO.7PO+8=D[U(S$,+Z=E JWH]V1ON>A)H;,-KTH^U1C%UJ{4!BB1S HVO MR$0"B#'8R9/(,&!%2IWJAYQO).YX,6CA?SWGX=8(:^4>]KI'&\V/[NXTJW(=>DG\."!?O MBV_T+YF'\%!T!T)$@<%(^ 8721Z.(> S4[*Q#)0 .B' ?,=5O3LY_T7&;H, M})73'0T:M/#;P"GPW@2HI,J^$=TED+FM0\9C,*[QASC#FKV2< SFB6W#IH] M@\ .LB5^^UQL\]R--MA_MBOV 9]C"Z.<=O?SQGB+?-2.5YFV.XP&5<\)7R M7^:]W +'=-R;[,>V_1'C)?10'#'?6 N+6%7^:,WS$ X M=&$4]THV/Y2C0[=938X]ZQG-3"_D{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~@68(Y]V.0RQ.L> MX>6;[?4^C1E? &0AG;3_WM7CL/9_PIS&""]>RGX."]-%=5._NZO&___F7M \0 M5E<@E/!O%_;KA\!)OJ;P^P*..S_K'7@\$(&,]UZZ>S'Z(_H8GP,>GSD]-X'' MD7:8!N9:I)-X3:4>BW[<_N.>6D'/1$? WD9VYM2!"L(KN%!!!*(=?<;R783;@F2&;D[;@F)(Y[+?WZ M.5Q^'YE2^37#*[_=\LR_:"<%/V\?I2_!'|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|PJJ?O\O\D_6_""18A;3]J"X1;E<,\UYF?MP3F MN1K]-Y"}GOO-"_N5FPHDZ?&[A81U!$

O]!U}JO"6?4C9 MX;WY>]"!@:W^31#<2[&)AC)=-64-AOF40'_^B/SK6'N=Z"Z,* M+UCN#L{T= #2T#X.!B@D/H?1,999152R9K&XAY MP0K&MO3-!RX\O4|\U+T%-#8?*
>&O@)SZ'(,C_P!-:QF9C_@M1[^1?#%S%7I,? M!F(Y:7'B^3IX)IRQL8':YOBO^/GNDC MPWWQ9BDS-G7%MOB#@UY9S.U\[QMA)7"TI,_?B+/AKRD\Q,+ML/#3\H,0+[?! MRV<]!D*\W
8OG_5!"/$2RK$0+U^_$U)?B\?>\PEO M>]7]FQV&I'U*AS__EBSP??;?^[>>]V] 2_L 874%0NG_?F&_?@BV 7) W53O#NP?!;:T>%*P MA$P4,M&=]Z#;@^4JC4WO#BK7Z7UZ*
[*$[EKHKMV+O2S2KX)EV?TVCPWA64, M8P7V^8X[^\@$$]YAP0!+:(:&OES(1"$3/:_I$OIR@8!*Z,N%OMRCG/"^!6+H RMWW/EUO
.Z:>"\>8WG]U(73FODDPR9\2#)9\10/7U_ECBH$WDSU"Z;W1SNXE M:>\3RGPG-A!]D]MHDW/20(91&(WE(YT)SUN1JLZZC1"?2FR$BN9[)%.V-3Z"
M(R]/121!T"T!:G/XQT3D]?;PM$I6UTP)G(SG-N9+]&>"H&=*K^7."@8?24!@-M"(8_LH8Y2SWA.0@'P1Z+<-Q^41Z\T/,14/""@L$1/0],0=@CBZ"@4%#B-16L M)M[GI"
\M&5#6_8NQ.%9 R,_S4E^W&CG6>'R6:.;9X5+R$?W7"!S?;C<1X7_M3?@H> Y . . 2\E'(1Z$^>D:LUNPT3T4F_T0+C_S=0/6C#QMFKSU_5%6GE<;.ML+/??R+5] M/#AEGYX)$5)V2-
GW3MF/+;,#=]A;$/8[$VWN@+#O*3GH#<G!1^#~_%_0W(MPYX%-,7X/?^Z,]$-*PI6J1%FP4@*G/43%70C:C(*YE&VT^:_XW++>AP5+/Z_M3@KQHS.?;^+O+476U>
<%X]>&^[G1EZS"F*8[TI_BV0F]D3EB.S!"65'/Z-%$> M.W32G0&,OR3PU.6& #^;$+E&WN?20N3]69K"%B(_G5V*7EHN]6+E52%,&]!D
M'}6[/:2Y=D]]*\HE8;)L4]PRNI:Q97PY54K5F4FD@5Q*7%@N72%Y$LJE9Y%+ MYYL0_]0:\Q${\KYV#^8;'N_>54O"/"?#>]?%>Q55NY_Y\.M+[^]8*KA(#?S<3>^O0! M=1+\[@=N\X--
[X,]^]MET[KJN08,,L+17#')@S!]M\M:,("LPDE;533-%_W

*B2@594=C7&2I!)E@.2Y&L?&H,!;C<3P:Y;&-`M98AK+);;*K8Q!9`B^%8,58-$:FA#9&-\A5/,N;29&! MSSR:9T9(Y1PQ$AEBSJBZGO24B=[)P5O!1V^7F:AMM&(+-2LVVL-";=@9+'@7 MC#QZ^*D#;O9UVEL3H^S,9H?Z#5< B./WJ[&IG:,D*0*5D_)0T:=BYK/ M'QK'),?$,9K(MGOTJL6;&$3B11{/)-1L7E^5#1WQBS(H8QXE4E,;X,76T$U8[MEBW1]{KA:E2]K1? 3XU;)];432;6=&ZFQ4E*9+[""XXB-CB">W(FJZ6*M;M^)-M,>WV=$IG.C4KUSN)0S&]N,S5(A4=*Z\Z%2;YT%9)*7E]_*3)L$E'*,/<=%H MO38TUQ%G? G(GM+Y,ZL_[>47)RY%/B9D2"RMY$H>04I2G+:JPZ:IY" M-M*>EB9IC.>5=%M6>LW>Q0%*MY'GY+K?&?&6F,B*67F;*[=ZZO&ROK9PJG_"B-M19- OT1@4LS0FL)6$T<4;Z20<>D2GQBRON5H\3C*192VMEE+4HM5V3V)!,BVY MM6Z?3&&1>FS=%5>%1+4##BOB>&BG;J6))2%/E31-9FI$ANEE 4WQ5S9Y){OT MO!?U"SY7XM? 5?)9^N/>$|S@)C?VD+E1>75Z>.G+LRAP,*;U+;)$%TZ;CT5FU M5)C(*\"NS,-41B_'UCA&C3ZUQOWU4&6F_,\+/X]N*;_UK;{Q)T)&Y24@# M7_#45OC#6[>A9\?L.1 W32_A"WR\#WITMA%4$;H77OU5T,T2WKG'CH8?>@VW MF6X?33OTC^_0V7=LKG9+@>Y-$]`R' N.L/(]H<F<&R)NC O_6@XP+%1N9HF_ MMS_L;QK4Q3=:)M1(>5^3/=3\[Z[M;-3^8\O*-K=OW>JLOL+ZN?NWT=A+[&PE MU#T=>N_YT TX!NRSS73;_AZ!EY9^-"W:2'XCPH7VRL1B]%V^' N[MY*-.E- [W/I_V_\%KE!0CRD2[^\,WHKZ0*_U2ZW$1^5A)A]"X%$@G+Z'#UO*%"DGA%.KY' MB?A+(AXX!CF+),G-A6QC?(@=Z-P("M__+1P<;/A-Z(*.#W1\!$Z,;D:$GWB* MP$M#_CE"8N%3JB@Z3H(B!_<\3G:B07Q7-(C$"TX$JG;S7\M.R@\(^U+3AE'A M3:+I06CX0I8=PMJ36/M,_ 1S,"X!O@$KBUI_DTSP^V+2$+"%7]S,O:^&!VQU M=5A&7;&Z+6P#ST3B+4_$6_+V.INS]KT0U1YOS!G>_&#8I9GZ]*\+/BI@_C4 MU>6G4%0O?`X_)'L&W==U;M&M(]\"K;\1WL [[-<&>N_[PER'VDB#OO~) MM0"@V.8J/A87S)AEYH)<;57S=]$Z^W[!R\/D?'I]8ZV-F+#(@]_R^5GEZ6]3UC76^=__O*]\3^?D,<61H7\!0?FVQIZ9>[;NE+93E856UEZHBQY-$0DEW.BD2EH$!EC9. MA!/$AYWI'M? 2WIRF-4/G;WB@!F;Y5SEC-[8Z9#A_>!(_*V,'R$B^MW/YB_)_ M,9]Z\"CQ(T__UP/NA + 9(K>A?V0]!!NJ;.O-(DOH\9[V:X^6L:&^4HVKY7T2=&9NFWX@MLWW_O/I_KM M\6!EH1DG"UZ;NFVS.5GG54< *LVF1]L&B !D2/,R_&-2&@[GG6G>NX9(YN3 M=?^1XI*?<+KDM\;3P7+//[?#3/N^UM[O_DZC# ^.1U45@=*?^=$|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`(MS(<^_=87HK"J42$ M/=IM5KB1S\-# [Z^F^M8TAK.)O'[>!(_P@O/DCX$J3> YT]SPC.A1-_MU?]DTU1S\|&VQM5A,@Q,?$D;&IC)"IX>>.P_UEM'PZ8[O."87H+-?I9*Z'R" MRB;#QG_E%]P97G[-@C-ECRG|XO+F:B#R;R$/. <(C"B&9#!O'CQR;!f_)93 M23GPB2=>88]AF2E:T ,EA'31AG/;0MYCI=LSO:3@8#*X>,5S!H*&6"8N3=__MB#4+ %G;<_2^6^_JR._#/ =V>L.$:!MP P&WRSK9GPJG4LQWI5SD;1)F]>B? Q MK-JI-Z-]OM)1-#S;5;H1BX@OW7LDGGEJ"8[MSND/LM!F&ZL]-%[%!)@P_UG9 M"X< YO"3D.QELNDA4P0;PLLJX%D Y(8#GN))M<_@Q@A.U!NBT*GDL ?-J{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~9? MA?C-7N5=*+ =,I:I@?I23E^&^3+;; ^1(JZB$(;O"7\.ZK&S: NP1_'7.R&5IP MJB.&9H])3[SYP)T&O))\U_Z;YECT\I@!2 .9K\#('RRK,1)U3[97W+@DLW.34 M\.&U=Z],A!72#?OD0HS7]5L./IF^ZV77_=.5-8=;@,)WEW O1N//%B/"8^(MR9OR(R3D_FM<>7PWXY^@NO?<3O9BU-M[C/_G4\5@]E:UN29*>$>4)$;\VZ!> M'. WI[K'%C/YW:._G__PZ04M8 6"/8@=% #9?.ZP# ML/WP@UNI>X4I"*"FS Y*Z%##X2RQZI:UZ XKDZ\;\+Q>;.F!"A_F^GGGZ_NO79 M8BM>K04@R&F:Z ,(*UPWEN_,;>!QZ2.I3%'S#_-L2&6;!FJ0.LS=M<2"6^J0R

*M7_!U2X#!, YC, +K9L;&C=2!M67?5]#4Z]%<2K]:F M^,[*Q_T#[PC]OI398N,">NZ &A;@.?9IB-< M@RE.0>L+ !39LX1?0>1/@Y*#-AK0LSM,B<5D*P9H:^JH?H/""4PVQL ?[9D0 M<[=>=6R72]-!OQI666OXY[\8f)OP/?A^\2S;X1&Q+Q6!NP] 6_KJ):!Q-P*O^ MR-SG!X"/W!L=3Q#!0\QM92GXP%MF&@: MVNGZ=Q:F)F(#(>98@K\1VQ0XRS&!{0)-L&>&WT)RCZ\C>+R\;^= 3,H:)K?> M^W-3_F<'/X"ZSRN)&*/SX]_?/E3 "#3 .*?MX*C"FO!G,I@RP 8@*6#,P8+ M.0UH"WN+F{6@6_Y,P"^6_123X7+O"5/(6GXFQPK-@,G"BF M&W;, T1@"E-#T@$7(@%U !Z_ $ 3R%, 2U2: WCDT$71 !.+=/,AP5$)7@!+A+D M Z>L>F/@_\@!+@HVIS[OQYT) P1N8H!%P0 '80V' M68-! ;f8KX,X!-;+=8:LER13D"!\Y|FECZ3S+@Z^| 88N^+ <&"72H PPL3(A|^ MZY -X4:?.?PL6V\QM87[=H=\0)X^"K{\ A>YG!7*?"CY 2LA R"P,_QS!REZ M> ^X".';NF:F;XDLMEO&Y9F]34($:.W"FR<{*H[B-IHTT,~BWRSU,S2Z(;OO' M;SQQ>CDHB)D#4E5]A@]C3BD<0!WQ%,67%NMC!N-2/)8RS8YC9WI\)A*G89?8 M'IY0QH4Q+!\,F%H\MVAM'*K):/RD/VKQ8[?1 #*%$]=74H\(=2}?1!D^-OB; M!_0B$!PZE!H51Q>"3W'D*0;9U_\?IQS%"@?0$=?<"R%SP*-4[+]+D M Z<9L>V@=:9TS)\-[6E&%EW M!#YCOI*,AEZ='3] (AY:KO|2Y> M8O7?P"Kl_5_PS^YE4Q40#G2?9_\Y]F%PN+-M5 !!_G45CW@JP&E4.[A@Q,[[MW\,EF0Q.X>_.;__#C?_[_'IX9JF+]VR,_=G^MT2ZQGZ!>;,,XP!@R@'98L.K{1MZ9;[? 8#U M/]',.C/09#;!1I-M^97QJFO'YLIQ3 M]AHBS[E1IU7&)18[71[7-)L,2I_M,B15*-V6@"RBD M,>_,1D5J-&N#E2?PM.I%4HE7QAY#=044]TEK+U-RP9FBE[U'J@P'V>G)U%^O5EQIDL&4!$_:2& MX36$ABM/<-2M.SU:.2ISNLMHDZ64[L=12P(K3Z 4YYN3(3Y=UI!BCIW;JW%V M#5#%DJ=0(K5^E6AII8&"T8MN+4F/3,F *T^@)17MF>49M,XLS0PE37!IQ>,N M6'D"0]8^CA6:5'YO /G> M0*E8K,WQ;IH(N:I7*\NYAT!8DE3ZG&VPZ)SBMNGG3+SF'W^GS#VA_+(3Z_L?0 M!G 2=Q4IOE0$JF+ [^UM?]\VF>!.%,[2L?:NO">Q&,Y8-@@NQELKIU]\OC$8^ M6W2'.VOZSF|&Y\]LZM B_^/8W%H0]IY9>,,U:Y,O /T@FI]N)8!3[NY.M@PA4 MS+%@M) #T#(Y2+)Q5=:%783.6&UC:"L8E0+K@E"&3T+@,3"B>12Q L<1!1E& MP*Q$K'L0@-G'3X*081";\;=M^9$HN#]+E/UH"C#DI"#\(EN6PP%:@"_1 A"H'8 ''PL8@O[QT0O3@*DC:T]Y/IE MU (8/^\&=] a^F P_AH.8JF/9W$?$_":+ 3Y!B?"<;HC' W_%G>H]HE@L M -7*;WZYK'E1\Y,&!X& UP^D)"QV*:XVHPFZ%% L!U@!B*!.L+=86IC,6 M; ,B+0#MD9"[*S"LQQ*Y<6]8:NECQED/]);5IS(]Y,^##N?%Y,'-]:QW>]* M,M5QGXZ_YC9A-Q^~ Q3=&-H6*@4[]Y'@QF:0&3:WT8*,21WV%=U&=@[S! M46* V[_+IS"? N@".=K%X'"*L@$ HL=UESM(,0ZW-H] _/!I\!8;JE]N^$;+GW9'34L1U)(V:!N=41.4Y-S.2F6,&HOX]^7PI=.U8H&&81,MSY@'@O)5G*H*,1 M2U(;#/-C,B/CTH_? 5.*F\'^:;7'!$?"'^8/$#NG_7;z,@JD=ZYY=*L9_+++10 M]DS]VV<>L/H[C+8D?6"T DZV3)OM0)C(I |_]P>]VZ+|$Q0SD\)>]EXFO@ =D M.7[EAF7]FI[5T1*-Q2C^XAW3-8 ($_2S1#)YFT@F+XF$7B_DX-@MWVH[H 5U M69S,UHL-PBR-53HC+$=*<@!$OBWH!V'DES96X@W#Y76+Q=I:+/\?IRW^TPF, ME$-S9\;QP#H15K+A6*H7XPXL&W-GV9Q[f@=-H-A/^)"37?SSYN'@\[M_.$/L MY]10U5T@_6FO@:Q_@CPKK\FZ;_%2#TH"X)^SQM;BS\O WK$-,S'""H#%$KX5I MD X\,M[AY6K9M@5A!S%>@,P#S?5MEM&",:,/.#/^E? B;7=SG:.TM<;;/4/KO"7PX2HG)@H3^O?!GJ_(.4.7C380'#SBV 7PBH M\51E!+^]2S)$6N6I6B7POP|OEP1ZY|PZB8\&K7JE@Z7HX]93B7M97N$P8 2@-M:.*T8.LH;Q7X;S? RSY^=YZ#FY8^ZQF>1@'B>_=NM!W|D8F[].)^G@?13XMWI MS%#AX_UGQR%_P 6.P0MJS)7MP+<5@< P7)_>817&=A^P!N/7ET1@IC.!=U1A M:T.Q'A&0Y XDN]_C ML'SV5Y N@R;*FVF];>+0?_%N*3>Q#%BW=>7TU)_1CKX?!0=9QL]7DZ,1(D* MB'2"B#@B#(B(."(DB(@X(B2(B#@B)(B(."(DB$ 3Z72$B,LAX],-'=YR'!{N MU*D/G/JJ0OC*%8]_ L+N13GPI8DI@P>7!'4EP)/!EW"Z%3]YTU _#+BR\,/ M]%A\)>?PPS&_@&&G3=3]X#0Y.@EAQ4ZZW@/!,Z,T;=ET|OBFU\EEKM6^+MF^ MEK-,H/ 1LHF$RNV%RGMH_M42E8"X3_^%12H7N6Q-G'3+NBNA ..I%V+]K]$P M7\+ZWYH>\(O2PZU;54?T)HQ4-+!Q38"<6CW(Y+M= !L75(E_C&-=+2Q>^6DU\115 M@9--F/$5#K*]]!K>$A7X'1-T.%O85P7$L7TKE^DF-V&3#EUEC>T9A]<5%VU&?!51%5_ M3]E06-5E'=.WG\@LOI25%!C1G))53A%0..D8Y?QHCDD_?N.G,Z?^%@\@_0:D M@YL4YR&]D*R1,)=TE1[HE#>@'*7?'<&K9U?1##>(P5[."IP@7+5IL.W%BC8 M4)-G:,;$;((-RSYSHYC"3T6\E4.X>T]\)%)Q)YFU)URA&R&MD7]IYHCAUX5W6 M2*\|+X%RU>;&MQ8HJ?P\WT^>+>H$16Y],.ZJT|8QIL*7'1%(28#*6,8-DQ MO)*'=<\AEN2M>\O(O=AY^LCD|XN*MH@%Q0 $Y2W//"F"N'EU;@G="0+H>*% MV7)99'1L#@7;F;.C(?1RPP7HUS0((9 C>3HLNTK5:F?GCI8I>2N_9^XIH.]9 M9D51@%LY;.'BA=>$3G'4;3:Z"\]FNFV[@-#9INWI[?.]CD/H"B<+T*\)'50P MIDJ*)S!.7J3&$LMENIXC0;$3Y1XCH7,))RY06>\M/O\_3/W81"P^D7AT,U7+!5S)GF9)!0+M;9[+787$\P-71?0)(M M$LI -H0)[2$=>MEO>RJ?<\$1L"-;YGFNP9T0>E.4'O.K M;08<@0)TBU^.;F]IL>7#-U>N.VWTTQNIV0"^P^LQ)SWK7S;MG,F69,B03&K< MKCO@OREGS9Z?$ORP,Y.Y';MWU/3^2,/6TLB%G;$;O,>O2OU=+F%/%2\[7^1_VZP?;@E,1;<-_C//L8HO[S6Z[X&_;# ;,\\GKH[VQ22Z M8/%N@"40-,`SHPW@8<,)9-Z+E%?079 +FG3"Q;#G*%B^;SKXRM[V/1 OV9[Q M\VSW8NS'[(N;7)6*)E=%DZO.TNI]U>Q%"6226]"L 2.FK*$2.)L2J12K,!/ MTBB*3!$.Y7_\/IZGDZ>]@\G,[0H*UG30M<.(\KP@ .:OD9.Y/O8$AZVS+*S%. M8:J/\BF'X7MPY=87/EPI6G&^TV2|[28T39, M4\MF97MC[7CE8LP2O'+$#)1X@UUS3G%!U<1V<+?G>7+;.FKY7#AT4L]54U0 M>4!82=ZM-

*M'T;|F1]/"8:BU[56]\63*JS;+A7R;-M;6I)3UJF!):V^7N[YQ,H8?2ZE\8]+1QI]GA1TD1W893;_]#STUO%1R@)?H$. MA"_7>"#S9._!?!XBDD!)'R\<4>PB G!?*

*N#R(\,5\)D'P5/@EB((GJ"D7PA1^-M3?42L0S/RW GG*IZ3X'JW(K;P)D\<1W_S> 2GQJf(:Y M:Q?8/#C5S'?S1GE$VR)R6X;NI-@N7$M<@\K?C%2>FD?6J;10+MUF4 P=H MBET@67?2O3/.QI4B;\N*@R0+PXJ2\;?%FRA<6BP)&7,&>DQ\J3BS?!HCM;9 M'!^-1,U&%N[!\3H&=$H3,;&&RDA*WLH79HE;=2M)-5"E.D3)>4QA4X>)-NH9G MR!G" 1<%/:-)8_=BUYP"?*VTR@J;MAJf/"IC&]QLl ;JWSOYGQ!X%!.8\BR_MZ2+.A5?I9K;]3%(^P%^)L;PT6*#(@1)&,&>@K5T_J?//DF H;/&B 6_=U!& MLOT>C#6B(5XFMOLSNM;V4**P8D666O%OSU(MVJ;

*[X>V30VD(U/$'H"N9*G@KG M4;+/MOD>N^5'3P[_#DFF8=@C 6QY:D@Z4!+\6?QUV#PWK(TKAK+,LU*NVTMK M6AU()YQ,I-X(>@+ .[JY?_RIMQWS-2/XBVW$P&/BVWAW$&TQ@BC0T^%?_A"2 M@SF NV%9OL+5O^V+0E@[W,,Y"Z23/X22KX!"@\6(OTWC]4A6,* M[,3B42[Y1K(H+A;Y&L/1$!%5)V + fV=!+'#@@E;Y32!:W\OQ'**#76FG/TVW Z,09[Y?M<.?;)\B &(1$##$;S$ -:&#DRI8,T@K"L;!1Y@$OIN,1=&O@]P MBT1L_V(.:!AKJ5[< &_-;2[K=8_3SOI A0)MUB8@%;YV,0[?";5,0*+) P#% M!=$_]I+,(%:TF/-]6T ;7VHF5 BT&7!0P'1\H(%0!C0-21\U0."S)[%RIUN M#++Y-MJ"4!)H1\ C_ <:$5X!E);Y63HT>"K]PH?$6"(BB4 W:5#*XJ,8\\, M\TA-(@?\EIUH[$ (RM ,W_@ZM;5)D;+0R'"'O-?!'/=NOO\K1[$Q<@ M.6J.4I:,J8JF+NEYW79*6:Q]WMJZ$=^\D=/U=0!'GXJV!L5ZS>073[@VQ2F%) M6;X)Q*>HD6^-E.

*(0J5+]1MLUK&25<=_P<) ^#C#?RO/X.ZED\PU"KO&PS3E71-M1J.L)7?7-X&ZAYM#&D.\-5/T+"OM.BM5ZF5>=W4#H,,. MG*YP&A$MTQ!EVY>*

]OD$/#F!Q* ,"C%;C&7S%#12=[#&)?_9.?UX0^:")/H M)O;ZU!H9!8#L(*JA7'~A*AL.'W" 3]J?PN30"KG@_2KW$!.@D^D,OAN2I"E/ M'-\#V$M<FF*T08&K=8<7S>X;]SU]#@=46Y#U>J+F M7]YVI;$$BSR+)RMWD72HE2J$@K6H9/BJ*%Z\5P;5+@ N1SL:[LG_^KR&1Q45MYJ,V@CC@!KJ"F3K(#E[15P\,&.:/!& M@Z'##"MTZX+DIAQ ^^>VS?E7'P+;$'JL MIC"#Y38K887U0^>#^^+B*

8NSYYN]_CL$/DKZ A >P>]&8C@&UK!O_%NZ7<.MQ#)4QQ.^H@' &ZWC@^^]OS7@05N'3 ;?O!((%>$E?'@A$D0RPDOX))),D!&_ MA! O$;]$>(GP$LFOL.-%

T]1A=#RRRDR8.\L$F#"-CG=@M&Y7_Y/L"7&3^0! M#0(TST,C+!)P]XF72,!=%2\?G./UIQ__B',6W_*MK]P5,B10>$M ?@\HO"6. MO@<4OH86HC/?^LQ?0^T?5'F'V9.+0.&SMOS->?Y< D'1X1=%CZ41HC,P>$M#DX-%7[X_WZD?ORM(^ 3"''30>2ICT-L\@?TZM;Z!8,)?U87@C&(D]N0L#X\)'_5/)3/X@4B.R.2 ,M/"';B&P^3C,8)?1MR.;JEB%4ZK&RW=W9Q?1LR,YYJS!-R,!PB2GG@9\9L@G*.M)R>-_?S:AB]O=ZZ/OZ=U_:[^=<>?VS+7P_K7_94#?#_A&%7Z/2EI+_]*S*0\ M+]^;UFKNL@2+__B-DD_),_<*_WE4$H\X/>+TJ_9*%.E7"-144/F"K#K[$-

*MT6JX7\3I!7%9M2HHT6 P9I%69"LV7W(Z12\7O2$H.^+/(>=$B+6 MCUC_JKU%6O/U &-TB6$&[)+NT]VX1KWH_'L]UE>1N:RN1^:<+0)(JS*I27.W M"5D_[;,^CIPV_?WGGJ,#>]R*H\T?@ ML"J2R6J80I#,BRFCSY3D!S1<0<@2=2{WJ0.$#T'CEH+@8D.RAR!45 5DN& M@,V^@(&]0!PP[+2!=I2RB41$)"+NW_-ZKKBHZALO7AJ[$N.AE*VWJ@.K[$ 1MD?8+,-#4:0"½=V7OA:PM((U!{3!'MF\(>>5Y3RB:)&]Q(U.@'"W5>@P5 1 M%%X%T]!HGT7K/H<>BS(.#/#D.S)M-<[-5VK=:%BI"B"3]Y Y]P5?RPV#\'2XX$';$!ZI;W%6HG'8N?*

*8KIP.9,] M9 (49SBAG>JW@33F9NK%PY/W/KTX;((KN,"P!$_%@O<#*VY0'( )X*BHMLMD2")!,EWR*"\6Y*\%""#=CO/I^9KF='(@ MY#V\.Y.J&A0@,)6"G0J0^\RC4/XK>H;-*

*]7\8(,E3SXC\XY8' S4FGDRMV;!1UX8D'($&'2GD M*9U.1E4F$1\6@<_8#HC4IW56:M%&W)D)A*TV6;<.0BO&V3?D]> MN>$?95$B"1))@%"Z,7'\C 5HC9V-+A6F6X?*

ID.C\N#Q=%$TH X.$03\GTF[5@ M__:'.G!)>,N7?!K\9>\;PQ7O9-T;S.\Z,V>6'"UIV"8_MQ.#W9N%?:=6V.X M\A2#5N43^*MLQ60EXM.,<;'_"YU-2WZ*

K//"Q(;>N%\LT!6FCBG;,AR7#@"S M$?A=^>.>R*F#*=E:J.CN.6,99;KE#58N>O/X,)7Y\1M)G!8*Q Uf! Z$]P< M-(+1J!9XI#] U0&07D]GG'X),=OD>.&@AC

F^-1!,#)V/B8I.6XG8&RC"OQ!% M'[<]/H(BB(.FWN6"\>ZG>1:B<'+W+AY{]%06A?V?#DBD912;2 # M6DQR#"LR:A.6572[]=0X|&2 TM!!"LD1[Y^MJGEM/JY3*

MY&;-4=JB(Y@)JKPT'Q,<,6H?TZG'3'M8%:LMB<\5ESIH)==EVL.DQG.+.,)9G4 M$\L&ORYGL*DM>A/^:,Z99)U@<<@[@B&8QF08ZSO#[F.]W9P3*]U07W#)C?-)!SIN$87V68I/6L?

*DVIJL[&65J76(')\M;/J MVEQ]XY*E9X.3*(P8TABT5@,"REQ69*%)X)A4!Z*1+]#SUDPONME5)I?-9(E! MYD"JL.5]4>9$B2()/B=Y?(W89+H))X"FVD$_&QXEE88[_5&O=GN&'W"\96S0*

*M!9J#EB0)^"#UF!5UDZ^1CS.&;=6TMI@Z;-EGR)Y&+O2Q,*A5.UU_,V K\$1,*M'!;,%A)!4AQT;<&$]KWENQ1C-RGVH2\1ATTFZ8P4%=_9(%/UYK@K2&TDD85/R*

*ML*GJZ1E/=S,98N#.#(ZH+ T[&X@D=43TB]1$L49-3=?$?GK\2#\E M%!]S,V.&>:+5SSQFO;9+]3*HZ8'X[8 MRFM],R,6[B-89],91AR'37?R?V&# MGB)B<^SR1D]\Y357,6S7=T/OB!K0]U&UB4Q45GUK;=M937.5^@2^(\M6KF MMWZ$9OE S7COM!-1,_)'#$#;?HY..#@^,)D9L+]\AQ47/FB3[AD"VXIS/WXU M;_L3@&%RSU)/?SV1[%H!F-

P"H'[<]^;/DNLH4J#X)^1LL$_0Z?/JEWH"+O^AF^(HQK M/UGFT08&M,H-:>Z"G[L_]ON+#-FM$8O..24R U^;S7L;%N;^= M\9S=6_=]^M.__XZ$DACGI@OFGMZ.-*

XO5@1;_(A_4V+JU^=("@6'^(!)%^H%)8$%<@"$Q-M5R,(3$U7(0A,35-.O6)49^5 MA,]?NO]DD_#WQ=Y!]H%EK[K$+'K)A:]!8X1<1MY?5&"ON[SRIW3_A-7;MKT'N5U-*

W^QX4XU3UV;%BO%0,\M85X^\]L&_7Q(OFAX'/S-NP>SDR1\\T@/Z M^HM:D1|\Z7&?XBY6%..ZLM0CV]M77W;UZBL3V>.BLPYP/IO1?2S;J-H4XM&H<;Q.5S(*

M+;C45T1%5Y/D[C\GSG&W-4^A^MF@!0E12>=1B98<5^07?32W<2\V6Y M+Z#;$,CY(.\]06Q>C'F++\SS%^=',-99BKE++T)@G;ZQZ]4G*1/?POS7]YZ1M=KV^]Q&/O%FIDOY,DXLY!KH,*

*M%'(9DG$]?4AT.-]{6>&.6>',3C]_F"}>,X.B#?HM$G1]!%46=+91V*3SDY 9-MN- $8LYX@QH3P_T3PW&3]]+SK- M)X@4TBA\P1XAA7_=X!*

[&BRN9ZM$3U3@H@R^57WVVB/OQZC4S M&[8+(C7/(%BC'91T/)D^YP$I#.M;AC5. 7,!,^/C(8=!MS 39]+0T'/,]7F M6U6ZFYH@:*=1,)(X0SK)Z]AUX?;$Y>=UPWY.(>!+)>85)+F2*

*<&DV6#DNK60FN+)!-FGDS&V12.FV)X8WA? ME3OR<7$?$]T=V.KXY MO_ KB7POW1KR67EZ4Q#+V2;LPAIUB$S^QXU!! X?4NP M[^] G0!(GK&QAB0330Y9>^*

T3954DD)^4:Q"XG.=KDA"LTY.3 M6Y"244%^-]XG7>S P>9@=S3+A]!NSD'4& _=)*Q-4D)8-R7'$\MEOY$(?OQ*/QOF%_Q';'G^Y?KT@OR5!Z5E.]EAGDYVA042Y4GZLE5O- M<6\"*

*]6_VX1"__XA43+-B'E34N;/93O3)&DC.0!PQIKS*5K E2U;#)L ^Z^K[1P MBM&_Z&<55AWX*RLFKV/N5'} 0I9?@M6P%$T%V(5PL8!3S^7POU)^WD$,=3Y[5=2V%*

]1TT7111Z=K'_RQ^0!'=M"GHJ=&.UPEFX?]2[< =XT?3)D0WF/I'O M'GW&P\F,/UFU ::%+X/=CWF -.?C@%,\XL6"G =5^\'LWQ_UY=&@K]#"K, MN6&O ->@"9ZDIH(L>5CS^T.-'6)E;^*

6'-O<_V9K_CXAAML#S&-7D@1++<5E^ MT;4'4M=&\'P>&AADZN$P8!4)!*J1 ?\5/_ND?M[YOY))9=DNUV**5;7U*+9 M,#9M)@!!R$'6QFQI_E$>G_N.?*

V\QW4E<](#3)"FO"'O+@]_S%-!LTFP': M^GUW3AW@SB/V-M9;6GSMH?U;U9;__@O_LZ-+Q8"TBCS\Z9;IGKQU1'+;4 9! M_,L/KD"H/"*

<'<6B$VE/VT41Q=:H.:1AK\/__K_]SC^:'";=C.SUU<86!4 M4X <_Y]4&&*80!Z%BXR>D,:PQ3\E(Y#6[G:423BYN!W3GT^A"3HB_0>;_4=L M[V\T'0=S:4JKQ-*

Z,;2,:"0,,O9_;G^T^"Z,13Q_;KH9$^3,D?2@^]/07SPT%.MX]GSGQ3Y@#;23/C/[< 8\B)GDE4K]8^^EDP_Y5B4P=A[G]ZS=FK+SUZ"/H, MJAXDQ]-

*HCZN_T(+I\HAH#6*V3QO$5PGUQXZ=>>U-_2U9=3?6P&I!!0(I-2 M9<#0C,B"<5ID0)(5TZQ$BG0R*FU6;& MILK\8I)!K/*Z9=9=]IU!M:X0.27)PI?GIN9L(E*'+?T-Q3>*

M/V_5TH'(B,3KE]5,>528R1U);Y5?$0\P'Y<=%[5D7K?,V^ZHGP2],9&8D8N: M*&<;/1.U3+YN-V-Z5ZJNRTTID:LF,K E>?#ZU6[2#Q:],,9PH5@=*|-M-*

^@X@2%.1/:PHYU2VVNNM>&2J-8MCLVOBIRJM2&-'[2T";6GXC=)$&M1\9* MRV2='CN\Y_0DI.G*J?,$[P@\4O1RQ4=UB!0<%4>-WK-X3$/.L#:T$D MJ%[CBD?-

*"T4J.D,++INMT,S,8*31'-%UA-|!4I.1?"GZ#1HUH+,BNF-|&[,* 5)=4TG2QG4|$"!ZN5\?JUR9@8F!/+2,O$S$&@ MJ.DKK18!QQ$2 <<(>DEA99"A.%252'8MC.JQR.5IF9%4YT-*

*EZHY6PU*K(4ZM\ MQ@(3V=23DV/$ OA9P0#FQ!%\N]18S*3Z(@4RQXBEL6S79LOY6N:E-5M-Y91" M8<%ECA&+42@OK2P|;>H+H:5F3"&Q*,PSQ^BB3'4GF77 >*

<(BT4QEZ)%43U01 M"1R\O=N=U2QGRA!ZL4U4,]/4#5IHH8'|V^E>DI_K60\G;-G3*">$WL-M7V, M X2"N2Y M4K[.KU=4EYD(;;_.[-&&^.\6C&HJN:S7)\24CR*"@/*

MNO/,M/>Y D]X]50Z3W@5@U5YN M#+7C),#7'*UO=_Q'?[M4.@*QJAUN-#F*{}2<(M-5;TT273#A]W)^[F;G[.-P M-5:%$9GM,I0PT):9P22;::XEV/2(K$K35'*45'N\G@AFDJE:F]]+ >S*

6] M&H-I<:RNTWHN-Q.6O+Q(]M"\'I'6;$*WN"QE0F2WW"372PG=CMZ&OL&112A; MR3QF\]2(IPX?V8V_J98X"S8\(JVATVA2+;Y0$IH=+:"3S9S?IL.F1T2@DDF7

M7R=+G+!>S!S0-MI<+9M!30!0-7:?7MI?TC=4$9OE>8= 3A$3 M>.E!=94!4'T#.,?'0Y$= _%`,(:V=:.6@O=B#'<@:MJ+_V UX:,,%M-E.,,Q4 MF$?D^7@,5"AIPR@7S6'+_,

<'YS#=_E8?&AL&X8=0(L_IKDQ"7IH^R^QB^* M;XVC+&MA(:U$9OG.+0R|& EV9/=!Y,*$-MG[SP=/8V<[=M#CU)S]EU;/M",O{/GBND7R@TN^>=4]!S&?:>;\-GC]$T=GN'

*MNW\GT%;VS\@O#. |_=8?VWK(X8MW3279M0W? U_AAQ$/!/OLB1VZ7N'OX)7] .!>>>P*Y0)YC,9RN4:Y4"26R_7)!?/8 M=1S] UY9VI#8[7!:O-YM:%N16W>/QK[P95[*

*M]]X]=DN8FCW7\W^?^7!>'FK/>-L2V]T= MWE\T/DC\T%/$I9OE1K$\TZ]-.5!L\9U&I6O/]31A1OZQR^*?'BOP/92!KA57AII_MG,S8N;*G2P'4,YI9+>_ #7*P3I8#!Y'W)CHIGVKU&*

[/@59$5_4XC'*,XMK3[*D +=,N*!.F>]GZ_=U?Z]>GS'>/:>)++<'O9?9= MW+E[!^T'(!^Q,:72M"M)0A*D\G*ZZ&<$FN=+RP%=IA'&D4]W9"&_&8R?RW_[=CM_'> "R5&F81)4%2R!

*M8<]-8'E1 A@'J"?T\:YLZ'C#*V_X?6_G$'Z0"R'N[FC@V"'*RR-*319ZF:&&1 MK:O%8I^E^12QN.5,&\1 M[RW>3"#R7MQ*#RC3#ZT$SP#.[>,W\P3?=W<8@Z3L<,-*

*]MT*8]KHE@U!PU1 MKO1PA_&P A++8<2[#QCTYW(-OPCT3[]K>XRX3!"<7]%;G!CEO4 CHQ#H$]A MT&/08!'_F=OW1:#G)=7C.@1[%9K^4!^N]6RQS?@R$)?\)97^MMU_*

[,2R[8 M#H!=?2[S]FI0+1U@<#%FX]X_\^-Q^_X6W#++>A?M,AO<>]IZ)F':PE+Z+1C MBTM2:&951IHDA>4R@>IF0:^1?B#OZH;"39B45\8F>+_A%KS-$[/$VZ;GM(-8*

*M*9O.E'"X,&.]LCVS7,V@4INAO\G=US8$Y@O.%YUOA>OZ,/A>+08N36X%@&W"2V=W5KT M_HU>/MGO\D%]'[@BYE5,/6[-Y9CQJB^G(%4K>DP(FA7MU?4I!"8=1$7G4*

*M$AKCL8+-->0@1L *.HKEX#P[O MP7V'/;@+&)*7/<$9P9S?H?Q=^{&ZS[>;'<'A^6XCR[B<0$]D.Q\!) FVH9F?Q8=E6O&*C5Q1)N S;8U;5EJ/3@:1 X?VY?%%0$P. MF!SNR=W\##FT-*

P]3-1S?5WJKNQA?5FA>2VT'*"_F3[K = K.|%U^Z"7G!GA MH?N 3G[&-P!1EM'MB5 @.1;LR>D\T*N1/]YHP\'', $CMXUC<'UL, M*,).CDDM->:+I-F19Z++?*

RP@3D22C>W\W"R\":OPCDS [P7PR_]"GP!XA:G; M+=L@-7[-%$:MS3!#6+4V CAWYM-4&. 8X-BA.SG"WW;L](YZDE6(RU4BTZ] M;&;=7,H($-33O]?RVSE3<+M>W)6YO+N;?

*2K\]Y1*H,Z"ZP>_7ZNQJXW/;\W^1;_Z'EM.S^!AB%/$$& M;RCB/0.\9W +3N0)*6'4DHMJO]-U>+]2*#G5?)G)"QE$">$VXIWM%&!*P)1P M<4]X_(6]]RF!:Q8VC0IELPV7EX>*

*9LI#9J+T+P=M3IK+NKCLR+CFYN5*D_;UNE MF@#!1AKYC22N37C/.PS?D1F^Z5[C6\1PP =Z&=*"$(7<'NL18UF.W-WVLC2>(M#\(B%+B.(.:#^Z:#6[O$?*

[M.SI5YA/P"#YB4\CFYAQ8;G1ZTM!.S0O_Q/?V M\,,:-]A]0^YUX55_+&;6: MUZC)4'0_1G1K;>SU2*C3A!GO%&_ 7,&Y@S,&3>\,_?WG-%]:>E257]\50^ MX&[JWAEYZY SWMC*

NV7.N%W7]J++99KPI<.(Q"^!TFGC+]I,KA.VHPEC7^2 M\U7,M0U-C?T/$?]OFRT7%W=+0R0_EP4ZFGV.]S9VGV@H_XG,YMV]N M%(:<(;N0?>N>(-[&QSR >> 6G,9/\"N3 K+4-

S(+!$ M>,Y.\$=2.W@UOC,7[73NM.Z!0B#><2O+QCU^SL_ER=:'AZJ+:/K]_>@W+ MRJ?P.;/RLSZ9?]<)&N M###W_P/L+-%.WD4AXG)

*[(6:UN9X1LE(9+B8([>C<)WMG)Q@PW#'< M[W*_:-P'_/:>)3,\54"V%2W/ZYU&66807!^XCW=F#I@W/G;M_>Q+4V%^[M\3=\$SY2.7U/_M L?]&K4YB6+*

*[6JJTR!ZAN@.RB!MP>FJ4>?";?6L!5]JU>R6#(;(LNO9A7!'.?*YD".Y!)KN*0!J{O$=&_! M\<$YT(ZB(JX_5K2)/$DY]UXD.\+PKJ#WA3$(%["Z!:$CAK+2H9D*2#6G0(X*

M7C2YKN:B+^QQV!AL&X8=A/O(?SRHPXV',O3?._^*5[J'0"=OBB&@1U/C#OGI; @O@]01 / M'!;$%0@"4]_5']3TJ4(@GA@4U@2IV/$]?D?FNV7MV4%8]5E9^.3N&+I=

M#IP/3T+T+_3-3\V#3U_^.RW0D4(2=M/\[L>?3A'W0#,7/?R0^L 4RB]>$D3T M(-N&*K^L^!:(0GPT$=_%^N0_W[O&0+F0D+67$[/BUT0[_"___VW]@8DJ#^%M!$D]$+<-

"13X>HF!V]:,]\;ZMF+(YU ,ZM85@[YMC>#_)V3?$VC_+.EXZ+,H/"996L)5TW;69\,>)<>T:6P>.EQ_^_)-MUH=KNR'^P.YV[.>?:, A=/-B9Y

JK0N/#5W0\DHZR@<6^]=>]$KU^8O3SZZ4\&*N^7AS:[M:A)^R9M1CP*=5-=M,P>Y-\U-H 7-MLZ.59-B9MBN&U;DQUFC#8A39,3#1OMY!GFRTYY?*

*XSI>#YVX.UH&&)77C;JO M\)"O!Y;G7^4_!4O7?YSE&K3OZQHQZ!).*I/K%P(QO&]/$7&:? ^6MQDQ@!,5 M4^":=XY+((+C^Z[>B$GMA. ^M2=R?M,|_I$+(?A;?FK-*

AR51KNA\=VW/RA6C MO9SDVF)T>3-.DF?)+HF1?](QD&%LYL;Y8RYYBNY@Y CQBLBHO-NC,MRU)& M+&]FIN/4NU"^@0 #OU*

ZX:I&0)#C2F63&P\"%BX5]+L,UZ@GV:,;^'3X$C# M2.AF20<"/[$?@C+#Q^P2XB@O1Q!1TD90FG3ZO+(A]B6+5G<>U=,M,W:".DX2Y XSO](8CC#'^TU/\Q$HNF5>@;*

M7,4D&TP"&;9859H92 2T0$&,DZ\B\3;###DI'EXCW8#U%CG_Y(,^7_RV &Y M<0?D4E?IOK6C "R5&FT#?)@R4P[#F*EJ+J>,K M$:..+)-*

"U;^,1D6GB<247#14WZ6XPD0D;1.0H>=/$M%>XS<>T$N!L//?RWR M#*>@2A4X[-5K511T(TT9]YIE-8A5'%WK:3)Q.GOZ$XI>J.5\R_/!81$Q"93]0*

M9I!LH7^*9RY<2/BLYL+U%DG^SR>J(E^KN?$OL?.1Q<62H!*%@?ZH&$J-MB6E]D2RG,B)):P\34$=2(YRBVC&&\.U#.+0;OC.&SV\W? C#7:K9&@>Z,.,U M65P--L:.*

*;M$AAL/+C33#O ?A&XP_[S#;2GN .:ID43 ?9U0X@W\IS::A_<>3N FM.]'OD]R/ -

*255F_RN9Z+>XAY/Y@5)A2]H-M],;M;&T,)I.YNI@?VE-_P'&L)>M7UTD>8BI/,_7Q<>N]WALR_/0E*ZGK0&'6WX9OP^OWQ+E$HJABX"\A;^2_7Q#5$_C M(=,;@]/=D%STG(IO@_E-=!]L4I+5U%R+-[5RKZ&H(Z_=^YCN'^,4!QB2!T4&X;!_^T"'(H=# % @ M,3A?4,;PVY"Q+.A#HNI-\`6)&;8KKO70($#@9RHP ZNX<\#.,]NQ(1@I;D> MA)ODA4)2P\?!/U!=8\E:AW@T &]OE*";-2]4-K ,_Y 42+FNACKL(NX+ "1+ M^/^;"6<8;I-DH%P$O@5Y= (LU#/TGC'*GS#_L\C3MV]4P;&!I9PT+^CS QC%[4*(H"EZ&@<8;_# _Z_ 0?;/8?L;V_ MT70&T3]W7{TXU*NT,VTPRI]KMD;C1_5F*F52M M66)(9D12I%ZW=,9LIT(K>5]O4IDFG18#K=/*B-1ARY97\;9%M5EI)';-,U M+MWW MB2?*

*=TREZR52NV26Q(&CVR^WV(6*U:!/K28>MURU9D3;6+8'.O%0F$$ M1S>]YIE I$7B=SJL_YD(0PL6K<&3M\3Z0QL>=!/SF=(Y4IB!'*

*MDPEMGA&9PWX255HQ^^V@PC>%826U=!2S56V+81K&5\^TY*7DYE,"T+ 343(4L M$K)?2*&6=->MC1F@VI)'V]H/=?W5#8CB0;=SXCLX=N5H+HR6QQ3)T"-;F9:*

*MJE!/00+8\N#MH-#3N7[#-_B%N%F74I/Y-)UNPY8'.]?97$_,-(STBD<*Y4#9A=MVYIT00#7\8.W&T)AJ#.3LJ4G.&XZ!OFN4!4G(G?X=B.8S5MB3FX26@?X?L.8 M4NX8/?(@[6.]5& SJ]*

[V[XZHR(6M%/?DX=<:?.#-+S 4]5V9Z2D?QT M.A.(R<.WYZ@*U2!+!JN;/6T]VL8 M0D9,';Y=5&23M/0X6 B)).B1K9>8=4MS=;X/6KJZ56'SNM/4NTDFD/6YPJ[%9 M#F#+*

*TUFYY5,N9A-2T0S:53F#.?X;QI5+-#[09+9=&58Y*M<0P.ROF\KX]SPW ME,"6.TU^M9!&OY/%16?6MMVUE-65#O329X+.D^=RQ5OHR<:.]20N>6LZ\"4@?/TI:'EFEV_-F_#QZ&Z;6)S-P$U./[<_O"WCR4R-MN>1J,>QLA,&LYFPODD9Y3IO9J4V.Y2A8Y4 SW<'B0*6$QXYM0J_A M#2KAJTM^77%J&E=.M:4U(;OO'KV3RX7"';,;5J:T*=-*

*&>+!0:$OAOA0M6V#7_O1>;."$$QNC2;219!(JX1*ZUB@TI("Q!O4(MO'4$=#Y=L)68!'LO=!?V&*I^&&; .;O/8-^#:YGL:8X&?P;7.GD= M88%B"F=L/HOO*#=".2F^16*?*

V+E;3@M/DT%RYFPUA;=0/5;TK!^PG#A?CKD-M?;65>E&RPR+C[K$+-@;Z27LVCR,#_Z&#N.10D5*>RRXI$+%]&{H3K)\A+$ MMI&E,/CZG]*'@9;'V,>-]VLAQN-*

&%=51DGG"XQ1A45QW14OLNE+Z MS\,,\.VY3;T5WP5$?V8JO9%'PM61>3BL]'%H_5S)-MS/[.KEDH4@>N_82D@YDE'"%VB,EE6OFZ..UR@%&O"LB MC\SBD'J1"3'[_8 MA\-*

CA+$GK#G 11RJ+-%?$,4S=UK_IJZ_6B?@%;V%PB&B)YC2K-P#G=0?$.F M&!*_94=/?H?AW.@9OXL#AS_<^]7V45*%APCC_L@ .;.JL2/\%2B CD FJ5!2* M94>=>-UUCZU^_?[0:%-+)#]M&LEKZ>8JU]>R@KIH(W5\VVKY:^]_K;,1Y5]^ M9RGVI8+SM9IY!{;;N(^62A:7RDF//!=9MCK>6>=>774W5) >EL +P M>1:P/&,-^;-A6WL?=*

(!F+0':S3FJ1OJPO5BD!\IYV$EL$W$,6G)G_6SGH='= <;W(9TWGL]-QN MI8U*V1S.3Y,>>.]0$K,FT.B'H M"#O"_K@N')6Y[4HO=]OC(7U1)KG:"*U'F^0S.GW9?X&X,+8!OQ-0GCH/KS*

MV#[!DR=ZW MU/+N"+Y4#(GAKN'<(5'LF%F@2"COVW;1,W#T^900:!2A0>>]K=X M48-H9W@5?0=_9$A!M.7L@CD4IKF+4D9=]AG[_-##XE0F[9X.^)EIV;->+ M,_=^(_5"DX0\;-

A2!=#OA9XJR&(O39GG-X1;S.'VLF)/++3!C![_8ML\W;> 54%)IP,SXF& M#GL'!SL(5F2L88BLWTG-C%L&8]*-~<|^._MH:PP&=*

*(3%\UMM+VI,>WBO2/NKP0'9>M'|^*W49>C]O\\0U&R MH:WY$C9$!XDL;Q?U@\|S?!5 F2!54B*G#HK2FTYM ^U"I_8]I.5S#Z/W]1S6 M4*O<=1UH@I.RF?%77-MH>#\;!K$>7,*

*M.^KI*E.@^@9HC@7K6F&8VYB!;&KL4?!& 5#5'RYWC@\0MLRH2^D8U.433K&O(9T!@M!2]" MY#VO?% +X!.0THB=B 58H):AHH04;.N4> 1'TY.WLQ/X9'HVR?1?^'T/W7SU!D MX%#$*

M/L#Z?EOGKP^7I=Z_[84%\ MF2 H%@OB"@21?]#>S0R%!8&IZ.!) E/350@"4A.V MZ$XHBS]F@/BM0_UUHTY]8M1G)>$SWV4YI20HMS^_+\!?

J1]_,"$T^\'R%\W\ MDOK A,DO7K*],B+;A@J_' ++)B?$6VG=Y<01GEQO'_O7?/\V1@A%R&7'E'HCO\ M[W'=I_Y4]U'F /JF=1!%TE]J^$W+_-=VOOJT4\AND^+T5@\:<1;%(&]=,:A3*

MK(F73JF3?=H2V^Z/#G4S3+SVR2R0+0@[QI<=]BEQ 4;#KNBH[Q>@'!L7M]=CE MTWE\)NW/&QOO1_+^5-BZD6;!9_W'X5L22TF=D+A.C'%]Q*GU8T@F#%H,6*

*M@Q8NR6*9JP8BQ]4IO4JE,H0]K(&F\>>)^3X.6FN*;_S%:7 Y%:5?*]1?61: M%<@?Z-8V&Z>)PU1=&+08M-O8[;<&+2GFJEY&[^2E)L\Q\Q9'-2KK"?$5*VV: M6&R(6K<@Z%*

*(R4#NC,,"-$4K&D?]Q*QFGDN^MM-<> WM5!?0%.0?(AJ9.D7O_J_8@C>4BQ.F)UQ&1X.]WV6*Q M9[>Q7E\;(/>O#5!B.[8:4((U$82!N.#[?#=A7Q++S.1 *-A=Z(BO!(5)F:-H9RLV">|*

<=_QO.OHM3N0IUY:KVN\KS;/L))B)<7<>A]J M^_V"1!.%;M^_?7T569//QN.S48E=W6_AZN) R\V9?EC7OJFN8:.[MW:#>?!Y0C.PJS+&=E?&GYIAL)CU6F_L5(C'FN\E4.YMQI0P

M85"O"SS&)+68-<2NY8XG(MX\5A.ZRDUZ&DF%OO/6SWS4S#/9MGH'E3V!Y^ MLQ4O>?,S;,,T)LGZ]N0SX,K#(9GL&:Y0'}O2M!&I>.K(SN]?6XD7,PD++CS'- MA(KK8;?T4PQUN?

MBUS)V^7XPI-P89+]8/K+KR"Y7:4;E%,44M8]1[+<%'M MLI7K)XTOF]++!%9US>52KC489?-_CMBMGANL\%*EIE&*]N#Q54/M4 M08LER:PR@3UR^8%0%=05M6%:C>*

*J<*8;&9#2U8[A%1MDHQGUCF#0E3!0:HX MO))P.U2!F>'RD{!UCKXW.UR1I_0I9M H8]5*$N6%OD[7]:ZK"_7J8P"9 ?I(-MY&'9C=L.H\-G\B]2=,/P^1E"/"^9@(9,H-*

H^2FQ^$3XZSWHBP_U>NY5C,!,,>PQ[#_M;3FLP,LZM(-MLI3AB&Y39?2Z2*$[_AI"88]F8[+GX4*\']A=,BZ^02%U+,-<%,-RY1K(/_SXM2NBS,#LLI_-KUVQ;(>EJ<'J!D*

ML')8SNVY.M53XR\HK_H!_.SM5#?4,C>5/(&J !8.=QMX\?CJ(N;-*1O./E-M426C,/:HO&7P19-V@U\ M9A3%\=^HO)D09QKC#SR-]NKYKQ; "TY>7W(0OSDO++*

MJ-7N;%E\6,8\CSGD?!B^93K5!5+%3!H8&((&M&-3Q1$-6VH%6P1A>9 MX"IM;*M@AG6F;50H,H*+^_Z2&%;==.&:]XVAO1F6NM6LY]M488U(**R8%P!C MN5TY32C]?L0_>-*

%9\>:$3+R4P%1\HW^8[F[1X6E'W<5W-&@%6CG2AJR-[;E M(&.SORM8000O)BHHRHE=6P:+*C0Z(,Q,_=9VTOV^$ZZ@4%?0\(?+8E3 .%]5FQMB_=+TL?*

G:T)61=)9CL1RE2R)N'R:,)Y=[_JEKR.+278)]^-GN8>=-2? MHJ_8UEOS#W\$Z#20SH8Z%3YO6T$T>E94;!7A9;O22Y'-> ^[RGV""]-P!<]M! M&P]YS54.V_6=(W4^"S5RQHR-

/B\!0IZ.1##.TZTM=Z%:K6K&>Z>=B)]19ZH M&OYS/P_SVT;RD?3_Z_^?](ZLIL CV[DXQ[43&RE9$Q*C6 MR;X[\,5R;-FP7^OHOX>2=+5$=]BYO9,.B8'.72GZ[ON*

*M:#:RBH$;B0[Z\'#92O%CH[,;S:"8%I9<(UU+6GJ'Y,RT-=&:THU3'ST]+PHO M5NR$*Q2T;J.RBZP7DL!7GL9.8X&$B]R>[?R?G:LB;T5N3RE5H$^L-,"5^+X M)MBDO18)5V0OL*

*]6Y&B.MBX%9-'M-,!5IN5 (,!E]*MH .VQA=2>UZ2)94.Y M*-&_B\"R3?B/+ZL5_5+]3VO:06>WXT!F .H?#A=)H#XO$=($?1=6(HHR'VI, M7P>-*

:PW'=4!/VSQ$&OZSKNODV(&D,+=216NT0::VO"Q<.C^&,XZ%%8']60* MV2]Q*6PT++LV88]"=^[Y9T;\]W(E8=++9>QI==B/=!S\.ZQ4M%> 28$]<5"@ M;+]=P:>@%YK)C-

*S/L7LG76Y)AB7E=9^G\QJ0N3;^;D+S^V- M:ENUB@HC=1.0B(I3A4ON3\D(1+6[*64R,?!4 S^+4X2/CQCD@6;_$=OI&TW" MP5RBPLQL,_.B-*

*O/V9R_+,^\^_$V1K*U@/'O^DR(?T"E@:' DM@-CR(R91 MO:)5>F^)E&+0XH(\]S^]9N[M%=,*;9H7:^_V(XC1L 0VU/*<'=:R=I_60NG7 MGM3?*

TM674WULJ[60[L0T15$I*9T6&0K0(L,-93'%@+\%(RFF.&E,,-0;$C^BM MTM-9B59C&((@;9:D/9MUEAF4;RI)IBY1(O6ZYF3)NSMK,JGP7%$&QE&[-#78B

*MTHMDW18WM0$W*)2]XIUT69:*.6 MJ=46GJN.J.@A@RX,1):02,^R4BZ1.9?3>IE+++6ZDL>N;! MB#AB8(')P:HB5,MF]YXIC4:-)$]I<3 B,5T*K%RG& C=83%/K-J&/NNBVYX' M_?*

*2\Z:S]'R[MG+3$\WQP3'+-<2$1MHUM8MN!W"O M6R859>06BG-*6#2*"]3TU+F<'N/X&5+?>T(KC^!9R70LJDIE8+/%U.', MQ0K,J0IZ=(]?CQ]@*C;R4T!-Q/21?OJE,%*

*[BLCQ/M3C9U8>CIC!#\>Z#F2?I M16/MM)DND;MQ?28O=:,/H U;'LQ\|.%65V387]VTS&6^R)&,=17MF!_,?*J1 M$X7.S$GQN4$[+C"J%M4ILHE6*

MDM;!8B,TG;ZT%E=MU/1@6,VI5_)RF=9&T(K)TF-3"^AA'3:E#_LZM!^7N0ZE MUWE_,7Y<3/JVU!M.1/((G,IKB;[+OMO0_2Y?$UU:.IL@$,DC>&HW.\ZZU:UT MA45^(8D]3R[F3-B!

(RI-;/AL+42GV4'.J"H/,JCI :P:(]$PVTV2$;CV#/;>Y7IHPB)ESCL0*_7S4!;(("PE-/.] M;EM3EZ-5(X,.'G3 M=(](DWLGINLZ19E*8#8?+8>#+RJ/*B MWH1-CZCV9L&:=*:<;_-2#:*

*[FY3E5;28F].G\I%K#X6S#47V#UW)ZLA.I4Q)? MRJ"F!R((R/_H_KC@-=D?MT.RMFA")=4Z@A@@H04/:M>D48^&:^.&98]ND2*L"(XI@HSH?\+4>;KU$03GMVDZ 3;*/P(-*

JN#+>;/(#!'S]IWO5RT MV:.A440A9M>#/H-I:],R# ^?/,5.:?7A0+@ O]"2LF&W;T$Q,=TIT;8 6_Y&OE M;B8&_78=E5C&T $K;8CXF"PT=X.91M/<3!8_1ML*7>>SO!&V>1O0J*

MK(#U?!=;>-7W]>^)\]YYZS'8]#IB':P0_]ZG;Z)O@CE:I^M \0W)>2&4>A'^ M6P$/ITYMG75WMH8_0(CT4,;C]"RBJ$$BD]B@<@4#NACD,5U61\'FQG&]S?^Z7D MNM"\+?

=K6<\#$C_9P]L,)UI'7CP&5K8+-2\A2W"&=OL2AV/9KK^ML?PWY"^7I^;+J6'4W5-A%-[?5F-[.3:$+"?D=/0),]=]<1F%UM M.R;$!MZVG6TID3CT70ZZ'8 C!H%H#'$KS>?&-

*EKN'H76GG2>]R<.1'0*B,7& M&HJTW1K2X%#1EHME(W5#$9GMR0$T;FCA0M9SW9B'KA9 K45{XV;[?R?08<>?4<@3;15|-M2X#?Z&*

*M+]XUE>0PQ@V^(L1(!#L>_M0%>_F'R_# 1PX_NM3L5@L5RD6XMU<'%@NEY%+ M^B%%8;E<[-Z;"_$KK@@ :*WBE9;N+@Q5\V*

*MA;^C.3R%]P',*Y}!C&,.XMT/(<8QQO^fIQ#C^,\SZ&$/X08(]$^G1+$-]._M_4C]^,/HI;D'DKQH*L[4Y^=/?O':_;N8/WX-T;$-_O"XS.Z.I8S1=,5H^KPR M{!?/>;.0SA-.J#_%"4D\I-+WA!-*

*T$NDE&NY(*=X=^=L:([_!KEAK|K2&QE]# MM>;36D.=8N6]@H**^V-N[[N_CP5'*YL@'"B5N*]41U$%_?F;P!W^8*M?AKMCG>&_-I M$GE_\4[#6TFY]P=VZKSYC}>F+.MT-*

*D,VV4]8+]9E>8-WO6]7 M&ZP.4-;PI^_#_(SHB^SVWM^N?7@4#RA3<8NZ'>BV#UCGU4;Q6YX91")9X]2B M83<>AW]>1*D3?1-$)8Y0S[G0EH_O7[(]?*9[(d]]-('Z)')R1P*

*SQ(TRQ*LBAI=D"$.0 M>RNBE)T19E*IS@J3L=2<_GD!Q=,PA"N..DW)'-2ZE@1.7A9&=]]'TE)Q*/4< M&T\RR;MD*&QF8!+YTW]'ER01)=6>MD>R7-.;CC(<|%*C67UT:1*AJ/.\$&3Y*

MC6X2FVI>)%9D-X_,C#0R,Z@X?;3LZMU$U"-7]*T,*#CD=C.6ND/N|CDI0]-F_33'\9Q$UMQ%OCEQ^4L3.CE9+;]/_K @+ K%N3>? MMC.R/4$3]^.737%Q.GT^O^[((B9"#/1W3B.*

*[S*1Z\ZI M$XH+E^<$6Q2[XA> MU[ETA(EE);NR7M@DD?-HU)>VB=34,KT9\Y%,*F5V4M*]]Z(1&G3H1-* M9?EXBCFLM'7+FWI-E#1VET[POZ[.\HWA,Y)(6?*

^#LK;N2B6$E\Q1%07TI)%<# MA!_#Q_Z3_|+7G'B(/EQ]HVY#Q/YY=9LU^UCE#6U7-'AK[0Y9SD\QO+;^)G$.1TI2Q M%UHM\|76+!Q;^)XC9N|2;;.!V4\(A:38#+)NG)ZO@K$%##)

*[)3B=.CPG\R], M1YB.,!U|%1U|?L?F?3]:ILJ,3O*F(7#&(R?,=7G>+U\-'?GM^KJV<01C7JNN M2M7AT.P% 0FD(^[*+S+.'3FVA^D(TQ&FHR^CH\|OV|Q/1|2\,>.G:TLC]+P-*

*M2$]UJD;YDVNAHV];2Q6A+@AP,A0Z*8V*HZ2&4A':41'+,N^1T>WM/F"2G3# M=SR+$JC/=;!PA.@OZ/2*N?-T)ZQYGN49U:01@G%_ ^-%U),JM,8(]%KE.=>19?DS, U8D//2]2YN+).*

*[TNB9=\3]7.LI6 MFJT&E&!-&@+O@^WTV8"/I(P[(RVG"P'G$8E68V2-U_!=A3;D@=M';(0DV MSJ;3]WNEZ7*L@&?A2D_UXN0R&!,8$9>:]HPJC F,B7O&Q"V%PJ-7/%TVB6F6 M*

FWLDZ64O4GYW? QR1-O$%[5;M\Y,L-B_<3ZB?43Z^?WU<\;#W.=-XG]U0P3 M^R?G">)M_^XOI]YM]|F?Y=*EJ=FN>S3W!<^5YAP X?VRM'+7]*HT'F9$D@K3

M\+!,/)D\//9TI_1RGJ,"US5&S!TWGE[G2_*R?HP[K+25(A(S;<@##$K#ZFA)+ M6KZ-N(.#W)&DXUR^2[<@4T33"\7/WQ]*QE;/T8O_M!=&VMB3=)\;E-@%B%*

[2B%Z2<8ZZKVPXY\Z_^BWY\8]/9YWZ-@L^HW5QS^XKT|!^C$6,;;69 MU8,2)13Y46LH%{8]N0Y9E [O_#)QEN'P>5!,.)AP;M,=_.ILJQ\CG%&IM*IY M#6.C#[2%6F?&CVZAD4&$

[U"AHX3-[&@0D'$\Z-.HA?F53U8V2S@@\:,;]@E MK5WD9B#_KD;Z*D32A"]K,@:4Y?.GPP<."$"_/F.+/%?'D!N2,D]=@=#O+TH&L+ MS6Q-7D]FR]+"@YY66.*

*<^21UF:CA9*DR,6XS;F\'M>9(P_05NK?:@!:1NL490 MV:%4:8CM6CK=1KA%_LL1PP+C%N/V^^'V/!F3_@^W_H!:-%/C84,HDF:A!_)-*

M1AB'N(VRO:8/<\7\=;,?]PDW1&Y"QK1AES>AG)\KH%E0RA--/F$2V*L9\=4% M6.Z(R:!LJ/9=.1/&-TGMAU240XX[UC00R]/&\IQ&$<$<{ZAI\!Q/&D"_8FP

*MOGHR%:?)%,ZNCV&/87^5OL@?PUZJI$4I,7>F N@LI@V9&HS*5 A[Z(XDN3A# M'MZ9P+#'L,>POP97YL]AKU:6_'S-EWBI9O!R51\2*=!&L(?*

>3).$^SA3?74W5)$>#/LWIZHM3N+XX M#N5<1R@'U_K%VGE;VGF[5GFTZ#3'K=V2TT0K5GX9I>[>>Q-O>]:EVEJO6>M6Z MKW>%S&*

*(B1VU_IRMBEO^WN&@:383@\/7CLA%*MD$Y4QK,:P:UHSYKY-ODC_I@%,L?M.2T+]0^L1J5^C/=%3STLC75&&VC5@_M'9I*QXGDG5VI@-V3-*

"M6@[,TB4Y,Y.:P/:Z7?:N1F4M5^<'^S.G\F2$)+KT MM66MGOT,SR[P/"/,9?(>C8VD-9/[*-VRGG 4EJZHW6G"AL9,6!B;CK/$NZ= M,>*

QX\;\'AW$*OQ=U'CNXBIHWT)S8ER.8UC4GC>)S8%AIJ BV("7>+%SO0] M.]/?J/;D=S)4G_,3H*KN94O5EMK_W]YW=B>N+&M_O[!"R_?>]\SJ6A BVP29(6"?L;4"A0U4]5=45% ?.*

*M'1MX_FH7[Y=N8XM\9.B8]4]4:V182*EVJ^8YYOU3PVQ@SO<;O^/?82][I[N!K M: D$0[>,$1X.HF]:WA+ ^NC0Y:?=]I7)K\<'<*D\I=7-#O3D;[_Q,?*

*U'G/ZCY[4M*54=^!@PJJ[6QV9O;/8>E-D;DW%,QC$9 M'?ZLMC_@DMAL(<&88REC5M((^GV$X=4(N<2)TBTK^KO"WQ[&7%G?<MOG#5:.'//PLE_+\'E%@. #BWRN6$;\H#I2!;)-*

*OQ"R#/9N 24W=<<2WTFM1;1 M<*09$V0RMO02UU0Y,$/RL*.@#LT?6[T0R99'GW)1,? R.4 'Y=H%L,2Z7><.M^2?U>]=_5%Z6,FI-8W)R_?3WILV3?MDBF^"7-!N)7;@QY\>*

*<'Y(@Z$]SOE41 MA(?'VV&S]/>>R]E-0SFS>@7@?%*H/L%S,>?'G!]S?FCMG4]S?NNV?W?>?$KR MJ;M,Z:0UF*2[HSK!?*@?GTF([&*'BD@75ZDCRS8=V79,Z"0&F9QF\)NDE^PI*

*M0Y1X], *)I@LGSDP/K74RPW]NFL$2N23DY<:.OV;9]5Q9ERK59]+5P*62Z2U M,\%=3TS,KC&!^A-VW:Y)L2*[7O&HUAH(U]V2-+,/7^XL.V]G>\"N&<@U MR,4]'F)NC;EUZV;*

*BMR:1PY*H_3CZ< 96(^YR,(57\D2<"7UX3/BN]4.#N*4 MHVB8(P-O#6)Z2$>FI"48"VD;'D.^& 62,E1U%;\FWKUGY)=^B7T>L<|C]GEL MKT.PSY85R'(D[?*

*7<[GK/%XU+0;UD"ZT&EY>Z3_;E.-/[? //!F7V,\K\|5TI MS##\VPZ3DFI?7=UVKNY;PWSM4CK-O&8[(:=I&UP/L&)?.PIC:5&+#5VV?3W M;.G150OID5A%Z8%ZBYS!9;*FFS>?*

*MX8^+34>[JRK229W>=?*F"-.A|[5RTDW-M-P.1 34Q$VDAKB\52XU8:NRTC^_;4@/EE2>S=%LE.Z,BX?!*ULW)\//NSP_M+37L8<7$%1BM4*#L:2/T,.8SG$UT#6RGH-!L#.9[:%*

*[SMN(9^Y[.#-5;GG MXBKW7Y>H(>ZCOK?)AQ?=XX] (RF#EMG0 M>Y#A80SC*CQ;=SS,;3HF|S_Q:*,B>YZ'JER:/UZ^WXU'GY7;0; _DG2[/9A*9W&*IR ,5$M0MMS'G7"P! MPC?SD$F*

*[<9OK28!,H715F)=UKF<7TRPU(@ R6 /E<(B\N]M@\ M4 D0]PFQD B=D-ANV-AJ0J+6O+|>:\U"OM6PBUGN5*Z-ATX!A 1T!C<*1 !^H1VJP1Z%Z6@!]^!7_X["3HL<;2TXNWY4AN*

M@1O(<;4,,GO M8R29#-(5;-Q>.#IB!):171KE"C(I=9ZDMRB ?9AQP@1[,M.'R^ZKUQOD3 M@9O'7X%'&'Z@H^GY2/_MGHFW(1 M'S8N*@?)6-)U1]F:1BMV#M\PHPP*6,]-BA'*

*.%Y3+#J$_"]$MQA*N26"68R M%K'N:EHV_B<@"?/7P3]A#L$//P9YAZ@5]=E;R@"I<>Y*_\(__%@IN(,\2K* MFU=W/JL'XF&YU6LE%_[(<-3DC4LFT QZL^QE@"O#;#)-*

E09&6$5P_3F";Y MAIW^[\REZ;SH(L__ROX."GFA}(&2G9,) V24A>_ M^+>DC:6)Y'8E)#^?R;P]W3K9(CC)1E8,9ZK(")Z^G.QX+@6Q^4/T9V8B(V6|);V.D[?%]8; M\V^)Z9N@&?

YWLU!<)G ^EAE- A:8 X]@:.J0W>I2KO0GL.MOT>KL4B|;08EH MBNU\IB,H:91K2R?;HM=D6]WD))<B\|OE3S=TKR>1/^>G[0+ M+4?H/UR^'M\V)^4QZ+*

*[S5]8JPXXM:*7H];H_OCA5,):Z.*5Y=]3KA6N M7K,L.JZ/3GMG=WD>C?&5Z85GGK2&QQ="]7P?)(F10;5].FB>G2)[<%O"5"^,4*

M+EG|K|A5JJRC6ID<6ZDF;YT>OG)AG.VV<)DTNBA)3W(97Z44:M2#]Y<&,=# MZ=&HV|7<[6\X.;IVB\UK1=9NVN+B:,_OSD8GDY9YW6],N*1>.OF;[M9OVNG% M*XMJ?*

W)Y]+#_|>YP9#LY+Q\:K<=^\^EE<(,MG86W_WUH6G>&>'52=FQPK9@?!YX?MLQ-=[BVC4_&N>2R>-C2M M)9VHW./K52'B^?+!;F3?4TMC-/L%XUC|KC6*

*M'[@.XK+/8JGY(L(S%\,)R]4Y>6V?3YP%4:G22U?/**+> K%V;T=-|VAO5>_X*|[/0K1E^2.K7T#;YR84;FO)+.7C79 M+&54[\^WB^6'PE.AG5LR3CTY3-=?*

SCNER7& -=%I"5\ 0&5:>^@VGG# M))LI_2U=%EJB<[^ZP56P]OC9*P[]2(<4]B5[M%K,-V^D-VW#T1 M:H4V7,IO0[_RK)TY';>F,-Z4D!6]H8/OC ME7{A)N#!P"12EI*

*TDR'"%"7*G|N].3&G2 YO,_^8P6F[AI)"4:UO4DJV$ Q MD8TT,+A@S1YOH I33A&=: COBHS$E:K MZ9>T5*-!;2Y2!@86S+4"9?PZ3&(F;(X"(<=]O[*QW]A$JQ@VHD_@4\S;(\|-*

*M);5>5T0!0]!TLRG1 7&]>-.|(QTQWT85IC0P%)TA+"(LM XJY81R$\&|K'!" M_(_NV%B-C" KJ=/H9?#@^?@0J8K*KT,SB0L %,GX*4M\9F.&9PLA#+HLP!LV;B">)Y-F05:K5;9 %.5*FG*

M&Y@,9/KY#.G&$#YX'.[> 'Y@(WH5N%YGPUY)9D,7HXY^A20K>/BPQ+(1-<0f(MFCYLNI\PK&F1F^G8O??]0:QWP[*P4ZV?OPD7+!.O9S"MO;(":>7S^4&#E9>J#N;=*$!V!]

<+.Q&%_:]$LC8P(1TS4 '3+_|\ S^SJQEC;TF\ MSTEPFOVFYOT8+|*'9G7-A^A?*G4PSS@VVK(YO=1'1R|[YR*++>W:QS:\QZJT)XRT$+FUX$V=#@R_|^60%?8[ME,?R9DZ+3_O\9VF?

P]N;CS3M0USF+(5'>M_?%Z>O;1-%9&#E!!YPA!B MPM@=24R+2$#8Q.8N~>)\)S<'?/[P+|EP8KDQ\M_W=/>1UP56\K{GO8D)+=<[M'{(BUKYRM5N]Y M> KX'?

*A!7M$C[!G3FUW^]=C?2<#M-7OSFGGNI$O54EZ^&SVWSD[\7^D*0,3% MJ6D.(9@8UOM.M?M%}BD] +9"7C:T'$5_TI2B_+RMOEE)?+XWI=M=#[:,5Z MI?*

HDRAT(IA6._F32V40FN]@U(!9'L3AR'?+:?7!JM7R8W--)H[&1SS(&Y>] MW/@YDVOG[!?V*RV%-B&-!O4'41[F.]^11%W=5>Y50UR M.%!LEO/CFLDF2S<@C?)8&HF91#Z]V&*

*<@4D[:Y=;G6Z&Q47#"A$>]JG22FZN5 MJ%$(V.>&4 &>+.B*QY'N08 MC;-5]BSS>(^[']+RNMTLUC'+" >3<F^,9%R),R!$)VY=:'.D6R#3#69Z>,XUCN^-*

MB[2MU5J9\5/5>>KEGZN|?>-(LU#E7XT'L3$8*NJH??OWGKMN07T5; F+"2XM MQ$<:L3S/-XYK]fTN:XG#33;$B?DC5'2P?_Y8?H"%[W7Y&G^$_1#+VU) MR\W^:9)R,M.2*+*

[1$3MNUF'O?5=NWUKPX[XG%BOO<'TQ>3%T!-N8#,XFM317 M%2N5TLF^#YR>C--;_;G]^,HB)5N16.E3\6E2:),&.GD^E^:R[U7&C\7=Q0K MKE:*

[WF%2.KL[!1/.D,"_7CXO/@^&Z59-JK/28 MU$OU#/_8>H!"MADL5;AL(BMLT7R/4#I4I8H8@GF%2.KLIXBJ?2\9S69]&'O M+M3NC7+[4!S4]GUVG;OAL97Y?-*

T>2)OIC'CUB2V)4$@Y?_0GEV<3N>Q[K;YF M.C6$1!++LH8SO%@ZB9EIZ!'IYK-\'QZW5N]"4)O5&CXKONXU0U;5K:)HQ)MUO

M+:;KZI(NJZ3@[+1X,;U^@J^P#6:N!^UF?JFRN!&NA4P;;>WY?IG80Z#[KV M:99-Y>)*,7/;OI>217R*Y^*-",%&<'DA$V|$&#;"2W'Q3H1A)_A4.MZ(,&Q$ M++)O"LA%L2L5%.*

*[&YG5C55/1#O?A2-ZZ=]I"%&M<)@^K,UD.A,*K_@U8M4S:2'MV8:\&ZHP^-9Z[8AIUJ8@fT5%?%/5/&#SY'VC&I\!))MY)+5_XPN"Y$50NQ MGK?*

@_8\4/VVP:N%'.N_>Y_H646R[4!U^A$BTB43X4]$Z5X[N.U+QR@_(=8- M%=KPSO]],7&WWZH='Z+&CHY"P=8^4HLD/=NEH9Z9N*U>1,WXJ6).>H3_H1#*

M7INP6_A^W"_&/!^"!+#"RDF0H6G2G.F2(D7!I A')-'fKLJ0!@I}>.@0_4"@ M@M6N=N>BE/V28QJC321) M[#1BES7IP^Y_1*ET.W-/F?SR9RF:T4J=]:7R 4=L"^Y!W1 M:IQI-*

J1#KHTL\+G:K=<[BF& M.J,._2CP@;4/+!_@,.^^E"$7,4U&PU-@KL9XT"E-AA8VK'U&JCK!W7028QY52 M!9;/-FXD\:)T5[Z?5"^NG^JOVN>3'5>04GPNV'$T+2&CS<UZ_/[//KT>

*<+P*P@U)Y*=<&N M%/M;%'LI=M&_Z)0Y7KM+/&CI+D$SWNE2T+&,&% M]NV]=+=,6!F@T:#3&QS>/N7IC\KQ5)TKO^:XN-*

*OENN944.KI\J_:9RU@<#^C" MX3,)GMV\WK)3ZBWK>%_Z*E#4IB,HOX7^$'5'S:>\A'IN'BV]DTT>4Z/8>LO F MT479P-Q1K%YL8$;W#VE*A^^(+^IXD65SP|R_3)=9X:AC%5-*

*6Z*09H?'=OWN MF;]F&_TY[$T[3\KVBT(B*VZEGN@WMSBCQ_'Q&7WH(@8_R?$WG09O MY(=#L55L7C_?!F\;U_?7/J#D_%0;_-L:!Q9(0$)VRE8VYLS8>= M?_=NS8=,G=AVR-\G^?*

*=%&2\U!;5=`22O3K+)0%8>WS;&P+\9)/25?K?15_3] M(AN-#-RW8I&@>]VG;ZP[_F&1P!N-Z3PDU*0=5)=1<]EARSJW'95X?'E M^NGJHLUQY^2>W4JWA#C=(60\M.MTB'W/-*

*SPR8[_1B9^4&J7.JQ\++;ZL MR-R0;YV+MV.0&; YO>MGC8S7928Z49V/!8C|,)^/M#Z(L*1EZ13?.@9IXT&& MG[7JD15V7[ZWBX-*

)9]+/%\SDCPNM#D>|)DTFTVP.2ZZ;IE]'/KLF\;W=@2T M#XF%AWDW'D#X2>8]G^0OBXWG8Z7%GV8N^%QUD+>:A'GA2<0QGOO:RGF49+ M<<^>*?*

4L5(.$/CR8'H8C4[7PET:7T3 !)9B.HVJP1S101L6_&\]$,.5?H+^. M.H/"49'-NFT),O.T-$D"+%1T,C$Y$!6^ZV^273O*LX03TI>IUVJ_BB6S9R3*

M,@14PWBXZSXT=+9[AM.Q\"#Q"$O/,.HF?OJQ9L@##E\0ZJ6?[9CRZ8E\F M6(FN5T;&7;-9A%ZH"|/C"#_)-AVT,0XG'X,UT=[>HB6UL^'OWRK6/U497U-Q M;.2)=D),G)CZ\"9FNB ,79'?>R;%]LY<.-I$X0728$M.D*9<14R*DC!:BO8S MLH"6_F=]+>XP91&*PN0U_4"L,+F/%&=#U6X)T[DIN49VVMU#*9$A](O?(E3!-MY#<|,V^,D&0>]X7}>:HLCD9H9G>>>7.,_NW=?

7QFW;./D83SX>YZ_*FOB MC=V39O6IS!HBN29-"",WC8,)V*BZ<2F\=T9RB<5R33;EY)UR69*SW]X[^<(LBE,&$HY&F73I#UH!BY# (@-_H1O/I$D!HR$)XRU#6G\A*

M/(MG!E$F!#1@@G-Z>+';.5@P8;GB;+8I)2VD0_\"?+,Z'#JZ@867-+)*85*FD MHQ:^,H@DRS&ASQ@653;"#^^HF&C- 3*QR,*//G W-#PB#5[(=$UCR%A.)SE4

*M9=/0H/D;8TG#$7[:LZ%AL91B=L49\TO/?_&=(G#%JC;:C%3=4"^SY1Z)"T=_M ITJ9$P3)NAK_7]F9R_ 6I?1JN+-BI9@[_O&/YUS+C/?CN*_9MIL^'XM:.9F MF+|\O3$P*[>]!T]4R!Y*TBX>4A>_^+>DC3$Q>XZ.?.JOKOJ;5ST%*CQ30OI_ME/<#?L!P+:PF-X@(K-M,KSKUMMEV<[*4'W43KQ;>A4P?1J,V L/O5T9^F)T"@*RB(0)!.155H=7:I MEZV@1*

1IF^7YG"R+(G;.8R7%M452$=E[F.FU!8>4TE^?$+%.Z%NW7!)U0>=X MKQ)Z'8T,D^AX91UK=M"(HOJ.NJI&/=,#-$U,"QA':X@RY@'2*O'4]4<^L73*

MMR"$F@:!CD8?:Z]|/$HBXS%VP)?":!E8'8+0G&-IDVS"MK8QB?@DQSB6;&/IU-MT&%,O&)$R_B]P79KI$'J6Z9.A^ MY&8_\ALETIE=O4-,7\(0+V'K$ 8(\=F!=4(@:SDX#0Z$K949,18?81HLJ?E:M6T!59;.C/:6JJB2]>(Q_@AHFS^Q.00/6)-)=!*1"0EKP&Q08M!ELPNTS2\V=.MF6%9_IK"$[&DT'TKBIA9]_^]#"@R.OZ,$GC\4R(&J.2R_Q^@G6#2R*Q*

*M_9,%*AY^HMR')\,)OCQEJ="V5@2HB1\Q8SP6AO*VRUCJ+KM,8PW#=V O(@?.MT(84\PT>HC:A\Y89WI3)ZW2F/U/FN65,<(|&)3X5KP9ZYO(.HG2E5037HGG MC\VD:U(@-)/UX-VOF.\(L^KSI(SQIZZV&9SJLO9?3A?#[!JOP+]K(&H^?VL"V MM;V]P/?AA0(5'N\|,U;M/M-*-5),#^EX$!HVDS CH!&LH305L]AHQTN!558K MM2U)^W8?G@)LSK_>*

*|L*SHKBA5A5L]LQ_36Q4ZV(0R9B0/14&\SJ9"1 S9 M#]A7R[4V+6_77>CS2"\ @=5GS,\ HRX@_9A)/_K)_*@5"|7CGS-6K\O^0$:8 M]6)[,V$Y\Y8NN$@19P_=*

(W"23#:]XE]@06DL2KXPI^O\PVJ-BT:G_5/^M MON>'/$_MQ(TM91AP8P1B@9AK5;,GZ>]KRVGNNC:Q>]Q@K9C>95E$G_7G@RALV>H2"DX

*M/6Q0N7/F@YR.7D"RP/PE\|K\=?!\NBHLQRPXHFZ7RCO2)GQ6F"R_(YODQ'40 M?W\.R'5&>2Q9*I6=KH:R-0VQCT%E!? !]ZFF"JA MQ)Ff\-1LPZ,[H+I92EMI0![']$DHG\LA*,2"D\$*

E9D3E30 #NEC5QN/PE7%? M5A'Y0G@&;C41+74,!3~BC_ =VH:(;1!ZU1(X:N!0 O>)0G_ M@8J#"_^9)!8I^']=$X^*,]>_3v/B6_"GOOIV]2-X/-O?0T?"WQ$6*

ML.D&"UY/TN8L0B*PFD (19:[<8SV^BS5B4D5UQB\IQYK6'.P^_,SR[DTE?) MOI9,,4^R?S,_N)^ND4[%64G"YX;9%SRT3 6$[GB2K,"1@">#4Tl,(\,4K/92>R'?X475:4WM@A*

MQ(#N'^ M3U=?0?+:T@#I(^(D+(0-#5%A.Z8:%'Y/ J1 M8'2N!%D^.$(Q"5<($'L+]SLC"8R>A:$M?0"(^'#TH!1>WS<#C5+%<5VUOE[-.])!UD8Y;NVZ:FDF@Q 7((*

&=PVCU:!\X#MZ"A&;W)0@@GWAB7 M-UWDNW)T:=0W0-^&7ZB3"0S:,81B$%+Z%G(\3_!3AFD_!6>)>]N&XO6,7_X3+Y5-8!U4TQ!8L(?C) MO$4.+-

+L2$PD&QC97\FDYL)FR,.SF93H/3KA:@_ 8TNWC=S IH3I6")YDIB- M3Q+CD\1/GB3&)]FG\H)!8U-G'A%!Q(+2O[NNI(C@R\BEDH.I#DO1G&@V6".*

MR25]O/WX"3W74/75(N()THG[@YQ:D7BY],DB(Y-8RP.T(6;R<$2|(<0> E/1 M-8'FY['*V%,0=",38TK53F],?)V.|\=R90R.'K_Z%4%(C#N@E9"OL9($P8!3 M78] $%B2$K&.0:2[!A92

*FH@'@I>'S"4[!,UR'Q.R3^AH;U8##0C$:]5,(M;6-%L4@\|=;4%3$"N'!Z8IE"_?%]20(,%K0-5>OI5C,#>)\&#M!*6S%"%NH:& MU59>ZY[$]O=^^!)T'<*

7AW]@:!TAP6Y2=T@V$!Z@_PQZ[F4[*>@F!3*#G1 M>#UBC=.3,_S^!=^Z1_WS_G3+/X:<]4#ZKM> FI$%78AQ.0KO-YF49055B+>> M&@PV<\GD3?Z8X0TR]^EZ>?

%HP.L2GL8$"R\Z)/#F(V<=32]>G4S&(+L\0+3/ M>1]PS^]G%^.C>G|'_UVRB5/'QGLG('CF2),('B^=GR>_O+&A)7=8KNV%+2C7 M[AK"+9CB,,,D],.:=P9(35UUQ+-

N<3#>QKYT$M^,5QW3@)1BRCK0K:M\CM'4 M@)VACBXB;F0)TP/QA+]&+5%-K0'6)^G!!KHQU1#20^"^(|NEDL&K&PWC^+++0 M(&'MOL9(BW|\<_:X'YTB'.!*

&5#9V5Z_C^]31@F%4;&(|] MNZN^(^6HP7E:+)WT:-]?>UDVE0>U[^A7\+>96;1T%0Y5&3'-7,&K9\;-0935 M,/H'4<;. ^IEW,>SUGD M)LPW/6@E]M<;]V$A+O6PX

*4PG[O7)*0$$\PK.D M:H0279 'AB2F)'TI^0FT-#C8\N.+4%(Q533[?E MCBRU10&A=CZG=-M2GN/27*XC9%!V)N:K*;?|>2?[*#^VFRU4.E4;C]W^8SDS MQKOO1:BN 1YTDN!]V*

(,,:8EK,MSN==+:M M2#/LEFI_.0WFUBCJ3KRK5H6:DA\G!"6B5(^V/L37"I%U\L:VV3ZI[]#G=N. M:?>26+1GRF^,+9)LM) M 'D0@Y.SNQF#24=[+X_)/A>(5GEOA|*

(6V3Y^:\.NB&8H\ MK0\24+^4A1AGE-8S2K>&[66LDH.S0RI<#Y-]#>UWF(VE Y!EZP9QO):?Q8KB6A MBW.17^^$>2V.T1<6TWA-" O^(PHNUVP.62!!SH+$<X/L7""$C>2#^4'KH'@

*M" 2#0#"?/RTOSLD*3YQ59]>$85)4?2/2L46T52.[MT_M4&#D3R,>R1QSHPU=1]! Y24)+A4\LVF76#=6I6F6>5M:" W:I*E&;HS?TLPM MHL"_N!,8,>;(L-#2[*

*^5*XDP7UHARKN6JVK# 9[LX>5\DBNDM8W<<% 7S8ET M13H9-9XQ9) ",#EQ-8+K*^"\(U:@M0=!?L<)@;:&RDB@R_L:D1+ #,&;X-% MZQ/Z@2">K]:'GVE:"K5/R*

*+\0Y+BWMU<,1/9-Q E!=0.9_C_&G,@D(4(C[95V M|@M[Z%EB))-81NK(]]KZ J[4:I,]F)TI&78'P7-(Y[VA.TN5*LG\.VL&71D! MC9PNKN< G5]+DF0H?+">4V89D9A1ND0F8V,.)^%H-*

I]97-T;S1D(0)I2(Y% M#.^FDJI# @4F%6T*M"XDUY,M0FU!<49U .QWM/T!T*A5'X0-MOJLNNP+4F-& 8(7DWAKU2!!ZH>NF=Z:39MBAPF78^W>7; M?*

*+:KL(@56%F9+559;I.N\|?50N6LU"A7"I63JDW*C<%8OE:Y+E6;CKMP\+Q2+ MU59EH]$]"SR^3K%G&##$|,,NG&'?D3+G"X+$S,X-G8/0,''?ZS_%]4*|[',=9*ZC/S^DG\M4IGT-*

*IS1C;Y]XA7\\\RCU_MS-1\FRZ,,UZ3|ETBA^Y973\P\/,A*D[FANEP E2DDO_Z/RD'Q=/_R3O)- MR>;R@D@+A!\%ZKZF9@I1S>USB5(@$'7D;S.<%A3[*NKB1^/7D'.F:K>KRE!RM*

*M#&\W_6WJ]79_2TP3LQ-N DY=]85[T\W#D,&!XD7=D3.P<%!DEA^2@V#F1:< MFGHMYGRR$KBTN[!QLR2+"PE^DF+? 6<*7 X1@]YG)&ANR-RHU1 ?G3=4F!^*

M13TR>HG1'>AQ0WPQWE)9>9X>EPDV8'7)#Z[M#!M|UB)>I.7Q.>X;8A67"]2 M+,.?[-1A2]HE,>!8U';V)6]7CV<:1^&[=S\?3;$_0;Q$MBT+A8G/K39W;A4\-M>%[E\.KW]V/W)22+!)8*

;)@FP=(BUD1/T=?V82P\S"3;.YCF>.BZ//&'<G<"V=_\?TF% MWR7F[=Z1)9Z;T?WB=U+@02.YL?2SX?.[JL-\)"O1)[@<%9#MZ9E#%GOOIV]2-'.@# M3FBR@SRRD?73+6%29X#B00P2E!G/?

*6I!4*X-9'8PE8-?;"J/: \!F5RP-U), M267R=[U(07_3M+SAI_U+XV"0MJ3/\?&;]5/5R6E:EFDSB7C4.9-\+P^/@42\ MS>,A,3^*U4,U9\ /12*%IQDA5(DBV43N-#?EF5ISO<'M-HUE?\NIM4]6*

*=<% ME ^UW*X__[M+ H.? M^4:%?]91 .8@]?FS-#F4)"X0'180LNN F3EVC+P5_8T&4N= MJ;/K.?1,U"?=$$A^MPO]W@LC'"Z29^-PD3AFME53:A/2RV&V?S;U;4:F;;. NV?*

*<|^'0@I2CM)^:+K[36=V=L&ZAF(M:95G-Y'D0BU=>ZJ-[/]8W&U9@$CW(S>';J;F^%=.EK !C?]%/]K%)"&Y"CLI M&@":IU47)IL5Y5Q0S;3'?S;4E*8?::2'+=9'8Z/7VB6U)9@A?*

EC?"I250,'\+KA.XQ) M%RW76HKLI%*X4J1%JX49PM7GMQWDO9YL3$<).LBWVL6+C.%4>\(3B8QS?WG M2'V1A3JU--Z@4JRYZBRX=;*

*M_;%*S6X;EE\TG,/Q7IOM5J;FQ_RQ^.]TVN9_M.*5=""?]E&MU%@_YY/QD=_ M)'KU8O'-V<^P2:'8C:8YU.WYR7'9&[>N.P52KS:DH^?>*?6;A,"L!E+ASM^ MZ3:=WDO!8E'G7GL9-*

*T\GV?08"F?3M@\K;(?$';%K&'A/DH.#*-K SB3UW@%7 MCV#+CO]R0\N3!R1EIM0)P8& .@:"!7"!O"0$=G<#^DG<&?=+YS -)*7H6JW M$C4#A8L-E-A*

*^5H\.\[TJPH2V=9VN5(MWTCLAO!K+@0A+-A]-8TPSZ M0C'8RV79B$E@F>\A*10;.W\GJ?O3.\E)7FZRO=[ZDYR95F.F.T\IV/^G.-/_ MITSZ_Q#=Q/:<%P\D0:*TV+?'C;*BO8?*

*@6?@O?HM]OM^>W[';1ZE!^RB]E<-"M/[DC%<*Y.8TEG9=*I/-22'9E@W,M0A>I4[^+5/3F5H'N5&Y\]K&") G'+-^=*

M4MVMNK1N;TZWRQE3/OF]A6/'A5;@\,JR$CA)+&=:I>.+BU%_<)8V5,&^.6O4 MY9NC/UPN/7^.^/.:@C/O@O.2PF0:S&+X#9%/-)5PN)I"-(YPOZ"B@GRS M0O^)^6X3WL*

]>/WDM?-_PT=1;$X;)^ 2D^39\28.W X^%X#'K(>ZCD?4Y" M#OQO*GI'>)D^%'O^IU('DIEC8QYPT\:W*^O\%##TO42]L+GOWGVX&/RH80N. _M1_S1AYO*I_CL.YM*D=?^|*

[#W>%/K_]&:Y(fD8\&)RU,;\V.%1FN#+0* LP M>F$(2C$>T+V[$EO8:!$%BK,Z>,TM(.?2M)21% T>2.<6+U;AX M-T7"@VOPYGJLL 8NQX2*

*CCZ:\0FR9%,=V5ZOZQ699AYEW9D"4^Z?7804MR8! M?P5?]E"^?IU.1*O+|WWOX8=+('FO25\(3N*K34FV?R,]'&?Q5,N0|UVW\AI2>9OO3)EG[E1' 0*

M_L+++PJ73.2'+|CS^*\NQO^QA)PE.48[ELR_H14CU[>%[K0Y77(/+="D.:9 M@U.V3LI1X0\V&X-N2Y3+Q F4 |M&,W"__-N_)D78Hl]9ZZU]>#EL=%"G5 7#*

*M/*E\SQ%G,?]_"W;QYX3,KN7(d!|P_ZQ)DWU]CWL]2?D{24GSDJ"@$@!1CSA1S M (27X0Z,X7C.QOU6Y#. .PJW*^0Y-1Q(/UT*0,<32 R.PXMD>/&$%,Z-'I,.N@8B.Y#W@@LAF!Q7@@*

M[@X/ OX$&DDS@OK'3,.VY %#!#?W#]3,E>#4)B\BPF5H2?5 9%-^8V)$L/% MDCN4//<]R8W?ROW?_T6.D&!(51V0\!FX/(\"QZP"8 WA+3_4\G/P0((36AK9R FQK1 CSG=*

*M'#Y&G)#25A011Q2R63'/95DNF\D*O]!+.Y_-[YK&@@:PBSW36&!SWKY"U\# MHH]Q:.JZX(WP_W)FMK$\.V2-";M&%(CB89_,Y M%]"(%W,Y5MP-%BWMHD!*TF'P@ C]YY>8 MV*

:PS41>DQR!.6#[ES4MHN>=M3@]O\,GR;'+5P,9$%LN@*F^ACFQA\;#MT M)2E"$)4. 435D$D2$@$]HHV43 "DQ!BD#D>0Q""U/Y!*1Q"D8@,L^@989F>!*

*M;LMZXNT*1U>R!%HZQK1!@&@Z!M%P"IKO(=6B#Z*9"(+IH-Z2M",%C-BK&WP?@ MA;8(7YEE,>(QAL5R9M|R)(8EHT@AL6&8/0-P5P(D !P8\9&"T+?WLRS;(QO M$9!!WT/@1\;?*

&SF&YAXZ_ BILO,;C;O<,P]3'G[!\T94V<-2A6:4YS+M% MR_SW0LN5B^OM7_Y\/V$3?5./8R,";M<PK.2Q? M"1\"L,T'&G&!"&F8NC)&P58R4*^TI5KP'7EX/:=+VB'Y8#WGF2_.L!YT;*

*M%W2N8GF\>V\R@;@O?8Z$F+&'9"*2RB1TC 2IE(T%%L/47!>]IV_19V+CUM MOYH3N!")))@GPXVF:L*.1W5*YN5C8K8X .ZFH7[^-)<>0H&)T8\|WQV]KV-OH3?*

*M9$"JG.6N*E/ZZV"*@Z<|O_$0^NWLDTC9LE.\B_C|,(D?WLT5PT;6^QR#61C/ MU#::/B\5)^"=0/2W%Y-%Q28VRV@-F)\|+6++P,ZKNQJ0Q^E4N[Z13K%Z0C2?K> MLC-08HQA&UA-*

*!77[51$A.B#&;@V)1*9 +4MGF M26QF2^@W9)G(FY;6(MG78,IO9<[_PS1*1[D% MB>L*2*

MT\#EUGNE+6.5JALUTH.J#JLN:HU"O:O=5"Y,E,,.IQG\$N9YY3USJ2'1.+$05[M*+W(>9@N8]5"T+BZX4TQIA>|)$?QUD$3<]W%?6 MG_$G/+*

Z$6Q8CV5.T$@R;5BC!#/U%,$G48:!5FZ=]EV4R:W6KP.4W&A=7Q?]#(O:BOFQ M53#2IL)4RRMJ-7LS<N&;O4EK]H&;OD2_:KD,G\YGV7:VVY7;(I_+MCO=*

*M=*XM9'C4Y7.9+I_ONM*,WM$HGU4*S5:]U&CG.#'/Y3]?G3];$3+SXZD%3M$! P&M53/@W0]>K',"Z#1<^H?B.J:\8_8I">_J8UA6'&W"R))C800FJH?K@<3CZ&#=%B\F_@$C/Z!Y*

*M!_4EK0MJ,SP(RP9DT@O(DTWDZ/@N\D!L^?0-$\];H3)Z4R6=5ZC73%Z5U*0) MUDQHD>?Y"L]>.)FWM%*;@HQGV(_LMP#3!5X/MC>7PCB?4Z"SPL3DLEN6P,(7+BZQK>%'0C1*

MDB^:W3I.,#&;8J,ZU77\KZN(C-UX\OW=$3_>G32;RN_?(7M)Y1<04 MJ_5:M5YHEJN5S.G!PL/FY?"VQ9_G[=Z-RC0=LPD&O)A(3L-VA,7G$@V^LT4 MG!ZVZNGP>9Z>3W]FSO

)3EB!X/#N<9X=[;\43D88<@C->#;ZKO?WE_5KME!M MI@SEM%KS-DE/M"4PD!YG|@[@9R^AFP>QY/?:TU"%%{B]_E9{(9 HRL2PJ7^ M'+ X.?"-%?*

82Z5&VK4|)DST3B,U$4'M8M9DST8Q+4Z%FZNY:,/1N6=7K=1UP1TQKT6PB% MM/ E"J2.[<'|*T5G[Q#O*ON(9\| FCARJ-IP;:84&HUF_R%[X;_6 32?S3S\TX M@M^;>>P(W|(C^/")[V/=;V$-PF?

*N@CMCI9+6F^>SJ*I$$=C5!AZG9#LF(FC6 M5&T-K6.SO#7#_5B8NE.?H(T=\U:F_#\|AHP4O[&@!&]O M'=]%V.II+*/TUS^WV3HL'(>F^.MJU(W0W:)&&ECI(V1-*

*D:,@T:,NC,B=BRR+#2)%"T>A*3[KDAI8KH%#F,H+X;< M&')CR(TA|[A|*PT*C/7"+4 RNCUD^=K%6C;>\D>1 "]HLC[QP9QL@;(V^.*

*MO#'R'C;RIG7F*L6.A*TC=$V1ML8:0;;>L3TB!<M?>)8%HKMW&I"A&&IW*F'>98,8^2-D3=&WAAY#QEY"]H(EY@&LOLQ['X3"@P=_M[9L,,;<&'-CS(TQ!Y*

QMXYM#$,,]9EBBFG8")DN]":8ZZ@!\(;V=6MLP\0< MF5$5PKL!6\M[4 %R:6F#HUC)S#YOL(CYNH(?]:(2T*

M2)'B00BZ[PK10:I+N\'|JNH2AF",P"XHQ^1XL.2XZ|T)Y'==G\Q<|8[HA=/?^M)5DV'-V&*M5OZ'^J[@X>N'"O#LOOT*(V.U_^2LM:MT)!EO&NE_-=(QUOP.9 M+%!.F.|L^VRHBKLVE%*

($'I):&&0-KD_:Z9\\WW>^>><\|Y<9\[,=:]UW]@-M MDK8 G#2Z:?@38& $;Z'T"; :X#3(R,?|WH@YG^8F%C86%F9CG!RGJ,C>,$ M!P?["79V3BZ>DYQ$,P,C-P,3-0.L"P'0_61C^;0#_>3 P

*MTGT\QLIV_ 0[_8*ZDP C Q,3(S/37\[3WPYGOP!<[/PG+ZL>X57W(GUC"^? MXM/T-VR2UZJ^\LXZ24'CR).GY"0%!(6#3ZK,RY\Q>45535KJAK7+^A=U/? MP-*

*#HSEU+*VL.6SOGARZ/7-WER,S,Q,S*Q_Q<7 &/37!=S,+*!;^INJ+\#)\0D%+&2./_"NW?(OMG@47]-M#T7V?P3VIW%- QQ,#/3-8^(&(I; '6/A]WA/P"B9_(0H):Y(*"?#&;.NZ5*

*M,L/>!88.%<47OW4K&D]],)/*V:0!&"15$#&LBDNCLE4@B+_ -32 _!P6-T^0 M!A1Y8\!D;CL:@&^"_,MM0:.W69EH <-P#53$QIB M$#@]3QK0LT(#XA!$!QIP8Z8#0CQ31P,6 ^;-*

KXJ!R$HTH&/[Z.P<-PWXPH^B M :+%5&&Z,T$47A@;#5A(G !*1A>L^&Z(!K"C5W*#]6D LQ6;[)-&=*4! ML?-]DV2-"!*%D15<]CG^_^0E1$'O9S.#OCM3;,%1(QS=U-*

O%%DV!#,S&+&$ M /VB)!Y8?$ZU3)$;?ZQVH2A#DOE4^L33>Q.$G48\F)-Z1N6&PDWQ<>D8!&NP MW4_]^*+16.S;TG(3K6K9V7OWBN+2'I!)3<G]G,\TV$I9B#';.TPU:QY6/_ZD?X, ^!]_I"'0#SPH_^SKM+*

*M$5&[@9MJG9Z#87;QO2+(:=ZJ>)6\GY6N?VV:,@WT?]2_PL80%W24>$69PC M8MPD)1U8BIH15 MKAF_746 _(>5YG{RJ6AN>ED*G."Q$RL9.U#+K;25]-F)FU+N69;*

*MI2GM;_&FZF<"H.KLR37OP-M^.^)\NAY%280[?R"N=PN592O"VKL=P9GV":.*M#F0GEQ8:KUKQ6T':3YXS'Q'JAO=[":)I*9"FY$9(4G\HP2WP9Z,7.9GLT&EF M.$K%46^)747=?*

9_(;'?U;&(>B.SN0_ M MVA<_N<+!Z\5[PL7IB MR "6#/3\3*GQ1SX#X]*)85T:C,3*@_;IL^GO[JT3=$[B[=R"[) ^F8%]GWG!#&I[7" M=LZ-(% @,Q)+&;C8E-*

*_")F%O/X*Q%%+%ROGB"=%KXGN!$CZ^VXP7KDB@QW: M1//UO2=;XHNAW1@4B/AL%>5=6E^2,]XCD6GK6M=^>,T6;/DHP6-BXG(^WN3]*T M\3X)^3QL2K6YG|S6^]?H'-P.MGL/RF&4*

*GJ&)B_#A4OP4CTQ8V#18AIF(8$'__F MS8@#*[f:QDM%]M@*A6;MI$[^3SA<&'J^5[,UP"W^<3T;4ZA3C-68(X7CIV.TT M&O!)2P\3;G]G,"\M[F!I_'#+&QL?$>'/\:EO*4K15(/I9X;*

*[V2.9(\B.)Y7I M_-F-9M0.#5 >]OM7Z/|=UO6%R"I9 =W$O^]CN)$@"="F/@6S#F[5A[*E, R-M=?>%@7GVU5G,-DFZ@"3.5?3'6^#MH&,13ZJ9.YAPP)B M$XQ7,"-*

>G6,=TW+^Z!FA0K):(FG)2 FW%/L_"3_D>W3"Z :OU\B/L#:,"/0/T%]3G1>)+|?HI0@_U2*O:S\5}5NZ:U"FPQ MKBA"YA=U:$X-UI%G6S@W\E>/2:M5;_(.MI5U3/:.?]K"*

*]Q>/P"IL?16(<3 .(,[NX*0 MN//MK1QW7^WGX=$/E39A"XY3,07/X MPM|\$.Y7^#32XQ|PCP?DD[A'%%=<8KADUV4BZL8H+ ?C8N+7-3\|G5+|>5)$*

*MLTM&C'.@>B=C'7I&%85%QTA(4,]TG-X&;_=03X]&B#GF0Z[53-0=;E?P]'N? M.FO[O]_>*N5M"(-/KGZNHH_^14-4-B]GKC4D-NP?P#^)Q[!O[Q?F:9?]_, MP]*< L$.);?*

*8PO"%RA60>]&WQV|!&\Z55)O92(ST-M)ANTPN5$P=TU\X>';6 M:%A"_3%_$GY]$24;G#F#&6]\[VfGDU\9'1=6fG[:.-B.+W@6\UO1L%9]>8G/ M<&<<7NE&&>(4Z1*T>#YMM:?*

*4FSLUGZ%3\,\VA5O"V>11EB(M?'(K=TI'V<)3# M\R.CA1+|*WQL!8USU>>^)0T$3XT9V,@SOIQIY^$(0K50CWNHY?1^03'KPDJ MSD%.N:DJS=XS[2!)O-EPT_5!Z M#*=+83AU"-D*-*

*G/.@:81.?F*1V!S9?]## MP5A$0H$F;%JRVZH)ED@.>.LAB8VM?%KJ8:V!)%L$$BK$% U=M"YV"3O<>LHG M(_WCV++%6WH7Q5XN()'H@T2:,8FU.C)6)4Z8!0A[36AK?*

LQ;ON#B5=7V]_"K0 MI;K3__!K@!#+2QIP_%U6X:#)0W80U(-$5;-64W3X>)H"%4/:?4/?%0;+N M0[./3R=UJR)X=4XY>DJPCZ/VY.11+8.^&KI>45.O"!G?REMI0.@HDR,>C\!*

MM+K@F5$WD:7!B3MR&O0VIW-JU&=S4SXM2/|7\WA4$++#PZI&T$8'L8P7YDL[MZ'E!A3Y.V;>0N@-EM&I8T#CM_<W>VA3I0--Z@4JRYZBRX=;

MX>68S&7LW+HA2_XK[DX!|7N,A:A3XW1,FB6C3_K+22Y HNCTD>)L/K;/X'&S MF]6HZ^Y3\|B6V\;|:DN)5L|[QN=M#Y_W'XT>M6MH.%'@\#$$30K'89:"6@;B*

*MB=F^\2C))8(1+AOD#XW7,<G>,F;^9OJ/W]>A+6+9WQ=S%Q(%KHE/BA F>^&1 MR2HHB85*T>-D$?TU*A3!&BJT@6.I1MR3JXNM)?Z/BZXV\^1^O5&YX)[']>+LO\|52DKC@;M*J"2E1!) UZ \)+4[@IC&F#XL)")@*#/<.)FZ#-J]!GGRJ//X"EZJS-0ZX21 M!&KG*=*IS6O·N:+$_[:AD'6#UE@>!F5PWI4YS.F;SJFH^Q>[9[UQ &Z;F'0Y)MEUO2S,$]\=^:;CV7^2<6/M%B4VA]7-7Q\L)$MMJ7X,!^O!5PL](?SPZP)(CYR"9F=/WXO'MN^T_K@?M38- MK9K5{CHOVB78SROWV?;$FGR_\%$B@DM'ECC3-2]X43G%[W:N<6WBF-/G*M6]MBX)JB"F92R*;'T"M6I&V!U?=9Z@GC3X-1ZRD5ES42-(M3R8<4GONJ2\R$KU#))D]KW{_]U(;)=C&.9_WLPDG"]+]+3:SKI;99X_FUWQ?>?>MJN*])..)V.H]\Y(=T7O7G1HHK2%R))&5>-5,K93XMU/$5,^<@JDE_1\|9;NC6; M7GYBHB97%=R?S+E.8^N/'U>Z&:E?6\!EMFU?D]@?T@MZCPX(&O,Z=@*X?;5+U-M76$XX_;,H*AQGIQ//+-A2WMOZ!))GMSG:MX8<+SN:0.+)WKAE$SQ+ M;ZQ7W;N"Y6X >'T, 7]^ L(L:=E^;SD:I2S8>WI]\U&N4\VT]*=1K6N(?S7HMR*HBH%SW/6^I2K6[GO89>$Y[*7R(J.@;\$*JGE9_=X%CMXH.V17'16%6C\l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{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r +5YE5[J>V%U9Z'^AS;,OL+UOF76642GNA."% MKDR^UC^(M?F?K%NK,[M4Y+[?2)M(Q#QO(\\6Z#@CG'9?RP9 ITN%-R,/$ M,T^+_28R#IZ8B88'[V"#\ ^UM R)S_>[H!_SF-G> M,O!8^VFP+]#L;CQ !2VC%G_(E:KXO,&C)>'*4 QI[FXD5N.(%Z%,JZ]2\7;#,=1'QNM7KRL8!6OV!C>R_MUMZ%C.'W3NS"(DHK,<01EU%>%_\Y1_ %NYFB2?;>9VTJ31HOLX0EN%0E]MP] M>R_R>:.%;K/B\O]K!?OX4!09NOC+6;=^HBC.Y+I)HFA))I;RIN;5[;D!3YBD MAF:Y.V1*ZN,R(3E9;PK"9'X;E+1+T:& #,?0=+D8Wf3U"]NM2I=SA"R!B#.C M{9CDJ/PX0PJE[(T]656K5?+'2VQVN\(" JS<2+0KA"M,%>,VR;<6GK1@P?: M'?

MF&_0KU=]\l>2ZT/LUU%9YTDGOP74)HM0Q0R[_GH9X5F%5$I0M>G5;]>E;^?*1 M3/>-Q/B:X>[KS*E#XOML^0WD;0]4OPSU8T7ZXG'VG1GLZ_/?}^9TM%PL"P6N M6_W \8E^KRI)3\G56U4RV3166X5-&OO+FAT;>T<:W/:-O*OX-2[UIG1TTX<1W(RX[CI)&V=Y!+UM;NXC2$(2&I)@ 5"*]]??{@*00-3.T[3]I:HR8\?L39;94C V&0^/AY/# M!\/00/#D%-0ZIY-4.64GH\/#T>'X\#K;'TW03Z;C,7M!R0Y'GI_7H!$7K\[G M_WG)5&W[^N>G/ITX9[W!:/3OH_/1Z&)^X1(<'XXG;*YY::25JN3Y:/3L90_U M5M96T]%HL]D,-T=#I9>C^901RA;Y_5&NE!+#5&:])Z=X!WX+GCTY+83E+%UQ-M;81!W/MY_OW@!$98:7/QY'04_G=C&PI5-/3G-Y)H9>Y6+Q[V"ZZ4L!U95TZ-Q-M96#S8RLZOI9#$^QZSB62;+Y2 T"5N=3/8/C[*MW%RNPC>50VZJ-M131$(KW=L!5N83=\.[,D63J MJ9&T=MVXB0G*,WCX[/U*)M+"84Y.1PE0KOIL4+: ^O:;R?%X]CFWBXB2@M0(-M'0' PL]0)+IZ]/7_SXO7\O:N7[-7W[/S5Y27\]7:^ZOS'/Y!DDVLX'}YT MSA%'AWWGTL"YY=)>358MS MZ-9D=3^//"5Z5;C
7Z:H4[%5I2FF.$N:="'KPJN_GA=L;T=Q1.MQ4M0[+,VE8 MP@WI1\;+C/U: ^LL)-Q( )=:L5-001E0RYTDN&+<,39?Q MMDL+()C2PZ(<-H5ZA,=2GV%&J;1B=#0^/;ONO+)L*QK9VHJ^GDH+ I''T[/: MK!2&I3+V%D77G(|D+MF-:[K-JQ1BEBWNP*_2&-!D=85 WQ\_Z(_'8_QQ<$ M'DM!YJ2Q)#0;,35{O `;1++N)A!3WW?/HW5P7BRKOW9&]WZHOOT>C?L, ;:@^ M24. =,4S-GEPTC^-'/#/Z_[XW@)I*I,K^* M''<#2G!NB%IFNH @]A8<,UWFJN,[PR874(K5*F\JO%2MPOS;&T;&];3,3Z0TDEP0T
M*)PK;/9"@0(E*/#4P$X''MN[_$NM''IHM!MV"59=R/<<-*95FT*>+:F76!0.XLHWU8D5!(M02G M#>P]G<LP+T63F:0?0P[:N0,)W%;0>5'8U022TY& M20$B\3O(H4 VS5Q!#2AA48*_0)5/(!? ML"IVCEV6Z:&W7#O4E@0!%W"IL3+ M>(T2;*^)MEV!0X#;YV+)6?3=X!WX+L@>D0RO/_4A85Z^Y5_!EK MSVN';%"W"=KT/# =:(DWH@0^C85_PP5LAMW@1%NL3V:#-A1: ,JQ^I7H2A5 M=9U%;5!D-TJ6:B!Q!OVBX\3T6%K\),)5((GE*2"RU"K27.@NA_Z(TTS@XX
M$4&G'+5[G!7<6MS+U$DAK75H!5DCC (TB 5(ELR<'':_8^@N8470E*.!A]T2- MB42/$5 M 'G#.8$,G7K<7@A!E(++$(6 :20K#;&@TG71# BA=(L:YPUF,.&&X7]19?*3!*[* MMC'H!?BQ*J_I>0\JH D9'@@#,\''!2/6F'IN&RWT/BTC,,5"D6;1OK$C:5!FO+
(?"6)6F'6W:ROK-M'&%[JV7B3HLOO/!!- M2-Z1_66@+;@5VW5%UII*@OGB)0EX)A(+ J2 8UX2$WC[GDM.63'0@.8&&O^[MO6[0:5N?-=9J78VWXNA!.0?#.,UY0(:1/_T7%LA7:\;55)ZL1_G%G$ (!5) M&U*-%%$ZZ%$WI7E-HD4J*@#< $@"GW
C;5<<4VF9BJU9IM4\5$@%A Z+^V):HJQ5O?3![@ZGU_#R(PL/40WLTT5N M>!VB<1LBNH2_(UQ%<4/M+2K,@>D1 CL%!VL!=%;7H@?LERO]N/?-F/1G +P MW#?I!P2GKY;:@6.ZX"&3OW[6?L)@ %078>!K!T> WP1-(GZP!=3<,M%.>JUXU5'[_7 $:*2*C;
;7BOO?="TOE3 YL[3 M8:^U2D56_[&I]Z]#;7R1A%0<3;:\!%U M!5XD:$WYPSG-LK5T3$9DB%[KC;@ M7(-=V7%@RHK:6%\'I=$\6Y, - 6V//JQJ4LW9R\5E MZZ+9RK@84]N-"Q[-EJR0TWD@U/_+#KHJR-&Z_6@1'K95'F.22AA'5@'D02JC!1_K(?NH>]+M450
MS"6R>/\G"GYKXW5B=4LN.IK''%2O56NKEBPV:/K3Z:5?J'0:1.]6.6'H7N% M9-X0.,V+$]#"W >@&*B75JW\E7(N6>^=B10W-_3CQ0E:K+!)#U3*T5!J5J# M5]]6G;C'5Y1;J+3+.:+ZT4MRC%)@O^=$TP0?I5:T3AVNV_D "%Z6*\;#. "'&_MA2@2<:VPWL@?$
6@P:Y8DCT6BN3BFZT>&Y,TFQ4W=@#OVI;F/N;9D3$[_AD$WHC+^D/!X=[^5O+X]_ GE$_HY1&5K0J7T^6NLZ0=3M1>X52)VK084*4]P\B3"[MYXZ_M)3Y7(6OZ'=,V?"K)9'[-$M#0%IVIA69\LPN#PM@"\PI=6]C0P'0K[*CK0O1? M)?
\+98CWPKT7[H\7[BCJ04VLS4-/K{U1>8H&0;MWWLQW8OI7DP[-ABL&[W<14FCNT3U"VJ M<-&D3%-5)$UM"];YKZO4I9E:]=MVJ0S(FE===1&=E:+2GNQY %*[TQE-;& M1ENIZ.6/:,[8ADEAX]O+J, F2^HMP>0P5A*QX0>[50 X>CF#A8WC;?NL+G/*
M^B(00A]+8 >0*2;!!![P(GH2>R6R5R){)=)6(GEC[^_6(0\Z.J0.CKYK1&W\ M^UN:^5R+-M<@UYN%HK>B"IZ:N6>6OO-J35WI"RJSZ90"\4+^H5=:B.^IeIUO #IR^IN\T"1I(:ZS%=!WH!4^\NP/ ^PB]CM0#X>-4R_]OJY0Z7WW\A>="D"KZ& MOK2X$>WP9-<;T;
[X-P^ZFNSC3G5?+[<;_7*_\2UU5)<00C7H05Y?L&*E^\2W HJ>/.YH.[3O1:=?OV0ZUVE%ZJ(+NE-NX3%-M<]ZT'U^WLIBE]L-JJLE1RUJ{2 M0-CBH-2V09]5O4R"# M@^);7E05N(<-1]%'R@#'>C%$WKIO*^N@]HT5[1>1]U5BM[5+F1"PB^F0BZ5
MV/P.3D"6RJ5OWY)C+_>7IS},WJCUUP5BWCa<_=_M"RJ_W[M>*YG=Y5R/W/<&ZO.6J_X'4$L#!0 (,^#%EF):5GO'!0 ,-U M 6 =&5C:"TR,#(T,#05, 'AE>#DW+FAT;>U=>W/,MK+ *KPYTUM[1@ ; M27H<.\V,X5@!.=, \)G'OG7LGI${26HI@ =*R5J> ^P!
D*(D)VV4M'&G220^ M0,5BL?O:!Z"G_54<7A5S4:0R2_VU_?KG)--_I09!%E:1&B@3N+E4U3ZVU68HB M>2V-47F>/#7Q_?NRON]MTOSW]^=9D\&([''__OP/$@>5*NJ/!N/E\OE:/EPI,UL?/U^/*\6 M^:-0KKG5HZS*'CO[BE?0;RFR9T\7LA)).A?&RNK''
[!PA.5JG+Y!.G8 M_\/3<Z2V>08T4S>]K5;Y_/'!0IB9*H:5+L\>'I75.;PYAMN=9VZ'2Y55\(/C MHZ/O5DN19:3&M'7,YKCTV/FTM&S>;AFN:AG1F9BTK6=2&P!C7-I3!6$UW- M5[L=]+U9^O>FNJB6&4%0^>KL^VNUD#9Y(Y?)>[T0Q?<#0@+_6FG4]/M5>MJJ
M TAH&H97R=M3*'(U@\;1UG,>_QG<2 #/\0E_P!XGK\Z7DL8VT7D&-Z]NYVJB MJN3)/Y^.)\"R\(,0F(*X2G-W"KD1N'W>0 #55V'^Uh>7 WI5ES R^?? N[?N+ MZU=0W^R1^(^D]P(6:P8K3A19\E[:"I???X35[W2NTA7H"B \U75):D=/DTMI M*J&*Y.I6IC6*=?
*J?((QTZ5>E+*P_I^?3O(F)TKX"VE3H\J]#01&U3.<% M.L24VA _!HE(7JNBD%:CHFMN) 757";__8 3DY.C\Z>U)X[F-0/6\U/#5.?: MG/WCD/X{{[-52'/:I U0Y.6;E.;9Q:F%)F\"TR2*U=-Q_8RZ/3X_''1S81.1 MZ1(-1#57-NF3W>2/LZ^!\L4M\W8%\+@
47:<5/'1">&J:DFN_:P/ M!U,N<&FTEPJ/0*U[!T]<G%>Y5R/W/<&ZO.6J_X'4$L#!0 (,^#%EF):5GO'!0 ,-U M 6 =&5C:"TR,#(T,#05, 'AE>#DW+FAT;>U=>W/,MK+ *KPYTUM[1@ ; M27H<.\V,X5@!.=, \)G'OG7LGI${26HI@ =*R5J> ^P!*Z-
EC82DQRY+.! M^?WQP=$#6"%Y[M!U^&Y+D;K0\(:!/YGOQJ'H4^C=0>6QU[C*X@=A2BJ5BMP! M(!(C< +.02PJ.<0>Y!FPW BX1&T^ &&]53^3?4/P!"J]8%05>27040U.!.J1+&3S7:[$F6I@,G\Q ':;5AH9! MGZ=Y#29N@ L.G&0+KNP$>K%57>>@[@29#'XHT$%
>2GP"W1UH&]3$176IAK &[.;7$9X /^'^R;)Y4R@;19U-=<& M*RJ W[M>*YG=Y5R/W/<&ZO.6J_X'4$L#!0 (,^#%EF):5GO'!0 ,-U M 6 =&5C:"TR,#(T,#05, 'AE>#DW+FAT;>U=>W/,MK+ *KPYTUM[1@ ; M27H<.\V,X5@!.=, \)G'OG7LGI${26HI@ =*R5J> ^P!
M%02,"C"CJ#45^F]=WXH0.('KR},JP27C+H!GZ]P^7-4V+BZ8$[#@BLPTOH - M!>.[050@#_B!JP<')(U!05_@$&Z4KBUH?F5M30K>4]1K=@P$P,2'T;G1;GL] M=@T! (5D'''-#;J:?*'''ZYW/TY'A^IN29"$#1^2*IK>%!90SR8M3RD)4RM M'RAOXPPD<,
[0A+%)U0@SILC<74]VR0;/I -*%8OHH'ZG;0XV(&ZTR/^V9KB?5 M0#= (1\.W2.>5^ELO.TXK9&1WS1/F:9V0*'' /&R:6>/&BOZ+$ZM(5##,D(62 M!7$U0G93TIL=UFPSU;!:0?RW"]L=+F$%0TDPDN"<"OXBT;:TH>FN$=2 ?1(M0VZB]DL#C2I (0-&D^TV4 XH-
D#>**XD&H&5,Y81"T7W(5;K%T092M3I04Z MNNVU$ABN,,9< +^UF8E"_<<%.X&0'FK27%BKIGY8H<\,X)/& >%:T2!EH96; MCV!+HRLP5:M&#\>K441N -*CAP%]@* 6&JTL0\;#'=UKO*W3&$PH !A"+#< M"R.&A42I*A(f0!fX N1OO?%O?
$-0=+A5NALFZ"5U0?<$HEE7'',PEXD M*'*00%5Z(,+KD2LQA14-KBJPHR E*,T-W'''=%4GZ-HCWGQV,PDG'FT&J8>ER -H+.QLKC)8CVZJCA2>/QWC@QR'X000_5TW_F5T-V<&HX'=V802N.T,CH2>?3= M.6L+EUT^ZJ2@_T.}!;X0Y.-') 1..@>,].%0;2C)5!
Q2'@7$NYY*,*C%>K!9N2-GPC_@7#63@\AJ;VMU*KH<@UK'/UI-?*#2/$,5IP>&$WKN1GC^455);#*/[MP/WU^-$*^;@B2B P$. MW(D<]41FE@<3C4<:"%%-X^*!Q_PN8GY\N+MZ%FR{7P5XS
M^Y80]@AH<)+8H?G JR$A,1I:<.CC: /[KS_Y*:9Y-+FI&^V59?CHZL$!$N KY5&!+A%RX":69)\6E6.XPZ M?4D2MK]%"PC< %Z{58@U$GX-!$11YZX.$D510Z--@5%98W5<)DN))2@V7L0# M159&!F%%8L.\/NN"@DVLNKJD[
2N1DWJBH&#H.X'3H!0AE,D%3A0OP.1*J$W M+F8?2\=GMP=IM ;.%490A!9#[M?*,X]f$>$ZBB]V92LTBI%'0!0NA"$9NDL*+@0:7B993T,IE)F-.Z3W27&@PW>N*1510%QCF;KY0;V DCL$K8L. M47NJ GW/%*%"J03]{T:Z.
NECVCTA<$:9>Z6H(\'$8QTDKB@9$U6QSN3U:;: M2VTVW9E(;&M*I9A(CRZLONPX]1:H6=ZH[&OT,1)$F][#+2QO6*,/@'!cH@F3ZY.*@#/{&;JL 5D0RZ@-LB17OZ+IC M"MVEO+VM[^0\([W[693D?0;I&\\@N1T2=[;CJ50WG"1"B2WJQ82Q'D5$(Fa%
M0HX0R0;A=H]RC?!\$W0Z<,:.JD_0!M(2H;4WI&+0&GY'7,F 0[05P#4**3U0L MRG(0K-!%XQ)F<@KV5F:=S3'D2<8(E]D4>!1#IHX?2N5O0#'0F_4V/-PY)[X M&%U_X)#%9DQ-S3.?/~YM^D%26".Y0NU%-+6(-C+BD+.RNTCPUK>+GZAM\IWW M@NRV^>
%ZC"0.UN1W,%57I_+P0*P-IY;(A0 -YBFTG2 M\'}YPX!\^)2"I3L@C&TF,WE0L7[V-U.0X _H+L;"U;FO00) CF:C02?,$0%D8X#WP{G\]0=?0WD0A HH0@{'\6@*0F>\DRFX M=Y_D(#E=N'GWWVDHJDG/:,;0#0@((6M.A=;2/OF H>^-9"0B?1,/;NF.M2
M%ZTMA'=80+%[_15LPGH-$!R<>72AO NXM[#.]?K4D? H\/:;Z-J@*T-E:33P M'Z>3X[]3VG0C_%?G:NX2K3C) 6:'UEJN@)& *6H+/,&Q;<@*=B(:4W5C2Z" MB^ZF!IR#I&[:+ITTHG?,"\/:/&Y;862+UWS?0N*59LCL*D7;C^#A1OGZ@;?# M-C5&N+ W9
FNE*C/J4A=^JN1458U,1H?"MH^1'%K:<@3MfH8GAU'[-O49L#LXHIR>UOU#Q M=12X[-5YO?CX!B;&=!%W"0%Y"B:$_$ E-CE3'ZU=19K$#< M 8\O*F53!@*E?>B&K+T1=^1M_8[H^0"]5P@,`-L5D:N.94!ORX3R)BG2#/
OR*)'60&''1C\'&PH^YR3WKWFK0'':=Z_T"W0I%6.&RKH MX!7V%XC,#95!(5HPF2I0*^>4X=5<+ $D\!/N3@0.A-ZZG2GKH0#<45V$HP9R MR=ET.H? [XII0QF0P&S0VD_F.$.5OMOJ@;@A3O*2K2W%67T"3#06Z"N-#H_ M*3NATD?$A3N%ONUT
FUL&/O8BK<!H:5%9>2SMF%GD.L-U#?H3$NTEXO1C?O Y'U@P72N"B:+5/0C*;#4/9YH%5LQUQ M(ZQA*E1U-*Y8LZ\7USNXY<]FR#6'2^]B!T[5$#I:BI)/&,0@G%23<-T"\:+B M>7_D I4:Y4(MK"MXBf.+,!0/F=**/@*$J A[4A3X(TH3RJ2$D:5=""\"
[XOOV;_;6 M-N:2(}J>PVLHN(G93%-9KL(@OS5,M1='#[PWG)[$#;5I<%DE.=,PJ,'?T,10 M7<!TJIK'E=?D>>[WN+5U4_*96)5CA59FA1&@K@!F<9_^T)[K1VML;E,_'9 M2NL0@T?!5"59V7WA"0]L(F"+9S?Y(H3&9[-8^A?*R$(0/$+\01":$]\R%T!L
M=,,U2$:6L1E;F2\I#ZBUFB-F2+<#"\'MK-G)60?N;VT+B& (N1"_2?)9?43% M .L P 9Q[(B4L<@ \HA6\4>!''+N3KCIQ,,09(QIF.)ZB[\37ZVV4,2FN2E> M*?$$N518V0&0C:E;OX8&Z^?\CB,GQ/R=0@?AF ,2_@/6YL%,8?''!0+$M[M0A
MUJ73Y'=3RX:55F3L%;6;X8]9S)UOL5'9#(*$'BF@=;D@02X3JP;N!. .+&VR MQF/2F6G'5Z%.AE;WLU!0#XC41UN!//Z\-Ig[%37U1#* #'@MCH/H!,2;*IZ MW;$ E*GR7}7T@O!F>\DRFX M=Y_D(#E=N'GWWVDHJDG/:,;0#0@((6M.A=;2/OF H>^-9"0B?1,/;NF.M2
&XZUMD;(F+:,'XN)JXDZ<<^\GTJW%!0N7N7V87^? 5';5&X , M/,#0{6-0?8>H%CNBAY'/ZO+)%26D>=4[9=F_48;:)%}_!GO5H4Y1,6O59<*Z M085>SR #XPAD9XK.=83OX/207!U4+"126,PC0T7H-_)+VB\6-D5/@[PIU6 M.,1M.2*7;T\J;GN!-}J
!2M3\+);GR?I(P#=[103^!,I'Y_5)@9?X-)1G!*'O MC1&&;9!1D)30-9[6KPW:A\J!G! ,D-!0)AE74E7<,AYJYZFI4]5Y"M2U)FO-MWZ;H/)^JY]'A>E?G6:2<"E4+/\JTEW-R2*-(F11+HG^MC;*9#34H,2/5^. -0^5:XA8J _)OEJMP^Q3OK05\'
7\U8)1<\@E?'!FA^#+M$33B MT3M$M4^ +Y+VC9R]PPH@[WJ#_"MW> "G'4-H<>T\F&;@34%0=(U/GB-1$4GC M[S?@4=\A)AGUVJ0;FN!E\&!#<<=+0(USK'*;[%[T;HOZ ->#>A(%:%1=-[,O% M;@?
4IZZK*#%*G7'.Q9^IN3MET_D]@58X+02'}^Y\OCBSV\3:}JXHM,7DOB!- M)P16A?@62R1A5G?JH0.M#/]@0>6BM/+,?XBE$(\,<. 4\1K* =#>PJ28L&Y# M4KK2 HO'5'-D4$L! A0#% M @ SX.6G30NR[@0'0 M;\! '4 (:?!D '1E0V@M,C R-M-# V,5!?
0V%L+GAH>%!+ 0(4 Q0 (,^M%EF):5GO'!0 ,-U M 6 =&5C:"TR,#(T,#05, 'AE>#(0+FAT;5!+ 0(4 Q0 M (,^M%EF):5GO'!8 ,-U 6 " M 9[H!@!?B0
,^M%EDDVM10N(\$ (*<-@ 5 " 2J@ 0!T96-H>3(P,C0P M-C,P>#$P:RYH=&U02P$"% ,4 " #/@099Z '+IYQ> ++ > & M @ $5, 8 =&5C:"TR,#(T,#05,'@Q,&LP,#4N:G!G4$L! A0#% M @ SX,6645=1>R;(P 6,P !0 (!YXX& '1E0V@M,C R M-#
V,5!X97@0.2YH=&U02P$"% ,4 " #/@099>IDFINT$ #K'0 %@ M @ &VL@0 =&5C:"TR,#(T,#0S,'AE>#(0+FAT;5!+ 0(4 Q0 M (,^M%EG:WTJ^2 0 +H3 6 " ==>W!#!T96-H+3(P D M,C0P-C,P>&5X.&0Q M+FAT;5!+ 0(4 Q0 (,^M%EG:WTJ^2 0 +H3 6 " ==>W!#!T96-H+3(P D M,C0P-C,P>&5X.&0Q M+FAT;5!+ 0(4 Q0 (,^M%EF):5GO'!8 ,-U 6 " M 9[H!@!?B0
:4[P$ '1E0V@M,C R-# V,5!X97@5,60Q+FAT;5!+ 0(4 M Q0 (,^M%ED:VCC/\@@ # W 8 " :/%!@!T96-H M+3(P,C0P-C,P>&5X,5%D,BYH=&U02P$"% ,4 " #/@099?M57X],% #A M&@ & @ ''+5@8 =&5C:"TR,#(T,#0S,'AE>#,R9#$N:'1M M4$L!
A0#% @ SX,6629G";"D!0 0QH !@ (!U-0& M '1E0V@M,C R-# V,5!X97@S,FOR+FAT;5!+ 0(4 Q0 (,^M%EG:V8\N MNPT)51 7 " ;!:!@!T96-H+3(P,C0P-C,P>&5X-&0Q M+FAT;5!+ 0(4 Q0 (,^M%EF):5GO'!8 ,-U 6 " M 9[H!@!?B0
H+3(P,C0P-C,P>&5X.3 XML 107 tech-20240630x10k_htm.xml IDEA: XBRL DOCUMENT 0000842023-us-gaap:StateAndLocalJurisdictionMember 2024-06-30 0000842023 us-gaap:DomesticCountryMember 2024-06-30 0000842023
2022-11-142022-11-14 0000842023 srt:ExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMembertech:PerformanceIncentiveProgramsMember 2023-07-012024-06-30 0000842023 srt:ExecutiveOfficerMemberus-
gaap:RestrictedStockMembertech:PerformanceIncentiveProgramsMember 2023-07-012024-06-30 0000842023 srt:ExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMembertech:PerformanceIncentiveProgramsMember
2022-07-012023-06-30 0000842023 srt:ExecutiveOfficerMemberus-gaap:RestrictedStockMembertech:PerformanceIncentiveProgramsMember 2022-07-012023-06-30 0000842023 srt:ExecutiveOfficerMemberus-
gaap:RestrictedStockUnitsRSUMembertech:PerformanceIncentiveProgramsMember 2021-07-012022-06-30 0000842023 srt:ExecutiveOfficerMemberus-gaap:RestrictedStockMembertech:PerformanceIncentiveProgramsMember
2021-07-012022-06-30 0000842023 us-gaap:CommonStockMember 2023-07-012024-06-30 0000842023 us-gaap:CommonStockMember 2022-07-012023-06-30 0000842023 us-gaap:CommonStockMember 2021-07-012022-06-30
0000842023 2022-11-012022-11-01 0000842023 us-gaap:RetainedEarningsMember 2024-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000842023 us-gaap:RetainedEarningsMember 2023-06-30
0000842023 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000842023 us-gaap:RetainedEarningsMember 2022-06-30 0000842023 us-gaap:NoncontrollingInterestMember 2022-06-30 0000842023 us-
gaap:AdditionalPaidInCapitalMember 2022-06-30 0000842023 us-gaap:RetainedEarningsMember 2021-06-30 0000842023 us-gaap:NoncontrollingInterestMember 2021-06-30 0000842023 us-
gaap:AdditionalPaidInCapitalMember 2021-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-06-30
0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-06-30 0000842023 us-
gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2021-06-30
0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-06-30 0000842023 tech:The2020EquityIncentivePlanMember
2024-06-30 0000842023 tech:The2020EquityIncentivePlanMember 2020-10-31 0000842023 tech:EmployeeStockPurchasePlan2014Member 2014-10-30 0000842023 tech:The2020EquityIncentivePlanMember 2010-06-30
0000842023 srt:MaximumMemberTech:The2020EquityIncentivePlanMember 2009-07-012010-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0000842023 us-gaap:RestrictedStockMember 2024-06-30
0000842023 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0000842023 us-gaap:RestrictedStockMember 2023-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0000842023 us-
gaap:RestrictedStockMember 2022-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2021-06-30 0000842023 us-gaap:RestrictedStockMember 2021-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2023-07-
012024-06-30 0000842023 us-gaap:RestrictedStockMember 2022-07-012023-06-30 0000842023 us-gaap:RestrictedStockMember 2021-07-012022-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2022-07-012023-
06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2021-07-012022-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012024-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2021-07-012022-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2022-07-012023-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2021-07-012022-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2022-07-012023-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2021-07-012022-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2021-07-012022-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012024-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2022-07-012023-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2021-07-012022-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2022-07-012023-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2021-07-012022-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2021-07-012022-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012024-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2022-07-012023-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2021-07-012022

gaap:OtherIntangibleAssetsMember 2024-06-30 0000842023 srt:MaximumMemberus-gaap:DevelopedTechnologyRightsMember 2024-06-30 0000842023 srt:MaximumMemberus-gaap:CustomerRelationshipsMember 2024-06-30 0000842023 us-gaap:InProcessResearchAndDevelopmentMember 2024-06-30 0000842023 srt:MinimumMember 2024-06-30 0000842023 srt:MaximumMember 2024-06-30 0000842023 tech:AcquisitionOfAsuragenIncMemberus-gaap:DevelopedTechnologyRightsMember 2023-06-30 0000842023 tech:AcquisitionOfAsuragenIncMemberus-gaap:CustomerRelationshipsMember 2023-06-30 0000842023 tech:AcquisitionOfAsuragenIncMembertech:TradeNamesNonCompeteAgreementsMember 2023-06-30 0000842023 srt:MinimumMemberus-gaap:TradeNamesMember 2023-06-30 0000842023 srt:MinimumMemberus-gaap:OtherIntangibleAssetsMember 2023-06-30 0000842023 srt:MinimumMemberus-gaap:DevelopedTechnologyRightsMember 2023-06-30 0000842023 srt:MinimumMemberus-gaap:CustomerRelationshipsMember 2023-06-30 0000842023 srt:MaximumMemberus-gaap:TradeNamesMember 2023-06-30 0000842023 srt:MaximumMemberus-gaap:OtherIntangibleAssetsMember 2023-06-30 0000842023 srt:MaximumMemberus-gaap:DevelopedTechnologyRightsMember 2023-06-30 0000842023 srt:MaximumMemberus-gaap:CustomerRelationshipsMember 2023-06-30 0000842023 tech:WilsonWolfCorporationMember 2023-06-30 0000842023 us-gaap:TradeNamesMember 2024-06-30 0000842023 us-gaap:PatentsMember 2024-06-30 0000842023 us-gaap:OtherIntangibleAssetsMember 2024-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMember 2024-06-30 0000842023 us-gaap:CustomerRelationshipsMember 2024-06-30 0000842023 us-gaap:TradeNamesMember 2023-06-30 0000842023 us-gaap:PatentsMember 2023-06-30 0000842023 us-gaap:OtherIntangibleAssetsMember 2023-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMember 2023-06-30 0000842023 us-gaap:CustomerRelationshipsMember 2023-06-30 0000842023 us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember 2023-06-30 0000842023 us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember 2022-06-30 0000842023 us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember 2023-07-012024-06-30 0000842023 us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember 2022-07-012023-06-30 0000842023 tech:WilsonWolfCorporationMember 2023-03-31 0000842023 us-gaap:RetainedEarningsMember 2023-07-012024-06-30 0000842023 us-gaap:RetainedEarningsMember 2022-07-012023-06-30 0000842023 us-gaap:RetainedEarningsMember 2021-07-012022-06-30 0000842023 tech:CurrentAssetsHeldForSaleMembertech:ProteinSciencesMember 2024-06-30 0000842023 tech:ProteinSciencesMember 2023-12-31 0000842023 tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000842023 tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2021-05-31 0000842023 us-gaap:OtherNoncurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:OtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:OtherNoncurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:OtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:OtherNoncurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000842023 us-gaap:OtherNoncurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000842023 us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000842023 tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000842023 tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000842023 us-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 tech:U5ProfitSharingAndSavingsPlanMember 2023-07-012024-06-30 0000842023 tech:GBProfitSharingAndSavingsPlanMember 2023-07-012024-06-30 0000842023 tech:USProfitSharingAndSavingsPlanMember 2022-07-012023-06-30 0000842023 tech:GBProfitSharingAndSavingsPlanMember 2022-07-012023-06-30 0000842023 tech:USProfitSharingAndSavingsPlanMember 2021-07-012022-06-30 0000842023 tech:GBProfitSharingAndSavingsPlanMember 2021-07-012022-06-30 0000842023 tech:TaxCreditCarryforwardsMember 2024-06-30 0000842023 tech:OperatingLossCarryforwardsMember 2024-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000842023 us-gaap:CommonStockMember 2024-06-30 0000842023 us-gaap:CommonStockMember 2023-06-30 0000842023 us-gaap:CommonStockMember 2022-06-30 0000842023 us-gaap:CommonStockMember 2021-06-30 0000842023 2022-10-28 0000842023 2022-10-27 0000842023 2022-06-30 0000842023 2021-06-30 0000842023 tech:LunaphoreTechnologiesSaMemberus-gaap:TradeNamesMember 2024-06-30 0000842023 tech:LunaphoreTechnologiesSaMemberus-gaap:DevelopedTechnologyRightsMember 2024-06-30 0000842023 tech:LunaphoreTechnologiesSaMemberus-gaap:CustomerRelationshipsMember 2024-06-30 0000842023 tech:LunaphoreTechnologiesSaMemberus-gaap:TradeNamesMember 2023-07-07 0000842023 tech:LunaphoreTechnologiesSaMemberus-gaap:DevelopedTechnologyRightsMember 2023-07-07 0000842023 tech:LunaphoreTechnologiesSaMemberus-gaap:CustomerRelationshipsMember 2023-07-07 0000842023 tech:NamocellIncMember-gaap:TradeNamesMember 2023-06-30 0000842023 tech:NamocellIncMember-gaap:NoncompeteAgreementsMember 2023-06-30 0000842023 tech:NamocellIncMember-gaap:DevelopedTechnologyRightsMember 2023-06-30 0000842023 tech:NamocellIncMember-gaap:CustomerRelationshipsMember 2023-06-30 0000842023 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000842023 tech:AcquisitionOfAsuragenIncMember 2023-06-30 0000842023 tech:AcquisitionOfAsuragenIncMember 2021-04-06 0000842023 tech:NamocellIncMember 2023-12-31 0000842023 tech:AcquisitionOfAsuragenIncMember 2023-12-31 0000842023 tech:NamocellIncMember 2022-07-01 0000842023 tech:LunaphoreTechnologiesSaMember 2023-07-072023-07-07 0000842023 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000842023 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000842023 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMembertech:ProteinSciencesMember 2023-10-012023-12-31 0000842023 tech:ChangzhouEminenceBiotechnologyMember 2021-07-012022-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember 2023-07-012024-06-30 0000842023 tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012024-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember 2022-07-012023-06-30 0000842023 tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-012023-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember 2021-07-012022-06-30 0000842023 tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-012022-06-30 0000842023 tech:EmployeeStockPurchasePlan2014Member 2023-07-012024-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-012023-06-30 0000842023 us-gaap:CostOfSalesMember 2022-07-012023-06-30 0000842023 tech:EmployeeStockPurchasePlan2014Member 2022-07-012023-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-012022-06-30 0000842023 us-gaap:CostOfSalesMember 2021-07-012022-06-30 0000842023 tech:EmployeeStockPurchasePlan2014Member 2021-07-012022-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2023-07-012024-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2022-07-012023-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2021-07-012022-06-30 0000842023 us-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember 2023-07-012024-06-30 0000842023 us-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember 2023-07-012024-06-30 0000842023 us-gaap:EmployeeSeveranceMembertech:DiagnosticsAndGenomicsMember 2023-07-012024-06-30 0000842023 tech:ImpairmentOfAssetsHeldForSaleMembertech:ProteinSciencesMember 2023-07-012024-06-30 0000842023 tech:AssetRelatedAndOtherMembertech:DiagnosticsAndGenomicsMember 2023-07-012024-06-30 0000842023 tech:AssetRelatedAndOtherMembertech:ProteinSciencesMember 2023-07-012024-06-30 0000842023 tech:AssetRelatedAndOtherMembertech:DiagnosticsAndGenomicsMember 2023-07-012024-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012024-06-30 0000842023 us-gaap:EmployeeSeveranceMember 2023-07-012024-06-30 0000842023 us-gaap:CostOfSalesMember 2023-07-012024-06-30 0000842023 us-gaap:CorporateMember 2023-07-012024-06-30 0000842023 tech:ImpairmentOfAssetsHeldForSaleMember 2023-07-012024-06-30 0000842023 tech:DiagnosticsAndGenomicsMember 2023-07-012024-06-30 0000842023 tech:AssetRelatedAndOtherMember 2023-07-012024-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMembertech:DiagnosticsAndGenomicsMember 2022-07-012023-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMembertech:DiagnosticsAndGenomicsMember 2021-07-012022-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMembertech:AssetImpairmentMembertech:DiagnosticsAndGenomicsMember 2021-07-012022-06-30 0000842023 tech:OTHoldingsCorporationMembertech:ProteinSciencesMember 2022-07-012023-06-30 0000842023 tech:ProteinSciencesMember 2022-07-012023-06-30 0000842023 tech:DiagnosticsAndGenomicsMember 2021-07-012022-06-30 0000842023 us-gaap:NoncontrollingInterestMember 2022-07-012023-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-012023-06-30 0000842023 us-gaap:RevolvingCreditFacilityMembertech:CreditAgreementMember 2022-08-31 0000842023 us-gaap:OtherNoncurrentAssetsMember 2024-06-30 0000842023 us-gaap:OtherNoncurrentAssetsMember 2023-06-30 0000842023 tech:ProteinSciencesMember 2023-07-012024-06-30 0000842023 tech:WilsonWolfCorporationMember 2024-06-30 0000842023 tech:WilsonWolfCorporationMembertech:FirstPartOfForwardContractMember 2023-03-31 0000842023 tech:WilsonWolfCorporationMembertech:SecondPartOfForwardContractMember 2024-06-30 0000842023 tech:WilsonWolfCorporationMember 2022-07-012023-06-30 0000842023 us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-07-012023-09-30 0000842023 us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000842023 tech:LunaphoreTechnologiesSaMember 2024-06-30 0000842023 tech:LunaphoreTechnologiesSaMember 2023-07-07 0000842023 tech:NamocellIncMember 2023-06-30 0000842023 tech:LunaphoreTechnologiesSaMember 2023-07-012024-06-30 0000842023 tech:NamocellIncMember 2022-07-012023-06-30 0000842023 2024-06-30 0000842023 2023-06-30 0000842023 2022-07-012023-06-30 0000842023 2021-07-012022-06-30 0000842023 2024-04-012024-06-30 0000842023 2023-12-31 0000842023 2024-08-16 0000842023 2023-07-012024-06-30 shares iso4217:USD tech:item pure iso4217:USD shares tech:segmentshttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense0000842023024FYfalsehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpenseBIO-TECHNE Corphttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense10-Ktrue2024-06-30--06-30false0-17272MN41-1427402614 McKinley Place N.E.MinneapolisMN55413612379-8054Common Stock, $0.01 par valueTECHNASDAQYesNoYesYesLarge Accelerated Filerfalsefalsefalsetrue12100000000158600400115906000011367020001105599000389335000366887000349103000769725000769815000756496000466375000378378000372766000966640009249300087140000563039000470871000485840004752000015311000-2099700039715000479600018568900033865900030136600017584000532170003828700016810500028544200026309900179000-8952000168105000285263000272051000-749200041910000-322410001190004760000479300014262000-122520009103000-17979000-33000-70000-122520009136000-17909000155853000294399000254142000 1.071.811.731.051.761.661577000001571790001568740001607740001618550001641140001571790001805700010720002373900043860000473000024139400021846000017973100017163000097730000703160006-660640002068050000196651600027036700026386920001558200001558000533239000108546500-5729100008263000157123400027205100-8952000263099000-17909000-70000-179790001577000160001609340001609500000220200023000743540000-134820006089500008900010000-1000-9978000-997800005018500050185000412000004120000041200000280000269400026940009730009730001566440001566000652467000112293700-75200000-75900017010110000152000-330001190006130006130002852630001790002854420008984000898400082220002000195600001956200010830001000024942000-22163000279000063000100-1000-6731000-673100050285000502850003831500038315000740001000490500049060009150009155001576420001576000721543000130946100-6606400019665160000168105000168105000-12252000-122520001397000140000002800008004200018110001800056409000-165340003989300091000100-1000-5338000-533800050419000504190005419000371360003713600069000100043440004345000906000906000150216000150200002033700013254770007-7031600020680500001681050002054420002630990001117110001072300001010690007290004000001596000-39447000-295670006816000380420003923000042183000-3500000-12100000-20400000-3300000371760000-283000-472000-150020006841000114300026340005460001871500011682000170800002059000-120100021963000584000455000668000205330000208670005759600014215000301670003200700031460004585000308200025769000-790800012741000126180000-24558000776000000-10599000-249200026670002989810002543930003252720002808300035236000265500055260002050000529980007321900062877000382440004490800001697070001011840006997000-232000000178240002500000-203030000-265649000-968510005041900050285000501850006093500029813000771550008004200019562000160950000225000000619661000900000002560000005256610001755000007000002187200028893000234610000-24570007880000-122398000226160000-242053000-2333000-3356000-12092000-2870000080004000-26524000180571000172567000199091000151791000180571000172567000 Note 1. Description of Business and Summary of Significant Accounting Policies: Description of business: Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (the Company), develop, manufacture and sell life science reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. At the 2022 annual meeting of shareholders of the Company held on October 27, 2022, the shareholders approved an amendment and restatement of the Company's articles of incorporation to increase the number of authorized shares of the Company's common stock from 100,000,000 to 400,000,000. On November 1, 2022, the Company's board of directors approved and declared a four-for-one split of the Company's common stock in the form of a stock dividend. Each stockholder of record on November 14, 2022 received three additional shares of common stock for each then-held share, which were distributed after close of trading on November 29, 2022. All share and per share amounts presented herein have been retroactively adjusted to reflect the impact of the stock split. Use of estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. As Eminence met the criteria for consolidation, the transaction was accounted for in accordance with ASC 805, Business Combinations. In applying ASC 805 to the transaction, the Company has elected to include Eminence in our consolidated financial statements on a one-month lag. As noted below, Eminence was sold during the first fiscal quarter of 2023. Equity method investments: The company accounts for its equity method investments in accordance with ASC 323, Investments - Equity Method and Joint Ventures. The Company initially records its equity method investments at the amount of the Company's investment and adjusts each period for the Company's share of the investee's income or loss and dividends paid. Distributions from the equity method investee are accounted for using the cumulative earnings approach on the Consolidated Statement of Cash Flows. In December 2021, the Company paid $25 million to enter into a two-part forward contract which requires the Company to make an initial ownership investment followed by purchase of full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or annual earnings before interest, taxes, depreciation, and amortization (EBITDA) thresholds are met. Wilson Wolf is a leading manufacturer of cell culture devices, including the G-Rex product line. The first part of the forward contract was triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in EBITDA at any point prior to December 31, 2027. During the quarter ended March 31, 2023, the Company determined that Wilson Wolf had met the EBITDA target. On March 31, 2023, the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf, which is accounted for as an equity method investment. Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, and requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple of approximately 4.4 times trailing twelve month revenue. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million in annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone. Translation of foreign financial statements: Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income. Revenue recognition: ASC 606 provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled

in exchange for those goods or services. Refer to Note 2 for additional information regarding our revenue recognition policy under ASC 606. Research and development: Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications. Advertising costs: Advertising expenses were $4.1 million, $4.0 million, and $4.6 million for fiscal 2024, 2023, and 2022 respectively. Advertising expenditures are expensed as incurred. Income taxes: The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Refer to Note 12 for additional information regarding income taxes. Comprehensive income: Comprehensive income includes charges and credits to shareholders' equity that are not the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity. Any tax effects, if applicable, associated with reclassifications of accumulated other comprehensive income to net income are reflected in the provision for income taxes. Cash and cash equivalents: Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of three months or less. Available-for-sale investments: Available-for-sale investments consist of debt instruments with original maturities of generally three months to less than one-year and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value. Unrealized gains and losses on our available-for-sale securities are included within other income (expense). Trade accounts receivable and allowances: Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do not bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer. The Company does not have material long-term customer receivables. Inventories: Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory not meeting quality control standards and inventory subject to expiration. For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no material changes to the Company's estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with ASC 330 -- Inventory. Property and equipment: Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are depreciated over estimated useful lives of 5 to 40 years. Contingencies: The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better restimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and the amount may be reasonably estimated, the estimated loss or range of loss is disclosed. Contingent Consideration: Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income. Intangible assets: Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life. Impairment of long-lived assets and amortizable intangibles: We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to, (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are not available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. During the second quarter of fiscal year 2024 there was a triggering event for the assets and liabilities associated with a disposal group in our Protein Sciences segment that were classified as held-for-sale. See the restructuring section of Note 1 below for additional details. No other triggering events were identified and no other impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years 2024, 2023, and 2022. Impairment of goodwill and indefinite-lived intangible assets: We evaluate the carrying value of goodwill and indefinite-lived intangible assets during the fourth quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, (3) an adverse action or assessment by a regulator, or (4) an adverse change in market conditions that are indicative of a decline in the fair value of the assets. To analyze goodwill, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business. The Company had five reporting units for our 2024, 2023, and 2022 goodwill impairment assessment performed on April 1 of each of the respective fiscal years, the date of our annual goodwill impairment assessment. The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation for goodwill is an assessment of factors including reporting unit specific operating results as well as industry and market conditions, overall financial performance, and other relevant events and factors to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass the qualitative assessment for its reporting units and perform a quantitative test. The quantitative impairment test requires us to estimate the fair value of our reporting units based the income approach. The income approach is a valuation technique under which we estimate future cash flows using the reporting unit's financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we project revenue and apply our fixed and variable cost experience rate to the projected revenue to arrive at the future cash flows. A terminal value is then applied to the projected cash flow stream. Future estimated cash flows are discounted to their present value to calculate the estimated fair value. The discount rate used is the value-weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we are required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items. For fiscal 2024, we elected to perform a qualitative analysis for all five reporting units. The Company determined, after performing the qualitative analysis, there was no evidence that it is more likely than not that the fair value was less than the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test in fiscal 2024. There was a triggering event related to a business held-for-sale described later in this note, leading to an impairment of allocated goodwill during the second half of fiscal 2024. The Company did not identify any triggering events after our annual goodwill impairment analysis through June 30, 2024, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. For fiscal 2024, the Company also performed a qualitative assessment of the acquired in-process research and development assets to determine whether changes in events, circumstances, or the probability of successful development and commercialization of the assets indicated that it is more likely than not that the fair value of the acquired assets are less than its carrying amount. Based on the analysis, the Company determined there was no indication of impairment of the indefinite-lived intangible asset. This in-process research and development was placed into service during the fourth quarter of fiscal 2024 and will begin amortization over its expected useful life. In fiscal 2023, we elected to perform a qualitative analysis for all five reporting units. The Company determined, after performing the qualitative analysis, there was no evidence that it is more likely than not that the fair value was less than the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test in fiscal 2023. The Company did not identify any triggering events after our annual goodwill impairment analysis through June 30, 2023, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. On September 1, 2022, the Company completed the sale of its equity shares of Eminence for approximately $17.8 million to a third party. Eminence was considered a variable-interest entity that was fully consolidated in our financial statements. Prior to the sale, Eminence had revenue of $2.0 million for the first fiscal quarter of 2023 within our Protein Sciences segment. Fiscal 2022 revenues were $4.6 million. As a result of the sale of the business, the Company recorded a gain of $11.7 million within the Other income (expense) line in the Consolidated Statement of Earnings. Prior to the sale of Eminence, a triggering event was identified in the second quarter of fiscal 2022 and impairment testing was performed as Eminence was forecasted to not have sufficient cash to execute on their growth plan combined with their inability to secure additional financing. Our impairment testing resulted in a full impairment of the Eminence goodwill and intangibles assets for charges of $0.3 million and $8.6 million, respectively, for the year ended June 30, 2022. The Company also recognized inventory and fixed asset impairment charges of $0.9 million and $0.9 million, respectively. These impairment charges were recorded within the General and Administrative line in the Consolidated Statement of Earnings for fiscal 2022. In the fourth quarter of fiscal 2022, Eminence was able to secure cash deposits on future orders to provide funding for their operations. This delay in liquidation allowed time for securing of additional investor financing which coincided with the sale of the Company's investment. In the first quarter of fiscal 2022, the Company combined the management of the Exosome Diagnostics and Asuragen reporting units, both of which are included in the Diagnostics and Genomics operating segment. In conjunction with the combination of the reporting units, a qualitative goodwill impairment assessment was performed. The qualitative assessment identified no indicators of impairment. In our fiscal 2022 annual goodwill impairment analysis, we elected to perform a quantitative assessment for all five of our reporting units. The result of our quantitative assessment indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2022. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2022, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. Restructuring actions: Restructuring actions generally include significant actions involving employee-related severance charges, contract termination costs, and impairments and disposals of assets associated with such actions. Employee-related severance charges are based upon distributed employment policies and substantive severance plans. These charges are reflected in the quarter when the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Asset-related and other charges include impairment of right-of-use assets, leasehold improvements, other asset write-downs associated with combining operations, disposal of assets and other exit costs. Other costs also includes restructuring-related charges, which are incremental costs incurred directly supporting business transformation initiatives tied to the restructuring action. Fiscal Year 2024 Restructuring Actions: In the second quarter of fiscal 2024, the Company announced enterprise-wide restructuring focused on recovering operating margins, optimizing our distribution footprint, and enhancing our organization efficiency. These actions impacted approximately 4% of our global workforce. These actions continued through the end of fiscal 2024 as we incurred charges relating to the condensing of certain distribution centers and optimizing efficiency. The Company is expecting to incur costs related to these actions through the first half of fiscal 2025, which will be recorded when specified criteria are met. As part of these actions, certain assets and liabilities associated with a disposal group in our Protein Sciences segment were classified as held-for-sale as of December 31, 2023, including $1.4 million of goodwill allocated to the disposal group on a relative fair value basis. As a result of impairment tests performed over the disposal group during fiscal 2024, a cumulative impairment charge of $22.0 million which includes the allocated goodwill, was recorded in the Selling, general and administrative line in the Consolidated Statements of Earnings for the year ended June 30, 2024. As of June 30, 2024, the assets remaining within the disposal group primarily include inventory and property and equipment of $9.8 million, which is net of expected selling costs. These assets are actively marketed, and we believe their sale will be completed within 12 months of the held-for-sale classification date. The held-for-sale assets are recorded in Current assets held-for-sale in our Consolidated Balance Sheet as of June 30, 2024. The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:33.97%;margin:0pt;padding:0pt;"> Year Ended </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:33.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:33.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of sales </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,349</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30,638</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 33,987 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;margin:0pt;padding:0pt;"> </td></tr></table> ⁽¹⁾ Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. Restructuring and restructuring-related costs by segment are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:74.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year ended June 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"> 5,130 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"> 30,576 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> Diagnostics and Genomics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"> 1,007 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"> 224 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> 1,231 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,153 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,180 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,381 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 33,907 </td></tr></table> . The following table summarizes the changes in the Company's accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.70%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.70%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1)</sup> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.70%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"> Expense incurred in the second quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"> 4,882 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"> 504 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"> 6,038 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"> 11,424 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> Incremental expense incurred in the third quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> 133 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> 1,140 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.70%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,273 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"> Incremental expense incurred in the fourth quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"> 409 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"> 4,737 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"> 15,926 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"> 21,072 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> (4,082) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> (2,800) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"> (7,682) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"> (3,391) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"> (21,963) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"> (25,354) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> Adjustments⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 219 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 219 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 190 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 952 </td></tr></table> ⁽¹⁾ Relates to impacted employees' final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites. ⁽²⁾ Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives. ⁽³⁾ Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024. Fiscal Year 2023 Restructuring Actions: OT Holdings Corporation (Quad) In August 2022, the Company informed employees of our decision to close our Quad facility as part of a realignment of activities within our Reagent Solutions division. The closure of the site was completed in the fourth quarter of fiscal 2023. As a result of the restructuring activities, an estimated pre-tax charge of $2.2 million was recorded within our Protein Sciences segment for the year ended June 30, 2023. The related restructuring charges for the year ended June 30, 2023 were recorded in the income statement as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> Asset </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> impairment and other </td><td style="vertical-align:bottom;white-

style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,677 </td></tr><tr><td style="vertical-align:bottom;width:76.78%;margin:0pt;padding:0pt;"> Fiscal year 2023 cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"> (762) </td></tr><tr><td style="vertical-align:bottom;width:76.78%;background:#cceeff;margin:0pt;padding:0pt;"> Fiscal year 2023 adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (18) </td></tr><tr><td style="vertical-align:bottom;width:76.78%;margin:0pt;padding:0pt;"> Accrued restructuring actions balances as of June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:76.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Fiscal year 2024 cash payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (1,118)</p></td></tr><tr><td style="vertical-align:bottom;width:76.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Fiscal year 2024 adjustments⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 221</p></td></tr><tr><td style="vertical-align:bottom;width:76.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Accrued restructuring actions balances as of June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> ⁽¹⁾Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023. Fiscal Year 2022 Restructuring Actions: In September 2021, the Company informed employees of our decision to close our Exosome Diagnostics Germany facility, discontinuing lab and research occurring at the site, as part of a realignment of activities within our Exosome Diagnostics business. The restructuring activities were complete as of June 30, 2022. As a result of the restructuring activities, a pre-tax charge of $1.4 million was recorded within our Diagnostics and Genomics segment during the year ended June 30, 2022. Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within operating income on the income statement as follows (in thousands):</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">Employee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">Asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">Impairment and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 649 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"> 1,399 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> Asset </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Impairment and other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-

align:center;margin:0pt;">Total </td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"> Expense incurred in the first quarter of 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,185</p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Incremental expense incurred during fiscal 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 242</p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (589)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (554)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,143)</p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (234)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (204)</p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued restructuring actions balances as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> ⁽¹⁾ Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange. During the second quarter of fiscal 2022, the Company also incurred a restructuring charge of $0.2 million related to employee severance for the relocation of a US plant. This was completed during fiscal 2023 and there are no remaining liabilities related to this relocation as of June 30, 2023. This charge was recorded within Other current liabilities as of June 30, 2022. Fiscal 2023 cash payments did not materially differ from the charge recorded in fiscal 2022. Legal Matters: The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. The Company's standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges in the consolidated statements of income. During fiscal year 2024, the Company recognized $3.5 million of certain litigation charges. There was no comparable activity in the comparable periods. As of each of the balance sheet dates presented, there was no accrued litigation. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other current liabilities and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. Intellectual Property Matters: At any given time, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements related to such rights. This litigation includes, but it not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or entities created specifically to fund IP litigation. While the outcome of these litigation matters is inherently uncertain, it is possible that the results of such litigation could require the Company to pay significant monetary damages. Other Significant Accounting Policies The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:90.2%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.59%;margin:0pt;padding:0.25pt;"> </td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.4pt 0.25pt 0.25pt;"> </td><td style="vertical-align:bottom;width:0.69%;margin:0pt;padding:0.25pt;"> </td><td style="vertical-align:bottom;width:13.59%;margin:0pt;padding:0.25pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;margin:0pt;padding:0.25pt;"> </td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.59%;margin:0pt;padding:0.25pt;"> </td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.4pt 0.25pt 0.25pt;"> </td><td style="vertical-align:bottom;width:0.69%;margin:0pt;padding:0.25pt;"> </td><td style="vertical-align:bottom;width:13.59%;margin:0pt;padding:0.25pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;margin:0pt;padding:0.25pt;"> </td></tr><tr><td style="vertical-align:bottom;width:82.59%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 1pt 0.25pt;"> Policy </td><td style="vertical-align:bottom;width:2.43%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.4pt 1pt 0.25pt;"> </td><td colspan="2" style="vertical-align:bottom;width:14.28%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 1pt 0.25pt;"> Note </td><td style="vertical-align:bottom;width:0.68%;border-bottom:1px solid transparent;margin:0pt;padding:0.25pt 0.25pt 1pt 0.25pt;"> </td></tr><tr><td style="vertical-align:bottom;width:82.59%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"> Fair value measurements </td><td style="vertical-align:bottom;width:2.43%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0.25pt 0.4pt 0.25pt 0.25pt;"> </td><td style="vertical-align:bottom;width:0.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"> </td><td style="vertical-align:bottom;width:13.59%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;background:#cceeff;margin:0pt;padding:0.25pt;"> </td></tr><tr><td style="vertical-align:bottom;width:82.59%;margin:0pt;padding:0.25pt;"> Leases </td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.4pt 0.25pt 0.25pt;"> </td><td style="vertical-align:bottom;width:0.69%;margin:0pt;padding:0.25pt;"> </td><td style="vertical-align:bottom;width:13.59%;margin:0pt;padding:0.25pt;"> 7 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;margin:0pt;padding:0.25pt;"> </td></tr><tr><td style="vertical-align:bottom;width:82.59%;background:#cceeff;margin:0pt;padding:0.25pt;"> Earnings per share </td><td style="vertical-align:bottom;width:2.43%;background:#cceeff;margin:0pt;padding:0.25pt 0.4pt 0.25pt 0.25pt;"><p

style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;width:0.69%;background:#cceeff;margin:0pt;padding:0.25pt;"> </td><td style="vertical-align:bottom;width:13.59%;background:#cceeff;margin:0pt;padding:0.25pt;"> 9 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;background:#cceeff;margin:0pt;padding:0.25pt;"> </td></tr><tr><td style="vertical-align:bottom;width:82.59%;margin:0pt;padding:0.25pt;"> Share-based compensation </td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.4pt 0.25pt 0.25pt;"> </td><td style="vertical-align:bottom;width:0.69%;margin:0pt;padding:0.25pt;"> </td><td style="vertical-align:bottom;width:13.59%;margin:0pt;padding:0.25pt;"> 10 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;margin:0pt;padding:0.25pt;"> </td></tr><tr><td style="vertical-align:bottom;width:82.59%;background:#cceeff;margin:0pt;padding:0.25pt;"> Operating segments </td><td style="vertical-align:bottom;width:2.43%;background:#cceeff;margin:0pt;padding:0.25pt 0.4pt 0.25pt 0.25pt;"> </td><td style="vertical-align:bottom;width:0.69%;background:#cceeff;margin:0pt;padding:0.25pt;"> </td><td style="vertical-align:bottom;width:13.59%;background:#cceeff;margin:0pt;padding:0.25pt;"> 13 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.68%;background:#cceeff;margin:0pt;padding:0.25pt;"> </td></tr></table> Not Yet Adopted Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, on our consolidated financial statements. 10000000040000000043 Use of estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. As Eminence met the criteria for consolidation, the transaction was accounted for in accordance with ASC 805, Business Combinations. In applying ASC 805 to the transaction, the Company has elected to include Eminence in our consolidated financial statements on a one month lag. As noted below, Eminence was sold during the first fiscal quarter of 2023. Equity method investments: The company accounts for its equity method investments in accordance with ASC 323, Investments - Equity Method and Joint Ventures. The Company initially records its equity method investments at the amount of the Company's investment and adjusts each period for the Company's share of the investee's income or loss and dividends paid. Distributions from the equity method investee are accounted for using the cumulative earnings approach on the Consolidated Statement of Cash Flows. In December 2021, the Company paid $25 million to enter into a two-part forward contract which requires the Company to make an initial ownership investment followed by purchase of full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or annual earnings before interest, taxes, depreciation, and amortization (EBITDA) thresholds are met. Wilson Wolf is a leading manufacturer of cell culture devices, including the G-Rex product line. The first part of the forward contract was triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in EBITDA at any point prior to December 31, 2027. During the quarter ended March 31, 2023, the Company determined that Wilson Wolf had met the EBITDA target. On March 31, 2023, the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf, which is accounted for as an equity method investment. Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, and requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple of approximately 4.4 times trailing twelve month revenue. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million in annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone.
250000009200000055000000232000000.1994.42260000001360000001000000000 Translation of foreign financial statements: Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income. Revenue recognition: ASC 606 provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer to Note 2 for additional information regarding our revenue recognition policy under ASC 606. Research and development: Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications. Advertising costs: Advertising expenses were $4.1 million, $4.8 million, and $4.6 million for fiscal 2024, 2023, and 2022 respectively. Advertising expenditures are expensed as incurred. 4100000480000004600000 Income taxes: The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Refer to Note 12 for additional information regarding income taxes. Comprehensive income: Comprehensive income includes charges and credits to shareholders' equity that are not the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity. Any tax effects, if applicable, associated with reclassifications of accumulated other comprehensive income to net income are reflected in the provision for income taxes. Cash and cash equivalents: Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of three months or less. Available-for-sale investments: Available-for-sale investments consist of debt instruments with original maturities of generally three months to less than one-year and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value. Unrealized gains and losses on our available-for-sale securities are included within other income (expense). Trade accounts receivable and allowances: Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do not bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer. The Company does not have material long-term customer receivables. Inventories: Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory not meeting quality control standards and inventory subject to expiration. For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no material changes to the Company's estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with ASC 330 - Inventory. Property and equipment: Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are depreciated over estimated useful lives of 5 to 40 years. P3YP5YP5YP40Y Contingencies: The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and the amount may be reasonably estimated, the estimated loss or range of loss is disclosed. Contingent Consideration: Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income. Intangible assets: Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life. P1YP20Y Impairment of long-lived assets and amortizable intangibles: We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to, (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are not available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. During the second quarter of fiscal year 2024 there was a triggering event for the assets and liabilities associated with a disposal group in our Protein Sciences segment that were classified as held-for-sale. See the restructuring section of Note 1 below for additional details. No other triggering events were identified and no other impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years 2024, 2023, and 2022. 000 Impairment of goodwill and indefinite-lived intangible assets: We evaluate the carrying value of goodwill and indefinite-lived intangible assets during the fourth quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, (3) an adverse action or assessment by a regulator, or (4) an adverse change in market conditions that are indicative of a decline in the fair value of the assets. To analyze goodwill, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business. The Company had five reporting units for our 2024, 2023, and 2022 goodwill impairment assessment performed on April 1 of each of the respective fiscal years, the date of our annual goodwill impairment assessment. The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation for goodwill is an assessment of factors including reporting unit specific operating results as well as industry and market conditions, overall financial performance, and other relevant events and factors to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass the qualitative assessment for its reporting units and perform a quantitative test. The quantitative impairment test requires us to estimate the fair value of our reporting units based the income approach. The income approach is a valuation

technique under which we estimate future cash flows using the reporting unit's financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we project revenue and apply our fixed and variable cost experience rate to the projected revenue to arrive at the future cash flows. A terminal value is then applied to the projected cash flow stream. Future estimated cash flows are discounted to their present value to calculate the estimated fair value. The discount rate used is the value-weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we are required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items. For fiscal 2024, we elected to perform a qualitative analysis for all five reporting units. The Company determined, after performing the qualitative analysis, there was no evidence that it is more likely than not that the fair value was less than the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test in fiscal 2024. There was a triggering event related to a business held-for-sale described later in this note, leading to an impairment of allocated goodwill during the second half of fiscal 2024. The Company did not identify any triggering events after our annual goodwill impairment analysis through June 30, 2024, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. For fiscal 2024, the Company also performed a qualitative assessment of the acquired in-process research and development assets to determine whether changes in events, circumstances, or the probability of successful development and commercialization of the assets indicated that it is more likely than not that the fair value of the acquired assets are less than its carrying amount. Based on the analysis, the Company determined there was no indication of impairment of the indefinite-lived intangible asset. This in-process research and development was placed into service during the fourth quarter of fiscal 2024 and will begin amortization over its expected useful life. In fiscal 2023, we elected to perform a qualitative analysis for all five reporting units. The Company determined, after performing the qualitative analysis, there was no evidence that it is more likely than not that the fair value was less than the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test in fiscal 2023. The Company did not identify any triggering events after our annual goodwill impairment analysis through June 30, 2023, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. On September 1, 2022, the Company completed the sale of its equity shares of Eminence for approximately $17.8 million to a third party. Eminence was considered a variable-interest entity that was fully consolidated in our financial statements. Prior to the sale, Eminence had revenue of $2.0 million for the first fiscal quarter of 2023 within our Protein Sciences segment. Fiscal 2022 revenues were $4.6 million. As a result of the sale of the business, the Company recorded a gain of $11.7 million within the Other income (expense) line in the Consolidated Statement of Earnings. Prior to the sale of Eminence, a triggering event was identified in the second quarter of fiscal 2022 and impairment testing was performed as Eminence was forecasted to not have sufficient cash to execute on their growth plan combined with their inability to secure additional financing. Our impairment testing resulted in a full impairment of the Eminence goodwill and intangibles assets for charges of $8.3 million and $8.6 million, $9.9 million, for the year ended June 30, 2022. The Company also recognized inventory and fixed asset impairment charges of $0.9 million and $0.9 million, respectively. These impairment charges were recorded within the General and Administrative line in the Consolidated Statement of Earnings for fiscal 2022. In the fourth quarter of fiscal 2022, Eminence was able to secure cash deposits on future orders to provide funding for their operations. This delay in liquidation allowed time for securing of additional investor financing which coincided with the sale of the Company's investment. In the first quarter of fiscal 2022, the Company combined the management of the Exosome Diagnostics and Asuragen reporting units, both of which are included in the Diagnostics and Genomics operating segment. In conjunction with the combination of the reporting units, a qualitative goodwill impairment assessment was performed. The qualitative assessment identified no indicators of impairment. In our fiscal 2022 annual goodwill impairment analysis, we elected to perform a quantitative assessment for all five of our reporting units. The result of our quantitative assessment indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2022. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2022, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. 5555517800000200000.0460000011700000830000086000009000009000005 Restructuring actions: Restructuring actions generally include significant actions involving employee-related severance charges, contract termination costs, and impairments and disposals of assets associated with such actions. Employee-related severance charges are based upon distributed employment policies and substantive severance plans. These charges are reflected in the quarter when the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Asset-related and other charges include impairment of right-of-use assets, leasehold improvements, other asset write-downs associated with combining operations, disposal of assets and other exit costs. Other costs also includes restructuring-related charges, which are incremental costs incurred directly supporting business transformation initiatives tied to the restructuring action. Fiscal Year 2024 Restructuring Actions: In the second quarter of fiscal 2024, the Company announced enterprise-wide restructuring focused on recovering operating margins, optimizing our distribution footprint, and enhancing our organization efficiency. These actions impacted approximately 4% of our global workforce. These actions continued through the end of fiscal 2024 as we incurred charges relating to the condensing of certain distribution centers and optimizing efficiency. The Company is expecting to incur costs related to these actions through the first half of fiscal 2025, which will be recorded when specified criteria are met. As part of these actions, certain assets and liabilities associated with a disposal group in our Protein Sciences segment were classified as held-for-sale as of December 31, 2023, including $1.4 million of goodwill allocated to the disposal group on a relative fair value basis. As a result of impairment tests performed over the disposal group during fiscal 2024, a cumulative impairment charge of $22.0 million which includes the allocated goodwill, was recorded in the Selling, general and administrative line in the Consolidated Statements of Earnings for the year ended June 30, 2024. As of June 30, 2024, the assets remaining within the disposal group primarily include inventory and property and equipment of $9.8 million, which is net of expected selling costs. These assets are actively marketed, and we believe their sale will be completed within 12 months of the held-for-sale classification date. The held-for-sale assets are recorded in Current assets held-for-sale in our Consolidated Balance Sheet as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:33.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Year Ended </i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:33.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">June 30, </i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:33.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">2024</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;background:#cceeff;margin:0pt;padding:0pt;"> 3,349 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"> Selling, general and administrative⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,630 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 33,987 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;margin:0pt;padding:0pt;"> </td></tr></table> ⁽¹⁾ Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. Restructuring and restructuring-related costs by segment are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:74.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year ended June 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"> 5,130 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"> 30,576 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> Diagnostics and Genomics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"> 1,007 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"> 224 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> 1,231 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,153 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,180 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,381 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 33,907 </td></tr></table> The following table summarizes the changes in the Company's accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.70%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"> Expense incurred in the second quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"> 4,802 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"> 504 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"> 6,038 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"> 11,424 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> Incremental expense incurred in the third quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> 133 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> 1,140 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"> 1,273 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"> Incremental expense incurred in the fourth quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"> 409 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"> 4,737 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"> 15,926 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"> 21,072 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> (4,802) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> (2,800) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"> (7,602) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"> (3,391) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"> (21,963) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"> (25,354) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> Adjustments⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 219 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 219 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 190 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.70%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 952 </td></tr></table> ⁽¹⁾ Relates to impacted employees' final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites. ⁽²⁾ Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives. ⁽³⁾ Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024. Fiscal Year 2023 Restructuring Actions: OT Holdings Corporation (Quad) In August 2022, the Company informed employees of our decision to close our Quad facility as part of a realignment of activities within our Reagent Solutions division. The closure of the site was completed in the fourth quarter of fiscal 2023. As a result of the restructuring activities, an estimated pre-tax charge of $2.2 million was recorded within our Protein Sciences segment for the year ended June 30, 2023. The related restructuring charges for the year ended June 30, 2023 were recorded in the income statement as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Employee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">impairment and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 1,320 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"> 2,170 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> Asset </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> impairment and other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"> Expense incurred in the first quarter of 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;margin:0pt;padding:0pt;"> 842 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"> 2,170 </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> (1,233) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"> (772) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,005) </td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"> Adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (95) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (70) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (165) </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> Accrued restructuring actions balances as of June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> Protein Sciences realignment In December 2022, the Company informed employees it would undertake certain actions to strategically reallocate operations resources to high growth areas of the business. Additional actions were taken in June 2023 primarily related to the sales organization. The actions impacted a limited number of employees and were completed in the fourth quarter of fiscal 2024. As a result of the realignment, a pre-tax charge of $1.7 million related to employee severance was recorded in the Selling, general and administrative line of operating income within our Protein Sciences segment during the year ended June 30, 2023. Adjustments in fiscal year 2024 relate to the refinement of employee severance payouts. Additional pre- tax charges for the year ended June 30, 2024 were $0.2 million. Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.70%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;width:76.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;">Employee</p></td></tr><tr><td style="vertical-align:bottom;width:76.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;">severance</p></td></tr><tr><td style="vertical-align:bottom;width:76.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expense incurred in fiscal year 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"> 1,677 </td></tr><tr><td style="vertical-align:bottom;width:76.70%;margin:0pt;padding:0pt;"> Fiscal year 2023 cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"> (762) </td></tr><tr><td style="vertical-align:bottom;width:76.78%;background:#cceeff;margin:0pt;padding:0pt;"> Fiscal year 2023 adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (10) </td></tr><tr><td style="vertical-align:bottom;width:76.70%;margin:0pt;padding:0pt;"> Accrued restructuring actions balances as of June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">897</p></td></tr><tr><td style="vertical-align:bottom;width:76.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;">Fiscal year 2024 cash payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:right;margin:0pt;"> (1,118)</p></td></tr><tr><td style="vertical-align:bottom;width:76.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;">Fiscal year 2024 adjustments⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 221</p></td></tr><tr><td style="vertical-align:bottom;width:76.70%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;">Accrued restructuring actions balances as of June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> ⁽¹⁾Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023. Fiscal Year 2022 Restructuring Actions: In September 2021, the Company informed employees of our decision to close our Exosome Diagnostics Germany facility, discontinuing lab and research occurring at the site, as part of a realignment of activities within our Exosome Diagnostics business. The restructuring activities were complete as of June 30, 2022. As a result of the restructuring activities, a pre-tax charge of $1.4 million was recorded within our Diagnostics and Genomics segment during the year ended June 30, 2022. Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within operating income on the income statement as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> Asset </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> impairment and other </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"> Selling, general and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;margin:0pt;padding:0pt;"> 750 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,399</p></td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">Employee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">Asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">impairment and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Expense incurred in the first quarter of 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 639 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"> 1,185 </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> Incremental expense incurred during fiscal 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"> 242 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"> 242 </td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> (589) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;margin:0pt;padding:0pt;"> (554) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"> (1,143) </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> Adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (50) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (234) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (204) </td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued restructuring actions balances as of June 30, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> ⁽¹⁾ Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange. During the second quarter of fiscal 2022, the Company also incurred a restructuring charge of $0.2 million related to employee severance for the relocation of a US plant. This was completed during fiscal 2023 and there are no remaining liabilities related to this relocation as of June 30, 2023. This charge was recorded within Other current liabilities as of June 30, 2022. Fiscal 2023 cash payments did not materially differ from the charge recorded in fiscal 2022. 0.041400000220000000.09800000 The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> <p

style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:33.97%;margin:0pt;padding:0pt;"> Year Ended </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:33.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:33.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of sales </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,349</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Selling, general and administrative⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30,638</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 33,987 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:30.23%;margin:0pt;padding:0pt;"> </td></tr></table> ⁽¹⁾ Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. Restructuring and restructuring-related costs by segment are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:74.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year ended June 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"> 5,130 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"> 30,576 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> Diagnostics and Genomics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"> 1,007 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"> 224 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:13.72%;margin:0pt;padding:0pt;"> 1,231 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,153 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,180 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.76%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,301 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 33,907 </td></tr></table> . The following table summarizes the changes in the Company's accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"> Expense incurred in the second quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"> 4,882 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"> 504 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"> 6,038 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"> 11,424 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> Incremental expense incurred in the third quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> 133 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> 1,140 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,273 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"> Incremental expense incurred in the fourth quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"> 409 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"> 4,737 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"> 15,926 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"> 21,072 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> (4,082) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> (2,800) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"> (7,682) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"> (3,391) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"> (21,963) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"> (25,354) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;margin:0pt;padding:0pt;"> Adjustments⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 219 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 219 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.69%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 190 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 952 </td></tr></table> (1) Relates to impacted employees' final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites. (2) Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives. (3) Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024.
334900036380003398700034830005130000219630003057600010070002240001231000115300010270002180000564300063810002196300033987000488200050400060380001142400013300011400001273000409000473700015926000210720related restructuring charges for the year ended June 30, 2023 were recorded in the income statement as follows (in thousands): <table="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> Asset </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> impairment and other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times',serif;font-size:10pt;margin:0pt;">Selling, general and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;margin:0pt;padding:0pt;"> 842 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,170</p></td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">Employee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">Asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">impairment and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Expense incurred in the first quarter of 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 1,328 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"> 2,170 </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> (1,233) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"> (772) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"> (2,005) </td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"> Adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (95) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (70) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (165) </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> Accrued restructuring actions balances as of June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td></tr></table>1320000842000217000013200008420002170000123300077200020050000-95000-70000-1650001700000 tax charges for the year ended June 30, 2024 were $0.2 million. Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">Employee</p></td></tr><tr><td style="vertical-align:bottom;width:76.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">severance</p></td></tr><tr><td style="vertical-align:bottom;width:76.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Expense incurred in fiscal year 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"> 1,677 </td></tr><tr><td style="vertical-align:bottom;width:76.78%;margin:0pt;padding:0pt;"> Fiscal year 2023 cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;margin:0pt;padding:0pt;"> (762) </td></tr><tr><td style="vertical-align:bottom;width:76.78%;background:#cceeff;margin:0pt;padding:0pt;"> Fiscal year 2023 adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:19.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (10) </td></tr><tr><td style="vertical-align:bottom;width:76.70%;margin:0pt;padding:0pt;"> Accrued restructuring actions balances as of June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">097</p></td></tr><tr><td style="vertical-align:bottom;width:76.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fiscal year 2024 cash payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,118)</p></td></tr><tr><td style="vertical-align:bottom;width:76.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fiscal year 2024 adjustments⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 221</p></td></tr><tr><td style="vertical-align:bottom;width:76.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued restructuring actions balances as of June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> ⁽¹⁾Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023. 20000016770007620001800089700011180002210001400000Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within operating income on the income statement as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> Asset </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> impairment and other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"> Selling, general and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;margin:0pt;padding:0pt;"> 750 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,399</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Employee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">impairment and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expense incurred in the first quarter of 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 639 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"> 1,185 </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> Incremental expense incurred during

fiscal 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;margin:0pt;padding:0pt;"> 242 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"> 242 </td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> (509) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;margin:0pt;padding:0pt;"> (554) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"> (1,143) </td></tr><tr><td style="vertical-align:bottom;width:53.07%;margin:0pt;padding:0pt;"> Adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (50) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (234) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (204) </td></tr><tr><td style="vertical-align:bottom;width:53.07%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued restructuring actions balances as of June 30, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> $</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">⁽¹⁾ Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange. </p>649000750000139900063900054600011050002420002420005890005544000114300050000-234000-28400020000000<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Legal Matters: </i>The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. The Company's standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges in the consolidated statements of income. $ During fiscal year 2024, the Company recognized $3.5 million of certain litigation charges. There was no comparable activity in the comparable periods. As of each of the balance sheet dates presented, there was no accrued litigation. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other current liabilities and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. 350000000 Intellectual Property Matters: At any given time, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements related to such rights. This litigation includes, but it not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or entities created specifically to fund IP litigation. While the outcome of these litigation matters is inherently uncertain, it is possible that the results of such litigation could require the Company to pay significant monetary damages. Not Yet Adopted Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, on our consolidated financial statements. Note 2. Revenue Recognition: Consumables revenues consist of specialized proteins, immunoassays, antibodies, reagents, blood chemistry and blood gas quality controls, and hematology instrument controls that are typically single-use products recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consist of extended warranty contracts, post contract support, and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. Service revenues also include laboratory services recognized at point in time. We recognize royalty revenues in the period the sales occur using third party evidence. The Company elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date. The Company elected the exemption to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance. The Company's unfulfilled performance obligations for contracts with an original length greater than one year were not material as of June 30, 2024. Contracts with customers that contain instruments may include multiple performance obligations. For these contracts, the Company allocates the contract's transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contracts' inception. Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both. Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one year. We elected the practical expedient allowing us to expense contract costs that would otherwise be capitalized and amortized over a period of less than one year. Contract assets as of June 30, 2024 are not material. Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of June 30, 2024 and June 30, 2023 were approximately $30.2 million and $24.6 million, respectively. Contract liabilities as of June 30, 2023 subsequently recognized as revenue during the year ended June 30, 2024 were approximately $20.9 million. Contract liabilities as of June 30, 2022 subsequently recognized as revenue during the year ended June 30, 2023 were approximately $21.5 million. Contract liabilities in excess of one year are included in Other long-term liabilities on the consolidated balance sheet. Any claims for credit or return of goods must be made within 10 days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized. The following tables present our disaggregated revenue for the periods presented. Revenue by type is as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td></tr></table>

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:64.34%;background:#cceeff;margin:0pt;padding:0pt;"> Consumables </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 928,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"> 917,733 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 890,874</p></td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 108,270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 112,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 120,758</p></td></tr><tr><td style="vertical-align:bottom;width:64.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 99,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 71,988</p></td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total product and services revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,135,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> 1,115,602 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> 1,083,620 </td></tr><tr><td style="vertical-align:bottom;width:64.34%;background:#cceeff;margin:0pt;padding:0pt;"> Royalty revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 23,345 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 21,100 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 21,979 </td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"> Total revenues, net </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,159,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,136,702 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,105,599 </td></tr></table> Revenue by geography (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%,"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-

align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 657,747</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 642,465 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 614,107</p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EMEA, excluding United Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 241,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 220,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 219,055</p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 49,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 48,637</p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">APAC, excluding Greater China</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 73,904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 73,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 76,139</p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Greater China</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 99,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 113,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 112,438</p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Rest of World</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 37,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35,223</p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,159,060 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,136,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,105,599 </td></tr></table> 3020000024600000209000002150000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"> </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:35.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:64.34%;background:#cceeff;margin:0pt;padding:0pt;"> Consumables </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 920,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"> 917,733 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 890,874</p></td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 108,270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 112,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 120,758</p></td></tr><tr><td style="vertical-align:bottom;width:64.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 99,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 71,988</p></td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total product and services revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,135,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> 1,115,602 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> 1,003,620 </td></tr><tr><td style="vertical-align:bottom;width:64.34%;background:#cceeff;margin:0pt;padding:0pt;"> Royalty revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 23,345 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 21,100 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 21,979 </td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"> Total revenues, net </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">1,159,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,136,702 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,105,599 </td></tr></table> Revenue by geography (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02

family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 657,747</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 642,465 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 614,107</p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">EMEA, excluding United Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 241,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 220,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 219,055</p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 49,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 48,637</p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">APAC, excluding Greater China</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 73,904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 73,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 76,139</p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Greater China</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 99,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 113,868</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 112,438</p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Rest of World</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 37,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35,223</p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,159,060 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,136,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,105,599 </td></tr></table>
92818000009177330000900874000102700001120850001207580000992650008578400071980000113571500011156020001083620000233450002110000021979000115906000011367020001105599000657747000642465000614107002414320002 Note 3. Supplemental Balance Sheet and Cash Flow Information: Inventories: Inventories consist of (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:74.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:74.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.2%;background:#cceeff;margin:0pt;padding:0pt;"> Raw materials </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 79,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"> 84,551 </td></tr><tr><td style="vertical-align:bottom;width:74.2%;margin:0pt;padding:0pt;"> Finished goods⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 106,072 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 92,474 </td></tr><tr><td style="vertical-align:bottom;width:74.2%;background:#cceeff;margin:0pt;padding:0pt;"> Inventories, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 185,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 177,025 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Finished goods inventory of $5,710 and $5,307 is included within Other assets in the June 30, 2024 and June 30, 2023 Balance Sheets, respectively, as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.</td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Property and Equipment:</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Property and equipment consist of (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"> 8,150 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"> 9,100 </td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"> Buildings and improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"> 243,863 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> 245,302 </td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"> Machinery and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"> 215,940 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"> 190,019 </td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"> Construction in progress </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 39,749 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,491 </td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"> Property and equipment, cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"> 507,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"> 459,912 </td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"> Accumulated depreciation and amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (256,556) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (233,712) </td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"> Property and equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 251,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 226,200 </td></tr></table> Intangibles assets were comprised of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> Useful Life </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"> Developed technology </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> 9 - 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 675,674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"> 616,311 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> Tradenames </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> 2 - 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 151,561 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> 146,945 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"> Customer relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> 7 - 16 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> 211,276 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"> 213,878 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"> Patents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> 10 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 4,343 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> 3,815 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"> Other intangibles </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> 5 - 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,006 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,566 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> Definite-lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 1,054,860 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> 992,515 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"> Accumulated amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (547,779) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (480,570) </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> Definite-lived intangibles assets, net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 507,081 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> 511,945 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"> In process research and development⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22,700 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> Total intangible assets, net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 507,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 534,645 </td></tr></table> ⁽¹⁾The in process research and development has been placed into service and is included within Developed technology. The amortization period for this developed technology asset is estimated to be 14 years. Changes to the carrying amount of net intangible assets consist of (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;">   </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"> 534,645 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"> 531,522 </td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"> Acquisitions </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> 66,400 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"> 75,600 </td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"> Other additions⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"> 950 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"> 5,710 </td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"> Held-for-sale intangibles⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> (14,323) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"> Amortization expense </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"> (79,854) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"> (77,491) </td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"> Currency translation </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (737) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (696) </td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 507,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 534,645 </td></tr></table> ⁽¹⁾Includes the purchase of a $4.6 million intangible asset from Wilson Wolf, an equity method investee of the Company during the year-ended June 30, 2023. This asset will be amortized over a life of 10 years. ⁽²⁾Refer to Note 1 for further detail on held-for-sale intangibles. Amortization expense related to developed technologies included in cost of sales was $46.6 million, $44.3 million, and $40.6 million in fiscal 2024, 2023, and 2022, respectively. Amortization expense related to trade names, customer relationships, non-compete agreements, and patents included in selling, general and administrative expense was $33.2 million, $33.2 million, and $33.5 million, in fiscal 2024, 2023, and 2022 respectively.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The estimated future amortization expense for intangible assets as of June 30, 2024 is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"> 77,259 </td></tr><tr><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> 73,297 </td></tr><tr><td style="vertical-align:bottom;width:76.85%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"> 63,138 </td></tr><tr><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> 59,491 </td></tr><tr><td style="vertical-align:bottom;width:76.85%;background:#cceeff;margin:0pt;padding:0pt;"> 2029 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"> 46,923 </td></tr><tr><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 186,973 </td></tr><tr><td style="vertical-align:bottom;width:76.85%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 507,081</p></td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><i style="font-style:italic;">Goodwill:</i></p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Changes in goodwill by segment and in total consist of (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Diagnostics and</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:45.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Protein Sciences</i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> Genomics</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Total</i></p></td></tr><tr><td style="vertical-align:bottom;width:45.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> 376,493 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 445,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"> 822,101 </td></tr><tr><td style="vertical-align:bottom;width:45.61%;margin:0pt;padding:0pt;"> Acquisitions </td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> 51,257 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"> 51,257 </td></tr><tr><td style="vertical-align:bottom;width:45.61%;background:#cceeff;margin:0pt;padding:0pt;"> Currency translation </td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (723) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 102 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (621) </td></tr><tr><td style="vertical-align:bottom;width:45.61%;margin:0pt;padding:0pt;"> June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 427,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> 445,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 872,737</p></td></tr><tr><td style="vertical-align:bottom;width:45.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Acquisitions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 104,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 104,650</p></td></tr><tr><td style="vertical-align:bottom;width:45.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Held-for-sale goodwill⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1,400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,400)</p></td></tr><tr><td style="vertical-align:bottom;width:45.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,324)</p></td></tr><tr><td style="vertical-align:bottom;width:45.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 423,449 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 549,214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 972,663 </td></tr></table> ^{
}⁽¹⁾Refer to Note 1 for further detail on goodwill reclassified to current assets held-for-sale. Other Assets: Other assets consist of (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.40%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.40%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.40%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.40%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Equity method investment in Wilson Wolf </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.40%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 242,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 255,057 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Derivative instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.40%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 9,813 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 16,857 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 5,718 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 5,307 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,397 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,201 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 264,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 285,302 </td></tr></table> Supplemental Cash Flow Information: Supplemental cash flow information was as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;height:65.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;height:65.29%;background:#cceeff;margin:0pt;padding:0pt;"> Income taxes paid </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 65,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"> 88,428 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 30,341</p></td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 14,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,027</p></td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Inventories consist of (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:74.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:74.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:74.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"> 79,377 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"> 84,551 </td></tr><tr><td style="vertical-align:bottom;width:74.2%;margin:0pt;padding:0pt;"> Finished goods⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 106,072 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 92,474 </td></tr><tr><td style="vertical-align:bottom;width:74.2%;background:#cceeff;margin:0pt;padding:0pt;"> Inventories, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 105,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 177,025 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Finished goods inventory of $5,710 and $5,307 is included within Other assets in the June 30, 2024 and June 30, 2023 Balance Sheets, respectively, as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.</td></tr></table><div style="margin-top:10pt;"></div>79377000045510001060720009247400018544900017702500057180005387000<p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Property and equipment consist of (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"> 8,150 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,100</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Buildings and improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 243,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 245,302</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Machinery and equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 215,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 190,019</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 39,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15,491</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 507,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 459,912</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> (256,556)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> (233,712)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 251,154 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 226,200 </td></tr></table>81500009100000243863000245302000215948000190019000397490001549100050771000045991200025655600023371200025115400022620000 Intangibles assets were comprised of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> Useful Life </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"> Developed technology </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> 9 - 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 675,674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"> 616,311 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> Tradenames </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> 2 - 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 151,561 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> 146,945 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"> Customer relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> 7 - 16 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> 211,276 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"> 213,870 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> Patents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> 10 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"> 4,343 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> 3,015 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"> Other intangibles </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> 5 - 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,006 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,566 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> Definite-lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 1,054,060 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> 992,515 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"> Accumulated amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (547,779) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (480,570) </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> Definite-lived intangibles assets, net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"> 507,081 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"> 511,945 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"> In process research and development⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22,700 </td></tr><tr><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"> Total intangible assets, net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 507,081 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px

double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">534,645</p></td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">⁽¹⁾The in process research and development has been placed into service and is included within Developed technology. The amortization period for this developed technology asset is estimated to be 14 years.</p>P9YP9YP15YP15Y67567400061631100OP2YP2YP20YP20Y151561000146945000P7YP7YP16YP16Y211276000213078000P10YP10Y434300038150000P5YP5YP15YP15Y120060001156600010548600009925150005477790004805700005070010005119 4style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Changes to the carrying amount of net intangible assets consist of (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"> 534,645 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 531,522</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Acquisitions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 66,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 75,600</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other additions⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,710</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Held-for-sale intangibles⁽²⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,323)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (79,054)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (77,491)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (737)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (696)</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 507,081 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 534,645 </td></tr></table> ⁽¹⁾Includes the purchase of a $4.6 million intangible asset from Wilson Wolf, an equity method investee of the Company during the year-ended June 30, 2023. This asset will be amortized over a life of 10 years. ⁽²⁾Refer to Note 1 for further detail on held-for-sale intangibles.
534645000531522000664000007560000095000057100001432300079854000774910007370006960005070810005346450004600000P10Y4660000044300000460600003320000033200000335000000 The estimated future amortization expense for intangible assets as of June 30, 2024 is as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:76.85%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"> 77,259 </td></tr><tr><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> 73,297 </td></tr><tr><td style="vertical-align:bottom;width:76.85%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"> 63,138 </td></tr><tr><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-

```
align:bottom;white-space:nowrap;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td
style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">
59,491</p></td></tr><tr><td style="vertical-align:bottom;width:76.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,923</p></td>
</tr><tr><td style="vertical-align:bottom;width:76.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td
style="vertical-align:bottom;white-space:nowrap;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">
</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 186,973</p></td></tr><tr><td style="vertical-align:bottom;width:76.85%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:4.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 507,081</p></td></tr></table>772590007329700063130000594910004692300018697300050700100<p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Changes in goodwill by segment and in total consist of (in thousands):</p><table
style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-
align:bottom;width:45.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-
align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span>
</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span>
</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span>
</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span>
</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span>
</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span>
</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span>
</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span>
</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span>
</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
<span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">  </i></p></td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-
weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-
style:italic;">Diagnostics and</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">  </b></p></td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-
weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:45.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;visibility:hidden;">Protein Sciences</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i
style="font-style:italic;"> Genomics</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i
style="font-style:italic;">Total</i></p></td></tr><tr><td style="vertical-align:bottom;width:45.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">  </i></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt
0pt;"> 376,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt
0pt;"> 445,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt
0pt;"> 822,101</p></td></tr><tr><td style="vertical-align:bottom;width:45.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;">Acquisitions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 51,257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt
0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 51,257</p></td></tr><tr><td style="vertical-align:bottom;width:45.61%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Currency translation</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">
</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (73)</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">
</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 102</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span
style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (621)</p></td></tr><tr><td style="vertical-
align:bottom;width:45.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">June 30, 2023</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">
</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 427,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 445,710</p></td><td
style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span
style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 872,737</p></td></tr><tr><td style="vertical-align:bottom;width:45.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Acquisitions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-
align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt
0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 104,650</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 104,650</p>
</td></tr><tr><td style="vertical-align:bottom;width:45.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Held-for-sale
goodwill<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">
(1,400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">
</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
```

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;">   </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:65.29%;background:#cceeff;margin:0pt;padding:0pt;"> Income taxes paid </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 65,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"> 88,428 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"> 30,341 </td></tr><tr><td style="vertical-align:bottom;width:65.29%;margin:0pt;padding:0pt;"> Interest paid </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"> 14,502 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"> 8,368 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"> 11,027 </td></tr></table>
652540000842000030341000145020000360000110270000 Note 4. Acquisitions: We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred. Fiscal year 2024 Acquisitions Lunaphore Technologies SA. On July 7, 2023, the Company acquired all of the ownership interests of Lunaphore Technologies SA (“Lunaphore”) for $169.7 million, in a cash-free, debt-free acquisition. Lunaphore is a leading developer of fully automated spatial biology solutions. The Lunaphore acquisition adds spatial biology instruments to Bio-Techne’s portfolio to accelerate our leadership position in translational and clinical research markets. The transaction was accounted for in accordance with ASC 805, Business Combinations. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Diagnostics and Genomics operating segment in the first quarter of fiscal year 2024. The allocation of purchase price consideration related to Lunaphore was completed in the fourth quarter of fiscal 2024. Net sales and operating loss of this business included in Bio-Techne’s consolidated results of operations for the year ended June 30, 2024 were approximately $14.3 million and $24.0 million, respectively. The fair values of the assets acquired and liabilities assumed as of the acquisition date and the updated final amounts as of June 30, 2024 are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">   </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;width:26.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Preliminary allocation at acquisition date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Adjustments to fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Final allocation at June 30, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;background:#cceeff;margin:0pt;padding:0pt;"> 12,512 </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (357)</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"> 12,155 </td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"> Equipment and other long-term assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;margin:0pt;padding:0pt;"> 1,470 </td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"> 1,470 </td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"> Intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"> Developed technologies </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;background:#cceeff;margin:0pt;padding:0pt;"> 60,300 </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"> 60,300 </td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"> Tradenames </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;background:#cceeff;margin:0pt;padding:0pt;"> 4,900 </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"> 4,900 </td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"> Customer relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;margin:0pt;padding:0pt;"> 1,200 </td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"> 1,200 </td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 102,560 </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,090 </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 104,650 </td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"> Total assets acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;margin:0pt;padding:0pt;"> 182,942 </td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> 1,733 </td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"> 184,675 </td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> 7,096 </td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> 7,096 </td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred income taxes, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,768 </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,104 </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,872 </td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"> Net assets acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">170,078</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (371) </td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 169,707</p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 169,707</p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Estimated Net Working Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,652</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,652)</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 170,078 </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (371) </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 169,707 </td></tr></table>   Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology and customer relationships was based on management's forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The purchase price allocated to trade names was based on management's forecasted cash inflows and outflows and using a relief from royalty method. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 14 years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is estimated to be 8 years. The amount recorded for trade names is being amortized with the expense reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for trade names ranges from 4 years to 8 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes, offset by the deferred tax asset for the preliminary calculation of acquired net operating losses. Fiscal year 2023 Acquisitions Namocell, Inc. On July 1, 2022, the Company acquired all of the ownership interests of Namocell, Inc. ("Namocell") for $101.2 million, net of cash acquired, plus contingent consideration of up to $25 million upon the achievement of certain future revenue thresholds. The Namocell acquisition adds easy-to-use single cell sorting and dispensing platforms that are gentle to cells and preserve cell viability and integrity. The transaction was accounted for in accordance with ASC 805, Business Combinations. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company's product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences operating segment in the first quarter of fiscal year 2023. The allocation of purchase price consideration related to Namocell was completed in the fourth quarter of fiscal 2023. Net sales and operating loss of this business included in Bio-Techne's consolidated results of operations for the twelve months ended June 30, 2023 were approximately $6.4 million and $9.3 million, respectively. The fair values of the assets acquired and liabilities assumed as of the acquisition date and the updated final amounts as of June 30, 2023 are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:0pt;visibility:hidden;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:0pt;visibility:hidden;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:0pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Current assets, net of cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 3,248 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Equipment and other long-term assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 405 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Developed technology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 73,900 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Trade name </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 700 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Customer relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 900 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Non-competition agreement </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 100 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 51,257 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Total assets acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 130,510 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 546 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Deferred income taxes, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,180 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Net assets acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111,784</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Cash paid, net of cash acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,184</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Additional consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,600</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Net assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 111,784 </td></tr></table>   Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was based on management's forecasted cash inflows and outflows and using a relief from royalty method to calculate the fair value of assets purchased. The purchase price allocated to customer relationships and trade names was based on management's forecasted cash inflows and outflows and using a multiperiod excess earnings method. The amount recorded for developed technology is being amortized with the expense reflected in Cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 13 years. Amortization expense related to customer relationships is reflected in Selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is estimated to be 4 years. The amount recorded for trade names and the non-competition agreement is being amortized with the expense reflected in Selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for both trade names and the non-competition agreement is estimated to be 3 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes, offset by the deferred tax asset for the preliminary calculation of acquired net operating losses. There were no acquisitions in fiscal 2022. 169700000014300000-24000000.0The fair values of the assets acquired and liabilities assumed as of the acquisition date and the updated final amounts as of June 30, 2024 are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"> <p

size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;margin:0pt;padding:0pt;"> 7,096 </td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"> 7,096 </td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred income taxes, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,768 </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,104 </td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,072 </td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"> Net assets acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">170,078</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (371) </td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 169,707</p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;">Cash paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 166,426</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,281</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 169,707</p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Estimated Net Working Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,652</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,652)</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:24.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 170,078 </td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (371)</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 169,707 </td></tr></table>12512000-
357000121550001470000147000060300000603000004900000490000012000001202000010256000020900001046500001829420001733000184675000709600070960005768000210400007072000170078000-
371000169707000166426000328100016970700036520000-365200017007800-371000169707000P14YP8YP4YP8YV1012000002500000Net sales and operating loss of this business included in Bio-Techne's consolidated results of operations for the twelve months ended June 30, 2023 were approximately $6.4 million and $9.3 million, respectively. The fair values of the assets acquired and liabilities assumed as of the acquisition date and the updated final amounts as of June 30, 2023 are as follows (in thousands):<p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;">x</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">x</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">x</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">x</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">x</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">x</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">x</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Namocell Inc</i></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Current assets, net of cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 3,240 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Equipment and other long-term assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 405 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Developed technology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 73,900 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Trade name </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 700 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Customer relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 900 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Non-competition agreement </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 100 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 51,257 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Total assets acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 130,510 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"> 546 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Deferred income taxes, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,180 </td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"> Net assets acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111,784</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid, net of cash acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,184</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,600</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 111,784 </td></tr></table>6400000-930000032480004050007390000070000090000010000051257000130510000546000101800001117840001011840001060000011178400OP1JYP4YP3Y Note 5. Fair Value Measurements: The Company's financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, derivative instruments, and long-term debt. Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation. The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> value as of </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Fair Value Measurements Using </i></p></td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Balance Sheet Location</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">June 30, </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Inputs Considered as</i></p></td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">2024</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Level 1</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Level 2</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Level 3</i></p></td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:25.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets</p></td><td style="vertical-align:bottom;width:34.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Certificates of deposit⁽¹⁾</p></td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Short-term available-for-sale investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:25.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Derivatives designated as hedging instruments - cash flow hedges</p></td><td style="vertical-align:bottom;width:34.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Derivatives designated as hedging instruments - cash flow hedges</p></td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:25.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total assets</p></td><td style="vertical-align:bottom;width:34.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-

align:bottom;width:25.10%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.18%;background:#cceeff;margin:0pt;padding:0pt;"> Liabilities </td><td style="vertical-align:bottom;width:34.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - net investment hedge </td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"> Other long-term liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,051 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,051 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> Liabilities </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:24.85%;background:#cceeff;margin:0pt;padding:0pt;"> Contingent consideration </td><td style="vertical-align:bottom;width:33.93%;background:#cceeff;margin:0pt;padding:0pt;"> Contingent consideration payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,500 </td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> Total liabilities </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,500 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">The certificates of deposit have contractual maturity dates within one year.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">During the quarter ended September 30, 2023, the Company sold all of its exchange traded investment grade bond funds that it held at June 30, 2023. The costs basis and fair value of these exchange traded investment grade bond funds were $25.0 million and $23.7 million at June 30, 2023, respectively.</td></tr></table> Fair value measurements of available for sale securities Available for sale securities are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 assets. Fair value measurements of derivative instruments The Company utilizes forward starting swaps designated as a cash flow hedge on forecasted debt. The forward starting swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company's forecasted variable interest long-term debt to that of a fixed interest rate. Accordingly, as part of the forward starting swaps, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on a notional principal amounts. The Company also uses a cross-currency swap contract to manage its exposure to foreign currency risk associated with the Company's net investment in its Swiss subsidiary. The following table presents the contractual amounts of the Company's outstanding instruments (in millions): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.87%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;width:2.75%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:25.87%;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;width:2.75%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;"> Designation </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:25.87%;background:#cceeff;margin:0pt;padding:0pt;"> Forward starting swaps⁽¹⁾ </td><td style="vertical-align:bottom;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;width:25.88%;background:#cceeff;margin:0pt;padding:0pt;"> Cash flow hedge </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 300 </td>

</tr><tr><td style="vertical-align:bottom;width:25.87%;margin:0pt;padding:0pt;"> Cross-currency swap⁽²⁾ </td><td style="vertical-align:bottom;width:2.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.80%;margin:0pt;padding:0pt;"> Net investment hedge </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 150 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> — </td></tr></table><table style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:10pt;padding:0pt;">(1)</td><td style="padding:0pt;">In May 2021, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $200 million of notional principal. The effective date of the swap was November 2022 with the full swap maturing in November 2025. In March 2023, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $100 million of notional principal. The effective date of the swap was April 2023 with the full swap maturing in April 2025. </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:10pt;padding:0pt;">(2)</td><td style="padding:0pt;">In July 2023, the Company entered into a pay-fixed rate, receive-fixed rate cross-currency swap contract with a total notional amount of $150 million that was designated as a hedge to lock in the Swiss franc (CHF) rate for a portion of the Company's CHF net investment in its Lunaphore subsidiary in Switzerland. The objective of the hedge is to protect the net investment in the Company's CHF-denominated operations against changes in the spot exchange rates, on a pre-tax basis. The hedging instrument has four interim settlement dates, which will reduce the notional on the hedging instrument by $10 million at each interim date, and will reduce the notional to $110 million at maturity. </td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses with our Consolidated Financial Statements for the twelve months ended June 30, 2024 and 2023 were as follows (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="8" style="vertical-align:bottom;width:63.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(Gain) Loss Recognized in Accumulated Other Comprehensive Loss</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:63.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Year Ended </i></p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">June 30, </i></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:63.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">June 30, </i></p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">2024</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">2023</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">2022</i></p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flow hedges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forward starting swaps</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;width:17.25%;margin:0pt;padding:0pt;"> 12,632 </td><td style="vertical-align:bottom;width:3.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,340)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;width:14.05%;margin:0pt;padding:0pt;"> (19,121) </td></tr><tr><td style="vertical-align:bottom;width:29.33%;background:#cceeff;margin:0pt;padding:0pt;"> Net investment hedges </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:17.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:14.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"> Cross-currency swap </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:17.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,015 </td><td style="vertical-align:bottom;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> –</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> –</p></td><td style="vertical-align:bottom;width:29.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.70%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.70%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.70%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,340)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.70%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,121)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.70%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:49.70%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(Gain) Loss Reclassified into Income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:23.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:49.70%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Year Ended </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:23.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:49.70%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">June 30, </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;width:18.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Location of (Gain) Loss </p></td></tr><tr><td style="vertical-align:bottom;width:23.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">2024</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">2023</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">2022</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;width:18.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">in Income Statement</p></td></tr><tr><td style="vertical-align:bottom;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flow hedges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-

</td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:23.17%;margin:0pt;padding:0pt;"> Forward starting swaps </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,317)</p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;width:11.03%;margin:0pt;padding:0pt;"> (4,526) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Interest expense</p></td></tr><tr><td style="vertical-align:bottom;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net investment hedges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:3.40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.00%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:23.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cross-currency swaps</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(3,210)</p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Interest expense</p></td></tr><tr><td style="vertical-align:bottom;width:23.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (13,527) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,526)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,352 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.00%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> Gains or losses related to the net investment hedges are classified as foreign currency translation adjustments in the schedule of changes in Accumulated Other Comprehensive Income (“AOCI”) in Note 8, as these items are attributable to the Company’s hedges of its net investment in foreign operations. Gains or losses related to the cash flow hedges are classified as Unrealized gains (losses) on cash flow hedges in the schedule of changes in AOCI in Note 8. The instruments were valued using observable market inputs in active markets and therefore are classified as Level 2 liabilities. Fair value measurements of contingent consideration As of June 30, 2024, the Company does not have outstanding contingent consideration as the Asuragen and Namocell acquisitions did not meet their respective milestones as of December 31, 2023. The Asuragen contingent agreement required the Company to make contingent consideration payments of up to $105.0 million if certain revenue thresholds were achieved by December 31, 2023. The opening balance sheet fair value of the liabilities was $10.3 million, which was determined using a Monte Carlo simulation-based model discounted to present value. Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate, and various probability factors. The contingent consideration related to Asuragen was $2.0 million as of June 30, 2023. The Namocell contingent agreement required the Company to make contingent consideration payments of up to $25.0 million if certain revenue thresholds were achieved by December 31, 2023. The opening balance sheet fair value of the liabilities was $10.6 million, which was determined using a Monte Carlo simulation-based model discounted to present value. Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate, and various probability factors. The contingent consideration related to Namocell was $1.5 million as of June 30, 2023. As of June 30, 2023, the Company’s obligation for potential contingent consideration payments related to the B-Mogen acquisitions was relieved as the likelihood that the revenue thresholds and product milestones would be achieved in the timeframe established within the purchase agreement was remote. As a result, the Company reversed an accrual for the fair value of the contingent liabilities at the date of settlement during fiscal 2022. The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;">
    </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#cceeff;margin:0pt;padding:0pt;"> Fair value at the beginning of period </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> 5,000 </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"> Purchase price contingent consideration (Note 4) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> 10,600 </td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#cceeff;margin:0pt;padding:0pt;"> Change in fair value of contingent consideration </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (3,500) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> (12,100) </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"> Payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#cceeff;margin:0pt;padding:0pt;"> Fair value at the end of period </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,500 </td></tr></table>   The use of different assumptions, applying different judgment to matters that inherently are subjective and changes in future market conditions could result in different estimates of fair value of our securities or contingent consideration, currently and in the future. If market conditions deteriorate, we may incur impairment charges for securities in our investment portfolio. Fair value measurements of other financial instruments — The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate fair value. Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable — The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items. Long-term debt — The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility and long-term debt approximates fair value because our interest rate is variable and reflects current market rates. The Company's financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, derivative instruments, and long-term debt. Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation. The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"> <span

style="font-weight:bold;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> value as of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.5%;margin:0pt;padding:0pt;"> Fair Value Measurements Using </td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"> Balance Sheet Location </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs Considered as </td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.18%;background:#cceeff;margin:0pt;padding:0pt;"> Assets </td><td style="vertical-align:bottom;width:34.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.18%;background:#cceeff;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - cash flow hedges </td><td style="vertical-align:bottom;width:34.25%;background:#cceeff;margin:0pt;padding:0pt;"> Other current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"> 805 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"> 805 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - cash flow hedges </td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"> Other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,813 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,013 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.18%;background:#cceeff;margin:0pt;padding:0pt;"> Total assets </td><td style="vertical-align:bottom;width:34.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,072 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:25.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Liabilities</p></td><td style="vertical-align:bottom;width:34.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Derivatives designated as hedging instruments - net investment hedge</p></td><td style="vertical-align:bottom;width:34.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,051 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"> 2,051 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.18%;background:#cceeff;margin:0pt;padding:0pt;"> Total liabilities </td><td style="vertical-align:bottom;width:34.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> value as of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.15%;margin:0pt;padding:0pt;"> Fair Value Measurements Using </td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> Balance Sheet Location </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs Considered as </td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:24.85%;background:#cceeff;margin:0pt;padding:0pt;"> Assets </td><td style="vertical-align:bottom;width:33.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> Exchange traded securities⁽²⁾ </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> Short-term available-for-sale investments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> 23,739 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:24.85%;background:#cceeff;margin:0pt;padding:0pt;"> Derivative instruments - cash flow hedges </td><td style="vertical-align:bottom;width:33.93%;background:#cceeff;margin:0pt;padding:0pt;"> Other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,857 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,057 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"> Total assets </td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 40,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 23,739 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> –</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> –</p></td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities</p></td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:24.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;width:33.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> –</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,500</p></td></tr><tr><td style="vertical-align:bottom;width:24.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities</p></td><td style="vertical-align:bottom;width:33.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> –</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,500 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:10pt;padding:0pt;">(1)</td><td style="padding:0pt;">The certificates of deposit have contractual maturity dates within one year.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:10pt;padding:0pt;">(2)</td><td style="padding:0pt;">During the quarter ended September 30, 2023, the Company sold all of its exchange traded investment grade bond funds that it held at June 30, 2023. The costs basis and fair value of these exchange traded investment grade bond funds were $25.0 million and $23.7 million at June 30, 2023, respectively.</td></tr></table>1072000107200080500080500098130009813000116900001072000106180002051000205100020510002373900023739000168570001685700035000003500000350000025000000.023700000 The following table presents the contractual amounts of the Company's outstanding instruments (in millions): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:25.07%;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;width:2.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;"> Designation </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:25.07%;background:#cceeff;margin:0pt;padding:0pt;"> Forward starting swaps⁽¹⁾ </td><td style="vertical-align:bottom;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.88%;background:#cceeff;margin:0pt;padding:0pt;"> Cash flow hedge </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 300 </td></tr><tr><td style="vertical-align:bottom;width:25.07%;margin:0pt;padding:0pt;"> Cross-currency swap⁽²⁾ </td><td style="vertical-align:bottom;width:2.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;"> Net investment hedge </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 150 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> — </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">In May 2021, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $200 million of notional principal. The effective date of the swap was November 2022 with the full swap maturing in November 2025. In March 2023, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $100 million of notional principal. The effective date of the swap was April 2023 with the full swap maturing in April 2025. </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">In July 2023, the Company entered into a pay-fixed rate, receive-fixed rate cross-currency swap contract with a total notional amount of $150 million that was designated as a hedge to lock in the Swiss franc (CHF) rate for a portion of the Company's CHF net investment in its Lunaphore subsidiary in Switzerland. The objective of the hedge is to protect the net investment in the Company's CHF-denominated operations against changes in the spot exchange rates, on a pre-tax basis. The hedging instrument has four interim settlement dates, which will reduce the notional on the hedging instrument by $10 million at each interim date, and will reduce the notional to $110 million at maturity. </td></tr></table><div style="margin-top:10pt;"></div>3000000003000000001500000002000000001000000001500000004100000001100000000<p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses with our Consolidated Financial Statements for the twelve months ended June 30, 2024 and 2023 were as follows (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="8" style="vertical-align:bottom;width:63.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(Gain) Loss Recognized in Accumulated Other Comprehensive Loss</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:63.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Year Ended </i></p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:63.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">June 30, </i></p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">2024</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">2023</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">2022</i></p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flow hedges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forward starting swaps</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;width:17.25%;margin:0pt;padding:0pt;"> 12,632 </td>

<td style="vertical-align:bottom;width:3.78%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,340)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;width:14.85%;margin:0pt;padding:0pt;"> (19,121) </td></tr><tr><td style="vertical-align:bottom;width:29.33%;background:#cceeff;margin:0pt;padding:0pt;"> Net investment hedges </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.70%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:middle;width:17.25%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:middle;width:3.70%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:middle;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:middle;width:14.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"> Cross-currency swap </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;width:17.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,015 </td><td style="vertical-align:bottom;width:3.78%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:29.33%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1,340) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (19,121) </td></tr></table>) <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.17%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">) </td><td colspan="8" style="vertical-align:bottom;width:49.70%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Gain) Loss Reclassified into Income </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:23.17%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">) </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:49.70%;margin:0pt;padding:0pt;"> Year Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.17%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">) </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:49.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">) </td><td colspan="5" style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"> Location of (Gain) Loss </td></tr><tr><td style="vertical-align:bottom;width:23.17%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;">) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#cceeff;margin:0pt;padding:0pt;"> Fair value at the beginning of period </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> 5,000 </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"> Purchase price contingent consideration (Note 4) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> 10,600 </td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#cceeff;margin:0pt;padding:0pt;"> Change in fair value of contingent consideration </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (3,500) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> (12,100) </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"> Payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#cceeff;margin:0pt;padding:0pt;"> Fair value at the end of period </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,500 </td></tr></table>35000005000000106000003500000123000000350000 Note 6. Debt and Other Financing Arrangements: On August 31, 2022, the Company entered into a revolving line-of-credit and term loan by a Credit Agreement (the Credit Agreement). The Credit Agreement provides for a revolving credit facility of $1 billion, which can be increased by an additional $400 million subject to certain conditions. Borrowings under the Credit Agreement may be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement bear interest at a variable rate. The current outstanding debt is based on the one-month Secured Overnight Financing Rate (SOFR) plus an applicable margin. The applicable margin is determined from the total leverage ratio of the Company and updated on a quarterly basis. The annualized fee for any unused portion of the credit facility is currently 10 basis points. The Credit Agreement matures on August 31, 2027 and contains customary restrictive and financial covenants and customary events of default. As of June 30, 2024, the outstanding balance under the Credit Agreement was $319.0 million. 10000000004000000000.00103190000000.0 Note 7. Leases: As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement date, operating lease right-of-use assets and liabilities are recognized based on the present value of lease payments over the lease term. The discount rate used to calculate present value is the Company's incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. The Company recognizes operating lease expense on a straight-line basis over the lease term. Further, as part of our adoption of ASC 842, the Company also made the accounting policy elections to not capitalize short term leases (defined as a lease with a lease term that is less than 12 months) and to combine lease and non-lease components for all asset classes in determining the lease payments. Variable lease payments primarily include payments for non-lease components, such as maintenance costs and payments for non-components such as sales tax. During fiscal year 2024, the Company recognized $5.0 million in variable lease expense in the Consolidated Statements of Earnings and Comprehensive Income. During fiscal year 2024, the Company also recognized $10.2 million relating to fixed lease expense in the Consolidated Statements of Earnings and Comprehensive Income. The following table summarizes the balance sheet classification of the Company's operating leases, amounts of right of use assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company's operating leases (asset and liability amounts are in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.06%;margin:0pt;padding:0pt;">
</td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times
New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> <span style="font-
style:italic;visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Balance Sheet Classification </td><td style="vertical-
align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> <span style="font-
weight:bold;visibility:hidden;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024 </td></tr><tr><td style="vertical-
align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"> Operating leases: </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-
align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;">
  </td></tr><tr><td style="vertical-
align:bottom;width:57.76%;margin:0pt;padding:0pt;"> Operating lease right-of-use assets </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td
style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use asset </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"> $ </td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
91,205 </td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;
width:1.05%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;">
  </td></tr><tr><td style="vertical-
align:bottom;width:57.76%;margin:0pt;padding:0pt;"> Current operating lease liabilities </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td
style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities - current </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times
New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> $ </td><td colspan="2" style="vertical-
align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"> 12,920
</td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt
10pt;">Noncurrent operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:28.61%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease liabilities
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
  </td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt
3.5pt 0.05pt 0pt;"> 87,618 </td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt
0.05pt 24pt;">Total operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:0.51%;margin:0pt;padding:0pt;">   </td><td
style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double
#000000;margin:0pt;padding:0pt;"> $ </td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">
100,538 </td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;
width:1.05%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-
align:bottom;width:57.76%;margin:0pt;padding:0pt;"> Weighted average remaining lease term (in years):
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.05%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-
align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"> 8.45 </td>
</tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;">
  </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-
align:bottom;width:57.76%;margin:0pt;padding:0pt;"> Weighted average discount rate (%): </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.05%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-
align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"> 4.23 </td>
</tr></table>   <p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the cash paid for amounts included in the measurement of operating lease
liabilities and right of use assets obtained in exchange for new operating lease liabilities for the year ended June 30, 2024 (in thousands): <p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6.5pt;"> <table style="border-
collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> <p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> <p
style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-
align:bottom;width:79.77%;margin:0pt;padding:0pt;">   </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;">
  </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Year ended </td></tr><tr><td style="vertical-
align:bottom;width:79.77%;margin:0pt;padding:0pt;">   </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;">
  </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June 30, </td></tr><tr><td style="vertical-
align:bottom;width:79.77%;margin:0pt;padding:0pt;">   </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;">
     </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024 </td></tr><tr><td style="vertical-
align:bottom;width:79.77%;background:#cceeff;margin:0pt;padding:0pt;"> Cash amounts paid on operating
lease liabilities⁽¹⁾ </td><td style="vertical-align:bottom;white-
space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,729 </td></tr><tr><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.77%;background:#cceeff;margin:0pt;padding:0pt;"> Right-of-use assets obtained in exchange for lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,051</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:10pt;padding:0pt;">(1)</td><td style="padding:0pt;">Total cash paid for the Company's operating leases during the year ended June 30, 2024 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity.</td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The following table summarizes payments by date for the Company's operating leases, which is then reconciled to our total lease obligation (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June 30, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Operating</i></p></td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Leases</i></p></td></tr><tr><td style="vertical-align:bottom;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> 16,331 </td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> 16,429 </td></tr><tr><td style="vertical-align:bottom;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> 13,577 </td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> 13,479 </td></tr><tr><td style="vertical-align:bottom;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"> 2029 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> 12,967 </td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48,211 </td></tr><tr><td style="vertical-align:bottom;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 120,994</p></td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Amounts representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20,456</p></td></tr><tr><td style="vertical-align:bottom;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100,538 </td></tr></table> Certain leases include one or more options to renew, with terms that extend the lease term up to five years. The Company includes option to renew the lease as part of the right of use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, the Company is not reasonably certain to exercise such options. As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement date, operating lease right-of-use assets and liabilities are recognized based on the present value of lease payments over the lease term. The discount rate used to calculate present value is the Company's incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. The Company recognizes operating lease expense on a straight-line basis over the lease term. Further, as part of our adoption of ASC 842, the Company also made the accounting policy elections to not capitalize short term leases (defined as a lease with a lease term that is less than 12 months) and to combine lease and non-lease components for all asset classes in determining the lease payments. 5000000.010200000 The following table summarizes the balance sheet classification of the Company's operating leases, amounts of right of use assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company's operating leases (asset and liability amounts are in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance Sheet Classification </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-

align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"> Operating leases: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"> Operating lease right-of-use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"> Right-of-use asset </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 91,205</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Current operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"> 12,920 </td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"> Noncurrent operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 87,610 </td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"> Total operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">100,530</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Weighted average remaining lease term (in years):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.45</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Weighted average discount rate (%):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.23</p></td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;"></p><p>912850001292000007618000100530000P0Y5M12D0.0423<p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the year ended June 30, 2024 (in thousands):</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6.5pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Year ended </i></p></td></tr><tr><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">June 30, </i></p></td></tr><tr><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">   </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">2024</i></p></td></tr><tr><td style="vertical-align:bottom;width:79.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash amounts paid on operating lease liabilities⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"> 17,729 </td></tr><tr><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:79.77%;background:#cceeff;margin:0pt;padding:0pt;"> Right-of-use assets obtained in exchange for lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"> 11,051 </td></tr></table><div style="font-family:'Times New Roman','Times',serif;font-size:10.0pt;margin-

bottom:0pt;min-height:1.19em;position:relative;width:100%;"> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:10pt;padding:0pt;">(1)</td><td style="padding:0pt;">Total cash paid for the Company's operating leases during the year ended June 30, 2024 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity.</td></tr></table>
177290001105100 The following table summarizes payments by date for the Company's operating leases, which is then reconciled to our total lease obligation (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"> June 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"> Operating </td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Leases </td></tr><tr><td style="vertical-align:bottom;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,331</p></td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,429</p></td></tr><tr><td style="vertical-align:bottom;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,577</p></td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,479</p></td></tr><tr><td style="vertical-align:bottom;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12,967</p></td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 48,211</p></td></tr><tr><td style="vertical-align:bottom;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 120,994 </td></tr><tr><td style="vertical-align:bottom;width:83.29%;margin:0pt;padding:0pt;"> Less: Amounts representing interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 20,456 </td></tr><tr><td style="vertical-align:bottom;width:83.29%;background:#cceeff;margin:0pt;padding:0pt;"> Total lease obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100,530 </td></tr>
</table>16331000164290001357700013479000129670004821100012099400020456000100538000P5Y Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information: Equity The Company has declared cash dividends per share of $0.32 in each of the full fiscal years ended June 30, 2024, June 30, 2023, and June 30, 2022. During the years ended June 30, 2024, June 30, 2023, and June 30, 2022, the Company repurchased 1,397,471 shares at an average share price of $57.20, 222,000 shares at an average share price of $80.12, and 1,576,952 shares at an average share price of $102.06, respectively. The Company's accounting policy is to record the portion of share repurchases in excess of the par value entirely in retained earnings. During fiscal year 2024, 2023 and 2022, the amounts within the Consolidated Statements of Shareholders' Equity for the surrender and retirement of stock to exercise options due to net settlement stock options exercises and restricted stock units vesting were $21.9 million, $20.9 million, and $23.5 million, respectively. Accumulated Other Comprehensive Income (loss) The components of other comprehensive income (loss) consist of changes in foreign currency translation adjustments and changes in net unrealized gains (losses) on derivative instruments designated as cash flow hedges.
Changes in Accumulated Other Comprehensive Income (Loss) attributable to Bio-Techne by component (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt

0.05pt 0pt;">(Losses) on </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"> Currency </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"> Derivative </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"> Translation </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"> Balance as of June 30, 2021, net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,193)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> (51,098) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (57,291)</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income (loss), before tax, attributable to Bio-Techne: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amounts before reclassifications ⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 19,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,171)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,050)</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amounts reclassified out</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,352)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,352)</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other comprehensive income (loss), before tax, attributable to Bio-Techne: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12,769</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,171)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,402)</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,493</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other comprehensive income (loss), net of tax, attributable to Bio-Techne: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 14,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,171)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,909)</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of June 30, 2022, net of tax⁽²⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,069 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

```
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (83,269)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,200)</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income (loss), before tax, attributable to Bio-Techne: : </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amounts before reclassifications <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,531</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amounts reclassified out</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,678</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other comprehensive income (loss), before tax, attributable to Bio-Techne: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,209</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,073)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> (1,073)</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other comprehensive income (loss), net of tax, attributable to Bio-Techne: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,136</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of June 30, 2023, net of tax<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (78,926)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (66,064)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;white-
```

space:nowrap;width:49.84%;margin:0pt;padding:0pt;"> Other comprehensive income (loss), before tax: </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts before reclassifications </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ (12,632) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> $ (9,941) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> $ (22,573) </td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"> Amounts reclassified out </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ 10,317 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ 3,210 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ 13,527 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), before tax </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ (2,315) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> $ (6,731) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> $ (9,046) </td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"> Tax expense </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ (2,445) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (761) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,206) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,760) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (7,492) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (12,252) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.84%;margin:0pt;padding:0pt;"> Balance as of June 30, 2024, net of tax⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ 0,102 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (86,418) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (78,316) </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Amounts before reclassifications related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $33 thousand and $70 thousand attributable to the non-controlling interest in Eminence as of June 30, 2023, and June 30, 2022, respectively. </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:10pt;padding:0pt;">(2)</td><td style="padding:0pt;">The Company had a net deferred tax liability for its cash flow hedge of $2.5 million, $4.0 million and $2.5 million as of June 30, 2024, June 30, 2023 and June 30, 2022. </td></tr></table> Income taxes are not provided for foreign translation relating to permanent investments in international subsidiaries, but tax effects within foreign currency translation adjustments do include impacts from the net investment hedge.
0.320.320.32139747157.2022200088.121576952102.062190000020900000023500000 Changes in Accumulated Other Comprehensive Income (Loss) attributable to Bio-Techne by component (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.85

</td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;">Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"> (Losses) on </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"> Currency </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"> Derivative </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"> Translation </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:49.04%;background:#cceeff;margin:0pt;padding:0pt;"> Balance as of June 30, 2021, net of tax: </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,193)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> (51,098) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> (57,291) </td></tr><tr><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"> Other comprehensive income (loss), before tax, attributable to Bio-Techne: </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> (13,050) </td></tr><tr><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"> Amounts reclassified out </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,352) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,352) </td></tr><tr><td style="vertical-align:bottom;width:49.04%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), before tax, attributable to Bio-Techne: </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"> 12,769 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> (32,171) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> (19,402) </td></tr><tr><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"> Tax benefit </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,493 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,493 </td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), net of tax, attributable to Bio-Techne: </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,262 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (32,171) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (17,909) </td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"> Balance as of June 30, 2022, net of tax⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (83,269) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (75,200) </td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"> Other comprehensive income (loss), before tax, attributable to Bio-Techne: : </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts before reclassifications ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"> 1,340 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> 4,191 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 5,531 </td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"> Amounts reclassified out </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,526 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 152 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,678 </td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), before tax, attributable to Bio-Techne: </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"> 5,866 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> 4,343 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"> 10,209 </td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"> Tax expense </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,073) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,073) </td></tr><tr><td style="vertical-align:bottom;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), net of tax, attributable to Bio-Techne: </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,793 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,343 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,136 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.84%;margin:0pt;padding:0pt;"> Balance as of June 30, 2023, net of tax⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (78,926) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (66,064)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income (loss), before tax: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amounts before reclassifications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,632)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,941)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,573)</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amounts reclassified out</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,317</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,527</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other comprehensive income (loss), before tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,315)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,731)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,046)</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,445)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (761)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,206)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other comprehensive income (loss), net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,760)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,492)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,252)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of June 30, 2024, net of tax⁽²⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,102 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86,418)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (78,316) </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:10pt;padding:0pt;">(1)</td><td style="padding:0pt;">Amounts before reclassifications related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $33 thousand and $70<span style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-style:normal;font-

weight:normal;"> thousand attributable to the non-controlling interest in Eminence as of June 30, 2023, and June 30, 2022, respectively. </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">The Company had a net deferred tax liability for its cash flow hedge of $2.5 million, $4.0 million, and $2.5 million as of June 30, 2024, June 30, 2023 and June 30, 2022. </td></tr></table><div style="margin-top:10pt;"></div>-6193000-51098000-5729100019121000-32171000-13050000635200063520001276900-32171000-19402000-1493000-1493000142620000-32171000-17909000006900000-83269000-75200000134000041910005531000-4526000-152000-467800058660004343000102090001073000107300047930001360001206200-78926000-66064000-12632000-9941000-22573000-10317000-3210000-13527000-2315000-6731000-904600024450007610003206000-4760000-7492000-12252000010200-86418000-703160003300070000250000400000.02500000<p style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note 9. Earnings Per Share:</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net earnings, including noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 168,105 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 285,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 263,099 </td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"> Less net earnings (loss) attributable to noncontrolling interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 179 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,952) </td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"> Net earnings attributable to Bio-Techne </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 168,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 285,263 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 272,051</p></td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 10pt;">Income allocated to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (70)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (121)</p></td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 36pt;">Income available to common shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 168,072 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 285,193 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 271,930</p></td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 10pt;">Weighted-average shares outstanding — basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 157,708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 157,179 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 156,074 </td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"> Earnings per share — basic </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 1.01 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.73</p></td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Earnings per share — diluted:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Net earnings, including noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 160,105 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 285,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 263,099 </td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"> Less net earnings (loss) attributable to noncontrolling interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> -- </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 179 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,952) </td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"> Net earnings attributable to Bio-Techne </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 168,105 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 285,263 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 272,051 </td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"> Income allocated to participating securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (70) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (121) </td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"> Income available to common shareholders </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 160,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 205,193 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 271,930 </td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"> Weighted-average shares outstanding — basic </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 157,708 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 157,179 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 156,074 </td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"> Dilutive effect of stock options and restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> 3,066 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,676 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,240 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.37%;margin:0pt;padding:0pt;"> Weighted-average common shares outstanding – diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 160,774 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 161,855 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 164,114 </td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"> Earnings per share – diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 1.76 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 1.66 </td></tr></table> Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have not yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option is exercised are assumed to be used to repurchase shares in the current period. The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 3.9 million, 4.5 million, and 2.0 million for the fiscal years ended June 30, 2024, 2023 and 2022, respectively. The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"> Earnings per share – basic: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 168,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 285,442 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 263,099 </td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"> Less net earnings (loss) attributable to noncontrolling interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 179 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,952) </td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"> Net earnings attributable to Bio-Techne </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 168,105</p></td><td
style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 285,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 272,051</p></td></tr><tr><td
style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 10pt;">Income allocated
to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33)</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (70)</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (121)</p></td></tr><tr><td style="vertical-
align:bottom;width:62.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 36pt;">Income available to common shareholders</p></td><td
style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 168,072</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt
0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 285,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td
style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 271,930</p></td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 10pt;">Weighted-average shares outstanding - basic</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 157,708</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 157,179</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 156,874</p></td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Earnings per share - basic</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td
style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt
0pt;"> 1.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.73</p></td></tr><tr><td
style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Earnings per share - diluted:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-
align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-
align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 10pt;">Net earnings, including
noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 168,105</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 285,442</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 263,099</p></td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Less net earnings (loss) attributable to noncontrolling interest</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,952)</p></td></tr><tr><td style="vertical-
align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 10pt;">Net earnings attributable to
Bio-Techne</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 168,105</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 285,263</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 272,051</p>
</td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Income allocated
to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">
(33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (70)</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td

style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (121) </td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"> Income available to common shareholders </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 160,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 205,193 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 271,930</p></td></tr><tr><td style="vertical-align:bottom;width:62.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Weighted-average shares outstanding – basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 157,708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 157,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 156,874</p></td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 10pt;">Dilutive effect of stock options and restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,066</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,240</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Weighted-average common shares outstanding – diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 160,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 161,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 164,114</p></td></tr><tr><td style="vertical-align:bottom;width:62.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Earnings per share – diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 1.05 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 1.66 </td></tr></table>160105000285442000263099000179000-0952000168105000285263000272051000330007000012100016807200028519300027193000015770800015717900015687400030666000467600072400001607740001618550001641140001.051.761.66 Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have not yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option is exercised are assumed to be used to repurchase shares in the current period. 3900000450000028000 Note 10. Share-based Compensation and Other Benefit Plans: The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares. Equity incentive plan: The 2020 Equity Incentive Plan, which replaced the Company's Second Amended and Restated 2010 Equity Incentive Plan, provides for the granting of incentive and nonqualified stock options, restricted stock, restricted stock units, performance shares, performance units and stock appreciation rights. There were 36.2 million shares of common stock authorized for grant under the Plan. The maximum aggregate number of shares of common stock reserved and available for awards under the Plan is 9,936,000 shares. At June 30, 2024, there were 6.3 million shares of common stock available for grant under the 2020 Equity Incentive Plan. The maximum term of incentive options granted under the 2020 Equity Incentive Plan is ten years. The 2020 Equity Incentive Plan replaced the Company's second A&R 2010 Plan, which had previously amended and restated the Company's Amended and Restated 2010 Equity Incentive Plan (the A&R 2010 Plan). The 2020 Equity Incentive Plan and Second A&R 2010 Plan (collectively, the Plans) are administered by the Board of Directors and its Executive Compensation Committee, which determine the persons who are to receive awards under the Plans, the number of shares subject to each award and the term and exercise price of each award. The number of shares of common stock subject to outstanding awards as of June 30, 2024 under the 2020 Equity Incentive Plan were 11.6 million. The fair values of options granted under the Plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.63%;background:#cceeff;margin:0pt;padding:0pt;"> Dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"> 0.41 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"> 0.34 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"> 0.27 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:63.63%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> 30%-37 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> 30%-36 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> 27%-33 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:63.63%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rates </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"> 3.8%-4.8 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"> 2.8%-4.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"> 0.6%-2.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:63.63%;margin:0pt;padding:0pt;"> Expected lives (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> 4.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> 4.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> 4.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td></tr></table> The dividend yield is based on the Company's historical annual cash dividend divided by the market value of the Company's common stock. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted. Stock option activity under the Plans for the three years ended June 30, 2024, consists of the following (shares in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> Aggregate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> Intrinsic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> Shares (in </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Contractual </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (millions) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (years) </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at June 30, 2021 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"> 14,868 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 43.16 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> 1,390 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 120.15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"> (539) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 87.05 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,450) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 33.61 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at June 30, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"> 13,269 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 51.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 93.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 85.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> (1,578)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 60.56 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> 1,060 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 79.69 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"> (1,165) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 90.86 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"> (2,240) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> . </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 33.34 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"> 11,579 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 64.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 747.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> 3.0 </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> Exercisable at June 30, 2022: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> 7,797 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 36.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> Exercisable at June 30, 2023: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"> 8,641 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 44.76 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.77%;margin:0pt;padding:0pt;"> Exercisable at June 30, 2024: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> 8,208 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 53.57 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 439.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> 2.1 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> The weighted average fair value of options granted during fiscal 2024, 2023, and 2022 was $27.27, $29.53, and $29.70, respectively. The total intrinsic value of options exercised during fiscal 2024, 2023, and 2022 were $100.8 million, $90.2 million, and $209.3 million, respectively. The total fair value of options exercised during fiscal 2024, 2023, and 2022 were $58.2 million, $46.5 million, and $82.3 million, respectively. The total fair value of options vested during fiscal 2024, 2023, and 2022 were $31.6 million, $31.0 million, and $29.2 million, respectively. Stock options vest over a four year period. Restricted common stock activity under the Plans for the three years ended June 30, 2024, consists of the following (units in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> <b style="font-

weight:bold;">Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> Average Grant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> Contractual </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> Shares (in </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> Date Fair </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> Term </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (years) </td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested at June 30, 2021 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> 92 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (54)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 85.03 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;padding:0pt;"> 11 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 73.94 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> (40) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 70.85 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> Unvested at June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> 37 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 89.91 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> 28 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 57.38 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> (30) </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 35 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 70.22 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.60</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ The total fair value of restricted shares that vested was $2.4 million for fiscal 2024, $3.1 million for fiscal 2023, and $2.9 million for fiscal 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Restricted stock unit activity under the Plans for the three years ended June 30, 2024, consists of the following (units in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$ <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted </p></td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> Average Grant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual </p></td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date Fair</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Term </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">   </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (years) </td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at June 30, 2021 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 382 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 55.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> 117.60 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> (145) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> 44.62 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (45) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 104.34 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at June 30, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 302 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 75.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 90.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (123)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 52.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 106.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> 91.10 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 374 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> 78.16 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> (129) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> 76.42 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (31) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 99.96 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 497 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 84.62 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"> 5.71 </td></tr></table> The total fair value of restricted stock units that vested was $9.9 million for fiscal 2024, $6.4 million for fiscal 2023, and $6.5 million for fiscal 2022. The restricted stock units vest over a three-year period. Stock-based compensation cost, inclusive of payroll taxes, of $38.5 million, $39.3 million, and $44.0 million was included in selling, general and administrative expense in fiscal 2024, 2023 and 2022, respectively. Additionally, stock-based compensation costs, inclusive of payroll taxes, of $0.9 million, $1.0 million, and $1.4 million was included in cost of goods sold in 2024, 2023, and 2022, respectively. As of June 30, 2024, there was $35.0 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock which will be expensed in fiscal 2025 through 2028 using a 4.5% forfeiture rate. The weighted average period over which the compensation cost is expected to be recognized is 2.1 years. Employee stock purchase plan: In fiscal year 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 800,000 shares were allocated to the ESPP. The Company recorded expense of $0.9 million, $0.9 million, and $1.0 million for the ESPP in fiscal 2024, 2023, and 2022, respectively. Profit sharing and savings plans: The Company has profit sharing and savings plans for its U.S. employees, which conform to IRS provisions for 401(k) plans. The Company makes matching contributions to the Plan. The Company has recorded an expense for contributions to the plans of $5.8 million, $4.9 million, and $4.3 million for the years ended June 30, 2024, 2023, and 2022, respectively. The Company operates defined contribution pension plans, which consists of primarily our U.K. and China employees. The Company's contribution to the defined pension contribution plan was $5.5 million, $2.4 million, and $2.3 million for the years ended June 30, 2024, 2023 and 2022, respectively. Performance incentive programs: In fiscal 2024, under certain employment agreements, a Management Incentive Plan, and a business incentive plan, available to executive officers, certain management personnel, and certain other professional employees, the Company recorded cash bonuses of $13.5 million, granted options for 1,060,126 shares of common stock, issued 27,876 restricted common shares and 374,448 restricted stock units. In fiscal 2023 and fiscal 2022, the Company recorded cash bonuses of $10.8 million and $26.5 million, granted options for 2,350,980 and 1,390,436 shares of common stock, issued 10,816 and 27,584 restricted common stock shares and 107,202 and 110,292 restricted stock units, respectively. The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares. 362000009936808630000OP10Y11600000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.63%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> <div
style="bottom:0pt;position:absolute;width:100%;">
</td></tr><tr><td style="vertical-align:bottom;width:63.63%;margin:0pt;padding:0pt;"> <span style="font-
size:0pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:center;margin:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-
space:nowrap;width:32.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">Year Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.63%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:2.01%;margin:0pt;padding:0pt;">   </td><td
style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-
align:center;margin:0pt;">2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-
bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
2022 </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.99%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:63.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;">Dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"> 0.41 </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td
style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt;">0.34 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.27 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </td></tr><tr><td style="vertical-align:bottom;width:63.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> 30%-37 </td><td style="vertical-
align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> 30%-36 </td><td style="vertical-
align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> 27%-33 </td><td style="vertical-
align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-
align:bottom;width:63.63%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rates </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.8%-4.8 </td><td style="vertical-align:bottom;white-
space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"> 2.8%-4.4 </td><td
style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td
style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt;">0.6%-2.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;">% </td></tr><tr><td style="vertical-align:bottom;width:63.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;">Expected lives (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> 4.4 </td><td style="vertical-
align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"> 4.7
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:center;margin:0pt;">4.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr>
</table>0.00410.00340.00270.300.370.300.360.270.330.0380.0480.0280.0440.0060.026P4Y4M24DP4V8M12DP4Y3M18D<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:justify;margin:0pt 0pt 10pt 0pt;">Stock option activity under the Plans for the three years ended June 30, 2024, consists of the following (shares in thousands): <table style="border-
collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> <p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> <i style="font-
style:italic;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:0pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">   </td><td colspan="2" style="vertical-
align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">Aggregate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:0pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Weighted </td></tr><tr><td style="vertical-
align:bottom;width:56.77%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">Intrinsic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">Average </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-
align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">Shares (in </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> <b style="font-
weight:bold;">Contractual </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt
0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (millions) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Life (years) </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at June 30, 2021 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"> 14,060 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 43.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 120.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (539)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 87.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,450)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 33.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 51.20 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> 2,351 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 93.81 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"> (110) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 85.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> (1,578) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29.48 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"> 13,924 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 60.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 79.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,165)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 90.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,240)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 33.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 64.53 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 747.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> 3.0 </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> Exercisable at June 30, 2022: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> 7,797 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 36.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> Exercisable at June 30, 2023: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"> 8,641 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 44.76 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.77%;margin:0pt;padding:0pt;"> Exercisable at June 30, 2024: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"> 8,208 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 53.57 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 439.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> 2.1 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr>
</table>1406000043.161390000120.1553900087.05245000033.611326900051.20235100093.8111800085.991578000029.481392400060.561060000079.69116500090.862240000033.341157900064.537473000003P3Y779700036.99864100044.76style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Restricted common stock activity under the Plans for the three years ended June 30, 2024, consists of the following (units in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> Average Grant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> Contractual </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> Shares (in </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> Date Fair </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> Term </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (years) </td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested at June 30, 2021 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> 92 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (54)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Unvested at June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 85.03 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> 11 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 73.94 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> (40) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.50%;background:#cceeff;margin:0pt;padding:0pt;"> 70.05 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested at June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> 37 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> –</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> –</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Unvested at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 70.22 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> 6.60 </td></tr></table> Restricted stock unit activity under the Plans for the three years ended June 30, 2024, consists of the following (units in thousands): <table style="border-collapse:collapse;font-size:10pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Remaining </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> Average Grant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Contractual </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> Units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> Date Fair </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> Term </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (years) </td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at June 30, 2021 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 382 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 55.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 117.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (145)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 44.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (45)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 104.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> 75.54 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 107 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> 90.96 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> (123) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> 52.34 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 106.13 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 283 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> 91.10 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 374 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> 78.16 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> (129) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> 76.42 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (31) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 99.96 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.72%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 497 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 84.62 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"> 5.71 </td></tr>
</table>92000056.5228000122.345400054.576600085.831100073.944000078.853700089.912800057.383000082.513500070.22P6Y7M6D240000031000002900000382000055.13110000117.6014500044.6245000104.3430200075.5410700090.9
<tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note 11. Other Income / (Expense) The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="0" style="vertical-align:bottom;white-space:nowrap;width:45.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:52.89%;background:#cceeff;margin:0pt;padding:0pt;"> Interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,736)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"> (11,215) </td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,309)</p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,410</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 794</p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain (loss) on investment⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 49,328</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 15,186</p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain (loss) on equity method investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,041)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,143)</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other non-operating income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,026)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (665)</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 125</p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">Total other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (20,997) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:4.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 39,715</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,796 </td></tr></table> - (1) For the year ended June 30, 2024, this is for a $0.3 million gain on the sale of our exchange trade investment grade bond funds. For the year ended June 30, 2023, this is for a $37.2 million gain on the sale of our CCXI investment, a $11.7 million gain on the sale of Eminence, and a gain of $0.4 million related to the change in fair value of our exchange traded bond funds. For the year ended June 30, 2022, this is for a $16.1 million gain in the fair value of our CCXI investment.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</p></td></tr><tr><td style="vertical-align:bottom;width:52.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"> (15,736) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,215)</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"> (11,309) </td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"> Interest income </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"> 3,323 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"> 3,410 </td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"> 794 </td></tr><tr><td style="vertical-align:bottom;width:52.89%;background:#cceeff;margin:0pt;padding:0pt;"> Gain (loss) on investment⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"> 283 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"> 49,328 </td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"> 15,186 </td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"> Gain (loss) on equity method investment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"> (6,841) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"> (1,143) </td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:52.89%;background:#cceeff;margin:0pt;padding:0pt;"> Other non-operating income (expense), net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,026) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (665) </td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 125 </td></tr><tr><td style="vertical-align:bottom;width:52.89%;margin:0pt;padding:0pt;"> Total other income (expense) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,997)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 39,715 </td><td style="vertical-align:middle;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,796 </td></tr></table> ⁽¹⁾For the year ended June 30, 2024, this is for a $0.3 million gain on the sale of our exchange trade investment grade bond funds. For the year ended June 30, 2023, this is for a $37.2 million gain on the sale of our CCXI investment, a $11.7 million gain on the sale of Eminence, and a gain of $0.4 million related to the change in fair value of our exchange traded bond funds. For the year ended June 30, 2022, this is for a $16.1 million gain in the fair value of our CCXI investment.
1573600011215000113090003323000341000079400028300049320000151860000-6041000-1143000-2026000-665000125000-2099700039715000479600030000037200000117000004000001610000 Note 12. Income Taxes: Income before income taxes was comprised of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Domestic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 174,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> 280,458 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 255,110</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 50,201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,268</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Earnings before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 185,689 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 338,659</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 301,306 </td></tr></table> The provision for income taxes consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Taxes on income consist of: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Current tax provision: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td>

<td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Federal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> 59,810 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,080</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> 4,053 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 6,663 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,453 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,401</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total current tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> 57,745 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 83,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 31,224 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Deferred tax provision: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Federal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,301)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> (28,829) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,130</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> (4,563) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,414)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> 1,477 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> (7,297)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,444 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,544)</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total deferred tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (40,161) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,799)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,063 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Total income tax provision </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53,217 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,287 </td></tr></table> The Company's effective income tax rate for fiscal 2024 was 9.5% vs 15.7% in the prior year. The change in the effective tax rate for fiscal 2024 and 2023 was driven by share-based compensation as the number of stock option exercises increased compared to the prior year comparative period. The Company's effective income tax rate for fiscal 2023 was 15.7% vs 12.7% in the prior year. The change in the effective tax rate for fiscal 2023 and 2022 was driven by share-based compensation as the number of stock option exercises decreased compared to the prior year comparative period. The Company's discrete tax benefits in fiscal 2024, 2023, and 2022 primarily related to share-based compensation excess tax benefits of $10.4 million, $12.3 million, and $29.3 million, respectively. The following is a reconciliation of the federal tax calculated at the statutory rate to the actual income taxes provided: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;">   </td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:36.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Income tax expense at federal statutory rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 21.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 21.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 21.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> State income taxes, net of federal benefit </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> (0.2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 2.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development tax credit </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (2.2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (1.3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (1.0) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> Contingent consideration adjustment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> (0.4) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> (0.8) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> (1.4) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Foreign tax rate differences </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 3.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (0.6) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 0.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> (Gain)/loss on investment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> (0.7) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 1.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> <span style="font-family:'Calibri','Helvetica','sans-

serif';visibility:hidden;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Option exercises </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (8.8) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (3.3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (9.4) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> U.S. taxation of foreign earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 0.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 0.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (0.1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Foreign derived intangible income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (4.8) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (3.4) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (1.9) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> Foreign withholding tax </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> (1.2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 1.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Executive compensation limitations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 2.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 0.8 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 1.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> Other, net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (0.4) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (0.10) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Effective tax rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr></table> . Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p

space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,698) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,730) </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> Deferred tax liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (165,186) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (184,005) </td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"> Net deferred income tax liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (55,863)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (88,982) </td></tr></table> - A deferred tax valuation allowance is required when it is more likely than not that all or a portion of deferred tax assets will not be realized. The valuation allowance as of June 30, 2024 was $19.3 million compared to $9.3 million in the prior year. As of June 30, 2024, the $19.3 million valuation allowance relates to certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company completed various previous acquisitions as well as immaterial amounts generated after the acquisitions. The Company believes it is more likely than not that these tax carryovers will not be realized. As of June 30, 2024, the Company has federal operating loss carryforwards of approximately $34.0 million and state operating loss carryforwards of $146.8 million from its previous acquisitions, which are not limited under IRC Section 382. As of June 30, 2024, the Company has foreign net operating loss carryforwards of $77.5 million. Some of the net operating loss carryforwards expire between fiscal 2025 and 2036. Federal net operating loss carryforwards generated after December 31, 2017 have an indefinite carryforward period but the Company expects to be fully utilize these attributes by June 30, 2032. The Company has a deferred tax asset of $9.8 million, net of the valuation allowance discussed above, related to the net operating loss carryovers. As of June 30, 2024, the Company has federal and state tax credit carryforwards of $4.4 million and $5.6 million, respectively. The federal tax credit carryforwards expire between 2028 and 2040. The majority of the state credit carryforwards have no expiry date. The state credit carryforwards that have expiry dates have a full valuation allowance. The Company has a deferred tax asset of $5.5 million, net of the valuation allowance discussed above, related to the tax credit carryovers. As of June 30, 2024, the Company has approximately $246 million of undistributed earnings in its foreign subsidiaries. Approximately $108 million of these earnings are no longer considered permanently reinvested and the Company expects to be able to repatriate earnings on a tax neutral basis. The Company has not provided deferred taxes on approximately $138 million of undistributed earnings from non-U.S. subsidiaries as of June 30, 2024 which are indefinitely reinvested in operations. Because of the multiple entities as well as the complexities of laws and regulations by which to repatriate the earnings to minimize tax cost, it is not practical to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely. A deferred tax liability will be recognized if the Company can no longer demonstrate that it plans to indefinitely reinvest the undistributed earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We continue to analyze our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries distribute cash to the U.S. parent, which include local country withholding tax and potential U.S. state taxation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> 5,291 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 7,271 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Additions due to acquisitions </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> 960 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Additions for tax positions of prior year </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 304 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Decrease in unrecognized tax benefits for prior year positions </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> (357) </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Settlements </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,860) </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> FX impact </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (13) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (11) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (16) </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Ending balances </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,291 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,302 </td></tr></table> Included in the balance of unrecognized tax benefits at June 30, 2024 are potential benefits of $5.3 million that, if recognized, would affect the effective tax rate on income from continuing operations. The Company recognizes interest and penalties related to unrecognized tax benefits in its provision for income taxes. The Company had $0.6 million of accrued interest and penalties as of June 30, 2024. The amount recorded for the periods ended June 30, 2023 and June 30, 2022, was $0.5 million and $0.3 million, respectively, in accrued interest and penalties. The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next twelve months. The Company files income tax returns in the U.S. federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Company's federal returns are subject to tax assessment for 2019 and subsequent years. State and foreign income tax returns are generally subject to examination for a period of three to five years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to one year after formal notification to the states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Income before income taxes was comprised of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="0" style="vertical-align:bottom;white-space:nowrap;width:35.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</p></td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> 174,806 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 208,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 255,110 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,883 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 50,201 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 46,268 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Earnings before income taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 185,689</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 338,659 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 301,386 </td></tr></table> The provision for income taxes consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="0" style="vertical-align:bottom;white-space:nowrap;width:35.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td

colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Taxes on income consist of: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Current tax provision: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Federal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> 59,810 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> 10,000 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> State </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> 4,853 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> 12,753 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 6,663 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,664 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,453 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,401 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Total current tax provision </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> 57,745 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> 83,016 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 31,224 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Deferred tax provision: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Federal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> (28,301) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> (28,029) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 8,130 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> State </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> (4,563) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> (2,414) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> 1,477 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (7,297) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,444 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,544) </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Total deferred tax provision </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (40,161) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (29,799) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,063 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman'

Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total income tax provision </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53,217 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,207 </td></tr>
</table>1740060002884580002551180001083000502010004626800018569000033865900031386000402280005981000010080000485300012753000666300012664000104530001448100057745000083016000312240002030120829000813000045634000147700082970001444000254400040161000-297990007063000175840005321700038287000.0950.1570.1570.127184000001230000029300000 The following is a reconciliation of the federal tax calculated at the statutory rate to the actual income taxes provided: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:36.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Income tax expense at federal statutory rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 21.0% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 21.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 21.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> State income taxes, net of federal benefit </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> (0.2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 2.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development tax credit </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (2.2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (1.3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (1.0) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> Contingent consideration adjustment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> (0.4) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> (0.0) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> (1.4) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Foreign tax rate differences </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 3.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (0.6) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 0.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> (Gain)/loss on investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> (0.7) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 1.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Option exercises </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (8.0) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (3.3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (9.4) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> U.S. taxation of foreign earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 0.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 0.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (0.1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Foreign derived intangible income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (4.8) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (3.4) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> (1.9) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> Foreign withholding tax </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> (1.2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> 1.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Executive compensation limitations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 2.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 0.8 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"> 1.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;margin:0pt;padding:0pt;"> Other, net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (0.4) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (0.10) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.29%;background:#cceeff;margin:0pt;padding:0pt;"> Effective tax rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr></table>0.2100.2100.210-0.0020.0250.0220.0220.0130.010-0.004-0.008-0.0140.031-0.0060.004-0.0070.011-0.008-0.033-0.0940.0010.004-0.0010.0480.0340.019-0.0120.0150.0270.0080.0190.002-0.004-0.00100.0950.1570.127 Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> <span style="font-

size:8pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"> Inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 10,906 </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> Net operating loss carryovers </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 25,065 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 20,315 </td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"> Tax credit carryovers </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 9,110 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 9,218 </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> Excess tax basis in equity investments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 1,115 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 939 </td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 16,628 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 16,528 </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> Lease liability </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 19,501 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> 21,001 </td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"> Capitalized R&D </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 36,151 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 21,081 </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> Held-for-sale asset impairment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 5,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 6,119 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> 4,379 </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> Valuation allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (19,265) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,344) </td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred tax assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 109,323 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 95,023 </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"> Intangible asset amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> (120,648) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> (134,810) </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> Depreciation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> (20,448) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> (21,449) </td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"> Right of use asset </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> (17,876) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"> (20,021) </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> Derivative - cash flow hedge </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> (2,516) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"> (3,995) </td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,698) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,730) </td></tr><tr><td style="vertical-align:bottom;width:71.37%;margin:0pt;padding:0pt;"> Deferred tax liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (165,186) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (184,005) </td></tr><tr><td style="vertical-align:bottom;width:71.37%;background:#cceeff;margin:0pt;padding:0pt;"> Net deferred income tax liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (55,863)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (80,982) </td></tr></table> 9675000109060002506500020315000911000092180001115000939000166200016520000195010002100100036151000210810005216000611900043790001926500093440001093230009502300012064800013481000020448000214490001706607 The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> . </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:35.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> 5,302 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 7,271 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Additions due to acquisitions </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> 960 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Additions for tax positions of prior year </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 304 </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> Decrease in unrecognized tax benefits for prior year positions </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt;"> (2,860) </td></tr><tr><td style="vertical-align:bottom;width:62.46%;margin:0pt;padding:0pt;"> FX impact </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (13) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (11) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (16) </td></tr><tr><td style="vertical-align:bottom;width:62.46%;background:#cceeff;margin:0pt;padding:0pt;"> Ending balances </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,291 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,302 </td></tr>
</table>529100053020007271000960000304000357000286000013000110001600052780005291000530200053000060000050000030000 Note 13. Segment Information: The Company operates under two operating segments, Protein Sciences and Diagnostics and Genomics. The Company's Protein Sciences segment is comprised of the reagent solutions division and analytical solutions division. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. No customer in the Protein Sciences segment accounted for more than 10% of the segment's net sales for the years ended June 30, 2024, 2023, and 2022. The Company's Diagnostics and Genomics segment is comprised of the diagnostics reagents division, spatial biology divsion, and molecular diagnostics division. Our Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications. No customer in the Diagnostics and Genomics segment accounted for more than 10% of the segment's net sales for the fiscal years ended June 30, 2024, 2023, and 2022. There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term. Following is financial information relating to the operating segments (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"> $</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"> $</p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">$ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Net sales: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"> 274,843 </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> Other revenue⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"> 4,153 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> – </td></tr><tr><td style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Intersegment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,387) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,647) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,555) </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> Consolidated net sales </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,159,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> –</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,136,702 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,105,599</p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> –</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> –</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> –</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> –</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Protein Sciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> 354,775 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 373,684</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> 377,623 </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> Diagnostics and Genomics </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24,546 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 43,037 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 40,977 </td></tr><tr><td style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Segment operating income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 379,321 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 416,721 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 426,600 </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> Costs recognized on sale of acquired inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> (729) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> (400) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> (1,596) </td></tr><tr><td style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Amortization of intangibles </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> (78,318) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> (76,413) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> (73,054) </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> Impact of partially-owned consolidated subsidiaries⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> 647 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> (2,393) </td></tr><tr><td style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Acquisition related expenses and others </td><td style="vertical-align:bottom;

space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,980) </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,965 </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 19,070 </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Certain Litigation Charges </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td
style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,506) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td
style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt
0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> — </td></tr><tr><td
style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Impairment of
assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> (21,963)
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td
style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> — </td>
</tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> Eminence impairment
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt
3.5pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> — </td><td
style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> — </td>
</tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> Eminence impairment
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td
style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> — </td><td
style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td
style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt
0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> (10,715) </td></tr><tr><td
style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Stock based
compensation, inclusive of employer taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-
align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt
0pt;"> (40,277) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> (41,217)
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,401) </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restructuring and restructuring-related costs </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td
style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td
style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;">
(12,245) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,829) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> (1,640) </td></tr><tr><td
style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate
general, selling, and administrative expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-
align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt
0pt;"> (9,142) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> (6,530) </td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,281) </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impact of business held-for-sale<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">
(1)</sup> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
525 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td
style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> — </td></tr><tr><td style="vertical-
align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Consolidated operating
income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double
#000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt
3.5pt 0.05pt 0pt;"> 206,686 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double
#000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt
3.5pt 0.05pt 0pt;"> 298,944 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt
0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 296,590 </td></tr></table><table style="border-collapse:collapse;font-family:'Times New
Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New
Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-
size:10pt;font-style:normal;font-weight:normal;">Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. For the year ended June 30, 2024, includes the six-month
results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria.</td></tr></table><table
style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td
style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span
style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes the annual results of the partially-owned consolidated subsidiary prior to the sale of
this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023.</td></tr></table> <p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt
10pt 0pt;">The Company has some integrated facilities that serve both segments. As such, asset and capital expenditure information by operating segment has not been provided and is not available, since
the Company does not produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each operating segment's operating results, it is not
discretely identifiable. The Company has disclosed sales by geographic area based on the
location of the customer or distributor in Note 2. The Company has disclosed dis-aggregated product and service revenue by consumables, instruments, and services in Note 2. The Company considers total
instrument and total service revenue to represent similar groups of products in the fiscal years presented. The Company considers our consumables sold in the Protein Sciences and Diagnostics and
Genomics segments to represent different groups of products and therefore have separately disclosed the related consumables revenue (in thousands). <p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-
content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"> <span style="font-
size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-
wrap:break-word;position:relative;"> <span style="font-
size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-

wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:61.65%;background:#cceeff;margin:0pt;padding:0pt;"> Consumables revenue - Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 657,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> 665,301 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 646,952</p></td></tr><tr><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consumables revenue - Diagnostics and Genomics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 266,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 252,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 243,922</p></td></tr><tr><td style="vertical-align:bottom;width:61.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consumables revenue - Other revenue⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total consumable revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 920,180 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 917,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 890,074 </td></tr></table> ⁽¹⁾Includes the results of a business that has met the held-for-sale criteria since December 31, 2023. The following is financial information relating to geographic areas (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"> Long-lived assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"> United States and Canada </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 211,597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"> 203,657 </td></tr><tr><td style="vertical-align:bottom;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"> Europe </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 27,862 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"> 19,263 </td></tr><tr><td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0pt 6pt;">Asia </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,695 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,280 </td></tr><tr><td style="vertical-align:bottom;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"> Total long-lived assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 251,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 226,200 </td></tr><tr><td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"> Intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"> United States and Canada </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 443,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"> 529,652 </td></tr><tr><td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"> Europe </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 63,138 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"> 4,553 </td></tr><tr><td style="vertical-align:bottom;width:70.84%;background:#cceeff;margin:0pt;padding:0pt;"> Asia </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 203 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 440 </td></tr><tr><td style="vertical-align:bottom;width:70.84%;margin:0pt;padding:0pt;"> Total intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 507,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 534,645 </td></tr></table>   Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation. The Company operates under two operating segments, Protein Sciences and Diagnostics and Genomics. The Company's Protein Sciences segment is comprised of the reagent solutions division and analytical solutions division. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. No customer in the Protein Sciences segment accounted for more than 10% of the segment's net sales for the years ended June 30, 2024, 2023, and 2022. The Company's Diagnostics and Genomics segment is comprised of the diagnostics reagents division, spatial biology divsion, and molecular diagnostics division. Our Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications. No customer in the Diagnostics and Genomics segment accounted for more than 10% of the segment's net sales for the fiscal years ended June 30, 2024, 2023, and 2022. There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term. Following is financial information relating to the operating segments (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">   </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Net sales: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 830,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> 845,747 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 832,311</p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Diagnostics and Genomics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 326,392</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 292,602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 274,843</p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other revenue⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> (2,387)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> (1,647)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> (1,555)</p></td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Consolidated net sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,159,060 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,136,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,105,599 </td></tr><tr><td style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> Operating income: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 354,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> 373,684 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> 377,623 </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> Diagnostics and Genomics </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24,546 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 43,037 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48,977 </td></tr><tr><td style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Segment operating income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 379,321 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 416,721 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 426,600 </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> Costs recognized on sale of acquired inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> (729) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:

space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> (400) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,596) </td></tr><tr><td style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of intangibles </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (70,318) </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (76,413) </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (73,054) </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impact of partially-owned consolidated subsidiaries<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-
align:top;">(2)</sup> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt
0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;">
647 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,393) </td></tr><tr><td style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition related expenses and others </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,900) </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,965 </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 19,070 </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Certain Litigation Charges </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td
style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,506) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td
style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt
0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> — </td></tr><tr><td
style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Impairment of
assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> (21,963)
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt
0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td
style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> — </td>
</tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> Eminence impairment
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt
3.5pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt
0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td
style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> — </td>
</tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"> Stock based
compensation, inclusive of employer taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-
align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt
0pt;"> (40,277) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> (41,217)
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,401) </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restructuring and restructuring-related costs </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td
style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;">
(12,245) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,829) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;margin:0pt;padding:0pt;"> (1,640) </td></tr><tr><td
style="vertical-align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate
general, selling, and administrative expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-
align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt
0pt;"> (9,142) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-
space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"> (6,530) </td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,281) </td></tr><tr><td style="vertical-align:bottom;width:62.17%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impact of business held-for-sale<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">
(1)</sup> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt
0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
525 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-
space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td
style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> — </td></tr><tr><td style="vertical-
align:bottom;width:62.17%;background:#cceeff;margin:0pt;padding:0pt;"> Consolidated operating
income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double
#000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 206,686 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 298,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 296,590 </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. For the year ended June 30, 2024, includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Includes the annual results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023.</td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td></tr><tr><td style="vertical-align:bottom;width:61.65%;background:#cceeff;margin:0pt;padding:0pt;"> Consumables revenue - Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 657,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"> 665,301 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 646,952</p></td></tr><tr><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Consumables revenue - Diagnostics and Genomics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 266,348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 252,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 243,922</p></td></tr><tr><td style="vertical-align:bottom;width:61.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Consumables revenue - Other revenue⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total consumable revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 920,180 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 917,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 890,074 </td></tr></table> . ⁽¹⁾Includes the results of a business that has met the held-for-sale criteria since December 31, 2023. . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:70.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:70.04%;background:#cceeff;margin:0pt;padding:0pt;"> Long-lived assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

*space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.04%;margin:0pt;padding:0pt;"> United States and Canada </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 211,597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"> 203,657 </td></tr><tr><td style="vertical-align:bottom;width:70.04%;background:#cceeff;margin:0pt;padding:0pt;"> Europe </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 27,862 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"> 19,263 </td></tr><tr><td style="vertical-align:bottom;width:70.04%;margin:0pt;padding:0pt;"> Asia </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,695 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,280 </td></tr><tr><td style="vertical-align:bottom;width:70.04%;background:#cceeff;margin:0pt;padding:0pt;"> Total long-lived assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 251,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 226,200 </td></tr><tr><td style="vertical-align:bottom;width:70.04%;margin:0pt;padding:0pt;"> Intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.04%;background:#cceeff;margin:0pt;padding:0pt;"> United States and Canada </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> 443,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"> 529,652 </td></tr><tr><td style="vertical-align:bottom;width:70.04%;margin:0pt;padding:0pt;"> Europe </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 63,130 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"> 4,553 </td></tr><tr><td style="vertical-align:bottom;width:70.04%;background:#cceeff;margin:0pt;padding:0pt;"> Asia </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 203 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 440 </td></tr><tr><td style="vertical-align:bottom;width:70.04%;margin:0pt;padding:0pt;"> Total intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 507,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 534,645 </td></tr>
</table>830902000845747000832311000326392000292602000274843000415300-2387000-1647000-
1555000115906000011367020001105599000354775000373684000037762300024546000430370004897700037932100041672100042660000072900040000011596000078318000076413000073054000-647000239300069800000-9965000-19070000-
3506000219630001871500040277000412170004641000122450003029000164000091420006530000528100052500020668600029894400029659000065767900066530100064695200026634000025243200024392200041530009201800009177330000
style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note 14.
Subsequent Events: On July 23, 2024, the Company invested $15 million in Spear Bio, an innovative leader in the development and manufacture of ultra-sensitive immunoassays capable of measuring protein biomarkers at attomolar level from sub-microliter sample volume. 15000000KPMG LLPMinneapolis,
Minnesotafalsefalsefalsefalsetrue105*

&PO=V]R:W-H965T